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Preface 
 
Over the last decade Tissue Engineering progressed rapidly and first biological 
substitutes were developed for several tissues in the body. Today, Tissue Engineering 
is one of the major approaches of Regenerative Medicine and represents a growing 
and exciting field of research. With the understanding and application of new 
knowledge of structure, biology, physiology and cell culture techniques, Tissue 
Engineering may offer new treatment alternatives for organ replacement or repair 
deteriorated organs.  Among the clinical applications of Tissue Engineering are the 
production of artificial skin for burn patients, tissue engineered trachea, cartilage for 
knee-replacement procedures, urinary bladder replacement, urethra substitutes and 
cellular therapies for the treatment of  urinary incontinence. 
The classical principle of Tissue Engineering is to dissociate cells from a tissue biopsy, 
to expand them in culture, and to seed them onto a scaffold material in vitro in order 
to generate a viable tissue construct prior to re-implantation into the recipient's 
organism. In the appropriate biochemical and biomechanical environment these 
tissues will unfold their full functional potential and serve as native tissue equivalents. 
Tissue Engineering products may be fully functional at the time of treatment, or have 
potential to integrate and evolve into the expected functional tissue after implantation. 
While these steps may seem logical and easy to understand, the underlying biology is 
far more complicated and more profound questions have to be answered before the 
engineering of tissue and organs becomes a routine practice.  
Even so, the Tissue Engineering approach has major advantages over traditional organ 
transplantation and circumvents the problem of organ shortage. Tissues reconstructed 
from readily available biopsy material implicate only minimal or no immunogenicity 
when reimplanted in the patient. This eventually conquers several limitations 
encountered in tissue transplantation approaches. 
This book is aimed at anyone interested in the application of Tissue Engineering in 
different organ systems. With a colorful mix of topics which explain the obstacles and 
possible solutions, it offers insights into a wide variety of strategies applying the 
principles of Tissue Engineering to tissue and organ regeneration. As more and more 
applications move toward clinical application, a reliable preclinical model system to 
X      Preface 
 
evaluate the developed techniques becomes crucial. Several animal models and Tissue 
Engineering approaches for a variety of organ systems are presented in this book.  
Finally, I would like to thank all the authors who have supported this book with their 
contributions.  
 
Daniel Eberli  
University Zürich 
Switzerland 
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Myocardial Tissue Engineering 
Tatsuya Shimizu 
Institute of Advanced Biomedical Engineering & Science 
Tokyo Women’s Medical University 
Japan 
1. Introduction 
Many lives are lost due to heart diseases including myocardial infarction and 
cardiomyopathy. Recent reports have demonstrated that regenerative medicine has 
promising potential for recovering severe heart failure. Regenerative therapies for heart 
failure include cytokine, gene and cell therapy. Because many types of cardiovascular stem 
cells have been identified and their clinical potentials have been demonstrated for the past 
decade, cell injection therapy has most attracted both researchers and clinicians (Wollert 
2008). On the other hand, significant cell loss due to washing out and cell death has become 
problematic in cell injection technique. So, as next generation of regenerative therapy for 
impaired heart, transplantation of myocardial patches fabricated by tissue engineering 
technology are emerging and are clinically applied. Furthermore, several challenges for 
fabricating functional myocardial tissues/organs, which are electrically communicated, 
pulsate synchronously and evoke contraction power, have also started (Zimmermann, Didie 
et al. 2006). These ambitious challenges may lead to reconstruction of malformed hearts and 
become alternative therapy for heart transplantation.  
Heart tissues are composed of high-dense cylindrical cardiomyocytes and fibroblasts with 
abundant vascular network and collagen-based extracellular matrix (ECM). Cardiomyocytes 
pulsate via sodium and calcium ion transient through cell membrane. They are also 
electrically coupled by gap junctions composed of connexion 43 and rapid electrical 
propagation realizes simultaneous beating as a whole. Continuous blood flow supplies 
oxygen and nutrition, and withdraw the waste for high metabolic demand of heart tissues. 
These structure and function produce mechanical contractions as a blood pump. Therefore 
the researchers should take into account high density culture of cardiomyocyte and 
surrounding cells, sufficient micro blood vessel fabrication, cell/ECM orientation and 
proper cell-to-cell coupling for engineering heart tissues/organs.  
Here, previous and current status of cell injection therapy, myocardial patch transplantation 
and pulsatile myocardial tissue fabrication is described with some future views.  
2. Cell injection therapy 
Cell injection therapy for damaged heart has been researched since the early 1990’s. Many 
researchers have demonstrated the therapeutic potential of isolated cell transplantation into 
myocardium using various types of cell sources both in animal models and in some clinical 
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trials (Puceat 2008). The mechanism of myocardial tissue regeneration has not been 
completely cleared, but most researchers have agreed that transplanted cells secrete several 
cytokines which promote neovascularization, prohibit fibrosis, decrease cell death and 
recruit stem cells, leading to heart function improvement. It has been also asserted that 
some of injected cells differentiate into functional cardiomyocytes and may directly 
contribute to heart contraction improvement. Although some differences may exist in 
according to cell types, multifactorial mechanisms seem to relate with myocardial tissue 
regeneration.  
In addition to cell sourcing, different routes are used for cell administration. Systematic 
intravenous infusion is performed through a central or peripheral vein. This method is 
simple and less invasive, however widespread distribution cause low ratio of cell 
engraftment. Most popular approach is intracoronary cell infusion via a balloon-catheter. 
Injected cells are reached directly in the target myocardial region, however, cells have to 
transmigrate across endothelium wall. Intracardiac injection is performed via pericardium 
during open heart surgery and via endocardium by a catheter with a 3-D 
electromechanical mapping system (NOGA mapping system). These methods realize 
relatively targeted delivery, but myocardial damage and arrhythmia induction are 
problematic. Future clarification will be needed to decide which is the best approach for 
cell injection.    
2.1 Skeletal myoblasts 
Skeletal myoblasts were the first cell source to enter the clinical application for heart tissue 
repair. They lie in a quiescent state on the basal membrane of myofibers and have the 
potential to start to proliferate and differentiate into functional skeletal muscle in response 
to muscle damage. They can be isolated autologously and be expanded from a single biopsy. 
In addition, skeketal myoblasts are relatively resistant to ischemia. Menasche and colleagues 
first applied skeletal myoblast injection via epicardium for patients undergoing coronary 
artery bypass grafting (CABG) (Menasche, Hagege et al. 2001). The phase I clinical study 
(MAGIC I) have shown the feasibility of skeletal myoblast implantation, however, increased 
risk of ventricular arrhythmias after the operation. Then, MAGIC II trial was performed to 
clarify the safety and efficacy, in which all patients received preventive medication and an 
implantable cardioverter-defibrillator for rescuing critical ventricular arrhythmias. In result, 
skeletal myoblast injection failed to significantly improve heart function, leading to sample 
size reduction (Menasche, Alfieri et al. 2008). On the other hand, the trial indicated the 
possibility that high dose cell injection might recover left ventricular dilatation. In addition, 
the other clinical trials of catheter-based myoblast implantation via endocardium have 
revealed functional efficacy (Opie and Dib 2006). According to these results, not the 
regenerative potential of myoblasts themselves but the amount of injected cells and delivery 
system may affect the efficacy. Therefore, it seems that skeletal myoblasts should not be 
excluded as a cell source for heart tissue repair. More optimization of cell delivery and 
comparison of cell sources can address these critical issues. 
2.2 Bone marrow-derived cells 
Bone marrow-derived cells are the most used cells in clinical trials for myocardial tissue 
repair (Wollert 2008). The discovery of circulating progenitor cells originated from human 
bone marrow has stimulated research and clinical use of bone marrow-derived cells 
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(Asahara, Murohara et al. 1997). Bone marrow cells contain different stem and progenitor 
cells which will differentiate into various types of cells including endothelial cells, smooth 
muscle cells and cardiomyocytes. Bone marrow mononuclear cells (BMNCs), which can 
be isolated simply by gradient sedimentation after bone marrow aspiration without 
culture expansion, have been clinically injected via coronary artery from the first. BMNCs 
include heterogeneous cell population of monocytes, hematopoietic stem cells and 
endothelial progenitor cells (EPCs). Therefore, some groups have used BMNCs selected 
by surface markers (CD34+, CD133+) and demonstrated more efficacy of their injection. As 
another cell population, mesenchymal stem cells (MSCs) have been researched and 
clinically used. Although, MSCs represent between 0.01 and 0.001% of all nucleated cells in 
bone marrow, they can be readily expanded in culture. MSCs have the potential to 
differentiate into various types of cells and injected MSCs in heart seem to differentiate 
into myocardial composing cells. Recent studies have revealed rare happening of 
cardiomyocyte differentiation, therefore MSCs seem to recover heart function via their 
cytokine secretion and partial differentiation into vascular cells. As a unique feature, 
MSCs have the potential to escape from immune detection due to the direct inflammatory 
inhibition and the lack of cell-surface molecules. This property has realized allogenic 
mesenchymal stem cell transplantation in clinic and has given high impact on cell therapy 
research field.  
Recent randomized controlled trials of bone marrow-derived cell injection revealed overall 
feasibility and safety. However the data has revealed only marginal increases of ejection 
fraction (EF) even in positive studies (0-5%) (Martin-Rendon, Brunskill et al. 2008). For 
establishing more effective bone marrow-derived cell therapy, optimization of cell source, 
cell dose, delivery method and deliver timing will be needed. 
2.3 Adipose-derived stem cells 
In addition to bone marrow-derived MSCs, stem cells isolated from the stroma of adipose 
tissues have represented regenerative potential for heart tissues (Psaltis, Zannettino et al. 
2008). Adipose tissue-derived stem cells (ASCs) display features similar to that of bone 
marrow-derived MSCs and their angiogenic potential have been reported. Some studies 
have also revealed cardiomyocyte differentiation from ASCs. It has not been clarified which 
mesenchymal stem cells are superior to other cell types, however, reatively easy isolation of 
adipose tissue may push the clinical application of ASCs.  
2.4 Cardiac stem cells 
Cardiac stem cells (CSCs) are also possible cell source for myocardial tissue regeneration. 
Two groups first reported CSC existence in 2003 (Beltrami, Barlucchi et al. 2003; Oh, 
Bradfute et al. 2003). Until then, it was common knowledge that heart was a post mitotic 
organ, but those reports accelerated the researches for identifying surface marker of CSCs 
and culturing them. Islet-1, Sca-1 and c-kit have been known as CSC markers. Recently, it 
has been also confirmed that heart has renewal ability at normal state and the annual rate of 
turning over is 1% at the age of 25 (Bergmann, Bhardwaj et al. 2009). Although the ability of 
CSCs may increase after heart injury, newly formed cardyomyocytes are not sufficient for 
replacing damaged muscle tissues. Therefore isolation and expansion of CSCs have been 
extensively examined. Some groups have used a different approach to make cardiospheres 
from biopsied myocardium, which lead to efficient CSC expansion (Lee, White et al. 2011). 
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Clinical trials for injection therapy of autologous CSCs isolated from biopsy sample are now 
on going.  
2.5 Embryonic stem cells 
Although abundant studies demonstrated that MSCs, ASCs and CSCs have the potential of 
cardiomyocyte differentiation regarding gene and protein expression, there are no studies 
clearly showing beating cardiomyocytes differentiated from those stem cells. On the other 
hand, many researchers have confirmed that embryonic stem cells (ESCs) can differentiate 
into beating cardiomyocytes in vitro and implantation of ESC-derived cardiomyocytes 
improves damaged heart function. Several signal pathways for cardiac differentiation have 
been already clarified and various molecules have been reported as its promoters. For 
example, noggin increased cardiac differentiation efficacy via regulation of Bone 
morphogenetic protein (BMP) signalling pathway (Yuasa, Itabashi et al. 2005) and insulin-
like growth-factor-binding protein 4 (IGFBP4) promotes cardiogenesis by inhibitor of 
canonical Wnt signalling (Zhu, Shiojima et al. 2008). In addition, fibloblast growth factor 
(FGF), retinoic acid, ascorbic acid and cyclosporine A have been reported to have the 
potential to enhance cardiac differentiation from ESCs. The important issue as well as 
cardiac differentiation is purification of cardiomyocytes from heterogeneous cell mixture, 
because contamination of immature cells leads to teratoma formation. Although gene-
modified ESCs harboring neomycin resistance gene or green fluorescent protein (GFP) gene 
in the cardiac-specific gene locus are very useful in non-clinical experiments, safe and 
efficient isolation technologies will be needed for clinical application. Culture media control 
focusing on the differences of cell metabolism may be useful for safe cell selection. Moreover 
immune response of the host is another critical issue. Nucler transfer or cell banking is 
possible approach avoiding immunoreaction.  
Electrical communication and simultaneous beating of implanted ESC-derived 
cardiomyocytes should be also requested for improving damaged heart function without 
arrhythmia. In vivo electrophisiological analyses and the transplantation technology for 
synchronization will be essential for clinical application of these cells.  
2.6 Induced pluripotent stem cells 
Induced pluripotent stem cells (iPSCs) also hold great promise for myocardial tissue 
engineering (Vunjak-Novakovic, Tandon et al. 2010). Terminally differentiated cells can be 
reprogrammed to have the same potential as ESCs by introducing 3 or 4 transcriptional 
factor genes. Furthemore none-gene transfer technologies have been developed in the 
world. The superiority of iPSCs to ESCs is autologous cells, which do not cause immune 
response. Cardiac differentiation of human iPSCs has been reported in the same manner 
with ESCs.  
Several critical issues must be clarified for clinical use, but ESCs/iPSCs-derived 
cardiomyocytes should contribute to myocardial tissue engineering in the view point of 
their pulsatile function and scaling-up.  
2.7 Problems of cell injection therapy 
Cell injection therapies for heart failure are now world-widely performed. While moderate 
success of direct cell injection has been observed, the efficacies seem not to reach the level 
that general clinicians think cell therapy a reliable treatment for heart failure. More 
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optimization of cell source, cell preparation process, injection route, injection timing and 
patient population may increase the effectiveness; however one of the essential issues is 
cell delivery methodology. Cell injection therapy has significant difficulties about cell 
retention in the target tissue. The shape, size, and position of the grafted cells are often 
uncontrollable and large amount of the cells are washed-out. Moreover, once retaining 
cells die due to necrosis and apoptosis. Time course quantification with TUNEL assay 
demonstrated that a large number of the grafted cells die within a few days after injection 
in rat models (Zhang, Methot et al. 2001). In the clinical trial using bone marrow-derived 
cells, it has been also demonstrated that only 1-3% of the cells infused via coronary 
arteries could be detected by 3D positron emission tomography (PET) imaging of the 
patient heart. In this study, a large percentage of cells were found in the liver and spleen 
immediately after the procedures (Hofmann, Wollert et al. 2005). To clear the problem of 
cell loss, hydrogel-cell mixture injection has been pursued. Fibrin, collagen and alginate 
hydrogels are now used. Hydrogels with cells are injected as a liquid phase through 
syringe or catheter, then, they are polymerized and fixed in the target tissues (Kofidis, de 
Bruin et al. 2004). In hydrogel-cell mixture injection therapy, local tissue damage due to 
space occupation of hydrogel itself and inflammatory reaction due to hydrogel 
biodegradation are problematic. 
Therefore, more advanced cell delivery systems have been requested to spread the 
regenerative therapy as one of the reliable treatments for heart failure.  
3. Tissue engineering  
Recent advance of tissue engineering technologies have realized the transplantation of 
tissue-engineered construct “myocardial patch” covering over damaged heart surface 
instead of simple cell injection into myocardium. Grafted cells within myocardial patches 
can survive more and secrete more cytokines, resulting in more heart function 
improvement. Furthermore pulsatile myocardial tissues have been successfully engineered 
by using cardiomyocytes as a seeding cell source. These tissues may directly help heart 
contraction and total heart wall replacement may be possible in future. There are several 
contexts of tissue engineering. 
3.1 Scaffold-based tissue engineering 
Most popular technology of tissue engineering is to seed cells into 3-D pre-fabricated 
biodegradable scaffolds which are made from synthetic polymer and biological material. 
Hydrogel formation after mixing cells and scaffold solution is another approach. 
Decellularized tissues have been also used as scaffolds. These scaffolds play as alternatives for 
extra cellular matrix (ECM), therefore, their cell-adhesiveness and porosity affect survived cell 
amount and engineered tissue quality. Scaffold modification can control its biodegradation 
and tissue formation. Growth factor linkage leads to accelerating tissue formation. Now these 
scaffold-based tissue engineering has been widely applied to cardiovascular tissue 
regeneration as well as other tissue repair (Vunjak-Novakovic, Tandon et al. 2010). 
3.2 Cell sheet-based tissue engineering 
In contrast to scaffold-based tissue engineering, our group have developed unique 
technique involving cell sheet stacking to fabricate 3-D tissues (Shimizu, Yamato et al. 2003). 
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Cell sheets are 2-D connecting pure cells without any scaffolds, therefore cell-dense 3-D 
tissues can be fabricated by stacking cell sheets. Cell sheets are harvested from intelligent 
culture surface “temperature-responsive culture surface”, which are covalently grafted with 
temperature-responsive polymer, poly (N-isopropylacrylamide) (PIPAAm) (Okano, Yamada 
et al. 1993). The surfaces are slightly hydrophobic and cell-adhesive at 37˚C, on the other 
hand, the surface changes to hydrophilic and not cell adhesive below 32˚C. Confluently 
cultured cells on the surface can detach as a contiguous cell sheet simply by reducing 
temperature. Furthermore, biological molecules underneath cell sheets are also preserved 
and play a critical role as an adhesive agent during cell sheet stacking. Cell sheet-based 
tissue engineering has been applied for a wide range of regenerative medicine including 
corneal epithelial replacement, heart tissue repair, pneumothorax repair, liver tissue repair 
and so on.  
According to the spread of the concept fabricating 3-D tissues from 2-D confluent cells, 
several other technologies using this concept have emerged. Cell sheet fabrication 
techniques using fibrin coated dishes or nanofibrous polycaprolactone meshes have been 
reported (Shin, Ishii et al. 2004; Itabashi, Miyoshi et al. 2005). Cell sheet-like constructs have 
been also engineered using magnetite nanoparticles (Ito, Hibino et al. 2005). Magnetically 
labelled cells are attached on culture materials by magnetic force and confluent cells are 
harvested as a cell sheet by magnetic force release. Thus, cell sheet-based tissue engineering 
has now spread in the world as scaffold-free tissue engineering. 
4. Myocardial patch transplantation  
Both scaffold-based and cell sheet-based tissue engineering have been used for myocardial 
patch fabrication. Not only cardiomyocytes but also other types of cells have been used for 
creating myocardial patches and some myocardial patches using non-cardiomyocytes have 
been already clinically transplanted over damaged hearts. (Fig. 1.) 
4.1 Scaffold-based mayocardial patch 
In myocardial patch fabrication, synthetic polymer, biological material and decellularized 
tissue have been used as prefabricated scaffolds. Li and colleagues, who were one of the 
pioneer groups of myocardial tissue engineering, first demonstrated that gelatine sponges 
seeded with cardiac cells have therapeutic potentials for cryoinjured rat hearts (Li, Jia et al. 
1999). Leor and colleagues reported that bioengineered heart grafts using porous alginate 
scaffolds attenuated left ventricular dilatation and heart function deterioration in infarction 
model (Leor, Aboulafia-Etzion et al. 2000). Eschenhagen and Zimmermann’s group have 
developed innovative myocardial tissue engineering approach (Zimmermann, 
Schneiderbanger et al. 2002). They have fabricated 3-D tissues by gelling mixture of cardiac 
cells and collagen solution. The constructs induced systolic wall thickening of the left 
ventricle infracted area and improved fractional shortening of damaged hearts in rat 
myocardial infarction model (Zimmermann, Melnychenko et al. 2006). Small intestinal 
submucosa (SIS) has also been used as a scaffold for myocardial patch. MSC-seeded SIS 
improved heart contraction in rabbit infarction model (Tan, Zhi et al. 2009). There have been 
various types of myocardial patches using different scaffolds and different cell sources. 
Although implantable human myocardial patches using beating cardiomyocytes have not 
been established now, clinical trials of collagen-based myocardial patch with bone marrow 
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cells (MAGNUM trial) (Chachques, Trainini et al. 2007) and vicryl mesh-based myocardial 
patches with fibroblasts (Anginera) ((Mirsadraee, Wilcox et al. 2006)) have revealed 
feasibility and safety of myocardial patch transplantation.     
 
Diseased heart 
Cells 
Stacking 
3. Cell sheet-based TE 
Temperature-responsive 
culture surface 
Cells & ECM 
mixture 
Gelling 
Scaffold 
1. Scaffold-based TE 2. Hydrogel-based TE 
Cell sheet 
Seeding 
 
Fig. 1. Tissue engineering (TE) strategies for myocardial patch fabrication 
4.2 Cell sheet-based myocardial patch 
Many types of cell sheets have been reported to improve impaired heart function (Shimizu, 
Sekine et al. 2009). Cell sheets are transplanted onto heart surface directly via open heart 
surgery and cells can be more effectively delivered as thin, but large-area cell-dense grafts 
than isolated cell injection. Scaffold-based myocardial patches are usually transplanted on 
myocardium with suture, on the other hand, cell sheets are transplanted with no suture 
because biological adhesive proteins underneath cell sheets promote the attachment. When 
neonatal rat cardiac cell sheets were transplanted onto infracted rat hearts, grafted 
cardiomyocytes communicated with host myocardium via gap junctions and blood vessels 
formed within the graft, resulting in significant improvement of heart function (Miyagawa, 
Sawa et al. 2005; Sekine, Shimizu et al. 2006).  
Sawa and colleagues have started to use skeletal myoblasts for cell sheet fabrication, because 
myoblasts can be isolated autologously and are relatively resistant to ischemic condition. 
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The recovery of heart function by skeletal myoblast transplantation has been confirmed in 
rat ischemic model, in dilated cardiomyopathy hamster model, in pacing-induced canine 
heart failure model and in pig infarction model (Memon, Sawa et al. 2005; Hata, Matsumiya 
et al. 2006; Kondoh, Sawa et al. 2006; Miyagawa, Saito et al. 2010). Regarding stacking cell 
sheet number, 3-5 layers are optimal and more layering cause primary necrosis of the 
constructs (Sekiya, Matsumiya et al. 2009). They have demonstrated more hematopoietic 
stem cells and less fibrosis in cell sheet transplantation than in isolated cell injection in 
accordance with more expression of stromal-derived factor 1 (SDF-1), hepatocyte growth 
factor (HGF), and vascular endothelial growth factor (VEGF). Based on these results, clinical 
trial of autologous myoblast sheet transplantation for severe heart failure has started and the 
detailed results will appear soon.    
In the same manner with cell injection therapy, MSCs are used as a candidate cell source for 
human implantable cell sheet. Adipose tissue-derived MSCs and menstrual blood-derived 
MSCs have improved damaged heart function in rat infarction model (Miyahara, Nagaya et 
al. 2006; Hida, Nishiyama et al. 2008). MSCs can gradually grow to form a thick stratum 
containing newly formed blood vessels and some cells seem to differentiate into 
cardiomyocytes at least by histological analyses. Further studies will be needed to confirm 
the differentiation into functional beating cardiomyocytes and possibilities to differentiate 
into unexpected cell types. 
As emerging cell source, cell sheets of stem cell antigen 1-positive (Sca-1-positive) CSCs 
ameliorates cardiac dysfunction in mouse infarction model through cardiomyocyte 
differentiation and paracrine mechanisms mediated via soluble vascular cell adhesion 
molecule 1 (VCAM-1)/very late antigen-4 (VLA-4) signaling pathway (Matsuura, Honda et 
al. 2009). In addition, cardiac cell sheets originated from ESCs/iPSCs have been successfully 
fabricated and their transplantation into animal models is now ongoing.  
For enhancing the efficacy of cell sheet transplantation, gene-modified cell sheets have been 
examined. Bcl-2 expressed myoblast sheets prolonged survival, increased production of 
proangiogenic paracrine mediators, and enhanced the therapeutic efficacy (Kitabayashi, 
Siltanen et al. 2010). HGF overexpression in myoblast sheets enhances their angiogenic 
potential in rat chronic heart failure model (Siltanen, Kitabayashi et al. 2011). As another 
concept, cell sheets co-cultured with endothelial cell sources have been transplanted in rat 
infarction models. Transplantation of EPC co-cultured fibroblast sheet improved heart 
function more than only fibroblast sheet implantation or EPC injection (Kobayashi, Shimizu 
et al. 2008). Furthermore, endothelial cell co-culture within cardiomyocyte sheets induced 
more neovascularization and more improvement of cardiac function than only 
cardiomyocyte sheets (Sekine, Shimizu et al. 2008). These studies indicate advanced 
strategies of cell sheet transplantation.      
As mentioned previously, it is considered that the main mechanism of heart function 
improvement is neovascularization, fibrosis inhibition, apoptosis inhibition and stem cell 
recruitment due to various cytokines secreted from grafted cells. In comparison with cell 
injection approach, increase of cell survival within myocardial patches leads to more 
cytokine secretion, then, resulting in more function improvement. In addition to cytokine 
secretion, myocardial patches may have girdling effect and prohibit heart dilatation. 
Therefore, myocardial patch transplantation is quite different cell delivery method from cell 
injection and has more potential to rescue diseased hearts. In the case of myocardial patches 
using beating cardiomyocytes, direct enhancement of contraction power is additionally 
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expected, however, electrical synchronization between host hearts and transplanted patches 
is a critical issue to be clarified. 
5. Engineering plusatile myocardial tisssue 
Beyond myocardial patch fabrication, several research groups have challenged to fabricate 
pulsatile myocardial tissues by their original tissue engineering strategies. Bioengineered 
contractile myocardial tissues may realize new therapeutics for severe heart diseases and be 
useful as alternatives for animal models.    
5.1 Pre-fabricated scaffold-based myocardial tissue fabrication 
The first approach for engineering functional myocardial tissue is seeding cardiomyocytes 
into synthetic or biological 3-D scaffolds. Vunjak-Novakovic and colleagues first reported 
that seeding primary cultured cardiomyocytes onto disc-shaped polyglycolic acid (PGA) 
scaffolds in rotating bioreactor system resulted in spontaneously pulsatile myocardial 
tissues (Papadaki, Bursac et al. 2001). Optimization of cell population, serum concentration 
and scaffold coating improved electrical conduction velocity of engineered constructs. 
Radisc and colleagues seeded rat cardiomyocytes in Matrigel onto collagen sponges and 
stimulated the constructs electrically. The stimulation improved the conductive and 
contractile properties in accordance with increased expression of myosin heavy chain and 
connexion 43. Furthermore, cardiomyocytes in the electrically stimulated constructs were 
more aligned and elongated as same as those in native heart tissue (Radisic, Park et al. 
2007).  
Following these studies, many research groups have started to engineer myocardial tissue in 
vitro by using various types of scaffolds. Scaffold porosity is one of the critical factors for 
pre-fabricated scaffold-based tissue engineering. High porosity increases seeded cell 
number and facilitates mass transport. Surface modyfication is also important for cell 
attachment and survival. Laminin coating improved cardiomyocyte adhesiveness. In 
addition, scaffold elasticity and degradability affect contraction property of engineered 
myocardium. Further studies are ongoing to development appropriate scaffold materials for 
myocardial tissue engineering.  
5.2 Hydrogel-based myocardial tissue fabrication 
The second approach is to form 3-D tissues by gelling of cardiac cell and matrix solution 
mixture. Eschenhagen and Zimmermann have continuously developed this strategy using 
collagen gel and successfully engineered macroscopically beating cardiac tissues 
(Zimmermann and Cesnjevar 2009). First, neonatal rat cardiomyocytes were suspended in 
collagen I solution and the mixture was poured into the mold. After gelling, the constructs 
were unidirectionally stretched with the mechanical devise. They have also realized 
contraction force measurement. Cyclic stretch introduced cell alignment along the stretching 
direction and increased mitochondrial density, leading to native heart-like tissue. The 
contraction force of engineered myocardium was comparative with native heart tissue and 
responded to pharmacological agents properly. Ring-shaped myocardial tissues were also 
fabricated and combined 5 constructs were transplanted onto infarcted rat hearts. 
Interestingly, the constructs synchronized to each other and improved damaged heart 
function. They have also confirmed that co-culture constructs including cardiomyocytes, 
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fibroblasts and endothelial cells were superior to cardiomyocyte rich constructs in 
morphology and function. Recently, they have also started to utilize human cardiomyocytes 
differentiated from ESC/iPSC as cell source and challenged to create human myocardial 
tissues (Zimmermann 2011). In contrast to pre-fabricated scaffold usage, relatively 
homogeneous myocardial tissues are engineered by hydrogel-based approach. Therefore 
collagen gel-based myocardial tissue engineering has now become popular in the world.        
5.3 Cell sheet-based myocardial tissue fabrication 
The third approach is to engineer 3-D pulsatile myocardial tissues by stacking cardiac cell 
sheets. As mentioned previously, 2-D cell sheets can be harvested from temperature-
responsive culture dishes only by lowering temperature and do not include any materials. 3-
D tissues are constructed by layering cell sheets. Because 2-D confluent cells are directly 
stacked without any scaffolds, resulting constructs are cell-dense 3-D tissues. It is well-
known that 2-D confluent cardiomyocytes connect to each other electrically via gap 
junctions resulting in synchronized beating. Cardiac cell sheets harvested from temperature-
responsive culture dishes maintain this synchronized pulsation (Shimizu, Yamato et al. 
2002). For creating 3-D functional heart tissues by layering cardiac cell sheets, morphological 
and electrical communications between cell sheets are critical. Multiple-electrode 
extracellular recording system revealed that double-layer rat cardiac cell sheets coupled 
electrically about one hour after layering and histological analysis showed the existence of 
connexin 43 between two cardiac cell sheets. Adhesive proteins deposited on cell sheet 
surface are considered to promote these rapid electrical communications (Haraguchi, 
Shimizu et al. 2006). Stacked cardiac cell sheets beat synchronously in macroscopic view and 
the constructs transplanted into rat subcutaneous tissues also pulsated continuously at least 
up to one year and eight months after implantation. Morphological analyses showed 
elongated cardiomyocytes, well-differentiated sarcomeres, gap junctions and multiple blood 
vessels, which were characteristic structure of native heart tissue (Shimizu, Yamato et al. 
2002). Long-term observation revealed that their size, conduction velocity, and contractile 
force increased in proportion to the host growth (Shimizu, Sekine et al. 2006). Recently, 
fabrication of cardiac cell sheets using ESC-originated cardiomyocytes have just started and 
human cardiac cell sheets will appear in near future. 
5.4 Fabrication of vascularized myocardial tissue 
One of the major obstacles in myocardial tissue engineering is scaling-up of the constructs. 
Insufficient supply of oxygen and nutrient, and waste accumulation limit their thickness. 
Actually, cells are sparse in the central area, on the other hand, cells are dense in the outer 
surface (100-200μm) area in scaffold-based myocardial tissue engineering. In the case of cell 
sheet-based myocardial tissue engineering, thickness limit is approximately 80μm (3 layers) 
(Shimizu, Sekine et al. 2006). Several approaches have been examined in the point of view 
overcoming diffusion limit. Perfusion of culture media through the constructs using porous 
scaffolds is one possible approach. Media penetration increased cell migration depth and 
improved cell metabolism. However shear stress due to media flow may prohibit tight cell 
attachment on the scaffold material. Media perfusion with oxygen carrier, perfluorocarbon 
(PFC) has been also examined for improving oxygen transport. PFC usage increased cell 
proliferation and improved pulsatile function. Media penetration is useful to some extent, 
however, it becomes more difficult as cell density increases. 
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To overcome this problem, it has been requested to develop new technologies for 
introducing vasculature or vascular-like structure into engineered tissues. Several 
researchers have tried to generate microchannel network within porous 3-D scaffolds by 
microfabrication techniques including CO2 laser ablation. The technology has not reached to 
mimicking native micro capillary network. On the other hand, recent studies have revealed 
that co-cultured endothelial cells within cardiac constructs can spontaneously form 
vascular-like network in vitro and tubular formation has been found in some parts. It has 
been also confirmed that this pre-vascular structure connected to host blood vessels 
immediately after transplantation and the newly developed vessels within the constructs 
were blood-supplied within a few days (Sekiya, Shimizu et al. 2006). We have already 
demonstrated that the tissue thickness of cardiac cell sheets co-cultured with endothelial 
cells were just twice as the thickness of cardiac cell sheets without endothelial cells (Sekine, 
Shimizu et al. 2008). Although endothelial cell co-culture is helpful for accelerating blood 
vessel formation, more scaling-up is still limited due to primary ischemia until sufficient 
vascularization.  
One possible idea for scaling-up is utilizing in vivo vascularization power. Our group has 
reported that triple-layer cardiac cell sheets were repeatedly implanted after waiting enough 
vascular formation within previously implanted tissues. In result, synchronously beating 
thick myocardial tissues with sufficient micro capillaries were successfully fabricated and 
10-times transplantation of triple-layer constructs (totally 30 sheets) formed 1-mm thick, 
pulsatile myocardial tissues. Furthermore, when triple-layer grafts were transplanted 
repeatedly over a surgically connectable artery and vein in leg, the multilayer constructs 
were blood-supplied from the thick artery and vein. The constructs were successfully 
resected with the connectable blood vessels and were ectopically transplanted in neck with 
direct vessel anastomoses (Shimizu, Sekine et al. 2006). Recently several groups have also 
utilized in vivo power for myocardial tissue engineering. Cardiomyocytes, ECM alternatives 
and native blood vessels were packed in the special chamber and incubated in vivo. 
Vascularized heart-like tissues were created in the body (Morritt, Bortolotto et al. 2007; Birla, 
Dhawan et al. 2009). 
Furthemore, next challenge is now in vitro fabrication of vascularized myocardial tissues. 
Kofidis and colleagues have constructed fibrin gel-based myocardial tissues containing rat 
aortas (1-2mm), through which culture media was perfused (Kofidis, Lenz et al. 2003). Cell 
survival and metabolism were improved, however formation of functional blood vessels 
connecting with central aortas were not clear. We are now trying to promote endothelial cell 
tubular formation within in vitro engineered cardiac tissues and to perfuse culture media 
through the newly formed vessels using perfusion bioreactors. Further studies will be 
needed to break through the obstacles for in vitro scaling up.  
5.5 From tissue engineering to organ engineering  
For future organ engineering, some groups have challenged to engineer myocardial 
constructs with pumping function. Ott and colleagues have used decellularized organ as a 
scaffold. They decellularized rat whole hearts and re-seeded cardiac cells into decellularized 
hearts. Heart contraction was recovered and pump function was generated (Ott, Matthiesen 
et al. 2008). Zimmermann’s group developed pouch-like myocardial tissue by their 
technology as previously described and covered heart with pouch-like constructs (Yildirim, 
Naito et al. 2007).  
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Regarding cell sheet technology, myocardial tubes have been fabricated by wrapping rat 
cardiac cell sheets around fibrin tubes and rat resected aortas. The engineered myocardial 
tubes revealed spontaneous, synchronized pulsation and small but significant inner 
pressure changes (about 0.1 mmHg) in vitro (Kubo, Shimizu et al. 2007). On the other hand, 
resected rat aortas wrapped with cardiac cell sheets were micro surgically transplanted in 
place of the abdominal aorta. After 1 month, in vivo myocardial tubes demonstrated 
spontaneous beating and evoked independent blood pressures (about 6 mm Hg). The value 
of in vivo myocardial tubes was much bigger than in vitro myocardial tubes (Sekine, 
Shimizu et al. 2006). Comparing in vitro and in vivo, it was considered that pulsation due to 
host blood flow has induced cardiomyocyte hypertrophy, leading to improvement of 
pumping function. Therefore pulsatile perfusion bioreactors may improve pumping 
function of in vitro engineered myocardial tubes. 
Thus, small size myocardial constructs evoking pumping function have been realized. 
Expansion and selection of cardiomyocytes, and sufficient blood vessel formation for 
scaling-up are now critical issues for organ engineering.   
6. Conclusions 
As the first generation of cardiac regenerative therapy, many clinical trials of cell injection 
therapy have been already performed. The controversial arguments about its effectiveness 
will be settled in next several years. Tissue engineered myocardial patches have now 
emerged as the second generation and previous studies indicate promising potential for 
rescuing damaged heart. As the third generation, tissue-engineered pulsatile myocardial 
tissues should support heart contraction physically. Furthermore, future development of cell 
sourcing and scaling-up technologies may realize “bioengineered hearts”.  
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1. Introduction 
In healthy human hearts, only 10-20% of the total cells are contractile cardiomyocytes and, at 
the age of 25 years, no more than 1% of them are annually substituted by progenitor cells, 
this percentage reducing to less than 0.5% at the age of 75. In total, less than 50% of 
cardiomyocytes are renewed during a normal human life span [1]. For this reason, the topic 
of cardiac repair is among the major challenges for the tissue engineers worldwide. In fact, 
cardiac diseases are a predominant cause of mortality and morbidity in industrialized 
countries, despite the recent advancements achieved in pharmacological treatment and 
interventional cardiology procedures. Nonetheless, end-stage heart failure management still 
relies on organ transplantation as unique approach, and, notwithstanding the use of massive 
immunosuppressive drugs, still a percentage falling within 20%-40% of patients encounters 
immune rejection during the first year post-transplant [2]. Among the patients not facing 
severe immune rejection, almost 70% is forced to retire or reduce their working activity, 
their survival rate falling below 70% during the first five years post organ transplantation 
[3]. Last, but not least, the economic impact of cardiovascular diseases and stroke has been 
estimated in 2010 at $503.2 billion [4]. 
Currently, post-infarction myocardial revascularization protocols include the administration 
of raw bone marrow stem cells, while a number of clinical trials have been performed or are 
currently in progress in which different cell subsets are implanted in the damaged tissue by 
means of surgical techniques. The results of such trials are still controversial. In fact, when 
autologous skeletal myoblasts were injected into the heart of patients suffering from 
ischemic cardiomyopathy, the modest functional improvement obtained was impaired by 
the arising of arrhythmia events, thus requiring the adoption of a pacemaker [5]. On the 
other side, intracoronary administration of bone marrow mesenchymal stem cells resulted 
in minimal improvements in cardiac contractile function in patients with dilated 
cardiomyopathy [6]. These mild results were mostly ascribed to a paracrine effect exerted on 
host tissue, rather than to a direct contribution of stem cells to the contractile activity. 
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Thus, among the criticisms to be challenged before efficient cell therapy protocols for 
cardiac diseases can be setup, the choice of the appropriate cell subset to generate new 
vessels and contractile cardiomyocytes, as well as the route of cell delivery remain key steps. 
The solution of such problems requires additional efforts in basic research to clarify the 
processes leading to stem cell differentiation as well as technological advancements to setup 
efficient protocols to implant the cells.  
In principle, adult stem cells could be extracted from patient’s own tissues and expanded in 
culture by means of well-known techniques (Figure 1).  
 
 
Fig. 1. Cardiac Tissue Engineering paradigm. Adult stem cells can be harvested, purified 
from the patient and expanded in culture. Such cells can be delivered to the injured heart by 
injection (intramural or through bloodstream with or without injectable carriers), or in the 
form of solid bio-constructs. Stem cell-derived bio-constructs can be obtained by culturing 
the cells on scaffolds or by scaffold-free technology 
Nonetheless, a number of issues should be challenged before safe procedures to 
manipulate stem cells in vitro for cardiac transplant can be setup. In fact, stem cells should 
be amplified in vitro to reach a critical number (Figure 1). During this passage, malignant 
transformation is likely to occur in ex vivo cells when standard culture conditions are 
adopted to expand stem cells [7, 8]. On the other side, stem cells could encounter 
senescence after a short number of passages in vitro [9]. Moreover, the use of animal-
derived supplements during the phase of cell expansion would hinder the use of stem 
cells for cardiac cell therapy. 
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The employment of autologous stem cells would avoid the problem of immune rejection 
and the need for immune-suppressive drugs, while, in the treatment of pathologies for 
which a genetic basis is suspected the use of autologous cells is hampered. As far as the use 
of autologous cells is concerned, the possibility that a significant patient-to-patient 
variability in stem cell quality exists should be taken into account [10]. Finally, the use of 
cellular and tissue-based products in human disease therapy is subjected to regulations 
issued by the European Union and Food and Drug Administration (FDA) aimed at 
establishing classification criteria for advanced therapy medicinal products (ATMP). In 
particular, the European Regulation states that human cells to be used in cell therapy have 
to comply with the principles of Good Manufacturing Practice (GMP) protocols [11, 12]. 
2. Adult stem cells for cardiac repair 
A number of stem cells and progenitors have been so far proposed for cardiac repair, due to 
the inability of cardiomyocytes to proliferate after birth [1]. Among the cell sources 
challenged for the possibility to produce new cardiomyocytes, skeletal myoblasts have 
proven to be able to acquire a contractile phenotype in vitro [13]. Moreover, when implanted 
in vivo in a canine model of dilated cardiomyopathy (DCM), they attenuated cardiac 
remodeling [14]. This result is likely to be due to the fusion of skeletal myoblasts with the 
surrounding myocardium rather than to direct cell differentiation, as suggested by in vitro 
experiments [15]. As discussed in the following section, clinical trials demonstrated that 
skeletal myoblasts are not able to couple electrically with host tissue, leading to arrhythmia 
events [5].  
The role of hematopoietic stem cells (HSC) in cardiac repair has been investigated by several 
research groups and their contribution to cardiac regeneration in vivo has been heavily 
debated, being the ability of HSC to transdifferentiate to other lineages still questionable. 
Indeed, evidence of the ability of bone marrow-derived c-kit+ HSC to help cardiac tissue 
healing has been given using two different approaches: c-kit+ cells were (i) either delivered 
to the infarcted site by intramural injection [16] or (ii) mobilized from bone marrow through 
growth factor administration [17]. More recently, elegant experiments compellingly clarified 
that HSC are not able to acquire contractile phenotype in vivo [18-20]. Nonetheless, a subset 
of bone marrow hematopoietic precursors expressing CD34 and CD133 has been proven to 
contain endothelial progenitors. Thus, they have been tested for revascularization protocols 
in hind limb ischemic animals and could be proposed for cardiac infarction therapy [21]. On 
the other hand, the results obtained in preliminary investigations in which another bone 
marrow-derived stem cell subset, mesenchymal stem cells (BM-MSC or MSC) were 
challenged as a candidate for cellular cardiomyoplasty, raised great enthusiasm for such a 
cell subpopulation. Recent studies clarified that the direct contribution of MSC to cardiac 
repair in terms of production of new contractile cells is minimal if any, while a paracrine 
effect on the diseased tissue of such cells is universally recognized [22]. Such cells are also 
appealing for their ability to induce a certain degree of immune tolerance [23].   
The presence of a small reservoir of cardiac resident progenitor cells (CPC or CSC) has been 
recently demonstrated in human as well as in other mammals’ heart [24]. Such tissue-
resident cells participate in myocardial homeostasis and retain a limited regenerative 
capacity throughout organism lifespan [1]. All the subsets so far identified through the 
expression of stemness markers (c-kit+, Sca-1+, Islet-1+) demonstrated the ability to give 
birth to new contractile cells in vitro, while only c-kit+, Sca-1+ progenitors were shown to be 
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involved in post-natal cardiac tissue homeostasis in vivo [25]. In fact, the presence of Islet-1+ 
cells appears to be limited to fetal life and their contribution to the endogenous program of 
cardiovascular repair is still unknown; on the other hand, the very low number of c-kit+ and 
Sca-1+ cells in the myocardium is considered the limiting factor of cardiac regeneration [26]. 
Furthermore, among the adult stem cells, a novel “artificial” subset can be recognized: 
induced pluripotent stem cells (iPSC, Figure 2). This cell type can be produced in vitro by 
transducing somatic cells with a combination of transcription factors able to induce the 
nuclear reprogramming of differentiated cells. These cells, which display the functional 
features of pluripotent embryonic stem cells, have been credited of the ability to produce 
new cardiomyocytes. They could thus be the source of autologous, although genetically 
modified, patient-specific contractile cells [27]. Moreover, the possibility to directly obtain 
functional cardiomyocytes by the genetic reprogramming of postnatal cardiac or dermal 
fibroblasts has been demonstrated [28]. Such a result was firstly obtained in vitro but also 
when the cells were transplanted into mouse hearts one day after transduction of 
transcription factors (GATA-4, MEF-2c, Tbx-5) known to be involved in cardiac muscle 
development. Nonetheless, the reprogramming and differentiation efficiency of these cells 
appears to be really low, thus requiring an efficient purification step before they can be 
implanted in vivo. Additionally, safety concerns due to the use of genetically modified cells 
and / or viral vectors remain.  
 
 
Fig. 2. Induced Pluripotent Stem Cell Generation. Induced pluripotent Stem Cells (iPSC) can 
be generated by reprogramming somatic cells through their transduction with four 
transcription factors. iPSC share functional similarities with Embryonic Stem Cells (ESC) 
and can be differentiated towards cardiomyocytes, thus representing an autologous source 
of contractile cells 
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3. Stem cell delivery to the injured heart 
As previously said, cell route of delivery to damaged heart represents the major topic in 
the setup of efficient, minimally invasive techniques to treat cardiac pathologies. 
Recently, a number of techniques to deliver stem cells to the injured site have been 
proposed but questions remain regarding the optimal approach able to favor high cell 
retention, differentiation rate and clinically relevant improvement in cardiac 
performance. 
a) Direct injection 
Stem cell direct intramural injection, including trans-epicardial and trans-endocardial cell 
injection, is the elective strategy for patients with severe occlusion of coronary vessels. In 
particular, trans-epicardial approach consists in the direct injection of a high number of cells 
into the infarcted area or around the border zone. Endocardial stem cell injection is 
performed using catheters such as MyoStarTM injection catheter (Biosense Webster) 
integrated with imaging systems like NOGA® system (Cordis Corp., Warren, NJ, USA), 
which allows real-time three-dimensional reconstruction of left ventricle as well as the 
targeting and functional assessment of specific myocardial area [29]. Such procedures are 
highly invasive since they require open-heart surgery and gave contrasting results so far. 
For example, pre-clinical studies performed on experimental animals demonstrated that, 
although a certain extent of cardiac repair was achieved when bone marrow Stro-3+ 
perivascular cells are implanted in vivo, the cells vanished from the application site within 
few days [30]. In other reports, when Sca-1+ cardiac resident stem cells were injected in 
infarction border zone, a modest but significant improvement in cardiac function was 
reported, with evidence of cell engraftment and differentiation [31]. Finally, in another 
pre-clinical study, bone marrow-derived c-kit+ cells were shown to repair entire 
ventricular areas while massively engrafting and differentiating in contractile and 
vascular figures in vivo [32]. Of interest, independent groups already demonstrated that c-
kit+ bone marrow-derived hematopoietic stem cells fail to acquire contractile phenotype 
when implanted in diseased myocardium [19, 20]. Such discrepancies are not surprising 
since different stem cell subsets or preparation protocols were probably used in these 
studies.  
Stem cells can be delivered intravenously to the heart, through coronary arteries or even 
through retrograde coronary sinus. The major drawback of stem cells being infused through 
peripheral venous system seems to be the low retention of cells into infarcted area. Results 
obtained in pre-clinical animal models showed that this minimally invasive approach results 
in a significant percentage of injected cells being sequestered in lungs, liver or spleen, due to 
blood flow [33]. On the other hand, intracoronary or retrograde coronary sinus infusion of 
the cells are mainly performed after acute myocardial infarction using an angioplasty 
balloon and high pressure to deliver cells to heart muscle [34]. The coronary route was 
proven to be free of stem cell systemic delivery, while a limited number of cells could be 
found in the infarcted area [35].  
Finally, an interesting attempt with stem cells being injected into the pericardial cavity has 
been proposed. By this means, a higher number of cells could be deposited and retained 
in the pericardial cavity, while migration across the visceral pericardium is required 
(Table 1).  
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Table 1. Advantages and disadvantages of injecting stem cells by intravenous, 
intracoronary, intramyocardial, retrograde coronary sinus or intra-pericardial route 
b) Injectable scaffolds  
Injectable scaffolds are defined as materials offering the unique solution of replacing 
damaged myocardial ECM and/or delivering cells directly to the infarcted region while 
holding the potential for minimally invasive delivery [36]. Such scaffolds can be composed 
of biocompatible microspheres or in situ gelling materials having reasonable dimensions as 
to surpass capillary barrier. They are considered a promising tool for stem cell delivery to 
damaged myocardium. In situ gelling materials are generally made of components of 
extracellular matrix (ECM), which are induced to a transition after being implanted in situ. 
Complex injectable gelling materials have been prepared by decellularization technique out 
of ventricular or epicardial ECM, thus possibly avoiding animal-derived components and 
paving the way to the definition of patient-specific treatments.  
The use of injectable, synthetic microspheres has already been proven promising in the 
treatment of neurological diseases in vivo [37]. Recently the possibility of using injectable 
scaffolds in cardiac cell therapy has been explored by interfacing murine mesenchymal 
(mMSC) and cardiac stem cell (mCSC) lines with poly-lactic acid (PLA) microspheres 
having a diameter of 30 and 100 μm. Preliminary in vitro experiments demonstrated that 
such cells can be grown onto PLA microspheres while preserving their phenotype, but the 
formation of cell clumps can hamper the application of this technique [38]. The use of 
dynamic seeding techniques (i.e. bioreactors) would favor a more homogeneous distribution 
of the cells. An interesting approach has been recently proposed to deliver human 
mesenchymal stem cells to the injured myocardium: RGD-modified alginate microsphere 
(diameter: 200-700 μm) encapsulation of hMSC was setup. In vitro experiments showed that 
hMSC could survive, proliferate and migrate through the porous material. When 
intramyocardially injected in a rat model of myocardial infarction by left anterior 
descendant coronary (LAD) ligation, cell-loaded alginate microspheres promoted 
angiogenesis and prevented LV negative remodeling [39]. Nonetheless, few human cells 
were found in the injection area after few days, while microbead remains were still present 
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within host myocardium 10 weeks after the injection. The aspect of microbead resorption 
should thus be addressed before clinical perspectives could be foreseen. 
c) Scaffold-based technology 
The possibility of using biocompatible scaffolds to deliver stem cells to the injured heart has 
been explored by a number of independent research groups so far. The scaffolds proposed 
are natural of synthetic but when designing cardiac-specific constructs, a number of 
requirements should be fulfilled. For example, it cannot be neglected that myocardial 
contractile function relies on the transmission of electrical and mechanical forces throughout 
a functional syncytium. So, the integrity of the tissue has to be preserved. For this reason, a 
cardiac-specific scaffold should comply with tissue architecture and thus be deformable 
enough to indulge and, if possible sustain cardiac contraction. Moreover, as far as stem cell 
engraftment is concerned, scaffolds should be able to start at least cell alignment and 
commitment to favor stem cell electromechanical coupling with host tissue. In this respect, 
the work of Mandoli and collaborators using Cerium Oxyde nanoparticles to affect poly-
lactic acid film surface and obtain a controlled nanorugosity appears intriguing [40]. In fact, 
far from being a noxious compound for stem cells, ceria was able to induce cardiac stem cell 
alignment and growth. Nonetheless, cardiac tissue is extremely complex and highly 
demanding in terms of blood supply and catabolite removal, so that porous scaffolds that 
could allow microvascular branches formation and oxygen perfusion are to be preferred. To 
fulfill such requirements, the first attempts were performed by the group of Thomas 
Eschenhagen. Neonatal cardiomyocytes were seeded in Collagen I + Matrigel to produce 
Engineered Heart Tissue (EHT). Continuous contractile activity up to 1 week in vitro as well 
as cell survival and integration in vivo in singenic rat hearts were reported [41]. In another 
attempt, anisotropic accordion-like honeycomb scaffolds were prepared by excimer laser 
microablation using poly(glycerol sebacate) as an elastomeric tool to mimic anisotropic 
cardiac muscle stiffness distribution [42]. Although the authors demonstrated that such 
scaffolds promote neonatal rat cardiomyocyte alignment and contraction, in vivo testing has 
not been performed so far. The same material has been utilized to produce elastomeric 
patches on which human embryonic stem cell-derived cardiomyocytes were grown, 
showing that it is indeed possible to observe spontaneous beating activity in vitro up to 3 
months [43]. Such patches were shown to be suitable as delivery systems and, when sutured 
in the absence of cells onto healthy rat left ventricle, they did not affect cardiac contractile 
activity. More basic studies were also conducted to study the ability of stem cells to interface 
with different synthetic and natural materials. In this respect, few research groups focused 
on the possibility to drive a certain extent of stem cell commitment through tailoring 
scaffold physical and chemical properties, independently of biological cues. In this respect, a 
common agreement on the ability of stem cells to sense substrate rugosity and elasticity has 
been reached [44]. Thus, in order to rule out the occurrence of spontaneous events of 
differentiation in implanted cells, the possibility to induce in vitro stem cell commitment on 
scaffolds towards a desired phenotype is being investigated. Indeed, Engler and 
collaborators compellingly demonstrated that the possibility to affect stem cell fate 
determination by simply tuning substrate elasticity as to match tissue-specific stiffness, 
exists. Recently, this concept has been corroborated by other research groups, showing that 
cardiac resident progenitors (Sca-1+ CPC) can be committed to cardiac phenotype by the 
physico-chemical signals arising from matrix, but biological factors are needed to complete 
the differentiation process [45, 46]. 
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d) Preparation of thick cardiac substitutes by Scaffold-free technology  
To overcome the problem of poor cell retention reported in cell injection experiments in the 
heart [30] and avoid the release of possibly harmful scaffold byproducts, scaffold-free 
technology has been developed, in which cells are grown in a monolayer onto thermo-
responsive surfaces and easily detached in the form of cell sheet by lowering the 
temperature [47]. Such technology takes advantage of the ability of polymers like poly-N-
isopropylacrylamide (PNIPAAm) to shift between hydrophobic and hydrophilic status 
when the temperature ranges from 37ºC to 32ºC. Cell sheets can be serially stacked to obtain 
multilayered scaffoldless constructs (Figure 3). Such an approach has already been applied 
to obtain cell sheets composed of rodent [48, 49] and human [50] cells. Given the need for 
thick cardiac substitutes suited to comply with cardiac muscle continuous contractility, 
thermo-responsive technology has been envisaged as a possible answer to the lack of heart 
donors. Pre-clinical trials performed onto experimentally infarcted animals demonstrated 
that when a murine adipose-derived monolayer sheet is leant onto injured myocardium, it 
can be retained and help tissue repair [48]. Similarly, striking results are obtained when a 
Sca-1+ cardiac progenitor cell-derived sheet is used [49]. Finally, an interesting approach has 
been recently proposed to deliver cardiac stem cells cultured in the form of cardiospheres to 
the injured heart: cardiospheres were embedded into a cardiac stromal cell-derived sheet 
obtained by using poly-lysine/ collagen IV-coated dishes [51]. The formation of mature 
vessels as well as new cardiomyocytes in vivo was reported after 3 weeks.  
 
 
Fig. 3. Generation of scaffoldless multilayered bio-constructs by means of thermo-
responsive technology: cells grown in a monolayer onto thermo-responsive poly-N-
isopropilacrylamide (PNIPAAm)-coated dishes can be detached by lowering the 
temperature below 32°C. At 37°C the surface is highly hydrophobic and allows cell 
adhesion. When the temperature is lowered, PNIPAAm becomes hydrophilic, the cell sheet 
is detached and extracellular matrix (ECM) preserved. Multilayered cell sheets can be 
obtained by serially stacking monolayered sheets 
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4. Clinical trials  
In the attempt to transfer bench experience to bedside, a number of clinical trials in which 
different stem cell or progenitor subsets are used have been approved (see 
http://www.clinicaltrials.gov). Most of them are still in the recruitment phase while some 
already gave indications and preliminary results. Since most of the ongoing trials are based 
on the injection of raw stem cell preparations (mostly bone marrow-derived cells), the time 
and route of cell application remain the key problems to be addressed before proceeding to 
routine clinical practice. In this respect, recent animal experiments demonstrated that the 
acute phase of myocardial infarction is probably not suitable for stem cell engraftment and 
differentiation [52]. Therefore, the right moment in which stem cells should be delivered is 
to be studied. An overview on some of the ongoing clinical trials is given below. 
1. MAGIC (Myoblast Autologous Grafting in Ischemic Cardiomyopathy). In one of the 
first phase II clinical trials setup to study the possibility to use stem cells to treat cardiac 
pathologies, ninety-seven (97) patients undergoing coronary artery bypass grafting 
(CABG) were enrolled. 400-800 X 106 autologous myoblasts harvested from patient 
muscle biopsy were implanted in the akinetic area of ventricular wall 21 days after in 
vitro culture. The follow-up after 30 days and 6 months demonstrated the arising of 
arrhythmia events, thus requiring the implantation of pacemaker. Moreover, no cardiac 
function improvement was reported. Such negative results were ascribed to the 
inability of skeletal myoblasts to balance cell death and achieve complete 
electromechanical integration with the recipient myocardium. Finally, skeletal myoblast 
administration was reported to determine no enhancement in major cardiac adverse 
events and mild effects on left ventricular remodeling process [53, 54]. More recently, 
final results from SEISMIC [Safety and Effects of Implanted (Autologous) Skeletal 
Myoblasts (MyoCell) Using an Injection Catheter] Trial, a phase II-a study 
encompassing 40 patients experiencing congestive heart failure and receiving 
percutaneous intramyocardial injection of autologous skeletal myoblasts, reported the 
feasibility and safety of this procedure without significant arrhythmogenic events 
recorded at 6-month follow-up with respect to control groups, although left ventricular 
ejection fraction did not result significantly improve. These encouraging results suggest 
that myoblast cell therapy could be considered as a potential effective treatment when 
associated with standard medical therapy in patients with previously implanted cardiac 
defibrillators [55].   
2. TOPCARE-CHD, -AMI, -DCM (Transplantation of Progenitor Cells and 
Regeneration Enhancement in Acute Myocardial Infarction, Chronic Stable Ischemic 
Heart disease or Dilated Cardiomyopathy). In this complex clinical trial, a total of 346 
patients were classified to CHD, AMI or DCM pathologies and infused either with bone 
marrow cells (BMCs), blood-derived stem cells, or no infusion. In TOPCARE-CHD, 121 
patients (mean age: 59) with chronic stable ischemic heart disease (CHD) were treated. 
Although complications occurred in 21% of the patients during 3 months follow-up, 
BMC intracoronary administration was related with a reduction of both brain and atrial 
natriuretic peptide (NTP) serum levels (indicators of LV remodelling process) in the 
remaining population (79%), especially in patients with higher NTP levels at baseline 
and receiving a greater BMC number with a high functional capacity. Moreover, these 
results were also correlated with a left ventricular ejection fraction (LVEF) increase and 
better survival during the further follow-up, suggesting that cell therapy could be 
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associated with cardiac function enhancements in patients with advanced chronic post-
infarction heart failure [56]. Similarly, two hundred and four (204) patients were treated 
using bone-marrow-derived progenitor cells directly into the infarct artery three to 
seven days after an acute myocardial infarction (AMI). A statistically significant 2.5% 
improvement in left ventricular ejection fraction at four months was reported for 
patients randomized to the bone marrow injection [57]. Finally, intracoronary infusion 
of bone marrow cells was performed in 33 patients with dilated cardiomyopathy 
(DCM) by using an over-the-wire balloon catheter. Three month follow-up 
demonstrated an improvement in left ventricular pump function while a modest 
improvement in Brain Natriuretic Peptide (BNP) levels was reported after 1 year [6]. 
Importantly, the conditions chosen in the present clinical trial were representative of 
different conditions (acute, chronic phase) encountered in the clinic. Unfortunately, no 
clear indication on stem cell characterization or on their actual ability to regenerate 
contractile cells is available.  
3. TRACIA STUDY (Intracoronary Autologous Stem Cell Transplantation in ST 
Elevation Myocardial Infarction). The phase II/ III clinical trial aimed at evaluating the 
effects of intracoronary administration of adult stem cells on LV ejection fraction and 
major adverse cardiovascular events (MACE) after 6 months follow-up. For this reason, 
1-2 million CD34+ cells were injected through the infarct-related artery few days after 
post-infarct angioplasty using an "over-the-wire" catheter in 80 patients aging from 20 
to 75 years. The results of this study are still to be published. 
4. Combined CABG and Stem-Cell Transplantation for Heart Failure. Intramyocardial 
delivery of autologous bone marrow cells extracted from iliac crest and purified by 
Ficoll centrifugation, during cardiac surgery for CABG intervention in 30 patients, as 
compared to 30 patients undergoing CABG without cell infusion. Although information 
on the number and characteristics of cells to be injected has not been given, the trial is 
currently ongoing and the follow-up is scheduled in 6-12 months 
(http://clinicaltrials.gov).  
5. POSEIDON-Pilot Study (The Percutaneous Stem Cell Injection Delivery Effects on 
Neomyogenesis Pilot Study) Poseidon-pilot Study is a phase I/ II multi-center trial in 
which the trans-endocardial injection of autologous Mesenchymal Stem Cells (20-, 100-, 
200 X 106) is compared to autologous non-purified bone marrow cells and to allogeneic 
human Mesenchymal Stem Cells. The implant is performed during cardiac 
catheterization using the Biocardia Helical Infusion Catheter in fifty (50) patients 
suffering from chronic ischemic left ventricular dysfunction secondary to myocardial 
infarction. The data collection is currently ongoing. 
6. SCIPIO (Cardiac Stem Cell Infusion in Patients With Ischemic CardiOmyopathy). 
This phase I clinical trial is aimed at assessing the safety and effectiveness of 
intracoronary autologous cardiac stem cell therapy. As such, forty (40) patients 
suffering from ischemic cardiomyopathy are exposed to intracoronary injection of 
cardiac resident stem cells (CSC). Cardiac stem cells are harvested from right atrial 
appendages and selected for c-kit expression, cultured and expanded in vitro prior to 
injecting them via intracoronary route, three to five months after CABG surgery. The 
hypothesis is that CSC infused into nonviable myocardial segments will regenerate 
infarcted myocardium by differentiating into cardiomyocytes and vascular cells. The 
preliminary results are encouraging: in the nine patients treated at four months after 
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CSC infusion, LVEF increased from 31.3 + 2.5 percent before CSC infusion to 38.8 + 3.2 
percent four months after CSC infusion. Moreover, in the five patients in whom data 
are available at 12 months after stem cell infusion, the improvement in LVEF observed 
at four months was even greater, averaging 15% at 12 months. The follow-up is 
scheduled in 1,5 years. 
7. ALCADIA (AutoLogous Human CArdiac-Derived Stem Cell to Treat Ischemic 
cArdiomyopathy). In this phase I, multicenter clinical trial, a rather different approach 
is followed. In fact, patients’ own cardiac stem cells obtained by endo-myocardial 
biopsies are delivered by a single intramyocardial injection. The cells injected are 0.5 
million cells/kg (patient body weight) and their engraftment should be favored by the 
concomitant implantation of gelatin hydrogel sheet releasing human recombinant beta 
Fibroblast Growth Factor (bFGF), during CABG surgery. The study has been designed 
to treat refractory heart failure, ischemic cardiomyopathy or ventricular dysfunction 
cases. Importantly, this is the first clinical trial, to our knowledge, in which a human 
recombinant growth factor is used. Unfortunately, the number of enrolled patients is 
limited to six (6).  
8. REGEN-IHD (Bone Marrow Derived Adult Stem Cells for Chronic Heart Failure). In 
this phase II/ III study, granulocyte-colony stimulating factor (G-CSF) is 
subcutaneously administered for 5 days to patients with heart failure secondary to 
ischemic heart disease to mobilize CD34+ bone marrow stem cells. A concomitant 
intracoronary  or intramyocardial administration of bone marrow derived stem cells is 
performed. The number of enrolled patients is high (165) and the aim of the study is to 
compare the effects of G-CSF and autologous bone marrow progenitor cell infusion on 
the quality of life and left ventricular function in the patients. The follow-up timepoint 
is scheduled in 6-12 months. 
A number of papers reporting statistical analyses and comparisons among the clinical trials 
in which stem and progenitor cells have been adopted are currently available. [For further 
information, please refer to www.clinicaltrials.gov].  
5. Conclusions 
The possibility to treat cardiac diseases by cell therapy techniques is an extraordinary 
promise. While a number of different approaches has been so far proposed to setup 
minimally invasive techniques for cardiac repair, few of them being already in the clinical 
experimental phase, basic questions still need to be addressed. In fact, the molecular 
processes leading to cardiac differentiation still need to be fully clarified, while the impact of 
novel, genetically modified cell types obtained from adult differentiated cells on cardiac 
microenvironment deserve further investigations. More importantly, the seek to identify 
suitable delivery systems (i.e. scaffolds) able to foster stem cell survival, growth and 
differentiation, while degrading without negative effects as the formation of new tissue 
occurs is still open. A look at the literature reveals that an impressive effort to translate the 
information obtained by in vitro and pre-clinical studies to the bedside is being produced. In 
particular, a number of stem cell subsets, which have been previously tested in vitro and in 
animal models, are currently being tested in phase I, II clinical trials. As expected, the 
predominant delivery system used in the ongoing clinical trials is intracoronary or 
intramural injection of stem cells. The possibility to adopt tissue engineering techniques to 
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design patient-specific cardiac substitutes containing synthetic or natural scaffolds is still far 
from being taken into consideration for clinical application, since any single formulation will 
have to be approved before clinical testing. 
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1. Introduction 
Cardiovascular disease is a major cause of death in the Western World. Novel drugs and 
innovative devices have enhanced the quality of life for patients with cardiovascular 
disease, but such treatments are not without limitations and complications. The major 
constraint with these current treatments is the inability for growth, repair and remodeling of 
the structure. The emergence of tissue engineering as an alternative therapy for 
cardiovascular disease has generated an intensity of research into the development of many 
components of the cardiovascular system, including heart valves, small-calibre vascular 
grafts and biological stent materials. The composition of the biomaterial used as a support 
for the developing cardiovascular structure is a key mediator of cell behaviour and function 
in the tissue, and the ideal scaffold biomaterial for development of a successful end-product 
continues to be a matter of debate. Fibrin, a major structural protein involved in wound 
healing, represents an ideal scaffold for the rapid synthesis of autologous tissue-engineered 
cardiovascular grafts, as its primary scaffold constituents (fibrinogen and thrombin) can be 
isolated directly from a blood sample of the patient requiring the graft. Fibrin gel scaffolds 
offer immediate high cell seeding efficiency and homogenous cell distribution by gelation 
entrapment, and have a degradation rate that can be controlled by protease inhibitors, e.g. 
tranexamic acid or aprotinin. Fibrin is also known to stimulate the secretion of reinforcing 
extracellular matrix (ECM) proteins by seeded cells.  The potential to control the fibrin 
polymerisation process also offers the opportunity to produce complex 3-D structures, like 
heart valve prostheses and to embed porous, textile or metal (stent) structures. This book 
chapter reviews the properties of fibrin that make it an ideal scaffold candidate for 
applications in the area of cardiovascular tissue engineering, and documents the successful 
development of fibrin-based heart valves, vascular grafts and biostents for clinical application.  
2. Scaffold materials 
Scaffolds play a central role in cardiovascular tissue engineering. Essential requirements for 
the ideal cardiovascular scaffold are easy handling properties and the ability to mould 
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complex 3-D structures from the material, such as aortic roots or vessels with complex side 
branches. The scaffold material should neither be toxic, nor elicit any immunological side 
effects. The diffusion barrier of the scaffold material should have the lowest possible 
resistivity in order to guarantee an optimal nutrition supply in thicker tissues. Furthermore, 
both the mechanical and the chemical properties (e.g. the integration of growth factors) of 
the scaffold material should be modifiable. Controllable degradation of the material is also 
important in order to adapt the structural support of the scaffold with regard to the 
developing tissue.  
A multitude of scaffolds are currently employed in the field of tissue engineering, e.g. 
synthetic polymers (polyurethanes, polyglyolic acid, polylactic acid, polyhydroxybutyrate, 
copolymers of lactic and glycolic acids, polyanhydrides, polyorthoesters) and natural 
polymers (chitosan, glycosaminoglycans, collagen), or biological scaffolds such as 
acellularised porcine aortic conduits (Bader et al., 1998; Chevallay & Herbage, 2000; 
Flanagan et al., 2006; Freed et al., 1994; Grande et al., 1997). Scaffold-related problems 
including cytotoxic degradation products, fixed degradation times, limited mechanical 
properties and the absence of growth modulation, etc. necessitate further extensive 
investigations in developing the ideal cardiovascular scaffold.  
3. Fibrin as scaffold material? 
Based on the assumption that successful tissue engineering should mimic the process of 
tissue regeneration, and that regeneration is closely related to haemostatis, fibrin (gel) seems 
to be an ideal candidate as a tissue engineering scaffold by virtue of its role as a 
“physiological scaffold” in tissue regeneration. Several influences of fibrin gel on tissue 
development have been described in the literature: it is known that fibrin gel is one of the 
major ligands for ß3 integrins, which leads to cell migration into a wound/tissue-engineered 
construct (Ikari et al., 2000; Nomura et al., 1999). Thrombin, fibrinogen, fibrin monomers 
and fibrinopepide B all increase DNA synthesis in smooth muscle cells (SMCs) and 
consequently the proliferation of the cell (Pakala et al., 2001). 
3.1 Physiology of fibrin 
Fibrin is the end-product of the coagulation cascade following the conversion of fibrinogen 
in the presence of thrombin and calcium (Figure 1). Fibrinogen is a soluble plasma 
glycoprotein, which is produced by the liver. Fibrinogen is an acute phase protein with a 
normal blood concentration of 1.4 – 3.5 g/l. The fibrinogen molecule has a length of 45 nm, a 
molecular weight of 340 KDa and consists of 2 subunits and 3 polypeptides chains - α, β and 
γ. During the polymerisation process, the fibrinopeptide A of the α-chain and the 
fibrinopeptide B of the ß-chain are cleaved by thrombin. The exposed N-terminal positions 
of the fibrinopeptides bind to the γ-chain of the fibrinogen and produce the so-called 
proteofibrils. In the subsequent step, the lateral association leads to apposition of the 
proteofibrils to form a 3-D fibrin network structure (Meyer, 2004). FXIIIa stabilises fibrin 
further by incorporation of the fibrinolysis receptors, alpha-2-antiplasmin and TAFI 
(thrombin activatable fibrinolysis inhibitor, procarboxypeptidase B), and binding to several 
adhesive proteins of various cells (Muszbek et al., 2008). 
The polymerised fibrin gel matrix is a hydro-gel, which contains ~95-98% water. The water 
content can easily be exchanged against a buffer solution or a cell culture medium, allowing 
an optimal nutrition supply of the cells that are embedded after the gelation process. 
 
Cardiovascular Tissue Engineering Based on Fibrin-Gel-Scaffolds 
 
37 
 
Fig. 1. Coagulation cascade: the conversion of fibrinogen into fibrin is triggered by thrombin 
and calcium 
3.2 Production of autologous fibrin 
The classical approach for production of autologous fibrin is the cryoprecipitation method: 
after the production of platelet-poor plasma (PPP), the plasma is frozen at -80°C and thawed 
overnight at +4°C. The precipitate formed contains ~60-70% of fibrinogen. After 
centrifugation, the supernatant is decanted and the precipitate is subsequently washed twice 
in rinsed water. After the precipitate is dissolved in water, overnight dialysis against 
calcium-free TRIS buffer solution is necessary to provide optimal conditions for the 
embedded cells. 
The cryoprecipitation method has two major disadvantages: (1) the efficiency of fibrinogen 
isolation is relatively low with only ~20-25% of the total fibrinogen content removed, and (2) 
the production process is time-consuming (~2 days). The low isolation efficiency is 
particularly problematic regarding the use of autologous fibrin gel scaffolds in paediatric 
  
Tissue Engineering for Tissue and Organ Regeneration 
 
38 
patients, as the volume of sampled blood needs to be kept to an absolute minimum. 
Therefore, the use of alternative precipitation methods with different chemicals has been 
evaluated: (1) ethanol (Kjaergard et al., 1992; Weis-Fogh, 1988), (2) ammonium sulphate 
alone, and (3) in combination with the cryoprecipitation method (Wolf, 1983), (4) albumin 
plus cryoprecipitation, and (5) polyethylene glycol (PEG) plus cryoprecipitation (Epstein et 
al., 1986). Heselhaus investigated each of these different precipitation methods with regard 
to their efficiency and their use in the development of fibrin scaffold materials for 
cardiovascular applications (Heselhaus, 2011):  
 
 
Fig. 2. [A] Fibrin gel after polymerisation in a 6-well plate. [B-D] Scanning electron 
microscopy (SEM) images demonstrating the nano-fibre network structure of the fibrin, 
which enables the gentle embedding of cells, with a vascular smooth muscle cell (SMC) 
shown in [D] immediately after the gelation of the fibrin within a web-like network 
surrounded by cell culture medium 
Figure 3 demonstrates that all of the reported alternative methods are more efficient than 
the standard cryoprecipitation method. Here, the technique using ethanol as the 
precipitation reagent is observed as the most efficient method, with an isolation efficiency of 
~80%, ~4-times higher than the efficiency of the standard method. The technique applying 
both albumin and cryoprecipitation indicates a false positive high result due to 
contamination of the precipitate with albumin (shown by a significant band in SDS gel 
electrophoreses) (Heselhaus, 2011).  
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Fig. 3. Comparison of different precipitation methods for the isolation of fibrinogen (Cryo – 
cryoprecipitation; EtOH – ethanol; A.-S. – ammonium sulphate; Alb.–albumin;  
PEG – polyethylene glycol) 
3.3 Control of scaffold degradation (aprotinin vs. tranexamic acid) 
In nature, fibrin production and fibrinolysis are finely balanced. Figure 4 demonstrates the 
process of fibrinolysis induced by plasmin and the role of different regulatory factors, which 
stimulate and inhibit the fibrinolysis, respectively. 
In the context of in vitro cultivation, both of these processes are restricted by the limited 
concentration of substrates. This offers the opportunity to adapt the degradation of the 
fibrin scaffold material to the individual need during the tissue maturation process. Until 
recently, the most commonly used substrate to control the degradation of fibrin gel was 
aprotinin with a concentration of 130 K.I.U. per mL medium (Ye et al., 2000). Aprotinin is a 
polypeptide serine protease inhibitor, which stops fibrinolysis by inhibiting kallikrein, 
plasmin and platelet-activation factors. Aprotinin was used as anti-fibrinolyticum for many 
years in the clinic, but negative side-effects in the post-operative recovery phase of 
cardiothoracic patients led to the suspension of aprotinin in the worldwide market.  
Therefore, tranexamic acid (trans-4-aminomethely-cyclohexane-1-carboxylic acid; tAMCA) 
was evaluated as alternative drug to control fibrin gel degradation in vitro and as far as 
possible in vivo. Tranexamic acid is clinically approved and competitively inhibits the 
conversion of plasminogen into plasmin via reversibly binding to the lysine-binding site on 
plasminogen.  
Cholewinski et al. (2009) demonstrated that tranexamic acid at a concentration of 160 mg per 
mL medium has a comparable inhibition effect on fibrinolysis in comparison with aprotinin. 
Furthermore, no negative side-effects with regard to proliferation, apoptosis, necrosis or the 
burst strength of the produced fibrin gel scaffolds could be demonstrated (Cholewinski et 
al., 2009). 
  
Tissue Engineering for Tissue and Organ Regeneration 
 
40 
 
Fig. 4. Balance between fibrin production and fibrinolyis ( →positive and --| negative effect) 
3.4 Fibrin as autologous growth factor delivery system (PDGF) 
The autologous source of fibrin, whole blood, contains a number of important growth 
factors. One major growth factor is the platelet-derived growth factor (PDGF), a cytokine 
produced in megacaryocytes and stored in the α-granules (Cianciolo et al., 1999; Ross et al., 
1986). PDGF has been described as one particular factor that positively influences 
proliferation, migration and ECM secretion of fibroblasts and SMCs (Claesson-Welsh, 1996). 
PDGF is released in conjunction with the platelet release reaction (Witte et al., 1978). Platelet 
activation induces the release of a variety of low-molecular weight growth factors and more 
than 60 of these growth factors are directly involved in tissue repair mechanisms such as 
chemotaxis, cell proliferation, angiogenesis, ECM deposition and remodelling (Borzini & 
Mazzucco, 2007). Platelets are easily isolated from blood, and can be concentrated in a low 
volume of plasma known as platelet-rich plasma (PRP). Thus, PRP is a storage vehicle for 
platelet growth factors. In addition to the abundant mixture of growth factors, PRP also 
contains proteins known to act as cell adhesion molecules and matrix for bone, connective 
tissue and epithelial migration, namely fibrin, fibronectin and vitronectin (Marx, 2004). 
PRP can be used as a fibrin-based scaffold material by inducing gel polymerisation. The use 
of PRP as an autologous scaffold material and growth factor delivery vehicle has attracted 
the attention of researchers in the field of tissue engineering as a new possibility to optimise 
the composition of the “ideal” autologous scaffold.  
To further optimise fibrin gel scaffolds, the use of PRP as a basis for autologous gel scaffolds 
instead of platelet-poor plasma (PPP) or pure fibrinogen solution has been evaluated. It was 
postulated that the use of PRP in contrast to PPP or fibrinogen solution as a basis for human 
autologous fibrin gels leads to an increased release of autologous PDGF-AB, which may 
have a consequent positive effect on tissue development. Therefore, a protocol for plasma 
preparation and subsequent plasma gel production was developed and the release kinetics 
of PDGF-AB from autologous plasma gels were investigated. Wirz and colleagues (2011) 
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analysed (i) the concentration of PDGF-AB in the PRP vs. PPP during gel preparation, (ii) 
the influence of plasma gels and particularly PDGF-AB (autologous and recombinant) on 
growth behaviour and cell proliferation, and (iii) the secretion of ECM by human umbilical 
cord artery smooth muscle cells (HUASMCs) in both plasma-based and pure fibrin gels. The 
study demonstrated that the use of PPP leads to almost complete loss of PDGF, whereas the 
use of PRP in combination with a concentration step (by a factor of two) retains almost 
serum levels of PDGF. The subsequent steps in the protocol allow the removal of all 
platelets without losing the PDGF in the concentrate (Wirz et al., 2011).  
But is the absence of platelets in the fibrin-based scaffolds good or not? To answer this 
question, Wirz et al. compared PDGF release from such fibrin-based scaffolds with and 
without incorporated platelets. Whereas the release of PDGF of platelet-rich and platelet-
free fibrin gels were similar during the first 3 days, the platelet-rich gels showed a 
significantly higher level of PDGF in the supernatant after the first medium exchange, 
indicating that the platelets with the α-granules continue to work as a ‘natural’ reservoir of 
the growth factor PDGF (Wirz et al., 2011). 
Nevertheless, against all expectations, the significantly higher level of PDGF-AB in fibrin 
gels was shown to have neither a significant influence on cell proliferation nor on the ECM 
synthesis of vascular SMCs. Although the vascular SMCs are the basic cell source for 
cardiovascular tissue engineering, these cells do not express the receptor for PDGF-A and 
lose the receptor for PDGF-B at a very early stage of in vitro primary cell culture (P0 to P4) 
(Wirz et al., 2011). Therefore, PDGF-rich fibrin gels may ultimately have a positive effect on 
fibroblasts and mesenchymal stem cells, for example, but not on primary vascular SMCs. 
 
 
Fig. 5. PDGF-AB release of platelet poor plasma (PPP), platelet rich plasma (PRP) before and 
after cryoprecipitation, after concentration of the plasma volume (by a factor of two), and 
after sterile filtration process (0.22µm filter) 
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4. Examples of fibrin-based cardiovascular tissue engineering 
4.1 Heart valve 
The principles of fibrin-based cardiovascular tissue engineering can be demonstrated using 
the example of a completely autologous heart valve prosthesis as shown in Figure 6 
(Jockenhoevel et al., 2001b). For paediatric application, the umbilical cord is the optimal cell 
source. The umbilical cord contains the myofibroblasts/vascular SMCs, which are 
responsible for the structural and mechanical stability of the neo-tissue. Furthermore, the 
endothelial cells of the umbilical cord vein are an ideal cell source for the luminal coating of 
cardiovascular structures. The endothelial cells are mainly responsible for the 
haemocompatibility of the tissue-engineered graft. The third component of the umbilical 
cord that is applicable to tissue engineering is the blood, from which the compounds for 
autologous fibrin-gel synthesis can be extracted. 
 
 
Fig. 6. Principles of fibrin-based tissue engineering using the example of a completely 
autologous heart valve prosthesis 
Based on clinical imaging methods such as echocardiography, it is possible to manufacture a 
mould that is customised for the individual. This allows the surgical correction of complex 
congenital heart defects with a shape-optimised implant.  
The production of the basic heart valve structure is realised using an injection moulding 
technique: at the outset, the first of two essential components is produced, and consists of 
myofibroblasts suspended in a buffer solution that is supplemented with calcium and 
thrombin. The second component consists of the autologous fibrinogen solution. With a 2-
piston-dual syringe system, both components are injected into the customised mould, which 
consists of a negative and positive stamp. The gelation process begins immediately and 
homogenously entraps the myofibroblasts in the fibrin gel. After the gel polymerisation is 
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complete, the newly moulded heart valve conduit is decast from the mould and transferred 
into a bioreactor system. A suitable nutrition supply and biomechanical stimulation are 
essential for the maturation of these tissue-engineered structures, as they are too fragile at 
the outset for direct implantation (Flanagan et al., 2007).  
After preconditioning in the bioreactor system, the mechanically stable heart valve 
prosthesis has been developed. The lining of the luminal surface with autologous 
endothelial cells is the final production step and is important for complete immunological 
integrity and physiological haemostasis. At the end of the production chain, a completely 
autologous heart valve implant is realised, which has the ability to withstand the mechanical 
properties in the low pressure/pulmonary circulation, as demonstrated previously 
(Flanagan et al., 2009). 
4.2 Vascular graft 
Autologous vascular grafts based on a fibrin scaffold have also been developed for 
applications in a number of settings, including coronary artery and peripheral artery bypass 
procedures, arteriovenous access grafts for haemodialysis patients, or in the paediatric 
setting for congenital pulmonary artery reconstruction. Fibrin alone does not possess 
sufficient mechanical properties for direct implantation into the high pressure setting of 
small-calibre arteries (< 6 mm); therefore, the fibrin-based grafts are supported by a 
bioabsorbable, macroporous mesh (poly(L/D)lactide 96/4; PLA) with a controlled 
degradation profile, which acts as a temporary supporting system upon implantation until 
the implanted cells have remodelled the fibrin matrix into an autologous tissue (Tschoeke et 
al., 2009). 
 
 
Fig. 7. Bioresorbable, macroporous mesh with a pore size of ~ 1mm before [A] and after [B] 
the embedding into the fibrin/cell matrix. [C] Fibrin-based vascular graft after implantation 
in the arterial circulation (ovine carotid model) 
The synthesis of the fibrin-based vascular graft is based on similar principles to those used 
in developing the autologous fibrin-based heart valve (i.e. injection moulding technique). 
Once the vascular grafts are constructed in a tubular mould, however, the mould acts as the 
bioreactor system and is connected to a flow support that imparts pulsatile luminal flow to 
the graft. We have shown for the first time that fibrin-based vascular grafts attain a 
supraphysiological burst strength sufficient for arterial implantation after just 21 days of 
mechanical conditioning in such a bioreactor system (Tschoeke et al., 2008). We followed up 
this report with a preclinical study in a large animal model, which presented data on the 
first series of fibrin-based grafts to be implanted in the arterial circulation (ovine carotid 
model) (Koch et al., 2010). In this model, the grafts showed no evidence for thrombus 
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formation, aneurysm, calcification or infection, and remained patent for at least 6 months in 
vivo. The grafts maintained a functional endothelial lining in vivo, and the fibrin-based 
scaffold was completely replaced by autologous connective tissue elements (e.g. collagen, 
elastin) after 6 months of implantation (Koch et al., 2010).  
4.3 BioStent 
During recent years, percutaneous stent angioplasty has become well established in the 
treatment of peripheral and coronary atherosclerosis. Nevertheless, the patency rates in 
small-calibre vessels, particularly those of the femoral and femoropopliteal region, are not 
satisfactory (Cejna et al., 2001; Grenacher et al., 2004; Schillinger et al., 2006).The incessant 
problem of instent restenosis is a result of: (1) the proliferation stimulus resulting from the 
pressure trauma of stent implantation (>10 bar in non-self-expanding stents), which leads to 
(2) an ingrowth of myofibroblasts through the gap of the stent structure, and (3) an 
increased production of ECM proteins; (4) finally, acute thrombotic occlusion can occur in 
the stented segment of the vessel. Occlusion rates of more than 20% after 6 months could be 
overcome with a viable stent prosthesis that includes a confluent, functionally active 
endothelial cell layer from the outset. 
 
 
Fig. 8. Concept of the BioStent [A]: the knitted, self-expanding Nitinol-Stent [B] is embedded 
into a fibrin-cell matrix [C] and can be deployed without tissue destruction [D]. H&E 
staining demonstrates a complete coating of the Nitinol stent structure with viable tissue [E] 
The BioStent concept merges the principles of self-expanding stent technology with those of 
vascular tissue engineering: the moulding process of vascular grafts based on a fibrin gel 
scaffold allows the complete integration of a self-expanding stent structure within the tissue-
engineered vessel. This process leads to a complete exclusion of the atherosclerotic section of 
the vessel from the blood stream on the one hand, and coating of the neo-lumen with a 
functional endothelial cell layer on the other hand (Figure 8).   
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The BioStent concept is a platform technology, i.e. by applying different cell types, a number 
of alternative therapies can be addressed, including (1) endobronchial stenting using 
respiratory epithelium, (2) oesophageal stenting using mucosa cells, or (3) urological 
stenting using urothelial cells, etc.  
5. Summary 
In our opinion, fibrin gel combines a number of important properties of an ideal scaffold for 
cardiovascular tissue engineering:  
• Fibrin gel is a naturally-occurring scaffold that can be isolated as an autologous 
substrate from blood of the patient in question (Heselhaus, 2011); 
• Starting with a cell suspension in fibrinogen solution, fibrin gel scaffolds offer 
immediate high cell seeding efficiency and homogenous cell distribution by gelation 
entrapment, with a minimal loss of cells during the seeding procedure; furthermore, 
there is no time-consuming cell ingrowth from the scaffold surface to the deeper parts 
of the scaffold (Jockenhoevel et al., 2001a);  
• Polymerisation as well as degradation of the fibrin gel is controllable and can be 
adapted to tissue development through the use of the protease inhibitors, such as  
aprotinin and tranexamic acid (Cholewinski et al., 2009); 
• Local, covalent immobilisation of different growth factors is possible, while PRP gels 
can be developed to enhance the content and delivery of growth factors (Wirz et al., 
2011); 
• Production of complex 3-D structures such as heart valve conduits or vascular grafts 
with complex side branches is possible through the use of an injection moulding 
technique (Flanagan et al., 2007; Jockenhoevel et al., 2001b); 
• Textile-reinforced fibrin-based grafts can be implanted in the arterial circulation and 
function for at least 6 months in vivo (Koch et al., 2010); 
• Fibrin-based tissue engineering can be merged with self-expanding stents to create a 
platform technology for cardiovascular, and other, diseases. 
These properties highlight the significant potential for creation of functional, autologous 
implantable cardiovascular prostheses in future using tissues derived from the patient. 
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1. Introduction 
Organ transplantation is a lifesaving procedure, yet the demand for transplants far exceeds 
the available supply. Each year, nearly seven thousand patients in the United States die 
while waiting for an organ transplant [1]. Developing heart muscles in vitro for 
transplantation [3] [4] is one approach that could ultimately overcome this critical shortage. 
For complex tissues such as a heart muscle, the final product has to mimic physiological 
functions as well as the regulatory system for regenerating the recipient’s tissue functions. 
Successful development of implantable and functional engineered tissues is currently  
hindered by the time-consuming and cost-intensive processes through which developers 
iteratively work to optimize tissue-fabrication protocols, needing to establish proper culture 
conditions and the ideal quantities of materials used. To overcome these burdens, it is 
critical to establish a prototyping process by which the developers can explore many 
parameters rapidly using minimal resources. To achieve this goal, 1) the prototypes of 
engineered tissues have to be small enough to save materials, including cells, extracellular 
matrices and growth factors that are necessary for the in vitro heart tissue development, and 
2) the assay system to evaluate the heart tissue function has to be automated for rapid high-
throughput analysis of prototyping results. In addition, a stable source of cells must be 
carefully selected to maintain the reproducibility of tissue production while scaling up the 
manufacturing capability.  
2. Miniaturizing biological samples and products   
Size of engineered tissue (ET) varies based on research needs. To systematically screen and 
analyze a large number of parameters that determine tissue function, the size of ETs has to 
be defined based on  the required throughputs and phenotying assays for the tissue function 
analysis. Fully-grown cardiac muscle cells in three dimensional matrices are at least 100 um 
in length along their longitudinal axis [5]. Therefore, engineered heart tissues (EHTs) should 
be at least several times larger than the size of single cells in order to form multi-cellular 
functional cardiac muscles. In addition, the statistical significance of data improves 
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significantly when using multi-cellular tissues rather than single cells [6] because the tissue 
samples contain from tens of thousands to over a million cells. The functional assay data 
collected using tissues represents an average function of many cells embedded in the tissues. 
By applying the photolithographical techniques, smaller, micro-scale (50-200 um) 
engineered tissues can be fabricated [7] to mimic intricate shapes of native tissues. However, 
in these micro-scale tissues, it is yet to be determined if there is an improvement of the 
statistical significance of functional data over that from single cells. At present, ETs in 
millimeter scale have been used for the functional assays with relatively good data 
reproducibility [8] [9]. By using ETs, a statistically significant data can be obtained using 
only 4-8 samples [9] instead of collecting ranging 60-600 data points per well in cell-based 
assays [10].  
Unlike the rapid prototyping of parts with synthetic materials, the prototyping of 
engineered tissues with live cells has to consider the behavior of tissues after fabrication in a 
given culture condition. Cells are a vital element of developing functional organs and 
tissues. While consuming nutrients and receiving extracellular stimuli, the cells synthesize, 
secrete, and degrade proteins, divide, and remodel tissues. Therefore, developers of 
engineered tissue have to take these aspects into account for the design and development of 
engineered tissue samples and products. Behaviors of cells have been studied extensively to 
understand the molecular mechanisms by which biological functions of cell are regulated 
[11]. Because the cell behavior should underlie function of tissues and organs, the vast 
amount of information that has been accumulated through studies of cells should be used to 
understand tissue and organ function. However, some recent findings indicate that biology 
of cells cultured in two dimension (2D) is not entirely the same as that of cells cultured in a 
three dimensional (3D) environment, which is more similar to the in vivo environment in 
which cells reside.   
3. 2D vs 3D cell based analysis   
Even though cells cultured on a 2D surface have been assumed to closely resemble those 
in tissues and organs, in some aspects they are quite different from those found in vivo. In 
vivo, most cells are found embedded within a 3D extracellular matrix (ECM), and their 
shape and cell-ECM adhesion are different from those in 2D culture [12]. In most 2D cell 
culture, cells are cultured on infinitely stiff solids. However, in 3D culture, the ECM in 
which native cells reside can be deformed, stiffened, softened, or degraded to change the 
mechanics of the tissue. Stem cell linage specification has been observed to be directed by 
matrix stiffness [13], which strongly suggests that mechanical signaling will play a pivotal 
role in developing physiologically functional and implantable tissues. A difference in 
mechanical signal transduction between a 2D and a 3D environment was also suggested 
[14]. For instance, fibroblasts cultured in 3D have intrinsically lower expression levels of 
the small GPTase Rac than those in 2D cultured cells, which switches the migratory 
pattern of cells from random to persistent [15]. Reduction of the activity of focal adhesion 
kinase (FAK) and ERK1/2 in 3D culture, as compared to 2D cultures, has also been 
reported [12]. There is significant concern over the biological differences observed 
between 2D cell-culture systems, which have been used to study almost all signal 
transduction pathways to date [16], and the arguably more physiological 3D cell-culture 
environment.  
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When testing mechanical signaling, the tissues are subjected to mechanical deformations 
including pushing and stretching. An application of cyclic mechanical stretch to cardiac 
myocytes and fibroblasts up-regulates various signal transduction pathways through 
Rho/ROCK activation [17, 18]. Activation of extracellular signal-regulated kinases (ERKs) 
and up-regulation of an immediate early gene family of transcription factors, and c-fos [19] 
are well-characterized early responses of cells to the stretching. Up-regulated cellular 
processes including protein synthesis [20] and myofibril organization [21] are also apparent. 
The Rho/ROCK signaling pathway also regulates a hypertrophic response in cultured 
cardiac myocytes after application of soluble factors such as endothelin-1 treatment [22]. 
Therefore, an intricate balance orchestrated by soluble stimuli, mechanical deformation, and 
extracellular stiffness dictates the tissue development. 
The tissue can function normally under homeostasis, at which the mechanical balance 
between extra- and intra-cellular activities is balanced. The homeostasis can be shifted by 
aging or other long term processes but is a quasi-steady state that is required for a tissue’s 
physiological function. For example, physiological wound healing restores the homeostasis 
in the granulation tissue – fibrous connective tissue of healing wounds – by active 
fibroblasts contracting open wounds, secreting factors and hormones, and degrading ECMs 
to reconstruct the damaged tissues [23]. Pathological wound healing, such as keloids and 
scars in skin [24], fails to restore the homeostasis. A schematic description of potential 
network system is in shown in Figure 1. Intracellular molecular sensors, such as the src 
family kinase substrate p130Cas [25], detect the stiffness of extracellular environment to 
initiate its down-stream signaling events including Ca2+ release, kinase activity, and gene 
regulation. Expressions of various genes are up-regulated through translocation of 
transcription factors from cytoplasm into nucleus. Furthermore the gene expression can be 
coupled to cell contraction. For instance, during the formation of actin stress-fibers in 
contracting fibroblasts, the balance of actin pools is shifted from a high prevalence of the 
monomer state to increased polymer levels. This balance shift frees up myocardin-related 
transcription factors (MRTF)-A, which are bound to monomer actins, and the unbound 
MRTF-As translocate into nucleus to promote gene expression. Therefore, MRTF-A’s 
downstream up-regulation of wound healing gene-family including collagen type I a1 is 
tightly coupled to the state of actin polymerization (F- and G- actin ratio) in fibroblasts 
[26].  
In parallel with changing the mechanical environment, the soluble factors, such as TGF β1, 
binding to their specific receptors initiate the similar downstream signaling events [27, 28]. 
Depending on the signaling pathways, the initial signal strength can be amplified. One of 
recent observations indicates that signal strength is amplified in three-tiered kinase module 
of Raf-MEK(mitogen-activated protein kinase or extracellular signal-regulated kinase 
kinase)-ERK (extracellular signal-regulated kinase) by increasing concentrations of kinases 
involving in downstream (e.g., 1:3:6 = raf-1:MEK:ERK) in COS cells [29]. The soluble and 
mechanical stimuli result in the development of contractility by actin-myosin interactions, 
which is one of end-points of the signaling pathways. We hypothesize that the activities of 
actin-myosin interactions is a part of feedback mechanism by which cells sense the 
strength of mechanical stimuli and stiffness of extracellular space [30]. Integrin-linked 
kinase and ECM protein, tenascin-C, have been demonstrated to be a part of the 
mechanical sensory systems in zebrafish heart [31], skeletal muscles [32], and fibroblasts 
[33]. 
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Fig. 1. Regulation of Mechanical Tissue Homeostasis Establishment  
As demonstrated elegantly for p130Cas [25], a simple analogy of the biological sensory 
mechanism is represented as a mechanical strain gauge that measures applied forces by 
detecting small deformations of proteins. Depending on an elastic strength of the gauge 
(i.e., protein), its sensitivity can be varied. In general the sensitivity becomes higher by 
reducing the elasticity of the gauge material since it can deform more with a same applied 
force. We and others [18] assume that the molecular strain gauges are coupled to the 
actin-myosin forming stress fibers whose elasticity or stiffness is modulated by activity of 
myosin. The receptor activation initiated by binding of various soluble factors triggers and 
modulates myosin activity. Therefore, the sensitivity of the mechanical sensor can be 
modulated. Eventually the mechanical properties of cell and extracellular matrix reach a 
steady state to find homeostasis. However, its specific mechanism by which sensors can 
modulate their sensitivity and determination of the homeostasis are yet to be elucidated. 
Nevertheless, the concept of the establishment of homeostasis between the cells and ECM 
comprising “tissue” should be considered carefully while designing and developing the 
functional tissues in vitro. The mechanical properties of engineered tissues have to match 
with donor tissues, especially for those carrying critical mechanical functions including the 
cardiovascular system. As described, varying stiffness of the extracellular environment takes 
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part in dictating stem cell fates [34]. Rapid high throughput tissue phenotyping can be used 
to test various soluble and mechanical stimuli to yield an optimal tissue with desired 
functions. 
4. Cardiac tissue phenotyping and their potential to assay-automation 
The assay system by which developers can evaluate the functional improvement that results 
from optimizing the tissue fabrication and culture conditions will have to accurately observe 
the physiological functions of cardiac tissues. The contractility of cardiac tissues is the most 
fundamental functional readout that can indicate the functional improvement by varying 
the tissue fabrication conditions. The regulatory system of cardiac contractility should also 
be reconstituted in the engineered tissues, which will be evaluated through rapid 
prototyping. As listed in Table 1, EHT-based contractility assessment is ideal for assessing 
cardiac functions in high-throughput, as compared to the other techniques that have 
traditionally been used to assess the function of myocytes, myocardium, and isolated hearts. 
Each method has its own advantages and disadvantages. The assay results using isolated 
adult cells and papillary muscles will continue to serve as references for the expected muscle 
cell and tissue contractility and its regulation. However, they can not report the tissue 
functions. Cardiac contractility assays using isolated Langendorff preparation has been 
gradually replaced by hemodynamic measurements using pressure-volume conductance 
catheters [35] as well as echo cardiography. Nevertheless, the whole heart functional 
assay can be used to assess functional improvement that results from the tissue 
transplantation. 
 
  Engineered 
Heart Tissues 
Isolated Adult 
Cells 
Papillary 
Muscles 
Langendorff 
Preps 
Sample viability period Weeks to months ~6 hrs ~6-8 hrs ~8 hrs 
Contractility 
measurements with 
preload. 
Yes (various) No * Yes (various) Yes (various, 
PV loop) 
Optical assessment of 
live cells 
Yes (easy) Yes (easy) Yes (not easy) No (generally) 
High throughput 
testing 
Yes Yes No No 
Sample damage by 
isolation 
No Yes Yes Yes 
Comments Reconstituted 
system 
High data 
variance 
 Widely used 
standards. 
* Isolated adult cells can be stretched by carbon fiber techniques [2]. High throughput measurements 
and range of stretching are limited.  
Table 1. Comparison of methods for measuring cardiac contractility in vitro 
Once the EHTs start contracting, they maintain contractility for at least 2-3 weeks. 
Assessment of acute and chronic changes in contractility and cell physiology can thus be 
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monitored for long periods using EHTs. Even though EHTs are artificially reconstituted 
organoids, their histological structure and functional properties are similar to those in 
native myocardium [5, 36]. Each EHT is fabricated by pouring a gel solution containing 
predefined concentrations of cells, matrix proteins, and growth factors into a precisely 
machined well [5]. Since 1993, similar engineered tissues have been used as a model 
system to study signal transduction pathways that regulate contractility of fibroblasts 
[37], smooth muscle cells, skeletal muscle cells [8]. We were the first to introduce the use 
of tissue models to determine effective drug doses [38] and have recently extended the 
application of this technology to include phenotypic screening [39]. We demonstrated the 
phenotypic difference in tissue mechanics between wildtype cells and mutant cells with 
truncated α1 integrin [40]. We also extended the applications of engineered tissue models 
by creating cardiac tissue constructs [41]. Recently, we introduced the concept of growing 
mini-tissues in 96-well plates for high-throughput drug screening [42]. Initially 
engineered heart tissues were fabricated using a tissue fabrication mold that cast hydrogel 
into a ring [5]. To miniaturize the tissues, we developed tissue fabrication wells similar to 
those used in 96-well format. The center-to-center distance of 96-well plates is 9 
millimeters. We developed 8mm x 8mm square wells to fabricate the engineered tissues. 
We demonstrated the automation of contractile measurements of EHTs to improve the 
productivity of the proposed studies. The generation of EHTs using pluripotent stem cells 
will open up the new pathways to develop engineered tissues using human cells. 
However, there are several issues that need to be solved before benefitting highly 
promising technology.  
5. Multi cell types require functional cardiac patches using iPSCs 
Human iPSCs, which are generated by genetic reprogramming of somatic cells to an 
infinitely self-renewing pluripotent state [43, 44], offer an excellent source for robust 
generation of large numbers of human cardiac myocytes (CMs), endothelial cells (ECs) and 
fibroblasts (FBs), which are all needed for producing a vital EHT in vitro [45]. Protocols to 
generate somatic cells from hPSCs typically attempt to recapitulate cardiac development in 
an accelerated manner by temporal application of differentiation cues[45]. For example 
directed differentiation protocols that achieve high yield and purity of CMs from human 
pluripotent stem cells apply basic FGF, TGFβ superfamily ligands, VEGF, and Wnt agonists 
and antagonists at precise differentiation stages [46, 47]. Recently CMs generated from 
human embryonic stem cells (hESCs) have been injected into rodent cardiac muscle; these 
CMs engrafted, survived, and resulted in functional improvement in myocardial infarction 
models [47];[48]. HESC-derived CMs and ECs assembled into spontaneously contracting 
patches and, when implanted on a rodent pericardium, survived and anastomosed [45]. This 
study clearly indicates that multiple cell types are necessary in generating functional cardiac 
patches.  
Because of the requirement of multi cell types to fabricate functional cardiac patches, the 
high throughput rapid prototyping system can contribute to identifying the optimal 
combination of cell types to fabricate the best cardiac patches. Not only varying the number 
of CMs, ECs, and FBs to initiate the fabrication, the response to each cell type to various 
hormones, growth factors, and mechanical environment will have to be screened again to 
find the best combinations. Therefore, a rapid prototyping system that can screen various 
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test conditions will be critically needed to establish functional tissues with desired 
phenotypes.   
6. Summary 
Systematically optimizing a tissue-fabrication protocol will require an iterative process of 
changing the parameters of fabrication and tissue culture conditions incrementally after 
measuring the resulting functional improvement. To test a large number of these parameters 
to the best outcome, many tissues have to be fabricated and their function has to be 
evaluated in high-throughput. To achieve this prototyping cost-effectively, the samples have 
to be miniaturized. Most importantly, establishing the tissue homeostasis in the engineered 
tissue has to be achieved either before implantation or by taking account how tissue 
homeostasis will be established with the acceptor’s existing tissue. In vivo tissue organ 
phenotyping with transplanted tissues will be as important as availability of rapid 
prototyping of engineered tissues.  
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Tissue Engineering of Skeletal Muscle 
Klumpp Dorothee, Horch Raymund E. and Beier Justus P. 
Department of Plastic and Hand Surgery, University Hospital of Erlangen-Nürnberg 
Germany 
1. Introduction 
1.1 Has Churchill been right? 
“Fifty years hence, we shall escape the absurdity of growing a whole chicken in order to eat the breast 
or wing, by growing these parts separately under a suitable medium”  (Churchill 1932) 
In 1932, Sir Winston Churchill predicted that it will be possible in future to grow and 
engineer muscle tissue in vitro. As a confirmation of his prediction, Vandenburgh et al. 
observed contracting muscle tissue engineered in vitro for the first time in 1988 
(Vandenburgh, H.H. et al. 1988). Only one year later – in 1989 – the group showed that 
mechanical stimulation of embrionic myoblasts in vitro facilitates longitudinal growth of 
engineered skeletal muscle tissue (Vandenburgh, H.H. & Karlisch 1989). This rapid 
development raised high expectations for future clinical applications of tissue engineering 
(TE) of skeletal muscle. Indeed, engineered muscle tissue could be used in a wide range of 
clinical situations.  
A frequent clinical application of skeletal muscle tissue is the microsurgical transfer of 
myocutaneous free flaps for the coverage of soft tissue defects. As one major disadvantage, 
the use of free flaps is inevitably linked with a certain morbidity at the donor site including 
the loss of functional muscle tissue. In this situation, engineered muscle tissue could help to 
reduce the donor site morbidity. Above all, the advantage of muscle TE lies in the 
generation of functioning muscle tissue to replace certain muscles after damage or 
denervation (Klumpp et al. 2010). For example, the treatment of facial nerve palsy is 
momentarily limited to the transfer of autologous muscle tissue innervated by another nerve 
(the trigeminus nerve, e.g.) or free transfer of distant muscle tissue (Terzis & Konofaos 2008). 
Though multiple techniques and modifications exist, the results yielded in those clinical 
situations are moderate (Kumar & Hassan 2002, Terzis & Noah 1997). Furthermore, Kim et al 
demonstrated that myoblast transplantation is a promising method for the reconstruction 
after partial glossectomy (Kim, J. et al. 2003). Herein, TE of skeletal muscle for the 
replacement of functional muscle tissue could offer an individual alternative.  
However, a clinical application of skeletal muscle TE has not been realized to date due to 
certain obstacles which will be discussed in the following. Though, in vitro engineered tissue 
of skeletal muscle could already play an important role for the clinical treatment of inborn 
muscle diseases as well as muscle injuries. Once again, Vandenburgh and co-workers 
engineered dystrophic muscle tissue using it as drug screening platform for Duchenne 
muscular dystrophy (DMD) treatment (Vandenburgh, H. et al. 2009). Thus, a wide range of 
possible drugs can be analyzed without using time-consuming and costly in vivo models 
(Vandenburgh, H.). Vandenburgh’s study demonstrates an economic approach for drug 
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screening in general and orphan drugs in particular. Beside the relatively rare 
musculoskeletal disorders, engineered skeletal muscle also enables the analysis of more 
frequent diseases. Kaji et al introduced an in vitro model of electrically stimulated and 
contracting muscle tissue to analyze the insulin- and exercise-dependant glucose uptake 
which plays a role in insulin resistance of type 2 diabetics (Kaji et al.). Thus, skeletal muscle 
TE already plays a role for clinical treatments, though a direct bench-to-bedside approach 
has yet to become reality. 
 
 
Fig. 1. Skeletal muscle precursor cells (myoblasts) in vitro. Immunofluorescent staining for 
desmin (green) an intermediate filament specifically expressed in myogenic differentiation 
prior to the formation of myotubes and fusion into muscle fibers. Nuclei are stained non-
specifically with DAPI (Diamidine-phenylindole-dihydrochloride; blue). Magnification 400x 
2. Finding the matrix for muscle TE 
2.1 Materials 
A variety of materials has been analyzed and reviewed regarding their suitability for 
skeletal muscle TE. On one side, natural materials like collagen I in the first place are 
preferred due to their biocompatibility and their close resemblance to the natural 
extracellular matrix (ECM). On the other side, synthetic materials generally show greater 
stability as well as cost-saving and easy handling.  
Regarding collagen I - the main component of the natural ECM of mature skeletal muscle 
tissue - its advantage lies in high elasticity which is a pre-requisite for muscle contraction. 
Thus, its mechanical properties in vivo meet the demands for new skeletal muscle tissue 
perfectly. Furthermore, bovine as well as avian collagen show very low immunogenicity in 
vitro and can be safely used in vivo (Peng et al. 2010). Therefore, collagen sponges and gels 
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have been studied in vitro (Madaghiele et al. 2008) and in vivo (Kroehne et al. 2008). 
However, the rapid shrinkage of hydrogels in vitro as well as the low stability of collagen I 
are important disadvantages (Beier et al. 2009) and limit its use in long-term experiments. 
Another material frequently used for tissue engineering in vitro and in vivo is fibrin. The 
stability of fibrin gel is dependent on the concentration of fibrinogen and thrombin and can 
be augmented by addition of aprotinin which inhibits fibrinolysis (Meinhart et al. 1999). In 
addition, fibrin is known to accelerate vessel ingrowth into the matrix in vivo due to its 
binding sites for vascular endothelial growth factors (VEGF), fibroblast growth factor (FGF-
2) and the cytokine interleukin-1 (IL-1) (Mosesson 2005). Still, fibrin gels show a definite loss 
of stability after 4 weeks in vivo (Arkudas et al. 2009). As an exception to the relative 
instability of natural polymers, silkworm fibroin, the structure protein of silk, shows an 
astonishing tensile strength of 100 –300 MPa and stability (Zhao et al. 2003). An in vivo 
stability of over 1 year has been reported for 17% fibroin concentration but, the cell-toxic 
HFIP (hexafluoro-iso-propanol) as organic solvent is necessary. Even in all-aqueous 
dissolution of silk fibroin with concentrations of 6 to 10% fibroin, the in vivo stability has 
been found to range between 2 and 6 months (Wang, Y. et al. 2008). Thus, silk fibroin 
provides an adequate stability for tissue engineering in vivo. Additionally, silk is in clinical 
use as suture material for a long time. However, hypersensitivity and adverse reactions 
have been reported and put the biocompatibility of silk into question (Soong & Kenyon 
1984). The chemical and immunogenic properties of silk of Bombyx mori silkworms have 
been studied intensively since and sericin, the glue protein of silk, has been identified 
subsequently as the immunogenic agent (Panilaitis et al. 2003). The use of sericin-depleted 
fibroin scaffolds clearly increased the biocompatibility of silk matrices and Meinel et al could 
show that the biocompatibility of pure fibroin is comparable to collagen I and even superior 
to poly(d,l-lactic-co-glycolic acid) (PLGA) (Meinel et al. 2005). Thus, silk fibroin derived from 
silkworms has been used extensively as sponge-like scaffold for tissue engineering in vitro 
(Mandal & Kundu 2009) and in vivo (MacIntosh et al. 2008, Unger et al.). But as a drawback, 
the high stability and tensile strength of silk fibroin comes along with low elasticity and 
hydrophilicity that lead to poor cell attachment in vitro. In addition, the low elasticity limits 
the use of silk fibroin scaffolds for TE of skeletal muscle.  
Biodegradable synthetic polymers have also been widely used for muscle TE. Their 
advantages lie in easy handling and very good stability in vitro and in vivo. For example 
poly(l-lactic acid) (PLLA) and the more lipophilic co-polymer PLGA have been used in 
different orthopaedic applications due to their non-toxic properties and long-term stability 
in vivo (PLLA: 24 months, PLGA: approx. 6 months) (Gunatillake & Adhikari 2003). 
Though, inflammatory responses (Bostman 1992) and cell toxic effects in vitro (Ignatius & 
Claes 1996) have been reported due to the acidic degradation products of PLLA and PGA. 
One of the most frequently used synthetic polymer in TE research is poly(ε-caprolactone) 
(PCL). This biodegradable synthetic polymer shows a slow degradation rate resulting in a 
long-term stability of approximately 1 year in vivo (Bolgen et al. 2005). Furthermore, PCL is 
highly biocompatible and therefore suitable for in vivo applications (Cao et al. 2009). PCL has 
been used as films (Sarkar et al. 2008) and more frequently as electrospun fibers. However, 
PCL is also highly hydrophobic and therefore shows poor cell attachment in vitro (Zhang, H. 
& Hollister 2009). Hence, the hydrophobicity of PCL has to be attenuated before cell seeding 
through plasma treatment (Martins et al. 2009) or by coating the scaffold or blending with 
other materials like collagen to enhance cell attachment (Schnell et al. 2007, Zhang, Y.Z. et al. 
2005). Among the variety of biodegradable synthetic polymers materials like poly(aniline) 
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(PANi) (Borriello et al.) and oxidized polypyrrole (Gomez & Schmidt 2007) stand out due to 
their electrical conductivity. Though their mechanical properties are similar to PCL 
including poor cell attachment, electrical conductivity is an interesting feature that qualifies 
those materials for muscle TE, especially (Li et al. 2006).  
Taking the properties of the most frequently used biopolymers and synthetic polymers into 
account, the complexity of mature skeletal muscle tissue asks for a combination of different 
complementary materials to engineer a matrix that meets the special demands of skeletal 
muscle TE. Composite scaffolds containing both, synthetic polymers for stability as well as 
biopolymers for enhanced cell attachment and elasticity, are therefore preferred in muscle 
TE research. E.g. PCL has been combined with collagen (Choi et al. 2008), gelatine (Kim, M.S. 
et al.), PLLA (Engelhardt et al.) and other materials. Also the combination of silk fibroin with 
collagen leads to suitable mechanical properties with good cell attachment in vitro (Wang, G. 
et al., Zhou et al.). 
2.2 Matrices 
Comparable to the wide variety of materials, the methods of processing different forms of 
matrices are equally numerous. Thereby, mechanical properties of a certain matrix, 
degradation rates and cell attachment depend on the scaffold’s architecture. Whereas single-
cell-layers can be easily cultured on two-dimensional scaffolds (films, micropatterned 
scaffolds), the architecture of three-dimensional scaffolds is more complex. To ensure cell 
survival and proliferation in vitro, a three-dimensional matrix should enable diffusion of 
oxygen, nutrients and metabolites as well as the migration of cells inside the scaffold. 
Otherwise, cells will only proliferate at the periphery but not in the scaffold’s centre (Ishaug-
Riley et al. 1998). Therefore, the most important features of matrices for three-dimensional 
TE are high porosity (ideally approximately 90% (Freed et al. 1994)), adequate pore-size (Lee 
et al have shown that a range of 50 – 200 µm pore-size are sufficient for smooth muscle cells 
(Lee et al. 2008)) and high interconnectivity of the pores (van Tienen et al. 2002) to enable cell 
migration inside the matrix.  
Concerning the pore size, hydrogels usually show freely diffusion of nutrients and oxygen. 
Cells incorporated in hydrogels can migrate through the scaffold by degrading the gel but at 
the same time the stability of the gel decreases continuously. Furthermore, the architecture 
of hydrogels randomly spread pores (Fig. 2). However, the natural extracellular matrix 
within functional skeletal muscle tissue is highly orientated.  
The parallel alignment of ECM and skeletal muscle tissue is the pre-requisite for effective 
muscle contraction and force-generation along a longitudinal axis. Curtis and Wilkinson 
first described the “cell guidance theory” by demonstrating that microgrooved matrices 
with a parallel micropattern provoke parallel aligned cell growth along the pattern of the 
scaffold (Curtis & Wilkinson 1997). This phenomenon is also present in myoblast culture 
(Choi et al. 2008, Huang et al. 2006, Huber et al. 2007) facilitating the generation of aligned 
myotubes (Gingras et al. 2009). Therefore, several techniques for aligned scaffold 
architecture have been developed including selective laser sintering or three-dimensional 
printing reviewed by Karande et al (Karande et al. 2004). Another method to gain spatially 
orientated pores in sponge-like matrices is unidirectional freeze-drying of materials like 
collagen (Madaghiele et al. 2008) or silk fibroin (Mandal & Kundu 2009, 2009). Hydrogels are 
gradually frozen leading to controlled formation of ice crystals which result in controlled 
porosity after evaporation of the aqueous part of the hydrogel. Additionally, Schoof and co-
workers demonstrated that also the pore-size can be controlled by variation of the freezing-
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temperature (Schoof et al. 2001). Though, there are certain disadvantages linked to the 
freeze-drying method. First of all, secondary surface modifications of the sponges like 
coating procedures to enhance cell attachment are difficult and sparsely controllable. 
Secondly, the alignment of the pores is only spatial whereas the architecture of the matrix 
surrounding the pores usually remains at random.  
 
 
Fig. 2. Scanning Electron Microscopy (SEM) of a fibrin-collagen blend hydrogel. The 
aqueous part of the hydrogel is evaporated after critical point drying and fibrillar structures 
of fibrin and collagen is left behind. The random architecture of the hydrogel is clearly 
visible. 5000x magnification 
On the contrary, electrospinning as an alternative method offers strict alignment of the 
resulting scaffolds (Ayres et al. 2006). The technique of electrospinning results in fibers 
formed by electrical voltage (Boudriot et al. 2006). Though, the process depends on multiple 
parameters, e.g. concentration and viscosity of the spinning solution, the voltage applied 
during the spinning process or flow rate of the spinning solution. The mechanical and 
chemical properties of electrospun matrices can be adjusted to the demands of the respective 
tissue by varying these parameters. Thus, a variety of synthetic and biopolymers can be 
electrospun at the micro- or nanoscale (Sell et al. 2009). Nanofibrous matrices electrospun 
from ECM proteins such as collagen I or hyaluronic acid mimic the natural ECM exactly and 
therefore ensure excellent cell attachment, cell viability and differentiation (Barnes et al. 
2007). As mentioned before, biopolymers often lack the suitable stability for in vivo 
application, whereas the hydrophibicity of synthetic materials prevents rapid cell 
attachment. Again, the special demands of skeletal muscle TE can be met by combination of 
synthetic polymers and biopolymers. Different polymers can therefore be combined 
primarily by spinning polymer-blend solutions, core-shell spinning or co-spinning of 
different polymer solutions. Methods for secondary surface modification are coating 
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(Riboldi et al. 2005) or plasma treatment (Martins et al. 2009) of the matrix after the spinning 
procedure. Blending different polymers, e.g. PCL and collagen (Fig. 3), is a very simple 
method to generate composite matrices that combine the properties of both polymers 
depending on the ratio (Schnell et al. 2007).  
 
 
Fig. 3. Scanning Electron Microscopy (SEM) of electrospun PCL-collagen blend nanofibers. 
A: Randomly spun nanofibers. Magnification 10000x. B: Muscle precursor cells cultured on 
electrospun nanofibers with parallel alignment. The cell growth along the fibers’ direction is 
clearly visible. Magnification 2500x 
The more complex core-shell-spinning technique uses two separate polymers which are 
electrospun co-axially with the second polymer surrounding the first polymer at the core. 
Zhang et al used PCL as core fiber with a shell of collagen. They proved the core-shell-
nanofibers to be superior to collagen-coated PCL fibers regarding cell attachment in vitro 
(Zhang, Y.Z. et al. 2005). Jiang and co-workers have introduced electrospun core-shell fibers 
as drug delivery system (DDS) (Jiang et al. 2005). Thereafter, the emerging field of 
nanofibers and nanoparticles as DDS has found its way into TE research (Sill & von Recum 
2008). Controlled release of different drugs e.g. growth factors (Sahoo et al.) or angiogenic 
factors (Yang et al.) upgrades nanofiber matrices into “smart” matrices (Moroni et al. 2008).  
However, electrospinning of aligned nanofibrous matrices is linked with poor control of the 
pore size as the main disadvantage. The generation of electrospun three-dimensional 
matrices, especially, results in densely packed scaffolds (fig. 3) that hinder cell infiltration 
(Baker & Mauck 2007, Telemeco et al. 2005). Therefore, co-spinning of water-soluble 
sacrificial fibers such as poly-(ethylene-oxide) (PEO) has been shown to overcome this 
problem (Baker et al. 2008). The sacrificial PEO fibers are interspersed inside the three-
dimensional matrix and dissolve easily in water and alcohol during sterilization procedure 
before cell seeding. The resulting interspaces between the residual fibers then enable cells to 
migrate through the matrix (Baker et al. 2008). Though the control of pore size and 
interspaces in orientated nanofiber matrices is still challenging, the electrospinning 
technique holds great potential for TE and regenerative medicine and therefore pretends to 
be the most promising matrix for skeletal muscle TE at the moment. 
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3. Cell source 
3.1 The satellite cell 
Satellite cells form the major source for muscle regeneration in vivo after injury (Snow 1977). 
First described by Mauro in 1961 by electron microscopy, the term “satellite cell” was 
initially used for resident cells beneath the basal lamina of mature skeletal muscle fibers 
(Mauro 1961). Meanwhile, the “genetical footprint” of this cell population is well-known 
and satellite cells are specifically identified by expression of the transcription factor Paired-
box 7 (Pax7) (Seale et al. 2000). Furthermore, satellite cells express MyoD (also known as 
Myf5; Fig. 4), M-cadherin, c-Met, syndecan-3 and 4 (Cornelison et al. 2001) and CD 34 
(Beauchamp et al. 2000). In the past, it has been a point of discussion whether satellite cells 
are stem cells or myogenic progenitor cells (Zammit et al. 2006). Kuang et al proved that a 
small sub-population, i.e. 10% of satellite cells, shows stemness properties and repopulate 
the satellite cell niche in vivo (Kuang et al. 2007). These true stem cells are positive for Pax7 
but negative for MyoD, whereas the majority of satellite cells are also positive for MyoD. 
The myogenic transcription factor MyoD marks the commitment of activated satellite cells 
to the myogenic line (Weintraub et al. 1991).  
 
 
Fig. 4. Muscle precursor cells (MyoD positive cells) in vitro. Left side: Immnofluorescent 
staining for MyoD which is mainly located at the nuclei. Right side: Merge of MyoD staining 
and DAPI-counterstain. Magnification 400x 
This myogenic imprinting renders the satellite cell to be a safe cell source for in vivo as well 
as clinical application without risking dedifferentiation and tumorigenesis. Therefore, 
satellite cells are the preferred cell source for clinically orientated muscle TE research (Otto 
et al. 2009). Kuang and his group have demonstrated that the Pax7+/MyoD+ cell population 
is renewed by the Pax7+/MyoD- cells through asymmetric self-renewal (Kuang et al. 2007). 
MyoD-positive cells in turn regenerate injured muscle tissue by differentiation into new 
muscle fibers. Thus, even large muscle tissue defects can be regenerated by a relatively small 
cell population in vivo (Collins et al. 2005, Le Grand & Rudnicki 2007). Unfortunately, this 
astonishing potential of self-renewal and myogenic differentiation of satellite cells in vivo is 
usually lost when satellite cells are isolated and cultured in vitro (Yaffe 1968). Boonen and 
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his group proposed the loss of the satellite cell niche at the basal lamina in vivo (Boonen & 
Post 2008). This highly specific niche preserves the stem cell status of quiescent satellite cells 
(Blau et al. 2001). Isolated satellite cells increase their expression of MyoD and differentiate 
after loosing contact with the basal lamina and thus loose their proliferative potential. 
Therefore, the generation of suitable numbers of satellite cells for muscle TE by in vitro 
culture and expansion is still challenging. Recently, Gilbert et al have demonstrated that the 
satellite cell function depends on substrate elasticity (Gilbert et al.). The group found the best 
proliferative potential of isolated satellite cells when cultured on PEG hydrogels cross-
linked with laminin with an elasticity of 12 kPa which equals the elasticity of muscle tissue 
in vivo. After implantation of the cultured cells in a muscle injury model in vivo the 
engraftment rate was even comparable to freshly isolated and directly implanted satellite 
cells. Hence, Gilbert and co-workers showed that the satellite cell niche can be mimicked in 
vitro and thus the proliferative potential of cultured satellite cells can be preserved.  
Recently, the existence of yet another cell population in adult skeletal muscle tissue has been 
proved: The telocyte was described by Popescu et al in cardiac muscle tissue first (Popescu & 
Faussone-Pellegrini). The typical shape of telocytes with their prolongations (“telopodes”) 
situated in the vicinity of nerves, vessels and cardiomyocyte progenitors suggests a role in 
intercellular signalling as regulators in myocardial regeneration and as “nursing cells” for 
cardiac progenitors (Gherghiceanu & Popescu). In a recent study, Popescu and his group have 
identified telocytes also in skeletal muscle tissue (Popescu 2011). Beside their typical 
prolongations, telocytes are known to express c-kit and caveolin-1, but are Pax7 negative and 
thus differ from the satellite cell population. Additionally, telocytes secrete VEGF (Suciu et al.). 
3.2 Stem cells 
Stem cells of different origin offer a unique proliferation potential as the main advantage. To 
date, adult stem cells play the most important role in TE research, though other sources exist 
(embryonic or induced pluripotent stem cells (iPSC) e.g.) (Klumpp et al.). Since engineering 
of three-dimensional tissue of skeletal muscle asks for a large quantity of muscle cells, adult 
stem cells are a suitable cell source in TE research and regenerative medicine (Barile et al. 
2009, Mollmann et al. 2009, Roche et al. 2009). Therefore, mesenchymal stromal cells (MSC) 
are a feasible alternative cell source for skeletal muscle TE due to their high proliferation 
rates in vitro and their low imunogenicity in vivo (Chen, L. et al. 2009) that even enables 
allogenic transplantation of MSCs (García-Castro J 2008, Rossignol et al. 2009). MSCs can be 
derived from different tissues, e.g. from bone marrow (BMSC) or adipose tissue derived 
(ADSC) (Deans & Elisseeff 2009). BMSCs are well-known and have been widely used for 
cytotherapy in regenerative medicine (Brazelton et al. 2003). However, in case of skeletal 
muscle TE, ADSCs should be preferred due to higher potential for myogenic differentiation 
as well as higher proliferation rate compared to BMSCs (Kern et al. 2006, Zhu et al. 2008). 
Still, the experiences of in vivo studies revealed a poor incorporation rate of transplanted MSCs 
into myofibers (Gussoni et al. 1997), ranging between 5 and 10% of the transplanted MSCs in 
DMD patients (Brazelton et al. 2003, Gussoni et al. 1997). Low incorporation rates are the main 
obstacle for cytotherapie in clinical settings. Though, Satija and co-workers proposed paracrine 
effects of transplanted MSCs in vivo as an important therapeutic effect (Satija et al. 2009). 
Therefore, transplanted MSCs secrete different cytokines resulting in anti-inflammatory, 
angiogenic and anti-apoptotic effects (Meirelles Lda & Nardi 2009, Sze et al. 2007) and thus 
facilitate local endogenous tissue repair (Nesselmann et al. 2008). Estrada and his group 
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explained the angiogenic effect of MSC through their secretion of Cyr61 (Estrada et al. 2009) a 
key factor for angiogensis and tissue repair in vivo (Mo et al. 2002). Estrada et al demonstrated 
that the sole addition of MSC secretome stimulates angiogenesis in vitro and in vivo.  
Though their poor incorporation into myofibers and – compared to satellite cells - less 
effective myogenic differentiation in vivo, the paracrine effects of MSCs could augment the 
cell viability and myogenic differentiation of co-transplanted satellite cells.  
4. Cell survival in vivo / vascularization 
Whereas the generation of two-dimensional skeletal muscle tissue in vitro has been 
demonstrated by several groups before (Dennis et al. 2001, Strohman et al. 1990), engineering 
three-dimensional muscle tissue exceeding the size of 1 mm in vitro is still a challenge. Since 
common in vitro cultures of muscle precursor cells depend on diffusion solely, the thickness 
of generated tissue is limited to 500 µm to prevent apoptosis of cells in the central region of 
the construct (Kannan et al. 2005). Herein, Freed and co-workers proved the superiority of 
dynamic flow culturing due to enhanced diffusion capacity compared to static culture 
conditions (Freed et al. 1994). Still, the in vitro generation of relevant tissue sizes asks for an 
adequate vascularization. Levenberg and his group proved that vascularization of skeletal 
or cardiac muscle in vitro is possible and enhances the transport of nutrients and 
metabolites (Lesman et al. 2010, Levenberg et al. 2005). In their study they co-cultured 
muscle precursor cells with embryonic fibroblasts and endothelial cells seeded into a 3D 
polymer scaffold. When implanted in vivo, the in vitro generated vessels connected to vessels 
of the host and the tissue showed less apoptosis (Levenberg et al. 2005). However, even this 
approach does not meet the demands of a clinical setting, since the muscle tissue, engineered 
in vitro, requires an axial vascularization to enable the transplantation in vivo including a 
microsurgical anastomosis to the recipient site. In most in vivo experiments, matrices and 
muscle precursor cells are implanted subcutaneously leading to random vessel ingrowth from 
the constructs’ periphery. In contrast to subcutaneous in vivo models, O. O. Erol and M. Spira 
introduced the arterio-venous (AV) loop model of the rat in 1980 (Erol & Sira 1980). For this in 
vivo model an AV-loop is created microsurgically between the saphenous artery and vein (Fig. 
5) which can be implanted into various matrices (Polykandriotis et al. 2008). 
Thus, vascularization in general as well as number and pattern of vessel ingrowth of 
different matrices can be analyzed (Arkudas et al. 2010, Polykandriotis et al. 2009) and the 
vascularized matrix offers a platform for tissue engineering for skeletal (Messina et al. 2005) 
or cardiac (Morritt et al. 2007) muscle in vivo. The feasibility of the AV-loop model in large 
animals (Beier et al. 2009) has been demonstrated recently and poses another step towards a 
more clinical setting (Beier et al. 2010). 
Depending on the matrix architecture, a certain period of time is necessary for 
vascularization of the whole construct. This pre-vascularization time plays an important role 
for survival rates of implanted cells in vivo: Thus, cells implanted after this time period show 
significantly lower apoptosis rates (Arkudas et al. 2007). Vascular growth factors such as 
bFGF and VEGF (Yancopoulos et al. 2000) are frequently used to reduce the pre-
vascularization time in vivo (Arkudas et al. 2007). Therefore, different approaches have been 
tried for controlled drug release of VEGF. Beside the use as soluble factor or immobilized in 
fibrin hydrogels (Arkudas et al. 2007), VEGF can be bound to nanoparticles (des Rieux et al.) 
or nanofibers (Vournakis et al. 2008) as drug delivery systems (DDS) to improve 
angiogenesis in vivo (Zisch et al. 2003). Kim et al have demonstrated the positive therapeutic 
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effect of nanoparticle based VEGF release in ischemic muscle tissue (Kim, J. et al.). Hypoxia-
regulated systems enable an even more selective delivery of VEGF to ischemic sites only, 
e.g. in myocardial repair (Ye et al.). Finally, the VEGF expression of (co-) implanted MSCs 
could also enhance angiogenesis in vivo.  
 
 
Fig. 5. Arterio-venous loop model in the rat as previously published by our group. The AV-
loop (asterisk) is implanted into a Teflon chamber (C) filled with fibrin hydrogel. In this 
setting, the engineered tissue could be transplanted by anastomosing the pedicle (arrow) to 
the recipient site 
Beside angiogenic growth factors, other factors such as insulin-like growth factor-1 (IGF-1) 
have been shown to increase survival rates of implanted cells in vivo (Wang, F. et al. 2009) 
and to improve myocardial regeneration (Davis et al. 2006, Padin-Iruegas et al. 2009). Thus, 
various methods exist to further ameliorate cell survival in vivo but still have to be analyzed 
in detail for their benefit for skeletal muscle TE. 
5. Myogenic differentiation 
5.1 Molecular factors for myogenic differentiation 
Beside the improvement of cell survival rates, the myogenic differentiation of implanted 
muscle precursor cells into functional skeletal muscle tissue in vivo is another point that has 
to be addressed by future research. To date, many different molecular factors have been 
identified which support myogenic differentiation, e.g. akirin-1, muscle specific microRNAs 
and insulin-like growth factor (IGF-1). 
The well-known factor IGF-1 has been demonstrated to increase the proliferation as well as 
myogenic differentiation of myoblasts in vitro by Allen and Boxhorn (Allen & Boxhorn 
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1989). Later on, this effect was affirmed in different in vivo experiments with overexpression 
of IGF-1 leading to muscle hypertrophy (Adams & McCue 1998) and improving muscle 
regeneration after trauma (Menetrey et al. 2000, Sato et al. 2003). Whereas many growth 
factors increase proliferation rates or differentiation of myoblasts only, IGF-1 enhances both, 
proliferation as well as myogenic differentiation of muscle precursor cells (Ten Broek et al.). 
Furthermore, IGF-1 overexpression improves survival rates of implanted cells in vivo (Wang, 
F. et al. 2009). These properties render IGF-1 as one of the most potential growth factors for 
myogenesis and skeletal muscle TE. Beside the mitogenic potential of IFG-1 and its positive 
influence on myogenesis, Haider et al have also shown that IGF-1 can mobilize stem cells 
and increase engraftment of implanted MSCs in vivo (Haider et al. 2008). The group 
explained this effect of IGF-1 through its activation of stromal cell derived factor (SDF)-1α 
and its receptor CXCR4. SDF-1α plays a crucial role in skeletal muscle regeneration and is 
therefore overexpressed after muscle injury as well as in dystrophic muscle to attract muscle 
precursor cells which express CXCR4 (Perez et al. 2009). Therefore, overexpression of SDF-
1α through transfected MSCs (Haider et al. 2008) or via controlled drug release (Grefte et al.) 
improves regeneration of skeletal as well as cardiac muscle in vivo.  
Another factor which influences early myogenic differentiation positively is akirin-1 (also 
known as Mighty) (Salerno et al. 2009). In skeletal muscle tissue, akirin-1 is known to activate 
quiescent satellite cells and thus promote proliferation of muscle precursor cells. Furthermore, 
akirin-1 consecutively induces the expression of IGF-2 and hence also increases myogenic 
differentiation indirectly (Marshall et al. 2008). Therefore, akirin-1 combines the activation of 
quiescent satellite cells with the promyogenic effect of downstream growth factors such as 
IGFs. Though promising for skeletal muscle TE, the mechanism and molecular pathways of 
akirin-1 still have to be analysed in detail in future. In addition, the administration of growth 
factors has to be critically analyzed concerning their risk of tumorigenicity in vivo.  
Recently, a novel class of regulating factors of myogenesis has been analyzed for their 
promyogenic potential: Small non-coding RNAs, called microRNA (miRNA) which consist 
of approximately 20-22 nucleotides (Callis et al. 2008). Herein, certain microRNAs (miR-1, 
miR-133 and miR-206) have been demonstrated as muscle specific. Whereas miR-1 and miR-
133 are also expressed in cardiac muscle, miR-206 is specifically expressed in skeletal muscle 
tissue and up-regulated in patients with muscular dystrophy (Eisenberg et al. 2009). 
Furthermore, the muscle-specific miRNAs differ in their effect on muscle precursor cells. 
MiR-133 increases proliferation of muscle precursor cells but also inhibits myogenic 
differentiation (Chen, J.F. et al. 2006). On the contrary, miR-1 and miR-206 have been shown 
to induce myogenic differentiation (Chen, J.F. et al. 2006, Kim, H.K. et al. 2006). In a recent 
study, Nakasa et al demonstrated that local injection of miR-1, miR-133 and miR-206 
improves muscle regeneration and prevent fibrosis following muscle injury in vivo (Nakasa 
et al.). However, further studies are still necessary to analyze the promyogenic potential of 
muscle-specific microRNAs in vitro and in vivo. 
5.2 Electrical stimulation and neurotization  
Despite great efforts in the past and various molecular factors which regulate and enhance 
myogenesis, engineering of mature skeletal muscle tissue still remains a big challenge. 
Though contracting myotubes – which mark the differentiation and fusion of myoblasts in 
myogenesis - have been generated by various groups, the generation of adult muscle fibers 
depends on neural or electrical stimulation (Wilson & Harris 1993). The influence of 
electrical stimulation on further myogenic differentiation has been analyzed in vitro 
  
Tissue Engineering for Tissue and Organ Regeneration 
 
72 
(Donnelly et al., Stern-Straeter et al. 2005) and in vivo (Fujita et al. 2007). For clinical 
applications, devices for electrical stimulation have to be implantable and suitable for long-
term stimulation (Jarvis & Salmons 2001, Lanmuller et al. 2005). The in vivo experiments of 
Dennis and co-workers using implantable stimulation devices in the rat demonstrated that 
muscle mass as well as the maximum force of a denervated muscle can be maintained by 
electrical stimulation (Dennis et al. 2003). Thus, the physiologic stimulation via motoric 
innervation can be simulated to support further myogenic differentiation. 
Liao et al showed that the combination of electrical stimulation with aligned micropatterned 
matrices even increases the positive effect on myogenic differentiation (Liao et al. 2008). 
Again, electrospun nanofibrous matrices offer the possibility to combine cell guidance 
through aligned matrix architecture with electrical stimulation via conductive nanofibers. 
Ghasemi-Mobarakeh and colleagues used electrospun PANi/PCL/gelatine-blend fibers as 
matrix for neural cell cultivation. Applying electrical stimulation to the matrices, they 
demonstrated enhanced cell proliferation and neurite outgrowth (Ghasemi-Mobarakeh et al. 
2009). The use of PANi/gelatine-blend fibers offers an acceptable cell attachment in vitro 
and can be used for cultivation and electrical stimulation of muscle cells in vitro (Li et al. 
2006). Finally, the influence of electrical stimulation on C2C12 murine myoblasts was 
analyzed by Jun and his group in vitro. In their experiments they found that electrical 
stimulation enhances myogenic differentiation via upregulation of myogenin which 
specifically marks early myogenesis (Jun et al. 2009). 
However, engineering functional skeletal muscle tissue in vivo not only asks for highly 
differentiated and organised muscle fibers but also the formation of neuromuscular 
junctions and neurite ingrowth between the muscle fibers is necessary (Fig. 6).  
 
 
Fig. 6. Immunofluorescent staining of a cross-section of adult skeletal muscle. A: The nuclei 
are stained with DAPI (blue) and mark the outline of the muscle fibers. The acetylcholine 
receptors (specifically stained with α–bungarotoxin; green) are reached by nerve terminals 
(stained for specific neurofilament (NF-100), red) forming the neuromuscular junction (B: 
DAPI-filter excluded). Magnification 400x 
The main component of the neuromuscular junction – the acetylcholine receptor (AChR) – is 
initially expressed in developing myofibers also in absence of neural cells, i.e. independent 
from motoric innervation (Witzemann 2006). The AChR clusters at this stage of myogenesis 
are located at the central regions of myofibers and this phenomenon known as 
“prepatterning”, marks the development of mature myofibers in myogenesis. However, the 
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accumulation of AChR at synaptic sites and further development into functional 
neuromuscular junctions depends on the specific neuronal factor agrin. Thus, the molecular 
signalling between developing myofibers and motor neurons is necessary for the generation 
of functional neuromuscular junctions (Brockhausen et al. 2008). The motoric innervation 
even defines further maturation of the developing muscle tissue into slow- or fast-twitching 
muscle fibers (Nehrer-Tairych et al. 2000). Dhawan et al proved that motoric neurotization of 
implanted muscle precursor cells in vivo leads to the formation of neuromuscular junctions 
(Dhawan et al. 2007). In a comprehensive study, they showed nerve-induced contractions of 
the in vivo engineered skeletal muscle tissue after explantation and analysis in vitro. 
Therefore, a successful approach for skeletal muscle TE in vivo will necessarily include a 
motor nerve for neurotization of implanted muscle precursor cells. But to date, in vivo 
models combining motoric neurotization with a pre-vascularized matrix are still rare. 
Recently, a new AV-loop model in the rat including motoric neurotization has been 
developed by our group (unpublished data). 
6. Conclusions 
As a conclusion, the main challenges in skeletal muscle TE are therefore: (1) engineering a 
suitable matrix for muscle TE including a clinical application, (2) improving further 
myogenic differentiation in vivo and (3) enabling the transplantation of functional skeletal 
muscle tissue to the recipient site including microsurgical anastomosis of an adequate 
vasculature as well as motoric neurotization of the engineered muscle tissue. Despite these 
obstacles, the achievements of the recent years demonstrate an encouraging progress of 
skeletal muscle TE research. Therefore, Churchill’s statement concerning skeletal muscle TE 
in vitro may still come true in the future. 
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1. Introduction 
The repair of large soft tissue defects, especially abdominal wall defects, is still a challenge 
for surgeons and continues to be a significant problem for patients (Gangwar et al., 2006; Lai 
et al., 2003). Free muscle transfer from local or distant sites is commonly employed for the 
surgical repair of muscle-tissue defects, but this practice is frequently associated with 
significant donor-site morbidity (Wei et al., 1995). A potential alternative includes the in 
vitro development of a functional three-dimensional muscle for transplantation or the 
construction of implantable biological biomaterials to direct myogenesis at the target site. 
The ideal biomaterial for abdominal wall repair should possess adequate strength, no 
hypersensitivity reactions, and biocompatibility to facilitate tissue ingrowths, which may 
help long-term maintenance of mechanical strength (Lai et al., 2003). In the reconstruction of 
a new tissue, two components are usually very important: the cells and the matrix 
(scaffolds) where they are seeded.  
Tissue engineering is an interdisciplinary field which applies the principles and methods 
of engineering and the life sciences towards the fundamental understanding of structural 
and functional relationships in normal and pathological tissue and the development of 
biological substitutes to restore, maintain or improve function (Skalak & Fox, 1988). The 
creation of skeletal muscle tissue using tissue engineering methods holds promise for the 
treatment of a variety of muscle diseases, including skeletal myopathies such as muscular 
dystrophy or spinal muscular atrophy, traumatic injury and aggressive tumor ablation 
(Guettier-Sigrist et al., 1998; Law et al., 1993). Tissues that are engineered using the 
patient’s own cells, or immunologically inactive allogenic or xenogenic cells have the 
potential to overcome current problems of replacing lost tissue function and offer new 
therapeutic options for diseases where currently no options are available. Moreover, this 
technology can play a vital role in the future management of paediatrics patients (Saxena 
et al., 1999a).  
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In general “Tissue engineering” refers to the science of creating living tissue to replace, 
repair or augment diseased tissue. The engineered tissue may be created in vitro and 
subsequently implanted into the patient or the tissue may be created entirely in vivo. 
Regardless of the technique, tissue engineering requires at least three components: a 
growth-inducing stimulus (induction), responsive cells (production), and a scaffold 
(biomaterials) to support tissue formation (Bronzino, 2006). 
Biomaterials are any material used to make devices to replace a part or a function of the 
body in a safe, reliable, economic and physiologically acceptable manner (Hench & 
Erthridge, 1982). The use of biomaterial for repair of abdominal wall defects is gaining 
increasing recognition and the use of biomaterials to achieve a tension–free repair has 
resulted in a significant reduction in post-operative pain, length of recovery period and the 
number of recurrence (Amid, 1997). 
Currently there is an increasing demand for cheap and ideal biomaterials which can be used 
in reconstructive surgery for repair of traumatic wounds suffer during war, traffic accidental 
and natural disaster and in the restore of the functions of diseased tissues or organs. 
Biomaterials are either synthetic (prosthesis) such as ceramic, polymeric and composite or 
biologic (bioprosthesis) such as heart valve, skin and other types of tissue graft (Black, 1992). 
The ideal biomaterials for abdominal wall repair should possess adequate strength, no 
hypersensitivity reactions and biocompatibility to facilitate tissue ingrowths, which may 
help long term maintenance of mechanical strength (Lai et al., 2003). 
Recently, new biodegradable biomaterials developed from biological materials mainly of 
collagen in nature have been tested for repair of body wall instead of the non-biodegradable 
synthetic materials. Bovine pericardium, human cadaveric fascia lata, human dura mater 
and collagen-based materials derived from porcine small intestine submucosa have been 
investigated for reconstruction of abdominal wall defects (Ueno et al., 2004; Saaverda et al., 
2001; Santillan et al. 1995; Rodgers et al., 1981). However in most research, it is indicated that 
these collagen based biomaterials are failed to be replaced by skeletal muscle tissue or 
regeneration of muscle tissue is not observed as whole therefore optimal muscle recovery or 
regeneration may require the use of novel technology like tissue engineering. Skeletal 
muscle comprises approximately 48% of the body mass and is responsible for voluntary 
control and active movement of the body. Application of tissue engineering techniques and 
successful fabrication of skeletal muscle mass holds now a promising future for the 
restoration of 3-dimentional contour as well as the loss of function for the affected part of 
the body. In order to generate skeletal muscle tissue, myoblasts which are skeletal muscle 
tissue precursors, have been employed (Saxena, 2005).  
One of the strategies for muscle tissue engineering involves the harvesting of satellite cells, 
their expansion in vitro, and their subsequent autologous implantation in vivo into the sites 
requiring repair or replacement. One of the main obstacles in the formation of new muscle 
tissue is the lack of an adequate support for expanded satellite cells. To overcome this 
obstacle, many researcher groups are trying to develop adequate synthetic and biological 
delivery systems for implanted cells (Conconi et al., 2005). Currently myoblast 
transplantations have been predominantly performed by injection of myoblast cell 
suspensions into mature skeletal muscle. These single cells have been shown to fuse with 
the host myofibers (Wernig et al., 2000).  Saxena et al. (1999b) were the first to implant 
successfully in vitro cultured myoblasts into a non-muscular environment. Their group used 
a polyglycolic acid (PGA) mesh as a scaffold for skeletal muscle cells (Saxena et al., 2001; 
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Saxena et al., 1999b). Myoblasts have also been seeded onto polyglycolic acid porous 
polymers with successful generation of vascularized new skeletal muscle in vivo (Saxena and 
Willital, 2000). Synthetic materials, such as Dacron and Polytetrafluorethylene, have been 
used to repair congenital muscles defects, e.g. Onfalocele and gastrochisis (Bauer et al., 1999; 
Calzolari et al., 1995; Meddings et al., 1993). However, all of these materials do not allow cell 
growth and do not follow host development. Evidence has been provided that biological 
materials can support in vivo and in vitro cell adhesion and proliferation.  
Bovine pericardium has been used as source of natural biomaterials for a wide range of 
clinical applications (Jose et al., 2001; Won et al., 2000; Marques et al., 1995). However, few 
clinical data are available in current literature about grafting of bovine tunica vaginalis 
parietalis for surgical use, although up to 10x7cm or larger collagen rich sheet of tunica 
vaginalis parietalis can be obtained from a testis of adult cattle. Naturally derived materials, 
including glutaraldehyde tanned bovine pericardium (James et al., 1991), small intestine 
submucosa (Clarke et al., 1996; Prevel et al., 1995) and also lyophilized and glycerolized 
bovine pericardium and tunica vaghinalis parietalis (Hafeez, 2005), have been tried in 
animal models. These biomaterials are less susceptible to infection and cause less foreign 
body response (Badylak et al., 1998; Hiles et al., 1995). Thus, the utilization of non-edible 
bovine offal’s of collagenous nature for the development of cheap and safe surgical patches 
for clinical use will be of economical importance in developing countries. However, fail to 
recover muscle tissue and also lack of strength over time is a concern for clinical application 
in which adequate tensile properties are necessary. Thus, for this reason, it is important to 
understand not only the biological response to degradable biomaterials, but also the 
expected mechanical properties of implant and replacement of tissue over time. These new 
collagen based biomaterials has to be improved its morphological and biomechanical 
properties just by seeding it with myoblast cells and must be evaluated first in animals’ 
model before being approved for test in human. 
In this study, biological collagen-based biomaterials were employed for reconstruction of 
abdominal wall defects in a rabbit model. These are bovine parietal pericardium and bovine 
tunica vaginalis parietalis which were collected from abattoir and processed by freeze-
drying preservation methods and sterilized using gamma irradiations system. In recent 
years, this preservation method in combination with sterilization using gamma irradiation 
has been reported in its good output (Zuki et al., 2007; Hafeez, 2005; Hafeez et al., 2005a, 
2005b). 
A reason for future use of collagen-based biomaterials seems functioning as temporary 
scaffolds which during resorption generate new permanent tissue. However, very fast 
resorption rates were reported for degradable materials of synthetic or natural origin (Smith 
et al., 1989; Tyrell et al., 1989). Moreover, fail to recover muscle tissue and also lack of 
strength over time is a concern for clinical application in which adequate tensile properties 
are necessary. 
2. Morphological evaluation of the myoblast seeded scaffolds in vitro 
The parietal pericardial sacs and tunica vaginalis parietalis were collected from healthy 
adult cattle immediately after slaughter, placed in polyethylene plastic bags containing cold 
normal saline and transferred into an icebox for transportation. The BP and BTV sacs were 
cleaned, trimmed into rectangular sheets and washed thoroughly under running tap water 
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and rinsed in serial changes of sterile saline (Figure 1). The BP and BTV sheets were then 
transferred aseptically into a sterile bottle containing 150ml of 0.05% sodium hypochlorite 
and shaken slowly for 10 minutes. The sodium hypochlorite were then washed off by 
shaking the tissue sheets in three changes of sterile normal saline for 20 minutes each 
change, then kept overnight at 4oC. The BP and BTV sheets were freeze-dried and sterilized 
by gamma irradiation at 25 KGy (Cobalt 60, JS8900, IR-174; CDM MDS NORDION, Ontario, 
Canada) according to the MINT (Malaysian Institute for Nuclear Technology) tissue bank 
work instruction Manual (1998) (Figure 2). Samples were taken from both BP and BTV grafts 
for histological and SEM examinations. The sections were stained with Haematoxylin and 
Eosin as described by Wilson and Gamble, (2002) for general histology and Masson’s 
trichrome method as described by Jones, (2002) for demonstration of muscles and 
collagenous tissue.  
 
 
Fig. 1. Photographs A and B show BP and BTV after cleaning, respectively 
 
 
Fig. 2. Photographs A and B show 3 x 4 cm2 scaffolds derived from BP and BTV, 
respectively. Note both have similar appearance macroscopically 
Biomaterials provide mechanical stability to the construct in the short term and serve as a 
template for the three-dimensional organization for the developing tissue (Hutmacher, 
2001). Therefore a critical step in skeletal muscle-tissue engineering is the identification of 
the optimal biomaterial scaffold, able to promote normal differentiation and maturation of 
myoblasts into myotubes and myofibers. At present, several kinds of natural scaffolds, such 
as porcine small intestinal submucosa (Badylak et al., 2002), acellular dermal matrix 
(Chung et al., 2003) and collagen (Lai et al., 2003) have been employed to repair 
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abdominal wall defects in experimental animal models. Acellular matrices, obtained by 
detergent-enzymatic method do not elicit rejection responses (Roeder et al., 1999) and 
could be employed as promising tissue substitutes (Parnigotto et al., 2000a, 2000b; 
Sutherland et al., 1996). 
2.1 Light and scanning electron microscopic evaluations of the scaffolds 
Bovine parietal pericardium and bovine tunica vaginalis parietalis were used to obtain a 
biological scaffold possessing morphological and mechanical properties resembling those of 
the native tissue. Bovine pericardium originated scaffolds seems have large pores and less 
interconnectivity with completely acellular (Figure 3A) and is collagenous-based in nature 
with no cellular and vascular element (Figure 4A), and this might be as a result of slight 
modification of preparation methods used in the previously reported methods by Hafeez, 
(2005) in conjunctions with light density of collagen as compared with BTV. However, BTV 
originated scaffolds possessing large pores and less interconnectivity with scanty cell 
remnant within dense collagen bundles (Figures 3B and 4B), and this perhaps contributed 
by high density of the structural fiber components. A similar result has been reported by 
Hafeez, (2005). The light and electron microscopic examinations revealed that nearly all 
cellular components were removed without ultrastructural evidence of damage to fibrous 
components. Even though similar acellular results were obtained by Chang et al. (2002) in 
their in vivo evaluation of cellular and acellular bovine pericardia fixed with a naturally 
occurring crosslinking agent (genipin). But, they had used a special cell extracting methods 
which was not used in this study. 
 
 
Fig. 3. Microphotographs of the collagen based of BP (A) and BTV (B) scaffolds show the 
pore size appears larger with less interconnectivity. Note also the scanty remnant cellular 
elements within a dense connective tissue matrix in B. H&E, Bar = 100µ 
Scanning electron microscopic examinations revealed that the serosal/inner surface of both 
type of scaffolds (BP and BTV scaffolds) had irregular polygonal shape structure (Figures 
5A and 6A). However, the outer layers were rough with irregular appearance of connective 
tissue (Figures 5B and 6B). The finding of this study is in accordance to the result reported 
by Hafeez (2005). They had reported that the surface of freeze-dried BP and BTV differ from 
fresh BP and BTV in many aspects such as the lost of the serosal layer and the exposure of 
underlying collagen bundles and separation of individual collagen bundles, and fibers, 
which appeared to be wavy and well defined. Adequate porosity with interconnected pores 
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is required not only to achieve sufficient cell seeding density within the scaffold, but also to 
facilitate cell proliferation and differentiation by allowing the transport of nutrients and 
oxygen into and out of the scaffold (Goddard & Hotchkiss, 2007). This study has also 
demonstrated that the processed collagen-based biomaterials such as BP and BTV are 
sufficiently porous in nature (Figure 7). A similar result had been reported on bovine 
parietal pericardium (Chang et al., 2005).  
 
 
Fig. 4. Microphotographs of the masson’s trichrome stained BP (A) and BTV (B) scaffolds 
show the scaffold is collagenous-based in nature with no cellular and vascular element in A, 
and dense collagenous tissue with scanty cellular elements in B. Bar = 100µ 
Based on the light and scanning electron microscopic analysis the prepared pre-implanted 
BP and BTV are fibro-collagenous in nature with no or very few cellular remnants which 
make this biomaterials weak antigenicity apart from its excellent biocompatibility and 
biodegradability. This is a fascinating result to address the need of non-immunogenic and 
non-prosthetic biomaterials that could guide perhaps the regeneration of normal tissue. This 
study has also revealed that processed BP and BTV are porous in nature that could achieve 
to accommodate sufficient cell seeding density and facilitate cell proliferation and 
differentiation by allowing the transport of nutrient and oxygen into and out of the scaffolds 
(Goddard & Hotchkiss, 2007). 
 
 
Fig. 5. SEM electronmicrographs of the A) serosal/interior and B) epipericardial surfaces 
of BP scaffold showing polygonal shape structure and irregular fibrous surface, 
respectively 
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Fig. 6. SEM electronmicrograph of the A) serosal and B) scrotal surfaces of BTV scaffold 
showing polygonal shape structures and irregular surface, respectively 
 
 
Fig. 7. SEM electronmicrographs of the cross sectioned scaffolds of BP (A) and BTV (B) 
showing good porosity 
2.2 Skeletal myoblast harvesting and isolation analysis 
Skeletal muscle tissue engineering depends on the unique regenerative properties of 
satellite cells and the ability to direct intrinsic cell programs associated with proliferation 
and differentiation. The development of muscle stem cells and genetically engineered 
myoblasts for transplantation has become in the past few years a very attractive and 
challenging method for treatment of patients with muscle diseases (Wu et al., 2003; Huard 
et al., 2003; Haider et al., 2003). However, the repair of extensive muscular defects or 
diseased regions may require voluminous tissue grafts seeded with large amounts of 
myoblasts.  
Skeletal muscle tissues were obtained from the hind limbs muscle (Soleus muscles) of 5-day-
old rabbit using a primary cell culture. Cell purity is assessed by desmin antibodies to prove 
the purity of the cultured myoblast using immunocytochemistry analysis and also 
quantified by flow cytometric analysis. This identification method has been also employed 
by many researchers despite their slight variation in techniques (Guarita-Souza et al., 2006; 
Ott et al., 2004; Lai et al., 2003; Winokur et al., 2003; Rando & Blau, 1994). The prepared 3 x 4 
cm2 scaffolds were seeded with myoblast at a density of 1.0 × 107cells. Cell morphology and 
growth in the scaffolds were examined using SEM. 
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During the initial stages of culture, the myoblast showed a rounded morphology. After the 
first 24 hours, the cells attached to the culture surfaces and also spindle-shaped cells started 
to sprout out from isolated muscle fibres and then proliferated. Therefore, this work allowed 
us to obtain muscle satellite cell-derived cultures, containing myoblasts, expressing the 
transcription factors involved in the skeletal muscle-cell differentiation program (Chen & 
Goldhamer, 2003). Moreover, cultured myoblasts are endowed with a high proliferation 
rate, so that only three weeks is needed to reach the optimal cell number for graft 
implantation.  Hence, this myoblast isolation technique appears to give a better result than 
those previously used to isolate satellite cells by Lai et al. (2003), Marzaro et al. (2002) and 
Van Wachem et al. (1999), but it appears to give  a similar results reported by Conconi et al. 
(2005).  
Moreover the culture technique that has been used allows the preferential growth of 
myoblasts over fibroblasts, and the yield of myogenic cells from the initial primary culture is 
very high and hence the percentage of myogenic cells increases with time in culture. Thus, 
from a mixed culture of myoblasts and fibroblasts, a nearly pure culture of myoblasts were 
achieved within three weeks and therefore the purity of the myoblast was confirmed using 
desmin immunocytochemistry which is a common preferable method employed by many 
researchers to produce a better result (Guarita-Souza et al., 2006; Conconi et al., 2005; 
Kamelger et al., 2004). Myoblast percentages were determined using flow cytometric 
analysis. According to desmin immunocytochemistry and flow cytometric analysis more 
than 97% of the isolated skeletal myoblast cells have got myogenic phenotype (Figures 8). 
However, Lai et al. (2003) had reported that approximately 80% of isolated skeletal muscle 
cells had a myogenic phenotype in desmin immunocytochemistry analysis which perhaps 
indicates the superiority of the present technique to isolate myoblast. 
 
 
Fig. 8. Flow cytometric histograms depicted FITC-conjugated desmin positive myoblast. 
Note that the percentage of pure myoblast is 97% whereas non myoblast cells are 3% in flow 
cytometry analysis. M1= Proportion of desmin negative cells, M2= Proportion of desmin 
positive cells 
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In vitro test revealed the ability of myoblast to form myotube in static culture on the surface 
of petri-dish which was not even a tissue culture flask. However, there were only few cells 
on the surface with haphazard arrangement which is perhaps related to the adhesion 
properties of the cell towards the petri-dish as showed in figure 9. This result is in 
agreement with Yan et al. (2006) who reported that if the myoblast cells are plated on plain 
plastic tissue culture or on non-aligned collagen gels, the satellite cells differentiate into 
skeletal myotube but the arrangement is haphazard.  
 
  A  B  C  
Fig. 9. The phase-contrast microphotographs showing A) the spindle-shaped myoblast at 24 
hrs post-seeding, B) long spindle-shaped myoblast at 72 hrs post-seeding with some 
multinucleated myotube (arrows) and C) long spindle-shaped myoblast and myotube at 120 
hrs post-seeding with some multinucleated myotube (arrows). Bar = 100µ 
 
 
Fig. 10. SEM electronmicrographs of the myoblast seeded bovine pericardium scaffold at A) 
24 hrs, B) 72 hrs and C) 120 hrs post-seeding. Note the myoblast covering almost the entire 
surface of the scaffolds (A), the unidirectional pattern of myotube (B) and the fusion of 
myotubes to form myofibres (C) 
The SEM examinations revealed that both type of BP and BTV scaffolds were able to support 
myoblast growth and differentiation, which were evidenced by few myoblast began to cover 
the whole surface of the scaffolds and fused into myotube within 24 hrs (Figure 10A). At the 
3rd and 5th day post-seeding, the myoblast continues to fuse and form a series of uniformly 
arrayed myotube (Figure 10B), whereas at 5th day post-seeding densely packed myotube 
with morphology reflecting myofibers were also observed (Figure 10C), and these results 
found to be almost consistent with result reported by Yan et al. (2006), where their study 
focused on tissue engineering of skeletal muscle using aligned collagen gel coated tissue 
flask. A similar result had been also reported by Conconi et al. (2005) on the homologous 
muscle acellular matrix seeded with autologous myoblasts as a tissue-engineering approach 
to abdominal wall-defect repair. A critical step in skeletal muscle-tissue engineering is the 
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identification of the optimal biomaterial scaffold, able to promote normal differentiation and 
maturation of myoblasts into myotubes and myofibers (Conconi et al., 2005). In this work, 
biologically originated collagen-based biomaterials were used to obtain a scaffold 
possessing morphological and mechanical properties resembling those of the native tissue, 
and in vitro findings confirmed that this matrix is able to support myoblast growth and 
differentiation. 
3. Post-implantation evaluations of myoblast seeded scaffolds 
In this study we used a total of 36 rabbit which were randomly divided into four 
experimental groups (Group I, II, III and IV), comprising of equal number of animals. Group 
I and II served as the treatment groups, while the other groups acted as control. Three 
rabbits from each group were randomly selected and scarified using an intra-cardial 
injection of sodium pentobarbital (CEVA, Sante animale, France) at a rate of 100mg/kg at 
7th, 14th and 30th day post implantation as described in Table 1. 
 
  Scarifying date  
  7th Day 14thDay 30th Day No of rabbits 
Treatment groups Group I 3 3 3 9 
 Group II 3 3 3 9 
Control Groups Group III 3 3 3 9 
 Group IV 3 3 3 9 
  12 12 12 36 
Group I -Myoblast seeded BP scaffolds 
Group II -Myoblast seeded BTV scaffolds 
Group III -Non-Seeded BP scaffolds 
Group IV -Non-Seeded BTV scaffolds 
Table 1. Experimental Design 
3.1 Post-operative care and follow up analysis 
The animals tolerate well to the surgical procedure and none of the rabbits died during 
surgical process with no post-implantation mortality which may be due to satisfactory 
anaesthetic technique (Table 2). Dullness, depression and partial anorexia in the immediate 
postoperative period was attributed to surgical trauma and inflammation at the site of 
reconstruction. A similar result was reported by Gangwar et al. (2006) using acellular 
dermal graft for repair of abdominal wall defects in rabbits. Neither the treatment groups 
nor its control groups in both types of scaffolds have showed any wound complication and 
infection as shown in figure 11, since, the complication rate after repair of large tissue 
defects strongly depends on applied reconstructive material. Wound infections, bowel 
fistulae, and repair failures can occur when synthetic materials were used for defect closure. 
However, naturally derived materials are less susceptible to infection (Drewa et al., 2005; 
Schlatter et al., 2003; Dolgin et al., 2000; Minkes, et al., 2000). 
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Groups No. of Rabbit 
No. of 
mortality (%) 
No. of 
Adhesion (%) 
No. of 
Seroma (%) 
Group I 9 0(0) 1(11.11) 0(0) 
Group II 9 0(0) 0(0) 0(0) 
Group III 9 0(0) 3(33.33) 0(0) 
Group IV 9 0(0) 2(22.22) 1(11.11) 
Table 2. Post-operative complications  
 
 
Fig. 11. Subcutaneous surface of the implanted scaffolds is covered by new/old fascia 
originated from surrounding fascia with overwhelming blood vessels in Group I on day 7 
post-implantation 
3.2 Macroscopic analysis 
The vascular change at reconstructive site is a part of normal body response to injury. It is 
an attempt to increase resorption and removal of clot and debris from the wound site and 
finally helping in the laying down of fibrous tissue (Silver, 1982). Therefore, the present 
results revealed the increased vascularity at the reconstructive site in all groups of rabbit in 
both type of scaffolds as the post-operative day advances. Although variable degree of 
angiogenesis were a common feature of the treatment and its control groups in both BP and 
BTV scaffolds, and hence overwhelming neo-angiogenesis were recorded in the treatment 
groups of both type of scaffolds which might be attributed by seeding of myoblast on the 
scaffolds. 
The study has showed that deposition of loose fibrous connective tissue and white 
connective tissue was observed in all the groups of rabbit regardless of the scaffolds type. 
However, it was on groups I and II complete neo-peritoniazation began with the appearance 
of glistening membrane covering the inner surface of the graft at day 7th of post-
implantation (Figure 12) which is indeed earlier than the study conducted by Singh et al. 
(2008) in acellular biomaterials of porcine origin for the reconstruction of abdominal wall 
defects in rabbits, where complete peritoniazation the graft occurred at 21st post-operative 
day, and their finding relatively similar with the control groups of our study where early 
peritoniazation on the implanted scaffolds was not observed in the control groups in which 
myoblast was not seeded. Therefore myoblast seeding might be a good justification for early 
peritoniazation.  
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Fig. 12. Peritoneal surface of the implanted graft in Group I (A) and group II (B) on day 7 
post implantation showing the surface is completely covered by newly formed white fibrous 
tissue including the fatty tissue (ft) and neo-peritoneum that appears smooth and shinny 
Naturally derived materials, including glutaraldehyde tanned BP (James et al., 1991), small 
intestine submucosa (Clarke et al., 1996; Prevel et al., 1995) and also lyophilized and 
glycerolized BP and BTV (Hafeez, 2005), have been tried in animal models. These 
biomaterials are less susceptible to infection and cause less foreign body response (Badylak 
et al., 1998; Hiles et al., 1995). However, fail to recover muscle tissue and also lack of 
strength over time is a concern for clinical application. Macroscopically, at day 30th of post-
implantation, our study revealed that the control groups III and IV have showed thinning 
and fascial weakness, which was evidenced by pouching and distension appearance of the 
abdominal wall as shown in Figure 13.  
Lai et al. (2003) had proven that scaffolds covered with cells had better mechanical 
properties than acellular/non-seeded scaffolds in body wall repair using small intestinal 
submucosa seeded with cells. Fauza et al. (2001) had also reported acellular collagen-based 
matrix alone may be insufficient scaffold for abdominal wall reconstruction. However, in 
our study none of the treatment groups, in both types of scaffolds have showed pouching 
and distension appearance of the abdominal wall, rather various degree of tissue 
regeneration was noticed, which was evidenced by graft opacity, and overwhelming blood 
vessels, fatty tissues, fibrous tissue and neo-peritoneum was observed in myoblast seeded 
groups of both type of scaffolds at 30 days of post-implantation (Figure 14). 
 
  A  B  
Fig. 13. Peritoneal surface of the implanted graft in group III (A) and group IV (B) on day 30 
post-implantation showing the implanted graft over-stretched and lead to pouching 
appearances with very few blood vessels 
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Fig. 14. Peritoneal surface of the implanted graft in group I (A) and group II (B) on day 30 
post-implantation showing the neo-peritoneum (np) covered all over the surface with 
numerous blood vessels and white fibrous tissue at host-graft junction (stars), fatty tissue (ft) 
In this study, the wound strength of repair was not evaluated. However, the firm integration 
was observed between the implant and host tissue produced by infiltration of fibro-
collagenous tissue which was indeed further strengthens by infiltration of skeletal muscle in 
the treatment groups. Therefore myoblast seeded scaffolds seems to have superiority over 
non- seeded scaffolds in cell infiltrations as well as mechanical performances. Similarly Lai 
et al. (2003) have stated that the success of a tissue-engineered composite might be determined 
by both the strength of the scaffold and the angiogenesis to support the new cells. 
The adhesion formation depends on material surface geometry and affects the correctly 
organized neo-peritoneum regeneration. In previous in vitro study in which mesothelial cells 
were seeded onto various biomaterials, it has been established that mesothelialization 
occurs early when the prosthesis is of laminar type. In contrast, when the biomaterial has 
the structure of a reticular mesh mesothelial deposition takes place in an irregular manner, 
with cells settling on the prosthetic filaments, achieving an uneven cover, therefore they 
speculated that early stage mesothelial deposition after implant is probably conditioned by 
the structural design of prosthesis (Bello’n et al., 2003). 
The origin of adhesions between the organs and the parietal peritoneum has yet to be 
determined. These formations also appear after biomaterial implantation to repair 
abdominal wall defect, mainly when macroporous biomaterials, such as polypropylene 
mesh, are utilized. This fact has been observed by several authors in animal models, such as 
the Sprague-Dawley rat and the New Zealand white rabbit (Bello’n et al., 1996). Moreover, 
in human it is well known that intra-peritoneal positioning of conventional parietal mesh 
provides efficient reconstruction, but it causes visceral adhesion formation in 80–100% of the 
cases (Balique et al., 2005). In our study, all the adhesion found between the implanted graft 
and the visceral organ (caecum) was mild. 33% and 22.22% of adhesion was found in control 
group III and IV respectively. Absence of adhesion in treatment group II was noticed. The 
early formation of a mesothelium covering the myoblast seeded graft probably explains the 
lack of adhesion formation observed following implantation. Besides, it is likely that the 
delay in mesothelialization associated with non-myoblast seeded groups (control) implant 
gives rise to the frequent adhesions that occur at the biomaterials-visceral peritoneum 
interface. Ironically, a single case out of nine (11.11%) rabbits from treatment Group I have 
showed mild adhesion with caceum which is likely to be affected by the individual variation 
factors rather than by the type of the implanted grafts (Tables 3 and 4, and Figure 15). 
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Date of euthanizing 
Day 7th Day 14th Day 30th
Adhesion 
degree 
S C S C S C 
0 3 2 3 2 2 2 
1 0 1 0 1 1 1 
2 0 0 0 0 0 0 
3 0 0 0 0 0 0 
Based on Mann-Whitney Test, P= 0.270, Since P > 0.05, there is no significant difference in adhesion 
formation between treatment and control groups 
S - Myoblast seeded BP (Group I) 
C - Non seeded BP (group III) 
1 - Showing minimal/ minor adhesion observed between the implanted and the underlying visceral 
organ 
Table 3. Scoring of adhesion formation at 7th, 14th, and 30th days of post-implantation for 
bovine pericardium scaffolds 
 
Date of euthanizing 
Day 7th Day 14th Day 30th 
Adhesion 
degree 
S C S C S C 
0 3 2 3 2 3 3 
1 0 1* 0 1* 0 0 
2 0 0 0 0 0 0 
3 0 0 0 0 0 0 
Based on Mann-Whitney Test, P= 0.145, Since P > 0.05, there is no significant difference in adhesion 
formation between treatment and control groups. 
S - Myoblast seeded BTV (Group II) 
C - Non seeded BTV (Group IV) 
1* - Showing minimal/ minor adhesion observed between the implant and the underlying visceral organ 
Table 4. Scoring of adhesion formation at 7th, 14th, and 30th days of post-implantation for 
bovine tunica vaginalis scaffolds 
 
 
Fig. 15. Peritoneal surface of A) group IV showing seroma formed between neo-peritoneum 
and the implanted scaffolds at day 7 post-implantation and B) minor adhesion between the 
implant and caecum at day 14 post-implantation 
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3.3 Light microscopic analysis 
The attack of body immune system on implant can cause failure of the biomaterials to serve 
as the tissue replacement. Biocompatibility involves the acceptance of biomaterial by the 
surrounding tissue and by the body as whole (Park & Lakes, 2007). Histopathologically, the 
present study revealed that the inflammatory response in all treatment and also controls 
groups of animals were significantly high during the first week (7th days) of post-
implantation (Figure 16). It was indeed an immediate response initiated by surgical trauma 
when the abdominal well defects were created which perhaps correlated with the 
inflammatory phase of defects. A similar observations was reported by many researchers 
(Singh et al., 2008; Zuki et al., 2007; Gangwar et al., 2006; Gamba et al., 2002; Tung et al., 
2002).  
 
  A  B  C 
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Fig. 16. Microphotographs of group I (A), group II (B) and group IV (C) at 7th day of post-
implantation showing the inflammatory cells surrounding the implanted scaffold (im). Note 
also the presence of neo-peritoneum (np), subcutaneous tissue (sb) and adiposity (ad) in A 
and B but neo-peritoneum was not detected in C. H&E, Bar = 500µ 
Moreover, the inflammatory process is a normal response to surgical injury and the 
presence of implant as foreign objects. In facts inflammation is necessary as the transitional 
linking stage between damaged tissue and repair of damaged tissue (Dumitriu, 1994). 
However, our study showed that the inflammatory process gradually decreased in every 
advancing period in all treatment and controls groups of both BP and BTV originated 
scaffolds. These findings suggest that the processing method to produce fibro-collagenous 
scaffolds is better to removes antigenic proteins and maintain graft integrity. It might also be 
associated with early degradation and resorption of the implant. As Hafeez (2005) had 
reported, the cervices and pores created by freeze drying and the fragmentation caused by 
gamma rays for sterilization in lyophilized grafts enhances inflammatory cells infiltration 
into the implant and leads to early degradation and resorption. Apart from its processing 
methods, collagen bundles of the implant in treatment group II and control group IV were 
not completely resorbed at 30th day of post-implantation, ironically the implant of treatment 
group I and its control group III has showed better resorption rate. This slight difference 
might be as a result of higher density of fibro- collagenous nature of BTV originated 
scaffolds than the BP originated scaffolds. 
Previous study that had been reported by Hafeez (2005) indicated that lyophilised BP and 
BTV graft were started resorption at week three post-implantation in a rat model. However, 
the present results showed earlier resorption which can be explained by species differences 
as showed in figure 17. Despite the unknown exact mechanism, several factors, including 
the animal species, age and site of implantation may play an important role in the rate of 
degradation of implant (Vialle-Preles et al., 1993).  
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This investigation showed that in both control groups (III and IV) the implanted grafts were 
overwhelmed by fibroblasts, mesenchymal cells and neovascularisation. These 
mesenchymal and fibroblasts were frequently observed throughout the biomaterials. In fact 
the collagen fibers and ground substance (matrix) were synthesised and deposited by newly 
migrating fibroblast as it was showed by the gradual spread of newly formed tissue in the 
implanted graft. The newly formed collagens in the first week were delicate, immature and 
unorganized. Later on the 2nd and 4th weeks post-implantation, the amount of collagen fibers 
increased and infiltrated throughout the implant in well defined and organized form. 
However, there was not even a single skeletal muscle fiber formation in the implant of 
control groups. This finding seems consistence with previous reports of biological 
biomaterials mediated wound repair (Singh et al., 2008; Zuki et al., 2007; Gangwar et al., 
2006; Gamba et al., 2002; Tung et al., 2002). 
 
 
Fig. 17. Microphotographs of group I (A) and group II (B) at 14th day of post-implantation 
show the graft is completely replaced by collagen fiber (green) and small delicate muscle 
fibers (red colour). Masson trichrome stain, Bar = 500µ 
In contrast to the above cases, in both the treatment groups (I and II), skeletal muscle tissue 
regeneration were clearly observed. The myoblast were originated from the seeded part, not 
from the host tissue. At 14th day of post- implantation, the newly formed muscles were 
young muscle fibers (Figure 17) but eventually at the 4th week post-implantation, they 
became matured and became well-defined muscle fibers (Figure 18). Since the seeded 
myoblast were labelled with fluorescence dye and therefore the newly formed muscles 
fibers were further confirmed by fluorescence microscopy (Figure 19).  
The importance of rapid mesotheliazation of biomaterials stems from the fact that adhesion 
formation is inversely related to the number of mesothelial cells on the peritoneal surface 
(Law & Ellis, 1988). Therefore, myoblast seeding on the scaffolds has proved well organized 
bridging of peritoneal lining (mesotheliazation) across the wound with better 
vascularisation and this could be contribute to the preventions of intra-abdominal adhesion 
between  the biomaterials and visceral organs. 
The formation of foreign body giant cells is a feature of chronic inflammation which occurs 
in the presence of microorganism or non-phagocytosable materials for long period of time. 
The foreign body reaction appeared as macrophage and foreign giant cells (Anderson, 1998). 
In our study absence of foreign body giant cells were noted in both the treatment and 
control groups of the two types of scaffolds. This could suggest (indicates) the 
biocompatibility of the scaffolds with the host tissue. Our study has also revealed that both 
type of myoblast seeded scaffolds showed similar appearance histopathologically, meaning 
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that apart from newly formed delicate collagens, newly formed young muscles were 
observed which eventually became matured and became well-defined muscle fibers. 
However, on both type of non-myoblast seeded scaffolds (control groups) only delicate, 
immature and unorganized collagens fibers were observed within the first week which is 
later on become organized and mature collagens fibers without a single skeletal muscle 
fibers development. 
 
 
 A  B 
 
Fig. 18. Microphotographs of Group I (A) and group II (B) at 30th day of post-implantation 
show the graft was completely replaced by collagen fiber (Green) and well developed 
muscle fibers (Red) and blood vessels (arrows). Masson trichrome stain, Bar = 100µ 
 
 
Fig. 19. Double-fluorescence microphotographs of the graph of Group I (A) and group II (B) 
at day 30th of post-implantation demonstrate the PKH26-labeled myofibers and its DAPI-
stained nuclei. Note the well developed myotube/myofibers. Bar = 100µ 
3.4 Scanning Electron Microscopic analysis 
The SEM examinations at 7th day of post-implantation in both I and II revealed infiltration of 
spherical shape of inflammatory cells with scattered polygonal and spindle shapes of cells 
on the peritoneal surface indicating the beginning of mesotheliazation as depicted on Figure 
20. On day 14th of post-implantation, the treatment groups (I and II) of both type of 
scaffolds, demonstrated the well organized mesotheliazation with confluent polygonal 
shapes of cells covering all over the peritoneal surfaces (Figure 21). By day 30th of post-
implantation, the treatment groups (I and II) of both type of scaffolds, revealed the well 
organized mesotheliazation (neo-peritoniazation) where the polygonal shapes of cells 
covering all over the peritoneal surfaces with numerous cilia like structure (Figure 22). 
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Fig. 20. Scanning electron micrographs of the peritoneal surface of group I (A) and group II 
(B) on 7th days of post-implantation show the infiltrated spherical shape of inflammatory 
cells (Yellow arrows) with scattered polygonal and spindle shapes of cells (Red arrows) 
 
 
Fig. 21. Scanning electron micrographs of the peritoneal surface of Group I (A) and group II 
(B) on 14th day of post-implantation show the well organized mesotheliazation of the surface 
with polygonal shape of mesothelial cells 
 
 
Fig. 22. Scanning electron micrographs of the peritoneal surface of Group I (A) and group II 
(A) on 30th day of post-implantation show the smooth appearance of the surface with 
numerous cilia in A 
The SEM analysis of the present study has showed a clear understanding by the speed at 
which mesotheliazation of the myoblast seeded scaffolds in both types of scaffolds on the 
peritoneal surfaces. These undoubtedly give rise an optimal interface between the graft and 
visceral organs in avoiding the formation of adhesion and also the appearance of 
complications related to adhesion because as Chew et al. (2000) had reported in their study 
 A B 
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that firm adhesion may become integrated within the biomaterials which can provoke long 
term complications such as intestinal fistula in some cases.  Moreover, the ultrastructure 
findings in this study are also indicates reduction of inflammatory cells as the day advances 
in all the treatment and control groups of both types of scaffolds. 
Ultrastructural analysis has further confirmed the profound differences between 
treatment and its control groups in mesotheliazation/neo-peritoniazation of the 
peritoneal surfaces. Treatment groups/myoblast seeded scaffolds in both type of scaffolds 
has showed a well-organized neo-peritoneum generation which might be induced by 
seeding of myoblast and it could be a good explanation for absence of adhesion. In 
contrast, on both type of non-myoblast seeded scaffolds (control groups) uneven 
peritoneum with an irregular mesothelium, which is prone to develop adhesion as 
reported by Losi et al. (2007). 
3.5 Fluorescence microscopic analysis 
Fluorescence microscopic analysis clearly demonstrates that myoblast seeded biomaterials 
can be successfully transplanted into artificially created full layer of abdominal wall defects 
except the skin. The prerequisites for using PKH26 for labelling of cells has been 
demonstrated in the previous study by many researchers that the incorporation of PKH dye 
does not physically weaken the membrane of the cells, does not interfere with the functions 
of the cells and appeared to be ideal for long-term tracking of cells. Animal studies revealed 
no toxicity of the PKH dye and no immune response appears to generate against labelled 
cells (Read et al., 1991; Slezak and Horan, 1989a, 1989b; Melnicoff et al., 1988). Most 
importantly, Johnsson et al. (1997) had reported in their ‘ex vivo PKH26-labelling of 
lymphocytes for studies of cell migration in vivo’ study of this labelling dye was found to be 
retained within the labelled cells and not transferred to other cells.  
As expected, the seeded myoblast onto two type of naturally originated collagen based 
scaffolds materials did not migrate into surrounding tissue rather it remained within the 
defects. Therefore, cell growth and fusion within the defects suggests that this technique 
might be suitable for filling volume defects in ectopic locations outside skeletal muscle.  
Engineering of multinucleated myotube which later on differentiated into mature striated 
muscle fibres and its existence for up to the end of the study period showing the superiority 
of this study to the previous case reported by Van Wachem et al. (1999) where failure of 
muscle regeneration noted. Lai et al. (2003) has also reported that scaffold covered with 
skeletal muscle cells did not differ from fibroblast construct in terms of hernia rate.  
However, Kamelger et al. (2004) have reported the successful regeneration of skeletal 
muscles in their comparative study of three different biomaterials in the engineering of 
skeletal muscle using a rat animal model. The fluorescence microscopy have clearly 
indicated that the similarity of the current results with their study. 
In the present study, in both type of myoblast seeded scaffolds the fluorescence microscopy 
has clearly indicated regeneration of multinucleated skeletal muscle with well developed 
vascularisation all over the implant and this finding seems consistence with the results 
reported by Kamelger et al. (2004) and Conconi et al. (2005). However, no PKH26 labelled 
myoblast was observed in both type of non-myoblast seeded scaffolds, and not even a single 
skeletal muscle tissue has been detected in the control groups (III and IV), meaning that all 
the skeletal muscle obtained in the treatment groups were originated from seeding rather 
from host tissue which indeed confirmed by its PKH26 fluorescence dye. 
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Van Wachem et al. (1999) reported one of the reasons for the failure of muscle regeneration 
may be absence of vascularisation. However, this study has showed that early well 
vesicularization (neo-angiogenesis) of the implant microscopically and also macroscopically 
which perhaps may have an impact on the successful regeneration of skeletal muscles at 
large. 
4. Conclusion  
In general, lyophilized and gamma sterilized BP and BTV scaffolds have showed a 
tremendous potential for in vitro cultivation of skeletal muscle, it renders great success when 
used as substrate for filling of wound bed or for the delivery of cells. Myoblast harvested 
from primary culture are able to proliferate and form myotube in vitro on both type of 
collagens based biomaterials. This study has also showed that well vascularised 
biomaterials-myoblast-construct can be successfully implanted for reconstruction of 
abdominal wall defects which profoundly results in regeneration of skeletal muscle tissue. 
Myoblast seeded scaffolds did not provoke a significant inflammatory response compared 
to the non-seeded collagen based scaffold. These engineered myoblast-constructs have 
better cell infiltration and mechanical performances that ultimately avoid adhesion between 
the graft and visceral organs than the non-myoblast seeded construct. These finding 
suggests seeding of myoblast to these scaffolds may be a viable alternative to engineer 
skeletal muscle tissue for body replacement and remodeling.  
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1. Introduction 
There are wide ranges of pathologies leading to critical adipose and skeletal tissue loss 
including trauma, cancer resection and congenital anomalies. With half of the adult 
population in the United States estimated to be affected by a chronic disease according to the 
World Health Organization, the biomedical burden for replacement tissue continues to rise. 
By 2030, the number of adults over the age of 65 is expected to double to over 70 million in 
the United States (Institute of Medicine, 2008). The use of autologous tissue grafts and 
allografts for multiple organ systems have been successfully employed clinically, however 
many inherent disadvantages to these strategies exist including graft failure, infection, 
donor site morbidity etc. (Becker et al. 2011). While synthetic materials are not limited by 
availability, they are prone to infection, rejection, and breakdown over time (Keefe, 2009).  
Due to these inherent limitations, true regenerative medicine remains the ultimate goal for 
tissue replacement.  
In 2001, researchers isolated a new population of adult multipotent cells in lipoaspirate 
(Zuk, et al. 2001, 2002).  Since the discovery of adipose-derived stromal cells, a tremendous 
amount of work has been done in characterizing this population of cells and defining their 
capacity for multipotent differentiation. Adipose-derived stromal cells have potential 
advantages over other types of stem cells such as mesenchymal stem cells in that they are 
widely available and easily harvested through a simple liposuction procedure without 
altering their viability. Adipose-derived stromal cells can differentiate into mesodermal cell 
lines and offer a broad range of possibilities for application within the field of tissue 
engineering. These cells have already been put through several clinical trials in the 
treatment of a diverse array of pathologies including ST-elevated myocardial infarctions, 
Crohn’s fistulas, and spinal cord injuries (Clinical Trials.gov, 2011).  
Bone regeneration is an area of great interest in the field of tissue engineering. Over sixty 
million Americans are expected to be diagnosed with osteoporosis or low bone mass by the 
year 2020 (Samelson & Hannon, 2006). This can generate critical pathology as 1 in 2 women 
and 1 in 4 men over the age of fifty experiences an osteoporotic fracture in their lifetime 
(National Osteoporosis Foundation, 2011). With limited availability of autologous bone 
grafts, a bioengineered tissue replacement would be an ideal clinical alternative. Adipose-
derived stromal cells were shown early on to have the capability for osteogenic 
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differentiation in vitro (Gimble & Gullak, 2003) and the ability differentiate into osteogenic 
tissue in vivo (Cowan & Longaker, 2004, Cowan & Longaker, 2005). With adipose-derived 
stromal cells osteogenic capability defined, research has focused on identifying specific 
methods and pathways that enhance the osteogenic capability of adipose-derived stromal 
cells. In this chapter, we will focus on the major pathways involved in osteogenic 
differentiation and their modulation to allow for greater osteogenic capability for skeletal 
tissue engineering.  
A critical aspect in skeletal tissue engineering is the ability for the implanted cells to 
function within the three-dimensional structure of the surrounding skeleton. The implanted 
cells must have the proper biomechanical characteristics of bone to allow it to have the form 
and function necessary for successful skeletal regenerative tissue. The development of 
scaffolds with osteoinductive properties has allowed for cells to be placed within a three-
dimensional structural environment mimicking the skeletal system. These scaffolds provide 
an environment or niche for cell differentiation and integration within the surrounding 
tissue and promote the proper healing of the skeletal defect. In this chapter, we will discuss 
several of the major synthetic scaffolds being used in skeletal tissue engineering and how 
certain scaffold properties can enhance osteogenic healing within the skeletal defect. 
Another potential clinical application of adipose-derived stromal cells with tissue 
engineering is their use for soft tissue replacement. Of particular importance is the use of 
adipose-derived stromal cells for reconstruction in post-mastectomy patients. According to 
the National Cancer Institute, 12.15% of woman will develop breast cancer in their lifetime. 
The safety of adipose-derived stromal cells for reconstruction was shown within the setting 
of breast cancer once active disease was eliminated  (Zimmerlan et al. 2011). In 2007, Cytori 
Therapeutics, Inc. received FDA approval for Celution® System apparatus which automates 
sorting of lipoaspirate to isolate adipose-derived stromal cells for the application of breast 
reconstruction. This device has already been used in Europe and Japan in the clinical setting 
and the application to breast reconstruction could be an avenue for a widespread clinical use 
of adipose-derived stromal cells meeting FDA approval.  
It is important for both clinicians and scientists to understand the current research with 
adipose-derived stromal cells given the great potential these cells have for future 
therapeutics. Therefore, we will cover the current research with adipose-derived stromal 
cells and their potential for osteogenic and adipogenic differentiation along with some of the 
major relevant pathways leading to their differentiation. In addition, we will cover different 
scaffolds that have been used to place these cells within the three-dimensional network of 
the surrounding tissue. Finally, we will discuss possible directions for future research.  
2. Adipose-derived stromal cells and osteogenesis 
The generation of skeletal tissue remains an elusive clinical goal of regenerative medicine. 
The relative paucity of available donor sites for autogenous bone grafts limits their use in 
clinical application. The need for bone replacement is increasing with an aging population, 
leading to an increase in the number of patients diagnosed with osteoporosis with 
subsequent fractures. In addition, the treatment of non-union fractures across all ages and 
populations remains a high biomedical burden. Since the isolation and characterization of 
adipose-derived stromal cells, significant work has been done defining protocols for 
inducing osteogenic differentiation within this population of multipotent cells.  
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2.1 In vitro methods of human and mouse adipose-derived stromal cell harvest 
Adipose derived stromal cells can be harvested following a liposuction procedure or an 
adipose tissue resection. While surgeons initially believed ultrasonic techniques would have 
a negative effect on adipose-derived stromal cell viability, it has been shown that they retain 
their osteogenic capacity following ultrasonic assisted liposuction (Panetta, et al, 2009). The 
other major difference between harvesting adipose-derived stromal cells after a liposuction 
procedure rather than an adipose tissue resection is the use of tumescent or saline fluid that 
is injected prior to liposuction procedures.  This injection decreases surgical bleeding and 
makes the procedure technically easier to perform. However, the additional fluid injected 
during lipoaspiration dilutes the adipose-derived stromal cells, and thus the total number of 
adipose-derived stromal cells able to be isolated in liposuction tissue. Therefore, adipose-
derived stromal cells harvest yields following a lipoaspiration procedure are often less than 
following an adipose tissue resection. 
Once the lipoaspirate is collected, the stromal cells within the heterogeneous population of 
cells within the lipoaspirate must be isolated. The adipose tissue settles into two layers 
consisting of the supernatant, which contains suctioned adipocytes along with stroma and 
the bottom layer of liposuction aspirate fluid containing larger pieces of lipoaspirate (Levi & 
Longaker, 2011). Adipose-derived stromal cells can be isolated from either layer, but there is 
a higher yield of stromal cells from the adipocyte supernatant (Yoshimura, et al. 2006). From 
there, adipose-derived stromal cells are isolated though a series of digestion, washing, 
straining, and neutralizing steps (Yu, et al. 2011) through readily available protocols. Once 
the progenitor cells are isolated, they can be plated for in vitro expansion and manipulation 
in culture or direct injection into a defect site.  
Adipose-derived stromal cells have been shown to be similar in profile to bone marrow and 
umbilical cord blood derived stem cells (Kern, et al. 2006). Adipose-derived stromal cells 
were first characterized by their ability to differentiate into certain mesenchymal cell 
lineages. Using flow cytometry analysis, researchers have attempted to define these stromal 
cells by specific cell surface markers. However, generating a defined list of concrete markers 
has been a challenge. This is likely due to variability in patient profile and number of in vitro 
passages along with variability in stages of differentiation. Despite these difficulties, the 
International Society for Cellular Therapy released a position paper in 2006 stating that the 
minimal criteria for being classified as a mesenchymal stromal cell according to cell surface 
markers to include the expression of CD105 (Endoglin), CD73, and CD90 while lacking 
expression of hematopoietic markers CD45, CD34, CD14, CD11b, CD79α, CD19, and HLA-
DR (Dominici M, et al. 2006).  
2.2 Osteogenic in vitro differentiation protocols 
The cocktails used for osteogenic differentiation do not vary as much as those for adipogenic 
differentiation.  In general, all osteogenic media protocols utilize β-glycerol phosphate and 
ascorbic acid, albeit in slightly different concentrations (Table 1).  Interestingly, mouse 
adipose-derived stromal cells have been shown to be less osteogenic than human adipose-
derived stromal cells when using these two components alone.  Studies have shown that 
mouse adipose-derived stromal cells require an additional osteogenic stimulus, such as 
retinoic acid (Wan, et al. 2006).  Moreover, growth factors such as fibroblast growth factor 
(FGF)-2 inhibit the osteogenic differentiation of mouse adipose-derived stromal cells, while 
human adipose-derived stromal cells osteogenic differentiation proceeds relatively 
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unabated in the presence or absence of FGF-2 (Quarto & Longaker 2006; Quarto & Longaker 
2008).  Interestingly, preliminary data from our group has demonstrated that TGF-β acts to 
inhibit both osteogenesis and adipogenesis in mouse adipose-derived stromal cells. Instead, 
it seems that TGF-β acts to drive mouse adipose-derived stromal cells toward a 
chondrogenic fate (James, et al, 2009; Xu, et al. 2007).  TGF-β has also been shown to inhibit 
osteogenic human adipose-derived stromal cell differentiation in large doses. Additionally, 
while retinoic acid can be utilized to augment mouse adipose-derived stromal cells 
differentiation, it has little effect on the ability of human adipose-derived stromal cells to 
undergo osteogenic differentiation (Levi, et al, 2010a; Wan, et al, 2007a) Human adipose-
derived stromal cells osteogenic differentiation can, however, be enhanced by 
supplementation with several cytokines, such as Insulin Like Growth Factor (IGF) (Levi & 
Longaker 2010a), Platelet Derived Growth Factor Alpha (PDGF-α)(Levi & Longaker 
2010a), Sonic Hedgehog (SHH) (James, et al. 2010), or Bone Morphogenetic Protein-2 
(Knippenberg M, et al. 2006). 
 
Cytokine Stimulatory or Inhibitory Target Osteogenic Concentration 
Retinoic Acid Stimulatory (in mouse ASCs) 1-10 uM 
Sonic Hedgehog Stimulatory 100-750 ng/ml 
BMP-2 Stimulatory 50-200 ng/ml 
BMP-4 Stimulatory 10-50 ng/ml 
IGF-1 Stimulatory 25-50 ng/ml 
PDGF-α Stimulatory 10-20 ng/ml 
Noggin Inhibitory 100-400 ng/ml 
BMPR-IB/ALK-6/Fc Chimera Inhibitory 0.5-2.0 ug/ml 
Table 1. Stimulatory and Inhibitory Cytokines for ASCs for use in Osteogenic Differentiation 
Media 
For osteogenic differentiation, cells should be plated in a 6-well plate (80,000-100,000 cells 
per well), a 12-well plate, (35,000-45,000 cells per well), or a 24-well plate (15,000-25,000 cells 
per well).  After attachment, adipose-derived stromal cells can be cultured in osteogenic 
differentiation medium.  
Early and late osteogenic differentiation has been defined to occur at specific time points, 
and these time points vary between species. While mouse adipose-derived stromal cells 
undergo early osteogenesis after 7 days in culture and late osteogenesis after 14 days in 
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culture. In contrast, human adipose-derived stromal cells begin to differentiate much earlier 
than mouse adipose-derived stromal cells and show evidence of early and late osteogenesis 
following 3 and 7 days in culture, respectively.  RNA analysis of adipose-derived stromal 
cells for specific osteogenic gene markers is a commonly used method to assess osteogenic 
differentiation in a quantitative manner. Specific gene markers for early osteogenic 
differentiation include Alkaline Phosphotase (ALP), Runt Related Protein-2 (RUNX-2), and 
Collagen Ia1 (COL1A1). Gene markers for intermediate and late osteogenesis include 
Osteopontin (OPN) and Osteocalcin (OCN), respectively.  Alkaline phosphatase staining and 
quantification is another method used to assess early osteogenic differentiation of adipose-
derived stromal cells (day 3 for human adipose-derived stromal cells, day 7 for mouse 
adipose-derived stromal cells). Late osteogenic activity can be assessed by Alizarin red or 
Von Kossa staining, which are assays for extracellular mineralization (day 7 in human 
adipose-derived stromal cells, day 14 in mouse adipose-derived stromal cells).  
2.3 Molecular pathways of differentiation 
There are several key molecular pathways that lead to the differentiation of a multipotent 
cell into a mature osteoblast in the process of osteogenesis. Runx-2 is considered the 
principal osteogenic switch and has a key role in the commitment of stem cells into an 
osteoblastic lineage. Runx-2 null mice show a complete deficiency in skeletal formation 
(Komori and Kishimoto, 1998). Runx-2 is transcriptionally upregulated by the bone 
morphogenetic proteins (BMP) through transduction via Smad 1 and 5 (Chen et al, 2004). 
Retinoic acid has also been shown to increase Runx-2 expression and stimulate mouse 
adipose-derived stromal cell osteogenic differentiation by increasing the expression of 
BMPR-IB protein (Wan, Longaker 2006).  While Transforming Growth Factor-Betas (TGF- 
βs) have been shown to be increased during bone development and growth, their effect on 
precursor cell differentiation into osteoblasts depends on cell type, stage of differentiation, 
and levels of expression (Linkart 1996, Komori 2002).  
The Wnt signaling pathway is a group of proteins involved in a wide array of 
developmental and cellular processes. In the canonical Wnt pathway, Wnts bind to cell-
surface receptors of the Frizzled family and their co-receptors, low-density lipoprotein 
receptor related protein (LRP), leading to inactivation of the axin-glycogen synthase kinase 
3β complex which stabilizes Beta-catenin. Beta-catenin translocates into the nucleus to 
promote Wnt gene expression. LRP5 knockout mice show a phenotype with low bone mass 
(Gong et al, 2001) while overexpression of the same gene is associated with high bone mass 
(Boyden et al, 2002). Wnt3A has been shown to have differing results on osteogenic 
differentiation depending on dosage and level of baseline differentiation along with age of 
the cells. (Quarto, Longaker 2010). Low dose treatment with Wnt3a enhanced bony 
regeneration in a mouse critical calvarial defect treated with differing doses of Wnt3a in 
juvenile mice, while higher doses decreased repair (Quarto, Longaker 2010). Conversely, in 
adult mice, increasing doses of Wnt3a enhanced bone regeneration.   
In the non-canonical Wnt pathway, Wnts bind to the receptors Frizzled and Dishevelled but 
the non-canonical pathway does not mediate its signal through the glycogen synthase 3β 
kinase complex or the Beta-catenin complex, but rather through G-proteins and GTPases. 
While the most studied aspect of the non-canonical Wnt pathway is their regulation in cell 
polarity, a growing body of evidence suggests that this pathway is important in bone 
development. Wnt5a has been shown to increase osteoblast formation from human bone 
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mesenchymal stem cells in vitro (Baksh & Tuan, 2007). In human adipose-derived stromal 
cells, the addition of Wnt5a in vitro increased the expression of Runx2 and osteocalcin and 
mineralized nodule formation (Santos, et al, 2010).  
2.4 Growth factors and hormones that promote osteogenesis 
Growth factors are signaling molecules that have a wide effect on cellular processes. The 
majority of growth factors are secreted as proteins or hormones and act in an autocrine, 
paracrine, or endocrine manner to affect cellular proliferation and differentiation by 
regulating gene expression, protein synthesis, and cell signaling. Through the modulation of 
specific growth factors, osteogenesis can be enhanced with the result of improved skeletal 
healing.  
Bone morphogenetic proteins are a group of secreted cytokines that belong to the 
Transforming Growth Factor-β superfamily. Throughout history, skeletal tissue was 
known for its ability to regenerate and efforts were undertaken to try to isolate an 
intrinsic property secreted by these cells that led to their regenerative properties. BMPs 
were first discovered and named in 1965 (Urist, 1965) and the first BMP gene was isolated 
and cloned by Wozney in 1988 (Wozney et al, 1988). In 2002, the FDA approved the use of 
recombinant BMP-2 to be used on a three-dimensional scaffold for anterior lumbar fusion 
(McKay et al, 2007). Today, over twenty different genes belong to the BMP family mainly 
involved in the regulation of bone and cartilage formation (Bessa C et al. 2008). The BMP 
proteins signal (Fig. 1) through BMP receptor Type I and II, which leads to the 
phosphorylation of receptor-regulated SMAD 1,5, and 8, which combine with the 
common-mediator SMAD 4. This complex then migrates into the nucleus to affect gene 
expression.  
A large body of research has validated the importance of BMP-2’s role in bone formation 
and healing. BMP-2 has been shown to induce chondrocyte and osteoblast precursor 
formation in mesenchymal stem cells (Wall et al. 1994) and specifically shown to induce 
osteogenic differentiation in adipose-derived stromal  cells (Dragoo et al. 2003) in vitro. Our 
group (Cowan, Longaker 2005) showed the use of BMP-2’s effect combined with adipose 
derived stromal cells in vivo on bony healing by culturing adipose-derived stromal cells with 
rhBMP-2 for 4 weeks prior to implantation onto a PLGA scaffold into a critical-sized 
calvarial defect in a mouse. With the treatment of BMP-2 ex-vivo, cells treated with 
recombinant human BMP-2 showed accelerated healing over unstimulated scaffolds with 
complete healing in as little as two to four weeks as demonstrated by histology and 
microCT. Interestingly, prolonged exposure to recombinant human BMP-2 was also shown 
to increase osteoclast activity and increase bone turnover and resorption. Therefore, to avoid 
increased bone turnover, our group used direct in vivo injection of recombinant human 
BMP-2 without the prolonged ex-vivo treatment (Levi, Longaker, et al 2010b) into a critical 
calvarial defect with and without adipose-derived stromal cells. Cells treated with 
recombinant human BMP injected subcutaneously into the skeletal defect on post-op days 1-
3 showed increased healing at 8 weeks over unstimulated scaffold alone and untreated cells. 
The increase in osteogenesis was observed with this method of BMP-2 augmentation, but 
without the stimulation of osteoclast-induced bone turnover and resportion. The current 
scope of research is concentrating on how to deliver BMP-2 into the skeletal wound 
microenvironment to promote osteogenesis and bony healing while minimizing side effects 
such as ectopic bone formation (Zara, Siu, Soo et al. 2011).  
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Fig. 1. Bone Morphogenetic Protein Pathway 
BMP ligand binds to BMP-R1 or 2, which phosphorylates SMAD 1,5, and 8. Co-smad 4 
complexes with Smad 1,5, and 8 and translocates into the nucleus and regulates gene 
expression   
In addition to BMP-2, BMP-7 (Osteogenic Protein-1) has also been shown to be effective in 
the augmentation of skeletal healing. In a monkey model, recombinant human BMP-7 was 
injected into a scaffold at the skeletal injury site and demonstrated healing in an 
ulnar/tibial segmental defect model. (Cook, et al 1995).  A randomized clinical trial 
compared the use of BMP-7 versus autogenous bone graft in the treatment of tibial non-
unions (Friedlaender, 2004) and found that using BMP-7 was equivalent in clinical 
outcomes without the morbidity of using an autogenous bone graft. Specifically with 
adipose-derived stromal cells, researchers using an adenovirus vector ex vivo to induce 
BMP-7 expression showed increased bone formation both in vitro and in vivo using rat 
adipose-derived stromal cells (Yang, et al. 2005) and in human adipose-derived stromal 
cells (Kang Y, et al. 2007). 
The fibroblast growth factor family has over twenty members and four receptors involved in 
diverse cellular processes from angiogenesis to wound healing. Similar to the BMP family, 
fibroblast growth factors have been shown to have a significant effect on osteogenesis 
(Ornitz and Marie, 2002). In particular, FGF-2 is expressed in osteoblastic cells and has been 
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shown to have important functions in the regulation of bone and cartilage formation. FGF-2 
knockout mice show decreased bone mass and bone formation compared to control mice 
(Montero et al. 2000).  Initial work on the effect of FGF-2 on adipose-derived stromal cells 
showed that FGF-2 expression was critical in maintaining clonogenicity and differentiation 
potential (Zaragosi et al. 2006) along with the maintenance of adipose-derived stromal cells 
proliferation in vitro (Quarto and Longaker, 2006). Evaluation of FGF expression during 
osteogenic differentiation of adipose-derived stromal cells showed that FGF-2 is down-
regulated during osteogenic differentiation (Quarto and Longaker, 2008) while FGF-18 is 
upregulated. This was explored further by examining different isoforms of FGF-2. The high 
molecular weight protein form of FGF-2 increased expression during osteogenesis while the 
low-molecular weight form decreased, suggesting a regulation at the translational level in 
the balance between maintaining multipotency and lineage commitment. In order to explore 
the effects of FGF-2 in vivo, we engineered feeder cells capable of secreting the FGF-2 protein 
when driven by the presence of a synthetic ligand, Shield-1, which stabilizes a protein-
destabilizing domain fused to the FGF-2 gene (Kwan, Longaker, 2011). Feeder cells and 
adipose-derived stromal cells were both seeded on a scaffold and placed into a mouse 
critical-sized calvarial defect. Shield-1 was delivered intraperitoneally and the mice were 
followed up to 20 weeks. There was significantly improved healing with FGF-2 versus the 
non-injected group of control adipose-derived stromal cells and scaffold alone in the defect. 
A possible explanation for the improved osteogenesis and calvarial defect healing in vivo 
may be linked to the increased proliferation of osteoprogenitor cells due to FGF-2 
expression.  
Insulin-like growth factors are proteins with sequence homology similar to insulin under the 
control of growth hormone. There are two types, IGF-1 and IGF-2, which play a wide 
variety of cellular roles from the regulation of proliferation to apoptosis. Both IGF-1 and 
IGF-2 have been shown to be associated with increase in bone formation and density  
(Adami et al. 2010, Chen et al, 2010) while their reduction has been shown to be associated 
with decreased bone density (Bennett, 1984). In order to specifically identify genes 
upregulated during osteogenesis, our group isolated RNA from human adipose-derived 
stromal cells during in-vitro osteogenesis and performed a microarray analysis (Lee, 
Longaker, 2010). Gene expression of IGF-1 was found to be elevated 3.5 fold from baseline 
levels at day three of osteogenic differentiation with the microarray. IGF-1’s ability to 
increase osteogenesis was then tested by augmenting osteogenic differentiation media with 
IGF-1 in vitro (Levi, Longaker 2010a). Alkaline phosphatase activity was elevated with the 
addition of IGF-1 and there was increased matrix mineralization evident with the treated 
group stained with alizarin red. Quantitative real-time polymerase chain reaction showed 
elevated levels of Runx2 and Osteocalcin when adipose-derived stromal cells were treated 
with IGF-1.   
The effect of estrogen on bone formation is well known. Decreasing levels of estrogen are 
one of the main culprits in the pathogenesis of osteoporosis with estrogen withdrawal 
causing an increase in bone remodeling (Seeman, 2003). While men do not have a 
comparable deceleration of hormone production, circulating levels of free estrogen also 
declines with men with aging leading to comparable long term loss of trabecular bone 
(Seeman, 2004). The addition of estrogen through 17-β estradiol increased levels of 
osteogenesis in human bone marrow mesenchymal stem cells through modulation of 
estrogen receptor α and β (Hong, et al 2006). Human adipose-derived stromal cells 
 
Skeletal and Adipose Tissue Engineering with Adipose-Derived Stromal Cells 
 
115 
augmented with 17-β estradiol in vitro showed increased evidence of osteogenesis through 
increased expression of alkaline phosphatase and osteocalcin as compared to control cells 
without estrogen augmentation (Hong et al, 2007).  
The effect of androgens on bone formation is less clear. It is recognized that patients with 
androgen deficiency have lower bone mass and higher bone turnover compared to patients 
with normal levels of androgen (Hofbauer & Khosia, 1999). The majority of in vitro studies 
indicate that testosterone and dihydrotestosterone have proliferative effects on osteoblast 
progenitors, but there is no consensus as to whether androgens promote or inhibit 
osteogenic differentiation (Vanderschueren, et al, 2004). Androgen replacement therapy in 
vivo has shown to be effective in increasing bone mass in hydogonadal patients, the effect is 
mitigated in patients with more modest decreases in testosterone (Vanderschueren, et al, 
2004). The full effects of estrogen and androgen and differences in sex hormones still must 
be worked out as well as the effect of sex of the donor adipose-derived stromal cells in 
differences on osteogenic differentiation.  
2.5 Gene therapy  
Another strategy for improving osteogenic differentiation is gene therapy to either express 
or knockdown specific proteins for the desired effect altering cellular function. Strategies in 
genetic therapy include in vivo direct gene delivery using a vector for transfection or ex vivo 
techniques, which involves treating the cell of interest with modification of the genome 
outside of the host prior to implantation.  
Gene therapy requires a vector to transfer the genetic material into the target cell. Vectors 
can be divided into viral and non-viral and also whether the strategy integrates the vector 
into the host-genome or is based on a transient effect. Viral vectors have the advantage of 
being efficient in their ability to infect host cells. Common viral vectors are adenovirus, 
lentivirus, and retrovirus. While the integrating viral vectors are efficient and express the 
DNA of question for the life of the cell, there is no way to completely control the site of 
integration leading to concern regarding mutations and oncogenic activity. Viral vectors 
can also elicit a host immune response causing rejection. Non-integrating strategies such 
as liposome based particles and electroporation transiently transfect the cells and have a 
decreased immune response, but are not as efficient and have variable expression.  
Zhang et al. (2006) used an adenovirus vector to overexpress Runx-2 in mouse adipose-
derived stromal cells to increase osteogenesis in vitro and in vivo by implanting seeded 
scaffolds on the back of nude mice. Several strategies have used BMP-2 gene therapy to 
promote bone healing and osteogenic differentiation. A segmental defect created in New 
Zealand white rabbits was treated with adenoviral vectors expressing BMP-2 resulting in 
increased healing in the treatment group (Baltzar, 2000). Lee SJ et al (2010) created a 
bicistronic vector for co-delivery of both Runx-2 and BMP-2 into human adipose-derived 
stromal cells. Using microporation for their transfection strategy, they showed increases in 
osteogenesis in vitro and implanted transfected human adipose-derived stromal cells on a 
PLGA scaffold subcutaneously in vivo showing increase in ectopic bone formation compared 
to control.  
Osterix is a zinc finger transcription factor that is expressed in osteoblasts whose role is 
critical during osteoblast differentiation. Nakashima et al. (2002) first identified osterix 
through a screen of expressed genes during osteogenic differentiation. Through homologous 
recombination, they produced osterix-null mice, which showed no bone formation. Osterix 
  
Tissue Engineering for Tissue and Organ Regeneration 
 
116 
appears to be downstream of Runx-2 as osterix-null mice had normal Runx-2 expression and 
normal cartilage formation. However, Runx-2 negative mice show impaired chondrogenesis 
and decreased osterix expression. Overexpression of osterix has been shown to increase 
osteogenic differentiation in embryonic stem cells by increased in levels of Osteocalcin and 
Runx-2 (Tai, et al. 2004) and in adipose-derived stromal cells  (Wu L, et al 2007). Lee SJ et al. 
(2011) used electroporation to co-transfect Runx-2 with osterix into adipose-derived stromal 
cells. Transfected cells with osterix alone and osterix with Runx-2 both showed significant 
increase in osteogenesis over control cells.  
Msx-2 (Hox-8) is a homeodomain transcription factor that functions as a transcriptional 
regulator of the osteocalcin promoter (Towler DA, et al 1994). Msx-2 has been found to be 
vital in craniofacial development, as mutations within the homeodomain of Msx-2 have 
been shown to lead to craniosynostosis, the premature fusion of calvarial sutures (Jabs, et al. 
1993; Liu et al. 1995). Msx2 null mice have deficient endochondral bone formation, defects in 
skull ossification and a persistent calvarial foramen (Satokata, et al, 2000). Using CMV-Msx2 
transgenic mice, Cheng et al, (2008) showed that overexpression of Msx2 leads mesenchymal 
progenitor cells into an osteogenic lineage enhancing osteoblast formation along with 
trabecular bone formation by activation of the canonical Wnt pathway. 
In looking for specific genetic targets to augment adipose-derived stromal cells for 
osteogenic differentiation, our group focused on the noggin protein, which is an inhibitor 
of BMP signaling. We evaluated the effect of noggin suppression on osteoblast 
differentiation by using siRNA constructs against the noggin protein in primary 
osteoblasts (Wan, Longaker et al, 2007b). Noggin suppression was confirmed using 
western blot and QT-PCR. Evaluation of BMP signaling in vitro with cells transfected with 
Noggin siRNA constructs showed an increase in BMP signaling with Smad1/5 along with 
evidence of osteogenic differentiation of preosteoblasts as compared to control. Noggin 
knockdown also increased skeletal healing in vivo when osteoblasts transfected with 
Noggin siRNA were seeded on a PLGA scaffold as demonstrated by microCT and 
histomorphometric analysis.  
3. Adipogenesis and adipose-derived stromal cells 
The adipogenic differentiation of multipotent stromal cells is of interest to many specialties 
of medicine. The growing body of research in obesity and adipose biology has opened the 
field of adipogenesis to numerous specialties in clinical medicine and science. Stem cell 
scientists, bone biologists, endocrinologists, and tissue engineers all have a vested interest in 
the study of adipogenesis. From a clinical standpoint, surgeons are faced with challenging 
reconstructive cases in patients afflicted with soft tissue deficiencies. For example, burn 
patients often have soft tissue atrophy and severe skin contractures and would greatly 
benefit from soft tissue augmentation.  Similarly, the widespread use of HAART (Highly-
active retroviral therapy) medications for HIV has left many HIV patients with facial 
lipodystrophy, which can be disfiguring and socially troublesome. In the pediatric 
population, patients with congenital malformations would greatly benefit from new soft 
tissue engineering techniques. For example, Parry-Romberg disease causes progressive 
hemifacial soft tissue atrophy in the face. Outcomes of these patients would greatly improve 
with the use of a tissue engineering approach to reconstruct their inadequate adipose 
compartment.  
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3.1 Adipogenic in vitro differentiation protocols 
The adipogenic differentiation protocols of primary mesenchymal stromal cells vary as 
reported in the literature. For the purposes of this chapter, two of the most commonly 
studied mesenchymal stem cells populations were examined: bone marrow mesenchymal 
stem cells and adipose-derived stromal cells. Generally, a three component cocktail is used 
to supplement media for bone marrow mesenchymal stem cell adipogenic induction, 
including Insulin, Dexamethasone, and IBMX (3-isobutyl-1-methylxanthine). There are 
several differences between mouse and human adipogenic differentiation protocols. For 
example, Insulin was not used in the majority of publications in human bone marrow 
mesenchymal stem cell adipogenic differentiation protocols, while insulin is present in the 
majority of murine adipogenic differentiation protocols. Additionally, human adipogenic 
protocols used an increase in dexamethasone along with the addition of Indomethacin in 
comparison to mouse bone marrow mesenchymal stem cell protocols. 
Adipose-derived stromal cells are multipotent mesenchymal cells and thus can be 
differentiated into adipocytes.  With regards to adipose-derived stromal cell adipogenic 
differentiation, there are a wide variety of reports of varied differentiation cocktails with 
many published articles in the last year (Romo-Yanex, et al 2011;  Ghosh, et al, 2010; James, 
et al. 2010; Valorani, et al, 2010, Lee JE, et al. 2010). Generally, a three or four component 
cocktail is used for adipose-derived stromal cell adipogenic differentiation, including 
Indomethacin, Insulin, Dexamethasone and IBMX.  Similar to bone marrow mesenchymal 
stem cell adipogenesis protocols, there are a wide variety of recommended cocktails that 
become even more heterogeneous when comparing protocols for mouse adipose-derived 
stromal and human adipose-derived stromal cell adipogenesis. For example, though insulin 
concentrations in the adipose differentiation media of both mouse adipose-derived stromal 
cell and human adipose-derived stromal cell are relatively similar, an approximate 10-fold 
increase in dexamethasone concentration exists in mouse adipose-derived stromal cell 
adipogenesis protocols when compared to human adipose-derived stromal cell protocols 
3.2 Molecular pathways of differentiation 
At the molecular level, several key genes are expressed during the differentiation of pre-
adipocytes to mature adipocytes including lipoprotein lipase (LPL), peroxisome 
proliferator-activated receptor (PPARγ), and enhancer binding proteins (EbP) (Kronenberg 
& Williams, 2008). In addition, several Hox genes have been recently identified that are 
highly expressed during the adipogenic differentiation of human adipose-derived stromal 
cell (Cowherd, et al. 1997; Cantile, et al. 2003). Other genes such as TAZ have been shown to 
activate the Runx-2 transcription factor and stimulate osteogenesis while inhibiting 
adipogenesis (Hong, et al. 2005).  
PPARγ is one of the most widely studied genes involved in adipogenesis, and has been 
translated for clinical use in the form of the agonist rosiglitazone, as well as the similar 
agents (troglitazone, etc). These PPARγ agonists have been used in the treatment of diabetes 
as they have been shown to speed up the differentiation process of pre-adipocytes or 
adipoprogenitor cells in vitro. Rosiglitazone functions by binding to PPARγ, thus 
‘sensitizing’ adipocytes to insulin (Mayerson, et al 2002). One of the major side effects of this 
class of pharmaceuticals is bone mineral density reduction, which is thought to be due to the 
diversion of mesenchymal stem cells to adipogenesis rather than osteogenesis in vivo 
(Bodmer, et al, 2009; Rosen, et al. 2006). To the full extent that rosiglitazone is able to induce 
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mesenchymal stem cell adipogenesis as a single agent is unknown. However, it is believed 
that this class of drugs is capable of enhancing the differentiation of pre-adipocytes to 
adipocytes in vivo (Ninomiya, et al 2010). Thus, PPARγ agonists may be useful in adipocyte 
induction cocktails for adipose-derived stromal cells. Furthermore, from a clinical 
standpoint, targeting the PPARγ pathway may improve the adipogenic potential of 
transplanted stem cells further improving soft tissue engineering outcomes.  
One of the surgical limitations of fat transfer is the high rate of adipocyte resorption over 
time. It is thought that adipocyte resorption during fat transfer is due to the inadequate 
blood supply and thus, surgeons have set out to improve circulation to transplanted 
adipocytes. Besides alterations in technique, recently, Yoshimura et al has reported 
enhanced adipocyte viability and vascularization when seeding adipocytes with human 
adipose-derived stromal cells from the same patient at the time of surgery (Suga et al 2010, 
Yoshimura, et al. 2008, Yoshimura, et al. 2009, Matsumoto, et al. 2006). This technique offers 
the use of an autologous scaffold seeded with autologous multipotent stromal cells.  Human 
adipose-derived stromal cells are a known vasculogenic cell type that have been shown to 
secrete vasculogenic cytokines, thus working in an autocrine and paracrine fashion to allow 
for improved survival of adipocytes and enabling possible adipogenic differentiation.  
Therefore, potential benefits of using human adipose-derived stromal cells to differentiate 
into adipocytes, include their ability to proliferate after transplantation, their release of 
angiogenic cytokines, and their ability to differentiate into endothelial cells and undergo 
neovascularization (Planat-Barnard et al., 2004; Miranville, et al. 2004, Moon, et al. 2006) 
4. Scaffold technology and adipose-derived stromal cells 
Almost as important as the proper engineering of multipotent cells into the desired lineage 
is their placement within the three-dimensional context of the target organ. This is especially 
true with skeletal and soft tissue engineering as their structure is critical to their function. 
Recent advancements in the design and quality of scaffold technology is critical for the 
advancement of successful in vivo application of multipotent cells. With the goal of 
engineering functional tissue, biomimetic scaffolds are designed to provide 3-dimensional 
structural support for the engineered tissue, uniform pore size and structure for a matrical 
distribution of cells, and combinations of substrates and growth factors to promote viability 
and differentiation along the appropriate cell lineage.  With technologies enabling the 
reliable production of mineralized biopolymers to nanospun fibers, scaffolds engineered 
from these materials promote healing in vivo, (Lew, et al. 1997; Osathanon, et al. 2009) and 
prove a powerful delivery system for adipose-derived stromal cells in the generation of 
functional tissue replacement.   
The growing incidence of craniofacial bone defects arising from congenital malformation, 
surgical resection and trauma necessitates the development for skeletal regeneration of bony 
defects to restore functional movement and protection to the head and its critical structures. 
Regenerated bone exists in a dynamic environment and must provide adequate structural 
support and tensile strength. One of the important models for skeletal regeneration in the 
craniofacial context is the critical size calvarial defect, in which a bony deficit is created in an 
animal model that is of a size that will not heal within the lifetime of an animal.  Thus, any 
healing observed is due to the experimental contribution.  Because of the availability of 
experimental animals and analytical tools, the laboratory mouse is a common model for 
 
Skeletal and Adipose Tissue Engineering with Adipose-Derived Stromal Cells 
 
119 
bone regeneration in calvarial critical-sized defects, which are between 3-4mm in diameter 
(Mooney & Siegel, 2005).  
Critical to the engineering of an ideal scaffold for bone regeneration are the 
biocompatibility, osteoconductive, and osteoinductive properties of the materials.  A 
biocompatible scaffold should be manufactured under sterile conditions, have an even and 
consistent pore size and distribution, and be non-toxic to the host tissues as it breaks down 
over time.  Osteoconductive properties refer to the characteristics of the scaffold framework 
and its impact on the resulting structure of newly formed bone, while osteoinduction is the 
promotion and induction of host or donor cells toward mature osseous formation. A variety 
of inorganic polymers and synthetic nanofibers are being used as the basis for 
manufacturing scaffolds and vary in their capability for osteoinduction, rate of resorption, 
and moldability.  
Polylactide (PLA) and poly lactic-co-glycolic acid (PLGA) polymers have been shown to be 
safe in human tissue (Frazza & Schmitt, 1971) and are resilient to fracture but lack significant 
osteoconduction.  Calcium phosphate and calcium sulfate salts, on the other hand, tend to 
be brittle and difficult to mold but contain natural bone elements of crystal salts found in 
bone matrix and tend to be more osteoconductive scaffolds than their polymer counterparts. 
 Of particular interest in this group is hydroxyapatite, a mineral salt composing a large 
proportion of naturally-occurring bone matrix with strong osteoconductivity (Chang, et al 
2000).  
In order to combine the tensile strength and load-bearing capabilities of a polymer scaffold 
with the osteoconduction and cellular substrate of mineral salts, Cowan et al employed a 
strategy combining osteogenic mouse adipose-derived stromal cells seeded on a PLGA 
scaffold coated with hydroxyapatite for bony regeneration of a 4mm critical-sized defect in 
mouse. (Cowan, et al, 2004)  The combined osteogenic potential of adipose-derived stromal 
cells and osteoconduction of apatite-coated PLGA promoted complete healing within 12 
weeks with major contribution from the transplanted adipose-derived stromal cells as 
shown by chromosomal analysis. Levi et al have recapitulated these results with apatite-
coated PLGA scaffolds in mouse calvarial defect using human adipose-derived stromal cells 
in immunodeficient nude mice, demonstrating the potential of human cellular therapy 
delivered on hybrid polymer mineral scaffold for translational development. (Levi, et al. 
2010b)   
Although significant bone regeneration has been achieved using osteoconductive scaffolds 
and adipose-derived stromal cells without the use of additional growth factors (Cowan, et al 
2004; Levi, et al. 2010b), the stimulation of well-characterized osteogenic pathways may 
enhance efficient new bone deposition in conjunction with biomimetic scaffolds and cell 
therapy.  Bone morphogenetic proteins (BMPs) along with valproic acid and other factors 
have demonstrated abilities to accelerate bone formation in vivo (Cowan, et al. 2005) and 
may be candidates for delivery in combination with ASCs and apatite-coated PLGA 
scaffolds for increased efficiency and reliability of osteogenesis. 
Similar to current clinical treatment modalities for bone defects, soft tissue deficits due to 
trauma, tumor, and congenital etiologies are treated with surgical grafts from autologous, 
allogenic, or alloplastic sources.  The successes of vascularized microvascular flap transfer, 
the gold standard modality, are often accompanied with limitations in source material and 
patient morbidity.  Because adipose tissue has numerous functions, including energy 
regulation, secretion of important paracrine and endocrine factors, and mechanical 
  
Tissue Engineering for Tissue and Organ Regeneration 
 
120 
protection, it is important to develop new strategies for replacement of functional soft tissue 
deficits. Of major consideration for clinical translation is the regeneration of adipose tissue 
following mastectomy, requiring adipose stroma and a biomimetic matrix for the 
replacement of breast tissue. 
Cellular transplants for adipogenic regeneration hinge on scaffolds that support cell 
adhesion and the differentiation and uptake of lipids while providing appropriate structural 
support.  Porosity is a critical factor in the scaffold structure to allow the development of 
angiogenic support necessary for functional tissue formation.  A number of synthetic and 
biological scaffolds have been studied as delivery systems of adipocyte precursor cells for 
effective adipose tissue generation with varying degrees of success and limitations. 
 Inorganic synthetics such as PLGA and polyglycolic acid (PGA) offer moldable, highly 
regular structures and non-toxic breakdown.  Gel-based delivery systems promote cell 
survival but lack the organizational regularity of inorganic scaffolds.  Natural proteins 
found in connective tissue such as collagen can be engineered into scaffold design with 
homogeneous structure and porosity, and mimic biological matrix found commonly in 
adipose tissue.   
Matrigel™ is a gel-like substance derived from animal connective tissue proteins and 
growth factors, and is readily available commercially.  Despite the translational barrier of its 
sarcoma derivation, Kawaguchi et al and others have reported successful angiogenesis and 
adipogenesis following injection of Matrigel™ in mouse fat pad (Kawaguchi, et al. 1998).  
The mixture of components in matrigel including collagen, laminin, and growth factors 
demonstrated sufficiency for the generation of new vascularized adipose tissue, but because 
of the stochastic organization of proteins within the gel, the distribution of cells in the de 
novo tissue reflect a scattered and uneven pattern of growth. Adipogenic tissue regeneration 
with eventual clinical translation in mind should promote predictable growth of new soft 
tissue.  An ideal scaffold would define the structure of the newly formed tissue to be 
populated by transplanted donor cells and stimulated endogenous pre-adipocytes and 
allow for angiogenic growth and support into newly forming tissue. 
One study performed a direct in vivo comparison of three disparate scaffold technologies for 
the delivery of mouse ASCs as an assay for adipogenic ability using PGA, collagen, and 
hyaluronic acid gel (Itoi, et al. 2010).  PGA represents the biodegradable synthetic group of 
scaffolds, extracellular matrix-derived collagen from tendon is a natural product that is 
prepped into porous sponges, and hyaluronic acid (HA) is a derivative of extracellular 
matrix of soft tissue involved in cell proliferation.  ASCs were harvested from GFP mice to 
allow visualization of transplanted cell proliferation and differentiation, grown in 
adipogenic supplemented media, and seeded into the respective scaffolds and transplanted 
into athymic mice.  In all groups tested, fluorescent cells were present at four weeks and a 
slight increase in angiogenesis was seen. In contrast, Oil Red O staining for triglycerides was 
positive only in PGA and collagen groups and negative in HA. At 8 weeks, the most robust 
GFP positive adipose-like tissue was detected in the collagen scaffold construct indicating 
that collagen served as the best adipogenic scaffold in this comparison. 
Promising data from Davidenko et al (2010) combines the naturally-derived extracellular 
matrix components collagen and hyaluronic acid into a hybrid cross-linked scaffold 
designed to provide an array of matrix protein components with the structural advantage of 
collagen.  Thus, this design allows for precise engineering of scaffold structure and porosity, 
even distribution of transplanted adipogenic cells, and physiochemical safety.  Pre-
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adipocyte cells were shown to proliferate and differentiate readily on the scaffold during in 
vitro adipogenic induction and gene analysis showed increased expression of Adipsin 
following differentiation.   
5. Future directions 
Given the abundant availability of lipoaspirate combined with a relatively simple procedure 
to harvest, adipose-derived stromal cells have a potential to be critically important in the 
generation of tissue for clinical use in a wide range of pathologies. While there is great 
promise for the use of these cells, significant hurdles remain before they become available 
for wide spread clinical application. The ultimate translational goal is the ability to harvest 
the lipoaspirate and be able to process and implant the cells into the area of need in the same 
patient during a single surgical procedure. Research in several key areas must happen prior 
to this scenario being realized.  
Currently, the process for sorting and isolating stem cells from the lipoaspirate is a manual 
process. The total number of cells typically obtained is around 300,000 cells per milliliter of 
lipoaspirate (Levi & Longaker, 2011). While this yield is higher then other adult-stem cell 
populations, the process can still be time consuming and labor intensive. For widespread 
clinical use to be possible, the ability to have an automated processing unit isolate the 
stromal cells in the lipoaspirate would be critical to decreasing the time and cost of this 
procedure. Cytori’s Celution® System was developed to automate the sorting process and 
takes around 1 hour to sort 250 ml of lipoaspirate. Using Flow Cytometry, the cells sorted 
using the Celution® system were found to be similar to cells isolated on a manual sort with 
the ability to differentiate into osteogenic and adipogenic cells (Lin, et al. 2008).  As more 
research is done characterizing specific populations within adipose-derived stromal cells, 
the technology should improve to better match and sort for specific populations of cells 
more likely to differentiate into the desired cell lineage.  
The importance of scaffolds and their ability to deliver cells into the proper niche 
environment has been stated. As the technology improves with scaffold development, they 
have become much more than inert materials where cells are placed, but rather can provide 
a highly inductive environment for cells to be “coached” towards a certain lineage. The 
ability to augment scaffolds with various growth factors and cytokines has been shown to 
improve healing within specific wound environments (Brown, et al. 2011). These scaffolds 
can have the advantage of release kinetics allowing for a controlled delivery of the growth 
factor of interest into the wound environment (Kwan, et al, 2011). The future of scaffold 
technology is moving towards the ability to induce genetic therapy within its three-
dimensional structure. The delivery of BMP-2 and BMP-7 through vectors within the 
scaffold structure into host cells has already proven to be effective (Nie, et al. 2007; Zhang, et 
al. 2011).  
6. Conclusion 
With the large clinical need for replacement tissue, adipose-derived stromal cells are easily 
obtained in large numbers and offer a viable option for future therapeutic application given 
their ability to differentiate into multiple cell lines. Through continued research into 
pathways of differentiation, the ability to maximize the yield of these multipotent cells will 
continue to improve. With the increased effectiveness of technology for the sorting and the 
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application of adipose-derived stromal cells, they could soon become an important clinical 
tool for the treatment of a wide range of clinical pathologies.  
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1. Introduction 
The main function of a ligament is to connect one bone to another bone across a joint, 
keeping them aligned to prevent abnormal motions and dislocations. The typical magnitude 
of force a ligament may experience during day-to-day activities varies. For example the 
anterior cruciate ligament of the knee can be exposed to daily tensile forces ranging between 
67N for ascending stairs to 630N for jogging (Vunjak-Novakovic, Altman et al. 2004), 
whereas large loads, exceeding 1800N, can cause rupturing. Depending upon anatomical 
location and the extent of vascularisation, the ligament may or may not be capable of self-
healing after a rupture. 
Some of the most frequently ruptured ligaments occur in the knee joint, often through 
sporting activities such as skiing, football and basketball and the number of injuries are 
increasing each year (Cooper, Lu et al. 2005). Ninety percent of knee ligament injuries 
involve the anterior cruciate ligament (ACL) and medial collateral ligament (MCL) (Woo, 
Abramowitch et al. 2006). The MCL can self-heal, but the ACL cannot due to poor 
vascularisation. Because of this, alternative methods such as regenerative medicine have 
focused heavily upon the ACL with the aim of producing a fully functional tissue in vitro.  
Figures indicate that approximately 250,000 people are diagnosed with ACL injuries each 
year in the USA (Doroski and Brink 2007), and approximately 150,000 need to undergo 
surgical treatment, known as an ACL reconstruction (Cooper, Lu et al. 2005). If the rupture 
is not treated it can cause loss of function of the associated joint which can then lead to early 
development of osteoarthritis (Cooper and Bailey 2006; Gentleman, Livesay et al. 2006). 
The current gold standard procedure for an ACL reconstruction is surgical autografting. 
This involves using part of the patients own patellar tendon, hamstring or quadriceps to 
replace the ruptured ACL (Beasley, Weiland et al. 2005). However, these techniques cause 
donor site morbidity (Goulet and Germain 1997; Van Eijk, Saris et al. 2004; Cooper and 
Bailey 2006; Hairfield-Stein, England et al. 2007) which is associated with pain and a 
recovery period for the donor tissue site (Cooper, Lu et al. 2005; Hairfield-Stein, England et 
al. 2007). Generally 75-90% of patients have good or excellent long term success rates from 
these current grafting techniques (regarding functional stability and symptomatic relief 
upon return to normal activities) but unfortunately a substantial number of patients exist 
who have unsatisfactory results which could be attributed to graft failure (Vergis and 
Gillquist 1995). Some of these patients continue to endure pain, suffer from loss of motion 
secondary to the operative procedure and continue with recurrent instability (Vergis and 
Gillquist 1995), while others suffer from degenerative joint disease such as arthritis or 
  
Tissue Engineering for Tissue and Organ Regeneration 
 
132 
experience re-injury (Hairfield-Stein, England et al. 2007). Alternatively, allografts can be 
used where the donor tendon is taken from a cadaver, but the disadvantages associated 
with this include donor scarcity, the risk of the recipient contracting a disease from the 
donor, or tissue rejection (Ahmed, Collins et al. 2004; Vunjak-Novakovic, Altman et al. 
2004). Prosthetic replacements (synthetic grafts) have previously been used, but these have 
shown to be inadequate due to wear and degeneration (Mascarenhas and MacDonald 2008). 
It is evident that surgical ACL reconstructions have limitations and do not always give 
completely satisfactory long-term results in a high proportion of patients, which 
consequently affects their quality of life (Vergis and Gillquist 1995; Lanza, Langer et al. 
2007). Because of this dilemma, regenerative medicine could be an option, where in vitro 
tissue engineering of ligaments can offer a solution to the problems associated with the 
current surgical methods (Van Eijk, Saris et al. 2004; Hairfield-Stein, England et al. 2007). 
Tissue engineered ligaments could provide better performance in the long run by improved 
biocompatibility, integration into host tissue and the ability to remodel their own 
extracellular matrix (Nesic, Whiteside et al. 2006).  
Tissue engineering is a method which combines knowledge from material science, 
engineering, molecular biology and medicine (Nesic, Whiteside et al. 2006). The basic 
procedure normally involves using scaffolds to act as structural supports for cell growth 
and maturation in-vitro, where a stimulus (chemical or mechanical) may also be applied to 
promote the formation of a functional tissue. This concept was originally developed to 
repair skin and cartilage, but is now being considered as a possible option to produce 
neoligament tissue. To date, many different types of material have been investigated as 
potentially suitable scaffolds for ligament tissue engineering, focusing upon their 
biocompatibility, degradability, surface properties for cell attachment and overall 
mechanical properties. These include polymers (such as polyurethane, polylactic acid, 
polyglycolic acid, polycaprolactone, polyhydroxyalkanoates and alginates), silk fibroin, 
glasses, hydrogels and biological materials such as de-cellularised tissues. 
There has been much research into the application of chemical stimulus upon cell culture 
in vitro. It is well documented that specific growth and differentiation factors can trigger 
various cellular responses such as cell differentiation, cell division and matrix remodelling 
(Evans 1999), making them useful in tissue engineering to influence cell behaviour. Some 
of the most commonly studied growth factors include transforming growth factor beta-1 
(TGF-β1), basic fibroblast growth factor (bFGF) and epidermal growth factor (EGF). 
Bioreactors also have applications in tissue engineering, where they can be used to 
optimise the cell culturing conditions; for example they can improve the mass transfer of 
nutrients to cells in a 3D scaffold (perfusion), improve cell seeding onto a scaffold 
(rotation), or provide a mechanical stimulus (in tension or compression) to influence cell 
behaviour. For ligament tissue engineering, the bioreactor is normally used to apply tensile 
straining forces within physiological ranges to promote differentiation and extracellular 
matrix (ECM) synthesis. From the literature, the mechanical loading regimes investigated 
have varied from 1-10% strain, 0.01-1Hz frequency, from ½ hour – 24 hours/day over a 
period ranging from 1 day to six weeks. Achieving the optimal culturing conditions for a 
ligament tissue engineered construct can be complex, where small changes can have large 
affects upon cell behaviour and their final product. This chapter will review in detail the 
different biomaterials, loading regimes and growth factors that have been currently 
investigated for this purpose. 
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2. Anatomy of the ligament 
2.1 Structure and function of a ligament 
A ligament is a capsule of connective tissue made of fibres joining one bone to another 
across a joint where they help to guide joint motions and prevent abnormal displacement of 
bones relative to each other (Einhorn, O'Keefe et al. 2007). They are very strong compared to 
other connective tissues, such as skin, because of the high tensile loads they need to 
withstand (Einhorn, O'Keefe et al. 2007). Although there are several hundred ligaments in 
the body, many of the examples given have focused upon the ACL because it is the most 
frequently injured knee ligament. Figure 1 indicates where the main knee ligaments are 
located around and within the knee joint. 
 
 
Fig. 1. The diagram illustrates where the fours main knee ligaments are located; the anterior 
cruciate ligament (ACL), the posterior cruciate ligament (PCL), the medial collateral 
ligament (MCL), and the lateral collateral ligament (LCL) 
There are three main types of connective tissue within the human body, connective tissue 
proper (loose and dense regular connective tissue), fluid connective tissue (transports 
substances in blood) and supporting connective tissue (cartilage and bone). Skeletal 
ligament is a dense regular connective tissue, which is comprised of fibroblasts (connective 
tissue cells), and extracellular matrix (proteins and water making up the connective tissue). 
The periodical change in direction of collagen fibres gives the connective tissue a distinct 
undulating pattern. The fibroblasts (located within in the ECM) are responsible for 
producing the ECM components to maintain and repair the connective tissue. After an 
injury, these cells become mobile, migrating to the wounded tissue to increase the synthesis 
of specific proteins to aid tissue repair (Rogers 1983; Alberts, Johnson et al. 2000). The ECM 
is composed of two main classes of macromolecules; polysaccharide chains of 
glycosaminoglycans (which have adhesion functions and attract water), and fibrous proteins 
such as collagen, elastin and reticular fibres which give structural support to the tissue 
(Alberts, Johnson et al. 2000). The ground substance of the ECM is a hydrophilic water-like 
gel containing the polysaccharides and fibrous proteins, allowing diffusion of waste 
products and nutrients between the tissue cells and capillaries (Hansen, Masouros et al. 
2006). 
Ligament connective tissue is classed as dense regular tissue because the closely packed 
collagen fibres are aligned in an ordered regular, way, giving tensile strength and support to 
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the tissue. The basic structure of collagen is very similar in all collagen types, where its 
formation starts with the synthesis of polypeptide chains on the ribosome which are 
composed mainly of glycine, hydroxylysine and hydroxyproline repeats (Carpenter and 
Hankenson 2004). Inside the cell, three polypeptide α-chains coil together into a right-hand 
twist to make a triple helix (super helix) forming the procollagen molecule which then 
becomes exocytosed from the cell. The procollagen molecules polymerize in the extracellular 
space firstly by aggregating together into a microfibrils, then aggregating into fibrils, where 
finally, the fibres become stabilized by covalent cross-links which form within and between 
the tropocollagen molecules (Alberts, Johnson et al. 2000). It is this extensive cross-linking, 
particularly in collagen I, which gives the collagen fibrils their stability and great tensile 
strength, which in turn makes the tissue very strong so that the ligament can resist 
deformation from stretching forces (Doroski, Brink et al. 2007).  Collagen type I, III and V 
are all structural components of ligament fibrils (Posthemus, September et al. 2009), where 
type I and III provide tensile strength and type V regulates fibre assembly and diameter 
(September, Schwellnus et al. 2007). Collagen type X is present where the ligament 
integrates into the bone. Tenascin-c, another type of protein found in ligament ECM, 
regulates the tissues response to mechanical loading (September, Schwellnus et al. 2007). 
The individual collagen fibrils are randomly orientated, but as they aggregate into fibres 
they gain a more parallel orientation with the longitudinal axis of the ligament, giving the 
tissue a crimping pattern (wavy appearance) (Goulet, Germain et al. 1997). 
2.2 Bone attachment 
Ligaments attach to the bone surfaces as an aggregation of collagen fibre bundles 
(Ellenbecker 2000), either by direct insertion, or both direct and indirect insertion. The ACL 
inserts into the bone by direct insertion, the most common ligament insertion type, where its 
collagenous fibres attach directly to the bone tissue. The collagenous fibres blend into the 
fibrocartilaginous layer, interweave through the fibrocartilage zone, through the 
mineralized fibrocartilage zone, then enter the bone (Beasley, Weiland et al. 2005; Woo, 
Abramowitch et al. 2006). The calcified collagenous fibres which anchor the ligament firmly 
to the bone are known as Sharpey’s fibres (Einhorn, O'Keefe et al. 2007). The medial 
collateral ligament (MCL), which is also a knee ligament, is inserted into the bone by both 
direct and indirect insertion, where the superficial fibres (near to the surface) merge with the 
periosteum (the connective tissue surrounding the bone), while other fibres penetrate the 
bone deeper and attach to the bone directly at acute angles (Woo, Abramowitch et al. 2006). 
2.3 Characteristic components of ligament tissue 
It is the variation in ratio between collagen types and other ECM components which gives 
each ligament type its diversity and characteristic mechanical behaviour (Woo, 
Abramowitch et al. 2006). Due to the absence of specific markers, ligaments can only be 
distinguished from other ligaments and other tissue types (eg tendon) by structural, 
molecular and mechanical properties. Although there is no single specific marker in the 
ligament, tenscin-c has been considered to be a marker due to its characteristically high 
amounts in the ligament (Doroski, Brink et al. 2007), where the presence of collagen types I 
and III, tenomodulin, biglycan, decorin, elastin and fibronectin are also characteristic of 
ligament tissue (Vunjak-Novakovic, Altman et al. 2004; Chen, Huang et al. 2008). The total 
amounts and specific ratios of the ECM components, ground substance and cells are 
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characteristic properties unique for each type of connective tissue which relate to its 
anatomical location and function (Vunjak-Novakovic, Altman et al. 2004). Connective tissue 
types can be differentiated by the presence and total quantities of collagen, tenascin-c, 
elastin, fibronectin, decorin, biglycan, ratios of collagen types, crimping pattern and collagen 
fibril diameter. Table 1 lists the main components of a typical ligament as a percentage of 
their wet weights, whereas those in table 2 are the dry weights of the main collagen types 
and ratio of collagen type I : III which are unique to the ACL, as reported by various 
authors.  
 
Tissue 
type (wet 
weight) 
Collagen 
type I 
(%) 
Other 
collagens  
such as 
type III, 
V, VI (%)
Elastin 
(%) 
Fibronectin 
and other 
glycoproteins 
(%) 
Proteoglycans 
(%) 
Water 
(%) 
Author 
Ligament 
(general) 
20 3-5 1-2 1-2 <1 70 (Einhorn, 
O'Keefe 
et al. 
2007) 
Table 1. The biochemical constituents of wet ligament tissue 
 
Tissue type 
(dry 
weight) 
Collagen 
type I (%)
Collagen 
type III (%)
Collagen 
type V (%) 
Ratio of collagen 
I : III 
Author 
ACL 70-80 8-10 10-12 9:1 (Woo, 
Abramowitch et al. 
2006; Doroski, 
Brink et al. 2007) 
Table 2. The collagen content of the ACL in dry tissue 
3. Cell adherence 
It is essential for fibroblasts to attach to a substrate and spread out to enable them to grow, 
proliferate, mature and produce functional tissue. In order for these cells to adhere to their 
substrate, ECM adhesion proteins such as fibronectin, vitronectin or collagen are required to 
adsorb to the substrate first, where the cells will then subsequently adhere to the adhesion 
proteins. Fibronectin can exist in two major forms; (1) soluble plasma fibronectin, a 
constituent of plasma, and (2) insoluble cellular fibronectin, a component of the ECM 
(Pankov and Yamada 2002). Cellular fibronectin can be expressed by different cell types 
including fibroblasts (Pankov and Yamada 2002), where it is found in ligaments and other 
connective tissues. Studies have found it be up-regulated during ligament formation in 
embryogenesis where it guides the migrating cells (Laurencin and Freeman 2005). 
Integrin-mediated binding enables the cell to become connected to its surroundings by 
linking the interior of the cell to the ECM proteins (outside the cell). The contact made with 
the ECM can generate intercellular signals which can affect gene expression, morphology, 
cell survival (Johansson, Svineng et al. 1997), control cell adherence, cell migration, 
  
Tissue Engineering for Tissue and Organ Regeneration 
 
136 
cytoskeletal organization (Sechler, Corbett et al. 1997) regulate growth, proliferation, 
differentiation, and subsequently affect development or maintenance of the ligament tissue 
(Alberts, Johnson et al. 2000; Vunjak-Novakovic, Altman et al. 2004). Two known 
intracellular pathways involved upon integrin-fibronectin binding are the Ras-MAPK (Ras-
mitogen activated protein kinase) and the FAK (focal adhesion kinase) pathways.  
Fibronectin mediated cell adhesion studies have been conducted by various researchers as a 
technique for improving cell attachment in vitro. Research has shown that cell retention of 
rat MSC’s on fibronectin-coated surfaces was improved (Dennis and Caplan 1993), whilst 
other studies indicate that it increases the adhesive strength of cells, suggesting it occurred 
due to the increased number of bonds between fibroblasts and fibronectin-coated glass 
slides (Athanassiou and Deligianni 2001).  
4. Response of fibroblasts to mechanical stimulus 
4.1 Mechanical transduction 
Mechanical forces play a major role in the formation and architecture of native tissues in 
vivo, but also help maintain healthy tissue (homeostasis) in adult tissue. During daily 
activities, human body tissues are subjected to mechanical forces of various magnitudes, 
depending upon the activity and posture during these movements. The ACL has been 
shown to withstand forces of up to 1730N in people aged 16-26 years, but much less in 
people aged 48-86 years, with a mean average of approximately 734N (Noyes and Grood 
1976). However, the forces which can be tolerated become significantly reduced when they 
are perpendicular to the bone insertion sites (Einhorn, O'Keefe et al. 2007). The externally 
applied forces can alter the cells structure, mechanical properties, behaviour, and function 
(Miyazaki, Hasegawa et al. 2000) which are required for tissue homeostasis (Fulton 1984; 
Altman, Lu et al. 2002). Tissue homeostasis occurs through ECM remodelling (re-
organization) which involves ECM degradation by apoptosis (programmed cell death) and 
the formation of new tissue by cell proliferation (multiplication). An equilibrium between 
proliferation and apoptosis is essential during ligament growth, healing, tissue homeostasis 
and adaptation to exercise (Chuen, Chuk et al. 2004). 
The cells are believed to sense mechanical forces either through their cell surface integrin 
receptors or through ion channels in the cell membrane, and respond accordingly. These 
external forces can alter the cell structure, its mechanical properties, behaviour, and function 
(Miyazaki, Hasegawa et al. 2000), where, for example they may increase or decrease ECM 
production, or regulate proliferate and differentiate. Transducing (converting) external 
physical forces into cellular signals across the membrane is known as mechanical 
transduction (Ingber 1999). Although the mechanisms of transduction are not well 
understood, many investigations have been carried out upon integrin receptors and the cell 
cytoskeleton that support the theory that the cell senses external mechanical forces from the 
ECM via the integrin receptors (subsequently causing deformation and reorganisation of the 
cell cytoskeleton) (Pertigliano, McAllister et al. 2006) and activates specific cellular 
pathways. 
4.1.1 Cytoskeletal tension 
Upon cell-substrate binding via the integrin receptors, this exerts a force upon the cell 
cytoskeleton, which generates an intracellular tension. In effect, this links the cell membrane 
to the nucleus which influences gene expression, by relaying signals from the plasma 
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membrane to the nucleus (Matyas, Edwards et al. 1994). The cytoskeleton is composed of a 
network of protein filaments within the cytoplasm, which maintains cell shape, giving it 
structure and support, and allowing the cell to bear stress without splitting (Alberts, 
Johnson et al. 2000). The cytoskeleton has a number of other functions including connecting 
each fibroblast to other cells and to the substrate, generating tension within the cell to 
produce stress fibres, and also assisting the cell in locomotion (Fulton 1984). There are three 
proteins in the cytoskeletal network, actin, tubulin and vimentin, which assemble to form 
the three main structural filaments of the network system (actin filaments, microtubules, 
intermediate filaments respectively) (Portner, Bagel-Heyer et al. 2005). Both actin and the 
intermediate filaments are involved in connecting the fibroblasts’ internal structure to other 
cells and to the ECM. When the fibroblast encounters a suitable substrate, it extends its 
projections (filopodia), which then attach to the substrate allowing the rest of the cell to 
adhere. This generates a small tension, where the cell subsequently spreads (Fulton 1984; 
Alberts, Johnson et al. 2000), promoting formation of stress fibres within the cell. This 
enables the cell to withstand the tension generated from the cell-ECM contact and make 
connections with the nucleus to modulate cell behaviour. The effects include activating 
specific genes (Fulton 1984; Altman, Lu et al. 2002) and generating key proteins (including 
degrading enzymes and ECM components) to remodel the ECM for promoting new tissue 
formation (Vunjak-Novakovic, Altman et al. 2004; Portner, Bagel-Heyer et al. 2005).  
4.1.2 Intracellular cell signalling 
The most widely accepted mechanism for mechanical transduction is that involving 
intracellular signalling pathways. Once the cell binds its substrate, the integrin receptors act 
as mechanoreceptors, receiving then relaying mechanical signals from the ECM through the 
cell (as biochemical signals) to the nucleus via intracellular pathways. This can either 
promote gene expression, regulate growth, proliferation or differentiation, subsequently 
affecting development or maintenance of the connective tissue (Alberts, Johnson et al. 2000; 
Vunjak-Novakovic, Altman et al. 2004). The most studied intracellular pathway is the Ras-
mitogen-activated protein kinase (Ras-MAPK) pathway, which is considered to be the one 
which acts as a general, but unspecific signal transducer, converting the signal from the 
applied mechanical stress and relaying it through the cell interior (Chiquet, Sarasa-Renedo 
et al. 2003). The Ras-MAPK pathway becomes activated once the receptor receives an 
extracellular mechanical signal. Briefly, the received signal causes a kinase on the receptor to 
become activated which then activates a GTP-binding protein (Ras protein). The Ras protein 
causes downstream phosphorylations by activating the first MAP kinase (Raf) in the chain 
to phosphorylate the next MAP kinase (Mek), which phoshporylates and activates the next 
MAP kinase (Erk), which subsequently activates other proteins. Eventually the signal 
reaches the gene regulatory proteins in the nucleus which interact with transcription factors 
and promoters to regulate gene expression and protein activity (Alberts, Johnson et al. 2000). 
4.1.3 Ion channels 
Besides mechanical transduction via integrin receptors, external forces (stress) can also be 
conveyed into the cell through stretch-induced ion channels which open and close in 
response to cell membrane deformation (Matyas, Edwards et al. 1994). Ion channels are 
cation specific channels located in the cell plasma membrane, which allows rapid diffusion 
of the ions down their electro-chemical gradients across the lipid bilayer. The channels are 
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gated, only opening briefly to allow specific cations (such as calcium, sodium or potassium) 
to pass through, and then close again. The channel gates open in response to several types of 
specific stimulus, one those being mechanical stress which operates mechanically-gated 
channels (Alberts, Johnson et al. 2000), subsequently affecting the cell behaviour. Cyclic 
stretching has been reported to stimulate Ca2+ influx into osteoblasts, and it is thought that 
mechanical stretch-induced Ca2+ signal transmission may involve the actin filaments (Wang 
2006). 
5. Injuries sustained and healing potential 
Ligaments in skeletally mature people are very strong and stiff at high loads, however, there 
can be some variation in the mechanical properties of each ligament type depending upon 
the individuals’ gender and age. Strength and stiffness of the ACL has been found to 
significantly reduce as age increases in adults (Noyes and Grood 1976) and can be 
significantly lower in  adult females compared to  their male counterparts (Chandrashekar, 
Mansouri et al. 2006). Ligaments reach their maximum strength when the loading forces are 
aligned with the ligament fibres and aligned with the direction of bone insertion, becoming 
three times as strong as when the force acts perpendicular to the bone insertion sites 
(Einhorn, O'Keefe et al. 2007). They rupture when the load (externally applied force) 
becomes too excessive to withstand and the collagen fibres tear apart. The ACL, for 
example, normally ruptures in the mid-substance (middle region) when the knee joint 
experiences too much force, but it can also tear at the bone insertion sites. The position of the 
tibia relative to the femur can increase the magnitude of the stress placed onto the knee 
joint. The stress becomes greatest when the tibia is fully extended and internally rotated 
simultaneously, increasing the tension upon specific fibre bundles which are trying to resist 
deformation and abnormal motion. A rupture of the mid-substance occurs when the cross-
links between the collagen fibrils slip allowing the tropocollagen helix to over-stretch, 
allowing the tissue to tear (Laurencin and Freeman 2005).  
Generally, the blood supply to ligaments is sparse when compared to other tissue types 
(such as the skin), affecting their healing potential (Einhorn, O'Keefe et al. 2007) which can 
be limited further by anatomical location, age and gender. The healing capacity of the 
mature ACL is very low due to its anatomical location. It is encapsulated within the knee 
joint (intrasynovial), being surrounded by the lubricating synovial fluid, and is poorly 
vascularised (Amiel, Frank et al. 1984; Ahmed, Collins et al. 2004; Cooper, Lu et al. 2005). As 
a result it cannot self repair (Cooper, Lu et al. 2005; Lu, Cooper et al. 2005), therefore medical 
treatment is necessary. There is no direct blood supply from the fibrocartilage zone of the 
bone to the ACL, so the ACL relies mainly upon diffusion of nutrients and waste through 
the joint fluid from and to the blood vessels of the surrounding synovial tissue respectively 
(Beasley, Weiland et al. 2005). The surrounding synovial tissue is vascularized by the medial 
genicular artery, and the lateral inferior genicular artery, forming a vascular plexus 
(network of vessels) around the knee. It is the small vessels from the plexus which supply 
the ligament with the essential nutrients by diffusion (Zantop, Patterson et al. 2005). It 
possible that a few of these small blood vessels may actually penetrate the ACL and directly 
supply it with nutrients (Arnoczky 1983). As a result of poor vascularization to the 
midsubstance, the ACL has a low healing capacity and can not self repair (Carpenter and 
Hankenson 2004). In contrast to the ACL, the MCL which is extrasynovial can self heal 
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spontaneously because it has a greater vascularisation and receives more blood (Carpenter 
and Hankenson 2004). 
After injury, those ligaments which are well vascularized have three stages of healing; 
inflammation, cellular proliferation and migration, ECM repair and finally ECM 
remodelling (Laurencin and Freeman 2005). Generally, these stages promote fibroblast 
proliferation. Fibroblasts and macrophages then migrate to the injured site and granulation 
tissue forms (stroma). GAG, elastin and collagen are synthesised to form new ECM, and 
finally the ECM is remodelled, where it initially forms into a disordered tissue but later 
becomes more organized (Alberts, Johnson et al. 2000; Laurencin and Freeman 2005). With 
avascular, or poorly vascularised ligaments, this process is not carried out, or only in a 
limited way, which prevents them from self-healing spontaneously and surgery may be 
needed to repair them. With the case of the ACL, if left untreated, this could eventually 
cause osteoarthritis in the knee because the ACL has failed to maintain correct bone 
alignment and control normal motion across the knee joint (Foster, Butcher et al. 2005; 
Utukuri, Somayaji et al. 2006).  
6. Surgical treatment 
After rupture, the ligament is normally repaired by surgery, which can be by suturing or 
grafting. Based upon clinical investigations, surgical grafting has become the gold standard 
for ligament repair (Einhorn, O'Keefe et al. 2007). In the case of the ACL, a surgical 
reconstruction is performed which is the only method shown to at least partially restore 
function, helping to improve the patient’s quality of life. This method involves implanting a 
graft to replace the damaged ligament.  
Three main types of grafts can be used; autografts, allografts or synthetic grafts. The current 
gold standard procedure for reconstructing an ACL is autografting, which involves using a 
ligament or tendon from another part of the patient’s body and using it to replace the 
damaged ACL. This can be a section from the patients patellar tendon (joining knee cap to 
tibia) or the hamstring tendon (joining calf muscle to bone in heal) (Beasley, Weiland et al. 
2005). Patellar tendon is often used because its strength and mechanical properties are 
similar to or exceed that of normal native ACL (Fenwick, Hazleman et al. 2002).  The central 
third of the patellar tendon is removed with a piece of knee cap (bone plug) attached to one 
end, and a section of the tibia attached at the other end (Beasley, Weiland et al. 2005). The 
damaged ACL is removed, a bone tunnel (channel) is drilled out from the femur and tibia, 
and the graft is threaded through and screwed into leg bones. This reconstruction operation 
takes approximately 2 ½ hours. Allografting involves using a ligament or tendon from a 
different human donor, normally a cadaver (corpse). The procedure is the same as 
autografting, and may give the same results, but disadvantages include donor scarcity, the 
risk of the recipient contracting a disease from the donor, or tissue rejection (Vunjak-
Novakovic, Altman et al. 2004). Clinical outcomes in the short term can be good, with 80% 
success rate in restoring knee stability (Einhorn, O'Keefe et al. 2007). Unfortunately, both 
autografting and allografting can be unsatisfactory methods for long term performance in 
some patients, where they suffer from instability (Woo, Abramowitch et al. 2006) due to 
mechanical failure, fatigue or creeping, (gradual stretching of the tissue under constant 
load). This occurs due to a slight mismatch in mechanical properties between the graft and 
native ligament tissue, where the injury may then recur at a later date (Lu, Cooper et al. 
2005). It has been suggested that even two years after the implantation the tendon graft 
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remains structurally and mechanically different to normal native ligament and never 
actually becomes “ligamentised” (Fenwick, Hazleman et al. 2002). Another disadvantage of 
autografting is donor site morbidity which can cause pain, swelling, local nerve damage, 
scarring, stiffness weakness or infection (Einhorn, O'Keefe et al. 2007). Synthetic grafts have 
also been used such as carbon, the Gortex prosthesis, the Stryker-Dacon ligament, the Leeds-
Keio artificial ligament, LARS ligament and Kennedy ligament augmentation devices, but 
creeping, fatigue and limited integration between host tissue and the graft have occurred 
several years after implantation (Ahmed, Collins et al. 2004; Cooper, Lu et al. 2005). The 
advantages and disadvantages of the current grafting methods are summarized in table 3. 
 
  
Autograft 
 
Allograft 
 
Synthetic graft 
 
Advantages No rejection. 
No disease 
transmission. 
No donor scarcity. 
No donor site 
morbidity. 
No donor site morbidity. 
No tissue disease 
transmission. 
No donor scarcity. 
Disadvantages Donor site morbidity.  
Patellar fracture. 
Quadriceps weakness. 
Limited bone 
integration. 
Mismatch in different 
tissue properties, 
causing mechanical 
failure, creeping, 
fatigue. 
Recurring injury. 
 
Donor scarcity. 
Limited bone 
integration. 
Tissue rejection. 
Mismatch in different 
tissue properties, 
causing mechanical 
failure, creeping, 
fatigue. 
Recurring injury. 
 
Limited bone integration 
(weak graft-host tissue 
interface). 
Mismatch in different 
tissue properties causing 
mechanical failure.  
Creeping (stretching & 
loosening).  
Poor long-term 
instability. Fatigue. 
Recurring injury. 
Table 3. The advantages and disadvantages of three types of graft 
7. Tissue engineering as regenerative medicine 
7.1 Background 
Tissue engineering is a rapidly developing area in regenerative medicine which uses 
knowledge of biological, chemical and engineering techniques to regenerate new tissue in-
vitro (Cooper, Lu et al. 2005). Some tissues in the body are capable of self repair after injury, 
while others are not, and tissue engineering is a relatively new technique which could offer 
alternative methods to restore tissues and organ functions (Quaglia 2008). The techniques 
enable various biophysiological parameters to be controlled in order to develop a functional 
tissue ready for implantation (Lanza, Langer et al. 2007). The procedure involves using a 
scaffold to act as a structural support for cell growth and maturation in vitro to eventually 
produce a functional tissue to repair or replace damaged tissue. This concept was originally 
developed to repair skin, cartilage and bone, but is now being considered as a possible 
option to produce neo-ligament tissue rather than using the traditional surgical grafting 
approach. Although the current methods of treatment may help to fully restore the 
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ligaments in some patients, its long-term success in others is unsatisfactory, indicating that 
there is a need to find more successful, alternative methods of treatment for full restoration 
of ligaments. Unlike synthetic grafts which can degrade and lose strength over time, tissue 
engineered implants could perform better in the long term with their biocompatibility, 
improved integration into surrounding host tissue, and their ability to remodel the ECM as 
and when required to (Nesic and Whiteside 2006). Tissue engineering also has the 
advantage of producing an immediately functional tissue (Vunjak-Novakovic, Altman et al. 
2004), but the successful incorporation of the soft tissue implant into bone could be a 
challenge. 
For applications in ligament tissue engineering, a scaffold is required to be biocompatible, 
biodegradable, allow cell adherence, have sufficient surface area and volume for cell in-
growth, be sufficiently strong to withstand mechanical loading forces in vitro and in vivo, 
and posses a similar stiffness to the native ligament tissue (if it is to be implanted before it 
degrades) (Christian, Jones et al. 2001 ; Cooper and Lu 2005; Probhakar, Brocchini et al. 2005; 
Gentleman, Livesay et al. 2006; Sahoo, Ouyang et al. 2006). These points are summarized in 
table 4. Often, three-dimensional (3-D) scaffolds are preferred to the two-dimensional (2-D) 
scaffolds because they not only allow cell in-growth, but can also retain cells in their 
differentiated state. From the literature, it has been reported that fibroblasts cultured in 2-D 
monolayers have de-differentiated (reverted back to their undifferentiated state) during cell 
culture (Schulze-Tanzil, Mobasheri et al. 2004), which may not be desirable for tissue 
engineering purposes. 
 
 
Scaffold requirements 
 
The purpose of this feature 
 
Biocompatible Avoids immunorejection (a cytotoxic 
response could kill the cells) 
Biodegradable To degrade at the same rate at which 
neotissue forms to avoid the need for 
surgical removal 
Enable cell adherence To allow cells attachment for growth and 
proliferation to occur 
Provide sufficient surface area/volume To provide sufficient space for cell spreading 
and growth 
Possess comparable strength/stiffness To withstand cyclic mechanical loading 
forces with magnitudes and strains similar to 
those found in vivo 
Surgical implantation Ease of fixing/bonding to bone (bio-active) 
Table 4. The main requirements of a scaffold with respect to their application 
7.2 Suitable cell types for ligament tissue engineering 
Fibroblasts and mesenchymal stem cells (MSC’s) have been considered to be the preferred 
cell type for seeding onto scaffolds in tissue engineering (Doroski, Brink et al. 2007). Some 
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reports suggest that MSC’s are a potentially better source for ligament tissue engineering 
than ligament fibroblasts due to their higher expression of collagen type I and III (Ge, Goh et 
al. 2005). Other reports however, feel that ACL fibroblasts are more appropriate because of 
the characteristic ratios of collagen types produced during tissue repair (Fu, Harner et al. 
1993). In one particular study MSC’s were isolated from a human ACL and the results 
demonstrated that both ACL-derived MSC’s and bone marrow MSC’s expressed marker 
genes for ligament fibroblasts, but mRNA expression levels for collagen I and III were 
higher in the ACL-derived MSC’s. It was concluded from this study that ACL-derived 
MSC’s have an increased potential to form ligament fibroblasts in comparison to bone 
marrow MSC’s (Huang, Chen et al. 2008). Co-culturing MSC’s with ligament fibroblast has 
been shown to successfully induce MSC differentiation into fibroblasts, where this 
conclusion was based upon the mRNA expression of key ligament genes (collagen I collagen 
III, and tenascin-c) and synthesis of these key ligament proteins (Fan, Liu et al. 2008). This 
feature makes them an attractive cell choice for ligament tissue engineering.  
7.2.1 Mesenchymal stem cells (MSC’s) 
Mesenchymal stem cells (MSC’s) are multipotent progenitor cells, meaning they can 
differentiate into specific cell types of various cell lineages. They are found in multiple adult 
tissue types including bone marrow, muscle, synovial tissue and adipose tissue (Centeno, 
Busse et al. 2008), where they have the potential to produce cartilage, bone, muscle, tendon, 
ligament or fat (Papathanasopoulos and Gaiannoudis 2008) in response to the appropriate 
stimuli (Lanza, Langer et al. 2007). MSC’s can be encouraged to move down specific cell 
lineages by using media which contains hormones such as dexamethasone, hydrocortisone, 
or growth factors such as transforming growth factor β (TGF-β) (Papathanasopoulos and 
Gaiannoudis 2008), cytokines, transcription factors  (Lanza, Langer et al. 2007) or using 
purely mechanical stimulus (Altman, Horan et al. 2001). MSC’s have been used successfully 
to regenerate articular cartilage in animal models and to regenerate bone in humans 
(Papathanasopoulos and Gaiannoudis 2008). Because they can be easily isolated and 
expanded (Papathanasopoulos and Gaiannoudis 2008; Yu, Chen et al. 2008), with the 
capacity to differentiate, this makes them desirable for tissue engineering applications 
(Papathanasopoulos and Gaiannoudis 2008). One of the first areas in which they were 
applied was in tendon and ligament tissue engineering (Lanza, Langer et al. 2007). 
Another appealing feature of MSC’s is their immunosuppressive and anti-inflammatory 
effects. They express low levels of major histocompatibility complex (MHC) class I 
molecules on their surface (preventing natural killer cells deleting them), and no class II 
MHC, allowing them to escape recognition by alloreactive T helper cells (Zhao, Liao et al. 
2004; Lanza, Langer et al. 2007; Popp, Eggenhofer et al. 2008; Swart, Martens et al. 2008). 
However, it has been reported that MSC’s infused into allogeneic MHC-mismatched mice 
have been rejected (Swart, Martens et al. 2008). In contrast, this was not the case when 
genetically modified MSC’s were injected into a baboon (Zhao, Liao et al. 2004).  
7.3 Biomaterials suitable for ligament tissue engineering 
To date, many different materials in their various physical forms have been investigated as 
substrates for tissue engineering applications in general. These include synthetic polymers, 
natural polymers, glasses, silk, hydrogels, composites and many more. Only those related to 
ligament tissue engineering, are covered in this chapter (summarized in table 5).  
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Synthetic polymers such as polylactic acid, polyglycolic acid and polylactide-co-glycolide 
(PLA, PGA and PLAGA respectively) are approved by the USA food and drugs agency 
(FDA) for a variety of clinical applications (Cooper, Lu et al. 2005). These polymers degrade 
by hydrolysis of ester bonds (water breaks up the molecule), and the components are 
removed by the natural pathways of the body (Rezwan, Ghen et al. 2006), making them 
biocompatible. Some of these have been produced into cell scaffolds and tested for their 
suitability as substrates. PLAGA fibres have been used to make 3-D braided scaffolds, which 
consisted of 3 regions – the attachment site for the femur bone at one end, the main ligament 
region in the middle, and the attachment site for the tibia bone at the other end. The results 
indicated that the scaffold was biocompatible by the observed attachment, spreading and 
growth of the ACL fibroblasts initially seeded onto it (Cooper, Lu et al. 2005). PLAGA has 
also been produced into nano-fibres which were electrospun into a knitted PLAGA 
scaffold to increase the surface area for cell attachment. It significantly improved MSC 
attachment and proliferation, but also demonstrated that cell function had improved due 
to the increased mRNA expression of type I collagen and decorin (Sahoo, Ouyang et al. 
2006). Braided PLA, PGA and PLAGA have also been found to enhanced rabbit ACL 
fibroblast attachment and support high cell numbers, being highest on PLA (Lu, Cooper 
et al. 2005). 
Alginates are a natural linear polysaccharide copolymers extracted from brown algae 
belonging to the phaeophyceae (Hua and Wang 2009). They are currently used in the food, 
cosmetic and agricultural industries (Hua and Wang 2009). Because they are easy to process, 
with good biocompatibility and low toxicity, they have been studied in drug stabilization 
and drug delivery (Lee and Mooney 2001; Drury and Mooney 2003) and for tissue 
engineering purposes (Sakai, Masuhara et al. 2005), where bone marrow cells have been 
successfully cultured on them (Wang, Shelton et al. 2003). Other report have also confirmed 
there suitability by enabling cell adhesion, migration, proliferation and differentiation to 
take place (Zhao, Deng et al. 2003).   
Polyhydroxyalkanoates (PHA’s) are currently under investigation for their uses in tissue 
engineering. They are naturally derived biocompatible polyesters which are produced by 
microorganisms as carbon and energy stores in unbalanced growing conditions become 
(Chen and Wu 2005). They are known to be biocompatible because they are found naturally 
occurring in mammal blood and tissues, where their purity can be increased by removing 
long-chain fatty acids and the endotoxin lipopolysaccharide, preventing any adverse 
reactions (Zhao, Deng et al. 2003; Chen and Wu 2005). They range from hard and brittle to 
soft and elastomeric, but can also be blended (combined) with other types of PHA or 
modified at the surface to alter their mechanical properties and biocompatibility, and 
produced either as a film or a foam (Rezwan, Ghen et al. 2006). So far, PHA’s have been 
used for a number of different applications including tissue regeneration, repair devices, 
sutures and bone marrow scaffolds (Shishataskaya, Volova et al. 2004). One report 
compared the mechanical and surface properties of several modified PHA’s and it was 
concluded that hydrophilicity and a low tackiness were found to be more important than 
the surface roughness for cell attachment and growth. Substrate stiffness also appeared to 
influence cell attachment, where the stiffer, more brittle PHA’s, retained a significant 
number of viable cells on their surfaces (Rathbone, Furrer et al. 2009). Because of their 
diversity in surface texture, flexibility and their biocompatibility, PHA’s show potential as 
cell substrates in tissue engineering.  
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Two types of glasses that have been used for medical research are bioglass (developed in the 
1969 by Larry Hench) and controlled release glass (CRG) which is a phosphate-based glass, 
developed in the 1970’s. Bioglass does not dissolve completely in fluids, but changes 
chemically upon its partial degradation, and is currently regarded as the most 
biocompatible material for bone regeneration due to its bioactivity and osteoconductivity 
(Wu, Hsu et al. 2009). Unlike bioglass, CRG dissolves completely in fluids at a 
predetermined rate, leaving no solid residues because phosphorous pentoxide is a main 
component within its formulation. The metal ions in CRG are found naturally occurring 
within the body (Probhakar, Brocchini et al. 2005) and upon glass degradation (dissolution) 
the released ions become removed by the bodies own metabolic system without causing a 
toxic response, avoiding the need for surgical removal if implanted into the body. Because 
CRG has a controllable solubility in body fluids and do not need surgical removal, this 
makes them an ideal scaffold material for promoting neotissue formation in vivo (Ahmed, 
Lewis et al. 2003). Very little work has been carried out with phosphate based glasses (CRG) 
for soft tissue engineering, however Bitar and colleagues cultured several cell types, 
including tendon fibroblasts, upon glass disks with various dissolution rates, where they 
successfully attached, proliferated while maintaining their phenotype, and it was concluded 
that the glass (of specific composition) would be ideal scaffold materials for engineering of 
both hard and soft tissues (Bitar, Salih et al. 2004). In fibrous form, phosphate based glasses 
have high tensile strength, making them useful for tensile applications, but it is also possible 
to produce them with dimensions similar to ligament collagen fibres in vivo, particularly the 
diameter, which can potentially assist cell attachment and spreading. Bitar et al suggested 
that the fibre diameter of the phosphate based glass which they tested influenced cell 
attachment (Bitar, Salih et al. 2008).  
Many other materials have been investigated. Silk fibroin scaffolds have supported and 
enhanced ligament- specific differentiation of human MSC’s. The silk was cabled into 6-cord 
wire rope matrices, improving its elasticity. The authors suggested that the silk matrix had 
similar a hierarchical structure to the collagen fibres in native ACL, making the mechanical 
properties comparable to ACL in stiffness and strength (Wang, Kim et al. 2006). Silk fibroin 
has also been produced as a microporous silk sponge and incorporated into a knitted silk 
mesh. After seeding them with rabbit MSC’s, the constructs were implanted into rabbits, 
where at 24 weeks the cells were well distributed throughout a regenerating ACL, and 
producing key ligament proteins (collagen I and III, and tenacin-c). Also a direct ligament–
bone insertion was achieved resembling native ACL-bone insertion (Fan, Liu et al. 2008). 
Collagen hydrogels have been shown to successfully promote higher production of type I 
and type III collagen from the cells, where the tissue formation was improved with a 
ligament-like organisation (Noth, Schupp et al. 2005; Gentleman, Livesay et al. 2006).   Poly 
desamino-tyrosine ethyl carbonate scaffolds have proved to be successful in supporting 
fibroblast growth while possessing the necessary strength for use as an ACL graft 
(Laurencin and Freeman 2005).  
Composites (consisting of more than one type of material) have also been constructed and 
analysed. Gelatin with silk fibroin has been produced into microporous sponges around Silk 
cables, where Fan and colleagues co-cultured rabbit MSC’s with ACL fibroblasts on the 
scaffold, which enabled MSC differentiation into ligament fibroblasts. They detected mRNA 
expression of collagen type I and III, and tenascin-c with the corresponding protein 
production (Fan, Liu et al. 2008). 
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Material 
 
 
Physical form 
 
 
Affect on cells/material properties 
 
 
Author 
Synthetic 
polymers 
   
PLAGA Braided Improved fibroblast attachment, 
spreading & growth. 
(Cooper, Lu 
et al. 2005) 
PLAGA Electrospun 
PLAGA nano-
fibres onto knitted 
PLAGA scaffold. 
Improved porcine MSC attachment & 
proliferation. Cells gave higher 
expression of type I collagen, decorin 
and biglycan genes in comparison to 
cells on just a knitted PLAGA 
scaffold. 
(Sahoo, 
Ouyang et al. 
2006) 
PGA coated with 
BioGlass 
Mesh coated with 
Bioglass. 
Increased fibroblast proliferation (208f 
cell line). 
(Day, 
Boccaccini et 
al. 2004) 
PLA, PGA, 
PLAGA coated 
with fibronectin 
Braided Enhanced rabbit ACL fibroblast 
adhesion and supported high cell 
numbers, (highest for PLA). 
(Lu, Cooper 
et al. 2005) 
DegrapolR PU Fibre-fleece Supported fibroblast adhesion & 
proliferation. 
(Milleret, 
Simonet et al. 
2009) 
Natural polymers    
Collagen 
hydrogel 
Hydrogel + 
collagen fibres 
Increased production of type I & III 
collagen fibres, giving better tissue 
formation, and ligament-like 
organization in the tissue. 
(Noth, 
Schupp et al. 
2005; 
Gentleman, 
Livesay et al. 
2006) 
Silk fibroin Rope matrix Enhanced ligament- specific 
differentiation of human MSC’s. 
(Wang, Kim 
et al. 2006) 
Silk fibroin Microporous silk 
mesh rolled 
around braided 
silk cord 
MSC seeded construct was implanted 
into pigs. At 24 weeks MSC’s 
differentiated into fibroblast-like cells, 
expressing collagen I and III, tenascin-c.
(Fan, Liu et al. 
2009) 
Silk fibroin Microporous silk 
sponge 
incorporated into 
knitted silk mesh 
Rabbit MSC seeded constructs 
implanted into rabbits. At 24 weeks 
cells were well distributed throughout 
the regenerating ACL, producing key 
ligament  proteins (coll I & III, 
Tenascin-c), direct ligament –bone 
insertion with 4 zones was 
reconstructed resembling native ACL-
bone insertion.  
(Fan, Liu et al. 
2008) 
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Silk fibroin Silk fibroin 
electrospun onto 
knitted silk base 
(random/aligned)
Aligned fibres showed improved cell 
proliferation and collagen production 
compared to random orientation. 
(Teh, Goh et 
al. 2008) 
Composites    
Gelatin + silk 
fibroin 
Microporous 
sponge around 
Silk cables 
Co-cultured rabbit MSC + ACL 
fibroblasts on the scaffold allowing 
MSC differentiation into ligament 
fibroblasts (mRNA expression of Coll 
1 & 3, Tenascin-c and corresponding 
protein production).  
(Fan, Liu et al. 
2008) 
Glass    
Phosphate-based 
glass 
Disks Increased adhesion & proliferation of 
fibroblasts when CaO content was 46-
48 mol%. 
(Bitar, Salih et 
al. 2004) 
Phosphate-based 
glass 
Fibres Increased adhesion & proliferation of 
fibroblasts when CaO content was 
46mol%. 
(Bitar, 
Knowles et al. 
2005)  
Bioactive glass Disks Supported rabbit MSC adherence and 
proliferation.  
(Meseguer-
Olmo, 
Bernabeu-
Esclapez et al. 
2008) 
Collagen fibres Braided/plied 
(cross-linked) 
Implanted into goats, analysed over 
11 months post implantation, 
concluded they were loosing strength, 
therefore not suitable as ACL 
substitute. 
(Chvapil, 
Speer et al. 
1993) 
Table 5. Some of the various different materials previously used as scaffolds (for ligament 
tissue engineering) their physical forms, and their suitability for cell cultures 
7.4 Material surface modifications using fibronectin 
Because fibronectin is known to function as a cell adhesion protein in vivo, it has been 
studied in vitro as a method for improving cell attachment.  It has been used to modify the 
surface of various biomaterials to improve cell attachment to the surface, making it useful 
for tissue engineering. Reports have shown that fibronectin has improved cell retention of 
rat MSC’s on fibronectin-coated surfaces (Dennis and Caplan 1993), increased the adhesive 
strength of cells, which was probably due to the increased number of bonds between 
fibroblasts and fibronectin-coated glass slides (Athanassiou and Deligianni 2001). Other 
studies concluded that braided PLLA and PLAGA polymers coated with fibronectin 
(10μg/ml) improved attachment of rabbit ACL cells and effected long term matrix 
production (Lu, Cooper et al. 2005). From the work carried out by Garcia and colleagues, 
their results indicated that cell adhesion strength (in osteosarcoma cells) increased on glass 
surfaces in a concentration-dependent fashion as fibronectin concentrations increased from 
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0.1-1μg/ml.  Plates coated with a concentration of 20μg/ml have been shown to improve 
cell adhesion of human MSC’s in comparison to uncoated plates (Salasznyk, Williams et al. 
2004), being more affective than coatings of collagen I or IV. However, in contrast to 
Salasznyk’s findings, Vohra and colleagues who also used a fibronectin concentration of 
20μg/ml (Vohra, Hennessy et al. 2008), suggested that although the fibronectin coating 
improved cell attachment compared to the negative control, MSC’s preferred to attach to a 
collagen I coating in comparison to the fibronectin and negative control. 
7.5 Bioreactor culture of tissue engineered ligaments 
A bioreactor is a vessel designed to contain cultures, where the environmental conditions 
can be optimised and carefully controlled to encourage certain biological and biochemical 
processes to take place (Martin, Wendt et al. 2004). Currently, many different types of 
bioreactors exist. They can be used to improve mass transfer of nutrients, waste products 
and oxygen through the culture medium, improve cell attachment, cell growth and 
proliferation. Bioreactors have been used in tissue engineering to apply mechanical forces to 
cell constructs (mechanical loading), and reported to promote differentiation of 
mesenchymal stem cells (MSC) into ligament fibroblasts (Zhang, Wang et al. 2004; Meyer, 
Buchter et al. 2005), induce alignment of fibroblasts with the direction of the applied force, 
upregulate mRNA expression of key ligament genes and produce helically organized 
collagen fibres (Altman, Horan et al. 2001). Mechanical conditioning can also be used to 
improve the structural and functional properties of a tissue once it has been engineered. 
Only those bioreactors related to ligament tissue engineering will be discussed here.  
When forces are applied to cells, the magnitude of the applied force, the way in which it is 
applied (constantly or alternating), the duration of time and the direction of forces 
(translational or rotational) will have a specific effect upon cell behaviour. These complex 
forces are experienced by the native tissue under physiological conditions. A specific 
combination or sequence of any of these can influence the cell to give a positive or negative 
response. Therefore variations in mechanical loading regimens can affect and alter the gene 
expression, and hence protein production and regulate tissue formation (Nesic, Whiteside et 
al. 2006).  
8. Response of cells to mechanical stimuli in vitro 
Many in vitro studies investigating the affects of mechanical loading have been performed 
with bioreactors. Kaplan and colleagues used a bioreactor to apply mechanical stimulation 
to mesenchymal progenitor cells seeded into a collagen 3-D gel matrix. The bioreactor 
applied multidimensional forces concurrently - translational (2mm) + rotational (90o) - at a 
frequency of 0.0167 Hz (one complete cycle of stress and relaxation per minute) constantly 
for 21 days, which was chosen to mimic the unique combination of forces experienced by 
the ligament under physiological conditions in vivo (Altman, Horan et al. 2001). Their 
results induced cell alignment parallel to the direction of the stretching force with an 
elongated cell morphology, mRNA expression of specific genes (type I and III collagen, 
tenascin-c and fibronectin), helically organized type I collagen fibres orientated in the 
direction of force, with the selective differentiation of human MSC’s into a ligament cell 
lineage rather than towards alternative lineages. The controls (non- loaded cells), showed 
few of these features. They concluded that “the mechanical forces could play a role in 
differentiation and not just promote formation of specific tissue types from the already 
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differentiated cells” and “the mechanical stimulation appeared to cause a selective 
differentiation to ligament-like cells” (Altman, Horan et al. 2001). Mechanical cyclic loading 
in compressed acellular collagen gels has been reported to encourage collagen fibril 
aggregation, promote fusion, resulting in an increase in its mechanical strength (Cheema, 
Chuo et al. 2007). Table 6 summarizes some of the mechanical loading conditions carried out 
in various studies, and the effects which they had upon the cells.  
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Table 6. The mechanical loading regimens which have been applied to tissue engineered 
constructs in vitro and the effects they have had upon various cell types 
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Cell type 
 
TGF 
concentration 
 
Combined with 
other GF’s 
 
Effects 
 
Author 
MSC hr TGF-β1 
10ng/ml 
Static culture 
 10ng/ml increased GAG 
expression & 
proliferation after 
14days, whereas 0.1-
1ng/ml did not. 
(Chen, Tsai et 
al. 2005)  
h ACL 
explants 
TGF-β1 
0.6ng/ml 
Static culture 
Ascorbic acid 
25ug/ml 
Cell number increased. 
Collagen production 
increased by 3 times. 
(Meaney 
Murray, Rice 
et al. 2003)  
 
h MSC TGF-β 
5ng/ml 
Static culture 
 
 
TGF+Insulin 
 
Adding ascorbic 
acid to TGF 
promoted 
greatest ratio of 
collagen:  total 
protein 
production 
TGF alone encouraged 
differentiation into 
fibroblasts (regarding 
morphology & 
alignment). Collagen 1 & 
3 express increased. 
Negligible expression of 
BSP & OSP. 
(Moreau, 
Chen et al. 
2005)  
 
h MSC TGF-β 
0.1, 0.5, 1, 5 
ng/ml 
Static culture 
 Proliferation rate 
increased as 
concentration increased 
(0.1-5ng/ml). 
1ng/ml TGF + FCS 
increased matrix 
production. 
(Locklin, 
Oreffo et al. 
1998) 
 
Rabbit ACL 
fibroblasts 
TGF-β1 
0.01, 0.1, 1ng/ml
Static culture 
 Increased collagen & 
non-collagenous protein 
synthesis as 
concentration increased, 
highest being at 1ng/ml. 
The increase was mostly 
for collagen 1 which 
increased by 1.5 times. 
(Marui, 
Niyibizi et al. 
1997)  
 
Sheep ACL 
explants 
hr TGF-β1 
10, 50, 100ng/ml
Static culture 
 Increased proliferation 
(seen at 96 hrs). 
(Spindler, 
Imro et al. 
1996)  
Human and 
rabbit 
mesenchymal 
progenitor 
cells 
hr TGF-β1 
Static culture 
 Chondrogenic (Chen, Tsai et 
al. 2005)  
 
Table 7. The effects of TGF-β1 upon fibroblasts and MSC’s 
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9. Response of cells to chemical stimuli in vitro 
During a cells life cycle, the cell needs to receive the appropriate signals at specific time 
points to instruct it to grow, proliferate, differentiate or synthesise ECM. These chemical 
signals are often provided by growth and differentiation factors. They bind the cell surface 
receptors on target cells to activate specific intracellular signalling pathways, controlling cell 
growth, proliferation, migration and differentiation (Quaglia 2008). The effect that a 
differentiation or growth factor has upon a cell can vary depending on the cell type, the 
stage in the cells life cycle and its environmental conditions. Such an example is 
transforming growth factor-β (TGF-β) which can be an inhibitor or stimulator of 
inflammation, or ECM remodelling by inducing mRNA expression of integrins, collagen 
and fibronectin (Evans 1999). 
In order for tissue engineering to be successful, it is necessary to create an artificial 
environment for the cells, and possibly mimic the in vivo environment, to promote 
formation of new tissue. Such an environment can be created by using, not only a suitable 
scaffold or mechanical stimulus, but also a chemical stimulus by incorporating growth 
factors into the culture media (Tabata 2003). From published research work, many authors 
report using various different growth factors such as basic fibroblast growth factor (bFGF), 
platelet derived growth factor (PDGF), transforming growth factor-β1 (TGF- β1), epidermal 
growth factor (EGF) and insulin-like growth factor (IGF) to encourage cells to proliferate, 
differentiate or increase the production of collagen (Schmidt, Georgescu et al. 1995; Spindler, 
Imro et al. 1996; Scherping, Schmidt et al. 1997; Murray, Rice et al. 2003; Pertigliano, 
McAllister et al. 2006). In vitro cell culture studies which used bFGF, PDGF, EGF or TGF-β1 
individually, have shown them to increase the proliferation of ACL fibroblasts (Schmidt, 
Georgescu et al. 1995; Spindler, Imro et al. 1996; Scherping, Schmidt et al. 1997; Murray, Rice 
et al. 2003), whereas a combination of TGF with bFGF or EGF has promoted MSC 
differentiation into fibroblasts (Pertigliano, McAllister et al. 2006). Growth factors have also 
been identified for their roles in regulating healing and repair of connective tissue after 
injury (Spindler, Imro et al. 1996). It is thought that the response of musculoskeletal tissues 
to injury or mechanical stress is modulated by growth factors such as PDGF and TGF-β 
(Spindler, Imro et al. 1996).  
9.1 In vitro studies with TGF-β1 
TGF-β1 has been used in various studies ranging in concentration from 0.1-15ng/ml. 
Specific concentrations have been shown to increase fibroblast proliferation, increase 
collagen production, glycosaminoglycan expression, and encourage MSC’s to differentiate 
into fibroblasts (Spindler, Imro et al. 1996; Locklin, Oreffo et al. 1998; Meaney Murray, Rice 
et al. 2003; Chen, Tsai et al. 2004; Chen, Tsai et al. 2005; Moreau, Chen et al. 2005; Giannouli 
and Kletsas 2006; Marenzara, Wilson-Jones et al. 2006). Table 7 summarises the effects that 
different concentrations of TGF-β1 have had on fibroblasts and MSC’s.  
10. Characterisation of a tissue engineered ligament 
When creating a tissue-engineered ligament, it is important to be aware of the characteristic 
components and properties found in native ligament as a comparing standard for 
functionality (shown in table 1). The ACL characteristics are demonstrated below in table 8. 
 
Tissue Engineering of Ligaments 
 
155 
The variation in tensile strength has been correlated to age and gender, where strength and 
stiffness of the ACL has been found to be lower in adult females (Chandrashekar, Mansouri 
et al. 2006), and can also significantly reduce as age increases, being 2-3 times higher in 
younger people, aged 16-26 years, compared to those aged at approximately 60 years old 
(Noyes and Grood 1976).  
 
 
Collagen fibre 
arrangement 
 
Fibroblast 
distribution and 
orientation 
 
Tensile 
strength - 
maximum 
force upon 
ACL at 
failure (N)
 
Maximum 
elongation 
of ACL at 
failure (mm)
 
Stiffness - 
Young’s 
modulus 
of 
elasticity 
(MPa) 
 
Author 
Aligned in a 
fairly parallel 
orientation 
with the 
longitudinal 
axis of the 
ligament 
Sparsely 
distributed 
throughout the 
ECM 
(approximately 
20% if the tissue 
volume), 
aligned on 
collagen fibre 
bundles 
556-1730 
 
8-12 9-13 (Noyes and 
Grood 1976; 
Laurencin, 
Ambrosio et al. 
1999; Azangwe, 
Mathias et al. 
2001; 
Chandrashekar, 
Mansouri et al. 
2006; Doroski, 
Brink et al. 2007) 
Table 8. Fibre organisation and mechanical properties of the ACL 
11. Conclusions  
Tissue engineering of ligaments is still in its early stages, but its prospects have great 
potential. Tissue engineering has the ability to overcome the limitations of autografts and 
allografts by generating a tissue with the correct structural and biomechanical properties for 
a more successful transplant, hopefully giving a better long-term mechanical performance. 
The benefits of using autologous cells from the patient reduces the risk of tissue rejection or 
transmission of infectious diseases associated with allografts, and also avoids donor site 
morbidity associated with allografts. Advances in research in this area continue to optimise 
a combination of the factors discussed in this chapter such as choice of biomaterial, cell type 
and stimuli for potential synergistic effects. 
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1. Introduction 
Anatomical descriptions of anterior cruciate ligament (ACL) can be found in Egyptian 
papyrus scrolls dating back to 3000 BC. Hippocrates (460-370BC) has described knee 
subluxation with ACL injury. Even today, the ACL of the knee joint is still the frequent 
target of trauma, especially in the young and active population (Murray, 2009). Rupture of 
the ACL of knee affects over 175,000 patients a year worldwide (Myer et al., 2004). Such 
injury often results from twisting or turning the knee while landing (e.g. non-contact 
rupture), valgus stress (knock-knee position), or hyperextension directly related to contact or 
collision. (Wu et al., 2010). For unknown reasons, this major knee joint stabilizer fails to heal 
after suture repair, (Murray et al., 2007). Often, other knee structures are directly affected 
when partial or complete ACL injuries occur, impairing knee function (Englund et al., 2009). 
The tibia and femur are more likely to rub against each other, leading to cartilage defects 
and osteoarthritis. While a variety of rehabilitation protocols have been assessed, 
rehabilitation doesn’t insure long-term maintenance of knee function. The clinical decision 
to replace a torn ACL is based on the extent of the damage caused by the injury and 
subsequent functioning of the knee, and the choice of ACL substitute that is grafted is made 
accordingly (e.g. autograft, allograft, synthetic, or potentially, a tissue engineered 
autologous construct). The surgery of the ACL is usually performed several weeks after the 
injury in order to allow the swelling and inflammation to subside, although in some 
countries the surgical intervention can occur within hours or days of the injury. After the 
surgery, physical rehabilitation is necessary to strengthen the surrounding muscles, stabilize 
the knee joint, prevent arthrofibrosis, and restore range of motion. 
1.1 Function of the ACL on the knee joint 
The ACL has both proprioceptive and mechanical functions. It is the first restraint to 
anterior translation of the tibia. The ultimate tensile load and stiffness of the human femur-
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ACL-tibia complex are 2160 + 157 N and 242 + 28 N/mm, respectively (Dargel et al., 2007; 
Woo, 2006). The forces applied on the ACL during normal walking are 303N or less 
(Peterson & Zantop, 2007). The highest loads and strains on the ACL during daily 
function are quadriceps-powered extension of the knee, moving it from approximately 40 
degrees of flexion to full extension (This explains why open kinetic chain exercises are 
avoided during early phases of rehabilitation). Secondly, the ACL forces the tibia to 
internally rotate during anterior tibial translation, indicating that the ACL primarily 
restrains internal rotational moments during anteroposterior translation, (Fukubayashi et 
al., 1982). 
1.2 Compromised healing of the injured ACL 
In contrast with extra-articular knee ligaments (e.g. the collateral ligaments), the healing of 
the intra-articular ACL in vivo is poorly understood. A complete tear of the ACL 
(midsubstance or at the insertion), would not leave a residual structure on which to form a 
scar. However, a partial tear should leave at least a partial template to form a scar. 
Interestingly, even if bleeding occurs after ACL injury, no fibrin-platelet plug is observed to 
form inside the joint, even at the injury site. One possible explanation for this observation is 
that circulating intra-articular plasmin breaks down the fibrin plug as fast as it can form 
(Murray, 2009). Recent work has shown that after trauma to the joint, the production of 
plasmin is upregulated via the increased secretion of urokinase plasminogen activator (Rosc 
et al., 2002). With the additional circulating plasmin, the fibrin network is quickly 
destabilized within the joint environment and no fibrin-platelet plug forms. This premature 
loss of the fibrin-platelet plug would have the significant clinical benefit of preventing 
overall joint scarring and stiffness (arthrofibrosis) and thus maintenance of joint mobility 
after injury. As formation of a fibrin-platelet plug is an essential first step for wound healing 
of musculoskeletal tissue outside the joint, the loss of this fibrin-platelet plug inside the joint 
may be the key mechanism behind the failure of intra-articular tissues to heal (Murray, 
2009).  
However, other possibilities likely also exist. In studies of partial injuries to the ACL in 
either rabbit (Lo et al., in preparation; Heubner et al., in preparation) or sheep models 
(Heard et al., 2011), the response to injury leads to an inflammation. In fact, a partial injury 
to one band of the ACL leads to an initial response not dissimilar to that of the MCL at 3 
weeks post-injury, which then fails to mature and ultimately fails to lead to functional 
repair, possibly due to persistent inflammation (Lo et al., in preparation). Thus, the failure of 
healing (non-union) and laxity observed in the ACL after suture repair may also be 
attributed to the adverse influence of synovial fluid (Murray et al., 2009; Woo et al., 2000), to 
alterations in the cellular metabolism after injury (Amiel et al., 1989), and to intrinsic cell 
deficiencies (Kobayashi et al., 2000). The superior capacity of the MCL to increase its blood 
supply through angiogenesis and increased flow is essential for ligament healing to occur, 
and may be the major difference in healing potential between the ACL and MCL (Kobayashi 
et al, 2000). Several growth factors have been studied in tendons post-surgery. The 
expression of Aggrecan, Versican, Biglycan, Lumican, Decorin, TGF-β and β-FGF mRNAs 
have been monitored in vivo, using a rabbit model of flexor tendon injury (Berglund et al., 
2006). The role and the mode of interactions between these various factors, as well as the 
sequential post-traumatic modulation of their expression remain to be defined. However, it 
is clear that whatever the mechanisms involved, the intra-articular environment is not 
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conducive to normal ACL healing, and this also has implications for the incorporation of 
ACL reconstructions with either natural tissues or tissue engineered tissues. 
1.3 Impact of torn ACL on the knee strength, stability and osteoarthritis (OA) 
Injury to the anterior cruciate ligament (ACL) is regarded as critical to the physiological 
kinematics of the femoral-tibial joint, with its disruption eventually causing long-term 
functional impairment. Both the initial trauma and the pathologic motion pattern of the 
injured knee may result in primary degenerative lesions of the secondary stabilisers of the 
knee, each of which are associated with the early onset of OA (Von Porat et al., 2004). 
Consequently, there is a wide consensus that young and active patients may profit from 
reconstructing the ACL. Several factors have been identified as significantly influencing the 
biomechanical characteristics and the functional outcome of an ACL reconstructed knee 
joint. These factors are: (1) individual choice of autologous graft material using either 
patellar tendon-bone grafts or quadrupled hamstring tendon grafts, or another type of ACL 
substitute, (2) anatomical bone tunnel placement within the footprints of the native ACL, (3) 
adequate substitute tension after cyclic graft preconditioning, and (4) graft fixation close to 
the joint line using biodegradable graft fixation materials that provide an initial fixation 
strength exceeding those loads commonly expected during rehabilitation. Based on such 
factors, the literature encourages mid- to long-term clinical and functional outcome 
assessments after ACL reconstruction (Dargel et al., 2007). 
At follow-up, patellofemoral OA is associated with higher activity level, meniscal injury, 
extension and flexion deficit, and ACL reconstruction. Although risk factors for 
posttraumatic OA are multifactorial, the primary risk factor that stood out in the study of 
Neuman et al. (2009), was whether a meniscectomy had been performed. Early activity 
modification and neuromuscular knee rehabilitation might also have been related to the low 
prevalence of radiographic knee OA. In patients with ACL injury willing to restrict 
themselves to moderate activity level to avoid re-injury, initial treatment without ACL 
reconstruction should be considered. (Neuman et al., 2009). Interestingly, the incidence of 
OA after an ACL tear appears to be similar whether or not the ACL has been reconstructed 
(Lohmander et al., 2007; Oiestad et al., 2010; Frobell et al., 2011), possibly due to concurrent 
injury to other joint structures at the time of the ACL tear. However, quality of life and a 
return to knee stability is gained by reconstruction, particularly in younger active patients. 
2. Current surgical approaches to restore knee function after ACL injury 
New options for ACL replacement are under development and some clinical studies are in 
progress (Altman et al., 2008; Murray, 2009). One of these options is tissue engineering of a 
tissue replacement, but the majority of reconstructions are performed with autologous or 
allogeneic tissues. By definition, tissue engineering involves a combination of knowledge 
and skills in biology and in biomechanics (Functional Tissue Engineering Conference 
Group, 2008). Such multidisciplinary science has opened the door to the conception and 
fabrication of new biocompatible materials for ACL reconstruction (Woo, 2009). However, 
independently from the type of ACL substitute chosen, successful reconstruction of the ACL 
depends on anatomic placement of a graft ligament substitute (Cole et al., 2000). Strength 
has been and remains a major consideration in the choice of grafts (Frank & Jackson, 1997). 
Accurate tunnel placement minimizes graft excursion and impingement against the roof of 
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the intercondylar notch. This will result in maximum knee stability and motion (Fineberg et 
al., 2000; Steiner et al., 2008).  
2.1 Autologous tendon for torn ACL replacement 
Orthopaedic autograft reconstruction of the ligament often uses a bone-to-bone technique 
for optimal repair (Frank & Jackson, 1997; Paxton et al., 2009). The central part of the patellar 
tendon, including bone fragments from the tibia and the femur, or the hamstring tendons is 
often used as an ACL substitute. Bone-patellar tendon-bone (BPTB) autografts have been 
proclaimed as the "gold standard" in ACL reconstruction (Woo et al., 2006). 
Biomechanically, a 10-mm wide BPTB graft has stiffness and ultimate load values of 210 ± 65 
N/mm and 1784 ± 580 N, respectively (Wilson et al., 1999), which compare well with those 
of the young human femur-ACL-tibia complex (242 ± 28 N/mm and 2160 ± 157 N, 
respectively), (Woo et al., 2006). It also shows the advantage of having bone blocks available 
for graft fixation in the osseous tunnels that leads to better knee stability. Unfortunately, 
ligament creep or laxity is observed post-surgery, adding to the morbidity associated to the 
partial loss of an healthy tendon, knee chronic pain, loss of motion, knee instability, 
quadriceps weakness and patella rupture. The mechanisms by which such grafts lose 
function is not known in detail, but it may involve replacement of the transplanted tissue by 
a scar-like matrix after neovascularization, infiltration of cells from the intraarticular 
environment, and a persistent inflammation as a consequence of the surgery. Thus, many 
orthopedic surgeons conclude that it is clinically highly justified to explore other strategies 
for ACL replacement. 
2.2 Cadaver allograft ACL implantation 
The use of allograft substitutes (ACL taken from cadavers) overcomes the need for 
autologous tissues, avoiding donor site morbidity. However, this approach has deficiencies 
considering the risks of disease transmission, graft rejection, delayed physiologic integration 
and inflammation (Murray, 2009). Allografts are relatively expensive and their availability 
might be limited. Nevertheless, patellar tendons taken from cadavers are still used for 
ruptured ACL replacement, depending on the short- and long-term needs of each patient 
that is treated. Cadaver allografts are readily strong and they are progressively remodelled 
by the cells of the host in situ post-grafting.  
3. Essential factors needed to translate tissue engineering into effective 
treatment modalities 
Over the last fifteen years, tissue engineered ACL substitutes have raised the interest of 
orthopedic surgeons for obvious reasons. The concept of producing a ligament in vitro 
solves the issue of morbidity associated with autologous tendon grafts.  Depending on the 
technological approach developed to reconstruct an ACL in vitro, the availability of tissue-
engineered products widens the spectrum of surgical options and provides a mid- to long-
term solution to prevent knee joint instability. However, the features of a tissue engineered 
ACL depend on the type of biomaterials that compose its scaffold. The potential and the 
functionality of any reconstructed ligament must be assessed in animal models. This is the 
critical step to evaluate the feasibility, the viability and the factors of failure associated with 
all new ACL replacement strategies under development. 
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3.1 Animal models: strengths and limitations 
Rabbit and goat models have been used to assess torn ACL replacement strategies 
(Xerogeanes et al, 1998). The advantage of the rabbit remains the wide choice of antibodies 
and biomarkers commercially available to analyze the various constituents of ACL 
substitutes post-grafting and ex-vivo. The main limitation of this model is its size, and the 
fact that it doesn’t compare with the human knee joint. The goat is larger and the size of its 
knee joint is close to the human structures. This facilitates development of a pre-clinical 
protocol for the implantation of a new type of ACL replacement. However, significant 
differences are observed between the magnitude of force experienced by the goat ACL and 
its anteromedial and posterolateral bundles when compared with the corresponding human 
ACL. Nonetheless, the caprine animal model is widely used for ACL characterization in 
vitro and in vivo (Tischer et al., 2009; Robayo et al, 2011; Tremblay et al, 2011). The most 
challenging preclinical model to study ACL repair is certainly the dog knee joint. As in 
humans, spontaneous ACL injuries are frequently observed in large dog knee joints. The 
medial meniscus is commonly damaged along with the ACL. The canine model also 
involves several other issues, including early OA development after torn ACL injury 
(Murray et al., 2006). For this reason, an ACL substitute tested with success in the canine 
knee joint would certainly indicate serious potential for use in the human knee. As well, 
success in the canine model could also have veterinary implications for prevention of OA 
development in valuable companion, working and show animals. 
3.2 Cell-seeded (stem cells, autologous cell sources) or acellular ACL substitutes?  
There are two groups of cell-seeded ACL substitutes: tissues populated with live cells (e.g. 
BPTB or semitendinous autologous ACL grafts), and grafts containing dead cells (e.g. 
cadavers allografts). In addition to the risks of immune and⁄or inflammatory reaction, 
autologous or allogenic dead cells must be eliminated post-implantation. The cellular debris 
present in a cell-seeded ACL substitute may slow down or delay its colonization and impair 
the growth of host cells that migrate into the grafts from the bone insertion sites towards the 
middle ligament substance. ACL graft vascularization post-implantation might also be 
delayed by the presence of microstructures that are subjected to an ongoing necrosis process 
in the implant. ACL substitutes already populated with live autologous cells that will not be 
rejected by the host have the potential to be quickly regenerated in situ, following 
neovascularization to restore blood supply, as well as reinnervation. 
Interestingly, tissue engineered ACL substitutes can be seeded with live cells before 
implantation to initiate matrix deposition and remodeling in the tissue. This may enhance 
the integration of the implant in situ post-grafting. However, the choice of the cells source 
remains controversial. The use of mesenchymal stem cells (MSC) is an attractive option as 
these cells have a long lifespan and are not fully differentiated, suggesting that they could 
be tolerated from one individual to another. The use of human serum instead of serum of 
animal source, seems to have a direct and a positive effect on the phenotype of human 
synovium-derived mesenchymal stem cells (MSC), (Tateishi et al., 2008). The results of this 
study indicated that human serum (HS) is superior for the culture of human MSCs 
compared with fetal bovine serum (FBS) in terms of cellular expandability, without losing 
chondrogenic or osteogenic differentiation capacity. Coupled with the advantage in 
eliminating the potential risk accompanied with the use of xeno-derived materials, pooled, 
well-characterized HS could be a useful reagent to promote cellular expansion for clinical 
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synovial stem cell-based therapy. Nonetheless, the use of a “universal” human cell 
population for large-scale production of ACL substitutes would be ideal for obvious 
technical and economic reasons (Hart et al., 2005).  Some issues regarding the source of 
autologous cells present the advantage to be non-immunogenic, but their amplification in 
vitro could also involve some risks of phenotypic changes.  
The source of the MSC is also an issue that needs to be addressed for optimal development 
of a functional tissue engineered construct for replaced of a ruptured ACL. MSC have been 
obtained from multiple sources including bone marrow (BM), muscle, synovial membranes 
(SM), and more recently, from synovial fluid (SF) itself (reviewed in Peng & Huard, 2003; 
McGonagle & Jones, 2008; Chanda et al., 2010;  Augello et al., 2010; Fong et al., 2011). Recent 
studies have indicated that SM-derived MSC are effective in generating tissue engineered 
constructs that can serve as articular cartilage  repair tissues (Ando et al., 2007; Shimomura 
et al., 2010), but whether such MSC can also serve as effective cells to generate a replacement 
ACL have not been explored in detail (McGonagle & Jones, 2008). Very recent studies have 
shown that porcine (Ando et al., in preparation) and normal human (Krawetz et al., in 
preparation) SF and SM MSC exhibit very similar properties, so this source may be a 
preferred population in the future for ACL repair constructs. Why such MSC are present in 
the SF is not known, but likely they are there to facilitate repair normal repair of 
microdamage to intraarticular tissues such as cartilage, menisci and ligaments, so they 
exhibit good potential for tissue engineering purposes. 
The use of fibroblasts isolated from skin instead of ACL biopsies to populate tissue-
engineered ACL substitute led to comparable results in the goat knee joint (Tremblay et al., 
2011). The fibroblasts isolated from both sources secrete the same types of collagen (I and 
III), but a skin microbiopsy is more readily harvested than a tissue sample collected under 
arthroscopy from a ruptured ACL in an injured knee joint. Ultimately, acellular ACL 
substitutes made of biodegradable and biocompatible biomaterials remain the safest option. 
However, such substitutes will have to be colonized by cells from the host post-
implantation. Therefore, tissue-engineered acellular ACL substitutes implies a delayed 
remodeling of the graft (Robayo et al., 2011), which may impair its long-term stability in 
situ. Cells seem to play an essential role in the development of such tissue in vitro. 
However, to keep the best of both options, it would be important to proceed in two phases 
to obtain a viable and efficient ACL substitute. The first phase would be based on the use of 
cells to structure and strengthen the ligament scaffold in culture. When strong enough to 
sustain the biomechanical stress in the joint, the ligament could be lyophilized before 
implantation in order to kill the cells initially present in the implant and allow cell 
colonization by the host, being sure that the structure of the scaffold will play its role, and 
thus enhance integration.  
3.3 Biomaterials: synthetic, native or both?  
To facilitate host cell migration, growth, colonization and remodeling of ACL substitutes 
post-implantation, the scaffold of the graft must be porous and entirely biocompatible. The 
graft must be biodegradable and the products generated by this degradation should also be 
readily eliminated through physiological mechanisms. Collagen I is the major and the 
natural component of the native ACL matrix. Therefore, this protein is highly suitable, alone 
or in combination with other biocompatible constituents, to build the scaffold of a tissue-
engineered ACL substitute (Goulet et al., 2004). For example, a collagen-platelet rich plasma 
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(collagen-PRP) bridging scaffold, added in a central ACL defect, can stimulate healing of the 
ACL histologically and biomechanically (Murray et al., 2006; Spindler et al., 2009). Other 
types of tissue-engineered biomaterial scaffolds have been described for their potential as 
ACL replacement alternatives, as long as they can be implanted and sustain the 
biomechanical stress to which they are subjected in vivo (Altman et al., 2008; Sandmann and 
Tischer, 2010). More recently, the concept of anatomic double bundle ACL reconstruction 
has been developed to replace antero-medial and postero-lateral bundles of the ACL. Such 
approach aims at improving the biomechanical functionality of tissue-engineered grafts, 
even when the knee is subjected to rotatory loads (Woo et al., 2006).  
3.4 Role of biomechanical stimulation in generating an effective tissue-engineered 
construct 
The main advantage of including living cells in any tissue-engineered ACL substitute is the 
possibility to stimulate early matrix synthesis and remodelling in the reconstructed tissue in 
vitro. Cyclic stretching is an example of biomechanical stimuli that increase collagen 
synthesis by cells in the tissue, thereby strengthening the resultant scaffold made of aligned 
fibre bundles (Goulet et al., 2000, Kaneko et al., 2009). Thus, the ACL substitute has already 
reached a first step towards matrix synthesis, and the process can continue to progress in 
response to the in vivo strains that are applied to the graft in the post-transplantation 
environment (Goulet et al., 2004).  
3.5 Placement and effective repair of the biomechanical environment  
The anatomic placement of a graft ligament substitute is crucial for its proper integration 
and functional behavior (Cole et al., 2000). As previously mentioned, accurate tunnel 
placement should be performed with respect to the original insertion sites of the torn ACL, 
to limit graft excursion and impingement against the roof of the intercondylar notch, 
(Fineberg et al., 2000;  Steiner et al., 2008). The ACL substitute must be able to resist an initial 
graft tension ranging from 44 to 88 N (Woo et al., 2006). An in vivo study on goats found no 
significant differences in knee kinematics and in situ forces, between high (35 N) and low (5 
N) initial tension at 6 weeks after surgery (Abramowitch et al., 2003). Viscoelastic studies 
have revealed that the tension in the graft can decrease by as much as 50% within a short 
time after fixation because of its stress relaxation behaviour. Variation in outcomes may also 
be influenced by additional variables associated with the individual such as age, sex, 
genetics, obesity, muscle strength, activity, and re-injury. Therefore, a return to joint stability 
and functional state is the main objective of the clinical management of the knee joint 
following ACL injury. A tissue-engineered ACL substitute that could stabilize the joint and 
maintain its functional state post-grafting is certainly needed. However, if the integrity of 
the grafted material is to continue to function and progress in biomechanical properties, 
then likely the intra-articular environment will have to be manipulated to limit surgery-
induced inflammation and promote anabolic conditions. 
4. Tissue engineered ACL substitutes assessed in vivo and under 
development 
Several tissue-engineered ACL substitutes have been proposed in the literature. Cross-
linked bovine collagen fibers, chitosan-based hyaluronan hybrid polymer fibers, alginate-
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based chitosan hybrid polymer fibers, polyglycolic acid scaffolds, silk matrix, and other 
biodegradable scaffolds seeded or not with living cells (Altman et al., 2008). However, 
presently only ligament augmentation devices have been subjected to clinical trials. In 
contrast, many biosynthetic and biological ACL substitutes are being assessed in preclinical 
models. Such is the case with the tissue engineered ACL substitute that was developed 
using bone blocks, type I collagen and autologous cells (Goulet et al., 2004). The scaffold for 
this ACL substitute is made of bovine type I collagen that is seeded with autologous 
fibroblasts isolated from the ACL of the goat to be grafted. This ligament is produced 
entirely in vitro (Fig.1).   
 
 
Fig. 1. Steps of production of a tissue engineered ACL substitute 
A type I collagen solution (1 mg/ml),  is mixed with autologous fibroblasts (0,5 x 106 cells 
⁄ml) in a test tube containing two bone plugs fixed with a pin at the top and at the bottom of 
it. The collagen polymerizes and is contracted by the cells to obtain a ligament that can be 
used as an in vitro model. To produce a ligament for implantation into a knee joint, a 
surgical thread is placed between the bones (not shown). A lyophilization step is then added 
to obtain a scaffold that is stronger. Once rehydrated, a second layer of collagen including 
cells is subsequently added to the construct. The collagen polymerizes and the ACL 
substitute is ready to be grafted into a knee joint. 
The ACL substitute is maintained under static tension in culture (Fig.2), with the tension 
applied by pulling one of the bone plugs in a programmed manner. This process also 
induces the alignment of the collagen fibers in the direction of the applied tension. 
 
 
Fig. 2. Tissue engineered ACL substitute 
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Macroscopic view of a tissue-engineered ACL substitute maintained in culture for two 
months under static tension, anchored with two spongious bone plugs. Note the central 
portion of the tissue that was contracted by the live cells that populate its type I collagen 
scaffold. A surgical thread, bioresorbed within a month in vivo, reinforces the links between 
the bones.  
The main features that orthopedic surgeons want to know regarding such ACL substitutes 
produced in vitro are their strength and their stiffness. Rupture assays were performed to 
evaluate the mechanical properties of the engineered ligament constructs before 
implantation (Table 1). Any natural collagen gel that is not reinforced using a thread or 
another type of support cannot resist a tension that is higher than 0.5 N (Fig3A). Once 
lyophilized, the collagen scaffold shows an ultimate strength of 2 N (Fig.3B), while the 
addition of a bioresorbed surgical thread will allow the structure to resist a tensile load of 
more than 60 N. 
 
Structure of the matrix Ultimate strength (N) Location of the rupture site 
1 layer of hydrated 
collagen (gel) 
0.2-0.5 (+ 5%) Interface bone-
ligament 
+ 1 layer of hydrated 
collagen lyophilized 
(rehydrated) 
2 (+ 5%) Middle of the 
ligament 
+ 1 layer of hydrated 
collagen lyophilized 
(rehydrated) around a 
resorbable surgical 
thread: Maxon 3.0) 
> 60N (grafted in goat 
knee joint) 
Not determinated 
Averaged cross-sectional area surface: 100 mm2  (+ 5%) 
N= Newton 
Table 1. Averaged ultimate strength values (n=12) of ex-vivo ACL grafts (n=6) 
The tissue-engineered ACL was grafted into goat knee joints for periods varying from one to 
13 months (Goulet et al., 2004; Robayo et al, 2011; Tremblay et al, 2011). An immobilising 
plaster cast was placed on the leg during the first week post-surgery to limit motion (to 
favour healing) and to prevent the goat from irritating the wound (Fig.4A). Following 
removal of the cast, the goats gradually returned to putting weight on the affected leg, 
walking freely thereafter (Fig.4B).  
Such implant is vascularized within a month in situ post-grafting. Nerve endings, Sharpey’s 
fibers, and fibrocartilage were observed in all of the grafts at six months post-implantation 
(n=3). Electron microscopic analyses demonstrated that the diameter of the collagen fibers 
synthesized by the cells in vivo, were comparable with native ACL fibers (Goulet et al., 
2004). One of the issues that could impede the potential use of this ACL substitute for 
clinical application would be the difficulty to harvest a torn ACL biopsy to isolate the cells 
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that are required. Recently, experiments conducted with tissue engineered ACLs seeded 
with autologous skin fibroblasts and grafted in goat knee joints for six months led to the 
same observations that were made with ACL cells (Fig.5). Thus, animal experimentation 
using skin fibroblasts has also shown promising signs of integration into the goat knee joint 
(Tremblay et al., 2011).  Interestingly, analyses by zymography demonstrated that caprine 
and human fibroblasts, isolated from ACL and skin biopsies, secrete the same types of 
gelatinases (collagenases), suggesting that they share similar potential for collagen 
remodeling (data not shown). 
 
 
Fig. 3. Collagen scaffolds of a tissue engineered ACL subjected to static tension in culture. 
Photomicrographs of histological microsections of the type I collagen scaffold of tissue-
engineered ACL stained with the Trichrome de Masson’s method. Note the good alignment 
of the collagen fibers that was induced by the horizontal tension applied on the tissue for 24 
hrs in culture. Shortly after collagen polymerization, the density of the fibers in the tissue-
engineered scaffold is low (A). After lyophilisation and rehydration of the scaffold, the 
collagen fibers become closer to each other, leading to an increased matrix density and 
strength. (x60) 
 
 
Fig. 4. A goat grafted with an autologous tissue-engineered ACL. 
Photograph of a goat three days (A) and one month (B) after the implantation in the right 
knee joint of a tissue-engineered ACL seeded with autologous fibroblasts. The animal could 
jump and run only one month post-implantation 
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Fig. 5. Implantation of a tissue engineered ACL substitute in a goat knee joint. 
Macroscopic view of a tissue-engineered ACL substitute at the time of implantation (A) and 
six months later (B). The articular cartilage didn’t show any sign of degeneration before and 
after tissue-engineered ACL implantation 
5. Conclusions 
The fundamental and clinical issues associated with the management of torn ACL 
replacement remain those that were described by Frank and Jackson (1997) fifteen years ago. 
Back then, the concept of an effective tissue-engineered ligament for permanent ACL 
replacement was a new and exciting distant possibility. Today, such a concept is a very 
realistic outcome, with the evolution of nanotechnology, combined with a wider spectrum 
of biomaterials developed through interdisciplinary skills and know-how (Functional Tissue 
Engineering Conference Group, 2008). The development of tissue-engineered ACLs in vitro 
presents several advantages for the patients and for the orthopaedic surgeons. It avoids 
healthy tissue morbidity and thus, reduces the period of rehabilitation post-surgery. It 
allows the production of a substitute that has the proper length, diameter and scaffold to fit 
the joint and stabilize it. The modulation of matrix fibers in vitro by mechanical stimulation, 
cell-matrix interactions and structural modifications of the scaffold, are good indicators that 
the tissue-engineered ACL substitute will become a viable surgical option in a very near 
future.  
However, generation of an effective engineered ACL replacement that can withstand the in 
vivo loading environment is only a critical first step in a process. Implantation and post-
implantation events are also critical to sustain the potential of such engineered constructs, 
and these include correct placement of the grafts to mimic normal loading patterns, as well 
as controlling the intraarticular environment of minimize the catabolic influence of 
persistent inflammation and maximizing the anabolic activities in this compartment. Such 
control could contribute to the long-term effectiveness of the constructs via prevention of 
loss of function via alteration of their creep properties and prevention of conversion to a 
structure with scar-like properties. With such control, knee function can be restored and risk 
for OA development later in life may be abrogated. 
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1. Introduction 
1.1 Cartilage injuries, the triad and quartet of tissue engineering 
Presently, focal cartilage injuries in humans are treated by abrasion arthroplasty with or 
without subchondral bone microfracture, autologous chondrocyte or mesenchymal stem 
cells (MSC) implantation and osteochondral plugs used in a sequential fashion pending 
severity and duration of the problem (Figure 1) (Williams et al., 2010; Steinert et al., 2007). 
Current strategies in human medicine for treatment of diffuse joint degeneration rely on 
replacement of the whole degenerated joint with inert implants. Excellent treatment 
outcome has been achieved for up to 15 years or more, but approximately 20% of treated 
patients require revision procedures after this time (Steadman et al., 2001). For younger 
patients this current state-of-the-art may translate to two or more revision surgeries during 
their lifetime. A biological solution to repair damaged cartilage that would provide life-long 
pain relief would be a major medical achievement.  
The tissue engineering triad refers to the use of cells, scaffolds and cytokines to engineer 
tissues in vitro or in vivo. Such engineered tissues can potentially be utilized for tissue 
replacement strategies, for pharmacological screening of agents for therapeutic or toxic 
effects, or to gain insight into tissue developmental processes. Cartilage tissue, engineered 
using this triad of components often exhibit hyaline cartilage morphology, but the tissue has 
inferior mechanical properties when compared to native joint cartilage (Grad et al., 2011; 
Schulz and Bader, 2007). A fourth component of tissue engineering, namely mechanical 
stimulation has been added to the classical triad in order to better replicate the in vivo 
environment of joint cartilage (Grad et al., 2011; Schulz and Bader, 2007). Using this 
“quartet” of tissue engineering (cells, scaffolds, cytokines, and mechanical stimuli), cartilage 
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with better mechanical properties has been produced. The mechanical properties of cartilage 
produced using mechanical stimulation may or may not be better than static culture 
depending on the cell source, timing of mechanical stimulation, method and duration of 
mechanical stimulation, and other variables. It is clear that each component of this tissue 
engineering “quartet” should be studied in detail since different cells respond differently to 
different cytokines, scaffold composition and topography as well as mode and timing of 
mechanical stimuli. This underlines the complexity of tissue engineering where each of 
these areas is a separate research field.  
Here, we will briefly discuss the cells used for cartilage tissue engineering followed by more 
detailed discussion of selected topics on scaffolds, cytokines and means of mechanical 
stimuli. Pre-clinical animal models of cartilage repair and future perspectives follow these 
tissue-engineering considerations.  
 
 
Fig. 1. Current articular cartilage treatment algorithm. ACI = autologous chondrocyte 
implantation, MACI = matrix-assisted autologous chondrocyte implantation, TJR = total joint 
replacement. Reprinted with permission from Williams et al. (2010)  
2. Cells of cartilage tissue engineering 
Articular hyaline cartilage is a very specialized tissue characterized by low cellularity, 
extensive extracellular matrix, lack of vascular, lymphatic, and nervous supply, and 
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insufficient number of resident progenitor cells needed for mounting an appropriate 
regenerative response to injury. The result is minimal intrinsic repair capacity.  
The obvious choice of cell for cartilage repair is the chondrocyte from hyaline cartilage since 
it is normally responsible for the production and maintenance of joint cartilage. However, a 
number of factors have limited the use or therapeutic success of chondrocytes. 
Chondrocytes only constitute about 5% of joint cartilage and insufficient chondrocyte 
numbers are therefore often retrieved for immediate therapeutic use, which in turn 
necessitate ex vivo cell expansion prior to re-implantation. Chondrocytes unfortunately tend 
to dedifferentiation towards the fibroblast cell lineage when expanded in culture making 
them less suitable for transplantation (Schulze-Tanzil, 2009). Another limitation to the use of 
autologous chondrocytes is the need for two surgical procedures, weeks apart to harvest 
and later implant the cells, which adds time, cost, anesthetic risk and risks of donor site 
morbidity (Schulze-Tanzil, 2009; Williams et al., 2010). Interestingly, osteoarthritic 
chondrocytes seem to perform equally well in vitro when compared to chondrocytes from 
healthy joints (Dehne et al., 2009; Stoop et al., 2007).  
Stem cells or cells with chondrogenic potential from various tissue sources have been 
investigated for cartilage repair. Adult cells such as bone marrow multipotent stromal cells  
(BM-MSCs) are attractive due to the decreased cost and risks associated with collection 
compared to autologous chondrocytes. Concerns raised with the use of BM-MSCs include 
potentially a decreased yield and differentiation potential of MSCs from the bone marrow 
with increasing age making the technique age-dependent. This is paradoxical to the fact that 
clinical cases often occur in aged individuals (Wilson et al., 2010; Kasper et al., 2009). Adult 
cells with chondrogenic potential have been isolated from a large number of tissues and 
have been reviewed elsewhere (Solchaga et al., 2011; Hildner et al., 2011; O'Sullivan et al., 
2011). Embryonic and recently, induced pluripotent stem cells (iPS cells), may also be 
valuable cell sources for cartilage repair (Hiramatsu et al., 2011; Medvedev et al., 2010; 
Waese and Stanford, 2011; Fecek et al., 2008). Neonatal stem cells with chondrogenic 
potential have been isolated from fresh umbilical cord blood of humans as well as horses 
(Berg et al., 2009; Koch et al., 2007; Santourlidis et al., 2011; Zhang et al., 2011). Human cord 
blood derived stem cells have showed increased proliferation capacity and broader 
differentiation potential compared to stem cells from bone marrow and adipose tissue 
(Zhang et al., 2011; Kogler et al., 2004). Also, cord blood MSCs may be more chondrogenic 
than bone marrow MSCs (Berg et al., 2009; Zhang et al., 2011). 
So far a reliable cell source and method of isolating cells with high chondrogenic potential 
has not been reported. From a tissue-engineering point of view this is a major limitation at 
the moment, since it precludes development of predictable and reproducible protocols for 
cartilage production.  
3. Biomaterials & scaffold fabrication technologies 
Joint cartilage regeneration can be achieved by two strategies, namely cell- and scaffold-
based therapies. Cell therapy has already reached the clinics in the form of autologous 
chondrocyte implantation (ACI) or matrix-assisted ACI (MACI). However, this regenerating 
technique appears to assist only partially in the repair process as it leads to the formation of 
mechanically inferior fibrocartilage compared to native joint cartilage. Although clinical 
outcome is better five years after surgery when compared to the baseline, recent 
comparative studies showed that ACI and MACI were not significantly better than marrow-
stimulating techniques (e.g. microfractures) or reconstructive techniques (e.g. 
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mosaicarthroplasty) using autografts, allografts or synthetic material (Ebert et al., 2011; 
Vasiliadis et al., 2010). The influence of scaffold composition and surface topography on cell 
function and differentiation is being increasingly recognized (Rosso et al., 2005; Milner and 
Siedlecki, 2007; Thakar et al., 2008; Patel et al., 2010). Improvement to the MACI technique 
and other scaffold-based approaches may therefore be made through precise engineering of 
three-dimensional (3D) porous biomaterials – 3D scaffolds – that promote cell lodging, 
migration, and differentiation while providing mechanical support during tissue repair.  
Different biomaterials are used to fabricate scaffolds, predominantly natural and synthetic 
polymers. In general two classes of polymers can be distinguished: (i) hydrogels formulated 
as cell carriers for minimally invasive surgeries; (ii) solid polymers designed for optimal 
mechanical stability. Hereafter, these biomaterials, their physicochemical and mechanical 
properties, and the correspondent fabrication technologies implemented to make 3D 
scaffolds will be discussed. 
3.1 Hydrogels  
A number of general properties should be possessed by hydrogels. Obviously, these 
materials need to elicit an appropriate host response and display satisfactory 
biocompatibility. If a specific hydrogel composition would be associated with prolonged 
inflammation, the resulting immune response toward the encapsulated cells might affect the 
success of the implantation. The gelation mechanism is also important. Typically hydrogels 
are formed by ionic or covalent cross-linking. Ionic cross-links are very dynamic and may be 
formed and disrupted in presence of a multivalent ionic fluid environment, which is like 
physiological fluids. This may hamper the control over the degradation properties of the 
resulting hydrogels. Conversely, covalent cross-links are more stable and confer enhanced 
mechanical and physical properties to the hydrogels. Yet, they are often more toxic and 
more difficult to break than ionic cross-links. This implies that the cross-linking yield should 
always be maximum and different routes for hydrogel degradation should be envisioned in 
the design of covalent cross-linking biodegradable hydrogels (Lee and Mooney, 2001). 
Alternative methods to form cross-links have been developed by exploiting the phase 
transition characteristics of polymers. Temperature sensitive hydrogels have been 
synthesized for tissue engineering applications. These polymers are subjected to a solid to 
gel phase transition at a specific temperature, called lower critical solution temperature, 
which can be tailored to be at body temperature (Fedorovich et al., 2009; Vihola et al., 
2005). Alternatively, stereocomplexation of amphiphilic polymers has also been used as a 
strategy to form physical cross-linked hydrogels. These hydrogels display customized 
physical and mechanical properties depending on the polymer molecular weight and 
relative concentration of the amphiphilic blocks (Hiemstra et al., 2005; Hiemstra et al., 
2006b). Finally, mechanical and degradation properties are important to consider when 
choosing a hydrogel for a specific tissue. Ideally, a hydrogel should possess a similar 
stiffness to that of the targeted tissue and a degradation rate matching the speed of tissue 
formation. 
Natural hydrogels. Among natural hydrogels, alginate, chitosan, hyaluronic acid and its 
derivatives, and collagen have been widely investigated for cartilage repair. Alginate is 
derived from brown algae and is composed of linear block copolymers of mannuronic (M) 
and guluronic (G) acids. It has been widely used in drug delivery and tissue engineering 
applications because of its biocompatibility, relative low cost, abundance, and easy gelation 
in presence of divalent cations (Shapiro and Cohen, 1997; Terada et al., 2005). Ionic cross-
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links are very dynamic and can lead to unpredictable and uncontrollable dissolution of the 
gel in a physiological environment. Therefore covalent cross-links were introduced and 
were shown to improve the mechanical properties and the control over the degradation rate 
of these hydrogels. Alginate is a rather inert biomaterial. In order to enhance cell-material 
interactions, alginate hydrogels have been modified with different biological factors to 
promote cell adhesion or differentiation into specific tissue phenotypes (Hao et al., 2007; 
Hsiong et al., 2008). An important issue is that alginate degradation products often are 
larger than the threshold size for renal clearance. Although previous approaches revealed 
new opportunities to control the degradation of alginates (Lee et al., 2000), more efforts are 
needed to translate these gels into the clinics.  
Chitosan is a polysaccharide forming the exoskeleton of many seashells. As it is mainly 
comprised of glucosamine, a component of cartilage extra-cellular matrix (ECM), chitosan is 
an attractive biomaterial for regenerative therapies of the skeletal system (Chenite et al., 
2000; Madihally and Matthew, 1999). Its positive charge allows complexation with other 
negatively charged ECM proteins present in articular cartilage like glycosaminoglycans. 
This would induce in vivo sequestration of growth factors embedded in the surrounding 
cartilaginous ECM. Chitosan can be processed in the form of a gel exploiting its pH-
dependent solubility, drawn into solid fibers, or foamed by freeze-drying (Chenite et al., 
2000; Yamane et al., 2005). This processing versatility enables the fabrication of scaffolds 
with fine-tunable mechanical properties. Although the intrinsic batch-to-batch variability 
during chitosan extraction is still a major drawback, its physical, mechanical, and biological 
properties are promising for articular cartilage regeneration.  
Hyaluronic acid is a highly hydrophilic proteoglycan present in the extra-cellular matrix 
(ECM) of several tissues. In cartilage, it contributes to maintain homeostasis and physical 
integrity thanks to its viscosity, capacity to retain water, and interactions with chondrocytes 
and other ECM proteins. When used as a biomaterial, hyaluronic acid can be covalently 
cross-linked or esterified to improve its mechanical properties and physical stability. In the 
latter case, hylans are formed. These biomaterials are currently used in the clinics as 
hydrogels or membranes to assist in autologous chondrocyte implantation (Brun et al., 1999; 
Campoccia et al., 1998; Hollander et al., 2006). Yet, the less-than-optimal mechanical 
properties and the potential presence of endotoxins and impurities are drawbacks that still 
need to be improved to consider these biomaterials a fully viable alternative to synthetic 
polymers. Furthermore, hyaluronic acid is present in high concentrations in the surrounding 
tissues of malignant tumors (Knudson et al., 1989). This evidence should be further studied 
to ensure that no risks are associated with the use of hyaluronic acids or its derivatives as 
biomaterials.  
Collagen is one of the extra cellular matrix protein most used to form natural hydrogels. It is 
easy to obtain from different sources as it is the most common protein present in numerous 
tissues and organs. Jellification typically occurs through thermally reversible physical cross-
links. These gels can be easily remodeled through production of collagenases by 
encapsulated cells, thus offering the opportunity to study cell-matrix interactions during 
tissue development (Mueller et al., 1999; Pachence, 1996; Nehrer et al., 1997). Collagen gels 
can also be formed in the presence of other proteins such as chondroitin sulphate or 
hyaluronic acid, so that the resulting semi-interpenetrating network can be functionalized to 
display biological moieties of interest in cartilage regeneration. Gelatin, a derivative of 
collagen formed by breaking its natural triple-helix structure, has also been used as a 
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hydrogel for cartilage regeneration (Choi et al., 1999). The main drawbacks of collagen and 
its derivatives lye in the potential immunogenic risks due to its origin, batch variation, and 
poor mechanical properties. Chemical cross-linking strategies by exposure to 
glutaraldehyde or genipin confer enhanced physical stability and mechanical properties to 
the resulting hydrogels, however without reaching similar stiffness to that of articular 
cartilage. 
Synthetic hydrogels. Among synthetic hydrogels, a number of derivatives based on 
poly(ethylene glycol) (PEG) have been developed and used for cartilage tissue engineering. 
This biomaterial is relatively inert, highly hydrophilic, and very versatile for the 
functionalization of its backbone with different biological moieties. PEG is known to have 
anti-fouling properties and is often used in vascular applications as a coating to prevent 
thrombogenesis. PEG can be synthesized either as a linear, branched, or star-shaped 
polymer. In its star-shaped form, different peptides or growth factors can be coupled 
depending on the number of arms. These biological factors can be covalently linked to the 
PEG chains through passive or active linkers comprised of an enzymatically sensitive 
peptide sequence, thus being able to release the payload depending on cellular activity 
(Adelow et al., 2008; Lutolf et al., 2003). PEG or its oxidized version poly ethylene oxide 
(PEO) can also be grafted to other polymers such as poly propylene oxide (PPO) or poly 
lactic acid (PLA). PEO-PPO-PEO is a tri-block copolymer, also commercially known as 
pluronic®, that jellifies through a temperature sensitive phase change. These copolymers 
have been conventionally used as drug delivery vehicles and recently also explored in tissue 
engineering applications for skeletal regeneration (Fedorovich et al., 2009; Park et al., 2009; 
Batrakova and Kabanov, 2008). Yet, PEO-PPO copolymers are not degradable limiting their 
potential use. PEG-PLA copolymers have been synthesized for tissue engineering 
applications. Gelation occurs via stereocomplexation of L- and D-lactic acid. By changing 
the molecular weight of the PLA and PEG blocks, it is possible to vary the mechanical 
properties of the resulting gels. Proteins and other biological factors can be easily 
incorporated during gelation in these degradable hydrogels, conferring them a high 
versatility and potential for clinical applications (Hiemstra et al., 2006a; Hiemstra et al., 
2006c). An alternative derivative of PEG is synthesized by linking acrylate groups to the 
main chain. PEG-diacrylate (PEGDA) is a photopolymerizable hydrogel that cross-links in 
presence of an initiator under UV light. PEGDA has been extensively used in cartilage tissue 
engineering as an inert encapsulating system or after modification with different peptides, 
growth factors, or in semi-interpenetrating networks with ECM proteins (Hwang et al., 2006; 
Lee et al., 2006; Sharma et al., 2007). It is a reproducible hydrogel system with fine-tunable 
physicochemical and mechanical properties that enable tissue regeneration without the 
potential risks associated to natural polymers, thus making it a promising candidate for 
clinical use. 
3.2 Solid polymers  
Within solid polymers, poly lactic acid (PLA), poly glycolic acid (PGA) and copolymers 
(PLGA) have been broadly used in tissue engineering as well as for cartilage regeneration 
(Anderson and Langone, 1999; Babensee et al., 2000; Chu et al., 1997; Freed et al., 1993; 
Honda et al., 2000; Sarazin et al., 2004). These biomaterials are approved by the food and 
drug administration (FDA) as they activate a minimal or mild foreign body reaction, and as 
such are considered biocompatible. The mechanical properties and degradation rate can be 
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tailored by varying the molecular weight and copolymer ratio. They have already been 
studied for drug delivery (Jang and Shea, 2003; Uhrich et al., 1999; Richardson et al., 2001; 
Nof and Shea, 2002; Sengupta et al., 2005) and are suitable for tissue engineering 
applications, as the degradation products (lactic and glycolic acids) obtained due to 
hydrolysis are normally present in the metabolic pathway and can be naturally eliminated 
by the body. However, their bulk degradation may be associated with the formation and 
accumulation of large amounts of degradation products in a short time frame (months vs. 
years) that cannot be easily discarded, resulting in local inflammation in tissues (Bostman et 
al., 1989) and enzymatic hydrolysis (Fu et al., 2000). Another polyester commonly used in 
tissue engineering is poly ε-caprolactone (PCL). This polymer is characterized by good 
biocompatibility and mechanical properties. It degrades at a much slower rate than PLA, 
PGA, and PLGA, which makes it attractive when long-term implants and controlled release 
applications are desired (Honda et al., 2000; Wang, 1989; Hutmacher et al., 2001; Choi and 
Park, 2002). It has been also shown that PCL can selectively adsorb vitronectin, a protein 
that is known to facilitate stem cell chondrogenic differentiation. Conversely, PLA 
selectively adsorb fibronectin and seems to be better suited to induce stem cell osteogenic 
differentiation. A different family of thermoplastic polymers that has been investigated for 
tissue engineering is poly ethylene oxide terephthalate-co-poly butylene terephtalate 
(PEOT/PBT). These polyether-ester copolymers possess good physical properties like 
elasticity, toughness and strength (Bezemer et al., 1999). By varying the molecular weight of 
the starting PEG segments and the weight ratio of PEOT and PBT blocks, it is possible to 
tailor physico-chemical and mechanical properties (Bezemer et al., 1999; van Dijkhuizen-
Radersma et al., 2002; Deschamps et al., 2002; Olde Riekerink et al., 2003; Woodfield et al., 
2004; Moroni et al., 2006b), degradation rate (Deschamps et al., 2002), and protein 
adsorption (Mahmood et al., 2004). PEOT/PBT copolymers have been demonstrated to be 
biocompatible both in vitro and in vivo for skin, cartilage, and bone regeneration (Malda et 
al., 2004; van Blitterswijk et al., 1993; Bakker et al., 1988; Beumer et al., 1994a; Beumer et al., 
1994b). A further modulation in degradation rate and drug release profile can be achieved 
by substituting part or all of the terephtalate domains with succinate blocks during the 
copolymerization reaction (van Dijkhuizen-Radersma et al., 2003; van Dijkhuizen-Radersma 
et al., 2004; van Dijkhuizen-Radersma et al., 2005). PLA, PGA, PLGA copolymers, PCL, and 
PEOT/PBT copolymers have proven to be interesting biomaterials to fabricate 3D scaffolds. 
Although their properties can be customized for specific purposes, some concerns over their 
degradation mechanism and rate still remain.  
To obviate bulk degradation, surface eroding polymers have been developed such as 
polyortho-esters (POEs) (Choi and Heller, 1978), polyphospho-esters (PPEs) (Wang et al., 
2001a; Wang et al., 2001b), and polyanhydrides (PAs) (Leong et al., 1986). Surface erosion is 
a degradation mechanism (Andriano et al., 1999; Burkoth et al., 2000), which affects the 
stability of the scaffolds to a lesser extent and elicits a lower in vivo inflammatory response, 
as compared to polyesters and polyether-esters previously considered. PPEs display 
adequate mechanical properties also for hard tissue engineering. Although PPAs, PAs, and 
POEs have been used in some cases for hard tissues repair, they might be more suitable for 
soft tissue engineering due to their generally low mechanical properties. More recently, 
PLA based polymers modified with photosensible chemical groups like fumarates or 
acrylates have been developed for biomedical applications (Melchels et al., 2009; Melchels 
et al., 2006). These biomaterials offer the advantage of being processed by rapid 
prototyping technologies with high resolution, thus enabling the fabrication of 
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sophisticated scaffold geometries. Yet, some issues may still arise from remnant toxicity 
due to the acrylic groups.  
3.3 Scaffold fabrication technologies 
A plethora of fabrication technologies have been developed and characterized to fabricate 
three-dimensional (3D) scaffolds for tissue engineering applications (Figure 2). Although 
these techniques can also be applied to hydrogels, they have been mostly used with solid 
polymers due to the intrinsic advantage of the former as a minimally invasive injectable 
biomaterial. Foams and textiles are the two predominant types of scaffolds used in tissue 
engineering. Foams can be fabricated by gas foaming, freeze drying, or porogen leaching 
(Barry et al., 2004; Sproule et al., 2004; Schoof et al., 2001; Ma and Zhang, 2001; Claase et al., 
2003; Sarazin and Favis, 2003). Textile scaffolds can be produced by wet or melt spinning, 
creating fibers that are randomly deposited on top of each other, woven, or knitted (Cima et 
al., 1991; Freed et al., 1994; Niklason and Langer, 1997). Once deposited, thermal or chemical 
treatments can be applied to improve fiber bonding, thus enhancing structural stability and 
mechanical properties (Kim and Mooney, 1998a; Kim and Mooney, 1998b; Mikos et al., 
1993). These methods are relatively easy to implement, but offer a limited control over 
mechanical properties, interconnectivity of of pore network, pore size and shape, and 
porosity. It has recently been shown that scaffolds mimicking the structural and 
architectural characteristics of the targeted tissue support enhanced tissue formation, and 
fabrication technologies that enable a fine control over scaffold pore network and strut size 
are needed. In the specific case of articular cartilage, three different zones can be 
distinguished: (i) deep, (ii) middle, and (iii) surface zones. In each of these regions, the 
alignment of collagen type II is distinct and results in the overall arch-like architecture 
typical of articular cartilage. Furthermore, chondrocytes behave in a different manner and 
are responsible for the production of different extra-cellular matrix proteins, namely 
different proteoglycans, depending on the zone where they are located (Klein et al., 2009; 
Klein et al., 2003; Schuurman et al., 2009). This has lead researchers to focus their attention 
on technologies that enable the fabrication of layer-by-layer scaffolds. This would enable not 
only a better control of different cartilage zones, but also the construction of more complex 
tissue such as osteochondral grafts. A simple and effective solution is to cross-link 
monolithic hydrogel regions containing chondrocytes of the different regions or other cells 
on top of each other (Elisseeff et al., 2002; Lee et al., 2008; Hwang et al., 2007).  
Where a better control over cell and tissue spatial distribution is desired, rapid prototyping 
(RP) technologies offer an appealing solution. RP is based on computer aided design (CAD) 
and computer aided manufacturing (CAM) to build porous 3D scaffolds in a layer-by-layer 
controlled manner. An extensive number of biomaterials can be processed by these 
techniques in a custom-made shape (Hutmacher, 2001; Yang et al., 2002; Yeong et al., 2004), 
with tailored mechanical properties to the specific application considered (Hollister, 2005; 
Taboas et al., 2003; Lin et al., 2004). The outcomes are 3D scaffolds that possess fine-tunable 
porosity, pore size and shape, and have a completely interconnected pore network, which 
permits a better cell migration and nutrient perfusion than 3D scaffolds fabricated with 
more conventional techniques like foaming or spinning (Malda et al., 2004; Sachlos and 
Czernuszka, 2003). In addition, the fabrication of personalized scaffolds can be envisioned 
with the acquisition and processing of computer tomography (CT) and/or magnetic 
resonant imaging (MRI) anatomical data from patient datasets (Hollister, 2005; Moroni et al., 
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2007a). Since RP is based on layer-by-layer processing, it is also theoretically possible to 
change the pore network structural and architectural characteristics in space in order to 
better mimic specific ECM and cell spatial arrangement. In practice, this has not been 
extensively explored. Moroni et al. (Moroni et al., 2006a) have been active in studying how 
mechanical properties can be optimized with different pore networks for the regeneration of 
different types of cartilage. Similarly, Woodfield et al. (2005) produced scaffolds with pores 
varying along the longitudinal axis in the attempt to mimic the spatial distribution of 
chondrocytes in articular cartilage. Oh et al. (2010) used a similar approach and fabricated 
scaffolds with different pore size ranges by a more conventional freeze-drying method. In 
these scaffolds, chondrogenic differentiation in adipose derived mesenchymal stem cells 
was better supported with pores in the 370-400 µm range. The resulting scaffolds showed 
enhanced tissue formation, while cell and ECM distribution resembled more closely that of 
native hyaline cartilage. By combining different materials, it was also possible to fabricate 
osteochondral constructs that functionally supported both bone and cartilage regeneration 
(Moroni et al., 2008; Sherwood et al., 2002).  
From these studies it is clear that 3D scaffolds fabricated by RP offer many advantages and a 
broad flexibility as a model to study new strategies for tissue engineering. However, they do 
not possess biologically active properties to improve communication with the adhered or 
encapsulated cells. This can be achieved by two means: (i) implementing drug delivery 
vehicles into the scaffolds, (ii) improving the fabrication resolution to achieve true synthetic 
ECM substitutes. In the former case, biological factors have been encapsulated or covalently 
linked into hydrogels (Ehrbar et al., 2007; Saha et al., 2007; Kong and Mooney, 2007) or 
incorporated into microspheres and fibers (Martins et al., 2010; Richardson et al., 2001), 
which were directly used for tissue engineering applications (see Delivery Methods section). 
Controlled drug delivery strategies showed to improve cartilage regeneration when 
combined with 3D scaffolds. However, local and spatial control over the release of biological 
factor is still lacking and might contribute to better mimic the native tissue architecture 
during regeneration. In the latter case, 3D scaffolds with feature dimensions in the range of 
ECM have been recently fabricated by two-photon polymerization (2PP). This technology 
exploits in situ polymerization of photosensible polymers at specific wavelengths 
(Ovsianikov et al., 2011). With 2PP, a number of rather complex structures can be fabricated 
with nanometric resolution (Ovsianikov et al., 2010). These can be interesting tools to study 
fundamental cell-material interaction at a single cell level, but the fabrication time window 
might be too long when clinically relevant scaffold dimensions are needed. An alternative 
technique that has been extensively used to mimic the ECM of tissues is electrospinning 
(ESP). Here, fiber meshes are fabricated by spinning a biomaterial solution into an electric 
field that destabilizes the solution flow and form a continuous jet of fibers collected on a 
target plate. The fiber deposition architecture can be modified depending on the geometry 
and electric properties of the collector plate (Zhang and Chang, 2008; Zhang and Chang, 
2007). ESP has been used with a large number of biomaterials (Li and Xia, 2004) and also 
enables the incorporation of growth factors, proteins, or cells during fabrication (Li et al., 
2006a; Patel et al., 2008). The fabricated scaffolds possess physical and surface properties 
that have already been shown to support cartilage tissue engineering (Li et al., 2006b; Li et 
al., 2005). These meshes may suffer from a lack of cell penetration due to the high fiber 
density and small pore size. However, spinning of more biomaterials with different 
degradation rate can obviate this. Virtually, water-soluble biomaterials would allow a fast 
degradation and a better infiltration of cells into the scaffold pores.  
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Fig. 2. Scaffold fabrication technologies. Different scaffold fabrication technologies can be 
used to create 3D porous biomaterials for tissue engineering applications. (I) Conventional 
foams can be obtained by (I-A) salt leaching or (I-B, I-C) by inverted colloidal crystal (ICC) 
template. In both case a porogen material is used to form a defined volume with the selected 
biomaterial and later removed through selective dissolution. In case of ICC, the resulting 
pore network is improved in terms of interconnectivity and (C) cell seeding efficiency (cells 
green fluorescent). (I-D) Textile scaffolds can be fabricated by rapid prototyping 
technologies. (I-D) Here, a meniscus shaped scaffold is shown. Insets display different fiber 
deposition methods, which affect the formed pore size and shapes. Not only solid polymers, 
but also hydrogels can be processed (no picture shown but available at Landers et al (2002) 
(Landers et al., 2002). (II) ECM mimicking meshes can be fabricated by electrospinning. (III-
A) The electrospun fibers typically have a smooth surface, but (II-B) depending on the 
solvent used can also display different surface morphologies. Panel (I-A, I-B, I-C) modified 
by Deschamps et al (2002) and Nichols et al. (2009). Panel (I-D) modified by Moroni et al 
(2007). Panel (II) modified by Moroni et al. (2008)  
4. Cytokines release 
Cartilage engineering is not only a result of cells and scaffolds coming together to form a 
’cartilage-like’ structure. As mentioned earlier there are two relevant cell choices – 
chondrocytes and MSCs. Chondrocytes need to be in an environment resembling the 
physiological properties of cartilage to maintain their phenotype. MSCs will need to go 
 
Joint Cartilage Tissue Engineering and Pre-Clinical Safety and Efficacy Testing 
 
191 
through the process of chondrogenesis. Chondrogenesis is an intricate process where MSCs 
go through stages of differentiation to become fully matured chondrocytes (Figure 3). Only 
when the cells have committed to the chondrogenic fate will they start to lay down cartilage-
type extracellular matrix (ECM). The differentiation process involves a range of stage 
specific molecules that include phenotypic determinants, adhesion molecules, and signalling 
molecules as described in great detail by Chen et al. (2009). 
 
 
Fig. 3. Chondrogenic differentiation. Chondrogenesis is an intricate process where MSCs go 
through stages of differentiation to become fully matured chondrocytes. Members of the 
TGF-β superfamily and IGF-1 are examples of important regulators in the differentiation 
process. Figure by L. C. Berg 
When attempting to produce tissue that resembles true cartilage both chondrocytes and 
MSCs will need the right molecular signals. Differentiation can be promoted by adding 
chondrogenic cytokines and growth factors to the construct. Some of the major players in 
the intricate network of chondrogenic cell signalling are well described in the literature, but 
other members are only known in very little detail or not at all. There is no question we still 
have much to learn, before we fully understand the temporal and spatial importance of the 
cytokines and growth factors involved in cartilage synthesis. However, studies have shown 
that even a simpler version with addition of only a few key molecules will strongly increase 
the quantity and quality of cartilage-like tissue produced. 
In the following sections, we will present some of these key factors currently being used in 
cartilage engineering, and the delivery methods available. 
4.1 Growth factors 
4.1.1 Transforming growth factor-β superfamily  
The transforming growth factor-β (TGF-β) superfamily includes the TGF-β and the bone 
morphogenetic (BMP) proteins. The most well described family members in relation to 
cartilage tissue engineering are TGF-β1, TGF-β3, BMP-2 and BMP-7 (also known as 
osteogenic protein-1 (OP-1)), but other members may prove to be equally important.  
TGF- β1, TGF-β2, and TGF-β3 have all been shown to be chondrogenic in vitro on MSCs 
(Kulyk et al., 1989; Blunk et al., 2002). They are believed to be involved in the early stages of 
the differentiation process (Chen et al., 2009). In vitro they are known to stimulate synthesis 
of ECM including collagens, fibronectin (Ignotz and Massague, 1986), and proteoglycans 
(Chen et al., 1987), and decrease the expression of collagen type 1 in MSCs (Kurth et al., 
2007). Studies on human MSCs have shown that TGF-β2 and TGF-β3 are more chondrogenic 
than TGF-β1 (Barry et al., 2001; Chen et al., 2009). 
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Unfortunately, the very promising results with TGF-β from in vitro studies have not been 
reproduced in animal models. In mice and rabbits intra-articular administration of TGF-β 
has been shown to have a number of side effects including inflammation and osteophyte 
formation (Bakker et al., 2001; van Beuningen et al., 2000). These side effects appear to be 
linked to the non-cartilaginous tissues of the joint (Blaney Davidson et al., 2007a; Scharstuhl 
et al., 2002), and can potentially be prevented if the growth factor only comes into contact 
with the cartilage. 
The BMPs involved in chondrogenesis include BMP-2, -3, -4, -5, -6, -7, and -9. They support 
chondrocyte phenotype and stimulate synthesis of proteoglycans (Li et al., 2003; Sailor et al., 
1996). BMP-2, and -7 have been shown to be the more chondrogenic of the BMPs in MSCs in 
vitro (Majumdar et al., 2001; Sekiya et al., 2005; Fan et al., 2010), and both have shown 
promising results in animal models (Badlani et al., 2009; Blaney Davidson et al., 2007b). The 
chondrogenic effect of BMP-7 is synergistically increased when used in combination with 
TGF-β (Xu et al., 2006; Kim and Im, 2009) or insulin-like growth factor (IGF)-1 (Loeser et al., 
2003; Chubinskaya et al., 2007a). BMP-2 is also a strong inducer of osetogenesis and is used 
clinically for bone fusion (Tang et al., 2011; Hamilton et al., 2011), which needs to be taken 
into consideration if using BMP-2 for cartilage generation. Only BMP-2 and BMP-7 are 
currently approved for clinical use in human patients (Haleem and Chu, 2010). 
In addition to the TGF-βs and BMPs, this large family of molecules also includes activin and 
growth differentiation factor 5 (GDF5) that have been shown to be chondrogenic inducers in 
MSCs (Jiang et al., 1993; Bai et al., 2004). 
4.1.2 Insulin-like growth factor-1 
IGF-1 is primarily synthesized in the liver regulated by growth hormone (GH). The 
responsiveness of cells to IGF-1 decreases with age and osteoarthritis (Boehm et al., 2007; 
Loeser et al., 2002). IGF-1 is capable of inducing chondrogenesis in MSCs on its own, but it is 
much more effective in combination with other growth factors e.g. TGF-β (Longobardi et al., 
2006) and BMP-7 (Loeser et al., 2003; Chubinskaya et al., 2007b).  
4.2 Delivery methods 
Most growth factors and cytokines have short half-lives (Nimni, 1997), and their effect 
would therefore be limited to the time right after implantation of the construct. Subsequent 
supplementary treatments entail several risks depending on the choice of route of 
administration.  
Systemic delivery presents a number of potential problems. Since the amount of active 
reagent actually reaching the site of interest will be a fraction of the initial dose, the 
administered dosage will have to be up regulated. This will increase both the cost of 
treatment and the risk of adverse reactions. In route to the target site the growth factors and 
cytokines will come into contact with a number of other tissues, where they may cause 
undesirable effects. Local injection into the construct provides a more controlled 
administration, but repeated joint injections are not desirable due to the risk of infection and 
added cost to the patient.  
Because of these issues, a number of delivery systems have been developed and tested, 
where growth factors and cytokines are released into the local environment of the construct 
in a time and dose controlled manner. Some of these delivery systems are closely linked to 
the scaffold materials, and may not work well with all types of scaffolds. Other systems are 
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linked to the cells. A requirement for the successful delivery system is that the active 
molecules are protected against degradation until time of release. The systems range from 
very basic soaking of the scaffold in growth factor suspension (Kanematsu et al., 2004) to 
highly sophisticated release systems, where attempts are being made to closely mimic the 
stage specific differentiation process or even create dual tissues by releasing different 
molecules at controlled time points, dosages, and locations in the scaffold (Wang et al., 2009; 
Suciati et al., 2006). These highly complex systems are still in their infancy. 
4.2.1 Direct attachment or incorporation  
The simplest version of delivery system is a direct attachment of growth factor to the surface 
of the scaffold material by soaking the scaffold in growth factor suspension (Kanematsu et 
al., 2004), or incorporation of the growth factors and cytokines into biodegradable scaffolds, 
usually hydrogels (Yamamoto et al., 2001; Nelson et al., 2011). The factors are then released 
passively from the surface of the scaffold or as the scaffold degrades. Current applications of 
hydrogels primarily include drug delivery, since the scaffolds are too soft to play the 
structural role needed in cartilage constructs (Woodfield et al., 2002). 
Molecule bound. Another way of incorporating growth factors and cytokines in scaffolds is to 
bind them to intermediary components in the construct. This method may prolong the effect 
of the growth factors by slowing down the release process. A study in rabbits using MSCs, 
elastic block copolymer scaffolds and TGF-β3, showed that chondroitin sulphate-bound 
TGF-β3 had a slower release profile than TGF-β directly incorporated into the scaffold (Park 
et al., 2010). Similar results have been achieved by binding TGF-β3 (Park et al., 2008) or bFGF 
(Jeon et al., 2006) to heparin.  
Loaded structures. The cytokines can also be delivered to the constructs in loaded structures. 
Microspheres (Kim et al., 2003; Elisseeff et al., 2001; Fan et al., 2007; Fan et al., 2004), 
liposomes (Hunziker et al., 2001), and micro sponges (Fan et al., 2010) loaded with growth 
factors have all been tested in studies in cartilage tissue engineering. Their advantage is a 
more controlled release rate, while the growth factors are kept relatively protected from 
their surroundings thus preserving their activity. 
Gene therapy. A different approach to delivery of growth factors and cytokines important to 
chondrogenesis is to make the MSCs themselves produce the factors necessary to the 
cartilage construct. This can be achieved by using gene therapy techniques. The use of gene 
therapy in cartilage tissue engineering has been thoroughly reviewed by Steinert et al. 
(2008). Here, we will simply provide a short introduction to the concept. There are several 
different methods available ranging from a simple direct delivery of genetic material at the 
defect site to complex procedures implemented as part of the cartilage engineering process. 
No matter which method is used, the most important factors in gene therapy are related to 
how well the gene material is transferred to the target cell, and how efficient the now 
transgenic cells are at producing the desired molecules. 
The gene therapy techniques fall into two categories – in vivo and ex vivo techniques. 
Common to them is the need for good vectors. These can be non-viral or viral. The non-viral 
vectors are safer but less efficient, while the viral vectors are more efficient but pose a 
potential safety risk especially if they are injected into the patient (Steinert et al., 2008). 
In vivo delivery is the cheaper option, where vectors harbouring the gene material are 
introduced to the cells directly at the site of injury. This method is simple and fast, but it is 
difficult to control the efficacy of transfer as well as the safety of the procedure. Especially if 
  
Tissue Engineering for Tissue and Organ Regeneration 
 
194 
viral vectors are used there is a risk of the vectors inserting themselves into the genetic 
material of host cells in the area. The in vivo method is particularly useful in tissues where it 
is not possible to remove cells for ex vivo transfection. Its use in studies on cartilage repair 
has been very limited. The ex vivo method is more time consuming, expensive, and 
technically challenging. The genetic material is transferred to the cells, before the cells are 
used in the patient. Using this method makes it possible to test transfection rate, and the 
risks associated with use of viral vectors are eliminated. Ex vivo gene transfer has been 
tested in a number of studies involving MSCs and cartilage tissue engineering. MSCs 
transfected with BMP-7 yielded better cartilage repair than non-treated control cells (Mason 
et al., 2000). Similarly, gene induced expression of TGF-β1 and BMP-2 promoted 
chondrogenesis in MSCs, while induced expression of IGF-1 did not (Palmer et al., 2005). A 
subsequent study from the same group showed that the use of combinations of those three 
chondrogenic genes had a strong synergistic effect on chondrogenesis (Steinert et al., 2009). 
5. Mechanical stimuli and bioreactors 
During daily activities, the cartilage is exposed to direct compression, hydrostatic pressure, 
or shear. It has been suggested that mechanical loading may increase extracellular matrix 
(ECM) synthesis during cartilage engineering (Portner et al., 2009). The hypothesis that 
mechanical stimulation enhances cartilage formation is based on studies of developmental 
biology where restriction of joint loading after birth leads to poor post-natal cartilage 
adaptation (Williamson et al., 2003a; Williamson et al., 2001; Williamson et al., 2003b; Mikic 
et al., 2004; Mikic et al., 2000). Overall, mechanical stimulation leads to increased cell 
expansion as well as increased extracellular matrix proteins production compared to regular 
static cultures (Portner et al., 2009).  
A bioreactor is defined as any device in which a biological/biochemical process is 
performed under controlled conditions. When compared to static cultures, bioreactors offer 
a number of advantages such as uniformed distribution and increased mass transfer, control 
of pH, temperature, gas supply (O2 and CO2), nutrients, waste product removal, and the 
opportunity to incorporate mechanical stimuli. Detailed reviews on the general concepts of 
bioreactors for tissue engineering and the application of bioreactors for the purpose of 
cartilage engineering are available (Godara et al., 2008; Chen et al., 2006; Chung and 
Burdick, 2008; Portner et al., 2009; Haasper et al., 2008; Huang et al., 2010b; Schulz and 
Bader, 2007; Concaro et al., 2009; Grad et al., 2011). Selected physical outcome parameters 
used in cartilage engineering in defined and described in Text Box 1.  
Bioreactors for cellular therapeutic use have being grouped into two categories. Bioreactors 
for tissue engineering and bioreactors for cell infusion therapies. However, the simpler 
systems used for infusion therapies have also been utilized for tissue engineering purposes 
due to ease and cost. Bioreactors for isolation and expansion of cells for cell infusion 
therapies are largely similar to or adapted from pharmaceutical monoclonal antibody 
production systems or industrial yeast-based methods. Spinner flasks and rotating wall 
vessels are examples of bioreactors for cell expansion (Concaro et al., 2009). In spinner flasks 
a magnetic stir bar moves the medium. The media movement provides the cell-scaffold 
constructs with nutrients and oxygen and facilitates waste removal by overcoming the 
normal diffusion limit of 100-200 μm. In this system a balance has to be struck between 
homogenous mass transfer including uniform pH gradient and shear gradients that can 
cause cell damage. Stirring at 50 rpm is a common starting point (Concaro et al., 2009). If the 
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speed of the rotating outer wall of rotating wall vessels is calibrated to the mass of the cell 
carrier constructs, then a microgravity environment is created where the cells are exposed to 
low shear stress and high mass transfer. However, hitting this “soft spot” of equilibrium can 
be challenging and failure hereof may lead to shear stress and constructs colliding with the 
walls, which adversely affect cell function (Concaro et al., 2009). However, rotating wall 
vessels have been utilized to study microgravity’s effect on cartilage tissue engineering both 
on Earth and in space (Vunjak-Novakovic et al., 2002; Marolt et al., 2006). Marked 
differences where noted between cartilage engineered on Earth and in space, on Mir, 
confirming that physical forces modulate musculoskeletal tissue such as cartilage (Vunjak-
Novakovic et al., 2002). Bioreactors for cartilage engineering have largely been used to 
evaluate response to compression, but bioreactors applying electrical fields, ultrasound, 
centrifugal forces, shear forces, perfusion of 3D constructs, tension of cell layers, hydrostatic 
pressure, and hydrostatic pressure with perfusion have also been reported (Schulz and 
Bader, 2007). These bioreactors are mostly custom made, but an increasing number of 
commercial bioreactors are becoming available for various purposes (Yeatts and Fisher, 
2011). Comparison between research groups is therefore exceedingly difficult. One major 
concern with many of the studies is the validation of the bioreactor prior to use and the 
continued calibration. Thorough evaluation and validation of the bioreactors prior to and 
continuously through their use by applying objective measurable parameters is critical in 
order to evaluate the results and conclusions. Many of the bioreactors can only stimulate the 
tissue and have limited, if any, possibilities of sampling and analyzing the tissue or culture 
medium without terminating the culture process.  
Most cartilage bioreactor studies have reported work using uniaxial direct compression 
(Grad et al., 2011). A general starting point for direct compression studies of cells adhered to 
a scaffold is 10% or 15% compression at a frequency of 1Hz (Grad et al., 2011; Terraciano et 
al., 2007; Mouw et al., 2007; Huang et al., 2004).  Recently, mechanical stimulation showed 
improved cartilage formation of porcine chondrocyte cartilage constructs compared to static 
culture, but no difference was noted between perfusion and perfusion-compression 
constructs (Tran et al., 2011). In the compression group, constructs where cultured with 
perfusion alone at a flow rate of 0.5ml/min for the first week followed by 1 Hz sinusoidal 
unconfined compression, 4 hours a day, 5 days a week, starting with a load of 0.5 N until 20 
N by the third week (Tran et al., 2011). Perfusion was maintained in this compression group 
for the 4-week duration of the study and compared to a control group of perfusion only. 
Biochemistry revealed a higher glycosaminoglycan (GAG) content, but a lower collagen 
content in the bioreactor construct compared to native cartilage. The discrepancy between 
GAG and collagen content could be due to enzymatic collagen degradation or simply reflect 
immature cartilage since rabbit studies have shown that the cartilage collagen network does 
not mature until 3 months of age (Julkunen et al., 2009; Riesle et al., 1998). Rabbit joint 
cartilage at birth is homogenous with collagen fiber alignment parallel to the surface, but as 
the cartilage matures the collagen fibers organize into the three zones seen in adult cartilage 
(Julkunen et al., 2011). However, the specific cartilage organization and biochemical content 
differ from joint to joint and even between opposing joint surfaces of the same joint 
(Julkunen et al., 2011). Recently, bovine bone marrow (BM) derived MSCs exposed to long-
term dynamic compression in chondrogenic culture were shown to exert improved 
mechanical properties compared to static culture as previously reported in studies of 
chondrocyte cultures (Huang et al., 2010a). Interestingly immediate mechanical stimulation 
of cartilage constructs appear detrimental and a more physiological approach of initial stem 
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cell chondrogenic differentiation using TGF-β without mechanical stimulation, as in utero, 
followed by mechanical stimulation, as post-natal, appear more effective (Terraciano et al., 
2007; Mouw et al., 2007; Thorpe et al., 2008). These observations would concur with the 
observations of normal rabbit joint cartilage development as described above, where the 
cartilage at birth is a homogenous structure that remodels post-natally in response to 
loading.  
Hydrostatic pressure in cartilage tissue engineering has been reviewed elsewhere (Elder and 
Athanasiou, 2009). Hydrostatic pressure does not exert any measurable strain on the cell 
and the mechanistic effect are believed to be mediated through deformation of 
transmembrane ion transport proteins leading to increased intracellular calcium 
concentrations (Schulz and Bader, 2007; Kornblatt and Kornblatt, 2002; Elder and 
Athanasiou, 2009). The effect of hydrostatic pressure is incompletely understood, but both 
dynamic and static pressure has been investigated in both normal chondrocytes, 
osteoarthritic chondrocytes and as a mean for chondrogenic cell differentiation (Elder and 
Athanasiou, 2009).  Physiological hydrostatic pressure of 5-10 Mpa are generally anabolic 
when applied in a dynamic fashion to both 2D and 3D chondrocyte layers, but if static 
pressure is applied anabolic effect is only noted in 3D layers (Elder and Athanasiou, 2009).  
Such physiological loads can also promote stem cell differentiation, chondrocyte 
redifferentiation, and exert chondroprotective effects and osteoarthritic chondrocytes (Elder 
and Athanasiou, 2009). Super-physiological pressures (20-50 Mpa) are particular detrimental 
to cell metabolism if applied for more than 2 hours (Elder and Athanasiou, 2009). Schulz and 
Bader have reviewed the mechanism of hydrostatic pressure stimulation and why 
prolonged loading leads to cartilage damaged (Schulz and Bader, 2007). Interestingly, 
compression likely acts through hydrostatic pressure as well. The reason is that negatively 
charged proteoglycans provide frictional resistance by binding water and preventing the 
water from being squeezed out of the tissue. The net effect is increased hydrostatic pressure 
within the tissue. However, the water does shift out of the tissue if the pressure persists. In 
this case, the load is increasingly carried by the collagen fibers until the fibers are orientated 
parallel to the load direction. Load beyond this point leads to tearing of the collagen 
network.  
One trend in cartilage bioreactor design is towards a more tribological approach, where the 
science and technology of interacting surfaces in relative motion is used to develop multi-
axial bioreactors that more closely mimic the movement of a natural joint (Figure 4) (Grad et 
al., 2011). Multiaxial compression and shearing stimulation represent more closely in vivo 
conditions and are associated with broader chondrogenic gene expression profiles 
compared to uniaxial compressive loading (Grad et al., 2011). Another trend is the ability of 
bioreactors to simultaneously provide mechanical stimuli and evaluate the physical 
properties of the developing tissue (Portner et al., 2009).  The ability to monitor the construct 
as it develops allows for a reduction in sample size since temporal changes can be assessed 
on the same sample. It may even be possible to perform online temporal molecular 
evaluation of the cells, the conditioned culture medium and extracellular matrix 
composition and responses in closed bioreactor system through the application of high-
resolution magic angle spinning nuclear magnetic resonance (HR-MAS NMR), matrix-
assisted laser desorption and ionization time-of-flight mass spectrometry (MALDI-TOF MS), 
combinatory phase sensitive scanning acoustic microscopy (PSAM), and confocal laser 
scanning microscopy (Schulz and Bader, 2007). Such advanced bioreactors can be valuable 
tools in preconditioning cell-scaffolds prior to clinical research use as well as model systems 
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for in vitro evaluation of cell response to a variety of physical as well as chemical stimuli. 
These systems may also have value as model systems to reduce the number of animals used 
for in vivo studies by allowing replacement and refinement prior to in vivo studies. 
However, their utility for commercialization of tissue replacement strategies may be 
hampered by high production costs and violation of GMP due to the often semi-sterile 
productions systems.  
 
 
Fig. 4. Advanced bioreactor. (A) Advanced tribological bioreactor capable of multiaxial 
stimulation of tissue-engineered constructs. Each chamber can be individually controlled to 
simulate the movements of complex joints, e.g. the knee (b and C) Reprinted with 
permission from Grad et al. (2011)  
Soft lithography produced microfluidic bioreactors have been advocated as the next 
generation of tissue engineering bioreactors to gain mechanistic insights due to affordability, 
flexibility and precision (Godara et al., 2008). Mesenchymal stem cells proliferation, motility 
and osteogenic differentiation in response to various culture regimes was studied using 
time-lapse imaging of 96 culture chambers within a single microfluidic chip (lab-on-a-chip) 
(Gomez-Sjoberg et al., 2007). However, one of the challenges is absorption of small 
hydrophobic molecules, typically hormones, by the plastic used for producing the 
microchips (Gomez-Sjoberg et al., 2010). Such methods may lend themselves well to 
studying the issue of MSC population heterogeneity, incomplete MSC chondrogenic 
programming, evaluation of novel chondrogenic inducing small molecules and signaling 
pathways involved in chondrogenic differentiation as identified elsewhere (Huang et al., 
2010c). A potential limitation of such micro-bioreactors is that they mainly evaluate 2D 
structures and cartilage tissue tends to prefer a 3D environment.  
As outlined, sophisticated bioreactors are currently available in a few labs for the generation 
and real-time analysis of cartilage constructs. However, the mechanical properties of the 
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produced cartilage remain significantly inferior to that of native cartilage although 
histological, biochemical and gene expression assays may indicate otherwise. A major 
drawback of most publications to date is the omission of a relevant positive biological 
control sample such as native cartilage. Most studies compare the test sample to a negative 
control sample consisting of the empty cell scaffold/carrier. Such study designs make it 
difficult to determine the biological relevance/utility of the engineered tissue. This being 
said, it is probably unknown when an engineered tissue is “good enough” for clinical 
implantation. This will likely depend on the constructs used as well as the patient age, lesion 
location and severity, and the accompanying rehabilitation program. Mature native tissue of 
the tissue of interest is likely the best biological yardstick presently, but the degree of tissue 
maturation preferable at the time of transplantation remains undetermined.  
As alluded to already, another major challenge is the development of aseptic, cost effective, 
bioreactor systems that will fulfill current regulatory requirements. A significant segment of 
the bioreactor industry is dedicated to the development of disposable systems as reviewed 
elsewhere (D'Aquino, 2006; Eibl and Eibl, 2009; Singh, 1999). These systems include wave-
mixed, orbital shaken and stirred bioreactors (Eibl et al., 2010). These systems may provide 
cost-effective solutions due to savings on operative utility, cleaning and validation costs as 
well as reduced water and cleaning agent consumption for cleaning. Some of the challenges 
are real-time analysis of the process due to range limitations of disposable sensors, pre-
validation that would shift the regulatory burden from the end-user to the manufacturer, 
incompatibilities with certain chemicals and temperatures, and limited accessories such as 
valves and sampling systems (Eibl et al., 2010; D'Aquino, 2006). These systems have not yet 
been significantly evaluated for cartilage engineering.  
De novo tissue engineering has also been investigated, where the so-called cell niche is 
relied upon to direct transplanted cells or tissue pieces towards the appropriate tissue has 
also been investigated (Grad et al., 2011; Shah et al., 2010; Stevens et al., 2005). This approach 
is often autologous in nature and associated with minimal handling and laboratory 
exposure of the cells. ACI and MACI are examples of this strategy. However, the resulting 
repair tissue remains inferior to native cartilage. Recently, self-assembling nanofibers were 
shown to promote cartilage repair of full thickness chondral defects in rabbits (Shah et al., 
2010). Alternatively, tissue can be made in vivo at a site distant to the ultimate repair site for 
later relocation to the injury site. Such de novo tissue formation was elegantly demonstrated 
for bone regeneration in a rabbit model (Stevens et al., 2005). Bone formation was induced 
by alginate injection under the tibial periosteum and later the neo-bone was removed and 
transplanted into an induced cortical bone defect where it promoted bone healing. Cartilage 
tissue was also generated using this model by adding molecules to the gel that inhibited 
angiogenesis and promoted chondrogenesis.  
The influence of oxygen tension during cell and tissue culture has also been investigated in 
relation to cartilage engineering and is an area, which appears to deserve further 
investigation. Low oxygen levels have been reported to be a more potent promoter of 
chondrogenesis than dynamic compression (Meyer et al., 2010). Previous studies have 
shown controversial findings in relation to the effect of oxygen tension on chondrogenic 
differentiation of mesenchymal stem cells with some reporting increased proliferation rates 
and chondrogenic potency and others reporting reduced proliferation and differentiation 
potency (Grayson et al., 2007; Merceron et al., 2010; Krinner et al., 2009; Holzwarth et al., 
2010). 
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6. Pre-clinical animal models for safety and efficacy evaluation of engineered 
cartilage 
Cartilage defects are “quality-of-life” lesions, as opposed to life-threatening conditions, for 
which therapies are available today that provide palliative relief for a large number of 
patients. Since long-term safety of new cell-based treatment modalities have yet to be 
determined it is possible that adverse effects could ultimately lead to worse quality of life 
than the initial cartilage problem caused. Thorough evaluation of efficacy and long-term 
safety is therefore prudent before introducing new cell-based therapies for such lesions. In 
vivo studies can generally be categorized into models where the animal is used as the 
bioreactor directly at the injury site or at a distant site for later relocation to the injury site, as 
discussed above, or as models were animals are used to evaluate in vitro engineered 
constructs. 
Members of the Orthopaedic Trauma Association (OTA) recently discussed pre-clinical 
animal models for cartilage and bone repair (Lansdowne, 2010; Martineau, 2010). This topic 
has also been reviewed by a number of authors (Pearce et al., 2007; Reinholz et al., 2004; Chu 
et al., 2010; Koch and Betts, 2007). The consensus with regard to cartilage defects is that the 
research question determines the choice of model, since there is no ideal pre-clinical animal 
model. General issues to consider are the lesion model (chondral, osteochondral, 
degenerative), most appropriate model (cost, availability, joint structure, age), cartilage 
similarity (thickness, structure, cell density, biochemistry, biomechanics), and the nature of 
the lesion (area, depth, location) (Martineau, 2010). Small animal models are rodents and 
rabbits. Rodent models have limited translational value, but are cost effective models for 
mechanistic studies of chondrogenesis, generation of proof-of-concept data and bridging in 
vitro and large animal studies. Rabbits are easy to handle and cost effective, but have thin 
cartilage with excellent endogenous repair potential as well as highly flexible joints which 
support a relatively low body weight (low loading of the joints). Large animal models 
include minipigs, goats, and horses (Martineau, 2010). Mini-pigs do not comply with 
rehabilitation programs, but advantages comprise joint size sufficiently large to allow 
arthroscopy, partial or full-thickness chondral defects, growth plate closure, poor 
endogenous chondral repair potential and the possibility of making 6-8 mm diameter size 
lesions. Goats (as well as sheep) are similar to mini-pigs in that they do not comply with 
rehabilitation programs, but allow arthroscopic approaches and large defects can be made in 
cartilage that have limited intrinsic repair potential. Goats and sheep studies are more 
expensive due to increased housing and handling costs. Horses can comply with 
rehabilitation programs, allow for defect sizes similar to human defects, exert low intrinsic 
repair potential and arthroscopic treatment modalities and make follow-up assessment 
possible. The drawback of equine studies is high cost, high loading forces, and hard bone, 
and it is difficult to achieve protected weight bearing in the horse. 
The OTA study group on bone defect models had the following universal considerations: 
consider the 3R’s of animal use and reduce, refine and replace before choosing the most 
relevant animal model; perform a pilot study if inexperienced with the model; animal 
models do not account for co-morbidities (e.g. obesity, diabetes etc); ensure optimal animal 
care before and after surgery by consulting with veterinary specialists in surgery 
(www.acvs.org or www.ecvs.org), anesthesia (www.acva.org or www.ecva.eu.org), and 
laboratory animal medicine (www.aclam.org or www.eclam.org); ideally standardize your 
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model with a negative and a positive control although in comparative studies comparison 
with the current “golden standard” treatment is sufficient (Lansdowne, 2010).  
The argument for increased use of domestic animal species as pre-clinical animal models is 
based on the fact that many human conditions have a spontaneous counter-part in animals 
that would allow for more physiologically relevant studies compared to induced lesions in 
inbreed subpopulations of small laboratory animals. Veterinary medicine today often rivals 
human medicine with regard to diagnostic and treatment modalities, some companion 
animals largely live in the same epigenetic environment as humans, and the veterinary 
market is of significant monetary value in itself (Koch et al., 2009; Koch and Betts, 2007). 
Most recently, induced pluripotent stem cells (iPS cells) have been generated from equine 
cells for the purpose of treating sporting horses as well as utilizing the horse as a pre-clinical 
animal model of comparative human disorders (Nagy et al., 2011). Stem cells and animal 
therapies have recently been reviewed elsewhere (Figueroa et al., 2011).  The sentiment from 
2004 by Fiester and colleagues that successful treatment of a spontaneous animal disorder 
may significantly advance stem cell research remains valid today and could be expanded to 
include the field of regenerative medicine (Fiester et al., 2004).  
7. Conclusion and future perspectives 
The field of cartilage tissue engineering is a very diverse research field investigating the use 
of bioreactors, scaffold compositions and designs in combination with a wide range of cells 
and cytokines. It is still an emerging research field and careful pre-clinical assessment of the 
potential treatment modalities is advised to avoid long-term adverse effects (Figure 5). 
However, these treatment modalities hold the potential of providing life-long solutions to 
the currently incurable problem of joint cartilage damage. Domestic animal models may 
provide valuable translation significance between proof-of-principle studies in small 
laboratory animals and expensive human pre-clinical trials. 
 
 
Fig. 5. Clinical roadmap for bone tissue engineering bioreactors. This roadmap is equally 
useful for cartilage engineering. In vivo proof-of-principle can be shown in laboratory 
animal models, but domestic animal models may be of more translation value prior to 
human clinical trials. Reprinted with permission from Yeatts and Fisher (2011)  
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Text Box 1. Selected physical outcome parameters used in cartilage engineering 
Stress, strain and frequency are often referred to in tissue engineering so a brief 
description of these terms is warranted. Stress, often denoted as sigma (σ), is the amount 
of force acting over a given cross-sectional area. Stress is expressed as force per area units. 
The unit of stress is pascal (Pa) or newtons (N) per area in the metric system, and psi in 
the English system. Conversions of these different units are as follows: 1 psi = lbF/in2, 1 
Pa = 1.45 x 10-4 psi, 1 Pa = 1 N/m2, 1 kPa = 1 where Newton (N) is the SI unit of force. 1 N 
= kg m/s2, e.g. the net force required to accelerate a mass of one kilogram at a rate of one 
meter per second squared. Engineering strain, often denoted as ε, is the nominal change 
in length of a material (ε = ΔL/L0 = (L – L0)/L0). The unit of strain is often mm/mm, 
cm/cm, etc, or no unit at all since it is the ratio of a given measuring system. Frequency, 
denoted with the SI unit hertz (Hz), is the number of cycles per second, typically of a sine 
wave. Shear stress, τ, as exerted on cells in perfusion systems with a laminar flow profile 
between the ingress and egress plates can be calculated as follows: τ = (6μQ)/(bh2), where 
μ is the viscosity of the medium, Q is the volumetric flow rate, b is the width of flow 
channel, and h is the distance between the two plates (Shiragami and Unno, 1994; Nagel-
Heyer et al., 2005). The shear stress unit is force per area, e.g. N/m2 or similar 
representation of force per area using psi, Pa and in2 or cm2. Other physical parameters 
often used in cartilage engineering such as Darcy’s law, Reynolds number (Re), mass flow 
rate, flow velocity has been reviewed elsewhere (Concaro et al., 2009). 
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1. Introduction 
Articular cartilage covers the end of bones in joints and determines the load-bearing 
characteristics and mobility of joints. It has a thin, smooth, low friction surface with a 
remarkable resiliency to compressive forces.  In general, chondrocytes occupy lacunae in the 
matrix, and produce cartilaginous ECM (extracellular matrix), which consists of type II 
collagen (13%), proteoglycans (7%), and water (80%).  
Cartilage defects result from aging, joint injury, and developmental disorders, causing joint 
pain and loss of mobility. Articular cartilage is metabolically active, however, the 
chondrocytes have a slow turnover rate. Thus, articular cartilage might suffer progressive 
damage and degeneration with a limited spontaneous repair capability. Total joint 
arthroplasty is the final choice of treatment, however, it is not suitable for young patients 
because of the limited life span of the artificial joint. Marrow-stimulating techniques such as 
microfracturing, multiple drilling, mosaicplasty and autologous chondrocyte implantation 
are clinically available for young patients, but have some limitations (Ikada, 2006). Marrow-
stimulating techniques result in a fibrocartilage with less mechanical strength than hyaline 
cartilage and only limited repair capacity. The major problems with mosaicplasty are a 
limited availability of autologous tissue and donor site morbidity, the destruction of healthy 
non-weight-bearing tissue to repair diseased tissue. Autologous chondrocyte 
transplantation with a periosteal graft has shown encouraging results, however, 
predictability and reliability are still questionable.  
Ochi et al. (2002) showed a clinical advantage of transplanting autologous chondrocytes 
cultured in collagen gel for the treatment of full-thickness defects of cartilage in 28 knees 
over a minimum period of 25 months. Arthroscopic assessment indicated that 26 knees 
(93%) had a good or excellent outcome. Wakitani et al. (2002) applied cell transplantation to 
repair human articular cartilage defects in osteoarthritis knee joints. The study group 
comprised 24 patients with knee OA. Adherent cells expanded from bone marrow aspirates 
were embedded in collagen gel and transplanted into the articular cartilage defects of 12 
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knees, with the other 12 knees serving as cell-free controls. Arthroscopic and histological 
grading scores were better in the cell-transplanted group than cell-free group. 
In spite of these successful clinical results to expand the clinical treatment of cartilage 
diseases, we need to establish a three dimensional culture technique for regenerating large 
cartilage tissue in vitro.  One solution is to use an RWV (rotating wall vessel ) bioreactor. 
2. Regeneration of cartilaginous tissue from rabbit bone marrow cells under 
three dimensional culture by RWV bioreactor 
2.1 RWV (rotating wall vessel) bioreactor 
Recently, three-dimensional cell culture techniques have attracted much attention among 
not only cell and developmental biologists but also clinicians who have an interest in tissue 
engineering (Abbott, 2003). The limitations of two-dimensional culture using conventional 
flasks or dishes are becoming clear. In the field of tissue engineering, the chondrocyte cell is 
a typical example of the major difference between a flat layer of cells and a complex, three-
dimensional tissue (Holtzer, 1960; Passaretti et al., 2001). Matured chondrocytes in the two-
dimensional condition dedifferentiated without maintaining their phenotype and lost their 
original phenotype after four rounds of subculture. Clinically, a method of regenerating 
cartilage tissue needs to be established to treat diseases such as osteoarthritis. Thus, the 
development of a cell culture system for the growth of three-dimensional cartilage is 
important. However, problems such as necrosis due to high-density cell culture and shear 
stress have not yet been solved using conventional stirred fermentors. We examined the use 
of a rotating wall vessel (RWV) bioreactor that simulates a microgravity environment with 
low shear stress for cartilage tissue regeneration (Fig.1). This bioreactor generates stress by 
the horizontal rotation of a cylindrical vessel equipped with a gas exchange membrane. The 
RWV bioreactor compensates for the effect of gravity, resulting in homogenous cell growth 
and differentiation without sinking, and cells aggregate and form a three-dimensional 
tissue. The advantage of using an RWV bioreactor for tissue formation was first reviewed by 
Unsworth and Lelkes (1998), who discussed the benefits of growing tissues in microgravity 
and simulated microgravity. The formation of tissue by, for example, endothelial cells 
(Sanfold et al., 2002), colon carcinoma cell lines (Goodwin et al., 1992), ovarian cancer cells 
(Goodwin et al., 1997), osteoblasts (Qiu et al., 1999), and erythroid cells (Sytkowski and 
Davis, 2001), has been reported. In particular, the RWV bioreactor has been shown to 
stimulate chondrogenesis (Baker and Goodwin, 1997; Duke et al., 1993). Moreover, a 
comparison of chondrocyte cells cultured in rotating bioreactors in space (Mir space station) 
and on earth was reported by Freed et al. (1997a). They performed rotating cultures of 
bovine chondrocytes in polyglycolic acid (PGA) scaffolds and concluded that the culture on 
earth produced cartilage tissues closer to the natural form than that in space. In this case, the 
culture period for obtaining tissue was 7 months. Very recently, the chondrogenesis of 
human cartilage by an RWV bioreactor has been reported (Marlovits et al., 2003). Good 
quality cartilage tissue was formed by rotating culture from aged human articular cartilage 
after 90 days of cultivation. In spite of numerous studies on the formation of cartilage tissue 
from chondrocytes, our report (Ohyabu et al., 2006) was the first on the production of 
cartilaginous tissue from bone marrow-derived cells by rotating culture. A three- 
dimensional cell culture technique was established for the construction of large and 
homogenous cartilage tissues without a scaffold using bone marrow-derived cells and an 
RWV bioreactor. 
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Fig. 1. RWV Bioreactor 
 
 
Fig. 2. Time-dependence of the rotation speed 
2.2 Regeneration of cartilage tissue in vitro using rabbit bone marrow cells and an 
RWV bioreactor 
Bone marrow cells were collected from the femora of six 10-day-old Japanese white rabbits 
and cultured in a standard medium consisting of Dulbecco’s Modified Eagle’s 
Medium(DMEM) containing 10% fetal bovine serum for 3 weeks. The cells were 
resuspended in a chondrogenic differentiation medium comprising DMEM containing 10% 
FBS and 10 ng/mL of TGF-β (Johnstone et al., 1998) and seeded in the discoidal vessels of an 
RWV reactor in a CO2 incubator. A rotatory culture was performed for 4 weeks. The rotation 
speed was adjusted manually in order to keep cell aggregates  freely suspended within the 
vessel. As a control, a tube culture was performed, a kind of three dimensional culture 
technique developed by Holtzer and Manning (Holtzer, 1960; Manning and Bonner, 1967) 
and established by Johnstone et al. (1998).  After the rotating culture in the RWV vessel and 
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static culture in the conical tube, the aggregates were harvested and prepared for 
histochemical and biochemical analysis. 
 
 
Fig. 3. In vitro cartilage tissue regeneration from rabbit bone marrow cells using RWV 
bioreactor 
The rotation speed of the RWV was adjusted manually to prevent the cell aggregates from 
sinking in the RWV vessel. The speed was varied between 11 and 25 rpm and increased 
steadily for 28 days (Fig.2). The change in speed originated from the steady increase in the 
mass of tissue formed in the vessel. Figure 3 shows images of the tissue formed in the RWV 
vessel and in the 15-mL conical tube  after 1 and 4 weeks of culture. The tissues are of a 
cylindrical shape. The size (height/diameter) of the tissue in the RWV vessel was 1.00/0.48 
cm at 1 week; 1.28/0.53 cm at 2 weeks; and 1.25/0.60cm at 4 weeks. This kind of single 
tissue formed in the reactor reproducibly in the same experimental conditions. By contrast, 
the tissue formed in the 15-mL conical tube was smaller: 0.20/0.90 cm at 1 week; 0.20/0.55 
cm at 2 weeks; and 0.28/0.74 cm at 4 weeks. The qualities of the tissues as cartilage were 
evaluated by histochemical methods including immunostaining of collagen type I and 
collagen type II and safranin-O and toluidine blue staining(Fig.4). The staining of collagen 
type II was more intense in the RWV than tube culture The results of safranin-O and 
toluidine blue staining are clearer as shown in Figure 4c and d. The time course of safranin-
O and toluidine blue staining in the tissues formed in the tubes shows that the tissue 
gradually became chondrogenic. However, this change occurred faster in the RWV tissues. 
Even at 1 week, chondrogenesis occurred in the RWV tissues, but no sign of chondrogenesis 
was detected in the tissues in the tubes. At 2 weeks, the difference between the two was 
clearer, and at 4 weeks, chondrogenesis of the RWV tissues was confirmed by the strong and 
homogeneous matachromasy of safranin-O staining. Comparing the results of safranin-O 
staining, the RWV tissue at 1 week appeared to be in a similar stage of differentiation as the 
tube tissue at 4 weeks. In conclusion, we succeeded in the rapid regeneration of three-
dimensional large and homogeneous cartilaginous tissue from rabbit bone marrow cells 
without a scaffold using a RWV bioreactor. Bone marrow cells cultured for 3 weeks were 
resuspended and cultured for 4 weeks in the chondrogenic medium within the vessel. Large 
cylindrical cartilaginous tissue 1.25 cm in height and 0.60cm in diameter formed. Their 
cartilaginous properties were demonstrated by immunohistochemistry of collagen types I 
and II, mRNA expression of aggrecan, collagen types I and II, GAG/DNA ratio, toluidine 
blue, and safranin-O staining, and polarization. 
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Fig. 4. Immunostaining of collagen type I (a) and collagen type II (b), safranin-O staining (c), 
and toluidine blue staining (d) of the tissues formed in the RWV vessels and in the conical 
tubes at 1, 2 and 4 weeks. Bar.1 mm. (Ohyabu et al., 2006) 
Despite numerous studies on the formation of cartilage tissue from chondrocytes (Baker and 
Goodwin, 1997; Duke et al., 1993; Freed and Vunjak-Novakovic, 1997b; Freed et al., 1997a; 
Marlovits et al., 2003), no report has been published on the production of cartilage tissue 
from bone marrow-derived cells in rotating cultures. Stem cell-derived tissue formation is a 
basic concept in tissue engineering. However, three-dimensional cartilage tissue has not yet 
to be produced in rotating cultures. Our study showed that (1) in vitro chondrogenesis was 
observed in 3D culture of bone marrow stromal cells and that (2) RWV culture yielded 
cartilaginous tissues that was superior to static culture. As shown in Figure 4, the 
cartilaginous tissue is homogeneous and showed no necrotic cells of large size 1.25/0.6 cm.  
These results are encouraging and promising for cartilage tissue engineering, and an 
experiment in which the tissue formed by an RWV bioreactor as transplanted to large 
osteochondral defects described in the next paragraph. It is true that it is the first study to 
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utilize bone marrow stromal cells, but we can gain a lot of benefit by using bone marrow 
cells. First, the number of autologous cultured chondrocytes is limited and applicable to 
only a limited area of cartilage damage, while a greater number of chondrocytes can be 
cultured from bone marrow cells (Wakitani et al., 2004). From this point of view, the clinical 
applications of RWV using bone marrow cells are wider than those using autologous 
chondrocytes. Second, bone marrow cells might be suitable for cartilaginous tissue 
formation by RWV culture. It has been reported that the exposure to RWV at an early stage 
of chondrogenesis severely limits the ability for cartilage growth, however, at a late stage of 
chondrogenesis, the RWV environment is beneficial and enhances growth and development 
using embryonic mouse pre-bone tissues (Klement et al., 2004). These results seem to 
contradict our results obtained using bone marrow stromal cells. Bone marrow stromal cells 
might be more suitable for RWV culture than embryonic cells. There are two major 
differences between the RWV culture and tube culture. One is the way in which the cells 
aggregate gathered manually in the RWV, whereas  they gathered  due to centrifugal force 
in the tube. The other point is that the unique mechanical stress due to the medium flow and 
gravity continued to apply to the tissue in the RWV (Klaus, 2001; Klement et al., 2004). We 
speculate that the major reason that superior tissue formed in the RWV was that the 
appropriate mechanical force was applied to the naturally gathered cells. To study the 
methodology of cartilage regeneration from bone marrow cells, a comparison of the tissue 
engineered in the RWV bioreactor with and without a scaffold would be useful. This kind of 
study was published by our group (Ohyabu et al. 2009). 
2.3 Regeneration of cartilage tissue in vivo using rabbit bone marrow cells and an 
RWV bioreactor 
As described in the last section, the application of a rotating wall vessel (RWV) bioreactor 
that simulates a micro-gravity environment with low shear stress for regenerating cartilage 
tissue and successfully established a three-dimensional (3-D) cell culture technique for the 
formation of large and homogenous cartilaginous aggregates from bone marrow-derived 
cells without using a scaffold. This bioreactor generates stress through the horizontal 
rotation of a cylindrical vessel equipped with a gas exchange membrane. The bioreactor 
compensates for the effect of gravity, resulting in homogenous growth and differentiation 
without sinking, and the cells aggregate and form 3-D tissue.  This section describes the 
usefulness of transplanting cartilaginous aggregates formed from rabbit bone marrow-
derived cells using an RWV bioreactor (Yoshioka et al., 2007). 
Cylindrical defects 5x5 mm in area and 4 mm in depth were created on the patellar groove 
of the rabbit femur with a hand drill.  For the control, the defects were left empty (Group-C: 
control group, n=18), whereas 3-D cartilage aggregates of 10 mm x 5 mm (height x diameter) 
were placed into the defects without any flap (Group-T: transplanted group, n=18) as shown 
in Fig.5. The rabbits were then caged and allowed to move freely without any splinting 
before being sacrificed 4 (n=6), 8 (n=6) and 12 (n=6) weeks after the operation. Fig.5 shows a 
macroscopic view of defects of the patella groove of the knee and histological view of a 
section of osteochondral tissue 4 weeks after transplantation. Large osteochondral defects in 
the knee joints were successfully repaired with hyaline-like cartilage after the 
transplantation of allogeneic cartilaginous aggregates formed from bone marrow-derived 
cells using the RWV bioreactor. As early as 4 weeks after the operation, the defects were 
filled with reparative tissue that resembled hyaline cartilage. The reparative tissue had a 
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smooth surface and there were no fibrous tissues between the reparative tissue and adjacent 
normal cartilage. At 8 weeks, enchondral bone had formed in the deeper portion of the 
reparative tissue. At 12 weeks, in some cases the intensity of staining with safranin-O was 
slightly reduced in comparison to that in the adjacent normal cartilage, but the reparative 
tissue retained its thickness. This is the first report of the rapid regeneration of critical 
osteochondral defects with allogeneic cartilaginous aggregates formed from bone marrow-
derived cells without any scaffold using the RWV bioreactor. 
 
 
Fig. 5. Transplantation of RWV tissue into osteochondral defects in rabbit knees 
There are two important advantages. First, the cells are derived from bone marrow and 
mesenchymal stem cells (MSCs). Therefore it is possible for the cells to proliferate in a 
monolayer culture and then to differentiate into cartilage and bone (Pittenger et al.1999, 
Caplan 1991) . An additional advantage to using bone marrow-derived cells in a clinical 
context is that they can be collected through aspiration of both sides of the iliac crest under 
partial anesthesia, a procedure that is very easy to perform and minimally invasive.  Second, 
we used the RWV bioreactor as the 3-D culture system which stimulates chondrogenesis in a 
simulated micro-gravity environment (Unsworth et al. 1998). In previous reports (Wakitani 
et al. 1994, Im et al. 2001), engineered cartilage from MSCs required a scaffold for the cells to 
remain in the defect and to act as a support for inducing the formation of hyaline cartilage. 
However, using our technique, it is possible to form large and homogenous cartilaginous 
aggregates without any scaffold which can thus be transplanted into large osteochondral 
defects, which do not spontaneously regenerate in the rabbit (Shapiro et al. 1993). These 
aggregates have already produced an abundance of extracellular matrix and type-II collagen 
which was used to identify the chondrogenic phenotype in vitro. This suggests that the 
aggregates formed in the RWV bioreactor have the characteristics of hyaline cartilage. Rich 
extracellular matrix embedded chondrocytes to maintain their phenotype protecting them 
from dedifferentiation. In addition, we had a specific reason to choose aggregates at as early 
as 1 week after culture in the RWV bioreactor for transplantation. According to our in vitro 
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study(Ohyabu et al.2006), the cells of cartilaginous aggregates after 1 week of culture are not 
mature, but consist of undifferentiated or chondrogenic precursor cells, which might exhibit 
plasticity to differentiate into another phenotype such as osteoblasts etc. The aggregates of 
such cells were influenced by various biological factors from the host bone marrow side 
(Engstrand  2003, Wozney et al. 1990) and interacted with adjacent cartilage (Tognana et al. 
2005, Zhang et al. 2005). A suitable distribution of mechanical stress and synovial factors 
(Serink et al., 1997, Yanai et al. 2005) also influence the lineage of these cells. These 
characteristics may thus make it possible to rapidly and suitably regenerate cartilage-bone 
structure in vivo.  
3. Rotating three-dimensional dynamic culture of adult human bone marrow-
derived cells for tissue engineering of hyaline cartilage 
The method of constructing cartilage tissue from bone marrow-derived cells in vitro is 
considered a valuable technique for hyaline cartilage regenerative medicine. Using a 
rotating wall vessel (RWV) bioreactor originally developed to simulate a microgravity 
environment, we attempted to efficiently construct hyaline cartilage tissue from human 
bone marrow-derived cells without using a scaffold (Sakai et al., 2009).  
Bone marrow aspirates were taken from the iliac crests of 9 patients using an 11G Bone 
Marrow Harvest Needle during orthopaedic surgery (mean age of 36 years, range of 23-62 
years; Table1) as shown in Fig.6. Briefly, 10 ml of bone marrow sample with anticoagulant 
was mixed with 25 ml of phosphate-buffered saline, and 35 ml aliquots of bone marrow 
suspension were overlaid onto a poly-sucrose gradient and centrifuged at 1500 g for 15 min 
at room temperature. The cell layer was carefully removed and suspended and cultured in a 
growth medium. The growth medium consisted of Dulbecco’s Modified Eagle’s Medium 
(DMEM) supplemented with 10% fetal bovine serum (FBS) and antibiotics. Approximately 
2-3 weeks later, confluent cells were subcultured  and seeded on two representative culture 
systems (RWV culture and pellet culture) for chondrogenic differentiation using 
chondrogenic differentiation medium(described in section 2.2)..  
 
 
Table 1. Summary of data from 9 samples (Sakai et al. 2009) 
In spite of some studies on the formation of cartilage tissue from chondrocytes cells (Freed 
et al. 1997a; Marlovits et al. 2003), no report has been published on the production of 
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cartilage tissue from adult human bone marrow-derived cells including mesenchymal stem 
cells by rotating three-dimensional dynamic culture. After 2 weeks of differentiation and 
induction of adult human bone marrow-derived cells to form cartilage, the two culture 
methods were compared using the RWV bioreactor and the pellet culture as shown in Figs 7 
and 8. The RWV system produced a larger tissue rich in GAG and collagen II, which are 
specific components of the cellular matrix of hyaline cartilage. These results suggest that the 
culture under hydrodynamic conditions using the RWV bioreactor provides a more suitable 
environment for the induction of cartilage differentiation from adult human bone marrow-
derived cells than a conventional static culture system (pellet culture). 
 
 
Fig. 6. Brief schematic of experimental protocol (Sakai et al., 2009)  
In RWV cultures, rotating the culture medium in the vessel provides an ideal three-
dimensional system to achieve high-density cell agglutination and obtain a spatially 
extended extracellular matrix. Decreased shear stress due to the rotating culture fluid makes 
high-density cell agglutination possible and affords effective nutrition supply and excretion 
owing to the circulating fluid. As a result, this system provides high tissue production and 
high maintenance. Cells tend to retain their differentiated phenotype in vitro only if 
cultured under conditions that resemble their natural  environment in vivo. Therefore, it is 
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reasonable to think that the tissue engineering of cartilage must be conducted in a 
physiological and mechanical environment similar to that during the in vivo ontogeny of the 
embryo. The formation of cartilage starts with cell agglutination, after early agglutination, 
an important event for maturation and skeletal patterning (Hall et al., 1992).  The formation 
of bone and cartilage in the fetus occurs in a mechanical environment very similar to an 
environment with microgravity because the amniotic fluid provides buoyancy to the cells. 
Many studies have shown the effects of gravity and mechanical load on tissue, and a 
microgravity environment has considerable effect on tissue formation (Klement et al., 1994, 
2004; Freed et al., 1999). Furthermore, some studies have shown an effect of gravity on 
embryonic bone and cartilage formation. It has been confirmed that the gravity load on 
mesenchymal stem cells during the early embryonic stages is an important factor 
determining the orientation of differentiation, and that the effect of a microgravity 
environment on cells differs between stages; however, the effects of microgravity on the 
differentiation of mesenchymal stem cells into bone, cartilage and adipose tissue remain to 
be determined. From the results of this study, the pseudo-microgravity environment 
provided by the RWV bioreactor may facilitate the differentiation of mesenchymal stem 
cells into cartilage.  
 
 
Fig. 7. (A) Comparison of the tissue formed in the pellet culture and RWVculture. 
Macroscopic photograph after 14 days of pellet culture (left), using an RWV bioreactor 
(right). (b) Wet weight of the tissue construct after 14 days. Data are expressed as the mean 
SD (n=9). : p<0.05 (Sakai et al., 2009)  
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Fig. 8. Safranin-O/fast green staining of cell aggregates cultured using an RWV bioreactor(A, 
B) and pellet culture system (C). (Original magnification x40). Cell aggregates from 3 donors 
showed distinct staining with safranin-O (A). Cell aggregates from 6 donors cultured using an 
RWV bioreactor showed partial staining with safranin-O (B). Construct cultured using the 
pellet culture system showed faint and heterogeneous staining (C). (Sakai et al. 2009)  
4. Automatic rotation control system for RWV bioreactors 
The RWV bioreactor proved quite useful for the three-dimensional culture of mesenchymal 
cells as described above. This system is expected to be of laboratory use as well as clinical 
use, however, it currently requires manual control of the rotation speed to match the 
increase of mass of the growing tissue as shown in Fig. 2. To overcome this inconvenience, 
we developed an automatic rotation control system for the RWV bioreactor as shown in 
Fig.9. A method of catching the position of the cell aggregates in the rotating vessel is key. 
 
 
Fig. 9. Automatic Rotation Control System for RWV Bioreactors (for laboratory use) 
An image of the vessel containing a medium and a cell aggregate is shown in Fig.8. As 
commercially available culture mediums are colored pink or red, it is difficult to visualize 
aggregates in a rotating vessel equipped with valves etc. The complex structure of the vessel 
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prevent simple visualization of the cell aggregate with a CCD camera. Consequently, a 
tricky method was developed using a dual illumination system as shown in Fig.10. The tissue 
growing in the RWV vessel was observed using the CCD camera in front of the vessel, and 
visualized by two illumination systems, cold blue light and white light at the back and front of 
the vessel respectively, which enabled the visualization of only the tissue. By regulating the 
RGB signals from the CCD camera, it would be possible to get a masked image of the growing 
tissue. The control system calculates the position of the tissue and sends a feedback signal to 
adjust the rotation speed. This automatic system frees up technicians and students. 
 
 
Fig. 10. Principle of visualization of a tissue in RWV vessel: The visualized tissue is judged 
by the program as to whether it is in the preset rectangular area in the vessel or not, and the 
control system sends a feedback signal to the rotation system in the RWV bioreactor to 
increase or decrease the rotation speed if it is outside of this area 
5. GMP grade automatic RWV cell culture system 
For using an RWV bioreactor, for instance for cartilage regeneration therapy, a rough 
scheme of a series of procedures could be drawn as shown in Fig.11. Bone marrow-derived 
cells aspirated from the iliac crest are cultured two dimensionally for expansion then three 
dimensionally by RWV bioreactor, after while they are transplanted into the damaged area. 
The procedures for cell treatment and cell culture are core processes to produce engineered 
tissues with structural integrity and functionality. Strict measures to prevent contamination 
and human error are needed due to the direct use of unsterile products and laborious nature 
of culture operations. For ensuring a reliable process and good quality products (engineered 
cartilage), a processing system for RWV culture is necessary and was developed, in which 
an automatic rotation control (described in the last section) and an automatic medium 
exchange process are available under GMP level as shown in Fig.12. The automatic RWV 
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cell culture system mainly consists of three blocks, a CO2 incubator and two refrigerators. 
The CO2 incubator is equipped with an RWV system which rotates two vessels 
independently, stops their rotation when a change of medium is necessary, and moves the 
vessels outside of the incubator, where two robot arms grasp two syringes from the 
refrigerators ( one with fresh medium from the refrigerator beneath the incubator, the other 
for wasted medium from the refrigerator on the incubator) and moves them to the top and 
bottom of the vessel, inserts their needles into the caps of the vessel and changes the 
medium(Fig.13). After the medium exchange procedure, the robot arms deliver each syringe to 
each refrigerator, the vessel moves to the normal position and the rotation culture starts. In the 
rotation culture, the rotation speed is controlled by the method described in the last section. 
 
 
Fig. 11. Procedure for cartilage regeneration therapy using an RWV bioreactor and bone 
marrow cells 
This system limits its function in rotation culture, however, such automatic processing 
systems are generally inevitable for safety processing for future therapeutic applications in 
tissue engineering and cell therapy (Kino-oka et al., 2009). 
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Fig. 12. Automatic RWV Cell Culture System 
 
 
Fig. 13. Two vessels in the CO2 incubator in the automatic RWV culture system (left) and the 
vessel out of the incubator with two attached syringes (right) 
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1. Introduction 
Replacement and reconstruction of pathological or absent cartilage within the human body 
has been a clinical challenge for many years. The avascular nature of cartilage tissue in all 
areas of the human body means it has little capacity for regeneration or repair beyond the 
production of functionally inferior fibrocartilage. Cartilage is injured in a number of ways; 
in the joint region, repetitive stress can cause irreparable damage, eventually resulting in 
Osteoarthritis, a debilitating disorder managed only with pain medication or joint 
replacement. A rise in the incidence of cancer has increased the prevalence of tracheal and 
nasal cancers, both frequently requiring radical resection as part of aggressive treatment 
regimes. Congenital disorders, such as Treacher Collins syndrome and Aperts syndrome 
can cause severe malformation of the ear and nose. It is evident that each of these clinical 
scenarios involves extensive damage to crucial skeletal cartilage and it is for these reasons 
that a drive for advancements in cartilage tissue engineering exists. 
Tissue engineering uses principles of cell biology, engineering and medicine to generate 
constructs that can successfully recapitulate the function of native tissues in terms of 
histology, mechanics and morphology. There is a need for a suitable scaffold that can 
provide a 3D environment for cells to proliferate and adhere. Debate still continues over the 
key characteristics needed for the ideal scaffold, but they are likely to differ according to the 
type and location of cartilage to be engineered. Should it be biodegradable/non 
biodegradable, natural/synthetic, and what impact do these features have on the flexibility 
and strength of neocartilage constructs produced? There are many scaffolds that have been 
extensively investigated in cartilage tissue engineering research from natural collagen and 
alginate, to the synthetic Polyhydroxyacids and PEG hydrogels. Nonetheless, despite 
advancements in scaffold design, neocartilage constructs are still mechanically inferior to 
their natural counterparts, and in vivo problems of poor biointegration, and deterioration in 
tissue quality over time limit there translation into clinical use.   
Nanomaterial science has introduced new methods for improving scaffold quality. Scaffolds 
can now be engineered on the nanoscale, using techniques such as electrospinning and 3D 
fibre deposition. Likewise, the incorporation of nanoparticles into polymeric material has 
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allowed the addition of nanoscale features into the matrix structure. Both of these methods 
produce scaffolds that more closely replicate the extra cellular matrix environment found in 
native cartilage. It is hoped that this will increase cellular interaction with the scaffold and 
improve the quality of constructs produced.  
With regards to the cell population to be used for engineering these constructs, there is a 
continued excitement over the possible application of stem cell technology. Stem cells are 
highly replicative and have multi lineage differentiation capacity. The traditional source of 
mesenchymal stem cells (precursor of chondrocytes) is bone marrow and various adjuncts to 
their propagation and differentiation have been explored in detail, such as growth 
hormones, biomaterials and environmental factors such as shear stress and oxygen tension 
that are important for culture techniques and bioreactor design. The discovery of new 
sources of mesenchymal stem cells, such as blood, adipose tissue or the synovium opens up 
a plethora of possibilities for clinical application, where methods of isolation and 
differentiation are being optimized.  
In light of the numerous advancements that have been made in the last decade, this chapter 
aims to give a detailed account of cartilage tissue engineering strategy, looking with 
particular focus at the effect of scaffolds on cell growth, the evolution of stem cell 
technology and the expansion of bioreactor design and application . We will also explore 
how an integration of this revolutionary and innovative bench work can be translated into 
much needed clinical application in the not too distant future.   
2. Cartilage in the human body 
2.1 Cartilage tissue biology 
Cartilage is a flexible connective tissue found in many areas of the human body, including 
the joints, ribs, nose, ear, trachea and intervertebral discs (Fig 1). In these regions cartilage 
can act as structural support, maintain shape or absorb shock during physical exercise. 
Unlike most other connective tissues, cartilage is largely avascular leading to hypoxic 
environments that limit the rate of cellular growth and tissue regeneration (115; 116). This in 
turn limits the capacity of cartilage to repair itself in the event of damage. The main cellular 
component of cartilage are chondrocytes, highly specialized cells that lie within spaces 
called lacunae and secrete the extracellular matrix (ECM) of cartilage . As with most 
connective tissues, the ECM of cartilage consists of a meshwork of macromolecules 
including collagens, elastin, glycoproteins and proteoglycans, each of which is present in 
varying amounts, depending on the type and function of cartilage. There are several cell 
surface receptors that allow chondrocytes to bind these proteins including the integrins, 
CD44, and the proteoglycan family of receptors e.g. syndecan (144).  
The three types of cartilage are hyaline, elastic and fibrocartilage. Hyaline is the most 
abundant type, white-blue in colour and macroscopically smooth on its surface. It is present 
on the articular surfaces of joints and in the nasal septum. Hyaline cartilage is covered 
externally by a fibrous membrane known as the perichondrium, and in the joint especially, it 
is diffusion from the synovial fluid that provides this tissue with nutrition. It is rich in 
collagen type II, which forms a meshwork that encases giant aggregates of proteoglycans 
(Proteins with glycosaminoglycan (GAG) side chains e.g. aggrecan, biglycan, decorin in the 
extracellular matrix; syndecan, CD44 and fibroglycan as cell surface receptors; serglycan in 
intracellular tissues) (20; 21). These GAG side chains, keratan and chondroitin sulphate are 
able to retain water. Cyclical pressures from joint loading are crucial for normal hyaline 
cartilage function, and encourage the passage of water and nutrients between cartilage and 
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synovial fluid. Elastic cartilage however, is more flexible, due to its rich elastin fibre content 
that is woven into a collagen mesh (20; 21). Elastin is an insoluble protein polymer that 
when cross linked with desmosine and isodesmosine make up the elastin fibres themselves. 
This type of cartilage is also surrounded by perichondrium and is more commonly found in 
the pinna, Eustachian tube, larynx and epiglottis, providing crucial structural support and 
flexibility. The third type of cartilage is fibrocartilage, which contains abundant thick 
collagen type I in addition to type II, that are interlaced into a mesh work of longitudinal 
and circumferential fibres (20; 21). These collagen bundles impart a great ability for this type 
of cartilage to withstand high tensile stresses. Fibrocartilage is usually found with the 
intervertebral discs, sacroiliac joints, pubic symphysis and costochondral joints.  
 
 
Fig. 1. A diagrammatic representation of cartilaginous regions in the human body 
2.2 Development of cartilage  
Central to effective tissue engineering practice is the understanding of tissue origin and 
development. This is based on the widely accepted hypothesis that natural tissue 
regeneration recapitulates developmental processes (118); hence embryological study can 
give an insight into the regulatory processes and patterns that govern tissue type and 
function, in addition to forming a foundation for understanding the degeneration and 
damage seen in tissues of the human body. We can only give a brief outline of the 
development of cartilaginous tissue specifically, however interested parties are advised to 
consult specific reviews (17; 70; 121) and books that devote entire chapters to this topic.  
Costochondral cartilage 
CARTILAGE IN THE HUMAN BODY 
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One of the epicentres of skeletal cartilage development is the growth plate which produces 
long bones via the cartilage template in a process known as endochondral ossification. It is 
important to note that this process is specific to the articular regions of bones and is 
followed by the eventual replacement by bony tissue. A milieu of hormones and paracrine 
factors govern a complex interplay of chondrocyte proliferation and differentiation, and the 
process can be divided into five stages, with the first three mainly being crucial for cartilage 
formation (144). Mesenchymal stem cells (MSCs) are first committed to becoming 
chondrocytes by paracrine factors that induce the expression of key transcription factors Pax 
1 + scleraxis, which in turn activate cartilage specific genes. During the second stage, the 
committed MSCs condense into compact nodules and differentiate into chondrocytes. 
Chondrocytes then proliferate rapidly during the third stage, increase their cytoplasmic 
contents and secrete large amounts cartilage specific ECM. Their volume increases 5-10 fold, 
proliferation slows and they are known as hypertrophic. After this stage, the expression profile 
of the cells change and collagen type X and fibronectin are secreted, enabling mineralization 
by calcium carbonate and osteoblast infiltration to make bone. Vascular infiltration leads the 
way to terminal differentiation and bone development, resulting in chondrocyte apoptosis and 
osteoblastic differentiation. Facial cartilage development is very different, as it is 
embryologically derived from the cranial neural crest cells that originate from the anterior 
hindbrain. These cells migrate to specific locations and differentiate under the instruction of an 
array of Hox genes, the complexities of which are outside the scope of this chapter.  
2.3 Clinical need for cartilage  
Due to the limited self healing capacity of human cartilage, the repair of defects caused by 
degenerative joint diseases, cancer or trauma gives rise to a challenging clinical problem. In 
the joint region in particular, lesions of the articular cartilage are frequently associated with 
debilitating pain and reduced functionality. If not successfully treated long term disability 
can only be averted by total replacement of the joint. Damage to facial cartilaginous 
structures such as the nose or ear are only resolved with a prosthesis or autologous 
transplantation surgery that results in the formation of a donor site and frequently requires 
a number of revision surgeries. Large scale damage to the trachea has even less options for 
reconstruction with stents and tracheotomy tubes being the mainstay of treatment.    
Cartilage regeneration has always been a key therapeutic target for treating articular 
cartilage damage in particular. Popular marrow stimulating techniques using micro-fracture 
or subchondral drilling of the bone have been developed to encourage the invasion of 
mesenchymal progenitor cells (MPC) into the affected site for spontaneous cartilage repair 
(94; 109). Unfortunately the outcome of such techniques varies greatly due to the lack of 
biological instructions for the MPCs to follow. This results in the formation of fibrocartilage 
which compared with hyaline tissue, has reduced durability and functionality (87; 140). The 
later invention of cell based therapies such as Autologous Chondrocyte Implantation (ACI) 
provided an important breakthrough treatment of articular cartilage damage and paved the 
way perhaps for more complex tissue engineering approaches with matrix assisted ACI 
introduced later on (16). ACI involves harvesting and propagating a population of 
autologous mature articular chondrocytes in vitro and re-introducing them into the defect 
site in cell suspension or in a supported matrix. They are then expected to lay down ECM to 
repair the site of injury (12; 102). Clinically the results of such procedures are good as they 
appear to provide symptomatic relief for patients. However, histologically the tissue 
produced is far inferior to native hyaline, being fibrotic in nature, again with limited 
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functionality and durability (19; 66; 120; 141). Further evaluations of such techniques has 
evidenced a strong correlation between the quality of tissue produced and the symptomatic 
relief of the patient from swelling and pain, once again highlighting the importance of tissue 
quality in cartilage regeneration. It can be postulated that these clinical breakthroughs 
buttressed the drive for advancements in cartilage tissue engineering technique. 
It is also essential to note that the desired characteristics of engineered cartilage depend 
heavily on the site to be reconstructed. For instance, in tracheal constructs mechanical 
integrity, strength, flexibility and durability are all crucial for function, whereas in the facial 
region the aesthetic properties of the constructs may be equally as important. Taking the 
specific requirements of the tissue to be regenerated into consideration informs the tissue 
engineering strategy and the expected out comes of such undertakings.  
2.4 Tissue engineering cartilage  
Cartilage tissue engineering paradigm is based on the isolation of chondrocytes/ 
chondrocyte precursors from a tissue biopsy, expanding the cell number in culture, seeding 
them onto 3D scaffold, incubating for a period of time before placing the construct inside a 
patient. Many studies over the last decades have demonstrated that animal cells, when 
utilised in this way can produce tissues approaching the biomechanical and histological 
properties of native cartilage, even after implantation in vivo (3; 8; 24; 48; 58; 64; 77; 99; 110; 
113; 152). However challenges do arise regarding the translation of such academic success 
into the clinical scenario. Challenges include isolating and propagating primary human 
cells, gaining relevant and reproducible construct morphology and size and ensuring good 
durability of the construct in vivo. Cell phenotype regulation, in vitro expansion of cell 
numbers, scaffold design and suitability, bioreactor design are all crucial components of the 
tissue engineering process that need to be optimized to advance cartilage tissue engineering 
from a mere academic prologue, into a clinical reality and success. These challenges will be 
discussed at length in the rest of this chapter. 
 
 
Fig. 2. A diagrammatic outline of tissue engineering strategy in cartilage tissue engineering 
for articular joint repair (an example of clinical usage) 
3. Stem cell technology 
Stem cells are unspecialised cells with a very high replication capacity. For cartilage 
regeneration, mesenchymal stem cells are the cell type of choice as they are multipotent 
stem cells, capable of differentiating into a number of lineages of the musculoskeletal 
MSC-rich Autologous 
Bone marrow aspirate
1. Isolate MSCs 2. Grow and differentiate 
MSCs into chondrocytes 
3. Seed onto optimized 
scaffold matrix 
Proliferate and differentiate 
into chondrocytes Culture in Bioreactor
4. Implant into Patient 
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system, including osteoblasts (bone cells), chondrocytes (cartilage cells) and adipocytes (fat 
cells). Although not immortal, these cells are capable of expanding through many passages 
in culture while retaining their growth and multi-lineage potential. 
MSCs can originate from various tissues including the bone marrow (11), skeletal muscle, 
adipose (106; 159) synovium (134), the embryo and periosteum. The optimal cell source for 
cartilage tissue engineering is still being identified. When selecting an ideal cell source, it is 
important to achieve a number of criteria, including: (i) easy access to/harvesting of the 
source of MSCs, (ii) extensive self-renewal or expansion capability of the cells (to generate 
sufficient quantities of cells for large scale tissue engineering, (iii) the ability to readily 
differentiate into the chondrocytic lineage when induced, and (iv) a lack of or minimal 
immunogenicity or ‘tumourigenic’ tendencies. The two most commonly used MSC 
sources are adipose tissue and bone marrow. Unlike other sources such as embryonic 
tissue, there are few ethical issues associated with harvesting and using these tissues in 
research and development. Additionally, bone marrow MSCs (BMSCs) and adipose 
derived (ADMSCs) are relatively easy to source compared with synovium-derived- or 
periostium-derived MSCs.  
Interestingly, bone marrow is the only organ in which at least two types of stem cells exist; 
hematopoietic and mesenchymal stem cells (137). The MSCs are found arrayed around the 
central sinus in the bone marrow. The cells can be isolated from the marrow using 
standardised techniques and expanded in culture through many generations, while 
retaining their capacity to differentiate along these pathways when exposed to appropriate 
culture conditions. Adipose tissue is an abundant, readily available source of MSCs. The 
cells can be isolated from fat that has been excised or ‘liposuctioned’ (lipoaspirate). There 
are advantages and disadvantages to both techniques. Anecdotally, it is thought that excised 
fat provides a higher yield of MSCs compared with lipoaspirate. This is due minimal 
mechancal impact upon cell membranes, which would ordinarily cause cell rupture, during 
the isolation process. Conversely, lipoaspirate is accessible without creating a large donor 
site defect, a major reason for pursuing tissue engineering methods at the outset. Some 
studies have compared adipose-derived MSCs and bone marrow-derived MSC (107; 122) 
and found that both BMSCs and ADASCs are capable of chondrogenic differentiation. There 
is some debate over which is the superior cell source, with numerous papers highlighting 
each source at optimum (107). 
Mesenchymal stem cells can be identified using a number of methods. These include i) 
examination of cell morphology, ii) FACS (fluorescence activated cell sorting) analysis to 
detect the expression of MSC specific markers and iii) proving their differentiation capacity 
by differentiating the cells into a number of lineages, namely; osteoblastic, adipocytic, and 
chondrocytic. For FACS analysis, the presence of MSC-specific cell surface proteins such as 
the following are sought; CD 105 (SH2), CD 90 (THY1) and CD 73 (SH3/4). Similarly, 
negative markers are used to mark and remove cells expressing cell surface proteins not 
typically seen on MSCs, such as CD 45, CD 34, and CD 14 (9).  
3.1 Stem cell differentiation to chondrocytes 
Chondrogenesis is the term used to describe the process by which a stem cell is 
differentiated into a mature chondrocyte and is one of the earliest morphogenetic events of 
embryonic development (112). The stages where introduced earlier in the section on 
cartilage tissue biology. They include: MSC condensation, the rise of chondroprogenitors, 
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chondrogenesis, terminal differentiation of progenitor cells and in skeletal development 
ossification (29).  
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Fig. 3. Schematic diagram of the stages of chondrogenesis, the main growth factors involved 
in each stage and the accompanying alterations in ECM. (Adapted from Vinatier C. 2009  
(144)) 
Condensation is directed by cell-cell and cell-matrix interactions as well as secreted factors 
interacting with their related receptors. Prior to condensation, the prechondrocytic MSCs 
secrete an extracellular matrix (ECM) which is rich in hyaluronan and collagen type I that 
prevents intimate cell-cell interaction (60). When condensation is initiated, there is an 
increase in hyaluronidase activity, thus causing a decrease in hyaluronan in the ECM. It is 
thought that hyaluronan facilitates cell movement, therefore, the increase in hylauronidase 
and subsequent decrease in hyaluronan allows for close cell-cell interactions. The 
establishment of the cell-cell interactions is thought to be involved in triggering one or more 
of the signal transduction pathways that initiate chondrogenic differentiation. Cell adhesion 
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molecules: N-cadherin (neural cadherin) and N-CAM (neural cell adhesion molecule) are 
also expressed in the condensing mesenchyme, but disappear in the differentiated cartilage, 
and later can be found only in the perichondrium. Perturbing the function of N-cadherin or 
N-CAM causes a reduction or alterations in chondrogenesis both in vitro and in vivo, which 
further evidences a role for these cell adhesion molecules in mediating the mesenchymal 
condensation step (46; 60). 
As mentioned earlier, cell-matrix interactions also play an important role in mesenchymal 
cell condensation. Fibronectin is a component of the ECM which has the ability to regulate 
N-CAM. TGF-β1, one of the earliest signals in chondrogenic condensation, stimulates the 
synthesis of fibronectin. The expression of fibronectin is increased in areas of condensation 
and decreased as cytodifferentiation proceeds. Syndecan binds to fibronectin and down-
regulates N-CAM thereby setting the condensation boundaries. One study showed that 
fibronectin mRNA undergoes alternative splicing during chondrogenesis. The isoform 
containing exon EIIIA is present during condensation but disappears once differentiation 
begins. This suggests that this isoform switching is important for cytodifferentiation to 
occur. A later study by the same group determined that the function of the fibronectin EIIIA 
exon seems to regulate mesenchymal cell spreading, therefore permitting and/or promoting 
adequate cell-cell interaction to take place during the condensation phase of chondrogenesis 
(46). 
The differentiation of chondroprogenitors is characterized by the deposition of cartilage 
matrix containing collagens II, IX, XI and aggrecan. SOX9 is one of the earliest markers 
expressed in cells undergoing condensations. It is required for the expression of the type II 
collagen gene (Col2a1) and other cartilage-specific matrix proteins, including Col11a2 and 
CD-RAP prior to other matrix deposition in the cartilage anlagen. Two other Sox family 
members L-Sox5 and Sox6, are not expressed in early mesenchymal condensations, but are 
co-expressed with Sox 9 during chondrocyte differentiation.  Figure 2 outlines the stages of 
chondrogenesis and the accompanying alterations to the ECM (46; 60). 
3.2 Inducing chondrogenesis 
3.2.1 Biochemical stimuli for cartilage tissue engineering 
Specific biomolecules are essential for cartilage tissue engineering. The role of these 
biomolecules is primarily to induce chondrogenesis and to maintain the chondrocyte 
phenotype. There are five main families of growth factors involved in chondrogenic 
differentiation. These are: the transforming growth factor-β super-family (TGFβ), the 
fibroblast growth factor family (FGF), the insulin-like growth factor family (IGF), the 
wingless family (Wnt) and the hedgehog family(HH) (144). Below is a brief introduction to 
each growth family. However, for a more detailed description, the following references are 
recommended (46; 144). Figure 3 outlines the sequence in which the transcription factors are 
involved in each stage of chondrogenesis. 
The transforming growth factor beta super-family is a family of proteins which have been 
shown to play a huge role in cartilage formation (11). Members include TGF-β, bone 
morphogenetic proteins (BMPs), inhibins and activins.  All members have been shown to 
regulate cell growth, differentiation and apoptosis of a large number of different cell types 
including osteoblasts, chondrocytes, neural and epithelial cells. TGF-β is a secreted protein 
and exists in five isoforms TGF- β1-5. TFG- β 1,2 and 3 are thought to stimulate 
proteoglycans and type II collagen synthesis in chondrocytes as well as to induce 
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chondrogenic differentiation of MSCs (144) . Studies have also shown that TGF- β isoforms 
differ in their effects on various cell types. For example, TGF- β1 has been shown to be 
responsible for the initial cell-cell interactions between condensing progenitor cells and 
TGF-β2 mediates hypertrophic differentiation (32).  
BMPs are also members of the TGF-β super-family and comprise of a group of 20 proteins 
each one playing an important role in chondrogenesis and osteogenesis during skeletal 
development. BMP -2,-4,-6,-7 and -13 have all proven their ability to stimulate 
chondrogenesis in MSCs (144) .  BMP2 in particular, has been found to be expressed in the 
condensing mesenchyme of the developing limb (101). It regulates chondrogenic 
development of mesenchymal progenitors (25) as well as stimulates the synthesis of 
chondrocyte matrix components by articular cartilage in vitro. Even combinations of many 
growth factors have been to enhance chondrogenesis, for example, BMP-2 with TGF-β3 and 
BMP-6 with TGF-β3 have been proven to stimulate chondrogenic differentiation and result 
in chondrogenic lineage development (73; 127). 
The FGF family is a group of growth factors consisting of 22 members. Most FGFs are 
secreted, except for FGF1, 2 and FGF 11 and 14 (144). Signalling by FGF18 and FGF receptor 
3 have demonstrated regulation, proliferation, differentiation and matrix production of 
articular cartilage and growth plate chondrocytes in vivo and in vitro (45). 
The IGF family is a group of proteins which have a high similarity to insulin. IGF-1 has the 
ability to mediate chondrogenesis by increasing proteoglycan and collagen type II 
production (144). Combining TGF-β3 and IGF-1, has been shown to enhance chondrogenic 
induction (72). One study examined the effect that IGF-1 has on the chondrogenesis of bone 
marrow MSCs in the presence and absence of TGF-β signalling. It showed that IGF-1 could 
modulate MSC chondrogenesis by stimulating proliferation, regulating cell apoptosis and 
inducing expression of chondrocyte markers. In addition, it proved that the 
chondroinductive actions of IGF-1 were equally potent to TGF-β1 and independent from the 
TGF-beta signalling (98). Another similar study investigated the effects of IGF-1 on TGF-β1 
induced chondrogenesis. It was found that the combination of IGF-1 and TGF-β1 produced 
higher amounts of glycosaminoglycan than TGF-beta1 alone at 8 weeks (124). 
3.2.2 Mechanotransduction in cartilage tissue engineering 
In vivo, articular cartilage experiences a variety of stresses and strains on a daily bases. 
Thus, many groups have extensively researched into the various mechanical stimulation 
methods for enhancing chondrogenic differentiation and cartilage tissue engineering (67; 68; 
135).Examples of the types of mechanical stimuli examined include: hydrostatic pressure (4), 
cyclic mechanical compression (4), shear stress (139; 143), pulsed ultrasound (130) and 
dynamic compressive strain (23). 
It has been found that exposing differentiating MSCs to various mechanical stimuli results 
in a shift in the types of protein expressed during chondrogenesis. For example, the 
application of cyclic, mechanical compression has been shown to result in an increase in 
proteoglycan and collagen contents as well as a higher amount of proteoglycan-rich, 
extracellular matrix production. Similarly, the application of shear stress by perfusion to 
differentiating BM-MSCs results in an enhanced ECM deposition and an increased collagen 
type II production (143). Low intensity pulsed ultrasound treated cell scaffold constructs 
show a significant increase of chondrogenic marker gene expression and extracellular matrix 
deposition in differentiating human BM-MSCs (130).  
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Collectively, the research shows that MSCs are mechanically sensitive and the chondrogenic 
differentiation can be modulated and enhanced by mechanical stimulation. 
4. Biomaterials  
It is well established that cells reside, proliferate and differentiate inside a complex 3-
dimensional (3D) ECM environment. In cartilage, chondrocytes are surrounded by a highly 
hydrated matrix of proteins which informs many of their phenotypic states. For example, 
research has shown that isolated chondrocytes will loose their differentiated phenotypes if 
cultured in 2-dimension (42). These chondrocytes display a shift towards a fibroblastic 
phenotype, evident on protein assays and histological evaluations. Type I collagen 
expression is increased and the typical rounded morphology of the chondrocyte becomes 
spindle in shape (128). This process has been shown to be reversible upon relocation to 3D 
matrix environments such as pellet and micro-mass culture systems, which mimic the high 
cell density phenomenon seen during MSC condensation, a crucial stage of cartilage 
development (47; 74; 92).  
It is in light of this that biomaterials have been proposed as engineered 3D environments in 
which chondrocytes can reside. For years, material scientists along with cell biologists have 
worked to optimize the tissue engineering characteristics of various biomaterials. There are 
a number of characteristics that are thought to be necessary for general tissue engineering 
attempts. These include a need for biomaterials to allow adequate cell adhesion and 
migration, with subsequent proliferation and differentiation. The overall architecture of the 
scaffold should guide and frame tissue formation, whilst providing mechanical support akin 
to that of native tissue. The scaffold should be porous, as porosity is thought to be crucial in 
maintaining the phenotype of the differentiated chondrocytes, considering their preference 
for 3D environments. It would also allow for mass transfer of nutrients and waste products. 
The scaffold should also be biocompatible with the ability to integrate into surrounding 
native tissue. 
Biomaterial scaffolds can be broadly divided into natural and synthetic scaffolds. In this 
section we will give a brief overview of existing natural and synthetic scaffolds used for 
cartilage tissue engineering research, focusing on the regulatory influence these scaffolds 
have on cell behaviour and the potential application of nanomaterial science to this research.  
4.1 Natural  
Natural materials used as bioactive scaffolds include agarose, alginate, collagen, Hyaluronic 
acid and acellular cartilage matrix (Table.1). The potential for clinical use of these scaffold 
matrices is hampered however by poor mechanical strength and flexibility, in addition to a 
potential for disease transfer and immune system reactivity if allogenically sourced. Their 
biochemical make-up leaves them prone also to host-related degradations. 
Agarose: a linear polysaccharide consisting of repeating units of agarobiose, derived from 
Asian seaweeds and capable of supporting the chondrogenic phenotype. Its ability to form 
hydrogels allows it to encapsulate chondrocytes providing a 3D matrix for their growth and 
development. A group in Germany performed allograft transplants of chondrocytes in 
agarose gel into osteochondral defects in the knee of rabbits. There we no graft versus host 
rejections, and after 18 months, 47% of grafts had morphologically stable hyaline –like 
cartilage (117).    
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Ref. Fabrication Method Cells Source Outcome 
Natural 
ALGINATE 
(49) Chondrocyt
es in 
suspension 
with 2% 
sodium-
alginate 
In vivo; 500µl of 
suspension injected 
subcutaneously into 
dorsa of nude mice. 
Calcium chloride then 
injected into this area 
to stimulate cross 
linking of the scaffold. 
Cartilage harvested 
from 14 to 38 weeks 
Human nasal 
septal 
chondrocytes 
Gross analysis showed that 14/15 
constructs resembled native 
human cartilage. 6 of the explants 
had histologically homogenous 
resemblance to native cartilage. 
The neo-constructs stained 
positively for Col II.  
(97) 3D alginate 
scaffold 
prepared by 
freeze 
drying 
In vitro; Cells were 
cultured in the 
alginate for 1-4 weeks 
in a bioreactor 
Porcine 
articular 
chondrocytes 
RT-PCR analysis showed the cells 
maintained their differentiated 
phenotype for up to 4 weeks. The 
cell also proliferated increasing 
from 5 x 105 cells to 3 x 107.  
(151) 3D alginate 
gels 
In vitro; cell/gel 
constructs were 
cultured for 0, 6, 12, 
18 and 24 days 
Human MSCs Results of qRT-PCR analysis 
provided a temporal analysis for 
marker expression during 
chondrogenesis. Stage I (days 0–
6): Col I and VI, Sox 4, and BMP-
2. Stage II (days 6–12): Cartilage 
oligomeric matrix protein, 
HAPLN1, Col XI, and Sox 9. Stage 
III (days 12 -18): Matrilin 3, Ihh, 
Hbx 7, chondroadherin, and WNT 
11. Stage IV (days 18–24): 
aggrecan, collagen IX, II, and X, 
osteocalcin, fibromodulin, PTHrP 
and alkaline phosphatise. 
(91) Alginate gel 
layer 
In vitro; To evaluate 
the effect of low-
intensity ultrasound 
(LIUS) on cell 
viability during 
chondrogenic 
differentiation 
Human MSCs When the cell/alginate construct 
was cultured with TGF-β1, cell 
viability decreased. However, 
addition of LIUS enhanced 
viability and inhibited apoptosis 
under the same conditions. 
Demonstrated by the expression 
profiles of apoptosis genes, p53, 
bax and bcl-2. 
(30) Hydrogel In vitro; Chondrocytes 
were seeded onto 
alginate after 1, 2 and 
3 passages in a 
monolayer.  
Human nasal 
septal 
chondrocytes 
Alginate stimulated GAG and Col 
I deposition supporting the 
chondrocytic phenotype. Results 
did not also support other research 
showing that culture with alginate 
beads can redifferentiate cells. 
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CHITOSAN  
(114) Fibrous 
scaffold vs. 
sponge 
In vitro; constructs 
analysed 3 days, 10 
days and 21 days 
after cell seeding 
Mouse BMSC 
line 
At 10 and 21 days the cells were 
embedded but did not aggregate, 
with fibrous scaffolds containing 
more ECM. The cells had a round 
morphology. Histology revealed 
cell and ECM distribution was not 
homogenous. mRNA expression 
for Col II was 3 times greater for 
the fibrous scaffold compared 
with the sponge at 21 days 
(22) Chitosan 
scaffold and 
Chitosan 
microspher
es 
In vitro; Scaffold and 
microspheres used 
asTGF-β1 carrier to 
see the effect of this 
growth factor on 
chondrogenic 
potential 
Rabbit 
articular 
chondrocytes 
Encapsulation efficiency of TGF-
β1 was 90.1%. TGF-β1 was 
released from chitosan in a 
multiphase fashion. TGF-β1 
loaded microspheres significantly 
improved cell proliferation rate 
and Col II production, compared 
with controls with no 
microspheres or controlled TGF-
β1 release.  
(61) Chitosan 
scaffold 
synthesized 
via freeze 
drying  
In vitro; cells seeded 
on to chitosan of 
varying porosity; 
<10µm, 10-50µm and 
70-120µm. Cultured 
for 28days in a 
rotating bioreactor 
Porcine 
articular 
chondrocytes 
Chitosan scaffolds remained 
intact compar4ed with the 
positive control PGA. However 
cartilage specific DNA levels and 
GAG were lower in the Chitosan 
groups compared with PGA. 
Chitosan also had the largest 
pores, with more Chondrocytes, 
but on histological analysis, the 
composition of cartilage produced 
on PGA resembled the structure 
of native cartilage more than 
chitosan constructs. 
COLLAGEN  
(38) PLGA mesh 
and 
Collagen 
sponge 
In vitro; hybrid disks 
of PLGA/Collagen 
scaffold with different 
structures. In vivo; 
week old cultured 
constructs implanted 
into dorsa of athymic 
nude mice and 
harvested after 2, 4 
and 8 weeks 
Bovine 
articular 
chondrocytes 
Homogenous cell distribution 
with natural chondrocyte 
morphology. Abundant ECM 
production. Levels of GAG and 
Collagen II DNA, and aggrecan 
mRNA increased on the scaffolds 
with more collagen (semi, 
collagen on one side of PLGA and 
sandwich, collagen on both sides). 
Semi and sandwich compared 
with natural articular cartilage, 
had a Young’s modulus of 54.8% 
and 49.3% respectively. 76.8% and 
62.7% in stiffness.  
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(156) Hydrogel In vivo: comparison of 
collagen hydrogel 
and collagen-alginate 
hydrogel. Gel injected 
subcutaneously into 
rabbit backs. 
BM-MSC Homogenous distribution of cells 
with chondrocyte characteristics 
demonstrated the chondrogenic 
differentiation of BM-MSCs. Both 
collagen hydrogel and collagen 
alginate hydrogel may induce 
chondrogenesis. Expression 
profile of cartilage specific genes 
differed between collagen 
hydrogel and collagen alginate, 
indicating that induction of 
chondrogenesis is materials 
dependent. 
(153) 3D collagen 
sponged 
In vitro; Cells seeded 
onto collagen sponges 
and cultured in either 
standard or serum 
free culture 
conditions for 1, 2 and 
4 weeks 
Bovine 
articular 
chondrocytes 
Overall chondrogenesis in serum 
free culture (Nutridoma 
replacement) was equivalent or 
better than control cultures in 
serum. Insulin-
transferrinselenium (ITS+3) 
serum replacement cultures were 
poor due to decreased cell 
viability. The porous 3D collagen 
sponges were able to maintain 
chondrocyte viability, shape, and 
synthetic activity with evidence 
from quantitative assays for 
cartilage-specific gene expression 
and biochemical measures of 
chondrogenesis. 
FIBRIN 
(83) Fibrin gel In vivo: ACI on 30 
patients using 
minimally invasive 
injection techniques. 
Mix of fibrin gel and 
chondrocytes.  
Autologous 
adult 
chondrocytes 
Patients evaluated 24 months post 
operatively using the Cincinnati 
knee ligament rating scores, for 
which 10 patients had excellent 
result, 17 with good results, two 
fair and one poor result. Further 
arthroscopy in 10 patients 
demonstrated good fill and 
integration in grafted areas.  
(131) PLGA/Fibri
n hybrid 
scaffold  
In vitro; PLGA 
scaffold soaked in 
chondrocyte-fibrin 
suspension 
(polymerized by 
thrombin CaCl2 
solution), Constructs 
were cultured for a 
maximum of 21 days. 
Rabbit 
articular 
chondrocytes 
Cell proliferation increased 
steadily until day 14, but declined 
by day 21. Cartilage formation 
evident at day 14, confirmed by 
the presence of cartilaginous cells 
embedded in basophilic ECM 
filled lacunae. Proteoglycan and 
GAG presence was confirmed. 
Suppression of the cart 
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dedifferentiation marker Col 1 
observed after 2 and 3 weeks in 
culture. sGAG production greater 
in fibrin/PLGA compared with 
PLGA control.  
(28) PLGA/Fibri
n hybrid 
scaffold 
In vivo; PLGA scaffold 
soaked in 
chondrocyte-fibrin 
suspension 
(polymerized by 
thrombin CaCl2 
solution) and 
constructs implanted 
subcutaneously into 
dorsum of nude mice 
for 4 weeks after 
culture for 3 weeks. 
Analysis performed 
at 1, 2 and 4 weeks.  
Rabbit 
articular 
chondrocytes 
Constructs maintained their 
shape and there was no 
significant difference between 
fibrin/PLGA and control PLGA. 
All exhibited smooth cartilage like 
properties 1, 2 and 4 weeks after 
implantation. Presence of 
proteoglycans and GAG was 
confirmed. The constructs were 
also strongly positive for Col II. 
Notably, sGAG production was 
greater on fibrin/PLGA scaffold 
than the control. Overall, both 
fibrin/PLGA and PLA showed 
comparable potential in 
sustaining the chondrogenic 
phenotype. 
HYALURONIC ACID(HA) 
(33) ***Hyaff®-
11, 
biodegrada
ble 
polymer, 
nonwoven 
mesh 
In vitro; Chondrocytes 
were harvested from 
OA patients and 
seeded onto Hyaff®. 
Constructs remained 
in culture for 28 days, 
analysed on day 0, 7, 
14, 21 and 28.  
Human 
Autologous 
chondrocytes 
Viability and proliferation of OA 
chondrocytes similar to cells from 
normal subjects. 
Immunohistochemistry showed 
no signs of ageing or degeneration 
in cartilage produced by OA cells. 
The experimental groups and 
controls both had significantly 
raised Col II, Sox 9 and aggrecan. 
Suggests OA cells benefit from 
the HA rich environment. 
(154) Hydrogel 
(in vitro), 
beads(in 
vivo) 
In vitro and In vivo; 
implanted into nude 
mice. Constructs were 
cultured in vitro for 2 
weeks prior to 
implantation. 
Constructs remained 
implanted for 2 
weeks. 
Human MSC Both in vitro and in vivo cultures 
of MSC-laden HA hydrogels 
enabled chondrogenesis. This was 
measured by the early gene 
expression and production of 
cartilage specific matrix proteins 
(aggrecan, Col II). HA hydrogels 
were compared to relatively inert 
poly(ethylene glycol) (PEG) 
hydrogels, and showed enhanced 
expression of cartilage specific 
markers 
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(107) HA 
immobilize
d on surface 
of PLGA 
scaffold 
In vitro; 
biodegradable 
macroporous PLGA 
scaffolds chemically 
conjugated to the 
surface exposed 
amine groups of the 
PLGA. Incubation 
times varied for each 
assay. 
Bovine 
articular 
chondrocytes 
Enhanced cellular attachment was 
observed compared with PLGA 
controls. GAG and total Col 
synthesis was significantly 
increased for HA/PLGA 
compared to the control. The 
HA/PLGA constructs exhibited 
morphological characteristics of 
cartilage and had cartilage 
specific Col II expression. 
Synthetic 
PLGA- Poly(lactic-co-glycolic) acid 
(107) PLGA 
scaffolds 
In vivo: PLGA 
scaffolds were seeded 
with AD-MSC, 
cultured in TGFβ1 
containing medium 
for 3 weeks, prior to 
implantation in the 
subcutaneous pockets 
of nude mice for 8 
weeks.  
Human AD-
MSC 
RT-PCR demonstrated the 
increased expression profiles of 
chondrospecific marker mRNA, 
compared with control samples 
after 3 weeks in vitro and 8 weeks 
in vivo.  
(150) HA 
modified 
porous 
PLGA 
scaffold 
In vitro; cells seeded 
onto HA/PLGA 
scaffolds and cultured 
for a total of 5 days. 
Human AD-
MSC 
The AD-MSC cultured in HA 
coated wells showed enhanced 
expression of cartilage specific 
mRNA. HA-modified PLGA did 
not affect cell adherence and 
viability, but did enhance gene 
expression after 1, 3 and 5 days in 
culture. GAG and Col I 
production enhanced after 4 
weeks in culture compared with 
PLGA control.  
(10) PLGA 
scaffolds 
In vivo; cells were pre-
cultured on poly-
HEMA coated dish, 
then seeded onto 
PLGA. The construct 
was implanted into 
the subcutaneous 
pockets of nude mice 
for 16 weeks. 
Chondrocytes Macroscopic signs of neo cartilage 
formation appeared at 8 weeks, 
and completed by 16 weeks. All 
constructs showed viable 
chondrocytes with normal 
lacunae and ECM. They stained 
positively for Col II. Control was 
a cell-free scaffold implanted into 
the other side of the dorsum on 
the same mouse.  
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(75) PLGA 
microspher
es 
In vivo; PLGA 
microsphere seeded 
with rabbit 
Chondrocytes 
injected 
subcutaneously into 
dorsa of athymic 
female mice 
Autologous 
rabbit 
Chondrocytes
The PLGA microsphere permitted 
cell adhesion. 4 and 9 weeks post-
implantation there was 
macroscopic and histological 
evidence of cartilage formation on 
the seeded PLGA microsphere 
compared with nothing on the 
PLGA and chondrocyte controls. 
(142) PLGA 
porous 
scaffold 
disks 
In vivo; MSC seeded 
PLGA scaffold disks 
implanted into 36 
week old Japanese 
white rabbits. 
Constructs were 
harvested after 4 and 
12 weeks. 
Rabbit BM-
MSC 
 
Engineered cartilage from 
autologous BM-MSC and PLGA 
scaffold filled the defects in the 
rabbit knees. The constructs were 
macroscopically and 
histologically similar to hyaline 
cartilage at 12 weeks post 
transplantation.  
PCL- Poly(carprolactone) 
(82) 3 porous 
PCL scaffold 
types 
investigated 
(1)PCL/Plur
onic F127, 
(2)PCL 
collagen and 
(3)PCL/Plur
onic 
F127/collag
en, in 
addition to 
(4) PCL only
In vitro; 3 porous PCL 
scaffold modifications 
investigated (1) 
PCL/Pluronic F127, 
(2) PCL collagen and 
(3) PCL/Pluronic 
F127/collagen, in 
addition to (4) PCL 
only. Cultured for 3 
weeks. 
Human BM-
MSC 
The 3 surface treated scaffolds 
had higher chondrospecific DNA 
content than the PCL only. GAG 
concentrations were also higher 
than in the PCL only, and RT-PCR 
showed that Sox 9 and Col IIA1 
were remarkably elevated in the 
modified PCLs. Notably, Col IA1 
and ColI0A1 mRNA levels were 
lower in the three modified 
scaffolds than in the PCL, 
suggestion prevention of the 
dedifferentiated phenotype.  
(95) Electrospun 
3D 
nanofibrous 
scaffold 
In vitro; MSC seeded 
onto pre-fabricated 
nanofibrous scaffold 
for 21 days 
Human BM-
MSC 
Histological analysis was 
congruent with cartilage 
formation when cells were grown 
in medium containing TGFβ1. 
The cartilage specific gene profile 
(Aggrecan, Col II and Col X) was 
low, but improved significantly in 
chondrogenic medium with 
TGFβ1. Col X levels were 
paradoxically down regulated. 
There was positive 
immunohistochemistry for 
cartilage specific ECM molecules.  
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PGA-Polyglycolic acid 
(158) Porous PGA 
and high 
density 
polyethylen
e composite 
scaffold 
In vivo; High-density 
polyethylene carved 
into cylindrical rods 
(internal support), 
with non-woven PGA 
sheets wrapped 
around the rods to 
form the scaffold. 
Implanted 
subcutaneously into 
nude mice. 
Porcine 
BMSC 
8 weeks post-implantation the 
constructs had formed mature 
cartilage with an abundant 
deposition of ECM on SEM. The 
experimental groups showed a 
positive histological likeness to 
cartilage with large number of 
lacunae and good expression of 
Col II.  
(157) PGA-HA 
composite 
scaffold 
In vivo; MSC were 
seeded onto the PGA-
HA and co-cultured 
for 72hours. There 
were then implanted 
into full thickness 
cartilage defects in 
the intercondylar 
fossa of rabbit femurs. 
Constructs were then 
harvested after 16 or 
32 weeks of surgery. 
Rabbit MSC Grossly, the constructs 
demonstrated hyaline cartilage 
formation and at 16 weeks, there 
appeared to be integration with 
surrounding normal cartilage and 
subchondral bone. At 32 weeks 
there was no sign of degradation 
of the neoconstruct.  
(160) PGA vs. 
PLA bio-
resorbable 
nonwoven 
scaffolds 
In vivo; Cells seeded 
onto scaffolds and 
cultured for 7 days in 
serum free media, 
before implantation 
into subcutaneous 
nude mice for 6 and 
12 weeks  
Human 
articular 
chondrocytes 
Aggrecan synthesis always higher 
in the PGA groups. mRNA gene 
expression for Col II significantly 
higher in the PGA groups after 6 
and 12 weeks. Expression of Col X 
and cartilage oligomeric matrix 
protein increased on both 
scaffolds.  
PEG- Poly (ethylene glycol) 
(125) PEG-
peptide 
copolymer 
gels 
In vitro; RGD and 
KLER sequences 
chosen as motifs to 
modify PEG gels. 
(KLER is a binding 
site from decorin 
protein, known to 
bind strongly to Col 
II, RGD promotes 
survival of 
encapsulated cells). 
Cells were 
encapsulated in the 
PEG peptide gel and 
cultured for 6weeks 
Human MSCs After 14 days, cells in RGD and 
KLER functionalized gels 
produced 2.5 times as much GAG 
as those only containing RGD. 
hMSCs also produced 27x as 
much hydroxyproline (a major 
component of collagen) than 
scrambled sequence gel controls. 
Col II was more prominent in 
KLER gels on immunostaining 
and RT-PCR analysis 
demonstrated higher levels of Col 
II and aggrecan synthesis.  
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(111) Hydrogel In vitro; cells were 
encapsulated in the 
PEG hydrogel and 
allowed to free swell 
for 24hrs.  
Bovine 
temporoman
d-ibular 
chondrocytes 
Condylar chondrocyte viability 
was maintained within the 
constructs during cell culture. 
RTPCR analysis showed the 
expression of cartilage specific 
markers, namely Col II, aggrecan 
and Col I was maintained 
Table 1. Summary of in vitro and in vivo studies that have used various scaffolds to engineer 
cartilage (2005-2010).  Abbreviations: AD-MSC, adipose derived mesenchymal stem cells. 
BMSC, bone marrow stromal cells. BM-MSC, bone marrow derived mesenchymal stem cells. 
Col, collagen. ECM, extra cellular matrix. GAG, glycosaminoglycan. Hbx, homeobox. Ihh, 
Indian hedgehog. OA, osteoarthritis. PTHrp, parathyroid hormone replacement hormone. 
RT-PCR, real-time polymerase chain reaction. SEM, scanning electron microscopy. sGAG, 
sulphated glycosaminoglycan 
Alginate: derived from brown marine algae and is consists of 1, 4-linked β-D-mannuronnic 
and α-L-guluronic residues, which are soluble in aqueous solutions. Cross-linking with 
bivalent cations such as Ba2+ or Ca2+ allows it to form stable gels.  
Chitin: a polysaccharide based analogue of GAG found in the exoskeleton of arthropods. 
Relatively unexplored bioactive scaffold for tissue engineering, perhaps because it is 
degraded in vivo by lysozyme; an enzyme found in many human bodily fluids.   
Collagen 1 and II: As the principle ECM components of cartilage, seeded chondrocytes can 
bind using inherent cell-surface receptors and use standard signalling pathways to regulate 
proliferation and growth. Can be fabricated as a sponge, foam, or gel, but like chitin, is 
subject to enzymatic breakdown. 
Fibrin: Can be derived from autologous blood samples, and has a comprehensive history of 
biocompatibility in its clinical use as a wound adhesive. Chondrocytes have integrins that 
can bind directly to fibrin, much like with collagen.  
Gelatin: A porous substance derived from hydrolysis of collagen. Its application as a scaffold 
for cartilage tissue engineering is relatively unchartered.  
Hyaluronic Acid: a non-sulphated GAG, found in abundantly within the cartilaginous ECM. 
It is crucial for maintaining the biophysical properties of the cartilage ECM for optimum 
chondrocyte growth and proliferation.  
4.2 Synthetic 
The main aim of biomimetic materials (synthetic biomaterials) is to generate 3D scaffolds 
that support essential cell functions in addition to mimicking the biomechanical properties 
of host tissues, whilst avoiding host immune responses (Table.1). These are two 
characteristics more difficult to find in natural scaffold alternatives. When considering 
clinical applications, susceptibility to vascular invasion is a key consideration and there is 
continued debate between groups about the need for biodegradation. Persistence and 
stability have been the focal aims for tissue engineering cartilage with the mechanical and 
biochemical properties of synthetic materials being more amenable to modification than 
natural scaffolds. 
Polyhydroxyacids: polyhydroxyacids such as PLLA [poly (L-lactic acid)], PCL [poly (L-
lactide-ε-caprolactone)] and PGA [poly (glycolic acid)] have been well studied as potential 
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cartilage scaffold matrices, where they are easily extruded into fibrous or open lattice 
sponges. PGA is reportedly highly biodegradable (5 weeks); PLLA can stay in vivo up to 3 
years. PCL and PGA used to fabricate ear templates for tissue engineering auricular 
cartilage (133).  
Elastomeric polyurethanes: Well documented history of use in a variety of biomedical 
instruments, ranging from urinary and vascular catheters to intra-aortic balloons and 
mammary implants. Can be fabricated in a biodegradable form, and have been shown to 
support chondrocyte attachment and growth.  
PEG [poly (ethylene glycol)]: FDA (Food and Drugs Administration) approved, and extensive 
research into its ability to promote chondrogenesis 
4.3 Regulatory influence of scaffolds on cell behaviour  
It is widely appreciated that soluble biochemicals such as cytokines, growth factors and 
chemokines affect the growth and development of all tissues including cartilage. 
Transforming growth factor beta (TGFβ) and bone morphogenic proteins (BMPs) have been 
evidenced as highly potent stimulators of cartilage tissue generation (78; 96; 118). In 
addition to such signalling mechanisms, ECM proteins such as collagens, 
glycosaminoglycans and proteoglycans exert an array of instructions on cells via 
transmembrane receptors that affect expression and therefore, cell behaviour. Much of this 
instruction will crosstalk with growth factor signalling (37; 44). Additional studies have also 
shown chondrocytes to be particularly receptive to mechanical loading, with this parameter 
having been evidenced as a crucial factor in the chondrogenic differentiation of MSCs 
during critical cartilage development. Repetition of these loads and varying the duration 
and force of the load has positive effects on the structural organization of cartilage ECM (7; 
62). The effects of mechanobiology on chondrogenesis have been discussed in detail in the 
section on stem cells.  
In recent times, tissue engineering research had broadened its horizons to understand the 
effect of scaffold physical properties on cell behaviour. Properties considered include; 
roughness (88; 89; 147), micro and nanotopography (reviewed in (132)), porosity (155) and 
surface energy (80; 147). The stiffness of the substrate (scaffold matrix) has been 
demonstrated as a crucial regulator of stem cell behaviour (15; 48; 52; 119). It is thought that 
the stiffness or elasticity of a matrix can act as a ‘passive’ cue for cell processes via a 
phenomenon known as mechano-transduction. This is a method by which cells convert 
mechanical stimuli into a chemical response, thus affecting their own behaviour. For 
detailed reviews see (2; 54). Cells bind to the matrix using integrins. The intra cellular 
domain connects to the actin and myosin (contractile) cytoskeleton of the cell, and the 
extracellular domain to the biomaterial. When cells are bound, they apply mechanical forces 
onto the matrix using their contractile cytoskeleton. Integrins cluster which in turn recruits 
structural and signalling proteins at the site of contact between cell and matrix, known as a 
focal adhesion. If a matrix is relatively hard, there is more resistance to the forces applied by 
the cellular cytoskeleton. This results in a more organized cytoskeleton, more integrin 
clustering and thus focal adhesions that are greater in maturity. Comparatively, if cells are 
seeded onto a soft matrix, there is little resistance to counterbalance the cell forces, therefore 
reduced development of the actin-myosin cytoskeleton. This phenomenon is fundamental 
considering that changes in cytoskeletal organization affect signalling, thereby translating 
mechanical processes into chemical responses.  
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So how can this trend be used in cartilage tissue engineering technology? Let us consider the 
application of stem cells in tissue engineering cartilage. Stem cells extracted from human or 
animal sources are frequently expanded in culture. Culturing stem cells on traditional tissue 
culture plastic could result in preconditioning of the cells in accordance with the stiffness of 
the plate (51; 52). Depending on the experimental aims, it may be wiser to culture and 
expand on softer substrates with stiffness comparable to that of native tissue. However 
conflicting data has shown that stiffer substrates increase the rate of proliferation, whereas 
soft substrates promote the dedifferentiation of cells (15).This suggests the stiffness of the 
material used for cartilage tissue engineering is an important parameter not just in terms of 
mechanical support but also in terms of propagating chondrocyte growth and matrix 
deposition.  
4.4 Nanomaterials 
Cell coverage over a matrix layer is directly correlated to the spread of microscale ECM 
proteins over its surface, irrespective of the geometric patterning of such proteins (93). 
This theory applies at the microscale level of tissue engineering, but at the nanoscale, 
there is increasing evidence to indicate that cells are able to alter their behaviour 
differentially in response to changes in nanotopographical surfaces. These changes can be 
cytoskeletal or a change in morphology, focal adhesions, motility, gene expression and 
differentiation. Much like the mechano-transduction discussed earlier, there is support for 
some sort of topography-dependent transduction that communicates independent of 
chemical signalling from ECM molecules (35). Studies have since demonstrated that this 
cellular response is heavily related to the pattern and spacing of adhesive ligands 
(36;41;79;148).  
In light of the revelation that nanotopography plays a major role in the governance of cell-
matrix interactions, many physical and chemical methods have been developed to engineer 
geometrically defined nanopatterns on biocompatible scaffolds. Crude methods of acid 
treatment (85), bonding with calcium cations (63), and coating with nanoparticles (reviewed 
in (126)) allowed scientists to introduce nanofeatures into the surface topography of 
scaffolds. Surface modifications with Lanthanum phosphate (LaPO4) nanoparticles 
increased osteoblast adhesion to traditional bioceramics; Hydroxyapatite and Tricalcium 
phosphate (53). Likewise with chondrocytes, the levels of adhesion increased on 70%/30% 
(wt) PLGA/titanium composite scaffolds manufactured to have a nanosurface (76). 
However the advancement of nanoscience allows more precise pattering of various 
nanofeatures to further affect cell behaviour. Nanofeatures now come in many forms 
ranging from nanopits and grooves, to nanopillars, nanodots and traditional nanoparticles. 
The pattern in which they are arranged is also on the nanoscale. The latest techniques used 
for nanosurface pattering (reviewed in (132)) include photolithography, electron beam 
lithography (40), Dip-pen lithography (71) and imprint lithography.  
Nanopatterning to mimic the surface density and arrangement of integrin-binding epitopes 
as seen in the ECM has been a challenge not yet beaten. Studies have shown that integrin 
mediated signalling operates with a minimum surface density however; the exact spatial 
organization of these ligands in vivo has not been elucidated. The nearest estimate has come 
from a group that developed a block-copolymer micelle nanolithography technique to label 
surfaces with hexagonal arrays of gold nanodots coated with one RGD peptide (found in 
adhesive glycoproteins such as fibronectin and vitronectin) (26;27). Upon cell seeding they 
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found that only 28nm and 58nm spacing between the nanodots would allow adequate 
clustering of integrins, which are approximately 8-12nm in size (138). Additional studies on 
RGD-coated gold nanoparticles have shown that the velocity of migrating cells decreases 
with an increased particle density, with a peak velocity at circa 120nm, suggesting the boost 
in particle density increased levels of adhesion (6;65). Interestingly enough, research has also 
shown the MSC osteoblastic differentiation can be hampered by regularly arranged 
hexagonal nanopits arrays compared with arrays with a slight irregularity (39). Similar 
results were found by Biggs et al 2007, where highly ordered nanopits resulted in decreased 
formation and length of focal adhesions, compared with controlled disorder increasing focal 
adhesion formation and size (13).  
With more research being conducted into the in vitro effects of surface nanopatterning on 
cell behaviour, there are implications for cartilage tissue engineering research. Data shows 
that nanostructured PLGA can accelerate chondrocyte attachment, growth and proliferation 
in addition to improving ECM production (76). In our lab, chondrocytes seeded onto 
nanocomposite polymer POSS-PCU (UCL nanoBio™) have a faster rate of proliferation 
compared with controls lacking the nano modification (unpublished data). And though the 
current research into nanomaterials and cartilage tissue engineering is just evolving, there 
are many lessons to be learnt from bone (80;81), skin (31) and vascular (100;108) tissue 
engineering research.  
5. Bioreactors 
Bioreactors are devices in which biological and/or biochemical processes develop under 
controlled and monitored environmental and operating conditions (104). It is the 
exceptional control over environmental conditions that makes bioreactor use particularly 
pertinent in tissue engineering research where specific factors need to be controlled in order 
to optimise tissue growth. Bioreactors can maintain physiological boundaries at desired 
levels, enhance nutrient and waste transport rates, and provide specific stimuli to promote 
optimum growth.   
The use of bioreactors has provided a promising method for tackling some causes for poor 
research outcomes in tissue engineering practice. Restricted, unspecific, or impermanent cell 
differentiation and poor tissue formation/ remodelling in cartilage tissue engineering 
largely results from a lack of correct physical stimulation in vitro (86). For example, 
mechanotransduction, the transduction of mechanical stresses into biochemical signals, 
affects chondrocyte function. Modifying the mechanical stressors applied to cells in vitro may 
therefore improve the quality of tissue constructs produced. In early parts of this chapter, the 
effect of cyclical loading, especially within the articular region has been shown to improve the 
ECM content of constructs, and therefore the overall construct viability. Mimicking some of 
these forces in bioreactor systems could also dramatically improve tissue growth. Studies 
which evidenced the effect of adaptive physical stimulation on mechanotransduction, led to 
the development of bioreactor devices that transmit forces including shear stress, hydrostatic 
pressure and compression to articular cartilage in vitro (129). 
5.1 Mechanical forces 
Key to tissue engineering in the joint region specifically is the use of exogenous mechanical 
forces to simulate loading forces (exerted during daily movement and exercise), which in 
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turn increases the metabolic activity of and ECM production by chondrocytes. Shear stress, 
compressive forces, tensile forces and hydrostatic pressures are all parameters that can be 
modulated to influence the quality of cartilaginous constructs engineered. The effect of these 
mechanical forces on chondrogenesis, have been described earlier in the chapter. We will 
examine briefly the bioreactors that have been used to study the effects of shear stress 
however, the different types of bioreactors available for exerting other forces are expertly 
reviewed in Schulz RM 2007.  
 
 
Fd 
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Fig. 4. Experimental appraoches to bioreactor tissue engineering. Representation of static, 
stirred and rotating vessels. Fc, Fd, Fg refer to centrifugal, drag and net forces respectively. 
(Adapted from Vunjak-Novakovic G 1999 (145)) 
The easiest method for examining the effects of shear stress in bioreactor systems is by 
placing constructs in culture either on a petri dish or in a dynamic or orbital shaker (56;57). 
Other methods developed have included using spinner flasks or vessels with magnetic 
stirrers (14;18;136). Extensive study in the nineties looked at the application of shear stress 
by comparing static and orbital shakers, stirred vessels with rotating vessels (Fig.4) (145). 
Rotating vessels are more advanced systems where constructs float freely within culture 
medium, whilst the whole vessel rotates around a central axis at a constants speed. 
Chondrocytes were seeded onto 97% porous scaffold discs and cultured in the 
aforementioned vessels for 8 weeks. Results showed that freely cultured constructs were 
larger than those cultured in static or stirred vessels. They formed cartilaginous ECM with 
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the greatest concentration of GAGs and collagen. Their mechanical properties where also 
shown to be superior.   
5.2 Oxygen tension 
Optimizing O2 tension within culture systems is an area of great importance in bioreactor 
design. O2 is the partial pressure of oxygen dissolved in a liquid such as blood.  Cells in 
culture require nutrients and oxygen to proliferate and this is usually achieved through 
mass transport (net movement of mass from one location to another). When oxygen and 
nutrients are limiting factors, larger grafts tend to contain a hypoxic, necrotic centre, 
surrounded by a rim of viable cells (Martin I 2004). In a tissue graft, the density of cells may 
be higher than the distance oxygen can freely diffuse across by mass transport to provide 
sufficient oxygen for the inner cells; therefore they are starved of oxygen. Limited O2 
diffusion can also affect the spatial distribution of cells and as the O2 concentration gradient 
decreases from the surface of the tissue compartment to its centre (34). In humans, this 
problem is solved by the circulatory system and thus nutrients are provided to all cells via a 
complex network of vessels, slowly decreasing in size the deeper into tissues they enter. It is 
the proximity of capillaries to somatic (body) cells that allows their mass transfer 
requirements to be met (105). So how is this problem solved in tissue engineering practice? 
The introduction of simple stirred flask bioreactors enables the mixing of oxygen and 
nutrients throughout the medium. So not only does it provide a shear stress which is known 
to be beneficial for chondrocyte growth and proliferation, but it also reduces the 
concentration boundary layer of oxygen at the construct surface (14;18;104). In a static 
culture environment, oxygen would diffuse into cells and carbon dioxide out. The medium 
in closest proximity to the cells would have a steadily decreasing O2 tension with a 
conversely increasing CO2 tension. This in turn limits the overall rate diffusion as O2 moves 
from areas of high tension to areas of low tension. Thus if the culture medium is not 
circulated or replenished the rate of diffusion will decrease and eventually cease at the point 
where there is no longer a concentration gradient, leading to cell death.  
Studies have also used bioreactors to investigate the effect of different partial pressures of 
O2 and pH levels on gene and protein expression, as well as the metabolic activity of 
chondrocytes. Results showed chondrocyte sensitivity to acidic conditions where reduced 
expression of Coll Type 1, SOX9 and VEGF (vascular endothelial growth factor) were 
observed. Conversely in hypoxic conditions, VEGF levels were found to be higher, with a 
pH dependent reduction in Coll Type 1 (43). Culture in bioreactors at low oxygen tension 
increases the production and retention of glycosaminoglycan (GAG) within the cartilage 
matrix without affecting chondrocyte proliferation or collagen deposition which typically 
would requires higher partial pressures of O2 (123). These studies highlight the twofold 
applications of bioreactors, in maximizing cell growth and tissue generation for clinical use 
and in research and development to investigate the effect of different biological factors on 
cell growth.  
5.3 Growth factors 
It has also bee suggested that bioreactors provide suitable environments to add growth 
stimulating factors to constructs to improve chondrogenesis. For example, transducing 
human MSCs with an adenoviral vector containing SOX9 and subjecting the construct to 
mechanical stimulation could increase GAG synthesis (90). Growth factor application of 
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BMP-2, IGF-1 and TGF-β1 in a bioreactor system can increase the compressive and tensile 
biomechanical properties of engineered tissue (50). The efficiency of chondrocyte 
proliferation from low initial seeding densities can also be enhanced by adding various 
growth factor combinations in to automated bioreactors systems (55). Chitosan scaffolds 
were used to engineer articular cartilage with the aid of a chondrogenic differentiation 
factor, BMP-6. Results showed that proliferated cells contained a higher value of GAG, Coll 
type II and DNA indicating improved chondrogenesis (1). Alternatively, inhibiting the 
expression of some factors, namely interleukin 6, has also been investigated with the aim of 
improving tissue growth in bioreactors. In 2010, Wang P et al demonstrated how high levels 
of interleukin – 6 have been found in osteoarthritic cartilage and suggested that inhibiting 
this expression may improve cartilage construct culturing in bioreactors (146).  
6. Challenges for the clinical application of regenerated cartilage 
Over the past two decades the amount of data on cartilage tissue engineering strategies has 
risen exponentially. There is now a plethora of exciting in vitro data evaluating 
chondrocyte/MSC seeded biomaterial constructs. Perhaps one of the most iconic studies in 
cartilage tissue engineering research was produced by Cao and Vacanti’s group in 1996, 
when they implanted an auricular shaped cartilaginous construct onto the back of a mouse 
(24). Even with all the advancements in stem cell and biomaterial technology, the invention 
of various bioreactor systems, little has progressed beyond this scientifically historic event. 
Most constructs fail to develop beyond immature, inflexible neocartilage that lacks the 
durability essential to most clinical applications.  
There are a number of reasons for the stagnation in translation to clinical practice. Many of 
which have been discussed throughout the course of this chapter. On a cellular level, 
reasons for poor research outcomes could also include;  (i)Regenerative cells being lost 
through leakage of the cell suspension (149), (ii) inflammatory cytokine, matrix 
metalloproteinase, nitric oxide mediated apoptosis and necrosis at the site of injury. These 
biochemical factors are released as part of the normal inflammatory and wound healing 
process, especially at the interface between host and repair tissue, which can also adversely 
affect biointegration of the neo tissue. The use of anti-apoptotic factors would be crucial in 
maintaining cell numbers but also in creating a favourable environment for biointegration 
(5). The poor migration capacity of chondrocytes could also be responsible for hampered 
infiltration of repair tissue into the host environment. The naturally slow rates of 
chondrocyte ECM production could slow down integration as well disparities in the 
organization of neocartilage matrix compared with the zonal arrangement of native cartilage 
tissue (69;84).  Dedifferentiation of chondrogenic cells is another problem, and is likely 
responsible to the highly fibrotic nature of neocartilage produced, suggesting that over time, 
cells may have dedifferentiated into fibroblasts or incompletely differentiated into 
chondrocytes. Solutions would include seeding with cells that have been fully differentiated 
in vitro, but again there would be difficulties with motility, proliferation and shelf life.  
In addition to the cell based scientific problems associated with cartilage engineering tissue 
research, ambiguous regulatory guidelines currently hamper the flow of development from 
laboratories to clinics and operating theatres. The EU regulation on Advanced Therapy 
Medicinal Products (ATMP), which includes tissue engineered constructs, is still in its 
infancy having only been formally established in December 2008. ATMP regulation aims to 
proved a coherent and tailored framework for tissue engineered products, however the 
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nascent and fast growing nature of the tissue engineering field means that there is a constant 
threat of irrelevance over the guidelines developed under this regulation. Tissue 
engineering technology needs to reach a level of quality controlled and quality assured 
reproducibility to allow for not just clinical efficiency, but also commercial viability. 
Methods of stem cell differentiation, cell seeding, scaffold fabrication and bioreactor 
development/implementation all need to be governed by Good Manufacturing Practice 
(GMP). Additionally, methods of commercialization ought to be better established, to avoid 
uncertainty in the markets, improve regulatory approval and clinical uptake/use (103).  
7. References 
[1] Akman, A. C., Seda, T. R., Gumusderelioglu, M., Nohutcu, R. M. Bone morphogenetic 
protein-6-loaded chitosan scaffolds enhance the osteoblastic characteristics of 
MC3T3-E1 cells. Artif. Organs 34: 65-74, 2010. 
[2] Alenghat, F. J., Ingber, D. E. Mechanotransduction: all signals point to cytoskeleton, 
matrix, and integrins. Sci. STKE. 2002: e6, 2002. 
[3] Alhadlaq, A., Mao, J. J. Tissue-engineered neogenesis of human-shaped mandibular 
condyle from rat mesenchymal stem cells. J Dent. Res 82: 951-956, 2003. 
4. Angele, P., Schumann, D., Angele, M. et al. Cyclic, mechanical compression enhances 
chondrogenesis of mesenchymal progenitor cells in tissue engineering scaffolds. 
Biorheology 41: 335-346, 2004. 
[5] Archer, C. W., Redman, S., Khan, I., Bishop, J., Richardson, K. Enhancing tissue 
integration in cartilage repair procedures. J Anat. 209: 481-493, 2006. 
[6] Arnold, M., Hirschfeld-Warneken, V. C., Lohmuller, T. et al. Induction of cell 
polarization and migration by a gradient of nanoscale variations in adhesive ligand 
spacing. Nano. Lett. 8: 2063-2069, 2008. 
[7] Arokoski, J. P., Jurvelin, J. S., Vaatainen, U., Helminen, H. J. Normal and pathological 
adaptations of articular cartilage to joint loading. Scand. J Med. Sci. Sports 10: 186-
198, 2000. 
[8] Atala, A. Engineering tissues, organs and cells. J Tissue Eng Regen. Med 1: 83-96, 2007. 
[9] Augello, A., Kurth, T. B., De Bari, C. Mesenchymal stem cells: a perspective from in vitro 
cultures to in vivo migration and niches. Eur. Cell Mater. 20: 121-133, 2010. 
[10] Baek, C. H., Ko, Y. J. Characteristics of tissue-engineered cartilage on macroporous 
biodegradable PLGA scaffold. Laryngoscope 116: 1829-1834, 2006. 
[11] Barry, F., Boynton, R. E., Liu, B., Murphy, J. M. Chondrogenic differentiation of 
mesenchymal stem cells from bone marrow: differentiation-dependent gene 
expression of matrix components. Exp. Cell Res 268: 189-200, 2001. 
[12] Bentley, G., Biant, L. C., Carrington, R. W. et al. A prospective, randomised comparison 
of autologous chondrocyte implantation versus mosaicplasty for osteochondral 
defects in the knee. J Bone Joint Surg Br 85: 223-230, 2003. 
[13] Biggs, M. J., Richards, R. G., Gadegaard, N., Wilkinson, C. D., Dalby, M. J. Regulation of 
implant surface cell adhesion: characterization and quantification of S-phase 
primary osteoblast adhesions on biomimetic nanoscale substrates. J Orthop Res 25: 
273-282, 2007. 
[14] Bouchet, B. Y., Colon, M., Polotsky, A., Shikani, A. H., Hungerford, D. S., Frondoza, C. 
G. Beta-1 integrin expression by human nasal chondrocytes in microcarrier spinner 
culture. J Biomed Mater Res 52: 716-724, 2000. 
  
Tissue Engineering for Tissue and Organ Regeneration 
 
258 
[15] Breuls, R. G., Jiya, T. U., Smit, T. H. Scaffold stiffness influences cell behavior: 
opportunities for skeletal tissue engineering. Open. Orthop J 2: 103-109, 2008. 
[16] Brittberg, M., Lindahl, A., Nilsson, A., Ohlsson, C., Isaksson, O., Peterson, L. Treatment 
of deep cartilage defects in the knee with autologous chondrocyte transplantation. 
N. Engl. J Med. 331: 889-895, 1994. 
[17] Brochhausen, C., Lehmann, M., Zehbe, R. et al. [Tissue engineering of cartilage and 
bone : growth factors and signaling molecules]. Orthopade 38: 1053-1062, 2009. 
[18] Brown, A. N., Kim, B. S., Alsberg, E., Mooney, D. J. Combining chondrocytes and 
smooth muscle cells to engineer hybrid soft tissue constructs. Tissue Eng 6: 297-305, 
2000. 
[19] Brun, P., Dickinson, S. C., Zavan, B., Cortivo, R., Hollander, A. P., Abatangelo, G. 
Characteristics of repair tissue in second-look and third-look biopsies from patients 
treated with engineered cartilage: relationship to symptomatology and time after 
implantation. Arthritis Res Ther. 10: R132, 2008. 
[20] Buckwalter, J. A., Mankin, H. J. Articular cartilage: tissue design and chondrocyte-
matrix interactions. Instr. Course Lect. 47: 477-486, 1998. 
[21] Buckwalter, J. A., Mankin, H. J. Articular cartilage: degeneration and osteoarthritis, 
repair, regeneration, and transplantation. Instr. Course Lect. 47: 487-504, 1998. 
[22] Cai, D. Z., Zeng, C., Quan, D. P. et al. Biodegradable chitosan scaffolds containing 
microspheres as carriers for controlled transforming growth factor-beta1 delivery 
for cartilage tissue engineering. Chin Med. J (Engl. ) 120: 197-203, 2007. 
[23] Campbell, J. J., Lee, D. A., Bader, D. L. Dynamic compressive strain influences 
chondrogenic gene expression in human mesenchymal stem cells. Biorheology 43: 
455-470, 2006. 
[24] Cao, Y., Vacanti, J. P., Paige, K. T., Upton, J., Vacanti, C. A. Transplantation of 
chondrocytes utilizing a polymer-cell construct to produce tissue-engineered 
cartilage in the shape of a human ear. Plast. Reconstr. Surg 100: 297-302, 1997. 
[25] Carlberg, A. L., Pucci, B., Rallapalli, R., Tuan, R. S., Hall, D. J. Efficient chondrogenic 
differentiation of mesenchymal cells in micromass culture by retroviral gene 
transfer of BMP-2. Differentiation 67: 128-138, 2001. 
[26] Cavalcanti-Adam, E. A., Micoulet, A., Blummel, J., Auernheimer, J., Kessler, H., Spatz, J. 
P. Lateral spacing of integrin ligands influences cell spreading and focal adhesion 
assembly. Eur. J Cell Biol. 85: 219-224, 2006. 
[27] Cavalcanti-Adam, E. A., Tomakidi, P., Bezler, M., Spatz, J. P. Geometric organization of 
the extracellular matrix in the control of integrin-mediated adhesion and cell 
function in osteoblasts. Prog. Orthod. 6: 232-237, 2005. 
[28] Cavallo, C., Desando, G., Facchini, A., Grigolo, B. Chondrocytes from patients with 
osteoarthritis express typical extracellular matrix molecules once grown onto a 
three-dimensional hyaluronan-based scaffold. J Biomed Mater Res A 93: 86-95, 2010. 
[29] Chen, W. H., Lai, M. T., Wu, A. T. et al. In vitro stage-specific chondrogenesis of 
mesenchymal stem cells committed to chondrocytes. Arthritis Rheum. 60: 450-459, 
2009. 
[30] Chia, S. H., Homicz, M. R., Schumacher, B. L. et al. Characterization of human nasal 
septal chondrocytes cultured in alginate. J Am. Coll. Surg 200: 691-704, 2005. 
 
Cartilage Tissue Engineering: the Application of Nanomaterials and Stem Cell Technology 
 
259 
[31] Chong, E. J., Phan, T. T., Lim, I. J. et al. Evaluation of electrospun PCL/gelatin 
nanofibrous scaffold for wound healing and layered dermal reconstitution. Acta 
Biomater. 3: 321-330, 2007. 
[32] Chung, C., Burdick, J. A. Engineering cartilage tissue. Adv. Drug Deliv. Rev. 60: 243-262, 
2008. 
[33] Chung, C., Burdick, J. A. Influence of three-dimensional hyaluronic acid 
microenvironments on mesenchymal stem cell chondrogenesis. Tissue Eng Part A 
15: 243-254, 2009. 
[34] Curcio, E., Macchiarini, P., De, B. L. Oxygen mass transfer in a human tissue-engineered 
trachea. Biomaterials 31: 5131-5136, 2010. 
[35] Curtis, A. S., Dalby, M., Gadegaard, N. Cell signaling arising from nanotopography: 
implications for nanomedical devices. Nanomedicine. (Lond) 1: 67-72, 2006. 
[36] Curtis, A. S., Gadegaard, N., Dalby, M. J., Riehle, M. O., Wilkinson, C. D., Aitchison, G. 
Cells react to nanoscale order and symmetry in their surroundings. IEEE Trans. 
Nanobioscience. 3: 61-65, 2004. 
[37] Czyz, J., Wobus, A. Embryonic stem cell differentiation: the role of extracellular factors. 
Differentiation 68: 167-174, 2001. 
[38] Dai, W., Kawazoe, N., Lin, X., Dong, J., Chen, G. The influence of structural design of 
PLGA/collagen hybrid scaffolds in cartilage tissue engineering. Biomaterials 31: 
2141-2152, 2010. 
[39] Dalby, M. J., Gadegaard, N., Tare, R. et al. The control of human mesenchymal cell 
differentiation using nanoscale symmetry and disorder. Nat. Mater 6: 997-1003, 
2007. 
[40] Dalby, M. J., Giannaras, D., Riehle, M. O., Gadegaard, N., Affrossman, S., Curtis, A. S. 
Rapid fibroblast adhesion to 27nm high polymer demixed nano-topography. 
Biomaterials 25: 77-83, 2004. 
[41] Dalby, M. J., Riehle, M. O., Sutherland, D. S., Agheli, H., Curtis, A. S. Use of 
nanotopography to study mechanotransduction in fibroblasts--methods and 
perspectives. Eur. J Cell Biol. 83: 159-169, 2004. 
[42] Darling, E. M., Athanasiou, K. A. Rapid phenotypic changes in passaged articular 
chondrocyte subpopulations. J Orthop Res 23: 425-432, 2005. 
[43] Das, R. H., van Osch, G. J., Kreukniet, M., Oostra, J., Weinans, H., Jahr, H. Effects of 
individual control of pH and hypoxia in chondrocyte culture. J Orthop Res 28: 537-
545, 2010. 
[44] Datta, N., Holtorf, H. L., Sikavitsas, V. I., Jansen, J. A., Mikos, A. G. Effect of bone 
extracellular matrix synthesized in vitro on the osteoblastic differentiation of 
marrow stromal cells. Biomaterials 26: 971-977, 2005. 
[45] Davidson, D., Blanc, A., Filion, D. et al. Fibroblast growth factor (FGF) 18 signals 
through FGF receptor 3 to promote chondrogenesis. J Biol. Chem. 280: 20509-20515, 
2005. 
[46] DeLise, A. M., Fischer, L., Tuan, R. S. Cellular interactions and signaling in cartilage 
development. Osteoarthritis. Cartilage. 8: 309-334, 2000. 
[47] Denker, A. E., Nicoll, S. B., Tuan, R. S. Formation of cartilage-like spheroids by 
micromass cultures of murine C3H10T1/2 cells upon treatment with transforming 
growth factor-beta 1. Differentiation 59: 25-34, 1995. 
  
Tissue Engineering for Tissue and Organ Regeneration 
 
260 
[48] Discher, D. E., Janmey, P., Wang, Y. L. Tissue cells feel and respond to the stiffness of 
their substrate. Science 310: 1139-1143, 2005. 
[49] Dobratz, E. J., Kim, S. W., Voglewede, A., Park, S. S. Injectable cartilage: using alginate 
and human chondrocytes. Arch. Facial. Plast. Surg 11: 40-47, 2009. 
[50] Elder, B. D., Athanasiou, K. A. Systematic assessment of growth factor treatment on 
biochemical and biomechanical properties of engineered articular cartilage 
constructs. Osteoarthritis. Cartilage. 17: 114-123, 2009. 
[51] Engler, A. J., Rehfeldt, F., Sen, S., Discher, D. E. Microtissue elasticity: measurements by 
atomic force microscopy and its influence on cell differentiation. Methods Cell Biol. 
83: 521-545, 2007. 
[52] Engler, A. J., Sen, S., Sweeney, H. L., Discher, D. E. Matrix elasticity directs stem cell 
lineage specification. Cell 126: 677-689, 2006. 
[53] Ergun, C., Liu, H., Webster, T. J. Osteoblast adhesion on novel machinable calcium 
phosphate/lanthanum phosphate composites for orthopedic applications. J Biomed 
Mater Res A 89: 727-733, 2009. 
[54] Forgacs, G., Yook, S. H., Janmey, P. A., Jeong, H., Burd, C. G. Role of the cytoskeleton in 
signaling networks. J Cell Sci. 117: 2769-2775, 2004. 
[55] Francioli, S. E., Martin, I., Sie, C. P. et al. Growth factors for clinical-scale expansion of 
human articular chondrocytes: relevance for automated bioreactor systems. Tissue 
Eng 13: 1227-1234, 2007. 
[56] Freed, L. E., Martin, I., Vunjak-Novakovic, G. Frontiers in tissue engineering. In vitro 
modulation of chondrogenesis. Clin. Orthop Relat Res S46-S58, 1999. 
[57] Freed, L. E., Vunjak-Novakovic, G., Langer, R. Cultivation of cell-polymer cartilage 
implants in bioreactors. J Cell Biochem. 51: 257-264, 1993. 
[58] Fuchs, J. R., Hannouche, D., Terada, S., Vacanti, J. P., Fauza, D. O. Fetal tracheal 
augmentation with cartilage engineered from bone marrow-derived mesenchymal 
progenitor cells. J Pediatr. Surg 38: 984-987, 2003. 
[59] Gabay, O., Sanchez, C., Taboas, J. M. Update in cartilage bio-engineering. Joint Bone 
Spine 77: 283-286, 2010. 
[60] Goldring, M. B., Tsuchimochi, K., Ijiri, K. The control of chondrogenesis. J Cell Biochem. 
97: 33-44, 2006. 
[61] Griffon, D. J., Sedighi, M. R., Schaeffer, D. V., Eurell, J. A., Johnson, A. L. Chitosan 
scaffolds: interconnective pore size and cartilage engineering. Acta Biomater. 2: 313-
320, 2006. 
[62] Grodzinsky, A. J., Levenston, M. E., Jin, M., Frank, E. H. Cartilage tissue remodeling in 
response to mechanical forces. Annu. Rev. Biomed Eng 2: 691-713, 2000. 
[63] Hanawa, T., Kon, M., Ukai, H., Murakami, K., Miyamoto, Y., Asaoka, K. Surface 
modifications of titanium in calcium-ion-containing solutions. J Biomed Mater Res 
34: 273-278, 1997. 
[64] Hildner, F., Albrecht, C., Gabriel, C., Redl, H., van, G. M. State of the art and future 
perspectives of articular cartilage regeneration: a focus on adipose-derived stem 
cells and platelet-derived products. J Tissue Eng Regen. Med. 2011. 
[65] Hirschfeld-Warneken, V. C., Arnold, M., Cavalcanti-Adam, A., Lopez-Garcia, M., 
Kessler, H., Spatz, J. P. Cell adhesion and polarisation on molecularly defined 
spacing gradient surfaces of cyclic RGDfK peptide patches. Eur. J Cell Biol. 87: 743-
750, 2008. 
 
Cartilage Tissue Engineering: the Application of Nanomaterials and Stem Cell Technology 
 
261 
[66] Horas, U., Pelinkovic, D., Herr, G., Aigner, T., Schnettler, R. Autologous chondrocyte 
implantation and osteochondral cylinder transplantation in cartilage repair of the 
knee joint. A prospective, comparative trial. J Bone Joint Surg Am. 85-A: 185-192, 
2003. 
[67] Huang, A. H., Farrell, M. J., Mauck, R. L. Mechanics and mechanobiology of 
mesenchymal stem cell-based engineered cartilage. J Biomech. 43: 128-136, 2010. 
[68] Huang, A. H., Stein, A., Tuan, R. S., Mauck, R. L. Transient exposure to transforming 
growth factor beta 3 improves the mechanical properties of mesenchymal stem cell-
laden cartilage constructs in a density-dependent manner. Tissue Eng Part A 15: 
3461-3472, 2009. 
[69] Hunter, C. J., Levenston, M. E. Maturation and integration of tissue-engineered 
cartilages within an in vitro defect repair model. Tissue Eng 10: 736-746, 2004. 
[70] Hunziker, E. B. Mechanism of longitudinal bone growth and its regulation by growth 
plate chondrocytes. Microsc. Res Tech. 28: 505-519, 1994. 
[71] Huo, F., Zheng, Z., Zheng, G., Giam, L. R., Zhang, H., Mirkin, C. A. Polymer pen 
lithography. Science 321: 1658-1660, 2008. 
[72] Indrawattana, N., Chen, G., Tadokoro, M. et al. Growth factor combination for 
chondrogenic induction from human mesenchymal stem cell. Biochem. Biophys. Res. 
Commun. 320: 914-919, 2004. 
[73] Indrawattana, N., Chen, G., Tadokoro, M. et al. Growth factor combination for 
chondrogenic induction from human mesenchymal stem cell. Biochem. Biophys. Res. 
Commun. 320: 914-919, 2004. 
[74] Johnstone, B., Hering, T. M., Caplan, A. I., Goldberg, V. M., Yoo, J. U. In vitro 
chondrogenesis of bone marrow-derived mesenchymal progenitor cells. Exp. Cell 
Res 238: 265-272, 1998. 
[75] Kang, S. W., Jeon, O., Kim, B. S. Poly(lactic-co-glycolic acid) microspheres as an 
injectable scaffold for cartilage tissue engineering. Tissue Eng 11: 438-447, 2005. 
[76] Kay, S., Thapa, A., Haberstroh, K. M., Webster, T. J. Nanostructured 
polymer/nanophase ceramic composites enhance osteoblast and chondrocyte 
adhesion. Tissue Eng 8: 753-761, 2002. 
[77] Kayakabe, M., Tsutsumi, S., Watanabe, H., Kato, Y., Takagishi, K. Transplantation of 
autologous rabbit BM-derived mesenchymal stromal cells embedded in hyaluronic 
acid gel sponge into osteochondral defects of the knee. Cytotherapy. 8: 343-353, 2006. 
[78] Kessler, M. W., Grande, D. A. Tissue engineering and cartilage. Organogenesis. 4: 28-32, 
2008. 
[79] Khang, D., Kim, S. Y., Liu-Snyder, P., Palmore, G. T., Durbin, S. M., Webster, T. J. 
Enhanced fibronectin adsorption on carbon nanotube/poly(carbonate) urethane: 
independent role of surface nano-roughness and associated surface energy. 
Biomaterials 28: 4756-4768, 2007. 
[80] Khang, D., Lu, J., Yao, C., Haberstroh, K. M., Webster, T. J. The role of nanometer and 
sub-micron surface features on vascular and bone cell adhesion on titanium. 
Biomaterials 29: 970-983, 2008. 
[81] Khang, D., Sato, M., Price, R. L., Ribbe, A. E., Webster, T. J. Selective adhesion and 
mineral deposition by osteoblasts on carbon nanofiber patterns. Int. J Nanomedicine. 
1: 65-72, 2006. 
  
Tissue Engineering for Tissue and Organ Regeneration 
 
262 
[82] Kim, H. J., Lee, J. H., Im, G. I. Chondrogenesis using mesenchymal stem cells and PCL 
scaffolds. J Biomed Mater Res A 92: 659-666, 2010. 
[83] Kim, M. K., Choi, S. W., Kim, S. R., Oh, I. S., Won, M. H. Autologous chondrocyte 
implantation in the knee using fibrin. Knee Surg Sports Traumatol Arthrosc. 18: 528-
534, 2010. 
[84] Klein, T. J., Schumacher, B. L., Schmidt, T. A. et al. Tissue engineering of stratified 
articular cartilage from chondrocyte subpopulations. Osteoarthritis. Cartilage. 11: 
595-602, 2003. 
[85] Knabe, C., Berger, G., Gildenhaar, R., Klar, F., Zreiqat, H. The modulation of 
osteogenesis in vitro by calcium titanium phosphate coatings. Biomaterials 25: 4911-
4919, 2004. 
[86] Korossis, S. A., Wilcox, H. E., Watterson, K. G., Kearney, J. N., Ingham, E., Fisher, J. In-
vitro assessment of the functional performance of the decellularized intact porcine 
aortic root. J Heart Valve Dis. 14: 408-421, 2005. 
[87] Kreuz, P. C., Steinwachs, M. R., Erggelet, C. et al. Results after microfracture of full-
thickness chondral defects in different compartments in the knee. Osteoarthritis. 
Cartilage. 14: 1119-1125, 2006. 
[88] Kunzler, T. P., Drobek, T., Schuler, M., Spencer, N. D. Systematic study of osteoblast 
and fibroblast response to roughness by means of surface-morphology gradients. 
Biomaterials 28: 2175-2182, 2007. 
[89] Kunzler, T. P., Huwiler, C., Drobek, T., Voros, J., Spencer, N. D. Systematic study of 
osteoblast response to nanotopography by means of nanoparticle-density 
gradients. Biomaterials 28: 5000-5006, 2007. 
[90] Kupcsik, L., Stoddart, M. J., Li, Z., Benneker, L. M., Alini, M. Improving 
chondrogenesis: potential and limitations of SOX9 gene transfer and mechanical 
stimulation for cartilage tissue engineering. Tissue Eng Part A 16: 1845-1855, 2010. 
[91] Lee, H. J., Choi, B. H., Min, B. H., Park, S. R. Low-intensity ultrasound inhibits apoptosis 
and enhances viability of human mesenchymal stem cells in three-dimensional 
alginate culture during chondrogenic differentiation. Tissue Eng 13: 1049-1057, 2007. 
[92] Lefebvre, V., Smits, P. Transcriptional control of chondrocyte fate and differentiation. 
Birth Defects Res C. Embryo. Today 75: 200-212, 2005. 
[93] Lehnert, D., Wehrle-Haller, B., David, C. et al. Cell behaviour on micropatterned 
substrata: limits of extracellular matrix geometry for spreading and adhesion. J Cell 
Sci. 117: 41-52, 2004. 
[94] Levy, A. S., Lohnes, J., Sculley, S., LeCroy, M., Garrett, W. Chondral delamination of the 
knee in soccer players. Am. J Sports Med. 24: 634-639, 1996. 
[95] Li, W. J., Tuli, R., Huang, X., Laquerriere, P., Tuan, R. S. Multilineage differentiation of 
human mesenchymal stem cells in a three-dimensional nanofibrous scaffold. 
Biomaterials 26: 5158-5166, 2005. 
[96] Lieberman, J. R., Daluiski, A., Einhorn, T. A. The role of growth factors in the repair of 
bone. Biology and clinical applications. J Bone Joint Surg Am. 84-A: 1032-1044, 2002. 
[97] Lin, Y. J., Yen, C. N., Hu, Y. C., Wu, Y. C., Liao, C. J., Chu, I. M. Chondrocytes culture in 
three-dimensional porous alginate scaffolds enhanced cell proliferation, matrix 
synthesis and gene expression. J Biomed Mater Res A 88: 23-33, 2009. 
 
Cartilage Tissue Engineering: the Application of Nanomaterials and Stem Cell Technology 
 
263 
[98] Longobardi, L., O'Rear, L., Aakula, S. et al. Effect of IGF-I in the chondrogenesis of bone 
marrow mesenchymal stem cells in the presence or absence of TGF-beta signaling. 
J. Bone Miner. Res. 21: 626-636, 2006. 
[99] Lu, H. H., Subramony, S. D., Boushell, M. K., Zhang, X. Tissue engineering strategies for 
the regeneration of orthopedic interfaces. Ann. Biomed Eng 38: 2142-2154, 2010. 
[100] Lu, J., Rao, M. P., MacDonald, N. C., Khang, D., Webster, T. J. Improved endothelial 
cell adhesion and proliferation on patterned titanium surfaces with rationally 
designed, micrometer to nanometer features. Acta Biomater. 4: 192-201, 2008. 
[101] Lyons, K. M., Pelton, R. W., Hogan, B. L. Organogenesis and pattern formation in the 
mouse: RNA distribution patterns suggest a role for bone morphogenetic protein-
2A (BMP-2A). Development 109: 833-844, 1990. 
[102] Marlovits, S., Zeller, P., Singer, P., Resinger, C., Vecsei, V. Cartilage repair: generations 
of autologous chondrocyte transplantation. Eur. J Radiol. 57: 24-31, 2006. 
[103] Martin, I., Smith, T., Wendt, D. Bioreactor-based roadmap for the translation of tissue 
engineering strategies into clinical products. Trends Biotechnol. 27: 495-502, 2009. 
[104] Martin, I., Wendt, D., Heberer, M. The role of bioreactors in tissue engineering. Trends 
Biotechnol. 22: 80-86, 2004. 
[105] Martin, Y., Vermette, P. Bioreactors for tissue mass culture: design, characterization, 
and recent advances. Biomaterials 26: 7481-7503, 2005. 
[106] Mehlhorn, A. T., Niemeyer, P., Kaiser, S. et al. Differential expression pattern of 
extracellular matrix molecules during chondrogenesis of mesenchymal stem cells 
from bone marrow and adipose tissue. Tissue Eng 12: 2853-2862, 2006. 
[107] Mehlhorn, A. T., Schmal, H., Kaiser, S. et al. Mesenchymal stem cells maintain TGF-
beta-mediated chondrogenic phenotype in alginate bead culture. Tissue Eng 12: 
1393-1403, 2006. 
[108] Miller, D. C., Thapa, A., Haberstroh, K. M., Webster, T. J. Endothelial and vascular 
smooth muscle cell function on poly(lactic-co-glycolic acid) with nano-structured 
surface features. Biomaterials 25: 53-61, 2004. 
[109] Mitchell, N., Shepard, N. The resurfacing of adult rabbit articular cartilage by multiple 
perforations through the subchondral bone. J Bone Joint Surg Am. 58: 230-233, 1976. 
[110] Mizuta, H., Kudo, S., Nakamura, E., Otsuka, Y., Takagi, K., Hiraki, Y. Active 
proliferation of mesenchymal cells prior to the chondrogenic repair response in 
rabbit full-thickness defects of articular cartilage. Osteoarthritis. Cartilage. 12: 586-
596, 2004. 
[111] Nicodemus, G. D., Villanueva, I., Bryant, S. J. Mechanical stimulation of TMJ condylar 
chondrocytes encapsulated in PEG hydrogels. J Biomed Mater Res A 83: 323-331, 
2007. 
[112] Pelttari, K., Steck, E., Richter, W. The use of mesenchymal stem cells for 
chondrogenesis. Injury 39 Suppl 1: S58-S65, 2008. 
[113] Peretti, G. M., Pozzi, A., Ballis, R., Deponti, D., Pellacci, F. Current Surgical Options for 
Articular Cartilage Repair. Acta Neurochir. Suppl 108: 213-219, 2011. 
[114] Ragetly, G. R., Slavik, G. J., Cunningham, B. T., Schaeffer, D. J., Griffon, D. J. Cartilage 
tissue engineering on fibrous chitosan scaffolds produced by a replica molding 
technique. J Biomed Mater Res A 93: 46-55, 2010. 
  
Tissue Engineering for Tissue and Organ Regeneration 
 
264 
[115] Raghunath, J., Rollo, J., Sales, K. M., Butler, P. E., Seifalian, A. M. Biomaterials and 
scaffold design: key to tissue-engineering cartilage. Biotechnol. Appl. Biochem. 46: 73-
84, 2007. 
[116] Raghunath, J., Salacinski, H. J., Sales, K. M., Butler, P. E., Seifalian, A. M. Advancing 
cartilage tissue engineering: the application of stem cell technology. Curr. Opin. 
Biotechnol. 16: 503-509, 2005. 
[117] Rahfoth, B., Weisser, J., Sternkopf, F., Aigner, T., von der, M. K., Brauer, R. 
Transplantation of allograft chondrocytes embedded in agarose gel into cartilage 
defects of rabbits. Osteoarthritis. Cartilage. 6: 50-65, 1998. 
[118] Reddi, A. H. Cartilage morphogenetic proteins: role in joint development, 
homoeostasis, and regeneration. Ann. Rheum. Dis. 62 Suppl 2: ii73-ii78, 2003. 
[119] Rehfeldt, F., Engler, A. J., Eckhardt, A., Ahmed, F., Discher, D. E. Cell responses to the 
mechanochemical microenvironment--implications for regenerative medicine and 
drug delivery. Adv. Drug Deliv. Rev. 59: 1329-1339, 2007. 
[120] Roberts, S., McCall, I. W., Darby, A. J. et al. Autologous chondrocyte implantation for 
cartilage repair: monitoring its success by magnetic resonance imaging and 
histology. Arthritis Res Ther. 5: R60-R73, 2003. 
[121] Robertson, W. W., Jr. Newest knowledge of the growth plate. Clin. Orthop Relat Res 
270-278, 1990. 
[122] Ronziere, M. C., Perrier, E., Mallein-Gerin, F., Freyria, A. M. Chondrogenic potential of 
bone marrow- and adipose tissue-derived adult human mesenchymal stem cells. 
Biomed. Mater. Eng 20: 145-158, 2010. 
[123] Saini, S., Wick, T. M. Effect of low oxygen tension on tissue-engineered cartilage 
construct development in the concentric cylinder bioreactor. Tissue Eng 10: 825-832, 
2004. 
[124] Sakimura, K., Matsumoto, T., Miyamoto, C., Osaki, M., Shindo, H. Effects of insulin-
like growth factor I on transforming growth factor beta1 induced chondrogenesis of 
synovium-derived mesenchymal stem cells cultured in a polyglycolic acid scaffold. 
Cells Tissues. Organs 183: 55-61, 2006. 
[125] Salinas, C. N., Anseth, K. S. The enhancement of chondrogenic differentiation of 
human mesenchymal stem cells by enzymatically regulated RGD functionalities. 
Biomaterials 29: 2370-2377, 2008. 
[126] Schmidt, R. C., Healy, K. E. Controlling biological interfaces on the nanometer length 
scale. J Biomed Mater Res A 90: 1252-1261, 2009. 
[127] Schmitt, B., Ringe, J., Haupl, T. et al. BMP2 initiates chondrogenic lineage development 
of adult human mesenchymal stem cells in high-density culture. Differentiation 71: 
567-577, 2003. 
[128] Schnabel, M., Marlovits, S., Eckhoff, G. et al. Dedifferentiation-associated changes in 
morphology and gene expression in primary human articular chondrocytes in cell 
culture. Osteoarthritis. Cartilage. 10: 62-70, 2002. 
[129] Schulz, R. M., Bader, A. Cartilage tissue engineering and bioreactor systems for the 
cultivation and stimulation of chondrocytes. Eur. Biophys. J 36: 539-568, 2007. 
[130] Schumann, D., Kujat, R., Nerlich, M., Angele, P. Mechanobiological conditioning of 
stem cells for cartilage tissue engineering. Biomed Mater Eng 16: S37-S52, 2006. 
 
Cartilage Tissue Engineering: the Application of Nanomaterials and Stem Cell Technology 
 
265 
[131] Sha'ban, M., Kim, S. H., Idrus, R. B., Khang, G. Fibrin and poly(lactic-co-glycolic acid) 
hybrid scaffold promotes early chondrogenesis of articular chondrocytes: an in 
vitro study. J Orthop Surg Res 3: 17, 2008. 
[132] Shekaran, A., Garcia, A. J. Extracellular matrix-mimetic adhesive biomaterials for bone 
repair. J Biomed Mater Res A 2010. 
[133] Shieh, S. J., Terada, S., Vacanti, J. P. Tissue engineering auricular reconstruction: in 
vitro and in vivo studies. Biomaterials 25: 1545-1557, 2004. 
[134] Shirasawa, S., Sekiya, I., Sakaguchi, Y., Yagishita, K., Ichinose, S., Muneta, T. In vitro 
chondrogenesis of human synovium-derived mesenchymal stem cells: optimal 
condition and comparison with bone marrow-derived cells. J. Cell Biochem. 97: 84-
97, 2006. 
[135] Smith, R. L., Carter, D. R., Schurman, D. J. Pressure and shear differentially alter 
human articular chondrocyte metabolism: a review. Clin. Orthop Relat Res S89-S95, 
2004. 
[136] Stading, M., Langer, R. Mechanical shear properties of cell-polymer cartilage 
constructs. Tissue Eng 5: 241-250, 1999. 
[137] Sterodimas, A., De Faria, J., Correa, W. E., Pitanguy, I. Tissue engineering in plastic 
surgery: an up-to-date review of the current literature. Ann. Plast. Surg. 62: 97-103, 
2009. 
[138] Takagi, J., Springer, T. A. Integrin activation and structural rearrangement. Immunol. 
Rev. 186: 141-163, 2002. 
[139] Tarng, Y. W., Casper, M. E., Fitzsimmons, J. S. et al. Directional fluid flow enhances in 
vitro periosteal tissue growth and chondrogenesis on poly-epsilon-caprolactone 
scaffolds. J Biomed Mater Res A 95: 156-163, 2010. 
[140] Temenoff, J. S., Mikos, A. G. Review: tissue engineering for regeneration of articular 
cartilage. Biomaterials 21: 431-440, 2000. 
[141] Tins, B. J., McCall, I. W., Takahashi, T. et al. Autologous chondrocyte implantation in 
knee joint: MR imaging and histologic features at 1-year follow-up. Radiology 234: 
501-508, 2005. 
[142] Uematsu, K., Hattori, K., Ishimoto, Y. et al. Cartilage regeneration using mesenchymal 
stem cells and a three-dimensional poly-lactic-glycolic acid (PLGA) scaffold. 
Biomaterials 26: 4273-4279, 2005. 
[143] ves da Silva, M. L., Martins, A., Costa-Pinto, A. R. et al. Chondrogenic differentiation 
of human bone marrow mesenchymal stem cells in chitosan-based scaffolds using a 
flow-perfusion bioreactor. J Tissue Eng Regen. Med. 2010. 
[144] Vinatier, C., Mrugala, D., Jorgensen, C., Guicheux, J., Noel, D. Cartilage engineering: a 
crucial combination of cells, biomaterials and biofactors. Trends Biotechnol. 27: 307-
314, 2009. 
[145] Vunjak-Novakovic, G., Martin, I., Obradovic, B. et al. Bioreactor cultivation conditions 
modulate the composition and mechanical properties of tissue-engineered 
cartilage. J Orthop Res 17: 130-138, 1999. 
[146] Wang, P., Zhu, F., Lee, N. H., Konstantopoulos, K. Shear-induced interleukin-6 
synthesis in chondrocytes: roles of E prostanoid (EP) 2 and EP3 in cAMP/protein 
kinase A- and PI3-K/Akt-dependent NF-kappaB activation. J Biol. Chem. 285: 
24793-24804, 2010. 
  
Tissue Engineering for Tissue and Organ Regeneration 
 
266 
[147] Washburn, N. R., Yamada, K. M., Simon, C. G., Jr., Kennedy, S. B., Amis, E. J. High-
throughput investigation of osteoblast response to polymer crystallinity: influence 
of nanometer-scale roughness on proliferation. Biomaterials 25: 1215-1224, 2004. 
[148] Webster, T. J., Ahn, E. S. Nanostructured biomaterials for tissue engineering bone. Adv. 
Biochem. Eng Biotechnol. 103: 275-308, 2007. 
[149] Wood, J. J., Malek, M. A., Frassica, F. J. et al. Autologous cultured chondrocytes: 
adverse events reported to the United States Food and Drug Administration. J Bone 
Joint Surg Am. 88: 503-507, 2006. 
[150] Wu, S. C., Chang, J. K., Wang, C. K., Wang, G. J., Ho, M. L. Enhancement of 
chondrogenesis of human adipose derived stem cells in a hyaluronan-enriched 
microenvironment. Biomaterials 31: 631-640, 2010. 
[151] Xu, J., Wang, W., Ludeman, M. et al. Chondrogenic differentiation of human 
mesenchymal stem cells in three-dimensional alginate gels. Tissue Eng Part A 14: 
667-680, 2008. 
[152] Yanaga, H., Imai, K., Yanaga, K. Generative Surgery of Cultured Autologous Auricular 
Chondrocytes for Nasal Augmentation. Aesthetic Plast. Surg 2009. 
[153] Yates, K. E., Allemann, F., Glowacki, J. Phenotypic analysis of bovine chondrocytes 
cultured in 3D collagen sponges: effect of serum substitutes. Cell Tissue Bank. 6: 45-
54, 2005. 
[154] Yoo, H. S., Lee, E. A., Yoon, J. J., Park, T. G. Hyaluronic acid modified biodegradable 
scaffolds for cartilage tissue engineering. Biomaterials 26: 1925-1933, 2005. 
[155] Zeltinger, J., Sherwood, J. K., Graham, D. A., Mueller, R., Griffith, L. G. Effect of pore 
size and void fraction on cellular adhesion, proliferation, and matrix deposition. 
Tissue Eng 7: 557-572, 2001. 
[156] Zheng, L., Fan, H. S., Sun, J. et al. Chondrogenic differentiation of mesenchymal stem 
cells induced by collagen-based hydrogel: an in vivo study. J Biomed Mater Res A 93: 
783-792, 2010. 
[157] Zhou, X. Z., Leung, V. Y., Dong, Q. R., Cheung, K. M., Chan, D., Lu, W. W. 
Mesenchymal stem cell-based repair of articular cartilage with polyglycolic acid-
hydroxyapatite biphasic scaffold. Int. J Artif. Organs 31: 480-489, 2008. 
[158] Zhu, L., Wu, Y., Jiang, H., Liu, W., Cao, Y., Zhou, G. Engineered cartilage with internal 
porous high-density polyethylene support from bone marrow stromal cells: A 
preliminary study in nude mice. Br J Oral Maxillofac Surg 2009. 
[159] Zuk, P. A., Zhu, M., Mizuno, H. et al. Multilineage cells from human adipose tissue: 
implications for cell-based therapies. Tissue Eng 7: 211-228, 2001. 
[160] Zwingmann, J., Mehlhorn, A. T., Sudkamp, N., Stark, B., Dauner, M., Schmal, H. 
Chondrogenic differentiation of human articular chondrocytes differs in 
biodegradable PGA/PLA scaffolds. Tissue Eng 13: 2335-2343, 2007. 
 
Part 5 
Hollow Organs 
 
13 
Bioengineering of Colo-Rectal Tissue 
Roman Inglin, Lukas Brügger, Daniel Candinas and Daniel Eberli 
Department of Visceral Surgery and Medicine, Bern University Hospital and  
Labor for Tissue Engineering and Stem Cell Therapy, Clinic of Urology,  
University Hospital Zurich 
Switzerland 
1. Introduction 
About 30 years ago, first reports have appeared in the literature on successful substitution of 
gastrointestinal wall defects by synthetic materials. An either absorbable or non-absorbable 
polymer patch sutured into a full-thickness wall defect of stomach, small intestine, and even 
colon of different animal species generally showed to be initially integrated and overgrown 
by neomucosa, and eventually absorbed or intra- or extraluminally extruded (Thompson et 
al., 1986; Harmon et al., 1979; Contieri et al., 1980; Smyrnis, 1982). Though this approach has 
been revived in several publications reporting good results (Oh et al., 2002; Uzun et al., 
2010), treatment of damaged bowel by implantation of synthetic material has never gained 
general acceptance in the surgical community, and is, therefore, out of common clinical 
practice. This may be due to the general concern regarding the use of synthetic material in 
tissue which is naturally colonized with bacteria, as it is particularly the case in the colon. 
More recently, also natural materials like collagen sponge or acellular matrix have been 
tested for their ability either to support healing of an intestinal wall damage or to entirely 
substitute a full thickness defect. Implantation of patches of these natural biomaterials 
yielded good results with respect to histological and, to some extent, even functional 
reconstitution (Wang et al., 2005; Wang et al., 2003; Demirbilek et al., 2003; Badylak, S. et al., 
2000; Isch et al., 2001; Kajitani et al., 2001; Mutter et al., 1996). As far as concerns the 
interposition of a synthetic or natural scaffold of tubular shape into esophagus or small 
intestine, results are less promising. Poor mucosal regeneration, stricture formation or high 
mortality rate of the experimental animals due to anastomotic leaks were reported, no 
matter whether the implanted biomaterial was synthetic absorbable (Thompson et al., 1986), 
non-absorbable (Fukushima et al., 1983; Watson et al., 1980), or of natural origin (Badylak, S. 
et al., 2000; Badylak, S.F., 2005; Chen & Badylak, 2001). There are no results reported in the 
current literature dealing with implantation of a tubular scaffold into the large intestine. In 
recent years there is a growing effort being done to apply tissue engineering methods for the 
complete, thus tubular, reconstruction of gastrointestinal organs. 
A driving force of the endeavours of gastrointestinal tissue engineering is the intention to 
circumvent transplantation and the associated lifetime need for immunosuppression as the 
sole alternative to the complete absence of the respective organ. Since loss of the entire colon 
is absolutely compatible with life, this is not a condition that would require transplantation, 
indeed. However, total colectomy leads to important changes in enterohepatic circulation, 
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microbiology, and in water and sodium absorption (Papa et al., 1997). Furthermore, a 
considerable number of patients suffer from a deficient or missing anorectal continence 
organ due to intractable neuro-muscular dysfunction, oncological surgery or congenital 
malformation. The impact on patient’s quality of life and the associated health care costs are 
considerable. Substitutes of the anorectal continence organ such as artificial bowel sphincter 
or musculoplasty still go along with a high morbidity and questionable functional results. 
Tissue engineering might have the potential to avoid some of the shortcomings related to 
these devices and reconstruction techniques. However, current gastrointestinal tissue 
engineering is clearly focused on esophagus, stomach and small intestine, whereas research 
on bioengineering of colon is scarce (Penkala & Kim, 2007). In this chapter we will address 
the different approaches that have been taken hithterto, and discuss new ground that might 
be broken to substitute colo-rectal tissue.  
2. Different approaches for colo-rectal tissue engineering 
As a matter of fact, colo-rectal tissue engineering has been struggling for its existence up to 
date. Given that most hollow organs are organized in a similar fashion, consisting of 
epithelium or endothelium on the luminal side surrounded by a collagen rich connective 
tissue and muscle layer, some of the knowledge gained in other fields of hollow organ tissue 
engineering might be successfully applied to bioengineering of large intestine. 
2.1 Biomaterials 
Studies on materials used with intent to bioengineer colonic tissue do not exist. However, in 
an attempt to prevent the feared complication of disruption of an anastomosis (a condition 
where two ends of the colon are sutured together in order to re-establish gastrointestinal 
continuity after resection of a part of the colon) many synthetic or natural biomaterials have 
been tested. Despite encouraging results, these biomaterials have not found their way into 
common clinicial practice yet.  
2.1.1 Synthetic polymers 
Technical aids such as the SBS-tube (Buch et al., 2002), a synthetic compound consisting of 
polyethylene glycol and a mixture of palmitic and stearic acid (nonattached intraluminal 
degradable tube) or Coloshield (Cuilleret et al., 1991), a nondegradable intraluminal Latex or 
silicone tube sewn to the bowel, were developped in order to support or even enhance 
regeneration of colonic tissue during the wound healing process. These synthetic materials 
act through diversion of the intraluminal fecal stream from the zone of the anastomosis 
rather than by exerting a direct promoting effect on the wound healing. Though, they 
showed to decrease anastomotic leakage and dehiscence, complications such as erosion of 
the tube through the bowel wall and obstruction were described(Egozi et al., 1993). Henne-
Bruns and colleagues enwrapped (Henne-Bruns et al., 1990) the anastomosis with 
polyglycolic acid (PGA) meshes. This approach turned out to be associated with motility 
disorders, delayed healing and leakage followed by peritonitis. Admittedly, these materials 
have not been tested for colon tissue engineering purposes. However, given the 
considerable complication rate, they do not qualify for being further assessed in this context. 
Implanted expanded polytetrafluoroethylene (ePTFE) graft (Uzun et al., 2010), or Dacron 
(Contieri et al., 1980) used to cover full thickness wall defects in the colon showed to 
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function as a guide for ingrowing tissue that originated from the wound edges, thus, 
enabling closure of the respective tissue gap. They have nevertheless not been integrated 
into the regenerating tissue, but were eventually rejected. Given the inert nature of their 
surfaces, it remains doubtful whether they were suitable for acting as „real“ tissue 
engineering scaffolds that would facilitate engraftment and promote growth of host tissue 
cells. 
PGA scaffolds are successfully being used for small intestinal tissue engineering (Mooney et 
al., 1994; Sala et al., 2009; Sala et al., 2011). These principles were applied to bioengineering 
of the colon. Grikscheit and colleagues constructed 2-mm thick nonwoven PGA tubes. They 
were then seeded with previously harvested mesenchymal – epithelial cell compounds, 
derived from dissection of autologous full thickness (sigmoid) colon wall and referred to as 
“oragnoid units”, and eventually implanted into the omentum of recipient animals. Within 4 
weeks, these constructs grew to neo-colon tissue that exhibited a mucosal architechture and 
electrophysiological parameters comparable to that of native colon (Grikscheit et al., 2002; 
Grikscheit et al., 2003). A big achievement beyond doubt. However, the so bioengineered 
colon derives from syngeneic tissue. This would currently exclude its use for the treatment 
of patients with diseased autologous donor cells. Furthermore, this technique is 
substantially limited of what concerns customization of size and shape of the 
bioengieneered tissue. Indeed, tissue engineering of organoid units is the creation of a 
premature tissue which has to be further processed in order to become a definite, functional 
organ.  
2.1.2 Natural scaffolds 
Since interests in bowel tissue engineering are focused on small intestine this is the field 
where natural scaffolds have mostly been evaluated. Natural scaffolds are synonymous with 
extracellular matrix (ECM), consisting of interstitial matrix and the basement membrane. 
ECM of different origin have been evaluated for their potential to serve as scaffold for 
regeneration of intestinal tissue. Extensive resection of small bowel followed by 
implantation of lyophilized dura mater was shown to induce neomucosa on the patch, with 
histological characteristics similar to normal. However, the authors stated that although the 
creation of neomucosa on dural patches is feasible and conditions a slight improvement in 
the animal's nutritive status the high perioperative mortality of the experimental animals 
casts its applicability in intestinal tissue engineering into doubt (Hernandez Bermejo et al., 
1993).  
Different natural biomaterials have been studied with respect to their influence on healing 
of colon wall injuries. Small intestinal submucosa (SIS) was shown to be largely successful in 
promoting healing of a 1 cm2 full thickness wall defect in unprepared large bowel and 
serving as a bioscaffold for regeneration of the native colonic tissue (Ueno et al., 2007). 
Another group used as what they referred to as reconstituted connective tissue patches 
consisting of elastin, fibronectin and collagen. Using these patches applied with fibrin 
sealant to the edges of a 1 cm diameter colonic defect, complete reconstitution of the 
mucosal as well as the circular and longitudinal muscle layer after 40 days was obtained. No 
retraction and inflammatory reaction were found, and the patch was slowly resorbed 
(Marescaux et al., 1991). Accordingly, placental-derived tissue matrix applied to a 1.5 x 2.0 
cm parietal whole in the large intestine healed significantly better than fibrin glue repair 
alone (Alam et al., 1998).  
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There is a growing body of evidence that surface characteristics of the biomaterial has a 
determining influence on cell adhesion patterns and the ability to support and maintain 
differentiated phenotypes and their functions. Brown and colleagus demonstrated that three 
different ECMs, including SIS, urinary bladder matrix (UBM) and liver extracellular matrix 
(LECM) displayd distinct surface properties. These differences were reflected in their 
ultrastructure, as demonstrated by scanning electron microscopy (SEM) as well the distinct 
surface pattern of proteins and their fragments. While luminal and abluminal surface 
topography differs in ECM origninating from hollow organs like urinary bladder (UBM) 
or intestine (SIS), such a sidedness could not be observed in ECM of solid organs, like 
LECM (Brown et al., 2010). It remains, however, unclear whether the molecular 
composition or the ultrastructure of these scaffolds determine to a greater extent the 
outcome of the cell-scaffold interaction. The authors suggested that it was likely the 
diverse combination of both the structural and the functional components that accounts 
for the success of ECM based materials in the respective organ system (Barnes et al., 2011). 
Given the aforementioned aspects SIS may appear most suitable for intestinal tissue 
engineering. However, the ideal natural scaffold for colo-rectal constructs has not yet 
been defined. 
2.2 Cells 
Generally, the combination of biomaterial with cells was shown to improve graft integration 
and mucosal regeneration compared to when biomaterial is used alone. Cell seeding has 
been found to induce smooth muscle regeneration with less inflammatory reaction and 
fibroblast ingrowth as well as reduced contraction and shrinkage than is seen in unseeded 
grafts (Oberpenning et al., 1999; Yoo et al., 1998). Cell-cell- and cell-matrix interaction play 
an important role in growth and differentiation of various epithelial cell types, including 
urothelium (Zhang et al., 2004), oral mucosa (Izumi et al., 2003) and intestine (Kalabis et al., 
2003; Rubin, 2007). Furthermore, epithelial and mesenchymal cells (i.e. smooth muscle cells 
[SMCs]) co-cultured on a biomaterial were shown to mutually influence their proliferation 
(Zhang et al., 2000; Baskin et al., 2001; Master et al., 2003). The principle of mesenchymal-
epithelial interaction has also been substantiated in gut tissue (Pinchuk et al., 2010; Kosinski 
et al., 2010; van der Flier & Clevers, 2009; Barker et al., 2008). Apart from that, in vitro 
seeded cells, whether of mesenchymal or epithelial origin, might also function as a place-
holder to facilitate ingrowth of host’s natural epithelium on the biomaterial in vivo. This 
might prevent luminal bacteria from getting into contact with the underlying biomaterial, 
thus avoiding scar tissue formation and contraction of the graft due to infection and 
inflammation. 
Taking into account the layered composition of hollow organs such as large intestine, 
smooth muscle cells and epithelial cells appear to be of pivotal interest for colo-rectal tissue 
engineering. Since particularly culture of intestinal epithelial cells still signifies a 
considerable challenge, alternative epithelial cell sources may keep on being necessary for 
successful colon bioengineering. It is of utmost importance that the cells used for tissue 
engineering do not grow in an uncontrolled fashion. Therefore, neither cancer nor 
immortalized cells qualify for being adopted in this context. On the other hand, primary cell 
cultures and stem cells seem currently to be the most reasonable of available cell sources for 
tissue engineering purposes. 
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2.2.1 Primary cell lines 
2.2.1.1 Smooth muscle cells (SMCs) 
Isolation and culture of SMCs were established in different species and hollow organ 
systems (Nakase et al., 2006; Raghavan et al., 2011; Raghavan et al., 2010a; Zhang et al., 2004; 
Kao et al., 1988). Raghavan and colleagues were able to successfully bioengineer a ring-
shaped SMC construct, that, once subcutaneously implanted remained viable until harvest 
at 28 days. The muscle-ring further maintained its alignment, phenotype as well as some 
physiological properties of SMCs (Raghavan et al., 2010b).  
Very recently, the same research group has co-cocultured SMCs originating from human 
internal anal sphincter with immortomouse fetal enteric neurons, which they eventually 
implanted in mice (Raghavan et al., 2011). This construct was neovascularized after 
implantation without signs of inflammation. The bioengineered muscle showed 
physiological function similar to normal. The cells exhibited a spontaneous myogenic basal 
tone, and adequately respondeded to direct electrical and chemical stimuli, such as 
relaxation after application of vasoactive intestinal peptide, or contraction response to 
cholinergic stimulation with acetylcholine. Such functional bioengineered muscle might be 
incorporated into the concept of a possible tissue engineered ano-rectal continence organ. 
Furthermore, a physiological model of longitudinal smooth muscle tissue was developed 
(Raghavan et al., 2010a). In this model, the SMCs isolated from rabbit sigmoid colon and 
arranged in the longitudinal axis formed a highly aligned cell sheet after being seeded at 
high densities onto laminin-coated Sylgard surfaces with defined wavy microtopographies. 
The so established longitudinal muscle construct not only maintained smooth muscle 
phenotype and characteristics of calcium-dependence, but also electrophysiological 
properties similiar to its archetype. 
2.2.1.2 Colon epithelial cells  
Though long-term cultures of primary colon epithelial cells (CEC) have been described, they 
remain a challenge (Chopra et al., 2010; Bartsch et al., 2004; Booth et al., 1995). Traditionally, 
the method referred to as organ culture was employed to study physiology and intestinal 
lineage outside of an organism. Small intestinal explants of fetal tissue (few mm2 in size) can 
be maintained with normal tissue organization for up to 3 weeks, allowing physiological 
studies on growth, differentiation, and ion transport across the epithelium (Quaroni, 1985; 
Pyke & Gogerly, 1985). On the other hand, adult intestinal mucosa in organ culture 
displayed an intense regenerative activity following an initial phase of epithelial cell loss 
(Ferland & Hugon, 1979; Moorghen et al., 1996). Using adjuncts like embedding on collagen 
gel or addition of promoting factors to the medium enabled maintaining viable tissue in 
organ culture for up to 28 days (Ootani et al., 2009). Yet, since organ culture techniques do 
not allow propagation of a specific cell (i.e. epithelial) lineage, it has limited appeal in tissue 
engineering applications. Attempts to generate epithelial cell cultures originating from 
passaged outgrowths of small tissue explants did not work well for intestinal mucosa 
(Chopra et al., 2010).  
Tissue dissociation approaches using chelating and/or proteolytic enzymes appear to 
qualify better for bioengineering purposes, since specific cell lines can be obtained, held in 
culture, and successfully passaged. However, certain prerequisites have to be followed if 
culture of intestinal epithelial cells should be fruitful. After preparation with the generally 
used chelating agent ethylenediaminetetraacetic acid (EDTA), colonic epithelial cells 
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normally do not attach to the unprepared plastic dish and rapidly degenerate (Deveney et 
al., 1996). This is presumably due to the disruption of extracellular matrix molecules that 
normally would facilitate cell-cell and cell-matrix interaction. These epithelial cells much 
more require plating on a suitable substrate like collagen matrix or a fibroblast feeder layer, 
whether chemically pretreated or not, to prevent apoptosis and allow cells to replicate 
(Kalabis et al., 2003; Wildrick et al., 1997). If isolated crypts are prepared from colonic tissue, 
they also contain stem cells positive for Lgr5, an approved intestinal stem cell marker 
(Barker et al., 2007). This enables these cell cultures to actively replicate and to form new 
crypts whose cells differentiate along the crypt-villous axis. Ootani et al. could also 
demonstrate that the crypt-villous structure is self-organizing, and that it can be generated 
from a single Lgr5-positive stem cell while any non-epithelial cell type is absent (Ootani et 
al., 2009). Proteolytic enzymes, including trypsin, dispase, DNAse and collagenase are being 
applied in order to circumvent the limitations of EDTA. Among a diversity of protocols of 
enzymatic isolation of epithelial cells, trypsin and collagen are predominantly used (Chopra 
et al., 2010).  
Apart from employing proteolysis, a variety of compositions of culture medium, application 
of growth factors and additional substances, like hydrocortisone or cholera toxin, culture 
conditioning with non-epithelial cells as well as the use of antimicrobial agents have been 
proposed in order to obtain several primary epithelial colon cell cultures of different species 
(Birkner et al., 2004; Deveney et al., 1996; Chopra & Yeh, 1981; Bartsch et al., 2004; Booth et 
al., 1995; Yeh & Chopra, 1980). Yet, since suggested concentrations of the respective 
substrates vary considerably between different authors, Chopra et al. stated in their recent 
comprehensive review that the precise combination of each substrate and additive must be 
defined for each system (Chopra et al., 2010).  
While even long-term culture of colon epithelial cells were successfully established, their use 
for tissue engineering purposes have not been published up to date. Given that in vitro 
seeding of different types of epithelial cells on a scaffold was reported to improve 
integration of the implanted biomaterial in vivo (Nakase et al., 2008; Oberpenning et al., 
1999; Yoo et al., 1998), we speculate that this might also apply to colonic epithelial cells. 
Furthermore, cell-populated biomaterials may be less prone to inflammation with 
subsequent fibrosis and scaffold shrinkage due to the fact that the commensal flora is 
prevented to get into contact with the biomaterial itself. These presumptions, however, have 
yet to be clarified. 
2.2.1.3 Alternative epithelial cells – oral keratinocytes 
Assuming that culture of colonic epithelium remains a challenge, alternative cells sources 
for bioengineering of large intestine are of substantial interest. Oral keratinocytes have 
already been successfully used in tissue engineering of epithelial cell-lined constructs. 
Nakase et al. (Nakase et al., 2008) evaluated healing of interposed tissue engineered 
esophagus in dogs. They prepared tubular composite scaffolds consisting of a PGA felt 
containing SMCs and, towards its luminal side, human amniotic membrane which was 
either populated with oral keratinocytes and a feeder layer of autologous fibroblasts or not. 
These scaffolds were rolled around a polypropylene tube that was 3 cm in length and 2 cm 
in diameter and wrapped with the omentum of the dog. Three weeks after, the now soft 
tubular tissue was harvested from the abdomen, and elevated into the right thoracic space 
as a pedicle graft to replace a 3 cm resection of the hosts’s esophagus. Absence of oral 
keratinocytes on the amniotic membrane side was associated with stricture formation 
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followed by almost complete obstruction after 2 to 3 weeks. Where keratinocyte containing 
constructs were implanted, however,  the in situ tissue-engineered esophagus showed good 
distensibility and the dogs remained without feeding problems through 420 days. 
Esophageal peristalsis transferred food to the stomach, despite the absence of peristaltic 
activity in the tissue-engineered esophagus graft itself. The implanted tissue-engineered 
esophagus displayed a histological architecture similar to that of the adjacent native 
esophagus. The capacity of buccal mucosa to prevent stricture formation and, thus, provide 
patency of bioengineered tubular constructs has been confirmed for the urethra when it was 
applied as either a patch graft (Li et al., 2008; Bhargava et al., 2008) or an entire tubular 
implant (Raya-Rivera et al., 2011). Buccal mucosa may, therefore, be a valuable alternative 
cell source for colon tissue engineering. 
2.2.2 Organoid units 
One of the few research groups who dealt with bioengineering of large intestine loaded 
mesenchymal – epithelial cell compounds, derived from dissection of autologous full 
thickness (sigmoid) colon wall and referred to as “oragnoid units”, into biodegradable 
polymer tubes that were eventually implanted into the omentum of recipient animals. After 
4 weeks, the constructs have grewn to cysts consisting of many representative elements of 
an intact colonic architecture including normal epithelium, vascularization, present ganglion 
cells, and muscularis propria. Furthermore, this neo-colonic tissue exhibited both absorptive 
and secretory functions. Those animals who have undergone anastomosis of the 
bioengineered cyst to the native colon suffered no electrolyte imbalances, showed fewer 
symptoms of dehydration, and had evidence of bile acid recycling as well as raised content 
of short fatty acids in the stool. These findings were reflected in less weight loss, less relative 
hyponatremia, decreased stool moisture, elevated transit times and more formed stool in 
animals with implanted neo-colon (Grikscheit et al., 2002). Further studies revealed that 
bioengineered large intestine out of previously tissue engineered colonic tissue completely 
retained the architectural and physiological characteristics of its archetype. Evaluation of 
physiological function using an Üssing chamber suggested adequate vectorial ion transport, 
barrier function, and viability (Grikscheit et al., 2003). 
These results are promising, of course. However, the fact that the so bioengineered colon 
derives from syngeneic tissue would currently preclude its use for the treatment of patients 
with abnormal autologous donor cells, i.e. autoimmune diseases like inflammatory bowel 
syndrome, or types of hereditary cancer including familial polyposis or HNPCC. 
Furthermore, this technique is substantially limited of what concerns customization of size 
and shape of the bioengieneered tissue. Finally, apart from the muscularis propria, smooth 
muscle layers that might render peristalsis possible are completely absent. Indeed, this 
approach facilitates the creation of a premature tissue which has to be further processed in 
order to become a definite, functional organ. Despite these limitations, organoids may be 
successfully used in combination with other techniques/biomaterials for future tissue 
engineering of large intestine. 
2.2.3 Progenitor and stem cells 
2.2.3.1 Muscle progenitor and stem cells 
The transplantation of muscle progenitor cells (MPCs) has been evaluated as for a treatment 
of genetic and acquired muscle disorders (Gussoni et al., 1999; Leobon et al., 2003; Yiou et 
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al., 2003b). MPCs are considered quiescent adult stem cells and are located under the 
membrane surrounding the muscle fibers. After trauma or damage, MPCs drive muscle 
tissue regeneration by proliferating and differentiating into myoblasts, further fusing and 
eventually forming new myofibers. While entire muscle naturally contains cells of different 
origins, including from the vascular and hematopietic compartment, MPCs represent a 
subset of muscle cells that are generally committed to the myogenic lineage (Benchaouir et 
al., 2004). Therefore, MPCs are of particular interest for muscle engineering, and may be a 
valuable alternative to more original smooth muscle cells in order to restore function of 
defective or absent anal sphincter. The potential use of injectable cultured MPCs for the 
treatment of stress urinary incontinence has been investigated in experimental models 
(Chancellor et al., 2000; Yiou et al., 2003a; Yokoyama et al., 2001). Our own results in dogs 
showed that autologous muscle progenitor cells are able to reconstitute irreversibly 
damaged urinary sphincter function. The injected cells were able to survive and formed 
mature tissue within the damaged sphincter region. This approach has recently been 
adopted to anal fecal incontinence. Three weeks after external anal sphincterotomy, MPCs 
from quadriceps myofiber explants were auto-grafted by injection into the anal sphincter of 
rabbits. The so transplanted MPCs displayed the potential for recapitulation of a myogenic 
program, yielding improved objective anal measures of resting and stimulated pressures as 
well as of electromyographic profile (Kajbafzadeh et al., 2010).  
An Italian research group reported new muscle fiber formation with increased contractility 
of sphincter muscle strips in rats after having injected bone marrow-derived mesenchymal 
stem cells into the previously injured and surgically repaired anal sphincter (Lorenzi et al., 
2008). Another study suggested increased contractility of the sphincter muscle in rats after 
cryoinjury followed by injection of autologous muscle-derived stem cells (Kang et al., 2008). 
While these results did not reach statistical significance, Frudinger and colleagues 
(Frudinger et al., 2009) were able to demonstrate a significant clinical improvement of fecal 
incontinence in patients who recieved an injection of muscle-derived stem cells into their 
anal sphincters. None of these patients showed signs of rejection or other side effects, 
proving that the injection of autologous cells is feasible and safe. However, the authors 
described a discrepancy between clinical improvement and unchanged sphincter pressure 
and, therefore, recommended that further clinical studies should be preceded by bench 
experiments. 
2.2.3.2 Intestinal stem cells 
Recent advances in tracking, proper isolation and further processing of intestinal stem cells 
have promoted the interest in their use as a potential cell source for biotechnological 
applications (Umar, 2010). The idea to potentially reproduce intestinal tissue out of a single 
intestinal stem cell (ISC) is very appealing. As part of the aforementioned progress, specific 
cell culture conditions have been developed that allow the generation of long-lived 
organoids from either crypts or even from single ISCs of the small intestine. Sato and 
colleagues reported that the resulting intestinal „mini-guts“ display all the characteristics of 
native gut epithelium (Sato et al., 2009). Although not yet elucidated in detail, ISC 
differentiation and self-renewal seems to be regulated in vivo by adjacent mesenchaymal 
cells, including endothelial cells, lymphocytes, muscle cells, and particularly subepithelial 
myofibroblasts (Powell et al., 2005). This microenvironment which controls the stem cell fate 
is referred to as stem cell niche (Scadden, 2006).  
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In an in vitro culture, however, where the mesenchymal niche elements are lacking, Paneth 
cells – specialized intestinal daughter stem cells – have been identified to act as a 
multifunctional guardian of the mother stem cell supplying both bactericidal lysosymes and 
essential niche signals (Sato et al., 2011). It could be demonstrated that intestinal organoids, 
consisting of a central lumen lined by villus-like epithelium and several surrounding crypt-
like domains, could be generated from one single Lgr5-positive stem cell (Sato et al., 2009; 
Barker et al., 2010). Alternatively, Ootani and colleagues used neonatal tissue to initiate 
three-dimensional intestinal organ cultures. In these long-term cultures architecture of the 
mesenchymal niche as well as the multilineage epithelial lining which is typical for 
intestinal mucosa was preserved (Ootani et al., 2009). In contrast to the sphere formation of 
other cultured epithelial cell types, intestinal stem cell-borne tissue arranges in an 
asymmetry in which proliferative and differentiated cell types are positioned in accordance 
to their natural locations in the epithelial lining. It has been speculated that this might be 
due to the presence of an appropriate niche microenvironment – provided by either 
available mesenchymal structures and/or Paneth cells – that facilitate local morphogen 
gradients, thereby generating progenitor zones that are seperate from areas with 
differentiated cells (Snippert & Clevers, 2011). 
Current research is giving rise to a more detailed understanding of the stem cell’s 
surrounding microenvironment and of the different signals that regulate self-renewal and 
maintain the balance between self-renewal and differentiation of ISCs (Umar, 2010). 
Accordingly, epidermal growth factor (EGF), Wnt3 and Notch have been identified as 
essential signals for stem cell support (Sato et al., 2011). Previous work of the same research 
group was able to demonstrate that the addition of EGF, the Wnt agonist R-spondin 1 and 
the BMP inhibitor noggin induced single Lgr5-positive stem cells plated in a Matrigel-based 
culture system to grow into crypt-like structures with de novo generated stem cells and 
Paneth cells at their bottom (Sato et al., 2009).  
This fastly growing knowlegde on regulation of intestinal stem cells’ growth and 
differentiation may stimulate new approaches for tissue engineering of both the small and 
the large intestine. It is a tempting idea to grow complete intestinal tissue out of a single 
stem cell whose growth and differentiation would be induced and regulated by the 
respective factors/signals tethered to the biomaterial itself. Therefore, initialization of an 
optimized microenvironment that immitates the respective stem cell niche as close to its 
archetype as possible will be one of the challenges of intestinal tissue engineering of the 
coming years. 
2.2.3.3 Adipose-derived stem cells 
Another type of adult stem cells being used in tissue engineering are adipose-derived stem 
cells (ADSC). ADSC have successfully been derived from fat biopsies and differentiated 
towards distinct mesenchymal and neurogenic cell lineages (Bunnell et al., 2008; Taha & 
Hedayati, 2010). Few results on generation of epithelial tissue from ADSC, including corneal 
(Du et al., 2010; Ho et al., 2011) and urothelium-like cells (Liu et al., 2009) as well as tracheal 
epithelium (Kobayashi et al., 2010) have been reported up to date. Theoretically, induction 
of ADSC to differentiate towards intestinal epithelial cells ought to be possible by adding 
the respective cocktails of chemical inducers or cytokines. This approach might be worth 
being pursued since the use of ADSC – like adult stem cells in general - does not imply the 
many socioethic issues that accompany the work with embryonic stem cells. Furthermore, 
ADSC are abundantly available and easily accessible by liposuction that is itself associated 
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with a low morbidity. Using ADSC for tissue engineering purposes also means that 
potentially both mesenchymal and epithelial cells can be generated out of one single cell 
source. However, there is still a way to go to achieve bioengineered tissue on the basis of fat-
derived stem cells. 
2.3 Bioreactors 
Once tissue engineering has grown out of its fledgling stages initialization of an adquate 
vascularization of the growing tissue has arguably become its biggest challenge. Currently, 
construct development is often restricted to smaller than clinically relevant size due to 
issues of (in-)sufficient oxygen and nutrient supply. Consequently, feasibility of in vivo 
integration of the bioengineered tissue may be constrained (Lovett et al., 2009). Interposition 
of bioengineered substitutes organized in a tubular fashion, such as the gut, appear to be 
particularly prone to complications (Badylak, S. et al., 2000; Chen & Badylak, 2001; 
Thompson et al., 1986). Given that inadequate oxygen supply and decreased local 
microperfusion are believed to be at the origin of many adverse events in gastrointestinal 
surgery (Anegg et al., 2008; Attard et al., 2005; Sheridan et al., 1987), hypoxia and ischemia 
presumably account for anastomotic leakage and stricture formation after interposition of 
bioengineered tubular constructs.  
In recent years, considerable effort has been done to develop bioreactors that allow 
nourishment of growing tissue masses in vitro whose size exceeds the largest possible unit 
accessible to oxygen and nutrients by sole diffusion. If successful, such bioreactors are 
believed to clear the way for the generation of clinically applicable, tissue engineered 
constructs tailored with respect to the required size and shape in vitro. 
In various fields of hollow organ tissue engineering, such as of the cardiovascular system 
(Song et al., 2011; Iyer et al., 2011), as well as the respiratory (Tan et al., 2007) and 
genitourinary tract (Wei et al., 2011) the rapidly growing know-how on bioreactor design 
and manufacturing has ultimately enhanced their more and more frequent use. The 
increasing application of these devices has not yet been parallelled in gastrointestinal tissue 
engineering. The recent report on a perfusion bioreactor with intent to optimize conditions 
for long-term culture of primary intestinal epithelium can, however, be considered as an 
initial step towards the development of such devices in gut bioengineering. Kim and 
colleagues (Kim et al., 2007) designed and fabricated that bioreactor consisting of a 
multichannel peristaltic pump, culture medium reservoir, oxygenation and gas exchange 
unit, air trap, and cell-polymer construct housing unit. The appliance allows tuning of tissue 
oxygenation and CO2 exchange as well as dynamic cell seeding onto tubular scaffolds. The 
authors could demonstrate that the dynamically seeded epithelial organoid survived for 
two days under flow conditions. Yet, they state that, despite the promising results, further 
optimizations are needed to be done regarding the parameters for dynamic seeding and the 
employed biomaterial itself in order to enhance cellular attachment and survival. In our 
opinion, if tubular bioengineered tissue of clinically applicable size ought to be successfully 
generated in vitro, gastrointestinal tissue engineering will not get by without efforts being 
performed towards development and use of appropriate bioreactor devices. 
3. Conclusion 
Colon tissue engineering is at its very beginning. There has been some important progress in 
the last decade. Yet, techniques and knowledge gained from other fields of successful 
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hollow organ tissue engineering should be evaluated, and if promising, applied. A lot of 
patients worldwide suffer from a deficient or absent colo-rectal continence organ and the 
subsequent impact on the patient’s psycho-social condition and the related health care costs 
are considerable. Therefore, it seems more than justified to give weight to that field of 
hollow organ tissue engineering. Given the ongoing progress in biomaterial development 
and refinement, the rapidly growing know-how on (stem) cell culture and programming 
towards desired daughter cells as well as the future prospects on potential applications, 
such as bioreactors, we are convinced that tissue engineering of the colon is awaiting a 
promising future. The achievement of tailored artificial colon tissue has the potential to 
facilitate a great step forward in the treatment of patients after abdominoperineal resection 
(total excision of the ano-rectal continence organ) and, if successful, may be applied to other 
diseases like intractable fecal incontinence or congenital anorectal malformations. 
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1. Introduction 
Factors affecting the homeostasis of the urological system stem from a multitude of different 
sources that include developmental miscues to aberrant signaling pathways leading to 
malignant transformations.  In order to create functional tissues that can act as surrogate 
tissues while simultaneously mimicking endogenous anatomical and physiological 
functions, strategies utilizing regenerative medicine based methodologies must be 
employed. The urological system is comprised of the kidneys and their corresponding 
ureters; the bladder and sphincter as well as aspects of the genitourinary system. The 
complex architectural makeup and intricate physiological processes of the urological 
system at the gross and microscopic levels make tissue engineering attempts to 
recapitulate these tissues a very difficult and arduous process. Although great strides 
have been made in the field of urological tissue engineering over the last two decades, the 
clinical needs of patients suffering from urological defects have largely gone unfulfilled. 
However,  the advent of novel approaches that span multiple disciplines including the 
material and clinical sciences as well as the constantly evolving field of stem cell biology 
have curtailed these issues to some extent. This Chapter will delve into strategies that are 
currently utilized for urological based tissue engineering while also providing alternative 
tactics to prevailing approaches.  
2. Conditions affecting the urological system 
2.1 The kidney 
A simplistic overview of nephrogenesis proceeds as three sequential yet overlapping phases 
during human embryogenesis. During the third to fourth week of development, primitive 
cell populations derived from intermediate mesoderm converge upon the cervical region of 
the embryo to form one of two transitory structures termed the pronephros. (McCrory, 1974) 
These converging cell groups form rudimentary excretory units or nephrotomes that join 
with the pronephric duct. Although the pronephros is non-functional in mammals, it serves 
as a precursor structure for the slightly more defined mesonephros. (McCrory, 1974)  The 
progressive development of the definitive kidney continues as the pronephros regresses and 
the development of mesenophric ducts again derived from intermediate mesoderm becomes 
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apparent. (Pelliniemi, 1983) The mesonephros is composed of two distinct structures, the 
mesenophric ducts and the mesonephric tubules. The mesonephric tubules acquire a bed of 
capillaries and are analogous in physiological function as well as anatomic structure to adult 
nephrons in the definitive kidney. These elementary nephrons include the glomerulus, renal 
corpuscles, and Bowman’s capsule.  The mesonephric ducts (Wolffian ducts) eventually give 
rise to the epididymis, the vas deferens, and the seminal vesicles in males and as vestigial 
organs in females. (McCrory, 1974; Hannema, 2006; Welsh, 2006)  An outpocketing from the 
mesonephric duct arises during the fifth to six week of development to form the ureteric 
bud which becomes the decisive ureter as well as the collecting system found within the 
kidney including major and minor calyces, and the renal pelvis within the final stage of 
kidney formation, the metanephros. (McCrory, 1974; Fischer, 2001)  The physiological 
aspects of kidney function are numerous in nature and non-exclusively include hormone 
production and regulation, homeostatic balance, pH and blood pressure control, waste 
removal and nutrient re-absorption. It is therefore imperative that the various physiological 
aspects of the kidney remain under proper control and maintenance. The introduction of 
insult in the forms of either trauma or aberrant developmental events can signify a poor 
outcome for the patient.  
Congenital abnormalities of the kidney and urinary tract (CAKUT) occur in 1 out of 500 
newborns which constitutes approximately 30% of all prenatal anomalies. (Toka, 2010)  
These include a plethora of conditions including horse-shoe kidney, ureter 
malformation/abnormalities, renal hypoplasia, renal agenesis, polycystic kidney disease, 
and Wilms’ tumor formation and can arise at varying stages of the developmental process. 
(Toka, 2010; Stahl, 2006; Gimpel, 2010; Acien, 2010)  Depending upon the severity of the 
malformation and organs affected, various strategies can been utilized to treat patients 
afflicted with CAKUT that include surgical and conservative management. However, even 
with treatment, kidney and urinary tract functions are typically far from ideal. Certain 
signaling pathways have been elucidated but only scratch the surface of this complex 
disorder. (Stahl, 2006; Nakanishi, 2003) 
Aside from congenital defects affecting the kidney, acute and chronic conditions also pre-
dispose patients to poor clinical outcomes. Acute renal failure occurs with rapid onset and 
can result in loss of kidney function with eventual renal failure. (Bellomo, 2004; de 
Mendonca, 2000)  As there are myriad circumstances that may cause acute kidney failure, it 
is a life threatening situation requiring great urgency in order to alleviate the underlying 
cause. Chronic conditions affecting the kidney are also in great number, most notably those 
involved with chronic hypertension and diabetes mellitus. The destruction of the kidney 
due to consistently high blood pressure or continual exposure to copious amounts of 
glucose results in several scenarios in which to manage the disease. Diabetes is the most 
common cause of kidney failure within the United States. Data from the 2011 National 
Diabetes Fact Sheet provided by the American Diabetes Association estimates that there are 
approximately 26 million people living with diabetes within the United States representing 
approximately 8% of the population. (http://www.diabetes.org/diabetes-basic/diabetes-
statistics)   Kidney failure as a result of diabetes accounted for 44% of new cases in 2008 and 
approximately 50,000 people began treatment for end stage kidney disease. Lastly, 
approximately 200,000 people were on either dialysis or underwent kidney transplantation 
as a result of chronic diabetes within the United States.  A total of $348 billion was spent in 
2007 to address diabetes related issues. This stagnating level of evidence suggests a great 
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medical need to overcome current shortcomings involved with kidney disease as tissue 
engineering and nanofabrication strategies for the kidney become more prevalent. 
Kidney transplants and dialysis are the only current means to treat kidney failure. Attempts 
to recapitulate the kidney involve the transplantation of fetal kidneys, the integration of new 
nephrons into the kidney, and the use of embryonic stem cells. Fetal kidney transplantation 
was thought to be a possible means in which to identify tissue for replacement therapies 
since it was believed that fetal tissue did not present the high levels of major 
histocompatibility complexes (MHC) I and II as well as other immunostimulatory antigens.   
Studies performed by Dekel el al demonstrate the use of fetal human kidneys that were 
transplanted beneath the renal capsule of immune deficient rats. (Dekel, 1997a)  Data 
suggests that fetal tissue displayed growth and development for as long as 4 months post-
transplantation without tissue rejection that may have been caused by populations of T- 
cells previously residing in the fetal tissue. Analogous adult tissue underwent graft rejection 
upon stimulus with allogeneic injections of peripheral blood mononuclear cells (PMBC). 
(Dekel, 1997b, 1997c, 2000)  Nephron transplantation became an alternative means in which 
to rejuvenate a faltering kidney. Woolf et al transplanted sections of metanephroi from E13-
E16 mice into the kidney cortex of newborn outbred mice. (Woolf, 1991)  Relevant kidney 
micro-architecture formed over time but complete incorporation of transplanted 
metanephroi was not found in the collecting ducts. A similar study using an analogous 
system (but not identical) failed to produce glomeruli. (Rogers, 1998)   The lack of positive 
data with regard to kidney replacement methodologies leaves alternatives such as 
xenotransplantation with embryonic porcine kidneys. This tissue is not pluripotent but 
rather precursor tissue that has been naturally differentiated along kidney specific 
pathways. (Hammerman, 2011) 
Lastly, highly compelling work by Roy and colleagues appears to be very promising in that 
they have created a bio-artificial implantable device that may take the place of damaged or 
deteriorating kidneys. Preliminary data suggests that this microfluidic bioreactor can mimic 
the physiological conditions found in the kidney with regard to fluid flow rate in the 
presence of kidney epithelial cells. (Ferrell, 2010) Furthermore, Roy et al has determined that 
nanofabricated silicon membranes used in this device demonstrate low levels of 
complement activation, low platelet adhesion, and low blood coagulability. 
(Muthusubramaniam, 2011)  Studies are currently under way to test the feasibility of this 
device in animal models.  
2.2 The ureter 
Conditions which may warrant the replacement of a new ureter include a myriad of 
congenital afflictions including congenital atresia, stricture, bifid ureters as well as ureteral 
cancer and trauma. Arising from the renal pelvis of each kidney, the ureter descends and 
crosses into the urinary bladder. Damage to the valve found at the distal end of each ureter 
can result in vesicoureteral refux with eventually kidney damage if not treated. Within this 
scenario, damage can also manifest itself within the ureters as evidenced by dilated ureters 
caused by increased internal pressures. Tissue transplant studies employed to replace 
defective ureters have been promising. Armatys et al report the use of ileum as a ureteral 
replacement for reconstruction purposes. (Armatys, 2009)   A retrospective study of 91 
patients who underwent ureteral reconstruction using grafted ileum revealed that only 3.3% 
and 6.6% of patients endured long-term anastomotic stricture and fistula, respectively, and 
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had attained normal kidney function.  Other groups have utilized vestigial tissue such as the 
appendix as well as buccal tissue with favorable results. (Dagash, 2008)   Ureters constructed 
from synthetic materials have been used in the past to bypass the use of autolgous tissue 
sources. Desgrandchamps et al published two reports in which ureters constructed from a 
silicone polytetrafluoroethylene bonded tube was introduced into the pyelocaliceal renal 
graft cavities and placed subcutaneously into the suprapubic area where it was eventually 
guided into the bladder within human patients. (Desgrandchamps, 1995, 1998)   A mean 2.5 
year follow-up demonstrated that all tubes were patent and displayed no evidence of 
encrustation or obstruction. More recently, xenogenic accellular collagen membranes have 
also been used with limited success. (Koziak, 2004)  The aforementioned studies provide 
evidence that various tissues derived and artificial matrices can be used for ureteral 
reconstruction. In order to further improve on the design and physiological function of the 
ureter, smart scaffolding material possessing antimicrobial attributes or capable of growth 
factor release, for example, may be incorporated into this setting such as those found in self 
assembling nanomolecules. 
2.3 The urinary bladder 
The urinary bladder is a hollow, musculocutaneous organ whose primary function is to 
expel waste products in the form of urine from the body. Damage or insult to this organ 
leads to bladder dysfunction which can have dire clinical consequences on upper and lower 
urological tracts including renal insufficiency with eventual renal failure. Patients suffering 
from severe bladder dysfunction caused by developmental defect, often resort to surgical 
means to stabilize poor bladder function. The various forms of spina bifida present the 
clinician and basic scientist alike with a battery of issues stemming from gross anatomical 
restructuring to the fine aspects of physiological function. The typical procedure to alleviate 
problems associated with the neurogenic bladder includes bladder augmentation 
cystoplasty. What is considered the “gold standard” procedure for patients suffering from 
end stage neurogenic bladder, a portion of the pathological, native bladder undergoes 
cystectomy. (Zini, 2004; Husmann, 2004) A detubularized portion of the bowel is then 
affixed to the cystectomized area of neurogenic bladder and hence serves as a neo-bladder 
in order to increase capacity. As the bladder is considered functional, it still lacks key 
attributes of a normally functioning bladder including sensory and contractile/expansion 
responses requiring lifetime self-catheterization. The reconstructed bladder also possess 
inherent complications including electrolyte imbalances as an absorptive tissue has been 
used to replace an excretory tissue; the high potential of infection; excess mucus formation; 
pronounced stone formation; spontaneous perforation, and the increased likelihood of 
malignant transformation. (Bankhead, 2000)  Although the augmentation cystoplasty 
procedure is considered standard care for this situation, it is still a stopgap measure.  
The biomedical applications of regenerated tissue took its roots from the pioneering work of 
Langer and colleagues. (Vacanti, 1988; Langer, 1993)  Within these studies, it was 
determined that donor derived cells could be seeded upon synthetic, biodegradable scaffold 
materials and subsequently manipulated in vitro for eventual in vivo applications. Applying 
these basic principles of cell biology and engineering, Atala and colleagues embarked upon 
a mission to recapitulate functional urological tissue with the goal of clinical applicability. 
Initial studies utilizing rabbit derived urological tissue subsequently seeded upon 
polyglycolic acid (PGA) meshes and implanted into the tissue within and adjacent to the 
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peritoneal cavity of athymic mice yielded poignant results. (Atala, 1992) Rabbit derived 
urothelium was able to proliferate and populate the PGA scaffold to an approximate 3 cell 
thickness while retaining key urothelial markers after 30 days in vivo. This initial study set 
the stage for several other studies that continued to evaluate the roles of specific cell types 
combined with synthetic scaffolds for bladder regeneration. (Atala, 1993, 1998)  
Concurrently, studies by Knapp et al and others were evaluating the use of small intestinal 
submucosa (SIS) as an alternative biological scaffold for bladder tissue engineering. (Knapp, 
1994; Kropp, 1995)  The results from these studies seemed to suggest that SIS was a suitable 
biological material for the bladder augmentation process. However, in two separate studies 
by Ashley et al, unseeded SIS would be found to be highly pro-inflammatory. (Ashley, 2009, 
2010)  The seminal work that laid the foundation for future bladder regenerative studies 
came from Oberpenning et al (Oberpenning, 1999) Within this study, autologous sources of 
canine urothelial and smooth muscle cells were harvested then seeded onto polymers and 
subsequently expanded ex vivo. Completely cystectomized canines were then transplanted 
with this new bladder construct and observed for approximately a year. Very compelling 
data suggested that the engineered bladders demonstrated a normal micro-architecture, 
mechanical properties and the ability to store and express urine. This study set the 
foundation for a human clinical trial utilizing neurogenic urothelial and smooth muscle cells 
from spina bifida patients with myelomeningocele as a model system with the hopes that 
the bladder milieu could be recreated in human. (Atala, 2006)  Following bladder biopsies, 
these two cell populations were isolated and expanded ex vivo and subsequently seeded 
upon either a collagen/PGA hybrid scaffolds or collagen alone scaffolds. These composite 
scaffolds were anastomosed to the native tissue following an initial cruciate incision to the 
native bladder. An approximate mean 4 year follow-up revealed no statistically 
improvement in collagen only based scaffolds for a number of different urodynamic 
functions including capacity, leak point pressure, and compliance. PGA/collagen scaffolds 
encased in omentum appeared to display a very modest increase in bladder capacity. The 
approach taken by Atala et al was bold and extremely novel and provided highly relevant 
data for this specific patient population. However, the data presented within the work failed 
to acknowledge that utilizing a pathological source of cells at the onset of this work could 
possibly result in abnormal cellular behavior or possible reformation of a diseased bladder 
state. Characterization of bladder smooth muscle cells derived from patients with 
myelomeningocele indicates that cultured bladder smooth muscle cells possess different 
characteristics than their normal counterparts. (Lin, 2004; Beqaj, 2005)  Finally, the 
aforementioned augmented bladders continued to be non-contractile thus requiring the 
patients to presumably self catheterize for the remainder of their lifespan. Although 
groundbreaking in nature, much work needs to be performed in order to fully realize the 
goal of creating a functional bladder. 
2.4 The urinary sphincters 
The urinary sphincters are composed of a collection of muscles whose primary function is to 
prevent the premature leakage of urine from the bladder. (Feki, 2007; Delancey, 2004)  The 
internal urethral sphincter is located at the proximal portion of the urethra and is a 
continuation of the detrusor muscle consisting of smooth muscle cells. The external urethral 
sphincter is comprised of skeletal muscle and is situated inferior to the prostate in males and 
at the bladder's distal inferior end in females. (Koyanagi, 1980)  Disruption or dysregulation 
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of the sphincter system can lead to incontinence that encompass various forms including 
stress urinary incontinence, structural incontinence, urge and overflow incontinence as well 
as mixed incontinence. (Botlero, 2011; Siegler, 2004; Brubaker, 2011)   The economic costs of 
urinary incontinence are quite staggering and account for greater than $20 billion dollars per 
year within the United States. (Wilson, 2001)   Attempts to alleviate the dysfunction 
associated with incontinence have been manifested in various tissue engineering attempts to 
rejuvenate or replace poorly functioning sphincters. Yiou et al tracked the fate of muscle 
precursor cells that were implanted into a rat model of striated urethral sphincter injury. 
(Yiou, 2003)   Muscle precursor cells were able to adapt to their environment and form 
myotubules in which acetylcholine receptors were present. Urodynamic studies 
demonstrated a 41% restoration of sphincter function at approximately one month post 
muscle precursor cell implantation. A second study similarly utilized muscle derived 
progenitor cells in a denervated female rat urethra model. (Cannon, 2003)   Two weeks 
following cell injection, urethral muscle strips were analyzed under electrical field 
stimulation. Injected muscle derived progenitor cells greatly improved the amplitude 
associated with fast-twitch muscle contractions at a rate of approximately 87% as compared 
to control animals. The aforementioned studies and those that have incorporated the use of 
synthetic bulking agents such as poly(lactic-co-glycolic acid) (PLGA) microspheres have 
demonstrated alternative means in which to overcome obstacles associated with urinary 
incontinence. (Berjukow, 2004; Oh, 2006) The foundation that these works have created 
has resulted in over 50 clinical trials related to urinary incontinence. 
(http://clinicaltrials.gov)   The field continues to evolve at a rapid pace partially driven 
by a need to create a solution to this problem as well as the potential for high financial 
benefits.  
2.5 The urethra 
Urethral narrowing is the most common affliction affecting the urethra. Physical trauma or 
insult by bacteria or virus can result in an abundance of scar tissue caused the local invasion 
of  inflammatory cells as the body attempts to resolve the situation at hand resulting in 
stricture. Clinical presentation includes painful urination, decreased urinary output, dark 
colored urine, pelvic pain, and incontinence among some of the symptoms. (Ghoniem, 1994; 
Barbagli, 2007; Mangera, 2010)  Depending upon the anatomical location and the severity of 
the stricture, different techniques have been utilized to remedy stricture exacerbation. 
Urethroplasty has been successfully utilized as a treatment option to repair the stricture. 
One method is to excise the stricture from the urethra and then rejoin the opposing ends. A 
second approach requires tissue grafting from typically autologous sources of buccal 
mucosa, amniotic membrane, or saphenous vein tissue. (Mangera, 2010; Goel, 2011, Levine, 
2007, Shaeer, 2006)   Complications associated with this type of surgery include fistula 
formation, infection, and stricture reformation. (Olajide, 2010)   Tissue engineering 
approaches using synthetic and biologic matrices have also been investigated as alternative 
approaches to urethral repair. Derivatives of PLGA have been created to mimic buccal 
mucosa with the added benefit of possessing superior mechanical and elastic properties. 
(Selim, 2011)   Other biomaterials such as SIS, bladder acellular matrix (BAM), and acellular 
corpus spongiosum matrix (ACSM) have also been utilized in studies with favorable results. 
(Feng, 2010; Powers, 2010)   Since host inflammatory responses appear to be a major culprit 
behind stricture formation and its persistence, means to address this issue should be 
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explored.  One practical solution may be the localized delivery of anti-inflammatory agents 
into the affected area to prevent further stricture formation. This may be accomplished via 
a number of delivery vehicles including hydrogel releasing anti-inflammatory agents as 
well as self-assembling nanomolecules capable of down-regulating the cellular 
inflammatory response through surface expression of anti-inflammatory epitopes. 
Current research is focusing upon the creation of peptide amphiphiles that may be 
capable of such feats. Combined with the anti-inflammatory characteristics of 
mesenchymal stem cells, this one-two punch to either attenuate inflammation or act in a 
prophylactic manner may help with stricture development and other biologically relevant 
other pro-inflammatory situations. 
3. Stem cells and potential applications in urological regenerative medicine 
Stem cells can be described in several different embodiments such as those that are derived 
from embryonic sources or somatic (adult) in nature. The differential capabilities of these 
cells can further be sub-categorized as being either totipotent, pluripotent, or multipotent. 
Totipotent stem cells are a result of a fusion of sperm and egg that have undergone limited 
divisions during early embryological development in mammalian systems. (Mitalipov, 2009; 
Seydoux, 2006)   At this early stage of development, totipotent stem cells have the potential 
to become any type of cell in the body which also includes extraembryonic tissue. 
(Mitalipov, 2009; Seydoux, 2006)    As a zygote undergoes further differentiation, totipotent 
stem cells lose their ability to create whole organisms and become more lineage restricted, 
hence becoming pluripotent. Pluripotent stem cells can give rise to tissues of endoderm, 
ectoderm, and mesoderm origin, but not extraembryonic tissue and can be derived from 
both embryonic and somatic cells. (Pittenger, 1999, Thomson, 1998; Takahashi, 2007; Ko, 
2009)  Multipotent cells are greatly restricted in their ability to generate specific 
differentiated cell types and subsequently tissue. These cells retain the ability to self-renew 
and divide into daughter progeny, but these characteristics are greatly limited. A highly 
characterized population of cells that fits this definition is mesenchymal stem cells that have 
been described to differentiate into adipocytes, osteocytes, chondrocytes, and others. 
(Pittenger, 1999, Phadnis, 2011) 
3.1 Mesenchymal stem cells 
The hematopoietic system and its constituents have been extensively characterized at 
multiple levels via decades of research and clinical experiences.  The hematopoietic system 
found within the bone marrow of long bones in mammals consists of a hierarchy of cells 
originating from a primitive hematopoietic stem cell. The hematopoietic stem cell is capable 
of giving rise to all blood derived cells including those of lymphoid and myeloid origin. 
(Akashi, 2000)   Also residing in the bone marrow are non-hematopoietic multipotent 
mesenchymal stem cells capable of variable cellular differentiation as previously described. 
(Takahashi, 2007; Ko, 2009; Phadnis, 2011) The frequency of which bone marrow derived 
mesenchymal stem cells are found within long bones is approximately 0.001% to 0.1% of 
nucleated cells which include adipocytes, macrophages, osteoblasts, and reticular 
connective tissue. (Pittenger, 1999)  Therefore, fibroblast cells that reside in the bone marrow 
are not synonymous with mesenchymal stem cells. The plasticity demonstrated by 
mesenchymal cells can be utilized in a variety of regenerative medicine settings, especially 
those targeting urologic defects.  
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In a series of studies utilizing bone marrow derived mesenchymal stem cells from normal 
human, adult donors, Sharma et al demonstrate the phenotypic and physiological 
similarities between bladder smooth muscle cells and adult mesenchymal stem cells. 
(Sharma, 2009)   The mesenchymal stem cells utilized throughout this study as well as 
subsequent studies were an epitope defined population of highly purified mesenchymal 
stem cells. This study further demonstrated that both populations of cells can respond to 
agonist stimulation with statistically indistinguishable contractile responses in vitro while 
possessing similar contractile machinery. A second study by Sharma and colleagues utilizes 
adult mesenchymal stem cells in a nude rat bladder augmentation model. (Sharma, 2010a)  
Within the context of this study, bladder regeneration occurred more potently with 
mesenchymal stem cells than normal human bladder smooth muscle cells and controls. 
Scaffolds seeded with mesenchymal stem cells expressed high levels of bladder smooth 
muscle markers along with typical muscle architecture in the form of muscle fascicles. These 
scaffolds also demonstrated an approximate 1:1 muscle to collagen ratio at the termination 
of the experiment which was vastly different from bladder smooth muscle cell seeded and 
unseeded controls. A third and more recent study by Sharma et al again demonstrate the 
utility of mesenchymal stem cells in a bladder regenerative setting except in this instance, 
autologous sources of epitope defined mesenchymal stem cells were utilized to establish a 
novel bladder augmentation model in a non-human primate. (Sharma, 2010b)   Data from 
this study provides evidence that mesenchymal stem cell seeded scaffolds performed 
exceptionally as defined by physiological measurements and tissue phenotyping studies 
with a battery of proliferative and smooth muscle markers compared to controls. More 
importantly, this newly described augmentation model demonstrates potential clinical 
feasibility as this non-human primate is highly analogous to humans both anatomically and 
physiologically. Hence the use of autologous sources of non-pathological cells can be 
successfully utilized in a bladder regenerative setting. 
Although the aforementioned studies provided strong evidence for bladder regeneration in 
hemicystectomized animals,   future endeavors will require a great deal of scientific prowess 
to regenerate a fully functional bladder. Hence, the natural course of action would be the 
continuance of these studies. One aspect in conjunction with regenerating tissue is to create 
an environment that can provide a robust blood supply to developing tissue. Genetically 
modified mesenchymal stem cells carrying pro-angiogenic growth factors under the control 
of inducible promoters may aid in this function. A second strategy involves the use of 
nanomolecules capable of delivering much needed growth factors to tissues undergoing 
regeneration.  Rajangam et al demonstrate robust in vivo angiogenesis via the delivery of 
heparin binding nanostructures. (Rajangam, 2006)   The cross-pollination of stem cell 
biology with nanotechnology derived materials can potentially provide reliable and 
reproducible results when applied to urologic tissue regeneration which is the basis for 
future studies. 
There are several tissue sources in which mesenchymal stem cells can be identified and 
isolated. Two of those sources are found within adipose tissue as well as amniotic fluid 
which bathes the fetus in utero. These cell populations have been shown to function within 
urological settings. Dyslipidemia has been associated with a variety of poorly compliant 
physiological conditions including erectile dysfunction. (Huang, 2010)   Damage occurs to 
the cavernous endothelium and associated nerves through mechanisms that are not quite 
fully understood. In order to facilitate recovery, adipose derived mesenchymal stem cells 
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have been utilized to augment repair in the penis with the understanding that various 
factors secreted from mesenchymal stem cells promote re-growth of endothelium and 
improved nerve conduction. Within the context of this study, adipose derived mesenchymal 
stem cells were injected into the corpus cavernosum of dyslipidemic rats. Following a 
period of recovery, erectile function was assessed and mean intracavernous 
pressure/arterial pressures ratios were superior to control samples. Increased levels of nitric 
oxide synthase and alpha smooth muscle actin were also observed. (Huang, 2010) This 
study provides preliminary evidence that adipose derived mesenchymal stem cells can be 
used to ameliorate the urologic complications that arise in urologic settings. In order to 
obtain continual exposure of these factors in the afflicted areas, seeding these cells upon 
implantable nanofabricated materials may allow for immediate regeneration accompanied 
by long term maintenance. Nanofabricated materials can recreate specific cell niches in 
order to potentially enhance the regenerative effect and this topic will be discussed in 
greater detail within subsequent sections. (Murtuza, 2009) 
Adipose derived mesenchymal stem cells have also been utilized in bladder regenerative 
settings and provide a means to obtain a multipotent cell source through adipose tissue 
aspirates. (Jack, 2009) Adipose derived mesenchymal stem cells maintain an approximate 
3% of all nucleated cells within a sample of aspirate. Jack et al seeded adipose derived 
mesenchymal stem cells upon PLGA scaffolds and implanted them in 50% cystectomized 
athymic nude rats. 12 weeks post-transplantation, physiological measurements were 
assessed as well histological and immunofluorescent analyses, and organ bath studies. All 
data derived from this study indicate that the adipose derived mesenchymal stem cells 
perform similarly or better than control samples in almost every biological aspect. The 
novelty of this study obviously involves the use of this unique population cells. Future 
studies involving potentially sub-total cystectomized large animal models will hopefully 
provide a great deal of physiological information that may be applied to the human condition. 
The recently described characterization of amniotic fluid mesenchymal stem cells offers 
another potential alternative cell source that may be applied to urologic tissue engineering. 
Initially described by In 't Anker et al, 2ml of  second trimester amniotic fluid was obtained 
through transcervical isolation. (In’t Anker, 2003) Subsequent cell populations were cultured  
in vitro and coerced to undergo terminal differentiation where they demonstrated 
differentiation into adipocytes and osteocytes. Transplantation studies also provided 
evidence that these cells could be used in an allogeneic setting, which suggests that these 
cells may possess a greater immune-privileged status than their adult counterparts. The 
application of amniotic fluid derived mesenchymal stem cells in a bladder injury model 
convincingly demonstrates the wound healing potential of these cells. (De Coppi, 2007)  The 
direct injection of amniotic fluid derived mesenchymal stem cells into the cryo-injured 
bladder resulted in markedly reduced levels of smooth muscle hypertrophy but also 
demonstrated a limited level of smooth muscle cell regeneration which may have been 
attributed to inadequate numbers of injected cells since a dose response curve was not 
performed.  Although both experimental procedures describe this source of cells as potent in 
function, the means in which they are acquired are highly invasive and pose great risk to 
fetus and mother. It is estimated that 1 in 300 women experience fetal loss, infection, 
cramping/vaginal bleeding or other complications during or following amniocentesis. 
(Simpson, 2007) The isolation and subsequent banking of these cells may allow a convenient 
means for future therapies in both autologous and allogeneic settings. 
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3.2 Endothelial progenitor cells 
The lack of a properly vascularized graft is the bane of many tissue engineering studies 
regardless of the tissue attempting to be regenerated. Inadequate or improper 
vascularization leads to poor tissue development or graft failure of implanted cell/scaffold 
composites. This is evident towards the center of grafted composites as these areas are 
typically inaccessible to nutrient and gas exchange potentially resulting in a necrotic core. A 
manner in which to avoid the aforementioned scenarios would be to utilize autologous 
sources of endothelial progenitor cells. These cells could promote vascular growth even at 
the most cell dense levels of the graft since the endothelial progenitor cells can 
simultaneously be seeded along with other bladder cell types thereby encouraging vascular 
growth. Endothelial progenitors can typically be isolated from either the bone marrow or 
rather innocuously from the peripheral blood as circulating endothelial progenitor cells. 
3.2.1 Bone marrow derived endothelial progenitor cells  
It was initially speculated that cells that were destined to become constituents of blood 
vessels as a result of vascular growth were present throughout embryonic and early stages 
of fetal development. This was later revealed to be somewhat inaccurate with the advent of 
specific antibodies utilized to phenotype specific cell populations.  The CD34+ hematopoietic 
stem cell has been greatly characterized over the last several decades and it has been 
demonstrated that subset populations derived from bone marrow sources have the capacity to 
either form functional vasculature in or contribute to its remodeling vivo. (Abu El-Asrar, 2009; 
Ruger, 2008; Baum, 1992; Takahashi, 1999)   CD34+/CD133+ cells derived from the bone 
marrow have provided evidence that this population can give rise to highly purified 
endothelial cells. (Quirici, 2001)  Sharma et al describe the in vivo potential of this cell 
population as it was seeded within a chicken chorioallantoic membrane model. (Sharma, 2009)  
Post experimentation analyses of this work clearly demonstrate the angiogenic potential of 
bone marrow derived CD34+/CD133+ cells as human specific vasculature was formed utilizing 
this model. Other derivatives of this cell population including CD34+/CD133+/VEGFR2+, 
CD34+/CD133+/VEGFR3+, CD34+/VEGFR2+, and CD133+/VEGFR2+ cells maintain similar 
properties. (Salven, 2003; Luppi, 2010) However some may argue that the CD34 epitope is not 
required to describe an endothelial progenitor/precursor cell, although those groups appear to 
be in the minority. (Friedrich, 2006) In all cases, the frequency of bone marrow derived 
endothelial progenitor cells is quite low, hence other alternatives cell sources should be 
examined for potential regenerative medicine purposes. 
3.2.2 Circulating endothelial progenitor cells 
The seminal discovery that endothelial progenitor cells were persistent throughout the 
vascular system gave a tremendous boost to a number of tissue engineering approaches. 
Approximately 11 years ago, Asahara et al describes a simplistic and non-invasive means to 
isolate circulating endothelial progenitor cells. (Asahara, 1997) By utilizing CD34+ cells 
isolated from peripheral blood, the study demonstrates that this population of cells was able 
to differentiate into endothelial cells in vitro while concurrently incorporating into sites of 
active angiogenesis in an animal model of ischemia. Data goes onto describe the concept 
that circulating endothelial progenitor cells can home to areas of pre-existing angiogenesis 
and contribute to the angiogenic process. Since this revelation, many studies have been 
performed that confirm the concept of circulating endothelial progenitor cells. (Dubois, 2011; 
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Baker, 2011)  One recent example demonstrates the construction of a tri-leaf heart valve seeded 
with circulating endothelial progenitor cells. (Sales, 2010) Data revealed that endothelial 
progenitor cells were able to colonize the heart valve and provide both interstitial and 
endothelial functions to the evolving valve. (Sales, 2010) This again demonstrates the potential 
utility of endothelial progenitor cells. The use of endothelial progenitor cells is pivotal for 
tissue regeneration and cannot be understated. The goal of utilizing endothelial progenitor 
cells for tissue regeneration is definitely not simplistic in the sense by just applying a 
population of endothelial progenitor cells to a graft and assuming angiogenic events. The 
shear number of molecules that are involved in the angiogenic pathway need to be carefully 
balanced in order to prevent aberrant results. This can be demonstrated as an over-abundance 
of localized vascularization leading to excessive bleeding and subsequent pathological issues.  
The strengths of using circulating endothelial cells are that they can be isolated in large 
numbers and more importantly, they can be isolated in an autologous fashion. The latter 
avoids a battery of immunological events and immunosuppressive therapies that may have to 
be endured for the lifetime of the patient. Unfortunately, works describing the use endothelial 
progenitor cells in urological tissue engineering is very limited and should be further 
investigated as this resource is being squandered.  
3.3 Neural stem/progenitor cells 
The greatest issue involved with urological based tissue engineering strategies (in this 
author’s opinion) is the recapitulation of functional nervous tissue. Although attempts have 
been made to provide neural functionality to urologic organs such as the bladder utilizing 
nerve re-routing techniques, these results have been met with skepticism and concern. (Xiao, 
2005; Kurzrock, 2010; Park, 2010) Thus, alternate avenues should be evaluated to create 
functional neural circuitry for urologic organs such as the use of stem cells. The initial 
isolation and identification of neural stem cells occurred in 1992 by Reynolds and Weiss. 
(Reynolds & Weiss, 1992)   Neural stem cells were isolated from the striatum of the mouse 
brain and under specific culture conditions coerced to differentiate into neurons and 
astrocytes. Further testing demonstrated morphological features that were indicative of 
functional neural cells. This seminal work provided compelling evidence that argued 
against the long established belief that brain derived tissue could not undergo neurogenesis 
after birth or damaging insult. Subsequent in vivo studies exploited the use of neural stem 
and more differentiated neural progenitor cells in a variety of in vivo settings as cells were 
also being isolated from peripheral nervous systems. (Gage, 2000)  One study in particular 
describes the transplantation of neural progenitor cells into the cortical region of the rat 
brain that underwent lesion induction. (Prajerova, 2010) Electrophysiological assessments of 
brain slices revealed the generation of action potentials created by the neural progenitor 
cells that were statistically greater than control samples. Evidence was also provided in 
which transplanted neural progenitor cells exhibited expression of differentiated neural 
markers by immuno-staining. (Prajerova, 2010)    
As of this writing, attempts to utilize bona fide neural stem or progenitor cells have not 
come to fruition in a urological regenerative medicine setting.  One study does report the 
use of neuronal-glial precursor cells which facilitated the mild improvement in bladder 
physiological function. These included various urodynamic parameters such as mean 
voiding pressure, capacity, bladder pressure, and mean contraction amplitude. These values 
were marginally better than control animals. (Temeltas, 2009)  It is quite apparent that a 
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considerable amount of research is required to address the major concerns regarding 
urologic tissue neuro-regeneration. Cultivating cross-discipline approaches may provide a 
suitable means to an end. 
3.4 Embryonic stem cells 
The seemingly limitless therapeutic potential of human embryonic stem cells has 
commanded the attention of the scientific community since its initial discovery. (Thomson, 
1998)  Derived from the inner cell mass of the developing blastocyst, pluripotent embryonic 
stem cells can be isolated and possess several unique features. These are typified by high 
nuclei to cytoplasm ratios, very pronounced nucleoli, the capability of indefinite cellular 
propagation, and most significantly, the ability to differentiate into cell types composed of 
all three germ layers. (Thomson, 1998)  The isolation and characterization of embryonic stem 
cells laid the foundation for literally thousands of studies that now spans multiple 
disciplines and aspects of regenerative medicine. (Birket, 2011; Nistor, 2005; Farzaneh, 2010)  
The use of embryonic stem cells is slowly making its way into the realm of urological tissue 
engineering. One study describes an in vitro culture environment in which conditioned 
media from primitive ureteric bud cells were used to support the differentiation of murine 
mesoderm cells initially derived embryonic stem cells. (Ren, 2010) The mesoderm cells were 
primed with activin and retinoic acid and subsequently forcibly differentiated into cells of 
renal lineage with the aid of the conditioned media. The strong inductive effect of the 
secreted molecules from the ureteric bud culture provides a means to elucidate potential 
mechanisms involved with mesoderm-renal cell lineage differentiation. A second, more 
recent study sheds light upon some of the molecules involved in the differentiation of 
murine embryonic cells into urothelium. (Mauney, 2010) As previously utilized in the 
aforementioned study by Ren et al, all trans-retinoic acid had the profound ability to induce 
pluripotent embryonic stem cells in to urothelial cells through a GATA4 and GATA6 
signaling pathway. Stimulation of the embryonic stem cells with all trans-retinoic acid 
caused a prominent increase in several uroplakin genes including UP1A, UP1B, UP2, and 
UP3B with a simultaneous down-regulation in the pluripotency factor OCT-4 compared to 
control cell populations. Concurrently, transcription factors GATA4 and GATA6 were also 
greatly up-regulated. GATA4/6 null embryonic stem cell lines demonstrated a marked 
reduction in uroplakin expression when undergoing similar treatments as compared to wild 
type controls. This data suggests a partial mechanism with regard to the inductive effect of 
all trans-retinoic acid and its ability to drive embryonic stem cells into urothelial cells. 
Several other studies have also utilized embryonic stem cells or embryoid body derived cells 
to generate bladder tissue to varying capacities. (Thomas, 2008; Kinebuchi, 2008; 
Lakshmanan, 2005) Unfortunately, a lack of follow-up studies has seemed to put a damper 
on this potentially ground breaking field of research.  
The utility of embryonic stem cells is obviously not without debate. Ethical and moral 
dilemmas have significant impact on political policy and are of grave concern for future 
studies utilizing embryonic stem cells that use federal funds to support research.  2001 saw 
restrictions placed upon the use and creation of embryonic stem cell lines, a ban that was 
later rescinded in 2009. The recent political atmosphere continues to be in a state of flux 
witnessed most recently by a recent court injunction that stopped the use of federal dollars 
to be used for embryonic stem cell research, thus effecting thousands of researchers. 
Although the injunction was temporarily stayed upon an appeal, it could set a damaging 
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precedent for the future. Privatized monies as found within the California Institute of 
Regenerative Medicine currently finance studies with embryonic stem cells with other states 
in pursuit. (http://cirm.ca.gov/for-researchers/researchfunding) Nevertheless, several 
clinical trials set forth by privately held companies such as Geron and Advanced Cell 
Technology are currently underway. (Strauss, 2010; http://www.advancedcell.com/news-
and-media/press-release) The controversies surrounded embryonic stem cell research in 
part fueled the scientific community to pursue other avenues of research that would lead to 
the identification of an alternative source of pluripotent stem cells. 
3.5 Induced pluripotent stem cells 
Preliminary observations involving studies with somatic cell nuclear transfer into recipient 
oocytes resulted in cell populations that displayed features that were highly analogous to 
embryonic stem cells in morphology and function. (McGrath, 1983; Campbell, 1996)  Via 
successive rounds of a highly selective molecular screening process, four genes were 
determined to be essential in the de-differentiation of terminally differentiated cells back to 
a pluripotent, embryonic-like state. Takahashi et al produced the first generation of induced 
pluripotent stem cells from human adult fibroblasts with the over-expression of four 
transcription factors including Sox2, Oct3/4, c-Myc, and Klf4. (Takahashi, 2007) These cells 
possessed embryonic stem cell-like qualities as they could differentiate into cells of 
endoderm, mesoderm, and ectoderm origin; were able to form teratomas in vivo; and  
proliferate indefinitely without losing their pluripotency. A subsequent study from Yu et al 
utilized a similar procedure derived from the Takahashi study but determined that a 
slightly different cocktail of genes (or proteins) could induce the same effect. (Yu, 2007) 
OCT4, SOX2, NANOG, and LIN28 were identified as pluripotency factors that had the same 
effect as the aforementioned gene set. Since a slightly different set of genes was utilized in 
the second study, it would be easy to speculate that different combinations of genes or yet to 
be identified factors that are tissue specific may be utilized to create pluripotent cell lines.  
This groundbreaking work led to a number of other studies focusing on specific cell type 
and disease states. (Moretti, 2010; Ebert, 2009) However, with each great discovery come 
certain drawbacks. It has been recently demonstrated that induced pluripotent stem cells 
outwardly function similarly to embryonic stem cells, but the gene expression signatures 
possessed by each cell type are quite different. (Chin, 2009) This is most likely a result of 
differential promoter binding by the reprogramming factors. Other studies also demonstrate 
the detrimental effects that coerced cellular reprogramming may induce upon target cell 
populations. (Hussein, 2011; Lister, 2011) The use of induced pluripotent stem cells in 
urological settings (excluding spinal and nerve injury scenarios) is still in its infancy with a 
paltry number of studies. (Morizane, 2009) As more data emerges with regards to the 
molecular machinery involved with the reprogramming process (along with potential 
consequences), perhaps these data will be applied to future urological regenerative 
medicine based studies. 
4. Polymeric materials and their potential applications in urologic 
regenerative medicine 
The choice of scaffold material is of paramount significance in determining the outcome of 
implanted cell/scaffold composites. There are a wide variety of scaffold materials that vary 
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greatly in composition, texture, mechanical and surface characteristics that could potentially 
be applied in a urological regenerative medicine setting. A number of these materials have 
been previously discussed in great detail such as bladder acellular matrix, small intestinal 
submucosa, varying embodiments of poly(lactic-co-glycolic acid) and polyglycolic acid, and 
collagen. Similarly, other chemically synthesized nano- and macro- based structures are also 
pivotal in creating hospitable environments for tissue growth and development. The focus 
of the forthcoming section will concentrate on relatively newly described elastic based 
materials that may be utilized for urological tissue engineering along with bioactive 
peptides and nanomolecules. 
4.1 Synthetic elastomeric substrates for urological tissue engineering 
4.1.1 Poly(diol citrates) 
The mechanical properties that contribute to the overall composition of various urologic 
organs in part define its ultimate structure and function, specifically with regard to  
the urinary bladder. The urinary bladder is a very dynamic organ as demonstrated by  
its wide elastic properties further exemplified by its ability to undergo repeated 
contractile/expansion cycles without permanent deformation. Characterization studies of 
human urinary bladder tissue describe the elastic modulus to be within the low-hundreds of 
kPa (kilopascal) (Dahms, 1998). Commonly used scaffolds for urinary bladder tissue 
engineering such as non-woven polyglycolic acid and poly(lactic-co-glycolic acid), and 
collagen typically exhibit elastic moduli in the giga- and megaPa range. These features 
predispose this materials to possess poor elongation characteristics of <10% hence making 
them unsuitable for functional urinary bladder replacement strategies. (Middleton, 2000) It 
has also been demonstrated that degradation byproducts of these polymers contribute to a 
localized decrease in pH which can have a negative impact on cell function, including 
decreased collagen synthesis and impaired cellular differentiation capacity. (Kohn, 2002) 
Cyclical mechanical forces have also been demonstrated necessary for bladder smooth 
muscle growth and development while static and non-contractile environments are less 
likely to produce robust contractile responses. (Heise, 2009) POC [poly(1,8-octanediol-co-
citrate)] is a relatively newly described member of a family of diols which is a synthetic 
polymer that has a wide range of applications including those for very elastic tissues such 
blood vessels, orthopedic applications, and perivascular wraps. (Yang, 2005; Qiu, 2006; 
Serrano, 2011) The elastic potential of this polymer is dependent upon several 
polymerization properties including the length and temperature of scaffold crosslinking. 
This allows for scaffold customization with regard to elastic potential. Sharma et al 
demonstrate the use of POC in a bladder augmentation model using bone marrow derived 
mesenchymal stem cells. (Sharma, 2010) Data from this study suggests the synthesis of a 
POC film that has elastic properties approaching that of a native human bladder and the 
ability of the POC scaffolds to undergo elongation up to 137% of their initial length. In vivo 
data suggests a high regenerative potential when utilizing POC/cell seeded composites as 
demonstrated by superior muscle to collagen ratios 10 weeks post-implantation (as 
compared to controls).  The non-toxic, degradative by-products of POC also appear to limit 
the level of stone formation with the context of this study, which may aid future bladder 
regenerative studies. Lastly, data also suggests that POC can be chemically modified to 
release pro-angiogenic growth factors over-time that contributes to robust levels of 
angiogenesis in vivo. (Sharma, unpublished data) 
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4.1.2 Elastomeric poly(ester urethane)urea 
A second well described elastomeric compound, poly(ester urethane)urea (PEUU), can also 
be configured into several different forms including those consistent with blood vessels 
while retaining elastic properties. (Stankus, 2007) By concurrent electrospraying and 
electrospinning of vascular smooth muscle cells and PEUU, respectively, a tubular conduit 
containing  the cells was formed with uniform cellular distribution in a radial and 
circumferential manner. Further testing revealed the ability of the material to remain 
sutured, while maintaining compliancy that was similar to native arteries. Modification of 
PEUU also demonstrates the ability to control gene expression utilizing a cleverly created 
gene induction system. (Baraniak, 2011)  Further modifications also allow for the release of 
bioactive molecules of insulin-like growth factor-1 and hepatocyte growth factor. (Nelson, 
2011)  Although this material has not been utilized in a urological regenerative setting to 
date, the implications of this material are obvious as this material could be structured for 
urinary bladder regenerative studies or the creation of synthetic ureters. An overly 
simplistic study design would include the seeding of porous scaffolds with relevant bladder 
cell types as previously described by Baraniak et al accompanied by the appropriate 
functional testing and immunohistochemical analyses. The added benefit of  utilizing PEUU 
is its ability to become modified so that relevant genes such as those found within urologic 
epithelial stem cells may contribute to regeneration, for example. (Pascal, 2007) It is hopeful 
that studies involving PEUU and urological tissue engineering will be seen in the not too 
distant future. 
4.2 Bioactive peptides and peptide amphiphiles for regeneration and wound healing 
Polymeric materials which are enhanced with bioactive peptides show perhaps the greatest 
degree of promise for application in tissue regeneration scaffolds. Short peptide sequences 
originating from the cell binding regions of extracellular matrix (ECM) proteins can be 
incorporated into a graft material to obtain biospecific adhesion of cells. RGD (arginine-
glycine-aspartic acid), the most commonly used peptide in cell adhesion studies, originating 
from fibronectin, collagen, fibrinogen and other ECM proteins, enhances adhesion and 
spreading of most cell types (fibroblasts, endothelial, and smooth muscle cells) and interacts 
with several different integrin receptors. (Humphries, 1990; Massia, 1991) It has been shown 
in the past that migration of smooth muscle cells and fibroblasts is biphasically dependant 
on the concentration of RGD attached to the migratory surface with intermediate loadings of 
RGD displaying maximal mobility. (Olbrich, 1996; Mann 2002) Polymers containing RGD 
sequence have been used in several wound healing in vivo and in vitro applications. For 
instance, incorporation of RGD peptide into PEG hydrogels partially eliminated 
inflammatory reaction of a scaffold implanted subcutaneously in immunocompetent in 
c57bl/6 mice resulting in a reduced presence of macrophages. (Lynn, 2011) Hydrogels 
containing RGD peptide were able to promote healing of ulcers, partial thickness burn 
wounds, and encourage ingrowth of glial tissue in the rat. PHSRN (proline-histidine-serine-
arginine-glutamate), a cell binding peptide sequence has been found to act synergistically 
with RGD sequence for cell adhesion. (van der Veen, 2010; Davis, 2001) When applied 
individually it can stimulate invasion of ECM by keratinocytes and fibroblasts in vitro and it 
can enhance the re-epithelialization and concentration of dermal wounds in healing-
impaired diabetic mice. (Livant, 2000) Other peptides sequences such as laminin-derived 
YIGSR (tyrosine-isoleucine-glycine-serine-arginine), LRE (leucine-arginine-glutamic acid) or 
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IKVAV (isoleucine-lysine-valine-alanine-valine) have potential application in nerve 
regeneration. (Fittkau, 2005; Pittier, 2005) YIGSR, unlike RGD and PHSRN, does not interact 
with the 67 kDa laminin binding protein. (Graf, 1987) In addition, YIGSR promotes the 
adhesion and spreading of many cell types including endothelial cells, fibroblasts, and 
smooth muscle cells. (Massia, 2011) It was found that PEG surfaces functionalized with cell 
binding peptide RGD and YIGSR, significantly increased microvascular endothelial cell 
migration rates relative to RGD alone. (Fittkau, 2005)  
Another group demonstrated that degradation of endothelial ECMs with bacterial 
collagenase releases proangiogenic peptide fragments which can stimulate epithelial 
responses to injury and wound healing in vivo. (Demidova-Rice, 2011)  It has been shown 
that sequences such as Col4-1, Col4-2, Fibr2, Fibr3, Ten1, Ten2, and Comb1 significantly 
increase the rate of sprout formation, which enhances cell-cell interactions and improves 
endothelial motility. Comb1 and Ten2 peptides contain the GXXPG sequence, which was 
previously reported to enhance endothelial migration and tube formation on collagen type I 
in vitro; both induce morphogenesis in a Matrigel-based assay. Comb1, as a larger 
combinatorial peptide with more complex tertiary structure, and two GXXPG sequences 
also stimulates cellular proliferation. The aforementioned sequences can also stimulate 
endothelial response to injury in complex environments where the cells remain viable for a 
prolonged time (up to one week). The 3D model of injury repair which was applied in that 
research consisted of two layers of Matrigel collagen mixture and a layer of endothelial cells 
sandwiched in between. Full thickness injury was created by aspiration, and the defect was 
filled with matrices containing serum, proangiogenic growth factors, or peptides. It was 
demonstrated that in addition to identification of promising proangiogenic or 
antiangiogenic therapeutics, the 3D model of injury repair can be employed to study the 
stability of wound healing compounds and to evaluate drug delivery systems. As described 
in this Chapter bioactive peptides play an important role in a wound healing process and 
tissue regeneration. Fabrication of scaffolds with a high specificity for the adhesion of a 
certain type of cells might require the use of a combination of bioactive peptides such as 
RGD, IKVAV, Ten 2, Comb 1, and biomimetic synthetic polymers, depending on the in vivo 
application.  
Peptide amphiphiles (PA) are small molecules that contain a peptide sequence and a 
hydrophobic segment such as an alkyl tail. (Silva, 2004; Rajangam, 2006)  Hydrophobic 
collapse of these filament-forming molecules under strong screening conditions leads to the 
display of biological signals on their surfaces in high density (on the order of 1015 signals per 
cm2). (Cui, 2010)  In vivo and in vitro studies have shown that certain PA molecules, bearing 
bioactive epitopes promote regeneration of spinal cord axons, angiogenesis, bone 
regeneration, cartilage repair, and selective differentiation of neural progenitor cells into 
neurons. (Sargeant, 2008; Webber, 2010; Silva, 2004) Previously, PAs were used to coat PGA 
microfiber scaffold for the improved attachment of smooth muscle cells. (Harrington,  
2006; Behanna, 2005) This PGA scaffold was submerged in a suspension of smooth muscle 
cells in media and modified with PA gel mixed with growth factors as a top layer for the 
entrapment of cells. The opposite face of the scaffold could them be modified using a second 
component, which in this case was a mixture of PGA and urothelial cells, since these cells 
could potentially send necessary signals to smooth muscle cells during regeneration. (Beqaj, 
2005; Imamura, 2007)  When the human bladder smooth muscle cells and urothelial cells 
where embedded in a PA-scaffold with a growth factor (bFGF) and incubated in vivo in a 
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subcutaneous nude rat model, it was found that the human bladder smooth muscle cells 
were retained and composed the majority of the scaffold cellular content. It was also found 
that the system which uses a combination of PGA, PA, growth factors and cells 
demonstrated higher levels of phenotypic alpha-smooth muscle actin than control scaffolds 
made of PGA and cells only. PAs offer a great potential in regenerative medicine due to 
their nanoscale filamentous assembly resembling the one in ECM, the ability to incorporate 
any bioactive epitopes into their structure, and propensity to form gels.  
4.3 Nano- and microstructured surfaces for bladder regeneration 
Nano- and microstructured surfaces offer great potential for a range of biomedical 
applications from biochips, bioarrays and biosensors to functional membranes and cell 
adhesion substrates. It is much easier to create nano- or micrometer patterns on surfaces 
such as metal, glass or silicon than on polymeric surfaces since the surface composition and 
flatness is much better defined. (Qin, 2010; Jackman; 1998)  The techniques that are usually 
employed for nano- and microstructuring of surfaces include nanoimprint lithography 
(NiL), microcontact printing, shadow-mask lithography, photolithography, chemical etching 
processes, robotic spotting techniques, and more. Unfortunately only very few of these 
techniques are suitable for the surface modification and structuring of (bio)polymers 
commonly used as the bladder regeneration materials such as PGA, PLGA, poly(L-lactic 
acid) (PLLA), poly(ε-caprolactone) (PCL), and poly(carbonate-urethane) (PCU). (Miller, 
2004; Pattison, 2006) Nanoscale roughness is believed to improve the adhesion of proteins 
due to its higher surface area and surface energy.  Surfaces functionalized with protein such 
as fibronectin, laminin, collagen I or IV, ECM-type of protein and surfaces with nanometer 
roughness visibly improve bladder cell adhesion and interactions with the substrate. This 
phenomena is important in bladder regeneration since many implanted polymeric 
membranes need to be relatively quickly and efficiently replaced by healthy host tissue. 
Tissue integration into the biomaterial must occur; therefore resident cells need to adhere 
appropriately to the substrate in order for subsequent cellular functions to occur at the 
implant site. Nanoscale roughness of biopolymers or synthetic biodegradable polymers 
used in bladder regeneration research can be achieved by numerous techniques including 
surface functionalization with nanometer-size fibers such as PAs, electrospinning, chemical 
etching, nano- and micromolding and more. (Harrington, 2006; Doshi, 1995; Thapa, 2003)  
The aforementioned techniques may be applied as potential methods for the fabrication of 
improved scaffolds for bladder regeneration. 
Alternative means to achieve nanostructured membranes for bladder regeneration research 
utilizes micro or nanomolding. PLGA or PU polymers can be easily cast into molds with 
pre-fabricated nanometer features made of poly(dimenthylsiloxane) (PDMS). (Thapa, 2003) 
The procedure relies on pouring a solution of a polymer (for example PLGA or PU) onto a 
PDMS master mold, curing the polymer until is solid and releasing the polymer from the 
mold simply by peeling the film off from the mold. The minimum size of the features that 
could be achieved is defined by the master mold. This process is commonly used in the 
fabrication of microcontact printing stamps for soft lithography purposes. In this process the 
mold is usually fabricated in silicon through photolithography or e-beam lithography and 
the polymer which is used for stamps is usually PDMS. (Xia, 1998) PLGA and PU 
nanostructured polymers showed advantage in ovine bladder smooth muscle cells adhesion 
over polymers with larger features. 
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An interesting method for the bladder surface nanostructuring is the application of 
nanoparticles to introduce nanoscale roughness or improve certain properties such as 
permeability of the scaffold. One example was recently introduced where hyaluronic acid 
(HA) modified PLGA nanoparticles (HA PLGA NPs) were applied for the modification of 
SIS as a scaffold for bladder regeneration to alter its permeability and simultaneously 
deliver pro-regenerative compounds. (Roth, 2010) When SIS scaffolds were modified with 
PLGA NPs of the size in the range of 200-500 nm the scaffold showed a decrease in 
permeability to urea when compared with unmodified scaffolds. In addition, PLGA 
modified scaffolds demonstrated significantly higher adhesion of endothelial cells in 
comparison to unmodified scaffolds. Introduction of pro-regenerative compounds into the 
SIS scaffold via modification of PLGA NPs with HA (which has been recognized for its 
ability to promote scarless wound healing), improved the SIS scaffold in vivo performance. 
HA was attached through electrostatic interaction to the positively charged PLGA NPs 
which were previously modified with polyethylene imine to produce cationic NPs. The 
attachment of particles to the SIS scaffold was conducted by incubation and absorption of 
particles from solution. The modified SIS membrane was investigated for angiogenesis and 
permeability studies. It was found that HA-NP SIS demonstrated a statistically higher 
number of blood vessels when compared with unmodified. In addition, HA-NP SIS 
significantly decreased or even eliminated the propensity to form calcifications, decreased 
urea permeability and improved full-thickness bladder regeneration.  
Electrospinning is one of the most commonly used techniques for the (nano)fiber formation. 
In this process, nanofibers can be formed through an electrically charged jet of polymer 
solution or polymer melt. The simplest setup for electrospinning is composed of a high 
voltage power supply, a polymer solution reservoir (e.g. a syringe with a small diameter 
needle), and two electrodes (one connected to the needle and the other to the surface of the 
collecting mat or other substrate). The polymer supply is connected with a power supply 
through an electrode clipped to the metal needle for electrospinning. Flow control pump can 
be used to precisely control the flow rate of the polymer solution which is spun onto a 
substrate. The fiber-collecting surface must be conductive in order to attract the electrospun 
polymer and can be either stationary or rotating plate for collecting nonwoven or aligned 
fibers, respectively. 
Electrospinning permits fabrication of biodegradable elastomers into matrices that can 
resemble the scale and mechanical behavior of the native extracellular matrix. There is a 
great selection of polymers available for the electrospinning of nanofibrous scaffolds used in 
tissue engineering applications. Moreover, this process can be easily scaled up making the 
transformation from small-scale laboratory research into large-batch processes feasible. 
(Greiner, 2008; Zhong, 2010)  In addition to being used to fabricate nonwoven mats for 
wound dressings, there is currently much interest in making scaffolds for bladder tissue 
engineering. (Roth, 2010; Gelain, 2008) Baker et al used a 3D electrospun nanoscaffold of 
polystyrene to determine whether the phenotype of cells isolated from the stroma of human 
ureter specimens could be modulated by growing cells within such scaffold. (Baker, 2008) 
Non-aligned scaffolds made out of fibers with mean diameter of 200 nm were used in that 
study. Unfortunately the analysis of SM-MHC protein expression in cultures grown in 3D 
revealed that those cultures failed to undergo differentiation. It was explained that 
nanostructured polystyrene scaffolds have a high propensity to adsorb serum which 
maintained stromal cell cultures in a synthetic non-differentiated phenotype. In this case, 
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the approach of growing cell cultures in a serum-free media on the 3D polystyrene scaffold 
did not bring positive results. It was found that despite of its promising advantages of 
electrospun scaffold, stromal cells did not differentiate primarily due to the high propensity 
of the scaffold to the absorption of proteins from the serum. However, serum-free media 
reduced the absorption of proteins but cells still showed a greatly reduced plating efficiency 
and cultures failed to survive.  
Findings describing the interactions between human bladder urothelial cells (TEU-2) and a 
scaffold composite consisting of an electrospun fibrous matrix made of PCU and PLLA  
fused to a thin film for potential use in urothelial tissue regeneration. (Kundu, 2011) Their 
results suggested that when electrospun scaffolds alone (without the thin film) were used, 
their fibrous surface structure while allowing good cellular adhesion, inhibited the 
proliferation of urothelial cells, whereas cells seeded onto thin films with non-fibrous 
surfaces proliferated quickly. In addition, it was found that cells on electrospun fibers 
demonstrated numerous cellular extensions along the matrix fibers, rather than the 
substantial cell-cell integrations. It was explained that this finding may suggest that the 
fibrous nature of the electrospun materials do not facilitate the formation of an intact 
urothelium. The addition of thin films onto electrospun scaffolds, enhanced urothelial cell 
proliferation, surface coverage, cell-cell interactions, and multilayering in vitro. Electrospun 
scaffolds alone offer highly porous structures and deep cellular penetration, however they 
are unlikely to provide a sufficient barrier to water and solute transport when not 
embedded in a biomimetic synthetic polymer. Furthermore, the three-dimensional structure 
of such scaffolds may affect cell proliferation, differentiation or adhesion.  
5. Conclusion 
The task to create functional organs as a replacement therapy is indeed quite daunting.  
Tissue engineering studies during the late 1980s and early 1990s laid the groundwork for the 
current windfall of clinical applications that have been deployed for organ replacement. The 
continual evolution of materials science influenced materials combined with discoveries in 
the field of stem cell biology provides hope that goals of regenerative medicine can be 
achieved. Although there have been many significant advances with regard to urologic 
tissue engineering, the field is still in its infancy. There is still a great need to pursue basic 
and clinical science studies in order to benefit those afflicted with urological trauma or 
disease.   
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Tooth Organ Engineering: Biological Constraints 
Specifying Experimental Approaches 
*Sabine Kuchler-Bopp1,2, Laetitia Keller1,2, Anne Poliard3 and Herve Lesot1,2 
1INSERM UMR977, Université de Strasbourg,  
2Faculté de Chirurgie Dentaire, Université de Strasbourg,  
3EA 2496, Université Paris Descartes, Faculté de Chirurgie Dentaire, Montrouge, 
France 
1. Introduction 
Basically, two types of approaches are currently being developed for tooth engineering. The 
first one consists in the engineering of dental constituents, such as the periodontium, the 
pulp/dentin, or the enamel/dentin complexes (Duan et al., 2011; Honda et al., 2009; Huang, 
2009; Park et al., 2010). In parallel with these experiments of tissue engineering, attempts are 
also made to reconstruct a whole tooth (Arany et al., 2009; Honda et al., 2008; Hu et al., 
2006a; Komine et al., 2007; Nakao et al., 2007; Ohazama et al., 2004). Most of this chapter will 
consider the second goal, and only use data from tooth tissue engineering, when they bring 
information about the cellular or molecular mechanisms that are involved and/or about the 
specific constraints, which they may illustrate. 
Few groups are interested in a biomimetic approach to engineer a whole tooth, including 
crown, roots, and periodontium by using cultured cell-cell re-associations and trying to 
recapitulate the successive steps of tooth development (Arany et al., 2009; Honda et al., 2008; 
Hu et al., 2006a; Nakao et al., 2007; Ohazama et al., 2004). Specific questions arising from 
this research concern the experimental design, and the search for easily available cell 
sources. The panel of approaches is progressively restricted by two types of biological 
constraints: those specifically related to tooth functionality and those related to more general 
biological aspects such as the maintenance of the cell heterogeneity in the dental 
mesenchyme and in the periodontium, keeping the gradients of cell differentiation and their 
3D-geometry, or the maintenance of the cell kinetic parameters to ensure the differential 
cusp timing and growth. These complementary points will be discussed in light of parallel 
approaches being developed by different groups. 
2. Abbreviations 
BMSCs: bone marrow stem cells, CGHT: chondroitin-6-sulfate/gelatin/hyaluronate tri-
copolymer, CL: cervical loop, DM: dental mesenchyme, DEJ: dentin-enamel junction, DFPCs: 
dental follicle precursor cells, DP; dental pulp, DPSCs: dental pulp stem cells, DRG: dorsal root 
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ganglia, ECM: extracellular matrix, ED: embryonic day, FGF: fibroblast growth factor, GFP: 
green fluorescent protein, HA/TCP: hydroxyapatite/tricalcium phosphate, IDE: inner dental 
epithelium, iDPSCs: induced dental pulp stem cells, iPSCs: induced pluripotent stem cells, 
MSCs: mesenchymal stem cells, NF-PLLA: nanofibrous-poly-Llactic acid, ODE: outer dental 
epithelium, PDLSCs: periodontal ligament stem cells, PEK: primary enamel knot, PGA: 
polyglycolic acid, PLGA: poly-L-lactate-co-glycolate, PLLA: poly-L-lactate, SBP: stromal bone 
producing cells, SCAPs: stem cells from the apical papilla, Shh; Sonic hedgehog, SI: stratum 
intermedium, SHEDs: stem cells from human exfoliated deciduous teeth, SPCs side population 
cells, SR: stellate reticulum, SMA: smooth muscle actin, β-TCP: β-tricalcium phosphate. 
3. Engineering a whole tooth using embryonic dental cells 
Embryonic dental cells are commonly used as they allow a full tooth development from cell-
cell re-associations (Honda et al., 2008; Hu et al., 2005; Nakao et al., 2007). A two stages 
methodology has been developed, where cell-cell re-associations are cultured in vitro before 
implantation in adult mice (Fig. 1; Hu et al., 2006a; Nakao et al., 2007). The in vitro culture 
allowed epithelial histogenesis, initiation of crown morphogenesis and odontoblasts to 
become post-mitotic (Fig. 2A, C, D). Ameloblast functional differentiation as well as root 
and periodontal tissue development started during the implantation period (Fig. 2B, E). This 
two steps method is quite well established and has been used with either dental or non-dental 
cell sources (Arany et al., 2009; Honda et al., 2007; Nakao et al., 2007; Ohazama et al., 2004).  
3.1 Epithelial histogenesis and crown morphogenesis 
During tooth development, the primary enamel knot (PEK), a morphogenetic center 
controlling crown morphogenesis, transiently forms in the enamel organ (Jernvall & 
Thesleff, 2000). The histogenesis and functionalization of this structure in cell-cell re-
associations is thus an essential step to be achieved. Using embryonic dental cells, the PEK 
reproducibly formed during early stages of the re-association in vitro (Fig. 2C) and was 
characterized by the condensation of non dividing cells in the epithelium, their expression of 
Shh and a local concentration of apoptosis (Hu et al., 2005). Four days after this PEK 
specification, cusps developed, showing that this structure was functional (Fig. 2A). 
However, up to now, this could not be achieved when using bone marrow cells instead of 
embryonic dental mesenchymal cells (Nait Lechguer et al., 2009). It was shown that the 
mesenchyme specifies epithelial histogenesis (Lesot & Brook, 2009; Nait Lechguer et al., 
2009) and that the number of mesenchymal cells used for re-association is a critical 
parameter in determining the number of cusps (Hu et al., 2006a). In contrast with bone 
marrow cells (Ohazama et al., 2004), the potentialities of the embryonic dental mesenchymal 
cells to stimulate tooth formation are lost in vitro (Keller et al., 2011). Attempts were made to 
recover it by pre-culturing these cells in the presence of FGF2 (Arany et al., 2009; Keller et 
al., 2011). Like FGF2, the use of FGF1 or FGF8 or their combination did not allow tooth 
formation (data not shown). In cell-cell re-associations, the potentialities of cells to engage in 
tooth development seem to be revealed during the first few hours of co-culture, several days 
before it became histologically visible. There is no molecular marker to anticipate the fate of 
cells in re-associations and to predict whether they can engage in tooth formation. On the 
other hand, there is no published example where cell-cell re-associations could engage in 
early stage of tooth re-formation and stop thereafter, as observed in several mutants where 
the bud to cap transition is critical (Jernvall & Thesleff, 2000; Peters & Balling, 1999). 
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Fig. 1. Schematic representation of the experimental procedures. 
The mandibular first molars were dissected from ICR embryos at embryonic day (ED) 14. 
All procedures with animals were in compliance with the recommendations of the European 
Economic Community (86/609/CEE) on the use and care of laboratory animals. The dental 
epithelium and mesenchyme were dissociated by using 1% trypsin in DMEM-F12 at 4°C for 
30 min. After separation, the dental epitheliums and mesenchymes were dissociated into 
cells by centrifugation through 70 μm nylon filters. Epithelial and mesenchymal cells were then 
pelleted by centrifugation at 9000 g., fragments of each pellet were re-associated and cultured 
for 8 days. After 8 days in vitro, the re-associations were implanted between skin and 
muscles behind the ears in ICR or GFP adult mice. The implantations were maintained for 
up to two weeks 
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Fig. 2. Histology of dental epithelial and mesenchymal cell-cell re-associations cultured for 4 
days (C), 8 days (A, D) and implanted for 2 weeks under skin (B, E).  
For histology, samples were fixed in Bouin-Hollande, embedded in paraffin, and 5 μm serial 
sections were stained with Mallory. Implants were demineralized in 4.3% EDTA before their 
inclusion in paraffin. At four days in culture, the PEK was visible (C) and cusps developed 
after 8 days (A). After 8 days in culture, preodontoblasts and postmitotic odontoblasts are 
facing preameloblasts (D). After implantation (B, E) ameloblasts became functional, gradient 
of differentiation and mineralization of the dental matrices were achieved. Am: ameloblasts, 
CL: cervical loop, D: dentin, DEJ: dentin-enamel junction, DM: dental mesenchyme, DP: 
dental pulp, E: enamel, IDE: inner dental epithelium, ODE: outer dental epithelium, Od: 
odontoblasts, pAm: preameloblasts, pD: predentin, PDM: peridental mesenchyme, 
PEK:primary enamel knot, pOd: preodontoblasts, SI: stratum intermedium, SR: stellate 
reticulum. Bars= 10μm (D, E) and 40 μm (A, B, C) 
The in vitro culture of embryonic dental cell-cell re-associations allowed the rapid deposition 
of a basement membrane at the epithelial-mesenchymal junction. A complete epithelial 
histogenesis could be achieved within 4 to 6 days, including the inner and outer dental 
epitheliums, the stellate reticulum and, later, the stratum intermedium (Fig. 2A, C; Hu et al., 
2005). This stratum intermedium plays an essential role in the functional differentiation of 
ameloblasts (Lesot & Brook, 2009; Nait Lechguer et al., 2011; Yoshida et al., 2010). Only in 
one report, non polarized ameloblasts-like cells expressing amelogenin appeared to be 
generated in the absence of a stratum intermedium (Honda & Hata, 2010). However, it is not 
known whether these cells, after longer implantation periods might indeed lead to the 
formation of organized enamel crystals.  
However, it remains to be determined whether and how far such potentialities can be 
maintained at later embryonic stages and also in the adult (Keller et al., 2011). 
Keratinization, leading to cyst formation, is indeed a major problem arising when culturing 
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cell-cell re-associations, or even after implantation (Arany et al., 2009; Honda et al., 2008; 
Komine et al., 2007). Such cysts may then mechanically interfere with tooth morphogenesis. 
It is not clear yet, whether embryonic dental epithelial cells can be expanded in vitro, 
without loosing their potentialities, as observed with mesenchymal cells (Keller et al., 2011). 
3.2 Functional cell differentiation 
During tooth development, the differentiation of odontoblasts and ameloblasts occurs in a 
progressive way. Gradients in the cytological and functional differentiation of the two cell 
types warrant the adhesion of enamel to dentin. It also allows the further growth of the 
tooth from the late bell stage, while it is already impaired at the tip of the cusps by the 
matrix accumulated there. In the absence of interposed scaffold, the exchanges between the 
epithelial and ecto-mesenchymal compartments can occur directly and the planar signaling 
within the preodontoblast-odontoblast cell layer can have a direct echo on the 
preameloblast-ameloblast layer (Ruch et al., 1995). It is not known how far this is 
transmitted to the stratum intermedium. In the absence of scaffold, gradients of 
differentiation and the progressive polarized deposition and mineralization of the dental 
matrices could be reproduced in cultured and implanted cell-cell re-associations (Fig. 2B, E). 
Recently, the organization of these mineralized matrices has been investigated (Honda et al., 
2008; Nait Lechguer et al., 2011). Tooth-specific constraints include the necessity to get a 
correct mineralization of the matrices (dentin, enamel and cementum), which itself requires 
a good vascularization of the reconstructed organ (Fig. 4A-D; Nait Lechguer et al., 2008, 
2011). Ultimately, the quality of the dentin-enamel junction (DEJ) and the orientation of the 
crystals in each matrix will determine the functionality of the tooth (Katz et al., 2007). The 
DEJ has been viewed as a connector between two matrices with distinct mechanical 
properties. The quality of this DEJ, with its own mechanical and bonding specificities, is 
thus a critical parameter to be preserved in tooth engineering. The risk of interfering with 
the integrity of the DEJ might then represents a major limitation in the use of scaffolds 
designed to shape engineered teeth (Xu et al., 2008). 
Depending on the region of the dental mesenchyme during tooth development, local 
specificities were observed, which supported differential timings in cusp formation, their 
individual kinetic of development, and their final different sizes (Lesot et al., 1999). These 
were suggested to result from regional variations in cell proliferation kinetics, thus requiring 
sophisticated mechanisms to coordinate these events in the ecto-mesenchyme and neighbor 
inner dental epithelium (Lesot et al., 2001; Lisi et al., 2003). These parameters have not been 
investigated in the case of cultured and implanted cell-cell re-associations, although they 
would determine the crown shape. To avoid probably very difficult questions, it was 
suggested to put efforts mainly on root engineering allowing then the implantation of an 
artificial crown (Volponi et al., 2010). 
3.3 Root formation 
More and more, the root appears as the key point in tooth engineering because its 
functionality is related to tooth anchoring as well as in the mediation of tooth movement in 
the jaw. For this reason, it is important to avoid ankylosis. As determining tooth 
functionality, the development of root in cell-cell re-associations has been investigated as 
well (Honda et al., 2010; Hu et al., 2006a; Nait Lechguer et al., 2011). 
Using embryonic dental cells, root formation could be initiated, but only after implantation 
of the cultured cell-cell re-associations (Fig. 3A, B; Hu et al., 2006a). In these conditions, the 
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periodontium formed and elongated cells, similar to periodontal ligament fibers, extended 
from the root dentin to newly formed bone (Fig. 3C; Hu et al., 2006a). During the two weeks 
of implantation, the periodontium remained as a non-mineralized zone in between the 
dentin/cementum (Fig. 3D, E) and newly formed bone (Nait Lechguer et al., 2011). Longer 
periods of implantation will have to be tested in order to determine whether the absence of 
mineralization of this area can be preserved. The maintenance of homeostasis after long 
term implantation will also have to be investigated since the periodontal ligament is a rather 
complex tissue (for review see Nanci & Bosshardt, 2006). 
Attempts to regenerate the periodontium were also performed using postnatal stem cells 
from the periodontal ligament (Table 3; Seo et al., 2004). However, this potential cell source 
only represents a few cells. Other approaches have been developed, using bone marrow 
stem cells (Kawaguchi et al., 2004), or muscle derived-stem cells (Yang et al., 2010). The role 
of blood vessels and the participation of progenitor/pericytic cells in periodontium 
development and regeneration have been extensively reviewed (Ripamonti & Petit, 2009). 
However, with these cells, the goal was very focused and no attempt was made to test how 
far, in a different context, they could give rise to other dental tissues. Such a hypothesis has 
been formulated recently (Rothova et al., 2011). 
 
 
Fig. 3. Histology of root formation in cell-cell re-associations cultured for 8 days and 
implanted for 1 week (A) and 2 weeks under skin (B, C, D, E). 
Between one week (A) and two weeks (B) of implantation, the root was forming. 
Cementoblasts (D) secreted cementum (E) and the peridontium (C) remained as a non- 
mineralized zone in between the dentin/cementum and newly formed bone. Am: 
ameloblasts, B: bone, BV: blood vessel, Cb: cementoblasts, Ce: cementum, CL: cervical loop, 
D: dentin, DP: dental pulp, E: enamel Od: odontoblasts, pOd: preodontoblasts, pD: 
predentin, PDL: periodontal ligament. Bars=10μm, (D) 20 μm (C, D) and 30 μm (A, B) 
3.4 Organ vascularization 
The primary role of vascularization is related to oxygenation and metabolic exchanges, thus 
allowing cell survival. Since it cannot be functional in vitro, culturing large sized samples 
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may be rapidly impaired, so that the implantation of the re-associations is absolutely 
necessary. The interstitial flow, generated by vascularization, may further mediate the 
extracellular transport of molecules, including growth factors, thus coupling mechanical and 
chemical signaling (Griffith & Schwartz, 2006). The requirement of vascularization for dental 
matrices mineralization, explains its specific patterning in time and space during tooth 
development, including in the enamel organ (Fig. 4C; Manzke et al., 2005; Nait Lechguer et 
al., 2008). Cultured dental embryonic cell-cell re-associations could be vascularized after 
they were implanted under the skin or in the jaw of adult mice (Fig. 4A-E; Nait Lechguer et 
al., 2008, 2011; Nakao et al., 2007). It has been suggested that dental pulp stem cells might 
give rise to functional blood vessels (Cordeiro et al., 2008). However, cultured embryonic 
dental cell-cell re-associations from ICR mouse embryos have been implanted in GFP mice, 
which showed that all newly formed blood vessels entering the dental mesenchyme and the 
enamel organ, originated from the host (Nait Lechguer et al., 2008).  
 
 
Fig. 4. Vascularization of subcutaneously implanted cultured epithelial/mesenchymal cell-
cell re-associations in adult ICR mice (A-H). 
Epithelial/mesenchymal cell-cell re-associations were cultured for 8 days in vitro prior to 
implantation for 2 weeks under skin. Histology showed that blood vessels can enter in the 
dental pulp (D), migrate in the pulp (A), and reach odontoblasts (B). In the enamel organ, 
blood vessels were in close contact with the stratum intermedium (C). Blood vessels were 
localized by immunofluorescent staining for CD31 (E, H) and pericytes were detected by 
immunofluorescence staining for αSMA (G, F, H). Cells detected by αSMA coming from the 
PDM could reach and enter in the pulp (G). All blood vessels detected by CD31 were not 
positive for αSMA (H). Implants were embedded in Tissue-Tek (Agar Scientific, Saclay, 
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France) and frozen at -30°C. Immunostaining was performed on serial frozen sections (7 μm) 
with rat monoclonal anti-mouse CD31 (1/100) (BD Pharmingen, Evry, France) and 
polyclonal rabbit anti-human αSMA (1/100) (Abcam, Cambridge, MA, USA). Sections were 
incubated for 2hrs at room temperature with the primary antibodies and for 1hr with 
donkey anti-rat secondary antibodies conjugated to Alexa 488 (1/200) and chicken anti-
rabbit conjugated to Alexa 594 (1/500) (Molecular Probes, Invitrogen SARL, Cergy Pontoise, 
France). Am: ameloblasts, BV: blood vessel, D: dentin, DP: dental pulp, E: enamel,  
Od: odontoblasts, P: pericyte, pD: predentin, PDM: periodontal mesenchyme, SI: stratum 
intermedium.  Bars=10μm, (A, C) 20 μm (B, G) and 60 μm (D, E, F, H) 
Vascularization may play a further role, at least in the mesenchymal compartment. Cells 
with a mesodermal origin participate in the dental pulp formation including the blood 
vessels, which develop there (Chai et al., 2000; Rothova et al., 2011). Some of the 
mesenchymal stem cells present in the dental pulp might originate from perycites (Feng et 
al., 2010; Lovschall et al., 2007). Since the perivascular environment may play an essential 
role as it remains a potential source of stem cells possibly involved in reparative processes 
(Shi & Gronthos, 2003), this context could explain the results published by Arany and co-
workers (2009). These authors could obtain the formation of a tooth when re-associating a 
clonal cell line derived from a dental mesenchyme with a competent enamel organ and 
implanting these re-associations. As far as the implants can be vascularized, external cells 
might thus participate in the re-formation of the dental mesenchyme and allow restoring the 
complex cellular heterogeneity of this tissue, which hardly could be expected to originate 
from a clonal cell line (Keller et al., 2011). Pericytes in implanted cell-cell re-association were 
visualized after immunostaining for a smooth muscle actin (αSMA) (Nehls & Drenckhahn, 
1991) and detected both in the apical part of the dental pulp (Fig. 4G) and peridental 
mesenchyme (Fig. 4F, H). All blood vessels detected by CD31 were not positive for αSMA 
(Fig. 4H). The presence of stem cells associated with the blood vessels during the early 
stages of vascularization of implanted cell-cell re-associations will have to be investigated to 
better understand the data from Arany et al. (2009). 
3.5 Innervation 
Besides the mediation of pain sensation, tooth innervation is involved in several 
complementary aspects such as the recruitment of immunocompetent cells (Byers et al., 
2003; Fried et al., 2000), the control of odontoblast function (Fristad et al., 1999) and the 
prevention of tooth ankylosis. Being necessary for tooth functionality, the innervation 
remains as a major challenge in tooth engineering. The innervation of the tooth is initiated 
relatively late during development and involves sensory and sympathetic nerves. Complex 
molecular mechanisms regulate the timing and pattern of tooth innervation (Fried et al., 2007; 
Kettunen et al., 2005; Luukko et al., 2008). It has been suggested that the epithelium instructs 
and controls dental axons navigation in the dental mesenchyme (Luukko et al., 2008). 
Attempts to implant extracted or engineered teeth in the jaw of adult mice could be 
achieved (Ferreira et al., 2007; Honda et al., 2006; Nait Lechguer et al., 2008; Nakao et al., 
2007). However, it always remained quite far from nerves. Still a correct positioning of the 
implanted cell-cell re-associations in the jaw cannot be controlled in the mouse or rat, where 
they are relatively small.  It is thus impossible to specifically position the prospective root-
forming part of the implant so that it is oriented towards the alveolar nerve (Honda et al., 
2006; Nait Lechguer et al., 2008). In parallel, preliminary experiments have been performed 
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to test the possibility to obtain the innervation of cultured cell-cell re-associations after 
implantation under the skin. For this purpose, embryonic dental cell-cell re-associations were 
implanted together with DRG (Fig. 5A). After 2 weeks of implantation, immunostaining for 
peripherin showed the axonal growth in the peridental tissues (Fig. 5C, D), but not in the 
dental mesenchyme (Fig. 5B, C, D). The impossibility to innervate the dental mesenchyme 
might be related to the embryonic stage (ED14) that was used to prepare dental cells. Indeed 
at ED14, innervation remains inhibited in physiological conditions, and only becomes 
possible postnatally (Luukko et al., 2008). The expression of semaphorins, which regulate 
innervation, will have to be investigated in implanted cell-cell re-associations. 
 
 
Fig. 5. Innervation of subcutaneously implanted cultured epithelial/mesenchymal cell re-
associations with DRG in adult ICR mice (A-D). 
Epithelial-mesenchymal cell-cell re-associations were cultured for 8 days in vitro prior to co-
implantation with DRG from ED12. After 2 weeks of implantation under the skin (A), axons 
and DRG were detected by immunofluorescent staining for peripherin. Axons growing from 
DRG in contact with the PDM (A, B) were detected at the limit between PDM and DP (C, D). 
However, they never entered the DP (B, C). Implants were fixed with 4% paraformaldehyde 
and embedded in paraffin. Immunostaining was performed on serial paraffin sections (7 
μm) with rabbit polyclonal anti-human peripherin (1/100) (Abcam, Cambridge, MA, USA). 
Sections were incubated for 2hrs at room temperature with the primary antibody and for 
1hr with chicken anti-rabbit conjugated to Alexa 594 (1/500) and to Alexa 488 (1/200) 
(Molecular Probes, Invitrogen SARL, Cergy Pontoise, France). BV: blood vessel, DP: dental 
pulp, DRG: dorsal root ganglia, PDM: periodontal mesenchyme, T: tooth.  Bars= 20 μm (C, 
D) and 40 μm (A, B) 
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4. Using matrix or artificial polymers instead of cells only 
A tricky point in the experimental designs being developed in different laboratories is 
whether to use scaffolds or not. Several scaffolds with different composition and 
complementary purposes have been used for tooth engineering (Fig. 6). 
4.1 Pre-shaped scaffolds 
In some instances, scaffolds of different natures have been designed to try to “pre-shape” 
the tooth to be engineered (Fig. 6; Kim et al., 2010; Young et al., 2005). Despite their potential 
interest to direct crown morphology, scaffolds also have their own limitations. Indeed, they 
may impair correct cell-cell interactions, and thus interfere both with the general 
histogenesis and with epithelial-mesenchymal interactions. This is critical since these 
interactions control all aspects of tooth development: epithelial histogenesis, crown 
morphogenesis, and cell differentiation, as well as root development (Jernvall & Thesleff, 
2000; Ruch et al., 1982; Slavkin et al., 1984).  
The question of tissue interfaces junction has been raised with other models such as the 
complex ligament-, tendon- or cartilage-bone interfaces. For this specific purpose, attempts 
are made to develop stratified scaffolds (Lu et al., 2010). Similar challenges exist when trying 
to restore dentin/enamel, dentin/cementum, or cementum/periodontal fibers interfaces 
and maintain their specific mechanical properties. During tooth development, tissues 
interfaces usually show multi-step formation where extensive matrix remodeling takes place 
(Bosshardt et al., 2005; Ho et al., 2009; Imbeni et al., 2005). In all these interfaces, there is a 
tight structure-function relationship. In case of multiple bone interfaces, these characteristics 
were taken into account to design biomimetic stratified scaffolds (Lu et al., 2010). In this 
specific case however, scaffolds were not designed to try shaping a tissue, but to set up a 3D 
spatial organization of cells activities. The ultimate goal was to reproduce physiological 
mechanical properties by patterning matrix heterogeneity. Similarly for periodontium 
engineering, attempts have been made to design hybrid scaffolds allowing the maintenance 
of the ligamentous fibers spatial organization (Park et al., 2010). According to these authors, 
the design will have to be further developed by introducing mechanical forces in order to 
better adjust the spatial organization of fibers.  
Depending on their structure and surface organization, scaffolds may also interfere with 
horizontal signaling within the odontoblast and/or ameloblast layer(s). The main problem 
would be related to the odontoblast layer, since the extent of the gradients which they may 
form will have direct consequences on the patterning of ameloblast differentiation and, 
ultimately, on enamel organization (Nait Lechguer et al., 2011). The morphology of the 
epithelial-mesenchymal junction, just before ameloblast differentiate, is thought to 
represent the physiological scaffold and template for the final crown shape (Skinner & 
Gunz, 2010). During tooth development, the different cusps show different specific 
kinetics of cell differentiation (Lisi et al., 2003). Still very little is known about the 
mechanisms involved in it despite active research to address this question (Salazar-
Ciudad & Jernvall, 2004, 2010). 
Obviously, the design of a scaffold is strongly related to the tissue to be engineered (Chan & 
Leong, 2008) and to the purpose of its use: either for organ shaping (Kim et al., 2010; Young 
et al., 2005), or, more simply to maintain high cell density and cohesion as discussed below 
(Arany et al., 2009; Nakao et al., 2007). 
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Fig. 6. Schematic representation of experimental procedures developed for tooth organ 
engineering 
4.2 Extracellular matrix constituents 
For tooth engineering, extracellular matrix (ECM) constituents (Fig. 6) were not used to 
shape the forming organ but either to maintain cells together and work with high cell 
density or to retain signaling molecules involved in stimulating morphogenesis and/or cell 
differentiation (Griffith & Schwartz, 2006; Honda et al., 2005; Huang et al., 2010; Nakao et 
al., 2007; Sumita et al., 2009). The level of signaling in the mesenchyme was recognized as a 
potentially limiting factor in tooth engineering (Hu et al., 2006a; Nait Lechguer et al., 2009). 
The matrix may be involved in signaling either directly through cell surface receptors, or 
indirectly because of its ability to differentially bind diffusible growth factors, and also 
because it contains enzymes modulating or tuning the two other ways (Discher et al., 2009; 
Reilly & Engler, 2010; Rhodes & Simons, 2007). These different molecules may explain why 
and how the ECM can interfere with distinct cellular activities such as the adhesion, migration, 
proliferation, survival and differentiation. For this reason also, it is difficult to design the 
composition of the ECM scaffold. Beside matrix stiffness, which may interfere with cell 
migration and thus with morphogenesis, Griffith and Schwartz (2006) took into account the 
formation of molecular gradients, one parameter, which may be very important for tooth 
formation. The main difficulty in using ECM constituents is related to the physiological 
complexity of the 3D environment, as it exists in a tissue. However, cells can rapidly modify 
and re-adjust this environment as far as ECM constituents can initially be populated by the 
different cell types present in a tissue, so that a physiological homeostasis and histogenesis can 
then be restored (Keller et al., 2011). ECM scaffold remodeling is thus an important parameter 
to be investigated when the organ formation progresses (Badylak et al., 2009). 
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Different matrix constituents have been used for tooth engineering (Table 1). However, 
collagen, under different forms, was by far the most frequently used (Honda et al., 2007; 
Nakao et al., 2007; Sumita et al., 2006). Collagen gel has been successfully used for dental 
cells encapsulation, as obviously neither interfering with the epithelial histogenesis nor with 
the patterning of cell differentiation (Arany et al., 2009; Honda et al., 2008; Nakao et al., 
2007). It would be interesting to analyze the behavior of epithelial cells in such an 
environment, which they physiologically never meet. 
Comparing the potentialities of different scaffolds, possible inhibitory effects of collagen on 
hard tissue formation have been reported (Ohara et al., 2010). However, other studies ended 
up with tooth formation (Arany et al., 2009; Nakao et al., 2007). Although their degree of 
mineralization was not measured, dentin and enamel were secreted in these two 
independent studies. 
 
 
Table 1. Extracellular matrix constituents used for tooth engineering 
4.3 Synthetic polymers 
Several synthetic polymers have been used to embed cells for tooth engineering (Fig. 6), 
mostly polyglycolic acid (PGA) and poly-lactideco-glycolide (PLGA) (Table 2). They were 
chosen for the possibility they offer to control their structural and mechanical properties 
(Hacking & Khademhosseini, 2009). For this reason, they have been widely used for tissue 
engineering. The possibility to re-create a specific histological organization has been 
investigated, in the case of lung tissue engineering by growing pluripotent cells seeded onto 
synthetic polymers, showing that identifiable pulmonary structures could develop (Cortiella 
et al., 2006). Although PGA is satisfactory to grow cells in vitro, this polymer can induce 
inflammatory reactions after implantation in immunocompetent hosts (Ceonzo et al., 2006; 
Cortiella et al., 2006).  
Different groups have used PGA for tooth engineering (Duailibi et al., 2004, 2008; Iwatsuki 
et al., 2006; Ohara et al., 2010), but the risk of inflammation was only discussed by Duailibi 
et al. (2008). Concerning biodegradation, PGA fiber meshes were still present after 10 days 
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of implantation (Iwatsuki et al., 2006). It will be important to more precisely evaluate what 
happens at later stages. 
As stated above, synthetic polymers might introduce discontinuities in the setting of 
gradients of cell progression towards differentiation and thus interfere with the geometry of 
epithelial-mesenchymal interactions. However, Honda et al., (2008) showed convincing 
images of tooth formation using dental cells seeded in PGA polymers, but coated with 
collagen. 
A comparative study suggested that the potential of PGA scaffold to support tooth 
formation was not as good as collagen sponges scaffold (Honda et al., 2010). Considering the 
initial stages of tooth formation, similar conclusions were drawn when comparing collagen 
or fibrin gels with PGA or ß-tricalcium phosphate (ß-TCP) (Ohara et al., 2010).  
 
 
Table 2. Synthetic polymers and inorganic scaffolds used for tooth engineering 
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5. Cell sources 
Although embryonic cells represent an excellent tool to set up methodologies for tooth 
engineering, they are not a cell source to be used in a clinical context. One possible 
alternative would be the use of the stem cells evidenced in numerous adult organs 
(Bergmann & Steller, 2010). To engineer a complete tooth and be able to reproduce the 
epithelial-mesenchymal interactions taking place during development, it will be necessary 
to combine mesenchymal and epithelial adult stem cells with odontogenic potentialities. 
The identification and selection of these two cell populations/sources is a major 
challenge.  
For the mesenchymal compartment, the use of mesenchymal stem cells (MSCs) certainly 
appears as first evidence. These cells were initially characterized in the bone marrow 
(Friedenstein et al., 1970; Pittenger et al., 1999). They appear as a subset of fibroblast-like 
cells able to form colonies that can be selected by their adherence to plastic and expanded in 
vitro. As classical stem cells, they are capable of self-renewal and of displaying multilineage 
differentiation ability in vitro, not only towards the classical “triumvirate”, osteoblasts, 
adipocytes and chondrocytes, but also towards the endothelial, cardiomyocytes or neural 
fate depending on in vitro induction (for review see Nombela-Arrieta et al., 2011). This 
multipotentiality together with their easiness of in vitro expansion has made these cells 
promising in regenerative medicine, mainly dealing with bone defects, cardiac repair, and 
MSCs immunosuppressive properties (for review see Augello et al., 2010; Chanda et al., 
2010). Bone marrow stem cells (BMSCs) have also been tested for tooth enginering (Hu et al., 
2006b; Nait Lechguer et al., 2009; Ohazama et al., 2004). They could substitute the dental 
mesenchyme, and engage in tooth formation (Ohazama et al., 2004). Furthermore, they 
could also be reprogrammed in situ to engage in ameloblast functional differentiation (Hu et 
al., 2006b). 
Since their first description, MSC-like cells have been reported in many embryonic and adult 
connective tissues (da Silva Meirelles et al., 2006), including some of the adult tooth: dental 
pulp of permanent (Gronthos et al., 2000) or deciduous teeth (Miura et al., 2003), periodontal 
ligament (Seo et al., 2004), apical papilla (Sonoyama et al., 2008) or dental follicle 
(Casagrande et al., 2011; Morsczeck et al., 2005). Among dental MSC-like cells, the dental 
pulp stem cells (DPSCs) are the most easily accessible. They have already demonstrated 
their plasticity and capacity to participate in tissue repair (for review see Huang, 2009). 
DPSCs have been described in human (Gronthos et al., 2000; Miura et al., 2003; Sonoyama et 
al., 2008), rat (Yang et al., 2007) and mouse (Balic et al., 2010). Most dental mesenchymal 
cells are believed to derive from the cranial neural crest (Chai et al., 2000; Lumsden, 1984), 
DPSCs appear as candidates of choice to substitute the mesenchymal component of the 
tooth. Moreover, they might have retained some type of “memory” of their tissue of origin 
and preferentially differentiate towards an odontogenic program (Batouli et al., 2003; 
Gronthos et al., 2000 and Fig. 4 therein). 
The stem cells of the dental pulp (Table 3, SHEDs, DPSCs or SCAPs) constitute per se an 
heterogenous cell population which, depending on the isolation, selection and culture 
procedures may display different features and degrees of stemness (Table 3, Bakopoulou et 
al., 2011; Huang et al., 2006). It is remarkable that although the majority of studies involved 
cells isolated by enzymatic dissociation of the pulpal tissue, the most immature dental pulp 
stem cells were obtained from explants culture (Siqueira da Fonseca et al., 2009). 
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Determining which type of DPSCs is the best suited for tooth engineering is therefore an 
essential question. The purification of a homogeneous DPSCs population is not possible due 
to a lack of known specific markers. Pulp stem cells are thus enriched on their ability to form 
colonies (Gronthos et al., 2000), their expression of cell surface molecules such as STRO-1 
(Gronthos et al., 2000), or CD34 (Laino et al., 2006) or on their capacity of exclusion of a 
DNA binding dye (Iohara et al., 2006). Not surprisingly, the resulting different cell 
populations display various differentiation potentials, upon appropriate in vitro induction 
(for review see Huang, 2009) and are able to participate in bone (d’Aquino et al., 2009; Seo et 
al., 2008), neuronal (Arthur et al., 2008) and corneal tissue formation in vivo (Table 3; Gomes 
et al., 2010). In an implanted tooth slice model, heterogeneous populations of DPSCs, SCAPs 
or SHEDs have already shown their capacity to participate in the formation of a pulp-like 
tissue with dentin secretion and apposition (Huang et al., 2010; Sakai et al., 2010). However, 
the potential of these different populations to participate in whole tooth formation has not 
yet been investigated. For this purpose, it will be necessary to set up models for preclinical 
evaluations and to standardize the procedures. A major drawback in this field lies in the fact 
that most of these pulp stem cell sub-populations are described in the human tooth, while 
experimental strategies to test their competence to participate in tooth formation have been 
set up with murine models (Arany et al., 2009; Hu et al., 2006a; Nakao et al., 2007; Ohazama 
et al., 2004).  
A hint that post-natal dental pulp cells may maintain such a potential, at least to a certain 
extent, comes from the work of Masaki Honda and coworkers. These authors have shown 
that unselected epithelial and mesenchymal cells derived from porcine third molar (6 
months after birth), are able to participate in the formation of a tooth-like tissue (Honda et 
al., 2008). The precise nature of these cells and their possible relationship with dental pulp 
stem cells will have to be investigated. It will also have to be determined why, in these 
experimental conditions, tooth formation was not impaired by mechanisms of cell sorting 
out (Manning et al., 2010; Steinberg, 1962, 1963).  
Tooth engineering also requires epithelial stem cells. Dental epithelial stem cells have been 
described in the continuously growing mouse incisor, which is a very peculiar tooth 
(Harada et al., 1999). However, all epithelial cells have disappeared in the erupted molar, 
except for the very restricted population of Malassez rests, when it exists (Huang et al., 
2009; Shinmura et al., 2008). Therefore, the search for non-dental epithelial cell sources is 
ongoing.  
The palatal mucosal epithelium isolated from embryos or newborn mice has been shown to 
be able to substitute for a dental epithelium, and to contribute to tooth formation in a re-
association model using embryonic dental mesenchyme. Cultured dissociated palatal 
epithelial cells can maintain this potential up to one month post-natally, provided they are 
cultivated as cell sheets to maintain epithelial cell properties (Nakagawa et al., 2009).  
Along the same line, young human skin keratinocyte progenitors, cultured in cell sheets, can 
contribute to tooth-crown like structure formation after chimeric re-association with ED 13.5 
mouse molar mesenchyme (Wang et al., 2010). However, in these conditions, ameloblasts do 
not differentiate. Their differentiation needed to be induced by exogenous FGF8 (Wang et 
al., 2010).  
In the ongoing search for cell sources, an interesting alternative resides in the induced 
pluripotent stem cells (iPSCs). Since the pioneer work of Takahashi and Yamanaka (2006), it 
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has been demonstrated that mouse adult somatic cells can be reprogrammed to an 
embryonic-like state, by the introduction of 4 transcription factors, Oct4, Sox2, c-Myc and 
Klf4 or Lin28. These cells exhibit the morphology and growth properties of murine 
embryonic stem cells and appear capable of contributing to virtually every cell type in the 
body (Maherali et al., 2007). Their human counterparts have subsequently been generated 
(Lowry et al., 2008; Takahashi et al., 2007). Emerging data suggest that iPSCs retain a 
memory of their tissue of origin (Quatrocelli et al., 2011; Tian et al., 2011) and therefore 
could differentiate more easily towards their original program (Hu et al., 2010). Human 
iPSCs have already been generated from dental pulp stem cells (SHEDs, DPSCs and SCAPs) 
(Duan et al., 2011; Tamaoki et al., 2010) and different types of epithelia (Buchholtz et al., 
2009; Novak et al., 2010). The potential of such cells will have to be evaluated when grown 
in re-association, to determine whether they are indeed valuable candidates for whole tooth 
engineering.  
Whatever the chosen cells, further studies to improve the success rate in tooth formation 
should focus primarily on the enrichment/purification, of competent cells. This will 
require the finding of markers permitting this enrichment as well as specific culture 
protocols allowing their expansion and the maintenance of their differentiation potentials 
in vitro. 
6. Maintenance of cell potentialities in vitro 
Adult stem cells are known to reside in defined anatomical compartments specified by 
cellular and acellular components. This specialized microenvironment is known as a niche 
and was first described as a concept in the context of hematopoiesis (Schofield, 1978). The 
existence of niches has then been validated in many other tissues (Weissman, 2000). It 
integrates systemic and local cues (growth factors, ECM as well as specific cell types) to 
maintain a balance between self-renewal and differentiation. In the absence of stimuli, adult 
stem cells remain quiescent but signals generated by inflammation, infection or lesion will 
lead to their recruitment/activation towards differentiation and repair.  
In contrast to the niche of the intestine, hair or blood stem cells whose understanding has 
progressed over the recent years (for review see Fuchs & Segre, 2000 and Li & Clevers, 2010 
and references therein), the dental pulp stem cell niche is still poorly understood. This might 
be explained by the facts that 1) the pulp is not an actively renewing tissue, 2) there is a lack 
of specific markers identifying its stem cells and 3) it is technically difficult to work with 
strongly mineralized tissue. DPSCs are thus essentially defined by their functionalities. 
DPSCs freshly established in culture, present a phenotype similar to BMSCs (Shi et al., 2001). 
They express STRO-1 and a series of surface markers, proposed by the International Society 
for Cell Therapy for the identification of human MSCs (Dominici et al., 2006). However the 
extent to which these markers reflect the in vivo phenotype remains an unresolved question. 
In normal pulp, the STRO-1 expressing cells are only found in the microvasculature (Shi & 
Gronthos, 2003), an observation compatible with the hypothesis that DPSCs, as MSCs from 
other tissues, might correspond to pericytes (Crisan et al., 2008; Feng et al., 2010). Indirect 
data from BrdU labeling experiments have brought support to this hypothesis (Ishikawa et 
al., 2010; Téclès et al., 2005). But the fact that DPSCs appear as a heterogeneous cell 
population raises the question of the existence of other potential stem cell niches in the pulp 
(Harichane et al., 2011; Mitsiadis et al., 1999, 2003).  
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Table 3. Different types of stem cells from the tooth: isolation, culture procedures and 
differentiation potentials 
Working with stem cells requires their growth and expansion in vitro. However, it is well 
known that in vitro culture conditions go along with major changes in gene expression. For 
instance, culture on specific substrates, in different media, serum substitutes, oxygen 
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concentration has been shown to deeply affect the transcriptome/epigenome of ES cells 
(Allegrucci et al., 2007; Forsyth et al., 2008). Recent studies have further shown that changes 
in culture conditions may modify the potency of stem cells or reprogram adult stem cells to 
endow them with a broader differentiation potential (for review see Roobrouck et al., 2011). 
Similarly, cultured DPSCs have been shown to undergo phenotypic changes, losing markers 
while acquiring others with subculture (Govindasamy et al., 2010; Patel et al., 2009; Yu et al., 
2010). Trying to improve the culture conditions of DPSCs for their use in whole tooth 
engineering is now a major challenge. 
7. Conclusion and prospects 
Recent studies in tooth engineering led to the analysis of different potential cell sources and 
to the development of several complementary experimental approaches. The biological 
constraints, which become better characterized as research progresses, will necessarily 
restrict the number of protocols and strategies. 
Potential human cell sources have been reported (Gronthos et al., 2000; Miura et al., 2003), 
while banks for autologous cell sources are being developed (Arora et al., 2009; Tamaoki et 
al., 2010; Woods et al., 2009). The biological potentialities of the different cells types, which 
recently were identified from human sources, will have to be tested both in vitro and in vivo. 
This will allow determining whether they may recapitulate the different developmental 
stages and lead to the engineering of a functional tooth. The next challenge will be to deal 
with the engineering of larger teeth, where full vascularization and innervation will become 
critical.  
As far as possible, it may be better to work in the absence of scaffold or matrices to engineer 
whole teeth (Hu et al., 2005, 2006a; Ohazama et al., 2004). It better fits with the necessity to 
preserve epithelial-mesenchymal interactions and with the maintenance of gradual cell 
differentiation. Furthermore, it is important to prevent any risk of delayed immune 
response, which may occur with collagen (Zippel et al., 2008) or PLGA scaffolds (Tavassol et 
al., 2010). As a broad question, related to tissue engineering and regeneration in general, the 
possible negative consequences of using collagen, PGA and other components to embed 
cells are investigated (Marx et al., 2008; Ohara et al., 2010; Pihlajamäki et al., 2010). Scaffolds 
made of PGA fibers were used to tooth bud cells from 6 month old miniature pig third 
molars (Ohara et al., 2010). PGA supported odontoblast-like cell functional differentiation, 
but these conditions did not seem to be optimal for histogenesis. PGA was also used by the 
same group to grow embryonic dental cells from molars at ED14 (Iwatsuki et al., 2006). In 
these conditions, after implantation, teeth formed, which showed all aspects of epithelial 
histogenesis and gradients of functional odontoblasts and ameloblasts (Iwatsuki et al., 2006). 
However, the same results could be obtained without scaffold (Nait Lechguer et al., 2008, 
2011).  
All together, these results indicate that the limitations in tooth engineering are more related 
to the cell sources and to the difficulty to maintain their potentialities during cell expansion 
in vitro. 
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1. Introduction  
The cornea is composed of a multilayered epithelium, Bowman's membrane, stroma, 
Descemet's membrane and endothelium. As compared to the stroma, tissue engineering of 
the corneal epithelium or endothelium is relatively simple and well established, as the 
stroma is mainly composed of continuous cells joined by tight junctions with a few 
subcellular extracellular matrix (ECM) proteins. Corneal stromal engineering, however, has 
yet to be fully achieved due to difficulties encountered when trying to constitute an artificial 
corneal stroma, which consists of few fibroblast-like keratocytes, nerve fibers, and a 
transparent ECM of collagen fibrils and proteoglycans. 
Stem cells or progenitor cells are defined by their capacity for self-renewal and the ability to 
generate different types of cells (multipotentiality), which leads to the formation of mature 
tissues. In contrast, the precursor cells are unipotent cells with a limited proliferative 
activity. Regenerative stem cells or precursors can be detected by the sphere-forming assay 
in various adult tissues, including the central nervous system (Nunes et al., 2003), bone 
marrow (Krause et al., 2001), skin (Kawase et al., 2004; Toma et al., 2001), retina (Coles et al., 
2004), corneal epithelium (Mimura et al., 2010a), corneal stroma (Amano et al., 2006; Mimura 
et al., 2008a, 2008b; Uchida et al., 2005; Yamagami et al., 2007), and corneal endothelium 
(Amano et al., 2006; Mimura et al., 2005a, 2005b, 2005c, 2007, 2010b; Yamagami et al., 2006a, 
2007; Yokoo et al., 2005). 
Despite the many successes achieved in the isolation and characterization of stem cells from 
various tissues, relatively few studies have investigated the efficacy of stem cell 
transplantation therapy in animals. While the three-dimensional structure that is responsible 
for maintaining the cell-to-cell interactions is indispensable for tissue engineering using 
stem cells, the structural complexity involved in tissue engineering does not easily allow us 
to extend the investigations of stem cell transplantations. 
In this chapter, we introduce our recent work about regenerative medicine and tissue 
engineering of corneal stroma using multipotent precursor cells. We isolated precursors 
with the propensity to develop into corneal keratocyte-like cells from the stroma of rabbit 
corneas and investigated the distribution and proliferative capacity of precursor cells 
derived from the central and peripheral regions of the cornea by the sphere-forming assay. 
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Additionally, we constructed corneal stroma using keratocyte precursors and porous gelatin 
hydrogels in vitro by tissue engineering and investigated the feasibility of the engineered 
corneal stroma with keratocyte precursors in a rabbit model. 
2. Origin and development of corneal stroma 
Corneal stromal cells (keratocytes) are derived from the neural crest (Bahn et al., 1984; 
Johnston et al., 1979; Mooy et al., 1990). During embryonic development, neural crest cells, 
from which the keratocytes originate (Bahn et al., 1984; Johnston et al., 1979), show two 
waves of migration and differentiation during the corneal growth (Liu et al., 1998; Meier, 
1982). In the first wave, the corneal epithelium forms and then synthesizes the primary 
stroma (i.e., periocular mesenchymal cells of neural crest origin). Subsequently, the neural 
crest cells migrate to the margin of the optic cup, and to the area between the lens and the 
corneal epithelium. This contributes to development of the corneal stroma and the 
trabecular meshwork. During the second wave of migration, neural crest cells invade the 
primary stroma and then undergo differentiation into keratocytes.  
In adults, corneal stromal cells are composed of keratocytes and bone marrow-derived cells 
of the monocyte lineage (Yamagami et al., 2006b). The latter cell population is continuously 
replaced from the bone marrow (Nakamura et al., 2005). We previously demonstrated that 
while the bone marrow-derived cells isolated from corneal stroma do not form spheres 
(Uchida et al., 2005), the keratocytes derived from the corneal stroma do form spheres 
(Mimura et al., 2008a). This suggests that the precursors isolated from the corneal stroma 
reside among the keratocytes. If so, these precursors might be able to supply new 
keratocytes and thus, they could a potentially promote corneal wound healing. Keratocyte 
precursors may also have a role in the healing of corneal stromal wounds, since proliferation 
and migration of residual keratocytes from the peripheral part of the stroma appear to 
promote healing (Wilson & Kaufman, 1990). 
3. Isolation of sphere colonies 
3.1 Primary sphere-forming assay 
Rabbits were handled in accordance with the ARVO Statement on the Use of Animals in 
Ophthalmic and Vision Research. New Zealand white rabbits (weighing 2.0-2.4 kg) were 
used. The animals were anesthetized with intramuscular injections of ketamine 
hydrochloride (60 mg/kg) and xylazine (10 mg/kg), after which the eyes were enucleated. 
Subsequently, the eyes were washed three times with sterile saline and then immersed for 5 
min in saline containing 10% povidone-iodine and 50 mg/ml gentamicin. After further 
rinsing with saline, the cornea was excised from each eye along the scleral rim. The 
epithelium was then carefully removed from the corneal stroma by scraping the outer 
surface of the cornea, while fine forceps were used to peel away the corneal endothelium 
and Descemet’s membrane in a sheet that covered an area from the periphery to the center 
of the inner surface of the cornea. Using appropriate trephines and forceps, samples of the 
corneal stroma were excised from the periphery of the cornea (6.0-10.0 mm in diameter) and 
from the central region (6.0 mm in diameter) (Fig. 1A). The stromal samples were cut into 
small pieces that were approximately 1.0 mm in diameter. These were incubated overnight 
at 37°C in basal medium containing 0.02% collagenase. Subsequently, the tissue pieces were 
washed with phosphate-buffered saline (PBS), incubated in PBS containing 0.2% 
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ethylenediaminetetraacetic acid (EDTA) for 5 minutes at 37°C, and then dissociated into 
single cells by trituration with a fire-polished Pasteur pipette. After centrifugation at 800 g 
for 5 minutes, the cells were resuspended in the basal medium, which consisted of 
Dulbecco’s modified Eagle’s medium (DMEM)/F12 medium supplemented with B27, 20 
ng/mL epidermal growth factor (EGF), and 40 ng/mL basic fibroblast growth factor (bFGF).  
 
 
 
 
Fig. 1. (A) Anterior view of a rabbit cornea and a diagram of the corneal epithelium and 
stroma. Stromal keratocytes were isolated from tissue specimens obtained from both the 
peripheral (6.0-10.0 mm in diameter) and central regions (6.0 mm in diameter). (B, C) 
Primary sphere formation by the keratocytes from the peripheral and central regions of the 
rabbit cornea. Scale bar=200 μm. (D) The number of primary spheres derived from stromal 
tissue was compared between the periphery and the center of the cornea. The number of 
sphere colonies obtained from samples of the peripheral stroma (n=10) was significantly 
higher than that for the samples of the central stroma (n=10) after seven days of culture (* 
P=0.00021, unpaired t-test ). (E) The sizes of the primary sphere colonies derived from the 
samples of the peripheral (n=10) and central (n=10) corneal stroma were compared. The 
mean size of the spheres from both regions gradually increased during the culture period 
and exceeded 250 μm by day 7 (periphery: 258±63 μm versus center: 203 ± 71 μm after seven 
days, mean ± SD). n.s.= not significant 
Isolated keratocytes were counted using a hemocytometer. Trypan blue staining indicated 
the viability of the isolated cells was greater than 90%. The sphere-forming assay was 
employed for the primary culture of the cells (Reynolds & Weiss, 1992). Basal medium 
containing a methylcellulose gel matrix (0.8%; Wako Pure Chemical Industries) was used to 
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prevent reaggregation of the cells, as per a previously described method (Gritti et al., 1999). 
Plating was done at a density of 10 viable cells/μL (50,000 cells/well or 2,500 cells/cm2) in 
the uncoated wells of 60 mm culture dishes. To measure the diameter of sphere colonies, 
culture dishes were observed under an inverted phase-contrast microscope with a 10× 
objective lens, followed by analysis of the images using the NIH image program developed 
at the US National Institutes of Health (n=10). The number of spheres per 10,000 cells was 
calculated for each well. To distinguish growing spheres from dying cell clusters, only those 
with a diameter of more than 50 μm were counted. 
After keratocytes were disaggregated into single cells and cultured for 7 days, the viable 
spheres grew larger and the non-proliferating cells were eliminated. To compare the density 
of the precursors between the peripheral and central regions of the cornea, primary spheres 
were isolated separately from the peripheral and central stroma. Representative spheres 
obtained from the peripheral and central regions are shown in the photographs in Figures 
1B and 2C. There were significantly more spheres (51.4 ± 10.1 per 10,000 cells, mean ± SD) 
obtained from the peripheral corneal stroma as compared to the central stroma (35.9 ± 3.0 
per 10,000 cells) (P=0.00021, unpaired t-test; Fig. 1D). Although this result suggests that the 
stroma from both the peripheral and central regions of the cornea contains precursor cells, 
there were significantly more precursors in the peripheral stroma versus the central stroma. 
Additionally, there were no significant differences noted with respect to the size of the 
primary spheres that were derived from the two regions after culturing for 3, 5, and 7 days. 
This suggests that there were no differences in the proliferative capacity of the precursors 
obtained from either region (Fig. 1E). 
3.2 Secondary sphere formation 
To further evaluate the proliferative capacity of the keratocytes, cells from the primary 
spheres were passaged under the same culture conditions that were used for the initial 
growth of the spheres. For passaging, primary spheres (day 7) were treated with 0.5% 
EDTA and after dissociation into single cells, they were then plated into the wells of 60 
mm culture dishes at a density of 10 cells/μL. Cultures were continued for 7 days in the 
basal medium that contained methylcellulose gel matrix to prevent reaggregation. 
Experiments were performed twice and representative results are shown in Figure 2 
(n=10). 
Secondary spheres were generated after dissociation of the primary spheres derived from 
the peripheral or central stroma. Replating to generate secondary sphere colonies was less 
efficient than the generation of the primary spheres, which indicates that the precursor cells 
appear to have a limited proliferative capacity. Photographs of representative secondary 
spheres are shown in Figures 2A and 2B. The number of secondary spheres per 10,000 cells 
was significantly higher when the primary spheres passaged were derived from the 
peripheral stroma versus the central stroma (45.6 ± 6.4 vs. 33.4 ± 2.1, respectively; 
P=0.000025; unpaired t-test; Fig. 2C). Despite differences in the properties of the cells 
derived from the keratocyte spheres that were obtained from the peripheral and central 
regions of the cornea, there were no significant differences noted in the expression of 
mesenchymal and neural cell markers. These findings imply that keratocyte precursors 
preferentially reside in the peripheral corneal stroma and have a stronger proliferative 
capacity as compared to the cells from the central stroma, while the precursors from both 
regions demonstrate similar multipotentiality. 
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Fig. 2. Formation of secondary sphere. (A, B) Secondary spheres were generated after the 
dissociation of the primary spheres that were derived from the peripheral or central 
keratocytes. Scale bar=100 μm. (C) The replating efficiency from the primary to the 
secondary colonies was higher for the spheres derived from the peripheral stroma as 
compared to the central stroma (* P=0.000025, unpaired t-test) 
3.3 Differentiation of sphere colonies 
Individual primary spheres (day 7) were transferred to 13 mm glass coverslips coated with 
50 μg/ml poly-L-lysine (PLL) and 10 μg/ml fibronectin in separate wells, as has been 
previously described (Reynolds & Weiss, 1992). To promote differentiation, 1% FBS was 
added to the basal medium, with the culture then continued for another 7 days. 
Immunocytochemical examinations of the 7-day-old spheres and their progeny were 
performed after 7 days of adherent culture on the glass coverslips.  
Nestin has been used as a marker for the detection of immature neural progenitor cells 
within the multipotential sphere colonies derived from the brain (Gage, 2000), skin (Toma et 
al., 2001), inner ear (Li et al., 2003), retina (Tropepe et al., 2000), corneal stroma (Uchida et 
al., 2005), and endothelium (Mimura et al., 2005b, 2005c; Yokoo et al., 2005). In addition, it 
was recently suggested that the stem cell marker CD34 could be a useful cell surface marker 
for human keratocytes (Toti et al., 2002). Most cells in the spheres were immunopositive for 
nestin, CD34, and 5-bromo-2’-deoxyuridine (BrdU) (Fig. 3A). Subsequently, we then 
examined whether the sphere colonies could give rise to cells expressing neural lineage 
markers. Some cells in the sphere colonies along with their progeny expressed microtubule–
associated protein 2 (MAP2: a neural cell marker) and neuron–specific enolase (NSE: a 
marker of neural differentiation) (Fig. 3A). Most of the cells in the spheres and their progeny 
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were immunoreactive for vimentin (which is a marker of mesenchymal cells) or for alpha-
smooth muscle actin (αSMA: a marker of fibroblasts). However, all of the cells were 
negative for staining by the control IgG and the differentiated epithelial cell marker 
cytokeratin 3 (Figs. 3A and 3B). Expression of nestin and vimentin by the spheres and their 
progeny was confirmed using RT-PCR (Fig. 3C). Both spheres were derived from the 
peripheral and central regions of the cornea and their progeny displayed the same patterns 
of immunostaining (data not shown) and mRNA expression (Fig. 3C). 
Spheres derived from both the peripheral and central regions of the rabbit cornea expressed 
a stem cell marker (CD34) and a neural stem cell marker (nestin), while their progeny 
expressed mesenchymal markers (vimentin and α-SMA) and neural lineage markers (MAP2 
and NSE). These findings indicate that spheres isolated from the corneal stroma of rabbits 
contained bi-potential precursors, with their progeny able to display the morphologic 
characteristics of keratocytes. Taken together, these results suggest that precursors from the 
corneal stroma remain close in nature to the tissue of origin and that they undergo 
differentiation into corneal keratocytes. Thus, since precursors need to be able to efficiently 
differentiate and produce their tissue of origin, precursors obtained from the corneal stroma 
may be more appropriate for tissue regeneration or cell transplantation than those that are 
derived from the multipotential stem cells. 
4. Tissue engineering of corneal stroma  
4.1 The organization of the corneal stromal matrix 
Adult vertebrate corneal stroma is primarily composed of collagen type 1 fibrils, smaller 
amounts of other extracellular matrix (ECM) proteins, and a few keratocytes. Therefore, 
both the cells and the stratified complex of the ECM, which forms a scaffold for the 
precursors, are necessary in order to be able to reconstruct a three-dimensional corneal 
stroma. The porous scaffolds that are used in tissue engineering contribute to cell 
proliferation and differentiation in suitable environments, as well as taking part in the 
maintenance of the structure and composition of injured tissues. Furthermore, three-
dimensional porous scaffolds provide a larger surface for cell attachment, migration and 
proliferation in contrast to the two-dimensional scaffolds, which facilitate contact inhibition 
in confluent cells. Because corneal keratocyte proliferation is substrate-dependent, increases 
in the surface area of the culture substrate are preferable. Several three-dimensional 
substrates that use collagen have been designed and tested for their capacity for 
proliferative enhancement (Takahashi et al., 2004, 2005; Yasuda et al., 2004). While their 
long-term safety, stability, and efficacy in vivo have been adequately established in humans, 
there are significant drawback of using collagen due to its poor biodegradation and 
bioabsorption. Biodegradation and biocompatibility are probably the two most important 
properties that have to be examined when considering the use of insoluble biomaterials. 
Unfortunately, biological reactions can develop when using these materials in vivo, 
resulting in tissue opacity. Gelatin, which is a denatured type of collagen, possesses most of 
the properties of an ideal scaffold and thus, has been clinically applied as an implant 
material (Waldrop & Semba, 1993). We have also used a biodegradable porous gelatin 
hydrogel as a carrier of the corneal keratocyte precursors, and found the material to be 
effective in facilitating cell migration and delivering oxygen and nutrients to the migrated 
cells.  
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Fig. 3. (A) Immunocytochemical analysis of sphere colonies from the peripheral stroma on 
day 7. Bright-field images and immunostaining of the spheres are shown. The spheres were 
stained for vimentin, alpha-smooth muscle actin (α-SMA), cytokeratin 3, nestin, 
microtubule-associated protein 2 (MAP2), neuron-specific enolase (NSE), and CD34. Each 
colony was also labeled by BrdU. As a negative control, IgG was used instead of the primary 
antibody. Scale bar=100 μm. (B) Immunocytochemical analysis of differentiated cells from 
spheres derived from the peripheral cornea. The cells that migrated out from the spheres 
expressed α-SMA, MAP2, and NSE, indicating that the colonies contain differentiated 
mesenchymal and neuronal cells. No staining with the control IgG was noted. Scale bar=100 
μm. (C) Reverse-transcription polymerase chain reaction analysis of the corneal stromal 
tissue, spheres, and sphere progeny. Glyceraldehyde-3-phosphate dehydrogenase (G3PDH) 
gene expression was detected in all samples except those processed without reverse-
transcriptase (RT). Vimentin was expressed by the corneal stromal tissues and the spheres 
derived from the peripheral or central regions and their progeny. However, it was not 
detected by PCR of the total RNA without RT. Expression of nestin by the progeny was 
lower than that seen for the spheres from both the peripheral and central regions of the 
cornea. No expression of keratin 3 or 12 was detected in any of these samples 
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4.2 Preparation of gelatin hydrogels 
Porous gelatin hydrogels were prepared through the chemical crosslinking of an aqueous 
gelatin solution with glutaraldehyde, using a method described elsewhere (Tabata et al., 
1999; Yamamoto et al., 2003). Briefly, an aqueous gelatin solution mixed with 
glutaraldehyde was cast into a polypropylene dish (138×138 mm2, BIO-BIK), followed by the 
crosslinking reaction, which was performed at 4°C for 12 h. The hydrogel samples were 
added to a 100 mM aqueous glycine solution at 37°C and stirred for 1 h to block the residual 
glutaraldehyde. After washing three times with double-distilled water, the hydrogel 
samples were freeze-dried and sterilized with ethylene oxide gas and ultraviolet for 2 hours. 
Before use, the desiccated sheets were trephined with a 5.0 mm diameter trephine and then 
immersed in sterilized saline for 10 minutes. 
4.3 Sphere or keratocyte seeding onto gelatin hydrogels and cell culture 
The 5.0 mm gelatin hydrogel disks were placed into wells of a 24-well culture dish. 
Subsequently, 10 primary rabbit corneal keratocyte spheres that had been cultured for 7 
days or 100,000 primary cultured rabbit corneal keratocytes were applied to the porous 
gelatin hydrogels. The reconstructed corneal stroma was then placed in the 24-well plates 
and centrifuged at 1000 rpm (176 g) for 10 min to promote the attachment of the cells to the 
porous gelatin hydrogels. To trace the localization in some of the experiments, primary 
rabbit corneal keratocyte spheres (cultured for 7 days) were labeled with a fluorescent cell 
tracker, as has been described elsewhere (Mimura et al., 2004). The corneal keratocytes or 
the corneal keratocyte spheres were cultured in the basal medium containing 10% FBS for 7 
days, with the medium changed every 2 to 3 days. 
4.4 Immunocytochemical analysis of ECM in gelatin hydrogels 
Corneal keratocytes or keratocyte precursors were cultured on porous gelatin hydrogels for 
7 days, with the degree of ECM production by the cells then evaluated. Vimentin expression 
was more frequent in the porous gelatin hydrogels that contained keratocyte precursors 
versus those with only the corneal keratocytes (Fig. 4). Weak expression of laminin was seen 
in the gelatin hydrogels with keratocyte precursors, while no expression was observed in 
those with the corneal keratocyte. There was little or no expression of type I and IV collagen 
found in either the porous gelatin hydrogels with corneal keratocytes or the keratocyte 
precursors (Fig. 4). 
Despite having a total cell number less than 100,000 corneal keratocytes within the 10 
corneal keratocyte spheres, when the porous gelatin hydrogels that incorporated the spheres 
were cultured ex vivo for 7 days, there was intense immunostaining for vimentin, a marker 
of mesenchymal cells. This staining was much more intense than that which was seen for the 
incorporated 100,000 corneal keratocytes that were also cultured for 7 days. This indicates 
that the corneal keratocyte precursors have a superior proliferative potential on the gelatin 
hydrogels as compared to the corneal keratocytes. While weak expression of laminin and 
collagens was detected in the gelatin hydrogels that incorporated the corneal keratocytes 
precursors, these ECM components were barely detected in the gelatin that incorporated the 
corneal keratocytes ex vivo before transplantation. These results indicate that the gelatin 
hydrogel, itself, does not have the ability to induce tissue regeneration either in vitro or ex 
vivo. 
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Fig. 4. Immunohistochemical analysis of the extracellular matrix in the porous gelatin 
hydrogel with corneal keratocytes or keratocyte precursors. Corneal keratocytes or 
keratocyte precursors were seeded onto porous gelatin hydrogels and cultured for one 
week. Vimentin staining was more intense in the gelatin hydrogels with corneal fibroblast 
precursors than that seen with the corneal fibroblasts (arrows). Except for a weak expression 
of laminin in the gelatin hydrogels with corneal keratocyte precursors (arrow), there was no 
expression of the other ECM components such as laminin, type I collagen, and type IV 
collagen in the gelatin hydrogel with the corneal keratocytes or keratocyte precursors before 
transplantation. Scale bar=200 μm. HE=hematoxylin and eosin staining 
5. Transplantation of gelatin hydrogels with corneal keratocyte precursors  
5.1 Surgical procedure 
New Zealand white rabbits (weighing 2.0-2.4 kg, n=24) were anesthetized with an 
intramuscular injection of ketamine hydrochloride (60 mg/kg) and xylazine (10 mg/kg). A 
diamond knife was used to make a 6 mm incision 1.0 mm inside the superior limbus, at a 
depth of 150-200 µm (Fig. 5A). A lamellar dissection of the cornea was then performed with 
a bevel-up crescent knife. The reconstructed corneal stroma with corneal keratocyte 
precursors and porous gelatin was then implanted into a mid-stroma corneal pocket with a 
jeweler's forceps (Fig. 5B). No sutures were used for the corneal incision after the 
implantation (Fig. 5C). An antibiotic ointment (0.3% ofloxacin) was applied to the eye. The 
24 rabbits were divided into three groups: the gelatin group (n=8) for which porous gelatin 
hydrogels alone were transplanted, the keratocyte/gelatin group (n=8) for which corneal 
keratocytes cultured on porous gelatin hydrogels for 7 days were transplanted, and the 
precursor/gelatin group (n=8) for which the corneal keratocyte precursors cultured on 
porous gelatin hydrogels for 7 days were transplanted. Histological examinations and 
immunohistochemistry were performed in the animals killed at 1 week (n=2 in each group) 
and at 4 weeks after surgery (n=6 in each group). None of the animals received any 
immunosuppressive treatment after the transplantation.  
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Fig. 5. Schematic illustration and clinical findings. A: Keratocyte precursors were isolate 
from the rabbit corneal stroma using a sphereforming assay. Corneal stroma was engineered 
by cultivating precursors in porous gelatin for one week. The engineered corneal stromal 
sheet with precursors was transplanted in a pocket of rabbit corneal stroma. B,C: Gelatin 
hydrogels (gelatin group), gelatin hydrogels with corneal keratocyte (keratocyte/gelatin 
group), or gelatin hydrogels with corneal keratocyte precursors (precursor/gelatin group) 
were implanted into the corneal stroma (indicated by arrows in C). D-F: Representative 
photographs of corneas four weeks after transplantation in each group are shown. No 
corneal opacity and no rejection were observed in any group four weeks after 
transplantation (indicated by the white circles in D-F) 
5.2 Clinical observation after surgery 
Each eye that underwent the surgical procedure was checked two to three times a week by 
external examination, in addition to being photographed on postoperative days 7, 14, 21, 
and 28. As seen in the representative anterior segment photographs from the gelatin group 
(transplanted with gelatin hydrogels alone, Fig. 5D), the keratocyte/gelatin group 
(transplanted with gelatin hydrogels with corneal keratocytes, Fig. 5E), and the 
precursor/gelatin group (transplanted with gelatin hydrogels with corneal keratocyte 
precursors, Fig. 5F), the corneas were clear, and there was no edema or mononuclear cell 
infiltration of the stroma in any of the groups. There were also no apparent inflammatory 
reactions suggestive of immunological rejection observed with a slit lamp microscope nor 
were there any increases of intraocular pressure, or possible side effects noted in any of the 
groups during the follow-up period. 
5.3 Histological examination and analysis of ECM production with 
immunohistochemistry 
The corneas were excised from the eyes 1 and 4 weeks after the transplantations and 
subjected to histological examinations and immunohistochemical staining. In the gelatin and 
keratocyte/gelatin groups, the few cells that did migrate into the thick transplanted gelatin 
hydrogels exhibited no changes in shape. In contrast, large numbers of cells migrated into 
the gelatin hydrogels of the precursor/gelatin group, which became thinner than the other 
two groups at 1 and 4 weeks after transplantation. The expressions of vimentin and ECM, 
such as laminin and type I and type IV collagens were more intense in the precursor/gelatin 
group versus the other groups after 1 week (data not shown), with their expressions 
significantly increased at 4 weeks (Fig. 6A). These results suggest that the gelatin hydrogel 
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by itself can induce ECM production to some extent in vivo, although the efficacy is not as 
high as that seen for the gelatin hydrogels with precursors. These findings clearly indicate 
that transplanted corneal keratocyte precursors possess the ability to generate new corneal 
stromal tissues in vivo by cell proliferation and differentiation properties, and ECM 
production. 
 
 
 
Fig. 6. (A) Histological findings and immunocytochemical analysis of the extracellular 
matrix at 4 weeks after transplantation. Transplanted gelatin hydrogels were found in the 
corneal stroma in all groups. HE staining revealed no mononuclear cell infiltration around 
the gelatin hydrogels in any of the groups. The precursor/gelatin group showed more 
intense staining for laminin, type I collagen, type IV collagen, and vimentin in the 
transplanted gelatin as compared to that seen in the gelatin and keratocyte/gelatin groups 
at 4 weeks after transplantation. Scale bar=100 μm. (B) Immunolocalization of CD34- or 
nestin-positive cells within the transplanted DiI-positive precursors in the precursor/gelatin 
group 4 weeks after transplantation of gelatin hydrogels with corneal keratocyte precursors. 
A computer software program (Adobe Photoshop) was used to superimpose the findings in 
a single image. In this image, bright light represents the background (black and white), 
while rhodamine (red color) shows the transplanted DiI-labeled corneal keratocyte 
precursors in the gelatin hydrogels, and FITC (green color) shows the CD34- or nestin-
positive cells. The light red color associated with the many DiI-positive corneal keratocyte 
precursors indicates the whole transplanted gelatin hydrogel. A few CD34- positive cells or 
nestin-positive spindle cells are seen scattered within the gelatin hydrogels.  
Scale bar=100 μm 
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5.4 Expression of stem or progenitor cell markers in the transplanted gelatin 
hydrogels 
We next examined the expressions of the stem cell marker, CD34, and the neural progenitor 
cell marker, nestin, in the precursor/gelatin group 4 weeks after transplantation. Many 
CD34-positive cells were detected in and around the transplanted gelatin hydrogels (Fig. 
6B). In addition, a few nestin-positive cells were also seen in the transplanted gelatin 
hydrogels, whereas nestin-positive cells were barely detected in the corneal stroma around 
the gelatin hydrogels (Fig. 6B). This indicates that corneal keratocyte precursors with a 
greater self-renewal potential continue to proliferate even after the transplantation, and 
thus, are able to supply the keratocytes that are necessary for regeneration of the host 
stroma. The nestin-positive cells were also present in the transplanted gelatin hydrogels, 
which indicates that they can contribute to the induction of the nerve regeneration. Large 
corneal nerves penetrate from the pericorneal nerve plexus into the anterior corneal stroma 
as thick nerve bundles, which provides sensory innervation of the cornea (Maclver & 
Tanelian, 1993). Since the transplanted corneal keratocyte precursors would be expected to 
consistently promote nerve regeneration in vivo, they may consequently be able to produce 
sufficient corneal sensation. 
5.5 Advantage of transplantation of keratocyte precursors with gelatin hydrogels 
The combined approach of transplanting the corneal keratocyte precursors along with the 
gelatin hydrogels into a corneal stromal pocket has several advantages over the use of 
penetrating keratoplasty in a full-thickness donor cornea. For example, complications 
associated with open-sky surgery that involve expulsive hemorrhage and risks of wound 
dehiscence are essentially eliminated. In addition, several postoperative complications, such 
as postoperative corneal irregular astigmatism, wound leakage, corneal infection, 
vascularization, and persistent epithelial defect can be avoided when using the combined 
approach. In conventional full-thickness human corneal allografting with local and/or 
systemic immunosuppressants, the leading cause of the failure is allograft rejection (Price et 
al., 1991; Wilson & Kaufman, 1990). Since histologically there was no apparent inflammatory 
reaction observed, this suggests that there was no immunological rejection detected in the 
current corneal keratocyte precursor allotransplantation. Thus, this finding indicates that the 
transplanted precursors can survive in the corneal stroma without rejection.  
6. Conclusion 
We demonstrated that as compared to the stroma from the central cornea, the stroma from 
the peripheral region of the rabbit cornea contains a higher density of precursors with a 
strong proliferative capacity. These keratocyte precursors are able to differentiate into both 
mesenchymal fibroblasts and neural cells. Furthermore, by using corneal keratocyte 
precursors and gelatin hydrogels, we were able to establish a new method of three-
dimensional reconstruction of the corneal stroma. This new approach that uses corneal 
keratocyte precursor–based corneal stromal regeneration combined with gelatin hydrogel is 
a potentially promising new therapy that can be used to attract keratocytes and ECM after 
the transplantation of the corneal keratocyte precursors. Additionally, the current findings 
have important implications with regard to the field of regenerative medicine, as this 
therapeutic tissue engineering approach appears to be applicable to any type of cell. The 
transplantation of corneal keratocyte precursors into a corneal stromal pocket proved to be a 
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simple and an effective treatment strategy. By being able to use precursors to initiate corneal 
regeneration, and ECM production to improve wound healing, this new method could 
potentially be used to replace conventional full-thickness corneal grafting, thereby helping 
to alleviate the worldwide shortage of donor corneas that exists at the present time. 
7. Acknowledgment 
This work is supported by a Grant-in-Aid for Scientific Research from the Ministry of 
Education, Culture, Sports, Science and Technology of Japan. 
8. References 
Amano, S., Yamagami, S., Mimura, T., Uchida, S., & Yokoo, S. (2006). Corneal stromal and 
endothelial cell precursors. Cornea, Vol.25, No.10(Suppl 1), (December 2006), pp. 
S73-77, ISSN 0277-3740 
Bahn, C. F., Falls, H. F., Varley, G. A., Meyer, R. F., Edelhauser, H. F., & Bourne, W. M. 
(1984). Classification of corneal endothelial disorders based on neural crest origin. 
Ophthalmology, Vol.91, No.6, (June 1984), pp. 558-563, ISSN 0161-6420 
Coles, B. L., Angenieux, B., Inoue, T., Del Rio-Tsonis, K., Spence, J. R., McInnes, R. R., 
Arsenijevic, Y., & van der Kooy, D. (2004). Facile isolation and the characterization 
of human retinal stem cells. Proc Natl Acad Sci U S A, Vol.101, No.44, (November 
2004), pp. 15772-15777, ISSN 1091-6490 
Gage, F. H. (2000). Mammalian neural stem cells. Science, Vol.287, No.5457, (February 2000), 
pp. 1433-1438, ISSN 0036-8075 
Gritti, A., Frolichsthal-Schoeller, P., Galli, R., Parati, E. A., Cova, L., Pagano, S. F., Bjornson, 
C. R., & Vescovi, A. L. (1999). Epidermal and fibroblast growth factors behave as 
mitogenic regulators for a single multipotent stem cell-like population from the 
subventricular region of the adult mouse forebrain. J Neurosci. Vol.19, No.9, (May 
1999), pp. 3287-3297, ISSN 1529-2401 
Johnston, M. C., Noden, D. M., Hazelton, R. D., Coulombre, J. L., & Coulombre, A. J. (1979). 
Origins of avian ocular and periocular tissues. Exp Eye Res, Vol.29, No.1, (July 
1979), pp. 27-43, ISSN 0014-4835 
Kawase, Y., Yanagi, Y., Takato, T., Fujimoto, M., & Okochi, H. (2004). Characterization of 
multipotent adult stem cells from the skin: transforming growth factor-beta (TGF-
beta) facilitates cell growth. Exp Cell Res, Vol.295, No.1, (April 2004), pp. 194-203, 
ISSN 0014-4827 
Krause, D. S., Theise, N. D., Collector, M. I., Henegariu, O., Hwang, S., Gardner, R., Neutzel, 
S., & Sharkis, S. J. (2001). Multi-organ, multi-lineage engraftment by a single bone 
marrow-derived stem cell. Cell, Vol.105, No.3, (May 2001), pp. 369-377, ISSN 0092-
8674 
Li, H., Liu, H., & Heller, S. (2003). Pluripotent stem cells from the adult mouse inner ear. Nat 
Med, Vol.9, No.10, (October 2003), pp. 1293-1299, ISSN 1078-8956 
Liu, C. Y., Shiraishi, A., Kao, C. W., Converse, R. L., Funderburgh, J. L., Corpuz, L. M., 
Conrad, G. W., & Kao, W. W. (1998). The cloning of mouse keratocan cDNA and 
genomic DNA and the characterization of its expression during eye development. J 
Biol Chem, Vol.273, No.35, (August 1998), pp. 22584-22588, ISSN 0021-9258 
  
Tissue Engineering for Tissue and Organ Regeneration 
 
360 
Maclver, M. B., & Tanelian, D. L. (1993). Structural and functional specialization of A delta 
and C fiber free nerve endings innervating rabbit corneal epithelium. J Neurosci, 
Vol.13, No.10, (October 1993), pp. 4511-4524, ISSN 1529-2401 
Meier, S. (1982). The distribution of cranial neural crest cells during ocular morphogenesis. 
Prog Clin Biol Res, Vol.82, (1982), pp. 1-15, ISSN 0361-7742 
Mimura, T., Yamagami, S., Yokoo, S., Usui, T., Tanaka, K., Hattori, S., Irie, S., Miyata, K., 
Araie, M., & Amano, S. (2004). Cultured human corneal endothelial cell 
transplantation with a collagen sheet in a rabbit model. Invest Ophthalmol Vis Sci, 
Vol.45, No.9, (September 2004), pp. 2992-2997, ISSN 0146-0404 
Mimura, T., Yamagami, S., Yokoo, S., Yanagi, Y., Usui, T., Ono, K., Araie, M., & Amano, S. 
(2005a). Sphere therapy for corneal endothelium deficiency in a rabbit model. Invest 
Ophthalmol Vis Sci, Vol.46, No.9, (September 2005), pp. 3128-3135, ISSN 0146-0404 
Mimura, T., Yokoo, S., Araie, M., Amano, S., & Yamagami, S. (2005b). Treatment of rabbit 
bullous keratopathy with precursors derived from cultured human corneal 
endothelium. Invest Ophthalmol Vis Sci, Vol.46, No.10, (October 2005), pp. 3637-
3644, ISSN 0146-0404 
Mimura, T., Yamagami, S., Yokoo, S., Araie, M., & Amano, S. (2005c). Comparison of rabbit 
corneal endothelial cell precursors in the central and peripheral cornea. Invest 
Ophthalmol Vis Sci, Vol.46, No.10, (October 2005), pp. 3645-3648, ISSN 0146-0404 
Mimura, T., Yamagami, S., Usui, T., Seiichi, Honda, N., & Amano, S. (2007). Necessary prone 
position time for human corneal endothelial precursor transplantation in a rabbit 
endothelial deficiency model. Curr Eye Res, Vol.32, No.7-8, (July-August 2007), pp. 
617-623, ISSN 1460-2202 
Mimura, T., Amano, S., Yokoo, S., Uchida, S., Usui, T., & Yamagami, S. (2008a). Isolation and 
distribution of rabbit keratocyte precursors. Mol Vis, Vol.14, (January 2008), pp. 
197-203, ISSN 1090-0535 
Mimura, T., Amano, S., Yokoo, S., Uchida, S., Yamagami, S., Usui, T., Kimura, Y., & Tabata, 
Y. (2008b). Tissue engineering of corneal stroma with rabbit fibroblast precursors 
and gelatin hydrogels. Mol Vis, Vol.14, (January 2008), pp. 1819-1828, ISSN 1090-
0535 
Mimura, T., Yamagami, S., Uchida, S., Yokoo, S., Ono, K., Usui, T., & Amano, S. (2010a). 
Isolation of adult progenitor cells with neuronal potential from rabbit corneal 
epithelial cells in serum- and feeder layer-free culture conditions. Mol Vis, Vol.16, 
(August 2010), pp. 1712-1719, ISSN 1090-0535 
Mimura, T., Yamagami, S., Yokoo, S., Usui, T., & Amano, S. (2010b). Selective isolation of 
young cells from human corneal endothelium by the sphere-forming assay. Tissue 
Eng Part C Methods, Vol.16, No.4, (August 2010), pp. 803-812, ISSN 1937-3384 
Mooy, C. M., Clark, B. J., & Lee, W. R. (1990). Posterior axial corneal malformation and 
uveoretinal angiodysgenesis--a neurocristopathy? Graefes Arch Clin Exp Ophthalmol, 
Vol.228, No.1, (1990), pp. 9-18, ISSN 0721-832X 
Nakamura, T., Ishikawa, F., Sonoda, K. H., Hisatomi, T., Qiao, H., Yamada, J., Fukata, M., 
Ishibashi, T., Harada, M., & Kinoshita, S. (2005). Characterization and distribution 
of bone marrow-derived cells in mouse cornea. Invest Ophthalmol Vis Sci, Vol.46, 
No.2, (February 2005), pp. 497-503, ISSN 0146-0404 
Nunes, M. C., Roy, N. S., Keyoung, H. M., Goodman, R. R., McKhann, G., 2nd, Jiang, L., 
Kang, J., Nedergaard, M., & Goldman, S. A. (2003). Identification and isolation of 
Transplantation of Corneal Stroma Reconstructed with  
Gelatin and Multipotent Precursor Cells from Corneal Stroma 
 
361 
multipotential neural progenitor cells from the subcortical white matter of the adult 
human brain. Nat Med, Vol.9, No.4, (April 2003), pp. 439-447, ISSN 1078-8956 
Price, F. W., Jr., Whitson, W. E., & Marks, R. G. (1991). Graft survival in four common 
groups of patients undergoing penetrating keratoplasty. Ophthalmology, Vol.98, 
No.3, (March 1991), pp. 322-328, ISSN 0161-6420 
Reynolds, B. A., & Weiss, S. (1992). Generation of neurons and astrocytes from isolated cells 
of the adult mammalian central nervous system. Science, Vol.255, No.5052, (March 
1992), pp. 1707-1710, ISSN 0036-8075 
Tabata, Y., Hijikata, S., Muniruzzaman, M., & Ikada, Y. (1999). Neovascularization effect of 
biodegradable gelatin microspheres incorporating basic fibroblast growth factor. J 
Biomater Sci Polym Ed, Vol.10, No.1, (1999), pp. 79-94, ISSN 1568-5624 
Takahashi, Y., & Tabata, Y. (2004). Effect of the fiber diameter and porosity of non-woven 
PET fabrics on the osteogenic differentiation of mesenchymal stem cells. J Biomater 
Sci Polym Ed, Vol.15, No.1, (2004), pp. 41-57, ISSN 1568-5624 
Takahashi, Y., Yamamoto, M., & Tabata, Y. (2005). Osteogenic differentiation of 
mesenchymal stem cells in biodegradable sponges composed of gelatin and beta-
tricalcium phosphate. Biomaterials, Vol.26, No.17, (June 2005), pp. 3587-3596, ISSN 
0142-9612 
Toma, J. G., Akhavan, M., Fernandes, K. J., Barnabe-Heider, F., Sadikot, A., Kaplan, D. R., & 
Miller, F. D. (2001). Isolation of multipotent adult stem cells from the dermis of 
mammalian skin. Nat Cell Biol, Vol.3, No.9, (September 2001), pp. 778-784, ISSN 
1465-7392 
Toti, P., Tosi, G. M., Traversi, C., Schurfeld, K., Cardone, C., & Caporossi, A. (2002). CD-34 
stromal expression pattern in normal and altered human corneas. Ophthalmology, 
Vol.109, No.6, (June 2002), pp. 1167-1171, ISSN 0161-6420 
Tropepe, V., Coles, B. L., Chiasson, B. J., Horsford, D. J., Elia, A. J., McInnes, R. R., & van der 
Kooy, D. (2000). Retinal stem cells in the adult mammalian eye. Science, Vol.287, 
No.5460, (March 2000), pp. 2032-2036, ISSN 0036-8075 
Uchida, S., Yokoo, S., Yanagi, Y., Usui, T., Yokota, C., Mimura, T., Araie, M., Yamagami, S., 
& Amano, S. (2005). Sphere formation and expression of neural proteins by human 
corneal stromal cells in vitro. Invest Ophthalmol Vis Sci, Vol.46, No.5, (May 2005), 
pp. 1620-25, ISSN 0146-0404 
Waldrop, T. C., & Semba, S. E. (1993). Closure of oroantral communication using guided 
tissue regeneration and an absorbable gelatin membrane. J Periodontol, Vol.64, 
No.11, (November 1993), pp. 1061-1066, ISSN 0022-3492 
Wilson, S. E., He, Y. G., Weng, J., Li, Q., McDowall, A. W., Vital, M., & Chwang, E. L. (1996). 
Epithelial injury induces keratocyte apoptosis: hypothesized role for the 
interleukin-1 system in the modulation of corneal tissue organization and wound 
healing. Exp Eye Res, Vol.62, No.4, (April 1996), pp. 325-327, ISSN 0014-4835 
Wilson, S. E., & Kaufman, H. E. (1990). Graft failure after penetrating keratoplasty. Surv 
Ophthalmol, Vol.34, No.5, (March-April 1990), pp. 325-356, ISSN 0039-6257 
Yamagami, S., Mimura, T., Yokoo, S., Takato, T., & Amano, S. (2006a). Isolation of human 
corneal endothelial cell precursors and construction of cell sheets by precursors. 
Cornea, Vol.25, No.10(Suppl 1), (December 2006), pp. S90-92, ISSN 0277-3740 
  
Tissue Engineering for Tissue and Organ Regeneration 
 
362 
Yamagami, S., Ebihara, N., Usui, T., Yokoo, S., & Amano, S. (2006b). Bone marrow-derived 
cells in normal human corneal stroma. Arch Ophthalmol, Vol.124, No.1, (January 
2006), pp. 62-69, ISSN 0003-9950 
Yamagami, S., Yokoo, S., Mimura, T., Takato, T., Araie, M., & Amano, S. (2007). Distribution 
of precursors in human corneal stromal cells and endothelial cells. Ophthalmology, 
Vol.114, No.3, (March 2007), pp. 433-439, ISSN 0161-6420 
Yamamoto, M., Takahashi, Y., & Tabata, Y. (2003). Controlled release by biodegradable 
hydrogels enhances the ectopic bone formation of bone morphogenetic protein. 
Biomaterials, Vol.24, No.24, (November 2003), pp. 4375-4383, ISSN 0142-9612 
Yasuda, K., Inoue, S., & Tabata, Y. (2004). Influence of culture method on the proliferation 
and osteogenic differentiation of human adipo-stromal cells in nonwoven fabrics. 
Tissue Eng, Vol.10, No.9-10, (September-October 2004), pp. 1587-1596, ISSN 2152-
4955 
Yokoo, S., Yamagami, S., Yanagi, Y., Uchida, S., Mimura, T., Usui, T., & Amano, S. (2005). 
Human corneal endothelial cell precursors isolated by sphere-forming assay. Invest 
Ophthalmol Vis Sci, Vol.46, No.5, (May 2005), pp. 1626-31, ISSN 0146-0404 
17 
Human Ear Cartilage 
Lu Zhang, Qiong Li, Yu Liu, Guangdong Zhou, Wei Liu and Yilin Cao 
Department of Plastic and Reconstructive Surgery, Shanghai 9th People’s Hospital, 
Shanghai Jiao Tong University School of Medicine,  
Shanghai Key Laboratory of Tissue Engineering, Shanghai 
 P.R. China 
1. Introduction 
The human ear (Fig. 1) is of an ovoid form, with its larger end directed upward. Its lateral 
surface is irregularly concave, directed slightly forward, and presents numerous eminences 
and depressions to which names have been assigned (Beahm, Walton, 2002; Walton, Beahm, 
2002). The prominent rim of the human ear is called the helix while another curved 
prominence, parallel with and in front of the helix, is called the antihelix; this divides above 
into two crura, between which is a triangular depression, the fossa triangularis. The narrow-
curved depression between the helix and the antihelix is called the scapha; the antihelix 
describes a curve around a deep, capacious cavity, the concha, which is partially divided 
into two parts by the crus or commencement of the helix; the upper part is termed the 
cymba concha, the lower part the cavum concha. In front of the concha, and projecting 
backward over the meatus, is a small pointed eminence, the tragus, so called from its being 
generally covered on its under surface with a tuft of hair, resembling a goat’s beard. 
Opposite the tragus, and separated from it by the intertragic notch, is a small tubercle, the 
antitragus. Below this is the lobule, composed of tough areolar and adipose tissues, and 
wanting the firmness and elasticity of the rest of the auricula. 
Up to now, total human ear reconstruction for congenital microtia or auricular traumatic 
amputation still remains one of the greatest challenges for plastic surgeons(Brent, 1999; 
Nagata, 1993; TANZER, 1959). Although tissue engineering is a promising method for repair 
and reconstruction of cartilage defects(Chung, Burdick, 2008; Langer, Vacanti, 1993), 
engineering cartilage with a delicate three dimensional (3D) structure, such as a human ear, 
remains a great challenge in this field(Ciorba, Martini, 2006; Sterodimas et al., 2009; Zhang, 
2010). Since in 1997 Cao et al. engineered the cartilage with a shape of human auricle in a 
nude mouse model(Cao et al., 1997), many researchers have tried to explore further 
developments of this tissue engineering system, but few of them have succeeded in in vitro 
regeneration of a cartilage construct with a complete and anatomically refined auricle 
structure(Haisch et al., 2002; Isogai et al., 2004; Kamil et al., 2003; Kamil et al., 2004; 
Naumann et al., 2003; Neumeister et al., 2006; Shieh et al., 2004; Xu et al., 2005)(Table 1). 
One major reason leading to the failure of in vitro engineering a cartilage construct with 
sufficient control over shape is the lack of appropriate scaffolds(Liu et al., 2010). The optimal 
scaffold used for engineering a cartilage construct with accurate designed shapes should 
possess at least three characteristics: good biocompatibility for cartilage formation, ease of 
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being processed into a specific shape, and sufficient mechanical strength for retaining the 
pre-designed shape during chondrogenesis. Polyglycolic acid (PGA) has proven to be one of 
the most successful scaffolds for cartilage regeneration(Cui et al., 2009; Frenkel, Di, 2004; 
Heath, Magari, 1996). Cartilage engineered with the PGA scaffold has structure and 
composition similar to the native tissue, as demonstrated by histological analysis and 
cartilage specific matrices(Aufderheide, Athanasiou, 2005; Moran et al., 2003; Yan et al., 
2009). However, the most widely used form of PGA material in cartilage engineering is 
unwoven fiber mesh, which is difficult to be initially prepared into a complicated 3D 
structure and would most likely fail to maintain its original architecture during subsequent 
in vitro chondrogenesis due to insufficient mechanical support(Gunatillake, Adhikari, 2003; 
Kim, Mooney, 1998; Moran et al., 2003). 
 
 
Table 1. 
To overcome these problems, two crucial issues should be addressed. First, the PGA-based 
scaffold should be prefabricated into the exact shape of a human ear. Second, the mechanical 
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strength of the above-mentioned scaffold should be further enhanced so that it can retain the 
pre-designed shape during in vitro chondrogenesis.  
 
 
Fig. 1. The outline of a human ear 
In order to meet these requirements, in the current study, a computer aided design and 
manufacturing (CAD/CAM) technique was employed to fabricate a set of negative molds, 
which was then used to press the PGA fibers into the pre-designed ear structure. 
Furthermore, the mechanical strength of the scaffold was enhanced by coating the PGA 
fibers with an optimized amount of PLA. Then, the feasibility of engineering a shape 
controllable ear cartilage in vitro was explored by seeding chondrocytes into the optimized 
scaffolds. In addition, the exactness of the shape of the ear graft was quantitively evaluated 
by a 3D laser scanning system. 
2. Materials and methods 
2.1 Preparation of scaffolds with different PLA contents 
40 mg of unwoven PGA fibers (provided by Dong Hua University, Shanghai, China) were 
compressed into a cylinder shape of 13mm in diameter and 1.5mm in thickness. A solution 
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of 0.3 % PLA (Sigma, St. Louis, MO, USA) in dichloromethane was evenly dropped onto the 
PGA scaffold, dried in a 65 ºC oven, and weighed. The PLA mass ratio was calculated 
according to the formula: PLA%= (final mass-original mass)/final mass×100%. The above 
procedures were repeated until the predetermined PLA mass ratios of 0%, 10%, 20% and 
30% were achieved.  
2.2 Mechanical analysis of the scaffolds 
The mechanical properties of the scaffolds were analyzed by a biomechanical analyzer 
(Instron-5542, Canton, MA, USA). The scaffold disks were compressed at a constant 
compressive strain rate of 0.5 mm/min until a maximum of 10% total strain was reached. 
The maximum compressive force and Young’s modulus were determined from the stress-
strain curve. 
2.3 Biocompatibility evaluation of the scaffolds 
Cell seeding:  Chondrocytes were isolated from the articular cartilage of newborn swine (2-
3weeks old) as described(Rodriguez et al., 1999). The harvested chondrocytes were adjusted 
to a final concentration of 50×106 cells/mL, and a 200uL cell suspension was pippeted onto 
each scaffold. The cell-scaffold constructs were then incubated for 5h at 37ºC with 95% 
humidity and 5% CO2 to allow for complete adhesion of the cells to the scaffolds. Then, the 
constructs were covered by pre-warmed culture medium and cultured under the same 
conditions.  
Cell adhesion:  After 24 hours of incubation, the cell-scaffold constructs were gently 
transferred into a new 6-well plate for subsequent culture to evaluate cartilage formation. 
The remaining cells were collected and counted. The cell seeding efficiencies of the scaffolds 
with different PLA contents were calculated based on the formula: (total cell number- 
remaining cell number)/ total cell number×100%(Moran et al., 2003). 
Scanning electron microscopy (SEM): The constructs were cultured in vitro and the 
attachment and matrix production of the cells on the scaffolds were examined by SEM 
(Philips XL-30, Amsterdam, Netherlands) after 2 weeks and 8 weeks.  
Evaluation of cartilage formation: The constructs were harvested after 8 weeks of culture. 
The cartilage formation on different scaffolds was evaluated histologically by staining with 
hematoxylin and eosin (HE) and Safranin O, and immunohistochemically with type II 
collagen(Zhang, Spector, 2009).  
2.4 Mold fabrication by CAD/CAM 
A patient’s normal ear was scanned by CT to obtain the geometric data. These data were 
further processed by a CAD system to generate the half-sized mirror image data (both 
positive and negative) of the normal ear, and the resultant data were input into a CAM 
system (Spectrum 510, Z Corporation) for the fabrication of the resin models by 3D printing. 
The negative mold was composed of two parts: the outer part and the inner part. In order to 
make the mold pressure-loadable, the outer part was replaced by a silicon rubber, which 
was molded according to the inner part of the resin negative mold.  
2.5 Fabrication of ear shaped scaffold 
Two hundred milligrams of unwoven PGA fibers were pressed using the negative mold for 
over 12 hours. A solution of 0.3 % PLA (Sigma, St. Louis, MO, USA) in dichloromethane was 
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evenly dropped onto the PGA scaffold, dried in a 65 ºC oven, weighed, and pressed again 
with the negative mold. This procedure was repeated until the final PLA mass ratio of 20% 
was reached. The edge of the scaffold was carefully trimmed according to the shape of the 
positive mold.  
2.6 Three-dimensional laser surface scanning 
A 3D laser scanning system was used for the shape analysis(Yu et al., 2009). The surface 
image data were collected from both the positive mold and the ear shaped scaffolds using a 
Konica Minolta Vivid 910 and Polygen Editing Tools version 2.21 (Konica Minolta, Tokyo, 
Japan). These data were further processed by RapidForm 2006 (INUS, Seoul, South Korea) 
and HP xw6200 (Hewlett Packard, Shanghai, China). The resultant data obtained from the 
ear-shaped scaffolds were compared to those from the positive mold, which served as a 
standard. Variations in voxels smaller than 1mm were considered similar, and the number of 
these similar voxels was divided by the number of total voxels to calculate the similarity level. 
2.7 In vitro construction of ear-shaped cartilage 
A 1mL aliquot of chondrocyte suspension with a density of 50×106 cells/mL was seeded 
into the ear-shaped scaffold followed by incubating for 5h, according to the cell seeding 
procedures described above. Then, the construct was gently transferred into a 50mL 
centrifuge tube for subsequent culture. The culture medium was changed every other day. 
The constructs were harvested at 4weeks, 8 weeks and 12 weeks for evaluation of shape 
exactness and cartilage specific histology. 
2.8 Statistical analysis 
The differences of cell seeding efficiencies (n=6), Young’s moduli (n=6), and maximum 
compressive loadings (n=6) among the four PLA content groups were analyzed using the 
Student’s t-test. A p-value less than 0.05 was considered statistically significant. 
3. Results 
3.1 Mechanical analysis of different scaffolds 
The mechanical properties of the scaffolds were analyzed to evaluate the effects of PLA 
coating with different amount on the mechanical strength. As shown in Figure 2, all the 
scaffolds had regular cylinder shapes with the same diameter of 13mm (Fig. 2A-2D). No 
obvious differences in appearance were observed among the PLA/PGA scaffolds with 
different PLA amounts (Fig. 2B-2D). As expected, the pure PGA group (0% PLA group) 
showed a flat compressive stress-strain curve close to the X axis, indicating that pure PGA 
scaffolds had relatively low mechanical strength. With an increase in PLA content, the 
compressive stress-strain curves became steeper and more linear before the maximum 
loadings were reached (Fig. 2E), and the compressive moduli (Fig. 2F) as well as maximum 
loadings (Fig. 2G) also increased. Noticeably, there was a significant increase (over 4 folds) 
in both compressive moduli and maximum loading in scaffolds fabricated with 20% PLA 
compared to those with 10% PLA. Furthermore, the scaffold with 20% PLA reached a 
compressive modulus around 45MPa (45.42±10.52 MPa), which was similar to that of native 
adult human articular cartilage [19]. As expected, the 30% PLA group achieved the highest 
maximum loading and Young’s modulus in all groups, although no significant difference 
was observed in Young’s modulus between the 20% and 30% groups. 
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Fig. 2. The influences of PLA contents on mechanical properties. PGA fibers are pressed into 
a regular cylindrical shape (A). No obvious differences in appearance are observed among 
the PLA/PGA scaffolds with different PLA ratios of 10% (B), 20% (C), and 30% (D). The 
scaffolds have different stress-strain curves (E), with significant differences in maximum 
loading (F) and Young’s modulus (G). Different lower-case letters indicate significant 
differences (p<0.01) 
 
 
Fig. 3. The influences of PLA contents on cell seeding efficiency. Scaffolds with different 
PLA contents of 0% (A), 10% (B), 20% (C), and 30% (D) absorb different volumes of the cell 
suspension. Cell seeding efficiencies decrease with increasing PLA contents in the scaffolds, 
and a significant decrease is observed in the scaffolds with 30% PLA compared to those with 
10% and 20% PLA (E). Different lower-case letters indicate significant differences (p<0.05) 
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3.2 Evaluation of the biocompatibility of the scaffolds with different PLA contents 
Cell seeding efficiencies, SEM, and histological examination were performed to evaluate 
the influence of PLA contents on cell compatibility of the scaffolds and on final cartilage 
formation. The results showed that the increase in PLA content could lead to the 
reduction in the ability of the scaffolds to absorb the cell suspensions (Fig. 3A-3D), which 
may be related to the different pore structures (Fig. 4A-4D) and hydrophobicity of the 
scaffolds with different PLA contents. Quantitative analysis demonstrated that all the 
groups with PLA presented significantly lower cell seeding efficiencies compared to the 
group without PLA (p<0.05). Most notably, there was a significant decrease in cell seeding 
efficiencies in scaffolds with 30% PLA compared to those with 10% and 20% PLA, while 
no significant differences were observed between the scaffolds with 10% and 20% PLA 
(Fig. 3E). 
 
 
 
Fig. 4. SEM examination for the influences of PLA contents on cell distribution and ECM 
production. Scaffolds with different PLA contents show different pore structures (A-D). At 2 
weeks, no obvious differences in cell distribution are observed among groups with 0% (E), 
10% (F), and 20% (G) PLA, while an obvious decrease in cell number is observed in 30% 
PLA group (H). At 8 weeks, inferior ECM deposition is observed in 30% PLA group (L) 
compared to the other groups (I-K). The white arrows indicate the coated PLA 
Naturally, the evaluation of final cartilage formation is the most important criterion to 
determine whether a scaffold can be used for cartilage engineering. As shown in Figure 5, 
after 8 weeks of in vitro culture, homogenous cartilage-like tissue with abundant cartilage-
specific extracellular matrices (ECM) was observed in the constructs with 0% (Fig. 5E, 5I, 
5M), 10% (Fig. 5F, 5J, 5N), and 20% (Fig. 5G, 5K, 5O) PLA. However, in the group with 30% 
PLA (Fig. 5H, 5L, 5P), there were high amounts of undegraded scaffold in the constructs, 
and only sporadic cartilage-like tissues were observed. These findings were consistent with 
the SEM examinations, which showed an obvious decrease in both cell number and ECM 
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deposition in 30% PLA group (Fig. 4H, 4L) compared to the other groups (Fig. 4E-4G, 4I-
4K). Therefore, these results indicate that 20% but not 30% is an acceptable PLA amount for 
preparing the scaffolds in terms of cell seeding efficiency, ECM production, and cartilage 
formation. 
 
 
Fig. 5. The influences of PLA contents on cartilage formation. Grossly, the construct without 
PLA shrinks a little in diameter (A). The constructs that contain PLA basically maintain their 
original sizes (B-D). Histologically, homogenous cartilage-like tissue is observed in groups 
with 0% (E, I, M), 10% (F, J, N), and 20% (G, K, O) PLA, except that more compact structures 
and more undegraded scaffold fibers are observed in 20% PLA group compared with 0% 
and 10% PLA groups. In the group with 30% PLA (H, L, P), obvious heterogeneous cartilage 
was observed with an abundance of undegraded scaffolds. The black arrows indicate the 
undegraded PGA fibers. The yellow arrows indicate void regions caused by fast 
degradation of the scaffolds. Scale bar = 100μm 
3.3 Preparation and shape analysis of ear-shaped scaffold 
Because sufficient mechanical strength and good biocompatibility could be achieved in the 
scaffold with 20% PLA, this formulation was further used for the preparation of the human 
ear-shaped scaffold. In order to prepare the scaffold into a shape that is mirror-symmetrical 
to the normal ear, a set of negative molds in half size of an ear (Fig. 6F-6G) was fabricated 
according to the mirror image (Fig. 6B) of the normal ear (Fig. 6A). The resulting ear-shaped 
scaffold (Fig. 6H-6J; Fig. 7A, 7E) achieved a similarity level of above 97% compared to the 
positive mold, the standard for comparison, (Fig. 6C-6E) according to the shape analysis. 
These results indicate that the mold fabricated by CAD/CAM technology is allowed to 
accurately fabricate a scaffold into an ear-shape mirror-symmetrical to the normal ear.  
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Fig. 6. Preparation and shape analysis of the ear-shaped scaffolds. (A): 3D image of the 
normal ear; (B): the mirror image of A; (C): The half-sized resin positive mold; (D): laser scan 
image of C; (E): color map of D; (F): inner part of the resin negative mold fabricated by 3D 
printing; (G): outer part of the negative mold cast from F with silicon rubber; (H): the ear-
shaped PLA/PGA scaffold; (I): laser scan image of H; (J): color map of I compared to D 
3.4 Construction of ear-shaped cartilage in vitro 
The scaffolds were then used to explore the feasibility of engineering an ear-shaped cartilage 
in vitro. Similarly to the cylindrical scaffold containing 20% PLA, the ear-shaped scaffold 
also had good compatibility with seeded chondrocytes (data not shown). Most importantly, 
all the cell-scaffold constructs largely maintained their original ear-like shape during in vitro 
culture, and the shape similarity of the engineered ear grafts was retained at a level of 85.2% 
at 4 weeks (Fig.7 B, F), 84.0% at 8 weeks (Fig.7 C, G), and 86.2% at 12 weeks (Fig.7 D, H) 
compared to positive mold, indicating that the mechanical strength of the scaffolds was 
strong enough to maintain the ear-shape throughout the in vitro culture period. 
Histologically, the structure of the ear-shaped constructs gradually became compact with 
prolonged culture time. At 4 weeks, cartilage-like tissue was preliminarily formed despite 
the presence of many undegraded PGA fibers (Fig.8 A, D, G). At 8 weeks, there was an 
obvious increase in both cartilage ECM deposition and the number of mature lacuna, 
although a few PGA fibers remained observable (Fig.8 B, E, H). At 12 weeks, the constructs 
had completely transformed into cartilage-like tissues with no visible residual PGA (Fig.8 C, 
F, I), and abundant cartilage ECM and mature lacuna were observed. Furthermore, the ear-
shaped neo-cartilage showed fine elasticity with a certain mechanical strength. 
4. Discussions 
Despite the rapid progress in cartilage engineering, in vitro engineering of cartilage with a 
fine controlled 3D structure, such as a human ear, remains a great challenge due to the lack 
of appropriate scaffolds. PGA has proven to be one of the most successful scaffolds for 
cartilage regeneration. However, for in vitro engineering of a cartilage with a precise shape, 
PGA unwoven fibers (the most widely used physical form) still have some drawbacks, such 
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as the difficulties in controlling an accurate shape and in gaining a proper mechanical 
strength. In the current study, aided by CAD/CAM technique, the PGA fibers were 
prepared into the accurate shape of a human ear. Furthermore, by coating with PLA, the 
scaffold could obtain sufficient mechanical strength to retain the original shape during cell 
culture until the ear-shaped cartilage was finally formed. These results may provide useful 
information for future external ear reconstructions by in vitro engineered cartilage as well as 
for the engineering of other tissues with complicated 3D structures.  
 
 
Fig. 7. Shape evaluation of the ear-shaped constructs. The scaffold shows an accurate ear-
like structure (A) with a high similarity level compared to the positive mold (E). All the cell-
scaffold constructs largely maintain their original ear-like structures at 4weeks (B), 8 weeks 
(C), and 12 weeks (D). Quantitative analysis show over 84% shape similarity in all the 
samples (E-H) compared to the positive mold 
Preparation of the PGA fibers into an accurate ear structure is the first important step to 
determine the final shape of the engineered cartilage. To achieve this, a negative mold 
corresponding to the desired shape is required. Traditionally, the negative mold was 
fabricated by casting impression materials onto a patient’s normal ear(Cao et al., 1997; Isogai 
et al., 2004), so that the shape of the PGA scaffold prepared by this mold exactly replicated 
the shape of the ear being casted. However, clinically, the ear aiming to reconstruct should 
be mirror-symmetrical to the contralateral normal ear. CAD/CAM, as a novel technique, has 
been widely used for the fabrication of anatomically accurate 3D models(Bill et al., 1995; 
Ciocca et al., 2007; Erickson et al., 1999; Subburaj et al., 2007). Particularly, this method can 
accurately perform complicated manipulations of the original 3D data, including Boolean 
operations, mirror imaging, and scaling(Al et al., 2005; Ciocca, Scotti, 2004; Karayazgan-
Saracoglu et al., 2009). CAD/CAM technique was therefore used in the current study for the 
fabrication of the mirror-image negative mold for a human ear in half size. Using this mold, 
PGA fibers were able to be accurately prepared into the ear-shaped scaffold that was mirror-
symmetrical to the normal ear in half size. 
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Fig. 8. Histological examinations of the in vitro ear-shaped constructs. At 4 weeks, the 
constructs form heterogeneous cartilage-like tissue along with undegraded PGA fibers (A, 
D, G). With prolonged culture time, the histological structure of the constructs gradually 
become compact, accompanied with increased numbers of lacuna structures at 8 weeks (B, 
E, H). Homogeneous cartilage with abundant ECM and mature lacuna are observed at 12 
weeks (C, F, I) with no visible scaffold residuals in the constructs. The black arrows indicate 
the undegraded PGA fibers. Scale bar = 100μm 
After the preparation of the ear-shaped PGA scaffold, the issue of shape retention during in 
vitro chondrogenesis becomes important. The shape maintenance of the cell-scaffold 
constructs mainly depends on the mechanical strength and degradation rate of the 
scaffold(Kim et al., 1994). The mechanical strength of PGA scaffold alone is not sufficient for 
the shape maintenance, and thus PLA coating was used to strengthen its mechanical 
properties as reported(Cui et al., 2009; Frenkel, Di, 2004; Yang et al., 2001). However, a high 
amount of PLA in the scaffold would negatively affect cartilage formation because of poor 
cell compatibility(Moran et al., 2003). Therefore, an appropriate PLA content in the scaffold 
is important for both cartilage formation and shape maintenance. In the current study, we 
evaluated the effects of four PLA contents on the scaffolds’ mechanical properties and 
cartilage formation. According to the current results, the mechanical strength of the 
scaffolds increased with increasing PLA content. However, homogeneous cartilage was only 
observed in groups with PLA contents of 20% or less. Fortunately, the scaffold with 20% 
PLA was strong enough to retain the original shape of the cell-scaffold construct until the 
ear-shaped cartilage was finally formed after 12 weeks. 
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Besides the mechanical strength, the degradation rate of the scaffold is also an important 
factor that determines the final shape of engineered tissue. The ideal degradation rate 
should match the rate of ECM deposition. If the degradation rate of the scaffold is much 
faster than deposition rate of ECM, the engineered tissue would gradually collapse due to 
insufficient support, and thus the shape cannot be maintained. According to the histological 
findings at 8 weeks (Fig.4), the constructs in both 0% and 10% PLA groups had some void 
regions and lower amounts of residual scaffold, indicating that the degradation rate of the 
scaffolds in these two groups might be faster than the deposition rate of ECM. In contrast, 
the constructs in 20% PLA group showed a relatively compact histological structure with 
more scaffold fibers, indicating the scaffold with 20% PLA has an appropriate degradation 
rate matching the ECM formation. 
In addition, for engineering a complicated structure like a human ear, it is necessary to 
establish a method to quantitively evaluate the shape exactness of the scaffold as well as to 
trace the deformation of the constructs during in vitro chondrogenesis. 3D laser surface 
scanning is one of the most popular data acquisition techniques, and has been successfully 
applied to quantify facial dimensions(Kau, Richmond, 2008; Kau et al., 2005; Toma et al., 
2009). It has also been introduced to determine the dimensions of the ear(Coward et al., 
2000; Sforza et al., 2005). However, no studies have applied this method to analyze the shape 
of tissue engineered ear grafts. In the current study, the introduction of 3D laser scanning 
system provided an effective tool for quantitively evaluating the shape exactness of the ear 
graft as well as tracing its shape change during in vitro engineering. 
5. Conclusions 
In summary, this study established a method to precisely engineer a cartilage in vitro with a 
shape that is mirror-symmetrical to the normal ear. Additionally, a quantitative system for 
evaluating the shape exactness of the constructs was established as well. These strategies 
may provide useful tools for future external ear reconstructions by in vitro engineered 
cartilage as well as for engineering of other tissues with complicated 3D structures. 
Moreover, the in vitro engineering system established in this study may also offer useful 
references for ear-shaped cartilage construction based on stem cells, since the ectopic 
chondrogenesis of stem cells requires a long-term induction in vitro(Liu et al., 2008). In 
future studies, we will also investigate the fate of this ear-shaped cartilage after 
subcutaneous implantation, especially in an immunocompetent animal model. 
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1. Introduction  
No long-term effective treatments are currently available for brain neurological disorders 
such as focal and global cerebral ischemia, traumatic brain injury (TBI) and 
neurodegenerative disorders. Current treatments are primarily focused on limiting the 
damage and slowing the degeneration and, most of them are only symptomatic while 
function restoration is rarely achieved. This underlies the need for alternative therapies such 
as brain cell therapy that allows functional replacement of missing or damaged neurons by 
transplanting cells that may differentiate into the desired phenotype and integrate the host 
parenchyma, or alternatively rescue the affected neuronal population. Due to the high cell 
death that occurs during neurodegenerative processes, brain neurological disorders are an 
ideal target for cell-based therapies. Several teams tried to prevent the loss of neurons or to 
replace them, using neuronal precursors and lately, since stem cell discovery, embryonic 
stem (ES) cells, adult stem cells, tissue-derived stem cells or more recently induced 
pluripotent stem (iPS) cells (for review see (Abeliovich & Doege, 2009; Joyce et al., 2010; 
Chen & Xiao, 2011; Loewenbruck & Storch, 2011). These studies demonstrated the potential 
of cell therapy to repair the injured brain even if poor survival of grafted cells was reported 
(Brundin et al., 1985; Schierle et al., 1999; Brundin et al., 2000; Isacson et al., 2003; Olanow et 
al., 2003). In this book chapter, brain cell therapy studies performed with adult non-
transformed cells that, by nature, allow the use of autologous tissues for transplantation and 
overcome the immunological, availability, as well as ethical concerns will be reported.  
It is important to bear in mind that, for organs with a higher level of complexity such as the 
brain, cell therapy remains a challenging task. Fortunately, relatively recent medical, 
biological and technological advances in tissue engineering approaches allow functional 
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tissue and organ recovery by using the appropriate combination of three fundamental 
“tools” known as the tissue engineering triad: cells, engineered materials and signalling 
molecules (essentially growth factors). In practice, this is translated into a great versatility 
of delivery systems, which mimic the natural repairing environment of the brain tissue, 
creating tuneable and customized spatio-temporal gradients of signals guiding tissue 
regeneration. Bioactive scaffolds are likely to reinforce the success of cell replacement 
therapies by providing a microenvironment that facilitates the survival, proliferation, 
differentiation, and connectivity of transplanted and/or endogenous cells 
(Pettikiriarachchi et al., 2010). However, delivery of cells with scaffolds to the damaged 
brain still remains challenging due to practical limitations of delivery. The second part of 
this book chapter will provide an overview of what solutions tissue engineering may 
provide for adult cell therapy of the brain. Since the brain is a functionally complex organ, 
cell growth and differentiation alone are not enough in order to achieve its functional 
recovery. The correct re-establishment of the axonal connections and neuronal circuits is 
also necessary. In general, scaffolds for brain therapy should meet several essential 
requirements like being biocompatible, biodegradable, immunologically inert and able to 
support neurite outgrowth. The most common materials, fabrication methods and 
desirable properties of biomaterials used for brain protection repair and regeneration will 
be presented. 
Brain tissue engineering has several limitations and many unanswered questions or 
concerns should be addressed before reaching the clinic. Moreover, with the current 
workflow, it takes a long time to select an effective brain tissue engineering strategy to 
translate into clinical studies. Additionally, recent developments in understanding the basic 
biology of brain tissue formation in physiological and pathological conditions have resulted 
in an explosion in the numbers of tissue engineering products that could be potential 
candidates for treating brain disorders. Screening platforms that bridge the gap between 
conventional tissue culture and animal models would help to improve understanding of 
cell-based therapies and optimize central nervous system (CNS) tissue engineering. In this 
regard, the usefulness of 3D brain organotypic cultures in CNS research as well as in the 
drug discovery process will be discussed in this book chapter. 
2. Adult cell therapy for brain neuronal damages 
2.1 Adult cells for cerebral ischemia and traumatic brain injury therapy 
2.1.1 Adult stem cell therapy 
Mesenchymal stem cells (MSCs) are the most widely investigated adult stem cells for brain 
cell therapy of cerebral ischemia and TBI (Table 1). Various animal models of ischemia have 
been used to investigate the therapeutic effects of MSCs on the lesioned brain and in all 
these models, bone marrow-derived MSCs resulted in an increased survival of neurons and 
most of the time in an improved cognitive function of the animals (reviewed in (van 
Velthoven et al. 2009)). In addition, MSCs have been described to reduce the thickness of the 
scar walls (Li et al., 2005) and may also favour angiogenesis (Chen et al., 2003; Chopp et al., 
2008) as well as synaptogenesis (Chen & Chopp, 2006). Functional improvements may be 
observed whatever the implantation route, intravenously or intracerebrally, even if 
reduction in infarct volume is not always observed (Li et al., 2000). This underlines the 
capacity of MSCs to migrate towards lesions, as was already observed by other groups 
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(Chen et al., 2001) after IV injection, or after intracerebral graft in a lesioned rat brain 
(Sykova & Jendelova, 2007; Delcroix et al., 2009). Noteworthy, in situ neural or neuronal 
differentiation of transplanted MSCs has been described in several studies. For example, 
systemic or intracarotid artery administration of MSCs in rat models of ischemia improve 
neurogenesis and functional recovery, with the detection of neuronal or glial markers 
expressed by a fraction of MSCs in the brain (van Velthoven et al., 2009; Li et al., 2002; 
Esneault et al., 2008; Perasso et al., 2011). However, due to the low grafted cell survival and 
neural/neuronal differentiation, neurological benefits are often assumed to mainly derive 
from the increased production of growth factors and other paracrine factors from MSCs in 
the ischemic tissue (England, 2009; Yarygin et al., 2009). Factors secreted by the ischemic 
brain itself, such as vascular endothelial growth factor (VEGF) and erythropoietin (EPO), are 
also thought to play a major role in brain protection from ischemia (Tang et al., 2006). MSCs 
combined with growth factors also provided functional effects and in some cases reduced 
the lesion volume, the number of apoptotic cells within the ischemic lesion and stimulated 
host repair responses as recruitment of host progenitor cells (Esneault et al., 2008; 
Rahnemai-Azar et al., 2011; van Velthoven et al., 2009). Modulation of inflammatory and 
immune response or production of neuroprotective chemokines such as fractalkine and 
monocyte chemoattractant protein-1 (MCP-1) by MSCs are others mechanisms that may be 
involved in neuronal protection during ischemia (Re & Przedborski, 2006; Ohtaki et al., 
2008; Madrigal et al., 2009; Garbayo et al., 2011). Recruitment of host progenitor cells may 
also contribute to MSC-induced repair processes in response to chemokines [growth-related 
oncogene (GRO), MCP-1] secreted by the implanted cells (Rahnemai-Azar et al., 2011; 
Gordon et al., 2009). After a first clinical trial that underwent criticisms a few years ago 
(Bang et al., 2005; De Keyser, 2005), there is a growing number of phase I-II clinical trials to 
evaluate the safety and efficacy of MSCs or CD34+ cells delivered either by arterial infusion, 
IV or intracranial injection in the context of stroke (see clinicaltrials.gov for up to date 
informations).  Moreover, two consecutive meetings have been held recently named the 
Stem cell Therapies as an Emerging Paradigm in Stroke (STEPS I & II), in order to provide 
guidelines for preclinical and clinical studies leading to the successful development of cell 
therapy for stroke (Broderick, 2009; Savitz et al. 2011).  
In the context of TBI, MSCs may also improve functional benefits whatever the injection 
route. However, a maximum of 10 % implanted MSCs may transdifferentiate into neuronal 
cells in vivo so that, again, this mechanism was assumed not to be solely responsible for the 
functional benefits observed in TBI animal models (Li & Chopp, 2009). Growth factor 
production by MSCs stimulated by the lesioned brain (Chen et al., 2002) was certainly the 
main mechanism leading to functional recovery by promoting glial, neuronal and blood 
vascular remodelling (Li & Chopp, 2009; Richardson et al., 2007). However, despite the 
benefits obtained using this approach, no significant changes in the lesion volume were 
observed, a problem that tissue engineering alternatives may resolve (see section 3 of this 
chapter).  Concerning adult neural stem cells (NSCs), very few studies were performed in 
the context of stroke, and none for TBI. It is however interesting to note that a fraction of 
adult NSCs, either derived from rat hippocampus (Zhang et al., 2011) or from human 
wisdom teeth (Yang, Chen et al., 2009),  survived within the brain after transplantation and 
led to significant improvements in stroke. Another population of CD31-/CD146- cells 
isolated from dental pulp has also been used in stroke rat models, leading to migration and 
differentiation of the endogenous neuronal progenitor cells as well as vasculogenesis 
(Sugiyama et al., 2011).  
  
Tissue Engineering for Tissue and Organ Regeneration 
 
382 
Cells Origins Recipients Scaffolds Benefits References
Mouse MCAO mouse model Functional benefits but no reduction in infarct volume Li, Chopp et al. 2000
Rat MCAO rat model IV transplantat ion: migration toward the lesion Chen, Li et al. 2001
Human MCAO rat model IV transplantat ion: importance of growth factor increase in the 
ischemic tissue
Li, Chen et al. 2002
Rat MCAO rat model
IV transplantat ion in combination with EPO: functional recovery 
and neurogenesis                                                                            
A fraction of MSCs with neuronal and glial markers
Esneault, Pacary et al. 2008
Rat MCAO rat model IV transplantat ion: reduced thickness of the scar walls Li, Chen et al. 2005
Human MCAO rat model IV transplantat ion: promotion of angiogenesis Chen, Zhang et al. 2003
Human tCCAO mouse model Modulation of inflammatory and immune responses Ohtaki, Ylostalo et al. 2008
Mouse 2VO rat model IV transplantat ion: increased number of pyramidal CA1 neurons Perasso, Cogo et al. 2011
Human ACA rat model FN-coated PLGA microspheres
Neuroprotect ion of CA1 hippocampal neurons with MIAMI cells: 
neuroprotect ion enhanced with microspheres Garbayo, Curtis et al. 2011
Human TBI rat model Collagen cylinder Scaffolds improved spatial learning, sensorimotor function & reduced the lesion volume Lu, Mahmood et al. 2007
Human TBI rat model Collagen cylinder Delayed transplantation: increased angiogenesis in the injured cortex & transcallosal fiber length Xiong, Qu et al. 2009
Human TBI mouse model Collagen cylinder Scaffolds improved spatial learning, reduced lesion volume & increased vascular density Qu, Xiong et al. 2009
Human Human            (autologous, stroke) Proof of safety for MSCs use in human Bang, Lee et al. 2005
Human
From teeth MCAO rat model Functional benefits Yang, Chen et al. 2009
Rat 
hippocampi MCAO rat model
Amelioration of neurological deficits
Reduced total infarct volume Zhang, Jin et al. 2011
CD31-
/CD146- 
progenitor 
cells 
Pig
Teeth-
derived
MCAO rat model
Migration and differentiation of the endogenous neuronal 
progenitor cells
Vasculogenesis
Sugiyama, Iohara et al. 2011
Mouse
Embryonic 
fibroblast-
derived
MCAO rat model Fibrin glue
Sub-dural injection reduced the infarct size compared to iPS cells 
directly injected in the parenchyma 
Functional improvements and no teratoma when sub-dural 
inject ion with f ibrin glue is used
Chen, Chang et al. 2011
Human 
Fibroblast-
derived
MCAO rat model
Migration of the cells towards injured brain area
In situ  neuronal differentiation of iPS cells
Improved sensorimotor funct ion 4-16 days after graft ing
Jiang, Lv et al. 2011
iPS cells
Abbreviations: ACA: asphyxial cardiac arrest; EPO: erythropoietin; FN: fibronectin; iPS: induced pluripotent stem; IV: intravenous; MCAO: middle cerebral artery 
occlusion; MIAMI: marrow isolated adult multilineage inducible; MSC: mesenchymal stem cell; NSC: neural stem cell; tCCAO: transient common carotid artery 
occlusion, UPDRS: unified Parkinson's disease rating scale.
NSC
MSC
 
Table 1. Adult and iPS cell therapies for cerebral ischemia and TBI 
2.1.2 Adult derived pluripotent stem cell therapy  
A growing interest is now observed in the scientific community for the iPS cells. These 
“embryonic-like” cells were primarily derived from adult fibroblasts by the expression of 
transcription factors (a combination of 4 factors within c-Myc, KLF4, LIN28, Nanog, Oct3/4 
and Sox2) (Takahashi et al., 2007; Yu et al., 2007). Several applications are currently 
envisioned for these pluripotent cells, which share the same potential than ES cells, without 
the associated ethical problems. In addition to their applications for drug discovery and 
toxicity testing (Laustriat et al., 2010) these cells may be helpful for complex disease 
understanding. They are also attractive for cell therapy studies, due to the possibility to 
obtain a large amount of cells from various lineages and to perform autologous grafts. iPS 
have now been derived from several types of adult tissues, with variable efficiency, and 
always using refined protocols to avoid permanent genomic integration and the use of 
lentiviruses for transducing the cells (Okita et al., 2011; Narsinh, et al., 2011; Lee et al., 2009; 
Gonzalez et al., 2009; Zhou et al., 2009; Page et al., 2009; Yu et al., 2009). Indeed, uses of 
viral-based protocols may be at the origins of tumour formation and may also lead to 
further difficulties to differentiate the cells toward a given phenotype (Yu et al., 2009). The 
propensity of iPS to form teratomas may also be related to the tissue of origin of the cells 
(Miura et al., 2009). Despite their great interest, one has to keep in mind that further 
developments are still required to fully understand their reprogramming process 
(Nakagawa & Yamanaka, 2011) in order to provide a safe cell therapeutic product for the 
Garbayo, Raval et al. 2011 
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clinic (Pera, 2011). In the context of ischemic stroke, an interesting study describes the use of 
iPS-derived neurons and astrocytes directly injected in the damaged cortex of a stroke 
animal model (Chen et al., 2011), which resulted in a reduced ischemic size with functional 
improvements. Another study describes the in situ migration and differentiation of human 
iPS cells in a similar context, with an improved sensorimotor function of the animals 4-16 
days after grafting (Jiang et al. 2011). 
2.2 Adult cells for neurodegenerative disorder therapy 
Huntington’s and Parkinson’s diseases (HD and PD respectively) have been widely studied 
in cell therapy programs due to the relatively small area affected by the diseases, 
particularly at early stages (see for reviews (Lindvall & Kokaia, 2009; Loewenbruck & 
Storch, 2011)). In opposition, Alzheimer’s disease (AD) would be more complex to treat due 
to the multiple sites of the brain affected in this disease. Moreover, no tissue engineering 
strategies have yet been described for AD so that we will only focus on HD and PD in the 
following (Table 2).  
2.2.1 Adult cell therapy 
An increasing number of studies performed with foetal tissue, ES cells or NSC grafts, mostly 
in quinolinic acid (QA)-induced animal models of the disease (Clelland et al., 2008) gave 
successful results leading to clinical trials with foetal-derived cells. However, cell therapy 
for HD, an incurable disease, is still not widely available in clinic due to ethical, logistical or 
safety concerns (Kelly et al., 2009). Adult cells have only been used in early studies with 
Sertoli cell grafts that protected the lesioned area in an animal model of HD; effects that may 
result from Sertoli cells trophic and anti-inflammatory potentials (Emerich, 2004). 
One of the first cell therapy strategies to treat PD has been performed with adult cell types 
synthesizing dopamine or its precursor L-DOPA, in order to replenish the striatum level of 
dopamine (for review (Drucker-Colin & Verdugo-Diaz, 2004; Fernandez-Espejo et al., 2005). 
Autologous adrenal medulla tissue were grafted in the caudate nucleus of 2 young PD 
patients, but observed functional improvements  were transitory and mainly due to trophic 
effects as only 1 % of the cells synthesized dopamine (Madrazo et al., 1987). Most 
importantly, very few cells were detected 1 or 2 years after transplantation (Hurtig et al., 
1989). Other studies were performed using cultured chromaffin cell suspensions, but few 
surviving cells in long term studies did not validate this approach (Drucker-Colin et al., 
1999). Human retinal pigment epithelium (hRPE) cells derived from the inner layer of the 
neural retina are isolated from human eye bank for transplantation purposes (reviewed in 
(Stover & Watts, 2008)). hRPE cells may be expanded, present a tyroxine hydroxylase 
activity (Pawelek & Korner, 1982), and produce L-DOPA, which is synthesized as a melanin 
precursor, so that these cells may supplement the oral administration of L-DOPA in situ. 
Moreover, it has been proposed that hRPE cells may be immune-privileged after 
transplantation due to their expression of Fas-ligand (Griffith et al., 1995; Jorgensen et al., 
1998). 
2.2.2 Adult stem cell therapy 
Adult stem cells are expected to better differentiate and integrate the host brain compared to 
adult non-stem cells and are therefore widely investigated for their therapeutic potential in 
the context of neurodegenerative disorders. Whole bone marrow cells [i.e. hematopoietic 
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stem cells (HSCs) & MSCs] implanted into the bilateral lesioned striatum of HD rat models, 
reversed functional deficits such as working memory (Lescaudron et al., 2003) even if the 
cell population responsible for the beneficial effects remained unknown. Noteworthy, 
autologous grafts may not be an appropriate strategy for the treatment of HD as 
transplanted cells would also carry the mutant huntingtin gene responsible for the disease. 
More recently, transplantation of MSCs, either intracerebrally or intravenously, resulted in a 
decreased atrophy of lesioned rat striatum (Amin et al., 2008) and in some functional 
benefits (Edalatmanesh et al., 2009) even though only a fraction of cells (1 %) expressed 
neural phenotypes. Thus, it was suggested that MSCs, by producing growth factors, 
allowed surviving cells within the caudate nucleus to function more efficiently and to 
facilitate other compensatory responses (Dunbar et al., 2006). In this regard, another study 
demonstrated the importance of factors such as stem cell factor (SCF), produced in situ in 
the lesioned striatum, to promote the migration and engraftment of MSCs via SCF 
receptor c-kit (Bantubungi et al., 2008).  
In the context of PD, several teams, including ours, reported the neuronal differentiation of 
human MSCs toward a dopaminergic phenotype in vitro, indicating that these cells may 
constitute an alternative dopamine secreting source of cells (Trzaska & Rameshwar, 2011; 
Barzilay et al., 2008; Trzaska et al., 2007; Tatard et al., 2007). An interesting study also 
reported no major differences between MSCs from normal patients compared to MSCs 
isolated from parkinsonian patients, which may be induced to produce up to 30 % of 
dopaminergic neurons in vitro (Zhang et al., 2008). Human MSCs, pre-induced towards a 
neuronal phenotype and transplanted in the totally dopaminergic deafferented striatum of 
rats, led to an improved functional recovery for up to 4 months compared to naïve hMSCs 
(Levy et al., 2008). A similar recovery has been observed in a rat partial lesion model of PD, 
in which dopaminergic fibers are spared in the striatum (Bouchez et al., 2008). Moreover, 
microdialysis demonstrated that part of the striatal pool of dopamine was restored upon 
MSCs transplantation. Naïve hMSCs or a subpopulation of hMSC pre-treated with 
epidermal growth factor (EGF) and basic fibroblast growth factor (bFGF) also led to an 
efficient recovery after partial lesions, suggesting a paracrine restorative effect by MSCs. 
Indeed, hMSCs, that migrate toward lesions (Hellmann et al., 2006; Sadan et al., 2009; 
Delcroix et al., 2011) may induce a protective or restorative effect on the remaining neurons 
within the host brain, due to the secretion of a large panel of neurotrophic factors, including 
brain-derived neurotrophic factor (BDNF) and glial cell line-derived neurotrophic factor 
(GDNF), which may also enhance endogenous neurogenesis (Levy et al., 2008; McCoy et al., 
2008; Bahat-Stroomza et al., 2009; Sadan et al., 2009). MSCs may also modulate the host 
response to the lesion (Kim et al., 2008) and probably ultimately replace functional cells 
within the host brain as a few MSCs with neuronal-like morphology and markers were 
observed in a total lesion model (Levy et al., 2008). We are therefore starting to better 
understand the mechanisms of action of these cells in the context of PD, while other teams 
try, with interesting results, to find new ways to deliver the cells to the brain. Indeed 
recently, a non invasive intranasal delivery of MSC in an animal model of PD, with 
significant improvements in the functional outcome of the animals was reported (Danielyan 
et al., 2011). The growing amount of MSC therapy studies for PD is starting to set the 
ground for pre-clinical studies, and a trial is already underway to evaluate the safety and 
efficiency of intrastriatal grafts of autologous MSCs to treat PD (Jaslok Hospital and 
Research Centre, India, sources clinicaltrials.gov).  
Advances in the Combined Use of Adult Cell Therapy  
and Scaffolds for Brain Tissue Engineering 
 
385 
NSCs isolated from the adult brain have been evaluated for the treatment of PD and HD due 
to their potential to differentiate into neurons in vivo (Lois & Alvarez-Buylla, 1993), despite 
the problems encountered for their isolation. A study reported the transplantation of NSCs 
from adult rat SVZ in a rat model of HD, with NSC survival up to 8 weeks after grafting and 
migration throughout the brain. To a larger extent than MSCs, up to 15 % of adult NSCs 
differentiated into mature neurons with specific markers of striatal medium spiny projection 
neurons and interneurons (Vazey et al., 2006). In addition, priming these cells with lithium 
chloride resulted in an even further improved functional outcome of the grafted animals 
(Vazey & Connor, 2011). To treat PD, a clinical trial has been performed with adult NSCs 
(reviewed in (Arias-Carrion & Yuan, 2009)) and gave interesting proof of concept for the 
autologous use of these cells. NSCs were isolated from the patient’s brain during the 
insertion of a thalamic stimulator and, after expansion and differentiation, a total of 6 
millions cells, and among them GABAergic and dopaminergic cells, were grafted 9 months 
later into the patient’s post-commissural putamen. An improvement in the Unified 
Parkinson's Disease Rating Scale (UPDRS) score was observed over the next 36 months, 
although results returned to baseline at 5 years post-operation (Levesque, 2009).  
2.2.3 Adult cell-derived pluripotent stem cell therapy 
As for several other disorders, iPS cell have been evaluated for PD cell therapy (Table 2). 
Dopaminergic neurons have efficiently been derived from iPS cells, and those cells have led 
to functional recovery in an animal model of PD (Wernig et al., 2008; Swistowski et al., 
2010). In addition, it was recently demonstrated that iPS derived from patients suffering 
from idiopatic PD, after dopaminergic differentiation in vitro, led to an efficient functional 
recovery of the grafted animals (Hargus et al., 2010). 
To conclude this section, it appears clearly that MSCs were, and still are, the most widely 
investigated adult cells for brain cell therapy. However, their neuronal differentiation potential 
remains very low or uncertain after transplantation, explaining the scientific interest of the 
recently discovered iPS cells. In addition, the poor cell survival and engraftment observed 
when using chromaffin cells, hRPE cells, MSCs and in general all kinds of transplanted cells, 
has called into question the efficacy of a cell therapy procedure. These issues may now be 
acknowledged by tissue engineering approaches, discussed in the following section.  
3. Combined use of adult stem cells and scaffolds for cell delivery and 
regeneration of CNS disorders 
It is now widely admitted that cell survival, differentiation, and more generally behaviour of 
cells in vivo may be greatly enhanced using adequate biomaterial supports. These 
supportive elements, called scaffolds, may be of various compositions and shapes and may 
improve cell behaviour due to the 3D environment as well as to the mechanical and 
signalling cues they provide to transplanted cells. In this regard, scaffolds may for example 
stimulate cell survival. These types of tissue engineering strategies for brain cell therapy 
have been primarily developed with neuronal cell lines (PC12 cells) or with cultured dorsal 
root ganglion neurons and foetal NSCs due to their availability, ease of expansion and their 
natural ability to integrate and differentiate within the brain. Benefits gained using these 
tissue engineering approaches are now being translated to adult cells such as MSCs in order 
to improve their survival, to guide their differentiation and integration within the host 
brain. In the following section, we describe the properties required for a scaffold in tissue 
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engineering applications within the brain, before reviewing the strategies used to improve 
brain cell therapy by combination with a tissue engineering approach. Improvement of 
classical scaffolds by means of a biomimetic approach as well as a novel strategy currently 
developed in our laboratory, the Pharmacologically Active Microcarriers (PAMs), will be 
presented. 
 
Cells Origins Recipients Scaffolds Benefits References
Sertoli 3-NP model Possible modulation of local inf lammation Emerich 2004
Choroid 
plexus
Rat QA rat model Alginate 
microcapsules
Selective neuroprotection, no evidence for sparing of striatal 
neurons
Borlongan, Thanos et al.  2008
HSC+MSC Rat QA rat model Reduction of working memory deficits Lescaudron, Unni et al.  2003
Rat QA rat model Decreased striatal atrophy Amin, Reza et al.  2008
Rat QA rat model Attraction of MSCs by SCF production in the striatum Bantubungi, Blum et al.  2008
Rat QA rat model IV transplantation: improved motor & cognit ive performance Edalatmanesh, Matin et al.  2009
Rat QA rat model Survival at 8 weeks, migration & 15 % of cells differentiated in 
mature neurons with marker of striatal medium spiny neurons 
Vazey, Chen et al.  2006
Rat QA rat model
Lithium chloride priming of the NSCs resulted in accelerated 
funct ional outcome of the grafted animals
Increased formation of projections from newly formed neurons in 
the damaged host striatum to the globus pallidus
Vazey and Connor 2011
Human Human (autologous) Functional improvements observed up to 10 months Madrazo, Drucker-Colin et al. 1987
Human Human (autologous) No cell detected after 1-2 years Hurtig, Joyce et al. 1989
Rat 6-OHDA rat model 
(unilateral)
Cytodex®       
Glass beads
Increased survival and functional benefits (8 months) Cherksey, Sapirstein et al.  1996
Rat 6-OHDA rat model (unilateral)
Cytodex®       
Glass beads Increased survival and functional benefits (12 months) Borlongan, Saporta et al. 1998
Human Human Improved dopamine production with in vitro differentiation Drucker-Colin, Verdugo-Diaz et al. 1999
Human 6-OHDA rat model (uni & bilateral)
Gelatine 
microcarriers 
(Spheramine®)
Functional recovery with chronic inflammation at late time-point Cepeda, Flores et al. 2007
Human MPTP primate model
Gelatine 
microcarriers 
(Spheramine®)
Long term functional improvements an cell survival                      
(18 months)                                                                                     
No immunosuppression required
Doudet, Cornfeldt et al.  2004
Human Human
Gelatine 
microcarriers 
(Spheramine®)
Open-label study: good tolerability, sustained motor clinical 
improvement up to 6 months after grafting                                      Bakay, Raiser et al. 2004
Human Human
Gelatine 
microcarriers 
(Spheramine®)
Analysis of the brain of a patient who underwent the last trial 
performed with Spheramine® (phase II double-blind, randomized, 
mult icenter, placebo-controlled clinical) with no significant 
funct ional improvements
6 months after graf ting, only 0.036 % of surviving cells
Farag, Vinters et al. 2009
Rat
6-OHDA rat model 
(unilateral & part ial)
Adipose tissue-derived MSCs secreting BDNF, GDNF & NGF        
Functional recovery after transplantation in SN but no neuronal 
differentiation in vivo
McCoy, Martinez et al.  2008
Human 6-OHDA rat model (unilateral & part ial)
Induction of MSCs to secrete GDNF & BDNF                               
Transplanted on the day of lesion, MSCs migrated toward the 
lesioned striatum and had a regenerative effect
Sadan, Bahat-Stromza et al. 2009
Human 6-OHDA rat model (unilateral & total)
Improved functional recovery with differentiated cells                 
(TH expression and DOPA secretion) Levy, Bahat-Stroomza et al. 2008
Human
6-OHDA rat model 
(unilateral & part ial) Trophic, restorative effect of MSCs Bouchez, Sensebe et al. 2008
Human 6-OHDA rat model (unilateral & part ial)
PAMs                   
with LM surface & 
releasing NT3
With PAMs: 
Increased MIAMI cells survival and differentiation in vivo 
Neuroprotection, neuroreparation of the nigrostriatal pathway
Functional recovery
Delcroix, Garbayo et al. 2011
MSC Rat 6-OHDA rat model (unilateral & total)
Innovative intranasal delivery
Migration of the cells throughout the brain
24 % of cells survival 4.5 months after grafting
Improvement of motor function of the Parkinsonian
forepaw
Danielyan, Schafer et al.  2011
Adult NSC Human
Human (autologous) 
Cort ical and sub-cortical 
tissue-derived
After expansion and differentiation in vitro , NSCs improved 
UPDRS score over 36 months after grafting                                    
Back to baseline 5 years post-operation
Levesque 2009
Mouse 
Fibroblast- 
derived
6-OHDA rat model 
(unilateral & part ial)
Neuronal differentiation in vivo  (TH-positive cells)
Functional improvements 4 weeks after grafting
Wernig, Zhao et al. 2008
Human 
Foetal-lung 
fibroblast-
derived
6-OHDA rat model 
(unilateral & total)
Survival of iPSC-derived dopaminergic neurons in vivo
Functional improvements 12 weeks after grafting 
Swistowski, Peng et al. 2010
PD patient
Fibroblast-
derived
6-OHDA rat model
Survival of iPS cell-derived DA neurons, with arborization
Functional improvements 16 weeks after grafting
Proof of concept for the autologous use of iPS cells 
Hargus, Cooper et al.  2010
Abbreviations: AD: Alzheimer’s disease; BDNF: brain-derived neurotrophic factor; GDNF: glial cell line derived neurotrophic factor; HD: Huntington’s disease; hRPE: human 
retinal pigment epithelium; HSC: hematopoietic stem cell; iPS: induced pluripotent stem; IV: intravenous; LM: laminin; MIAMI: marrow isolated adult multilineage inducible; 
MPTP: 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; MSC: mesenchymal stem cell; NP: nitropropionic acid; NSC: neural stem cell; NT3: neurotrophin 3; OHDA: 
hydroxydopamine; PAMs: pharmacollogically active microcarriers; PD: Parkinson’s Disease; QA: quinolinic acid; SCF: stem cell factor; SN: substantia nigra; UPDRS: unified 
Parkinson's disease rating scale.
MSC
HD
Adult NSC 
(SVZ)
iPS cells
MSC
PD
hRPE
Adrenal 
chromaffin
 
Table 2. Adult and iPS cell therapies for neurodegenerative disorders 
Flores, Cepeda et al. 2007 
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3.1 Scaffold requirements for brain cell therapy  
Implementation of tissue engineering in combination with adult cells for brain therapy is an 
emerging field and many requirements need to be taken into account in order to produce an 
appropriate tissue engineered product. The first consideration in scaffold tailoring for brain 
is size, but scaffolds must also be fully biodegradable and biocompatible, minimizing 
macrophage and microglial reaction, without inducing neurotoxicity. Scaffolds must be 
small enough to be easily implanted into the skull cavity in discrete and precise areas of the 
brain without perturbing the brain 3D organisation as observed with 30 μm microspheres 
(Veziers et al., 2001). Moreover, small-sized scaffolds render repeated implantations possible 
by stereotaxy, with no need for open-surgery (Menei et al., 2005). In this sense, 
microstructured and nanostructured scaffolds, produced by various techniques may be used 
(reviewed in (Seidlits et al., 2008)).  
Scaffolds are based either on natural or on synthetic biomaterials used alone or in mixtures, 
providing scaffolds with different properties (see for review (Potter et al., 2008; Dalton & 
Mey, 2009). Scaffolds based on biodegradable gels encapsulating various molecules and cells 
have been studied, with e.g. polyethylene glycol (PEG) (Namba et al., 2009), diblock 
copolypeptide (Yang, Song et al., 2009) or hyaluronic acid (Wang & Spector, 2009) 
hydrogels. However, gel-based scaffold strategies most of the time require open-surgery, 
unless an in situ gelling process is used (Kim, 2009; Yang, Song et al., 2009) but no gel 
swelling must be observed. In opposition to gel-based scaffolds, particulate scaffolds, that 
may be constituted of aliphatic polyesters, including poly(lactic-co-glycolic acid) (PLGA), 
overcome this problem of delivery and have been intensively studied with embryonic cells 
and NSCs (Newman & McBurney, 2004; Bible et al., 2009). Cell-material interactions may be 
advantageously increased due to a large specific surface as with microsphere-shaped scaffolds 
or scaffolds based on nanofibrous technology (Valmikinathan et al., 2008; Cao et al., 2009).  
The adverse host cell response, such as glial scar and inflammation, occurring after scaffold 
implantation have to be minimized (see for review (Fournier et al., 2003)) therefore 
rendering the biocompatibility and biodegradability of the biomaterials a crucial parameter 
(Vert, 2009; Yang, Song et al., 2009). For example, implantation of PLGA microspheres into 
the brain does not induce a specific astrocytic or macrophage/microglia reaction, which is 
similar to the one observed after control fluid injection. Moreover, PLGA microspheres fully 
degrade into CO2 and H2O (Menei et al., 2005). Scaffolds should be able to degrade with 
time, with degradation products that may also be eliminated by the host, allowing a full 
integration of transplanted cells into the brain. This criteria was not observed for synthetic 
poly(methylidene malonate 2.1.2) microspheres implanted into rat brains even if 
biocompatibility of the intact microspheres was satisfactory (Fournier et al., 2006). It is 
interesting to note that size of particles may also affect the extent of the host response. In 
vitro, small size phagocytable hydroxyapatite particles (1-30 µm) have been shown to induce 
a strong production of the inflammatory cytokines tumor necrosis factor-alpha (TNF), 
interleukin 6 (IL6) and interleukin 10 (IL10) by human monocytes, the first cells recruited to 
the inflammation site, which may be correlated to a stronger host inflammatory response.  
On the other hand, this effect decreased for particles of more than 30 µm in diameter. 
Importantly, shape is also critical for the extent of the response, needle-shape being 
potentially more detrimental compared to spherical-shaped particles (Laquerriere et al., 
2003).  
Cell attachment to the biomaterial critically depends on its surface charges, cells being 
attracted to positive charged surface due to sialic acid residues on the cell membrane which 
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produce a net negative charge on the cell surface. Furthermore, the first step following 
implantation of a scaffold within the brain is its coverage by a non-specific layer of proteins, 
which may contribute to the inflammation process and biocompatibility problems (Fournier 
et al., 2003). Surface characteristics (charge, hydrophilicity and hydrophobicity) are therefore 
important points to consider when designing a new type of scaffold. Outer but also inner 
topography of scaffolds may affect cell behaviour once implanted into the brain. For 
example, the presence of pores and channels on the surface of synthetic poly--caprolactone 
(PCL) scaffolds may enhance host astrocytic infiltration and affect host cell migration (Wong 
et al., 2008). Moreover, access to nutrients is a critical parameter for neuronal cells, which 
require large amounts of nutrients such as glucose. Therefore, if larger implants are used, 
vascularisation is required for cell survival. In this sense, porous scaffolds, or scaffolds that 
become porous after implantation during degradation, may alleviate vascularisation 
problems.  
Finally, a very interesting study first described the effects of matrix elasticity to direct 
MSCs lineage specification. Soft type matrices mimicking brain being neurogenic while 
stiffer matrices appeared to be myogenic and furthermore osteogenic. The observed 
phenotypic specification was irreversible after several weeks in culture, therefore 
reflecting neuronal commitment of the MSCs cultivated on soft matrices (Engler et al., 
2006). Noteworthy, new data from this team seem to indicate that stiffness variation, not 
just stiffness alone, can be an important regulator of MSCs behaviour (Tse & Engler, 2011). 
Again, this underlines the importance of the choice of the biomaterial for brain tissue 
engineering. 
3.2 Scaffold design and manufacture 
The following section reviews materials and fabrication methods used in the development 
of scaffolds to enhance brain tissue regeneration. 
3.2.1 Materials 
One of the first considerations when designing a scaffold for brain tissue engineering is the 
choice of the material. Some of the aspects that should be carefully taken into account are: 1) 
if the material maintains an appropriate shape after implantation, 2) if sterilization of the 
scaffold prior to implantation is possible, 3) if the scaffold is brain biocompatible to avoid 
abnormal immune responses, 4) if the material has the appropriate degradation rate for the 
desired application and 5) the ability to provide a controlled release of the drug, in case of 
materials encapsulating a therapeutic molecule such as growth factors. Materials used in the 
development of scaffolds for brain tissue engineering can be broadly divided into 
biodegradable and non-biodegradable. Due to the transient nature of the biodegradable 
polymers, they are preferred for a brain application because they do not require surgical 
removal when the treatment is finished. Depending on their nature they can be classified in 
natural and synthetic materials. Both of them used alone or in combination have been tested 
in clinical practice. Natural materials are very interesting because they contain sites for cell 
adhesion, allowing for cell infiltration. These natural materials also exhibit similar 
properties to the soft tissues they are replacing. However, since these materials are obtained 
from natural sources, they must be purified before use and it is difficult to control the 
homogeneity of product between batches. Synthetic materials in contrast, have a known 
composition and can be designed to minimize the immune response or the degradation rate. 
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Materials (natural and synthetic) used in brain tissue engineering applications, with their 
benefits and drawbacks will be discussed below in this section.  
3.2.1.1 Natural materials  
Collagen. Collagen, one of the most common extracellular matrix (ECM) proteins, has been 
extensively used as a potential scaffold for neural tissue. Collagen is an easily accessible 
material that can be isolated from mammals, including rats, bovines and humans. One 
advantage of collagen use is that the scaffold properties can be easily varied by using 
different concentrations of collagen or by covalently modifying the cell adhesion sites. 
However, immune response could arise if cross-species transplantation is used. In the CNS 
collagen has been mainly used as  scaffolds for the treatment of TBI among others (Qu et al., 
2009; Qu et al. 2011).  
Alginate. Alginate is a natural anionic polysaccharide composed of D-mannuronic (M) and 
L-guluronic (G) residues in varying proportions. It is easily obtained from algae and can be 
cross-linked to form three dimensional scaffolds. Cross-linking and gel formation takes 
place when divalent cations, such as calcium, ionically bind carboxylic acid groups of blocks 
of guluronic residues between chains. They must undergo extensive purification to prevent 
immune responses after implantation. The main use for alginate in the area of brain tissue 
engineering is in encapsulating cells with the purpose of immune-isolation from the host. Its 
efficacy has been evaluated in models of CNS diseases like PD, stroke, ALS, spinal cord 
injury, TBI and HD among others (Orive et al., 2003; Grandoso et al., 2007; Orive et al., 2009; 
Purcell et al., 2009). 
Fibrin. Fibrin is a protein involved in the clotting of blood. Similar to collagen, fibrin 
scaffolds contain sites for cell adhesion and the scaffold properties vary depending on the 
concentration of fibrin used. Fibrin matrix has favorable features as a scaffold, that would fit 
well in the fragile CNS tissue, including biocompatibility, biodegradability, binding capacity 
to the tissue, low risk of foreign body reaction, physiological flexibility, good plasticity. 
Fibrin scaffolds have been proposed as potentially suitable vehicle for cell transplantation 
therapy and, combined with bone marrow stroma cells, have been evaluated after cortical 
injury in rats  (Yasuda et al., 2010). 
Chitosan. Chitosan is a polysaccharide industrially derived from partial deacetylation of 
chitin, the major compound of exoskeletons in crustaceans. Chitosan has been reported to be 
suitable for preparation of particulate systems (micro and nanoparticles) for brain 
application due to its good biodegradability, biocompatibility, stability and low toxicity. 
Chitosan nanoparticles coated with polysorbate 80 have been proposed for brain targeting 
(Aktas et al., 2005). However, despite its desirable characteristic, its actual use is limited 
because of its poor solubility in water.  
Other natural materials. Other examples of natural materials used in the fabrication of brain 
tissue scaffolds are dextran, fibronectin (FN), laminin (LM) or hyaluronic acid. An 
interesting approach used hyaluronic acid and collagen to develop a tridimensional 
biodegradable porous scaffold which is a sponge with an open porous structure and 
mechanical behaviour comparable to brain tissue (Wang & Spector, 2009). Dextran 
hydrogels have been investigated as drug delivery vehicles and as macroporous scaffolds 
However, the dextran non-cell-adhesive nature has limited its use in tissue engineering. To 
overcome this limitations, Levesque et al., proposed the use of macroporous scaffolds of 
methacrylated dextran (Dex-MA) copolymerized with aminoethyl methacrylate (AEMA) 
introducing primary amine groups for covalent immobilization of extracellular-matrix-
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derived peptides for axonal guidance (Levesque & Shoichet, 2006). Recently, the use of 
bioactive scaffolds generated by cryogelation of dextran or gelatine linked to LM to create 
niche-like structures that promote the differentiation of stem cells was proposed (Jurga et al. 
2011). LM and FN scaffolds have been proposed as appropriate extracellular-matrix based 
scaffolds that can be exploited to improve cell transplantation into the injured brain (Tate et 
al., 2009).  
3.2.1.2 Synthetic materials  
Poly(-hydroxyacids). Poly (α-hydroxyacids) were found to be bioabsorbable and 
biocompatible in the 1960’s. They are the most widely known, studied and used polymers 
for brain drug delivery due to its biodegradable properties, biocompatibility and the 
absence of significant toxicity (Athanasiou et al., 1996; Shive & Anderson, 1997). They 
have suitable mechanical properties for its use in scaffold fabrication. Poly (α-
hydroxyacids) are approved by the Food and Drug Administration (FDA) for its use in 
humans and have been used extensively in medicine in a variety of applications. For 
instance, more than 100 different molecules have been incorporated in PLGA 
microspheres since their first application (Menei et al., 2005). Poly (α-hydroxyacids) are 
constituted of lactic and/or glycolic acid units and degrade in vivo by nonenzymatic 
hydrolysis to lactic and glycolic acids. These can be further metabolized or excreted via 
normal physiological pathways.  
Polycaprolactone (PCL). PCL is a biodegradable polyester with minimal bio-reactivity that has 
been widely used in the biomedical field and in CNS applications in particular. PCL 
degrades very slowly by hydrolysis of ester bonds. PCL based matrices have been used for 
instances, as scaffolds for tissue regeneration after controlled cortical impact induced-TBI 
(Wong et al., 2008). 
Others. Other examples of synthetic materials used in the fabrication of brain tissue scaffolds 
are poly (glycerol sebacate) (PGS), gelatin-siloxane (GS), poly (ethylene glycol)/poly 
(ethylene oxide), poly (ethylene-co-vinyl acetate) (EVA), poly (2-hydrixyethil methacrylate) 
(pHEMA) and poly (2-hydroxyethyl methacrylate-co-methyl methacrylate) (pHEMA-
MMA). 
3.2.2 Scaffold fabrication techniques  
As brain tissue engineering progresses, the need of novel scaffold structures and fabrication 
techniques has become of great importance (See Walker et al., 2009; Subia, 2010). The most 
common scaffold production methods are revised below. After fabrication, all of these 
scaffolds are then characterized in terms of morphology, mechanical, bulk and surface 
properties. 
Phase separation. Phase separation technique is based on temperature changes to separate a 
polymeric solution in two phases. When liquid-liquid phase is separated, it is quenched to 
form two solid phases. Finally, solvent is removed and porous scaffolds are obtained. 
Biological molecules can be incorporated to the polymeric solution to obtain drug-loaded 
scaffolds. Phase separation technique can be combined with other fabrication techniques like 
leaching or prototyping to create 3D-scaffolds with controlled pore morphology.  
Particulate Leaching. Leaching is a reproducible technique to fabricate porous, sponge-like 
scaffolds with a desirable cellular structure for tissue engineering applications. Salt, wax or 
sugars known as porogens are used to create porous scaffolds. The fabrication process 
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involves casting the polymer mixed with a porogen into a desired shape, and then 
introducing a solvent that would dissolve the salt and leave the polymer intact, leaving a 
foam-like structure. 
Electrospinning. Electrospinning is an efficient method to produce nano or micro-scaffolds 
comparable to the ECM fibers natively found in the tissue. In this fabrication method, a 
polymer solution is pumped through a syringe connected to a high voltage source. As a 
droplet forms at the needle tip, electrostatic repulsions form long fibers that are collected 
onto a grounded metal plate in the form of a nanofibrous mat. Due to the simplicity of this 
method, it has received considerable attention for use in tissue engineering and more than 
200 polymers have been used for electrospinning. However, it is difficult to obtain 3D 
scaffolds with well defined pore structure and complex geometry using this technique and 
electrospinning is preferably used to produce thin 2D sheets. 
Rapid prototyping. Rapid prototyping describes different manufacturing processes that allow 
automated fabrication using methods of material bonding or deposition. This fabrication 
method produces objects with geometry difficult to be created using the “traditional” 
machining methods of milling, turning, or drilling. Generally, files generated using standard 
computer aided design (CAD) software are used to produce the scaffolds. 
Other techniques. Stereolithography uses a laser and a photosensitive liquid polymer solution 
to fabricate scaffolds. Three dimensional printing has been employed to fabricate porous 
scaffolds by inkjet printing liquid blinder droplets onto particulate matter.  
3.3 Overview of strategies used to combine adult stem cells and scaffolds 
The following section reviews primary studies that investigated the potential of different 
combinations of cells and scaffolds to improve the cell therapy benefits for PD, HD, cerebral 
ischemia and TBI. Studies on hRPE cells in combination with gelatine-based scaffolds, a 
device that underwent a phase II clinical trial for the treatment of PD will also be described. 
Several strategies are now focusing on improving cell interactions with the biomaterials by 
modifying its surface using biological molecules, mainly derived from ECM, to better 
regulate grafted cell behaviour. After briefly describing the molecular mechanisms of cell- 
ECM molecule interactions and its effect on cell behaviour, we will present some studies 
using such “biomimetic scaffolds”. Finally, the PAMs developed in our laboratory, that 
constitute a more advanced approach combining a bioactive surface with the controlled 
delivery of a growth factor will be presented.  
3.3.1 Gel-based scaffolds and cell encapsulating technology 
By contributing to maintain brain’s integrity as well as by favouring the integration of host 
cells inside the marginal cavities, gel-based scaffolds, without cells, may be advantageous to 
repair the brain after an ischemic stroke (Yamashita et al., 2009). Moreover, differentiated 
iPS injected together with a fibrin glue under the dura mater enhanced the effect of these iPS 
injected alone, which led to a reduced infarct volume as well as to  functional recovery after 
an ischemic stroke; thereby underlining the importance of a support for the cells (Chen & 
Xiao, 2011).  
In the context of TBI, degradable collagen scaffolds did not reduce the lesion size nor did 
they improve functional recovery, unless if seeded with hMSCs (Lu et al., 2007). Indeed, 
four days after TBI, transplantation of a cylindrical collagen scaffold seeded with hMSCs in 
the lesion cavity induced a reduction in the lesion volume, together with an improved 
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spatial learning and sensorimotor function of the animals. Recently, the same team reported 
that delayed transplantation of these complexes (7 days after TBI) further enhanced spatial 
learning and sensorimotor function, and induced angiogenesis in the injured cortex as well 
as transcallosal fiber length (Qu et al., 2009; Xiong et al., 2009). In experimental models of 
TBI, MSCs are usually injected adjacent to the lesion within the parenchyma to avoid 
injection within the lesion cavity. An advantage of this gel-based strategy was the possible 
use of 3 fold more MSCs compared to parenchymal injection, therefore increasing the 
regenerative potential. However, the major limitation was the need for open-surgery to 
implant the device. This issue may potentially be addressed using an in situ gelling process 
(Perale et al., 2011), even if the possible expansion and ensuing damage to the brain 
parenchyma of the solidifying gel has to be taken in consideration. Nevertheless, all these 
studies demonstrate the benefits of a 3D support which are probably improving cell 
survival, even if the underlying mechanisms are still not always fully understood. 
3.3.2 Cell adhesion on particulate scaffolds 
As previously described, the major problems encountered when grafting chromaffin cells in 
the context of PD was the poor cell survival and the absence of long term effects in vivo 
(Drucker-Colin & Verdugo-Diaz, 2004). Two studies gave the proof of concept that 
particulate scaffolds may enhance survival of cells adhered onto collagen-coated dextran 
(Cytodex 3®) or glass bead microcarriers into the brain of hemi-parkinsonian rats. The 
pivotal finding of these studies is that adult rat adrenal chromaffin cells implanted in the 
brain after attachment to microcarriers retain their ability for a prolonged period (8-12 
months) to correct a striatal dopamine deficit as judged by their efficacy in reducing 
apomorphine-induced rotation (Cherksey et al., 1996; Borlongan et al., 1998). Even if the 
underlying mechanisms were not studied, it is noteworthy that no inflammation was 
detected when implanted into the striatum. During the same period, these scaffolds were 
used for transplanting human FVM cells in similar rat model of PD (Saporta et al., 1997) and 
the Cytodex® microcarriers allowed an increased cell survival without immunosuppression. 
This effect was thought to result from the presence of a protective astrocytic cloak around 
the cell/microcarrier complexes. These data were the first to demonstrate the need for cell 
attachment to a 3D complex to improve grafted cell survival, and it also underlined the 
immunomodulatory benefits that may be gained from the use of a tissue engineering 
strategy. 
A similar strategy combines cultured hRPE cells attached to biocompatible, non 
biodegradable cross-linked porcine gelatine microcarriers, with a mean diameter of 100 µm. 
Several preliminary studies in parkinsonian rat models (unilateral and bilateral lesions) 
proved the efficacy of these grafted complexes, named  Spheramine® (Watts et al., 2003). An 
increased survival of hRPE cells, without immunosuppression, and long term functional 
improvements were observed, although chronic inflammation was reported at later time-
points (5 months) (Flores et al., 2007). These microcarriers have also been implanted in the 
brain of hemi-parkinsonian monkeys and resulted in long term cell survival and functional 
improvements at 18 months (Doudet et al., 2004). As expected, hRPE cells unattached to 
microcarriers did not survive well in the brain, and did not produce a lasting therapeutic 
effect in various PD animal models. These encouraging results led to an open-label clinical 
study that included 6 patients with advanced PD receiving 325,000 hRPE cells attached to 
microcarriers and demonstrated a good tolerability to Spheramine®. Moreover, at 6 months 
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post-operation, the mean UPDRS-M (off) score improved to 34 % from the pre-operation 
baseline. Half of the patients also demonstrated a reduced Dyskinesia Rating Scale scores 
(Bakay et al., 2004). The success of this strategy finally led to a phase II double-blind, 
randomized, multicenter, placebo-controlled (sham surgery) study to evaluate safety, 
tolerability, and efficacy of Spheramine® implanted bilaterally into the postcommissural 
putamen of patients with advanced PD, even if the mechanisms underlying the improved 
survival of hRPE cells upon attachment to gelatin are not yet well elucidated (Stover & 
Watts, 2008). Unfortunately, preliminary results of the phase II clinical trial seem to indicate 
that the study failed to demonstrate the efficacy of Spheramine® beyond a remarkable 
placebo effect. A reason for that may be the lack of long term survival of the cells in the 
human brain, as only around 0.036 % of cells survival was observed in the brain of a patient 
who died 6 months after surgery (Farag et al., 2009). 
Adult rat choroid plexus cells have the potential to secrete a wide range of growth factors, 
and have been used as candidate cells for HD cell therapy (Borlongan et al., 2008). In this 
study, choroid plexus cells were encapsulated in alginate beads to improve cell viability and 
to prevent host rejection. Transplantation of these cells into rat striatum resulted in an 
encouraging neuroprotection when a QA lesion was performed 3 days after cell 
transplantation, even if no evidence was provided concerning the specific sparing of 
GABAergic medium spiny projection neurons, especially sensitive to degeneration in the 
context of HD. 
3.3.3 Molecular mechanisms of cell adhesion to scaffolds 
The ECM contains adherent glycoproteins, glycosaminoglycans and ions. ECM proteins, 
such as collagen, FN, LM, tenascin and proteoglycans, interact with each other forming a 
supportive scaffold for the cells within the tissue (see for review (Bosman & Stamenkovic, 
2003)). Composition and proportion of its constituents vary depending on the type of tissue, 
thereby giving different mechanical, chemical or signalling cues to the surrounding cells. 
We will here focus on FN and LM because of their astonishing variety of effects on cells as 
well as because of their wide use for brain tissue engineering applications. FN and LM 
structures have been described a few decades ago and are constituted of an assembly of 
large polypeptides, all of them having specific interaction sites with other ECM molecules or 
cell surfaces (Hynes & Yamada, 1982; Engvall & Wewer, 1996; Powell & Kleinman, 1997). 
LM and FN interact with cells via the integrin family of receptors, therefore allowing cell 
attachment to the matrix and further signal transduction. Integrins are a family of proteins 
constituted of an α subunit and a β subunit which assemble into distinct integrin receptors 
having specific binding affinities with ECM molecules (Barczyk et al., 2009). These 
interactions result in highly complex downstream signalling pathways that originate at the 
focal adhesion sites, where a variety of proteins (e.g. Ilk, Fak, Src) interact with the integrin 
tails on their cytoplasmic ends, thereby regulating cell survival, proliferation and 
differentiation (Hynes, 2002; Chen, 2010). 
Potential roles of ECM molecules for brain repair are now widely admitted. Endogenous 
levels of FN and LM increase in a TBI context in vivo, thereby suggesting a reparative role of 
these molecules (Tate et al., 2007). Tissue repair benefits have also been obtained by 
transplanting LM-based hyaluronic gel scaffolds, without cells, in a rat model of cortical 
lesion (Hou et al., 2005). A recent study demonstrated an enhanced survival in vitro of 
human MSCs within a PEG hydrogel modified with RGD peptides, a motif involved in 
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ECM-cell interactions. In this study, RGD peptides attached to the scaffold provided the 
required adhesion sites to maintain MSC survival, while soluble peptides resulted in a 
strong decrease of cell viability. Noteworthy, the presence of a glycine spacer between the 
RGD peptides and the gel further improved MSC survival, therefore underlining the 
importance of the presentation context of the peptide within the gel (Salinas & Anseth, 
2008). Another team described the effect of FN and LM-derived peptides (RGDSP and 
IKVAV, respectively) using a PEG-hydrogel array to screen the effect of these ECM 
molecules on hMSCs viability. Their strategy allowed to also analyse the consequences of 
the hydrogel used, for example, the combination of the IKVAV peptides with degradable 
gels resulted in decreased sustained viability compared to non-degradable gels 
(Jongpaiboonkit et al., 2008). A recent study described the single-cell encapsulation of 
hMSCs in FN- and fibrinogen-containing hydrogel capsules that rescue the cells from 
apoptosis induced by loss of anchorage, while providing an increased cell metabolic activity 
in culture. Effects that were certainly mediated via the MAPK/ERK signalling cascade and 
upstream integrin/ECM molecule interactions (Karoubi et al., 2009). Using a subpopulation 
of hMSCs, we recently showed in a rat model of global ischemia, that marrow-isolated adult 
multilineage inducible (MIAMI) cells (D'Ippolito et al., 2004) adhered onto PLGA 
microcarriers with a FN biomimetic surface enhanced the neuroprotection effect observed 
with the cells alone (Garbayo et al., 2011). This effect may be attributed to an increased 
survival of the cells on these carriers, or the increased production of neuroprotective 
mediators by these cells or both.  
ECM molecules may also affect proliferation as well as life span of cells, this being the 
rationale for expanding MSCs on ECM molecules in several in vitro protocols (see for 
example (D'Ippolito et al., 2004; Matsubara et al., 2004)). Modification of PLCL (poly(L-lactic 
acid)-co-poly-(ε-caprolactone)) nanofibrous scaffolds with collagen I resulted in an increased 
proliferation of human MSCs and neuronal differentiation after exposure to an induction 
media, compared to standard PLCL scaffolds (Prabhakaran et al., 2009). The benefits of 
collagen I was assumed to result from its high cell adhesion properties, thought to be 
required to ensure a proper neuronal differentiation. In our laboratory, we observed an 
increased proliferation of the human stromal MIAMI cells expanded on FN compared to 
standard culture substrates (Delcroix et al., 2011). Extensive crosstalk takes place between 
integrin and growth factor receptor signalling pathways to stimulate progression through 
the G1 phase of the cell cycle, as mitogenic signalling may be weak and transient in the 
absence of integrin-mediated cell adhesion for cells with an anchorage dependent growth, 
such as MSCs (see (Danen & Yamada, 2001) for review).  
Neural precursor differentiation, by enhancing neurite outgrowth in vitro or in vivo is 
certainly one of the first and most studied effects of LM and its derived bioactive peptides 
(Rogers et al., 1983; Grimpe et al., 2002). Accumulating evidence support a bioactive 
signalling role of LM in the morphological and molecular induction of MSCs toward a 
neuronal lineage (Qian & Saltzman, 2004; Ho et al., 2006; Delcroix et al., 2011). In our 
laboratory, the enhanced expression of β3-Tubulin and NFM when human mesenchymal 
stromal MIAMI cells were differentiated on a LM substrate was also accompanied with an 
increased cell length and a decreased proliferation rate (Delcroix et al., 2011). In this regard, 
a study reported the increased length of neurite-like extensions of MSCs, when incorporated 
within a collagen gel containing FN and LM, an effect at least partly mediated via the FAK 
pathway (Lee et al., 2011). Specific fragments of LM, e.g. the peptides IKVAV & YIGSR play 
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crucial signalling roles in neurite outgrowth and cell adhesion. Accordingly, studies also 
aim at functionalizing scaffolds with similar peptide fragments to reproduce the effect of the 
native ECM molecules, but also to isolate one of its specific effects (Powell & Kleinman, 
1997; Orive et al., 2009). Some observations of how ECM components control MSC 
behaviour are summarized in Table 3. 
 
Effects ECM component or derived peptides Observations References
RGDSP & IKVAV
PEG-hydrogel                                                                                                                                        
Both pept ides improved hMSCs survival                                                                                               
Combinat ion of IKVAV with degradable gels decreased the benef its compared to non-degradable 
ge ls
Jongpaiboonkit, King et al. 2008
FN FN substrate                                                                                                                                         
Increased proliferation of MIAMI cells in vit ro
Delcroix, Garbayo et  al. 2011
LM substrate                                                                                                                                         
Induction of nest in expression by MSCs in vitro 
Ho, Yu et al. 2006
LM substrate                                                                                                                                         
Morphological changes in hMSCs during neuronal dif ferent iat ion in vitro                                               
Increased percentage of cells with secondary and tert iary branching on LM vs  FN or PDL 
Qian and Saltzman 2004
LM substrate                                                                                                                                         
Increased cell length and expression of neuronal proteins (β3-Tubulin and NFM) during 
differentiation of MIAMI cells in vit ro vs  FN  or glass
Delcroix, Garbayo et  al. 2011
Abbreviations: ECM: extracellular matrix molecules; FN: fibronectin; LM: laminin; MIAMI: marrow isolated adult multilineage inducible; MSC: mesenchymal stem cell; NFM: 
neurofilament medium; PDL: poly-D-lysine; PEG: polyethyleneglycol; PLCL: poly(L-lactic acid)-co-poly-(e-caprolactone).  
Prabhakaran, Venugopal et al.  2009
RGD Salinas and Anseth 2008
Lee, Yu et al. 2011
PEG hydrogel                                                                                                                                        
RGD improved hMSCs survival in vitro
Improvement enhanced with the use of  a g lycine spacer between RGD and the gel
Sing le-cell encapsulation of hMSCs in FN- or fibrinogen-containing hydrogel capsules  
Enhanced survival of cells + increased cell metabolic activity in  vitro 
Validation of  the concept in vivo (uninjured hindlimb model in rats)                                                       
PLCL/collagen I nanof ibrous scaffolds                                                                                                  
Increased proliferation of hMSCs vs  standard PLCL scaffolds 
Effect due to adequate cell adhesion propert ies of collagen I
Allow neuronal d ifferentiation of hMSCs when exposed to  the appropriate inducers
Collagen gel enriched with  FN and LM
Increased neurite length of MSCs incorporated within the gel
Effect mediated via  the FAK pathway
LMNeuronal differentiation
Collagen I
Karoubi, Ormiston et al. 2009
Proliferation
Survival
FN & fibrinogen
 
Table 3. Control of MSC behaviour by ECM components 
3.3.4 The pharmacologically active microcarriers (PAMs): a tool to combine the 
biomimetic approach and the controlled release of a growth factor 
In addition to the biomimetic approach, another way to improve the efficiency of cell grafts 
is to deliver a growth factor by the transplanted scaffolds, further affecting the fate of both 
transplanted and host cells. Interestingly, the potential of microsphere-hydrogel scaffolds to 
deliver 2 growth factors at specific rates has been described (Burdick et al., 2006), but has not 
yet led to in vivo studies. For reviews, see (Tatard et al., 2005; Delcroix, Schiller et al., 2010). 
Our group has formulated PLGA microspheres which deliver therapeutic proteins in a 
sustained and controlled manner. The use of these growth factor delivery vectors for 
neuroprotection or for the repair of the nigro-striatal dopaminergic system has been 
successfully validated in animal models of AD or of PD, respectively (Pean et al., 2000; 
Jollivet et al., 2004; Menei et al., 2005). In this sense, we developed the PAMs that combine 
these two approaches and may be easily injected in the desired tissue (Figure 1). These 
PAMs are biodegradable and biocompatible PLGA microspheres conveying cells on their 
surface, therefore providing an adequate 3D microenvironment in vivo. Moreover, the 
controlled delivery of a trophic factor in combination with a biomimetic surface act 
synergistically to stimulate the survival and/or differentiation of the grafted cells toward a 
specific phenotype, therefore enhancing their engraftment after their complete degradation 
(Tatard et al., 2005). Finally, it should be noted that the delivered molecule may also affect 
the host microenvironment allowing the integration of the grafted cells and/or stimulating 
the lesioned brain repair capacities. 
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Fig. 1. A) Schematic representation of PAMs. These PAMs are PLGA microspheres with a 
biomimetic surface that convey cells and release a growth factor in a controlled manner. B) 
Scanning electron microscopy image of PAMs conveying MIAMI cells on their surface 
The proof of concept of this unique and simple device of cell and protein-delivery in 
neuroprotection and tissue repair for the treatment of neurological disorders has first been 
validated in a PD rat model using a neuronal cell line (PC12 cells) transported by nerve 
growth factor (NGF)-releasing PAMs. (Tatard et al., 2004). The efficacy of PAMs for cell 
therapy of PD in a clinical paradigm was then demonstrated using GDNF-releasing PAMs, 
conveying a small number of embryonic ventral mesencephalon dopaminergic cells (Tatard 
et al., 2007). We next implemented the PAMs transporting MIAMI cells for PD adult stem 
cell therapy. MIAMI cells, may differentiate toward neuronal-like cells in a neurotrophin 3 
(NT3) dependent manner (Tatard et al., 2007), especially when pre-treated with EGF and 
bFGF (Delcroix, Curtis et al., 2010). Moreover, a LM surface enhances the neuronal 
differentiation (Delcroix et al., 2011). We designed PAMs made of 60 µm PLGA 
microspheres encapsulating NT3 and covered with a LM biomimetic surface. After adhesion 
of dopaminergic-induced (DI)-MIAMI cells, the PAM/cell complexes were grafted in the 
partially dopaminergic-deafferented striatum of rats and led to a strong reduction of the 
amphetamine-induced rotational behaviour together with the protection/repair of the 
nigrostriatal pathway. These effects were correlated with the increased survival of DI-
MIAMI cells which differentiated towards dopaminergic-like cells and may also secrete 
growth factors (Delcroix et al., 2011). We thus showed that combining growth factors, cell 
adhesion molecules and an adapted 3D structure in the same polymeric scaffold allows the 
synthesis of an adaptable and very efficient system that can deliver stem cells and give them 
appropriate cues allowing better stem cell survival, differentiation and integration into the 
host tissues after implantation. After deeper characterization of the underlying mechanisms, 
this tissue engineering strategy may ultimately set the ground for pre-clinical studies with 
non-human primates to increase the efficiency of MSC therapy of the brain.  
4. Unanswered questions in tissue engineering for targeting CNS disorders 
using conventional tissue culture and animal models 
Although brain tissue engineering has shown a certain level of therapeutic benefits, there 
are still many unanswered questions and concerns that need to be addressed. For instance, 
Advances in the Combined Use of Adult Cell Therapy  
and Scaffolds for Brain Tissue Engineering 
 
397 
one general problem found in cell therapy is the difficulty to reproduce results between 
laboratories. Differences on the source, method of preparation, differentiation status and 
age of the stem cells used may be the cause. Moreover, with the current workflow it takes 
a long time to select an effective stem cell strategy to translate into clinical studies. The 
main steps to follow include the selection of the source of cells (MSC, NSC, ESC, iPS), the 
choice of the culture media, the state of stem cell cycle (undifferentiated vs differentiated), 
the mode of culture, the form of growth (neurosphere vs monolayer for instance), the study 
of substrate variations (FN, LN, matrigel among others) and the use of different animal 
models to test each therapeutic variation. Moreover, very little is known about the exact 
mechanisms by which stem cells may repair damaged tissues. It is not yet totally 
understood if stem cells may directly replace lost cells via their differentiation potential or 
if the beneficial effect could be due to their paracrine secretions or their immune 
regulatory functions, or if it is due to a combination of these effects. An additional and 
very troublesome problem is the difficulty to track the location and activity of stem cells 
once they are grafted into the animal. Several strategies have been proposed to follow the 
grafted cells in vivo. One of the most commonly used is to label the cells with fluorescent 
markers like quantum dots, organic dyes or fluorescent proteins among others. Other 
authors have grafted sex mismatched stem cells to identify them by fluorescent in situ 
hibridation (FISH) on the X and Y chromosomes. The injection of human cells into rodent 
animals or vice versa to use species-specific antibodies for its identification is another 
approach.  
In general, it is difficult to understand stem cell mechanisms of action and fate using 
conventional tissue culture or animal models due to the limitations of both systems. In vitro 
models are a good high throughput screening tool but they do not realistically mimic the in 
vivo situation. Moreover, the 3D integration of grafted cells into the host tissue cannot be 
studied using tissue culture models. On the other hand, it is clear that animal models are 
essential in proof-of-concept principle experiments and in establishing the preclinical safety 
and efficacy data required before human clinical trials. However, most of them are 
expensive, laborious and time consuming to be useful as screening tests. Generally, it can be 
stated that as a system becomes more complex, the throughput in terms of screening 
capacity decreases (Sundstrom et al., 2005). Moreover, the real-time monitoring of grafted 
cells using animal models is not easy. A screening platform in-between in vitro and in vivo 
models is required to improve understanding of stem cells. A possible option would be the 
use of brain organotypic slice culture for optimization of CNS cell therapies. These 
organotypic cultures mimic in vivo models of brain diseases better than cell cultures, they 
are cost-effective and easier to optimize, use and manipulate than rodent and primate CNS 
disease models. The usefulness of brain organotypic slices in CNS research as well as in the 
drug discovery process has been increasing in recent years and will be discussed in the next 
section. 
5. Organotypic 3D culture models: novel platforms for optimization of CNS 
cell therapy and tissue engineering  
Since their introduction, organotypic cultures of rat brain slices have become a useful tool to 
study drug effects. Brain organotypic slices are ex-vivo cultures that bridge the gap between 
in vitro and in vivo models. Slices are easy to prepare and they preserve the tissue 
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architecture of the brain regions that they originated from, allowing interaction of multiple 
cell types like neurons, astrocytes and microglia and maintaining neuronal activities. This 
3D environment has tremendous importance to evaluate the efficacy of tissue engineering 
approaches since most of the cells require cues from a truly 3D environment to form 
relevant physiological tissue structures in vitro. This 3D provides external mechanical inputs 
and cell adhesion parameters, which affects intracellular signalling. Importantly, these slices 
permit direct treatment or injection of drugs, virus, cells, microscaffolds... making them 
ideal for screening (Cho et al., 2007). 
5.1 Preparation of organotypic cultures of CNS tissue 
Organotypic brain slice culture was developed by inspiration on explant cultures techniques 
of various anatomical origins. Since then, several methods have been developed to prepare 
and maintain slices alive in long-term culture. The roller-tube technique based on the use of 
roller tubes was first described in 1981 (Gahwiler, 1981). However, most studies now use the 
membrane interface method described in 1991 (Stoppini et al., 1991) which provides an 
easier access to the slice culture. The principle of the membrane interface method is to 
maintain brain slices on a porous membrane filter at the interface between medium and a 
humidified atmosphere. The medium provides adequate nutrition to tissues through the 
membrane via capillary action. Rats and mice are the most common donor sources, but also 
rabbits, pigs and human fetuses have been used. Most organotypic brain slice cultures have 
been derived from neonatal (P0-P10) animals, but recently also adolescent or adult rats have 
been used and even human postmortem brain tissue slices have been kept alive for a few 
weeks in culture (Noraberg et al., 2005). Brain slices are relatively easy to prepare (Figure 2).  
 
 
Fig. 2. Organotypic preparation; 7 to 11 days old rats are commonly used to prepare brain 
organotypic cultures. First the brain is dissected free of skull. Second, slicing is performed 
with a vibrating microtome. Finally, slices are maintained in cultured using the membrane 
interface method. Representative bright field images of hippocampal and nigrostriatal 
organotypics are shown in the figure 
Briefly, the brain is dissected free of the skull and placed into a saline solution whose 
composition resembles that of the cerebro-spinal fluid and is thus often referred to as 
artificial cerebro-spinal fluid (ACSF). Slicing is performed with a vibrating microtome at 
high amplitude and very slow speed. Slice thickness varies according to specimen and the 
type of experiment, from 150 to 400 μm (Lossi et al., 2009). Over the years, slice culture 
systems have been successfully established from a variety of brain regions including 
hippocampus (far more frequently), striatum, cortex, spinal cord and cerebellum. 
Furthermore, a number of tissue slice co-cultures have been developed, which allow the 
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assessment of inter-neural responses across brain regions. Moreover, when organotypic 
slices are exposed to certain toxic conditions (oxygen-glucose deprivation, neurotoxins, 
glutamate-mediated excitotoxicity) they develop many pathophysiological features found in 
brain disorders and consequently, brain organotypic slices can be used as ex-vivo models of 
CNS diseases. Nowadays, organotypic models for global cerebral ischemia, ischemic stroke, 
Alzheimer’s disease, PD, HD, TBI, epilepisa and amyotrophic lateral sclerosis have been 
described (For review see (Noraberg et al., 2005; Sundstrom et al., 2005; Cho et al., 2007; 
Cimarosti & Henley, 2008; Lossi et al., 2009)). Among them, hippocampal organotypic slices 
exposed to oxygen-glucose deprivation, a model for global cerebral ischemia is the most 
commonly used. 
5.2 Applications 
Organotypic slices have been commonly used as models to investigate mechanism and 
treatment strategies for neurodegenerative disorders. Interestingly, the utility of brain slices 
to test CNS cell therapy efficacy has recently started to be investigated. Organotypic cultures 
are a very useful tool for screening of candidate stem cells for a specific pathology. They also 
could be used to track survival, differentiation, proliferation and migration of the 
transplanted cells with or without microscaffolds or to study graft and host interactions 
(Figure 3). Stem cell mechanisms of neuroprotection or paracrine secretions of MSCs could 
be also studied using brain slices. Charriere et al.,(Charriere et al. 2010) analyzed the 
interactions between bone marrow stromal cells and hippocampal slice cultures to clarify 
putative cross-interactions between MSCs and the CNS that could explain the molecular 
mechanism of stem cells. The dopaminergic differentiation of ES in a PD organotypic model 
and the effect of morphogenetic proteins such as LM on the differentiation of the cells has 
also been studied (Kearns et al., 2006). It was also shown that olfactory ensheathing cells 
(OEC) when co-cultured with the auditory brain stem slice culture not only promoted 
neurite outgrowth from the cochlear nucleus region of the brain stem slice but also 
supported the OEC indicating positive interactions between both  (Jiao et al. 2010). Recently, 
our group examined the potential of MIAMI cells injected into the hippocampus to prevent 
neuronal damage induced by global ischemia using rat hippocampal slices exposed to 
oxygen-glucose deprivation. We showed that MIAMI cells prevented neuronal damage. 
MIAMI cell therapeutic value was significantly increased when delivering the cells 
complexed with FN-coated biomimetic microcarriers probably by increasing stem cell 
survival and paracrine secretion of pro-survival and/or anti-inflammatory molecules as 
concluded from survival, differentiation and gene expression analysis (Garbayo et al., 2011). 
Furthermore, brain organotypic slices can be used to perform tissue biocompatiblity studies 
of scaffolds prepared for brain tissue engineering application and to determine how changes 
in the composition or in the functionalization of the scaffold could compromise their brain 
biocompatibility. In this context, Kristensen et al., have used organotypic brain slice cultures 
to assess silicon-based arrays biocompatibility (Kristensen et al., 2001). Other exciting 
application could be to use them to determine what scaffold composition best promotes 
proper adhesion and proliferation of the stem cells. Recently, in various pathologies it has 
been reported that multiple growth factor delivery is more effective than single growth 
factor administration since it mimics better the natural microenvironments of tissue 
formation and repair (Richardson et al., 2001; Barrientos et al., 2008). The difficulties of this 
approach are principally to find the optimised growth factor ratio, each factor at a 
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physiological dose and in a specific spatiotemporal pattern. Brain organotypic slices could 
be used to determine proper growth factor cocktail for a specific brain damage and to 
control the relationship between growth factor concentration gradient and timing.  
 
 
Fig. 3. A) Nigrostriatal organotypic culture with GFP-hNSC forming complexes with PAMs 
injected into the striatum. GFP-hNSC cells were kindly provided by Dr Martinez-Serrano. B) 
Hippocampal organotypic culture with MIAMI cells forming complexes with PAMs injected 
into the CA1 hippocampus 
An innovative approach using modified organotypic slices derived from a transgenic, 
mutant, null, gain-of-function, loss-of function, knock-in, or knockout animals was recently 
proposed (Li & Loudon, 2008). They discuss the possibility of using modified organotypic 
slice cultures to understand how implanted cells interact with resident cellular matrix and 
injured residential cells to predict their in vivo behaviour (Li & Loudon, 2008). Organotypic 
cultures could also be used to evaluate how temporal expression levels of stem cell 
chemokine receptors can be quantitatively related with their migration capacity toward 
brain tumor- or lesion producing -signal ligand SDF-1. The foundation of this experimental 
platform is to establish a system that mimics in vivo properties, first to maintain stem cells in 
a quiescent state, and then induce stem cells to produce targeting molecule cytokine 
receptors and matrix remodeling enzymes. Li & Loudon showed that migration of stem cells 
was enhanced by an intermediate concentration of SDF-1 gradient but inhibited by higher 
concentrations, with no stimulation at low concentrations (Li & Loudon, 2008). 
5.3 Limitations of organotypics 
Organotypic slices are not without limitations. The most limiting features are: 1) currently 
brain slices are only produced from juvenile donor animals as it is known that young tissue 
has more neuronal plasticity and are more resistant than older tissue. Recent reports have 
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used older donors to prepare brain organotypic slices but although it is possible, a low yield 
was observed and slices remained viable for only 3 to 4 weeks. 2) Automation is a challenge 
since a skilled operator is required for the production of the slices. 3) Not all brain areas are 
amenable to culture being the most appropriate the regions with a lamellar structure that 
can be aligned parallel to the plan of slicing. 4) Organotypics do not have a functional 
vascular compartment (for review see Sundstrom et al., 2005). 
6. Conclusions  
Although the ideal brain scaffold that satisfies all the requirements does not exist yet, the 
past several years have seen considerable progress in this field of study. For instance, 
materials of many types have been used to create brain scaffolds capable of providing 
sustained delivery of signalling molecules and an adequate 3D support for transplanted 
cells, thereby increasing cell survival and even guiding cell differentiation and fate in vivo 
Scaffold surface characteristics have also been modified to better mimic the natural brain 
environment, to control cell attachment, growth and differentiation or for specific uses. A 
key-point to remember is that most regenerative technologies in the future will probably be 
combinatorial, including biocompatible scaffolds, stem cells and the various factors 
necessary for their survival and function. This might be especially true in order to 
implement iPS cells therapy in the future, to control their proliferation and differentiation 
potential. Continual progress in the design and fabrication of future scaffolds is required to 
improve current delivery platforms since there is a need for development of custom 
matrices either tailored for purpose, or for the individual patient. Recent developments in 
understanding the basic biology of brain tissue formation in physiological and pathologic 
conditions have resulted in an explosion in the numbers of bio-engineered and tissue 
engineering products that could be potential candidates for treating brain disorders. A 
major challenge for the pharmaceutical industry is to find useful tools for screening since a 
bottleneck exists between the number of compounds that are interesting and the relatively 
limited in vitro and in vivo existing methods. Animal models are still the main choice for 
such studies but over the past years, brain organotypic cultures have begun to emerge as 
useful tools for screening of new neuroprotective and neuroregenerative approaches. In the 
current chapter, the combination of adult stem cells with microscopic scaffolds has been 
revised. Recently, research on the application of nanotechnology in stem cell and tissue 
engineering research has gained much attention in the scientific community. A significant 
and exciting area of research is the use of nanoparticles to engineer different patterned 
topographies of scaffolds that mimic the ECM, to study their effects on stem cells.  
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1. Introduction 
Diabetes mellitus is a disease of insulin insufficiency, which causes hyperglycemia and has 
both acute and chronic complications. Acute complications consist of hyperglycemic 
ketoacidosis and hypoglycemic episodes. Chronic complications consist of micro- and 
macro-angiopathies. Micro-angiopathy leads to diabetic nephropathy, neuropathy and 
retinopathy; macro-angiopathy leads to brain infarction, brain hemorrhage and cardiac 
infarction.  Both acute and chronic complications significantly deteriorate the quality of life 
of diabetic patients and are sometimes fetal. 
More than 23.7 million people suffer from diabetes in the USA today and that number will 
reach 44.1 million in 2034 (Huang et al., 2009).  It has been demonstrated that the loss of 
beta-cell mass is approximately 95% in type 1 diabetic patients, 65% in type 2 diabetic 
patients, and even 50% in metabolic syndrome patients (Butler et al., 2003, 2007; Meier et al., 
2005, 2008). 
From the treatment viewpoint, diabetes is categorized into non-insulin dependent diabetes 
mellitus (NIDDM) and insulin dependent diabetes mellitus (IDDM).  The standard therapy 
for the IDDM is insulin injection (Table 1).  However, in the advanced phase, those patients 
are not able to control blood glucose levels by insulin injection.  Beta cell replacement 
therapies including whole pancreas transplantation and islet cell transplantation are 
currently applied clinically for such patients (Matsumoto, 2010a) (Table 1).  Unfortunately, 
there are more than one million IDDM patients in the United States and the number of 
cadaveric organs available is approximately 7,000 in each year. There is a clear donor 
shortage and regenerative medicine and/or tissue engineering for creating insulin-
producing cells are critical to overcome this issue. 
Diabetes is an excellent candidate for regenerative medicine and tissue engineering because 
only the beta cell with or without alpha cells is necessary to be generated for improving 
glycemic control.  Since islet cell transplantation has already been proven to be an effective 
treatment for diabetic patients, generating insulin-producing cells is guaranteed for clinical 
effectiveness. 
Indeed, tissue engineering using pig islet cells has already been clinically attempted as a bio-
artificial islet transplantation for the treatment of IDDM patients (Table 1). In addition, some 
approaches including direct signal delivery to pancreas and neural relay of signal from liver 
to pancreas have been established for beta cell regeneration experimentally  
(Table 1). 
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Category Treatment Clinical 
application 
Donor 
sources 
Need for 
Anti-
rejection 
drugs 
Prevention of 
acute and 
chronic 
complications 
Insulin 
therapy 
Insulin 
injection 
Standard 
therapy 
N.A. No No 
Beta cell 
replacement 
Pancreas 
transplant 
Standard 
therapy 
Cadaveric or 
living donor
Yes Yes 
Beta cell 
replacement 
Islet 
transplant 
Semi-standard 
therapy 
Cadaveric or 
living donor
Yes Yes 
Bio-artificial 
islet 
Xeno islet 
transplant 
Under clinical 
trial 
Pig No Possible 
Bio-artificial 
islet 
Generated 
islet 
transplant 
Not clinically 
available 
Stem cells 
(ES cells,  
iPS cells, 
pancreatic 
stem cells) 
Yes or No Unknown 
Beta cell 
regeneration 
Direct signal 
delivery 
Not clinically 
available 
N.A. Yes for type 
1 diabetes 
Unknown 
Beta cell 
regeneration 
Neural relay 
of signal 
Not clinically 
available 
N.A. Yes for type 
1 diabetes 
Unknown 
Table 1. Current and future treatments for insulin dependent diabetes mellitus (IDDM).  
Allogeneic islet transplantation for the treatment of type 1 diabetes is considered as the 
standard therapy in some countries.  Of note, bio-artificial islet transplantation using pig 
islets has been already initiated for the treatment of type 1 diabetic patients.  ES cells: 
Embryonic stem cells, iPS cells: induced pluripotent stem cells, N.A.: not applicable 
Thus this field is one of the most advanced areas for regenerative medicine and tissue 
engineering. 
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In this book chapter we describe the current status of regenerative medicine and tissue 
engineering for creating insulin-producing cells and clinical application or the path to the 
clinical application of those technologies. 
2. Regenerative medicine of beta cells 
Regenerative medicine of beta cells consists of two major categories.  The one is a 
replacement/implantation of alternative cell sources instead of human islets from cadaver 
donors.  Such cell sources include embryonic stem (ES) cells, induced pluripotent stem (iPS) 
cells, or other systemic stem cells. They are expanded and differentiated to insulin 
producing cells in vitro, and implanted into a diabetic patient.  However, although several 
straightforward protocols were established, both the efficiency of in vitro programming and 
the function of derived-beta cells remain unsatisfactory.  In addition, safety concerns due to 
inherent risks of neoplasm originating from residual stem cells remain a major hurdle 
(Borowiak & Melton, 2009; Ricordi & Edlund, 2008; McKnight et al., 2010).  To avoid the 
risks of neoplasm of beta cell generation from stem cells, beta cell transdifferentiation from 
exocrine tissues has been performed (Minami et al., 2005). Impressively, simple culture of 
exocrine tissue with EGF and nicotinamide enabled the transdifferentiation of exocrine 
tissue to beta cells.  Additionally, exocrine tissues from type 1 diabetic mice model were able 
to trans-differentiate into beta cells (Okuno et al., 2007). However, the efficacy was not 
effective yet to generate enough beta cells to reverse diabetes, and this approach requires 
human exocrine tissue. 
Another medical approach is bona fide regeneration of islet cells/beta cells in a patient.  
Because there is a slow rate of beta cell turnover in the human pancreas even after injury, 
regenerative medicine is focusing on stimulating either beta cell replication or neogenesis.  
Finding a molecular intervention that can be safely used in vivo seems challenging but not 
impossible.  There are ways in which neogenesis might be stimulated to expand beta cell 
mass using agents such as exendin-4, gastrin and epidermal growth factor (Bonner-Weir & 
Weir, 2005).  Another method is differentiation/transdifferentiation in which either existing 
stem cells or differentiated cells can be programmed/reprogrammed to change their 
identity.  To achieve this goal, most studies have used a gene induction method with a viral 
vector.  It was demonstrated that pancreatic acinar cells might be reprogrammed in mice 
with injections into the pancreas of adenoviruses expressing three transcription factors, 
pancreatic duodenal homeobox-1 (PDX-1), musculoaponeurotic fibrosarcoma oncogene 
homolog A and neurogenin-3 (Zhou et al., 2008).  However, gene delivery with viral vectors 
has shown adverse effects, which have been related to enhancer-mediated mutagenesis of 
genomic DNA (Hacein-Bey-Abina S et al., 2003) or immunological responses to viral 
proteins (Manno et al., 2006). Before these permanent or long-term side effects are fully 
understood and resolved, the safety of using viral vectors must be established. 
In this chapter, for bona fide beta cell regeneration, we will introduce two unique methods.  
The first method is gene delivery using ultrasound targeted micro-bubble destruction 
(UTMD) technology. UTMD technology allows us to deliver genes specifically into the 
pancreas by using ultrasound without using viral vectors (Chen et al., 2006, 2010).  The other 
method is activating neural relay mechanism to stimulate beta cell regeneration and insulin 
secretion in naïve pancreas (Imai et al., 2010).  The initial signal is activated in the liver and 
the signal relay to pancreas via neural system.  The unique signal in the liver can actually 
stimulate beta cell regeneration and insulin secretion in the naïve pancreas. 
  
Tissue Engineering for Tissue and Organ Regeneration 
 
420 
2.1 Ultrasound targeted micro-bubble destruction (UTMD) for gene delivery to 
regenerate beta cells 
2.1.1 Development of UTMD for gene delivery 
In order to obtain high gene expression after gene delivery in vivo without viral vectors, we 
have established an ultrasound-mediated gene transfer method named Ultrasound Targeted 
Microbubble Destruction (UTMD) and achieved efficient gene transfer of plasmid DNA 
(pDNA) in vivo (Chen S et al., 2006, 2010; Korpanty G et al., 2005).  Delivery of pDNA does 
not transport toxic or immunogenic viral protein or polymer particles.  UTMD is known to 
be a novel and potential gene delivery method in vivo.  The mechanism of gene delivery is as 
follows: the microbubbles consist of lipid shell and perfluorocarbon gas on the inside. The 
plasmid gene to be delivered resides in the shell. After infusing the microbubbles with 
pDNA intravenously, they are detected in the target organ by echography. Under 
ultrasound exposure, the microbubbles burst and the energy creates transient pores in 
membranes of surrounding cells, and pDNAs are inserted into the cells (Figure 1). 
UTMD has many of the desired characteristics of gene therapy including low toxicity, low 
immunogenicity, potential for repeated application, organ specificity and broad 
applicability to acoustically accessible organs. 
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Fig. 1. The mechanism of Ultrasound Targeted Microbubble Destruction (UTMD) for gene 
delivery.  In vessels, microbubbles can be destroyed with high mechanical index ultrasound 
in the target organ, and the released genes (pDNAs) pass through the vasculature, thus 
releasing the genes (pDNAs) into the surrounding tissue.  The microbubble destruction can 
only happen under ultrasound 
Using this technology, plasmids containing rat insulin 1 promoter (RIP)-human insulin and 
RIP-hexokinase I were successfully delivered to the islets of adult rats (Chen S et al., 2006).  
Delivery of RIP-human insulin plasmid resulted in clear increases in circulating human C-
peptide and decreased blood glucose levels.  Delivery of RIP-hexokinase plasmid resulted in 
a clear increase in hexokinase I protein expression in islets. Furthermore, delivery of RIP-
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NeuroD1 by UTMD technology into streptozotocin induced diabetic rats resulted in 
promotion of islet regeneration in the naïve pancreas with the return of normal glucose, 
insulin and C-peptide levels (Chen S et al., 2010).  Thus, an exciting new possibility has 
emerged with this technology.  Much work is now underway to determine the potential 
clinical applications of this in vivo gene induction used alone or in combination with other 
regeneration techniques. 
2.1.2 Path to clinical application of beta cell regeneration by UTMD 
Even though UTMD for gene delivery is promising for beta cell regeneration, there are 
several issues that remain to be solved before clinical application.  First of all, the safety of 
this technology needs to be confirmed using a large animal model.  Microbubbles have been 
clinically used as contrast agents for ultrasound; however, the material of microbubbles for 
UTMD is modified for gene delivery. Therefore, it is necessary to assure the microbubbles 
for UTMD is safe.  Furthermore, since the ability of beta cell regeneration in rodent is much 
higher in human or large animal (Noguchi et al., 2009b, 2010), it is important to confirm the 
efficacy of beta cell regeneration in large animal. The next issue is the long-term effect of 
beta cell regeneration by gene delivery with UTMD. In the rodent model, normoglycemia 
were maintained for up to 3 months (Chen et al., 2010). Identifying the mechanisms of 
failure to maintain long-term insulin independence is important.  On the other hand, the 
UTMD technology is relatively easy to be applied. Therefore repeating this technology is 
feasible.  In such case, the effect and safety of repeated UTMD need to be assessed. 
When applying the UTMD method for type 1 diabetic patients, it is necessary to prevent 
autoimmune recurrence. Therefore, immunosuppressive drugs might be necessary to 
prevent the immunological rejection of regenerated beta cells. 
2.2 Neural relay for beta cell regeneration in naïve pancreas 
The concept of neural relay is very unique. Beta cell proliferative activity changes 
dynamically to meet systemic needs throughout life. One condition in which beta cell 
proliferation is enhanced is obesity-related insulin resistance. However, the mechanism 
underlying this compensatory beta cell response is not well understood. 
Recently, Katagiri et al. have identified a neuronal relay, originating in the liver, which 
enhances both insulin secretion and pancreatic beta cell proliferation for the possible 
mechanism of obesity-related insulin resistance (Katagiri et al., 2009). Blockade of this neural 
relay in murine obesity models inhibited pancreatic islet expansion during obesity 
development, showing this inter-organ communication system to be physiologically 
involved in compensatory beta cell proliferation.  They demonstrated that proliferation of 
pre-existing beta cells contributes to a beta cell increment by neural relay mechanism.  
Therefore, this neural relay system is not only for explaining the mechanism of obesity-
related insulin resistance but also might be applicable for beta cell regeneration in the naïve 
pancreas for the treatment of diabetes. 
2.2.1 Discovery of neural relay 
Metabolism in different organs and tissues works in a coordinated manner.  This 
coordinated metabolism requires inter-organ/tissues communication, therefore the 
communication among organs and tissues are critical for maintaining normal metabolism 
(Katagiri et al., 2009).  It has been demonstrated that humoral factors including hormones 
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and cytokines play major roles.  However, a number of studies have shown that unexpected 
metabolic phenotypes also make a contribution suggesting the presence of currently 
unknown metabolic communication systems. 
Recently, it was demonstrated that neuronal signaling plays important roles in inter-organ 
metabolic communication (Yamada et al., 2006).  Obesity induces insulin hypersecretion and 
pancreatic beta cell hyperplasia in response to insulin resistance.  These compensatory 
responses of pancreatic beta cells prevent hyperglycemia; however, this causes 
hyperinsulinemia which is involved in the pathogenesis of the metabolic syndrome.  To 
elucidate the mechanisms of these compensatory mechanisms, Katagiri et al. activated 
several proteins which are known to be activated in the livers of obese and lean mice.  They 
discovered that extracellular signal-regulated kinase (ERK) plays an important role in 
compensatory pancreatic beta cell responses.  To activate ERK in the liver, they used 
adenoviral gene transduction system and discovered that liver-selective ERK activation 
induced insulin hypersecretion and pancreatic beta cell proliferation (Fujishiro et al., 2003).  
These pancreatic effects of hepatic ERK activation were inhibited by either splanchnic 
afferent blockade with pancreatic vagus dissection or midbrain transection.  This result 
indicated that a neuronal relay system from liver to the pancreas consists of the afferent 
splanchnic nerve, the central nervous system and efferent vagus (Figure 2). 
Furthermore, blockage of the neuronal relay at several levels in murine obesity model 
inhibited pancreatic islet expansion during obesity development indicating that the neural 
relay played an important role in the inter-organ mechanism in compensatory beta cell 
responses. 
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Fig. 2. The concept of neural relay for beta cell regeneration.  The signal of hepatic ERK 
activation reaches the brain via the splanchnic nerve.  Then the signal reaches the pancreas 
via the vagal nerve.  This signal stimulates insulin hypersecretion and beta cell proliferation 
in the pancreas 
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2.2.2 Potential application of neural relay for beta cell regeneration 
Regeneration of beta cells in the original pancreas could be an ideal cure for type 1 diabetic 
patients. Since the neural relay system can stimulate beta cell proliferation and insulin 
secretion, this system might be used for beta cell regeneration. 
Indeed, it has been demonstrated that liver-selective activation of extracellular signal-
regulated kinase (ERK) using an adenoviral gene transduction system resulted in an 
increase in beta cell mass and normalization of serum glucose levels in streptozotocin 
(STZ) induced diabetic mice and Akita diabetic mice (Imai et al., 2008). A 
bromodeoxyuridine (BrdU) staining study demonstrated that beta cell proliferation was 
the mechanism for increasing beta cell mass by neural relay (Imai et al., 2008).  Therefore, 
stimulating the ERK pathway is a promising idea for beta cell regeneration in the naïve 
pancreas. However, it should be noted that they used only the STZ model and Akita 
diabetic mice model.  STZ model is a model of insulin dependent diabetes mellitus, 
however, no autoimmune mechanism is involved. Therefore, although the neural relay 
works on the STZ model it is still unknown whether this method can be effective on the 
type 1 diabetic patients with autoimmune disease.  In addition, the STZ model cannot 
completely eliminate beta cells therefore beta cell proliferation was possible.  On the 
contrary, type 1 diabetic patients without insulin secretory ability have completely lost 
their beta cells.  Therefore, it might be impossible to induce beta cell proliferation because 
no beta cells remain.  In order to apply neural relay technology for type 1 diabetes, it is 
necessary to confirm the efficacy using NOD mice which is an autoimmune induced type 
1 diabetes model.  Additionally, it is necessary to examine the minimum number of 
remaining beta cells which will be proliferated to reverse diabetes.  If a significant amount 
of beta cells are necessary, this method can only be applied for the patients who still have 
insulin secretory ability.  Akita diabetic mouse is a model of type 2 diabetes.  In general, 
patients with type 2 diabetes do not require insulin injection; therefore the indication of 
neural relay for type 2 diabetes should be limited.  However, currently, insulin therapy is 
applied for type 2 diabetic patients in order to save functional beta cell mass.  Therefore, 
neural relay therapy might be an excellent option for type 2 diabetic patients with insulin 
therapy.   
The advantage of this method is that no stem cells such as embryonic stem (ES) cells 
(Thomson et al., 1998) or induced pluripotent stem (iPS) cells (Takahashi et al., 2007) or 
pancreatic stem cells are necessary.  Therefore, the notorious problem of carcinogenesis of 
those stem cell derived beta cells is no longer an issue.  In addition, ex vivo manipulation to 
create beta cells from stem cells is not necessary.   
The possible disadvantage of this method is hepatic injury by activation of hepatic ERK.  
Also, the adenoviral system may not be appropriate for clinical trials because of the risk of 
viral infection. UTMD system for activation of hepatic ERK might be useful approach to 
avoid using viral transfection.  Identifying the efficient activation of hepatic ERK should be 
the key for beta cell regeneration.  When ERK stimulation for beta cell regeneration will be 
applied for type 1 diabetic patients, the prevention autoimmune recurrence and 
immunosuppressive drugs might be necessary. Furthermore, in advanced type 1 diabetes, 
all beta cells are destroyed as mentioned above. Therefore, it might be impossible to 
proliferate islets because no original islets exist. In this case, a combination of beta cell 
generation from pancreatic stem cells and neural relay might be useful. 
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3. Bio-artificial islets using pig islets 
Islet transplantation using the bio-artificial islets created from alternative sources instead of 
human islets is very attractive to overcome the issue of severe donor shortage for the 
treatment of diabetes. 
Very importantly, two clinical trials using bio-artificial islets consisting of piglet islets have 
been already clinically performed with promising results.  The first trial was performed in 
Mexico using neonatal pig islets combined with Sertoli cells for the treatment of pediatric 
type 1 diabetic patients (Valdes-Gonzales et al., 2005a, 2007).  Islets and Sertoli cells were put 
into a chamber. The Sertoli cells protected islets from immunological attacks. The other 
series were performed by New Zealand group for the treatment of adult type 1 diabetic 
patients with severe hypoglycemic episodes (Elliott et al., 2011). The New Zealand group 
used microencapsulated pig islets and those bio-artificial islets were transplanted into the 
abdominal cavity. 
Impressively, both groups achieved insulin independence after transplantation in some 
cases without use of immunosuppressive drugs. 
3.1 Bio-artificial islets with Sertoli cells 
3.1.1 Preparation of bio-artificial islets with Sertoli cells and transplantation 
Valdes-Gonzalez et al. performed bio-artificial islet transplantation into twelve pediatric 
type 1 diabetic patients (Valdes-Gonzalez et al., 2005a). Their bio-artificial islet consists of 
collagen-generating devices, islets from neonatal pigs and Sertoli cells. The collagen-
generating devices were not considered as immune-isolation devices.  Islets were isolated 
from male 7-10 days old piglets. The animals were bred in New Zealand in a specific 
pathogen-free environment in accordance with the Association for Assessment and 
Accreditation of Laboratory Animal Care. After pancreas retrieval, pancreases were 
digested using collagenase for islet isolation (Elliott et al., 2000; Valdes-Gonzalez et al., 
2005b). Islets were placed in RPMI-1640, 2% human serum albumin, 0.12% nicotinamide and 
1.5mg/l ciproxine at room temperature and centrifuged at 1000 rpm for 20 min.  The 
average islet yield was 290,730 islet equivalents (IEQ: 1IEQ=1 of 150 μm islet).  The purity of 
islets was assessed with dithizone staining and was greater than 85% in all cases.  The 
viability of islets assessed by acridine orange/propidium iodide staining was more than 
85% in all cases.  Isolated Sertoli cell-enriched testicular cells were placed in DMEM media 
with 0.12% nicotinamide and 1.5mg/l ciproxine. All cell preparations underwent full 
microbiologic screening both in New Zealand and again at the time of transplantation.  Cells 
from ten neonatal pigs were used for each transplant.  Sertoli cells and islets were mixed 
together immediately prior to transplantation. 
Two devices were implanted subcutaneously in the upper anterior wall of the patient’s 
abdomen under general anesthesia.  The devices were left in place for two months to allow 
formation of vascularized collagen tissue that completely surrounded and penetrated the 
device. 
Both islets and Sertoli cells were isolated in New Zealand and sent at room temperature in 
culture media to Mexico. Islets and Sertoli cells were cultured for one day before 
transplantation.  The transplant procedure was carried out by infusing 250,000 islets with 
30-100 Sertoli cells per islet. The number of islets per body weight ranged from 
approximately 14,000 to 21,000IEQ/kg.  From 6 to 9 months later, all patients except one, 
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received a second islet and Sertoli cell transplant into previously implanted new devices.  
No immunosuppressive drug was administered at any point.   
3.1.2 Clinical outcomes 
Immediately upon entering the study, the patients followed a diet and exercise regimen 
standard for diabetic patients, with periodic weight and height measurements.  The patients 
were instructed to record blood glucose determination seven times a day (pre- and 
postprandial, and 3 am). Eleven age and disease matched control group was subjected for 10 
months to exactly the same exhaustive endocrine monitoring, and diet and exercise program 
without receiving a transplant. 
In the transplanted patients following the first and more markedly after the second 
transplant, cluster analysis revealed that two distinct insulin requirement patterns appeared. 
Half of the patients had a 50% or greater reduction in their insulin requirements, and the 
other six patients showed a slight increase. This increase in these patients seen corresponded 
with that that seen in the control group.  Half of the patients significantly reduced amount 
of insulin compared to the control group from the first month post transplant onwards. Two 
patients achieved insulin independence. The first one was a 15 year old female who had 
exogenous insulin requirements of 61 U/day before transplant and HbA1c was 13.4%. After 
the first transplant, she reduced her insulin requirements by 73% and after the second 
transplant she began to have intermittent period of 3-5 days, alternating between periods of 
no insulin injections, followed by periods of 1-2 U/day. This pattern last for 3 months, and 
HbA1c reached 9.6%. The second patient was a 16-year-old female who had exogenous 
insulin requirement of 55 U/day and HbA1c was 12%.  Six months after the first transplant, 
the patient showed a 6 week reduction to 1-3 U/day and HbA1c was 6.8%.  After the second 
transplant she was totally free of insulin for two consecutive months and her HbA1c was 
6.5-7.8%.  Interestingly all patients improved glycemic control after transplantation 
irrespective of the amount of insulin reduction.  Long-term follow-up of those patients 
revealed that all patients have positive porcine C-peptides in urine (Valdes-Gonzalez et al., 
2010). 
In terms of safety, routine microbiological screening of all patients and close family have 
been consistently negative, although two patients exhibited transient chimerism as 
evidenced by porcine DNA thru polymerase chain reaction (PCR).  No complication related 
to the surgery or to the presence of the cells has occurred at any time. 
3.2 Bio-artificial islets using micro-encapsulation technology 
3.2.1 Preparation of bio-artificial islets using micro-encapsulation technology and 
transplantation 
Elliott et al. performed bio-artificial islet transplantation into adult type 1 diabetic patients 
with severe hypoglycemic episodes (Elliot et al., 2011).  Their bio-artificial islets were made 
of micro-encapsulated islets from neonatal pigs. This group used the same islet isolation 
procedures using the same herd with Valdes-Gonzalez.  The islets were micro-encapsulated 
using alginate. The capsule allows entering nutrients and glucose inside the capsule and 
passing insulin outside the capsule (Figure 3). Meanwhile, the capsule blocks antibodies 
resulting in protecting the islet from immunological attack (Figure 3). 
The encapsulation process was a modification of the method described by Calafiore 
(Calafiore et al., 2006).  Encapsulation material was started with raw pharmaceutical grade 
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alginate powder. The alginate powder was dissolved in sterile pyrogen-free deionized water 
over 24 to 36 hours in the dark at room temperature and 3% NaCl was added.  The solution 
underwent multiple sequential passages through methylcellulose and polyester filters to 
ensure sterility.  The final 1.6% solution was stored in the dark room at 4oC to avoid alginate 
depolymerization. The islet tissue pellet, usually amounting to a few tenths of a milliliter, 
was thoroughly mixed with the 1.6% alginate solution. The alginate/islet proportion was 
adjusted so that one capsule would contain one islet, with fewer than 5% empty capsules. 
The suspension was extruded through a microdroplet generator, combining air shears with 
mechanical pressure: the alginate droplets were collected in 1.2% CaCl2 immediately turning 
into gel micro-beads.  They were sequentially overcoated with poly-L-ornithine and an 
outer alginate layer. 
 
 
 
 
Nutrients & 
 glucose 
Anbodies 
Insulin 
Capsule 
Islet 
 
Fig. 3. The concept of microencapsulation of an islet.  Nutrients, glucose and insulin can 
pass through the capsule, but antibodies cannot enter into the capsule 
Bio-artificial islets consisted of microencaplusted neonatal pig islets were transplanted into 
the peritoneal cavity via a laparoscope under general anesthesia.  Four patients received 
10,000 IEQ/kg body weight islets and the other four patients received 15,000IEQ/kg body 
weight islets. 
3.2.2 Clinical outcomes 
In order to perform clinical trials, they gained regulatory approval from the relevant 
authorities after prolonged national and international consultation (Elliott et al., 2011).  A 
national consensus on the bioethical issues was conducted and a separate national 
consultation on the acceptability of the science was also conducted.  Approval from Medsafe 
the relevant department of the Ministry of Health was obtained.  Eight adult patients with 
longstanding proven type 1 diabetes who met all inclusion and exclusion criteria, were 
selected on the basis of severe recurrent hypoglycemia usually with hypoglycemic 
unawareness.   
To date, most patients have shown modest reduction in insulin dose commencing about 
four weeks after transplantation with reduction in HbA1c levels.  Most outstanding has 
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been the reduction in severe hypoglycemic episodes and reduction or abolition of unaware 
hypoglycemia. For example, the first patient had an average of 4 episodes of unaware 
hypoglycemia per week, which was completely diminished after 8 weeks of transplantation.  
Transitory insulin independence of several months duration has been seen. 
In terms of safety, evidence of xenosis in the xenotransplant recipients has been diligently 
sought but not found.  This is reasonable given the credentials of the source herd used.  No 
serious adverse events related to the surgery or to the presence of the cells have occurred at 
any time. 
3.3 Future direction of bio-artificial islets 
Since year 2000 after the publication of the Edmonton protocol, allogeneic islet 
transplantation has become popular as the treatment of type 1 diabetes (Shapiro et al., 2000).  
Using the Edmonton protocol, type 1 diabetic patients who had severe hypoglycemic 
episodes became insulin independent and free from hypoglycemic episodes after allogenic 
islet transplantation (Shapiro et al., 2000). The allogeneic islet transplantation has been 
expanded using non-heart beating donors (Markmann et al., 2003; Matsumoto et al., 2006b) 
and even living donor (Matsumoto et al., 2005, 2006a). However, the drawbacks of the 
Edmonton protocol include necessity of multiple donor organs, unstable islet isolation 
results, necessity of immunosuppressive drugs, difficulty of maintaining long-term insulin 
independence and severe shortage of donor organs (Ryan et al., 2005; Shapiro et al., 2006).  
Currently, we introduced new pancreas preservation (Matsumoto et al., 2002a, 2002b, 2010b) 
and islet isolation strategies (Noguchi et al., 2009a; Shimoda et al., 2010) and 
immunosuppressive therapy to improve the efficacy of islet isolation (Matsumoto et al., 
2011). Now, we have a very stable islet isolation method, in addition, a single donor 
pancreas is enough to achieve insulin independence (Matsumoto et al., 2011).  Our 
preliminary data demonstrated that super-high dose islet transplantation could lead to long-
term insulin independence after allogeneic islet transplantation (Matsumoto et al., 2010c).  
However, the severe donor shortage can be never be solved by allogeneic islet 
transplantation alone.  Bio-artificial islets using porcine islets can solve the issue of donor 
shortage.  In addition, both bio-artificial islets with encapsulated islets and islets with Sertoli 
cells do not require immunosuppressive drugs.  This is huge benefit of bio-artificial islet 
transplantation because one of the major issues of allogeneic islet transplantation is the side 
effects and cost of immunosuppression (Hatanaka et al., 2010). 
Currently, bio-artificial islets were transplanted into the abdominal cavity or under skin.  
These transplant sites have unique advantages. In the case of allogeneic islet transplantation, 
islets were transplanted into liver.  Multiple infusions of isolated islets into liver cause portal 
hypertension.  Therefore allogenic islet transplantation has the limitation of the numbers of 
transplantation.  In the case of bio-artificial islet transplantation, there is no risk for portal 
hypertension. Therefore, there is no limitation of number of transplantation.  These 
comparisons were summarized in table 2. 
Impressively, pigs in New Zealand have been maintained in a clean, non-pathogenic 
environment and seem suitable for clinical use.  Both clinical trials of bio-artificial islets used 
these pigs.  Expansion of the herd of pigs should be the key to enhancing the bio-artificial 
islet project.  Islet isolation from neonatal piglets is relatively easy and stable; this is 
important advantage for commercialization. 
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 Standard 
Allogeneic Islet 
Transplantation 
Advanced 
Allogeneic Islet 
Transplantation 
Bio-artificial Islet 
Transplantation 
Primary Endpoints Preventing 
hypoglycemia 
Insulin free Preventing 
hypoglycemia 
Secondary 
Endpoints 
Insulin free 
Preventing 
diabetic 
complications 
Preventing 
diabetic 
complications 
Insulin free 
Preventing 
diabetic 
complications 
Donor numbers 2 or more human 
pancreases 
1 human pancreas 10 piglets 
pancreases 
Stability of islet 
isolation 
Not stable Stable Stable 
Transplant site Liver Liver Intra-peritoneum 
Under skin 
Immunosuppression Necessary Necessary Not necessary 
Attaining insulin 
independence 
Most likely Most likely Possible 
Long-term insulin 
free 
Difficult Possible Difficult 
Long-term function Possible Most likely Possible 
Re-transplant Up to 3 or 4 times Up to 3 or 4 times No limitation 
Table 2. Comparison among the standard allogeneic islet transplantation, the advanced 
allogeneic islet transplantation and bio-artificial islet transplantation.  Of note, bio-artificial 
islet transplantation has several important advantages including using alternative source, no 
immunosuppressive drugs and no limitation of re-transplantation 
As shown Elliott et al., the bio-artificial islets can eliminate hypoglycemic unawareness, and 
this is the one of the major goals of allogeneic islet transplantation.  Therefore, the patients 
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with hypoglycemic unawareness will be suitable candidates for bio-artificial islet 
transplantation instead of allogeneic islet transplantation in future. 
More importantly, allogeneic islet transplantation can reduce or eliminate diabetic 
secondary complications such as diabetic nephropathy, retinopathy and neuropathy 
(Thompson et al., 2011).  Especially, if the bio-artificial islet transplantation can also reduce 
or eliminate such diabetic secondary complications, this treatment will be very valuable 
because the real problems of diabetes are the secondary complications.   
Cost effectiveness is an issue of bio-artificial islets, because maintenance of clean pigs is 
expensive. The system to maintain cleanness of a huge herd of pigs needs to be developed to 
overcome the cost issue. The major concern of bio-artificial islet transplantation is zoonosis.  
Especially, creating a new viral disease by xeno-transplantation must be avoided.  Infection 
of porcine endogenous retrovirus after xeno-transplantation into immune compromised 
mice demonstrated the risk of the combination of immunosuppression and xeno-
transplantation (van der Laan LJ et al., 2000). Therefore current bio-artificial islet 
transplantations have been performed without immunosuppression. 
Acceptance of pig islets by patients is an emotional and highly debated issue for xeno-
transplantation.  Our survey of type 1 diabetic patients revealed that more than 60% of type 
1 diabetic patients were willingly to accept pig islets if the treatment was effective 
(Hatanaka et al., 2010). 
4. Conclusions 
We introduced two unique gene therapies UMTD and neural relay for beta cell 
regenerations.  Both methods are not clinically applied yet; however due to their relatively 
safe feature, we believe those methods can be clinically used in near future.  We also 
described the clinical applications of bio-artificial islets using neonatal porcine islets with 
promising results.  Most importantly, so far there are no severe adverse events.  Although 
the results of bio-artificial islet transplantation are not as effective as allogeneic islet 
transplantation there are many aspects including islet isolation methods (Shimoda et al., 
2011a, 2011b), islet culture methods, transplantation sites and patients’ treatments, which 
can be improved. 
Currently, diabetes is considered a non-curable disease therefore current treatments are 
focusing on improving quality of life and preventing diabetic complications (Takita 2011, 
Hatanaka 2011).  However, we believe that the bio-artificial islets and/or gene therapy for 
beta cell regeneration will cure a majority of both types of diabetes in the future. 
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1. Introduction 
Diabetes mellitus, the metabolic disorder is rapidly on the rise, becoming one of the main 
threats to human health and imposing large socio-economic burden on the society in the 
21st century (Dall et al.; 2010). International Diabetes Federation in 2011 estimated that over 
300 million people around the world have diabetes and is expected to rise to 500 million 
within next 20 years. The global prevalence of diabetes is shifting significantly from the 
developed countries to the developing countries. Current therapy for diabetes involves oral 
antidiabetic drugs and insulin administration; these approaches do not mimic the pulsatile 
insulin secretory patterns of native β islets for the regulation of glucose in real-time nor 
provide tight control of blood glucose to avoid late complications of the disease. Whole 
pancreas transplantation holds promise towards a cure for diabetes, but this procedure 
requires major surgery and lifelong immunosuppression to prevent graft rejection. 
Transplantation of islet cells isolated from a donor pancreas has been shown to control 
glucose levels successfully. Being less invasive, it is a better alternative to pancreas 
transplantation yet scarcity of donors, maintenance of islet functions such as cell growth and 
survival in vitro, and concern over the adverse effect of life long immunosuppressants used 
to prevent graft rejection precludes the benefits of islet transplantation from becoming 
universally acceptable. 
One approach to overcome these obstacles of immune rejection is islet encapsulation (Kizilel 
et al., 2005; Mikos et al; 1994) that uses an immuno-protective biomaterial to create a 
permselective membrane around a group of islet cells. Transplanted islet cells are separated 
from the immunological system of host by means of an artificial selectively permeable 
membrane which allows passage of metabolites and nutrients, while excluding based on 
size, the larger proteins and cells of the immune system. Thus, encapsulation is designed to 
limit, and ideally eliminate, an immunological response to the non-host islet cells. Isolation 
of the islet cells from the human immune system may also make xeno-transplants such as 
porcine islets, stem cells derived insulin producing cells possible, eliminating the supply 
problem that exists and the usage of immune suppressive drugs.  
Current research is directed towards exploration of alternative sources of pancreatic islet 
cells. Pancreatic  β- cell lines, embryonic stem cells (ESC), adult progenitor cells (APC), and 
regenerating native islet cells, generation of β cells by therapeutic cloning and 
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differentiation of islets from pancreatic duct cells as well as stem cells are being explored for 
their potential to serve as β-cell sources. Large numbers of cells can be generated from β cell 
lines, although their unrestricted proliferation is also a serious concern in the context of 
cellular therapies. Unlike stem and progenitor cells, β islet cells have limited ability to 
multiply under normal conditions, although investigations into factors that stimulate β-cell 
regeneration have yielded promising results. Therapeutic molecules capable of increasing β-
cell mass in vivo may eliminate the need for invasive surgical procedures. However, the 
extent of adult β cell regenerative capacity is unclear. Ex-vivo expansion of islets is 
indispensable prior to transplantation regardless of the source of islets.  Monolayer culture 
of islets fail to maintain the three dimensional shape and integrity of islets resulting in 
consequent apoptosis and necrosis. In vitro culturing of pancreatic islets result in the loss of 
extracellular matrix (ECM), basement membrane and introduction of free radicals in 
isolation procedure, that cause islet cells to loose their three dimensional (3D) structure, 
function and ultimately undergo apoptosis (Parakevas et al., 1997). These problems could be 
alleviated by using tissue engineering principles and culturing pancreatic islets in 3 
dimensional (3D) scaffold which can help in maintaining cell-cell, and cell-matrix 
interactions.  
2. Islet transplantation 
Islet cell transplantation is an effectual treatment for improving glycemic condition in 
diabetic patients thereby reducing the late complications of disease (Shapiro, 2003). The 
procedure involves isolating islets from a deceased organ donor, purifying, processing and 
infusing them into diabetic patients.  
In the early 1970’s, Dr. Clyde Barker at the University of Pennsylvania and the late Paul 
Lacy at the Washington University in St. Louis were the pioneers in exploring the concept of 
islet transplantation as a means to cure diabetes. In 1972, Ballinger and Lacy reported 
amelioration of diabetes in islet recipient rats (Ballinger & Lacy, 1972). In 1973, Reckard and 
Barker were the first to show that islet transplantation could completely and permanently 
restore normoglycemia in rodent models of chemically induced diabetes (Reckard & Barker, 
1973). 
Human islets isolation procedure is more complex than rodent islets isolation (Gray et al., 
1984). Ricordi’s automated isolation method had given hope for the production of abundant 
islets for the clinical use (Ricordi et al., 1989). Scharp et al. performed the islets 
transplantation under immunosuppression in diabetes patients and patients were insulin 
independent at the period of 22 days (Scharp et al., 1990). This was followed by several 
other cases, but success rates continued to be low (International Islet Transplant Registry). In 
1999, Bretzel  et al reported a markedly improved 3-month islet graft function rate of at least 
75% in 24 consecutive patients (Bretzel et al., 1999). In the 1-year follow-up of 37 patients, 
24% had achieved insulin independence (Bretzel et al., 2000). Between 1999 and 2005 about 
650 patients were treated worldwide (Bretzel et al., 2007).Unfortunately, long-term results 
did not prove that promising. 
The first successful islet allograft was reported in 1990 with steroid free immunosuppressant 
tacrolimus (Tzakis et al., 1990). The success rate of islet transplantation became outstanding 
after the Edmonton trial in 2000, which described successful intraportal alloislet 
transplantation, defined as insulin independence, in 7 consecutive patients with hyperlabile 
diabetes and frequent episodes of hypoglycemia (Shapiro et al., 2000). The success was 
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partly ascribed to the usage of a steroid free immunosuppressive regimen which was a new 
combination of immunosuppressive drugs, consisting of sirolimus, tacrolimus and 
daclizumab, excluding the diabetogenic glucocorticoids and large numbers of donor islets 
(Shapiro et al., 2006). 
The short-term results of islet transplantation with Edmonton trial were promising, with 
insulin independence in approximately 80% of patients  at 1 year post-transplant but the 
proportion of insulin independent recipients declined after the first year post-transplant. 
Five year follow-up study after transplantation revealed that only 10% of the patients 
remained insulin independent (Ryan et al., 2005; Shapiro et al., 2006). The suggested reasons 
attributing for this decline include alloimmune rejection, autoimmune recurrence, and/or 
toxicity of immunosuppressive medications (Monti et al., 2008). However, about 80% were 
still C-peptide positive, indicating functioning grafts. Now, a slightly modified Edmonton 
protocol is used worldwide with reproducible results (Shapiro AM et al., 2006).   
Though islet transplantation research has made significant progress, concern over toxicity as 
well as cost of immunosuppressive therapy still remains.  Insulin independence and long 
term graft survival were achieved for more than three years through a modified 
immunosuppressive protocol (Bellin et al., 2008) even so the requirement of multiple donors 
to obtain 10000 islet equivalents per kilogram of patient’s weight remains unsolved. 
Although insulin independence remains the ultimate goal, today, stabilization of glucose 
levels and avoidance of hypoglycemia are considered to be the main indications for islet 
transplantation. 
3. Alternate sources of pancreatic β cells  
The scarcity of donor pancreas for islet transplantation is a major obstacle to the widespread 
use of islet transplantation which urged the focus towards alternate sources of β cells for 
future transplants. Several alternative means have been suggested which include use of 
xenogenic islets and immortalized beta cell lines (Narushima et al., 2005). Recent advances 
in the field of stem cell differentiation and regeneration therapy have focused on new ways 
to generate insulin-producing beta cells that can be used for transplantation. Several 
candidate cells have been identified including embryonic stem cells (ESC) and adult stem 
cells or progenitor cells residing in the pancreas or other organs. The differentiated beta cells 
have shown to regenerate by replication, which opens the possibility to generate novel beta 
cells in vitro and / or in vivo from pre-existing beta cells. Additionally, there are reports that 
show the successful use of liver cells, endocrine cells from the gut, and bone marrow 
derived stem cells as source to generate islets by cell transdifferentiation.  
3.1 Xenogenic islets 
In a xenogenic approach, islets from different species are used for transplantation purpose. 
Porcine islets serve as a potential source in view of the fact that porcine insulin differ from 
human insulin by 1 amino acid. Neonatal porcine islets were also induced to mature 
endocrine phenotype under in vitro and in vivo conditions (Korbutt et al., 1997). Xenogenic 
tissues induce more vigorous rejection than that of allogenic tissue; hence 
immunosuppressant dosage should be high enough to prevent graft rejection. Alternately, 
the cells of xeno origin can be immunoisolated by encapsulation technology to separate the 
transplanted cells from host immune system which will be discussed later in this review. 
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Risks associated with transfer of endogenous virus from porcine cells to human genome 
(Patience et al., 1997; Van der Laan et al., 2000) and the public concerns regarding the use of 
animal organs for transplantation are major factors impeding the success of this approach in 
clinical applications. 
3.2 Stem cells to treat diabetes 
Stem cells are non specialized cells which have the ability to self regenerate and differentiate 
into specialized cell types depending on the niche or external signaling cues  (Smith, 2006). 
Stem cells offer a limitless supply source for islets as well reduces the graft rejection 
problems (Street et al., 2004). Ideally stem cells used for cell based therapy should meet the 
following criteria (Gimble, 2003) : It should be available in abundant quantities (millions to 
billions of cells), harvest procedure should be less invasive, have multilineage 
differentiation potential and could be efficiently transplanted to the host.  
3.2.1 Embryonic Stem Cells (ESC) 
Embryonic stem cells which are derived from the inner cell mass of pre-implantation 
blastocysts have gained the attention of researchers due to its pluripotent nature. Human 
embryonic stem cells (hES) hold promise for research and clinical applications. hES have 
some unique abilities as compared to all sources of adult cells: 1) the expansion of ESC in the 
undifferentiated state is nearly unlimited; and 2) ESC can give rise to all cell types including 
pancreatic insulin-producing beta cells. Attempts of directed differentiation of hES to 
cardiomyocytes (Klug et al., 1996), and neurons (Li et al., 1998) have been reported. Many 
studies have reported the differentiation of mouse and human embryonic stem cells to islet 
like clusters (Segev et al., 2004; Vaca et al., 2006) either by modifying the culture conditions 
or by genetic manipulation.  Lineage tracing experiments revealed that beta cells are derived 
from the embryonic endoderm followed by a sequential and transient activation of specific 
transcription factors like Pdx1, NeuroD / Beta 2, Isl1, Nkx6.1, Nkx2.2, MafA, Pax4, and 
Pax6.  Most published protocols aim to mimic these differentiation factors for the stepwise 
development of the endo and exocrine pancreas during the embryonic phase. In one 
approach ESC were induced to generate embryoid bodies under in vitro culture and the 
nestin positive cells were selected to differentiate towards β cell lineage by culturing in 
serum free conditions (Lumelsky et al., 2001). Manipulation of the culture conditions with 
various growth supplements like insulin, transferrin, selenium and fibronectin (ITSFn), 
B27,bFGF and nicotinamide resulted in regulated secretion of insulin. Phosphoinositide 
kinase inhibitors have been reported to promote the differentiation of larger numbers of 
ESC towards functional β cells (Hori et al., 2002). Genetic approach involves the 
incorporation of a reporter selector gene whose expression controlled by an insulin 
promoter. Here mouse embryonic stem cells were cultured in manipulated culture 
conditions to develop into embryoid bodies which were then differentiated to insulin 
producing cells. Insulin containing population which exhibited in vitro regulated hormone 
secretion was selected for transplantation into diabetic mice. Genetically engineered insulin 
producing cells maintained glucose homeostasis in vivo in mouse models but 40% of animals 
reversed to hyperglycemic condition after 12 weeks (Soria et al., 2000). ESC culture under 
serum-free conditions or only low-level fetal calf serum together with stage specific 
differentiation factors results in temporal expression of pancreatic lineage genes. The final 
differentiated cells do express insulin secretory granules / C peptide in about 2 – 8 % of the 
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total cell population and secrete insulin / C-peptide after glucose challenge (D’Amour et al., 
2006; Baharvand et al., 2006; Jiang et al., 2007). Feeder free conditions were developed for the 
differentiation of embryonic stem cells to insulin like clusters which allowed single species 
propagation of ESC thus avoiding possible zoonotic infection of cells evident by the increased 
expression of Pdx 1 and reduced expression of Oct-3/4 (Assady et al., 2001). The activation of 
Pax-4 and Pdx 1 gene expression in embryonic stem cells upregulated the genes involved in 
the differentiation towards pancreatic endocrine lineage. Pax-4 expression led to an increase in 
nestin positive cells and insulin producing beta cells but not glucagon producing alpha cells 
(Moritoh et al., 2003). The development pathway for induction of ESC to insulin producing 
cells involves series of events which include generation of endoderm lineage cells followed by 
precursors of pancreatic endocrine lineage cells, and finally the insulin-secreting cells. 
D’Amour et al., developed a five stage protocol for differentiation of hES to pancreatic 
endocrine hormone expressing cells through a series of endodermal intermediates resembling 
those that occur during pancreatic development in vivo (D’Amour et al., 2006). Controversial 
findings also have been reported regarding the differentiation of ESC to pancreatic beta cells.  
Insulin immunoreactivity was demonstrated to occur as the consequence of insulin uptake 
from medium (Rajagopal, J., 2003). Few authors proved that nestin positive cells tend to 
differentiate towards neuronal lineage rather than pancreatic lineage (Sipione et al., 2004). 
Kania  et al explained the cause for the controversial results in generation of pancreatic cells. 
It was suggested that insulin producing cells derived from embryonic stem cells without 
applying lineage selection is dependent on the differentiation factors and protocols (Kania et 
al., 2004).  
Though hES are versatile cells, ethical concerns on the use of human hES, and chances of 
teratoma formation (Fujikawa et al., 2005) limits their usage. Direct transplantation of 
embryonic stem cells has reported to culminate in teratoma formation (Nussbaum et al., 
2007) from contaminating undifferentiated ESCs. Safe transplantation of hES could be 
attempted by viral vector mediated transfection in vitro, yet the risks associated with 
cytomegalovirus promoters in transfection cannot be ruled out.  
3.2.2 Adult Stem Cells 
The potential use of adult stem cells offers the advantage of an autologous model whereby a 
patient’s own cells can be used, thereby circumventing immune rejection. Adult stem cells 
(ASC) are multipotent cells capable of self renewal. They have been reported to be present in 
almost every tissue like bone marrow, blood, heart, liver, pancreas, adipose tissue and could 
be transplanted directly without genetic modification or pre-treatments. They exhibit high 
degree of genomic stability during culture conditions. ASC lack tissue specific 
characteristics but it could be differentiated to specialized cell types under the influence of 
appropriate signaling cues (Barry & Murphy, 2004). The stem cell microenvironment plays 
an important role in its differentiation to committed cells (Galli et al., 2000; Zhao et al., 2002). 
The potential of adult human stem cells from various sources to differentiate to insulin 
producing cells have been explored by various research groups. The relative ease of 
isolating adult stem cells and their expansion makes it an ideal source for cell based therapy. 
3.2.2.1 Pancreatic stem cells 
Pancreatic progenitor/stem cells which are closely related with beta cell lineage represent 
an attractive source for generation of beta cells (Serup et al., 2001). Human pancreatic ductal 
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cells and islet stem cells have been expanded and differentiated to islet like clusters capable 
of producing insulin in vitro which were capable of reversing of diabetes in non obese 
diabetic mice thus normalizing blood glucose levels for more than 3 months (Ramiya et al., 
2000). Nestin positive cell derived islet cell clusters expressed pancreatic endocrine markers 
like Glut2, glucagon, and homeodomain transcription factor PDX-1 as well as pancreatic 
exocrine genes (Zulewski et al., 2001). Glucagon like peptide -1, an intestinal hormone was 
shown to stimulate the neogenesis of beta cells by inducing the expression of various 
transcription factors involved in beta cell development (Abraham et al., 2002).  Exocrine 
pancreatic tissue (Baeyens et al., 2005) and neurogenin 3 positive cells (Gu et al., 2002) could 
also serve as alternative source for beta cells.  Even though pancreatic cells seem to be the 
better source than embryonic stem cells, the fraction of precursor cells isolated from 
pancreas is very less and heterogenous. Furthermore the harvest procedure from pancreas is 
also invasive thus limiting this source being applicable in clinical purposes. 
3.2.2.2 Bone marrow stem cells (BMSC) 
Bone marrow stem cells were induced to differentiate to mature endocrine pancreatic 
lineage in vitro (Y. Sun et al., 2007). The in vitro differentiation of human bone marrow stem 
cells (hBMSC) to endocrine pancreatic cell types were investigated by genetic manipulation 
using adenovirus coding for mouse transcription factors involved in the early phase of 
endocrine developmental pathway (Karnielli et al., 2007). The results suggested that bone 
marrow stem cells shifted towards pancreatic endocrine phenotype with expression of 
insulin and other transcription factors involved in β cell development. Enhanced green 
fluorescent protein (GFP) system based genetic approach was utilized to study the 
differentiation of BMSC to islet like cells. BMSC from transgenic (GFP) male mice were 
transplanted into sublethally irradiated female mice. After 4 weeks 1.7-3% bone marrow 
derived GFP positive cells were found only in the pancreatic islets which ruled out the in 
vivo occurrence of cell fusion. The results indicated that bone marrow derived cells activated 
insulin gene expression after entering pancreatic islet niche (Ianus et al., 2003). However 
controversial finding was also reported suggesting that bone marrow derived stem cells 
cannot differentiate to beta cells without the influence of differentiation factors (Lechner et 
al., 2004) and favorable microenvironment (Moriscot et al., 2005).  Recently Phadnis et al 
evaluated the fate of transplanted epithelialised human bone marrow stem cells under the 
kidney capsule of pancreatomized NOD/SCID mice (Phadnis et al., 2011).The results 
suggested that regenerating pancreas secreted paracrine factors and provided the niche 
which induced the differentiation of hBMSC to mature islet like aggregates capable of 
secreting insulin.  
3.2.2.3 Adipose stem cells 
Human subcutaneous adipose tissue, abundant and easily accessible serves as a potential 
source of adult mesenchymal stem cells. The harvest procedure by lipoaspiration / 
liposuction is less invasive. Adipose stem cells have been reported to exhibit an increased in 
vitro proliferative potential than bone marrow stromal cells (De Ugarte et al., 2003). Adipose 
stem cells release cytokines TGF-β and IL-10 which are responsible for its 
immunomodulatory properties (Puissant et al., 2005). The immunosuppressive property of 
adipose stem cell has been exploited for the treatment of severe graft versus host disease 
(Yanez et al., 2006). The differentiation potential of these cells to pancreatic endocrine cells 
have been investigated by several research groups. Human adipose stem cells induced to 
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islet like cells in serum free differentiation medium for 3 days exhibited an upregulation of 
pancreatic developmental transcription factors like Isl-1, Ngn3 along with islet hormones 
such as insulin, glucagon and somatostatin (Timper et al., 2006).  A novel protocol using 
taurine designed for islet differentiation generated 47-51% C- peptide positive cells when 
compared to reports where the yield was only 2-8% (Jiang et al., 2007).  
3.2.2.4 Progenitor cells and stem cells from other tissues 
The mechanisms involved in the generation of new beta cells in postnatal life remains 
controversial. Lineage tracing experiments suggest that after partial pancreatectomy, the 
majority of novel beta cells derive from pre-existing beta cells by beta cell proliferation 
rather than stem cell differentiation (Dor et al., 2004; Georgia and Bhushan, 2004). These 
findings raise new hope that it may be possible to use beta cells as source for the in vitro cell 
expansion in cell therapy. For example, it has been shown that human beta cells can 
transiently dedifferentiate to fibroblast-like cells, which can proliferate and redifferentiate 
into insulin-positive cells (Gershengorn et al., 2004; Lechner et al., 2005). However, direct 
evidence that this process can be used to produce fully mature beta cells for transplantation 
is missing, thus far.  
It is important to note that the above mentioned experiments do not exclude the existence of 
pancreatic stem cells. There is convincing evidence that under specific experimental 
conditions adult stem cells, which reside in the pancreatic ducts, within islets, or exocrine 
tissue, can develop into beta cells. Bonner-Weir and colleagues as well as other groups 
provide evidence in several studies that murine and human stem cells or progenitor cells 
reside in the epithelium of the small pancreatic ducts, expressing the marker cytokeratin-19 
(CK19). The ductal cells can expand and give rise to novel beta cells after 90% 
pancreatectomy or treatment with streptozotocin (Bonner-Weir et al., 1993; Wang et al., 
1995; Bonner-Weir S et al., 2003; Gao et al., 2003). This suggests that still unknown cellular or 
soluble factors are needed to induce terminal differentiation into the endocrine fate. The 
identification of these critical factors is one focus of current research. 
Amnion epithelial cells (Hou et al., 2008; Kadam et al., 2010a), and stem cells from liver 
(Yang et al., 2002), wharton’s jelly of umbilical cord (Chao et al., 2008), umbilical cord blood 
(Phuc et al., 2010), placenta (Kadam et al., 2010b), gall bladder (Sahu et al., 2009) etc were 
also differentiated to insulin producing cells. In every case the differentiated islets expressed 
islet specific proteins and were capable of secreting insulin in response to glucose 
stimulation, albeit less than native islets. A better understanding of the events that control 
stem cell commitment and the signaling pathways for differentiation to pancreatic lineage is 
required to improve the culture conditions for in vitro generation of islet like clusters. 
4. Tissue engineering based strategies 
Tissue engineering applies the principles of cell transplantation, material science, and 
engineering towards the development of biologic substitutes that can restore and maintain 
normal function. The success of tissue engineering relies on the development of a suitable 
scaffold, cell source and defined culture conditions. Tissue engineering strategies employed 
for islet transplantation could be categorized into use of scaffolds for simulation of the 
native ECM and immunoisolation via encapsulation of islets.  
The biomaterial chosen to synthesize the scaffold should be biocompatible and 
biodegradable (Mohan & Nair, 2005). The scaffold should reproduce an extracellular 
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environment for supporting cell function (Dufour et al., 2005). Neither the scaffold nor its 
degradation products should be toxic to host. Biocompatibility of chosen biomaterial plays 
an important role in controlling the rate of protein adsorption and fibrosis.  The scaffold 
should provide three dimensional space for neotisssue formation and the mechanical 
strength should match the native tissue to withstand in vivo forces. It should be highly 
porous and pores should have interconnectivity to facilitate tissue ingrowth, diffusion of 
nutrients, oxygen and metabolites (Blomeier et al., 2006). Scaffolds should provide an initial 
support for the islet grafts during the early post transplant period, enabling the 
development of a capillary bed and recovery of extracellular matrix interactions (Stock & 
Vacanti, 2009). Polymers such as polylactic acid, polyglycolic acid, polylactide-co- 
polyglycolide (PLGA) (Mao et al., 2009), polyvinyl alcohol – polycaprolactone (Mohan et al., 
2010) were  extensively used for scaffold fabrication purpose for the tissue engineering of 
various tissues.  
4.1 Extracellular matrix - Mimicking nature 
A major limitation with two dimensional cultures is the lack of microenvironment 
indispensable for appropriate spatial organization and function of cells which in turn is 
provided by extracellular matrix (ECM) in native tissue. The ECM of native islets is mainly 
constituted by type IV collagen, laminin although fibronectin, collagen I, collagen V also 
have been detected (Stendahl et al., 2009). The effect of ECM proteins on adhesion and 
proliferation of rat islets have been studied. The results indicated that there were strong 
interactions between islets and ECM proteins via integrins (Chen et al., 2008). ECM protein 
coated scaffolds have shown improved graft efficacy at implanted site (Salvay et al., 2008). 
Earlier reports of islets cultured under two dimensional conditions exhibited low survival 
rate and reduced insulin secretion (Paraskevas et al., 1997). Progress in survivability of  
islets and increased insulin secretion has been achieved by adopting 3D culture conditions. 
Polyglycolic acid scaffolds coated with lysine were shown to promote islet cell adhesion and 
survival. The control cells grown in 2D culture underwent apoptosis by day 7 due to 
accumulation of metabolites and shortage of nutrients (Chun et al., 2008).  
Pancreatic islets cultured on agarose cryogel sponge (Bloch et al., 2005) were reported to 
secrete 15 fold higher insulin at 3mM glucose than islets cultured on polystyrene cell culture 
dish but failed to respond to stimulation at 16.7mM glucose. The failure was due to limited 
oxygen and nutrient diffusion across agarose cryogels. Adequate oxygen is a critical 
parameter to islet cell function and survival (Sweet et al., 2002). The decreased insulin 
response of pancreatic islets cultured on scaffold for prolonged period due to inefficient 
oxygen transfer were also reported (Cui et al., 2001). 
A novel 3D culture system comprising a semi-interpenetrating polymer network of gelatin 
and polyvinyl pyrrolidone was designed in our laboratory for pancreatic islets and stem 
cells to promote  their survival and function. The porous nature of the scaffold facilitated 
efficient nutrient and metabolite exchange. Islets seeded on this scaffold maintained their 
morphology for more than 30 days whereas control islets cultured on cell culture dish 
underwent apoptosis by 7th day. The test islets secreted insulin on stimulation with glucose 
which was comparable to that of freshly isolated mouse islets (Muthyala et al.,2010). 
Zhao et al demonstrated the use of three dimensional self assembling peptide nanofiber 
hydrogel scaffold for islet culture. The peptides formed two beta sheet structures with 
hydrophilic and hydrophobic surfaces in aqueous solution. The hydrophobic moiety 
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facilitated its self assembly in water and the nanofiber structures were flexible for  
fabrication to different geometrical shapes that allowed for efficient nutrient and metabolite 
transfer.  The nanofiber scaffold simulated the microenvironment in vitro as in native 
condition which accounted for improved islet viability and function (Zhao et al., 2010).   
4.2 Immunoisolation strategies for islet transplantation 
The principle behind immunoisolation is protection of islets from host immune system 
using a selectively permeable membrane as a barrier. Low molecular weight substances 
which include nutrients, oxygen, secretory molecules and cell signaling molecules freely 
diffuse through the membrane, but passage of immune cells and its products which have 
high molecular weight is prevented. Immunoisolation mechanism encourages the use of 
allogenic/ xenogenic sources of islets for transplantation and holds promise towards use of 
autologous stem cell derived islets in type I diabetic patients. Immunoisolation mechanism 
includes macroencapsulation and microencapsulation (Narang & Mahato, 2006) of cells. 
4.2.1 Microencapsulation 
Microencapsulation is the encapsulation of single islets or small groups of islets. These 
capsules are usually spherical in shape (Chang, 1964). Microcapsules offer the advantage of 
increased oxygen and nutrient transport due to the large surface area to volume ratio. 
Microcapsules are advantageous due to several reasons like greater surface to volume ratio, 
and ease of implantation. The spherical shapes owe to better diffusion capacity and are 
mechanically stable. The primary drawback of microencapsulation is the difficulty in 
removing the implants if necessary. Moreover the implantation could be achieved by simple 
injection procedure (De Vos et al., 2002).  Porcine islets microencapsulated in alginate-
polylysine-alginate transplanted to diabetic monkeys could achieve normoglycemia without 
immunosuppression for more than 800 days (Y. Sun et al., 1996). Human and rat islets 
encapsulated in alginate gels when transplanted in mice survived for 7 months (Schneider et 
al., 2005). Xenogenic islets immobilized in microcapsules fabricated from alginate –PLL 
when implanted into peritoneum of non immunosuppressed diabetic rats remained in 
excellent condition for more than 40 weeks (Lanza et al., 1999). Despite of these advantages 
some authors have reported reduced functionality of microencapsulated islets in response to 
glucose challenge (Sandler et al., 1997). 
4.2.2 Macroencapsulation 
Macroencapsules contain a large mass of islet cells within a diffusion chamber, which are 
usually formed from spun coat membranes or spun drawn hollow fibers. The advantages of 
macrocapsules are they could be easily retrieved when required and can be shaped in 
required geometries such as tubes or discs. Two approaches such as intravascular and 
extravascular have been tried out in macroencapsulation. Intravascular approach utilizes the 
principle of perfusion chambers which consists of microporous tubular structures perfused 
with blood and enclosed within another tube. Islets were seeded in the space between the 
hollow fibers and the device is anastomised to the host vasculature (Chick et al, 1975). 
Polyacrylonitrile and polyvinylchloride copolymers have been chosen as materials for 
creating artificial microcapillaries. Results from implantation of intravascular macrocapsules 
of islets have shown restoration of normoglycemia in various animal models (AM. Sun et al., 
1977). Due to the direct contact of device with the blood, intense anticoagulation is required 
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to prevent thrombus formation, consequently the material chosen should be highly blood 
compatible and thromboresistant. These concerns have shifted the attention towards 
extravascular devices. 
Extravascular devices are based on the principle of diffusion chambers which does not 
require anastomosis to host vasculature. The geometry could be planar in the form of flat or 
hollow fiber model (Scharp et al., 1984). This approach does not pose severe 
biocompatibility issues and risks to the patient as that of intravascular devices. 
Extravascular devices can be implanted to different sites such as peritoneal cavity (Lanza et 
al., 1999), subcutaneously or under kidney capsules (Siebers et al., 1990) with minimal 
surgical risks. Most commonly used biomaterials for macrocapsule fabrication are 
nitrocellulose acetate, 2-hydroxyethyl methacrylate (HEMA), acrylonitrile, polyacrylonitrile 
and polyvinylchloride copolymer, and alginate.  
The biocompatibility of immunoisolation membrane depends on several factors like 
geometry of the device, implantation site and material chosen. Hollow fiber geometry is 
preferred because of its reduced surface area of contact with the host per islet and reduced 
foreign body response. Higher density of islet cells often results in reduced viability and 
necrosis at the center due to nutrient limitation. Smooth outer surface and hydrogels have 
been reported to improve the biocompatibility by the absence of interfacial tension, thus 
reducing protein adsorption, cell adhesion and fibrosis (Burczak et al., 1996). Nair et al 
studied the effect of degree of hydrophilicity on tissue response of polyurethane 
interpenetrating networks (IPN) (Nair et al., 1992).The results indicated that an increase in 
hydrophilicity of polyurethane –polyvinyl pyrrolidone IPN’s elicited an inert tissue 
response.  
George et al., (2002), Nair (2009, Indian Patent 230740) demonstrated the use of non porous 
polyurethane membranes and porous polyurethane IPN macrocapsules as islet 
immunoisolative matrices. Islet cell morphology remained intact and insulin secretion 
ability was also retained within the immunoislation membranes. Membranes allowed 
diffusion of glucose and insulin while retained transplant rejection factors like antibodies, 
immunoglobulins and immune cells. Reduced protein adsorption and cell adhesion on 
polyurethane membranes contributed to improve the biocompatibility which made them 
ideal for immunoisolation. The IPN macrocapsules also served as an in vivo bioreactor cum 
immunoisolation device permitting immature islet like clusters derived from a variety of 
stem cell sources to mature completely and control glycemic levels of streptozotocin 
induced diabetic animal models without immunosuppression for periods upto 3 months. 
(Kadam, 2010a; Phadnis, 2011;  Muthyala, 2011;; Kadam, 2010 b).Hybrid systems involving 
macro and microencapsulation have also been fabricated and analyzed for its efficiency in 
immunoisolation. Chitosan/gelatin hydrogel system was used as an immunoisolative 
matrix to protect the microencapsulated islet cells from recipient’s immune system in 
xenotransplantation. Mouse insulinoma /agarose microspheres macroencapsulated in 
chitosan/gelatin hydrogel reversed diabetes in rats. The study suggests that this could be 
applied as a cell carrier for injectable bioartificial pancreas after certain modifications (Yang 
et al., 2008).  
4.3 Combined approach of tissue engineering and immunoisolation 
Muthyala et al (2011) employed a combination approach utilising the properties of scaffold 
to mimic the native ECM and macroencapsulation for immunoisolation to protect the islets 
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from immune cell responses. Pancreatic progenitor derived islets were seeded on gelatin-
polyvinylpyrrolidone scaffolds and further macroencapsulated in a polyurethane–
polyvinylpyrrolidone semi IPN macrocapsule. The construct when implanted into 
peritoneal cavity of diabetic rats normalized glycemic condition all through the study period 
of 3 months. Animals implanted with tissue engineered islets without macroencapsulation 
showed no reversal of hyperglycemia and died within 15-20 days due to infiltration of host 
immune cells. Hence the combination approach was found to be very effective in achieving 
euglycemia by maintaining islet survival and functionality as well as protecting the cells 
from host immune attack. 
5. Site for transplantation  
The optimal site should be chosen for transplanting islets inorder to meet its high energy 
requirement and metabolic rate (Hardy et al., 2010). The implantation site has effect on 
hypoxic conditions which determines islet survival. Safety considerations have been raised 
regarding the optimal site for transplantation so as to improve islet engraftment and 
survival (Dufrane et al., 2006; Pillegi et al., 2001). Graft vascularization is an important 
criterion in islet survival and function (Jansson & Carlsson, 2002). Although 
immunoisolation prevents the integration of host blood vessels with transplanted islets 
effective diffusion of nutrients and oxygen can occur within 200μm distances hence highly 
vascularised sites should be chosen for transplantation. Islet transplantation into 
prevascularized sites dramatically improves graft survival and function relative to 
transplantation into non-modified tissue (Balamurugan et al., 2003). Vascularization can be 
introduced in graft by incorporation of angiogenic growth factors like VEGF (Stendahl et al., 
2008) or endothelial cells (Miki et al., 2006). Insulin independence have been achieved by 
intra-portal islet transplantation in diabetic patients (Shapiro et al., 2005), however liver 
could not be considered as an optimal site since islets in liver will be exposed to high 
nutrient concentration and other factors that are toxic and may result in impairment of  beta 
cells(Hiller et al., 1991; Wilson & Chaikof, 2008). Peritoneal cavity has also been tried for 
implantation of islets which requires 200%-400% more islets (Siebers et al., 1993). 
Subcutaneous site (Pillegi et al., 2006) have been chosen in diabetic athymic mice for  
transplantation of islets cultured on plasma –fibroblast gel scaffold (Perez-Basterrechea et 
al., 2009). Normoglycemia was achieved over 60 day period and vascularization was 
observed in and around islets. Kidney subcapsular spaces have also been chosen as 
implantation site to improve biocompatibility of tissue engineered constructs. Islets cultured 
on biodegradable polymer scaffold transplanted to omental pouch of diabetic dogs resulted 
in achievement of euglycemia upto 152 days till graft was taken out (Kin et al., 2008). 
6. Conclusions 
Curative therapy for diabetes mellitus mainly implies replacement of functional insulin-
producing pancreatic cells, with pancreas or islet-cell transplants. Shortage of donor organs 
spurs research into alternative means of generating cells from islet expansion, encapsulated 
islet xenografts, human islet cell-lines, and stem cells. Embryonic and adult stem cells are 
potential sources for cell replacement and merit further scientific investigation. The expense 
of the benefit of cell transplantation is the need for immunosuppressive treatment of the 
recipient, with all its potential risks. Biocompatible macrocapsules for transplantation of 
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islets and islet-like cell clusters differentiated from stem cells help overcome the immune 
rejection without Immunosuppressive drug therapy.  A tissue engineering approach aims to 
mimic the natural extracellular matrix environment for supporting the transplanted islet 
cells without sacrificing form and function. A combination approach of tissue engineering, 
immunoisolation and most appropriately differentiated islet may propel clinical trials 
involving engineered strategies for cell replacement in diabetic patients, in the not too 
distant future. 
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